08-09-2017
10:00 - 11:30 Type: Special Session Palma Title: Medical oncology as a contributor to global policy: How to improve national cancer Auditorium plans Chair(s): G. Curigliano, IT; L. Stevens, US
10:00 - 10:05 Introduction L. Stevens, Rio De Janeiro, BR
10:05 - 10:20 Overview of NCCP, including forming the multi-disciplinary and multi-sectoral partnership A. Ilbawi, Geneva, CH
10:20 - 10:35 Example from Central Asia Leadership Forum D. Kaidarova, Almaty, KZ
10:35 - 10:50 Example from Central Europe J. Jassem, Gdańsk, PL
10:50 - 11:05 Example from Eastern Europe S. Krasny, Minsk, BY
11:05 - 11:30 Interactive Q&A G. Curigliano, Milan, IT
Last update: 02-09-2017 06:01:33pm esmo.org 12:00 - 13:30 Type: Opening session Madrid Auditorium Title: Opening session and Award lectures Chair(s): F. Ciardiello, IT
12:00 - 12:10 ESMO Presidential Address F. Ciardiello, Naples, IT
12:10 - 12:15 EACR Presidential Address A. Berns, Amsterdam, NL
12:15 - 12:20 Welcome to Madrid M. Martin Jimenez, Madrid, ES
12:20 - 12:25 ESMO 2017 Scientific Address A. Sobrero, Genova, IT
12:25 - 12:30 EACR 2017 Scientific Address R. Marais, Manchester, GB
12:30 - 12:32 Presentation of the ESMO Award by C. Zielinski, Vienna, AT
12:32 - 12:47 ESMO Award lecture - Oncology: The importance of teamwork M. Martin Jimenez, Madrid, ES
12:47 - 12:49 Presentation of the ESMO Translational Research Award by C. Zielinski, Vienna, AT
12:49 - 13:04 ESMO Translational Research Award lecture: Monitoring and targeting colorectal cancer evolution A. Bardelli, Candiolo, (TO)/IT
13:04 - 13:06 Presentation of the ESMO Lifetime Achievement Award by C. Zielinski, Vienna, AT
13:06 - 13:21 ESMO Lifetime Achievement Award lecture J. Baselga, New York, NY/US
13:21 - 13:21 Close and Welcome refreshments in the exhibition
14:00 - 15:30 Type: Proffered Paper session Barcelona Auditorium Title: Gastrointestinal tumours, non-colorectal 1 Chair(s): E. Van Cutsem, BE; Y.-K. Kang, KR
Last update: 02-09-2017 06:01:33pm esmo.org 14:00 - 14:12 LBA27_PR - Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) for resectable esophagogastric cancer: updated results from multicenter, randomized phase 3 FLOT4-AIO trial (German Gastric Group at AIO) 1 2 3 4 5 6 7 S.-E. Al-Batran , C. Pauligk , N. Homann , H. Schmalenberg , H.-G. Kopp , G.M. Haag , K. Luley , G. 4 8 9 2 10 11 12 Folprecht , S. Probst , P. Thuss-Patience , J. Trojan , M. Koenigsmann , U. Lindig , M. Pohl , S. 13 14 1 13 1 15 1 Kasper , M. Möhler , T. Goetze , M. Schuler , E. Jaeger , R.D. Hofheinz ; Frankfurt Am Main,
2 3 4 5 6 7 DE, Frankfurt, DE, Wolfsburg, DE, Dresden, DE, Tübingen, DE, Heidelberg, DE, Lübeck, 8 9 10 11 12 13 Schleswig-Holstein/DE, Bielefeld, DE, Berlin, DE, Hannover, DE, Jena, DE, Bochum, DE, 14 15 Essen, DE, Mainz, DE, Mannheim, DE
14:12 - 14:24 615O_PR - Hybrid Minimally Invasive vs. Open Esophagectomy for patients with Esophageal Cancer: Long-term outcomes of a multicenter, open-label, randomized phase III controlled trial, the MIRO trial 1 2 3 4 5 6 7 C. Mariette , S. Markar , T.S. Dabakuyo-Yonli , B. Meunier , D. Pezet , D. Collet , X. D'journo , C. 8 9 10 11 12 1 2 Brigand , T. Perniceni , N. Carrere , F. Bonnetain , G. Piessen ; Lille, CEDEX/FR, London, GB,
3 4 5 6 7 8 9 Dijon, FR, Rennes, FR, Clermont Ferrand, FR, Bordeaux, FR, Marseille, FR, Strasbourg, FR, 10 11 12 Paris, FR, Toulouse, FR, Besançon, CEDEX/FR, Lille, FR
14:24 - 14:39 Invited Discussant LBA27_PR and 615O_PR A. Roth, Geneva, CH
14:39 - 14:51 616O - Pertuzumab (P) + trastuzumab (H) + chemotherapy (CT) for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (mGC/GEJC): Final analysis of a Phase III study (JACOB) 1 2 3 4 5 6 6 7 6 J. Tabernero , P. Hoff , L. Shen , A. Ohtsu , M. Shah , K. Cheng , C. Song , H. Wu , J. Eng-Wong , 8 1 2 3 4 5 6 Y.-K. Kang ; Barcelona, ES, Sao Paulo, BR, Beijing, CN, Kashiwa, Chiba/JP, New York, NY/US, 7 8 San Francisco, US, Shanghai, CN, Seoul, Songpa-gu/KR
14:51 - 15:03 617O - A Phase 3 Study of nivolumab (Nivo) in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Updated results and subset analysis by PD-L1 expression (ATTRACTION-02) 1 2 3 4 5 6 7 8 N. Boku , Y.-K. Kang , T. Satoh , Y. Chao , K. Kato , H.C. Chung , J.-S. Chen , K. Muro , W.K. Kang 6 9 6 10 11 12 1 2 , T. Yoshikawa , S.C. Oh , T. Tamura , K.-W. Lee , L.-T. Chen ; Kawasaki, Kanagawa/JP,
3 4 5 6 7 8 Seoul, Songpa-gu/KR, Suita, Osaka/JP, Taipei, TW, Tokyo, JP, Seoul, KR, Taoyuan, TW, 9 10 11 12 Nagoya, Aichi/JP, Yokohama, JP, Osaka, JP, Seongnam, KR, Tainan, TW
15:03 - 15:15 LBA28_PR - KEYNOTE-059 Update: Efficacy and Safety of Pembrolizumab Alone or in Combination With Chemotherapy in Patients With Advanced Gastric or Gastroesophageal (G/GEJ) cancer 1 2 3 4 5 6 7 8 6 Z. Wainberg , S. Jalal , K. Muro , H. Yoon , M. Garrido , T. Golan , T. Doi , D. Catenacci , R. Geva , 9 10 11 12 11 13 13 13 G. Ku , J. Bleeker , Y.-J. Bang , H. Hara , H.C. Chung , M. Savage , J. Wang , M. Koshiji , 14 15 1 2 3 4 R. Dalal , C. Fuchs ; Los Angeles, CA/US, Indianapolis, IN/US, Nagoya, Aichi/JP, Rochester, 5 6 7 8 9 10 MN/US, Santiago, CL, Tel Aviv, IL, Kashiwa, Chiba/JP, Chicago, IL/US, New York, NY/US, 11 12 13 14 15 Sioux Falls, SD/US, Seoul, KR, Saitama, JP, Kenilworth, NJ/US, Rahway, US, New Haven, CT/US
15:15 - 15:30 Invited Discussant 616O, 617O and LBA28 E. Van Cutsem, Leuven, BE
Last update: 02-09-2017 06:01:33pm esmo.org
14:00 - 15:30 Type: Proffered Paper session Sevilla Auditorium Title: Genitourinary tumours, prostate Chair(s): J. de Bono, GB; S. Gillessen, CH
14:00 - 14:12 LBA31_PR - Adding abiraterone acetate plus prednisolone (AAP) or docetaxel for patients (pts) with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): directly randomised data from STAMPEDE (NCT00268476) 1 2 3 4 5 6 7 6 M. Sydes , M. Mason , M. Spears , N. Clarke , D. Dearnaley , A. Ritchie , M. Russell , C. Gilson , R. 7 6 8 3 9 10 6 11 Jones , J. de Bono , S. Gillessen , R. Millman , S. Tolan , J. Wagstaff , S. Chowdhury , J. Lester , 12 13 14 15 1 2 3 4 D. Sheehan , J. Gale , M. Parmar , N. James ; London, UK/GB, Cardiff, GB, Wcb Nh, GB, M 5 6 7 8 9 10 11 Hd, GB, Sutton, GB, London, GB, Glasgow, GB, St. Gallen, CH, Wirral, GB, Swansea, GB, 12 13 14 15 Wales, GB, Exeter, GB, Portsmouth, GB, London, London/GB, Birmingham, GB
14:12 - 14:24 783O - Benefits of Abiraterone Acetate Plus Prednisone (AA+P) When Added to Androgen Deprivation Therapy (ADT) in LATITUDE on Patient (Pt) Reported Outcomes (PRO) 1 2 3 4 5 6 7 K. Chi , A. Protheroe , A. Rodriguez Antolin , G. Facchini , H. Suttmann , N. Matsubara , Z.-Q. Ye , B. 8 9 10 11 12 13 9 14 1 Keam , T. Li , K. McQuarrie , B. Jia , P. De Porre , J. Martin , M. Todd , K. Fizazi ; 2 3 4 5 6 Vancouver, British Columbia/CA, Oxford, GB, Madrid, ES, Napoli, IT, Hamburg, DE, Kashiwa, 7 8 9 10 11 12 Chiba/JP, Wuhan, CN, Seoul, KR, Raritan, NJ/US, Horsham, PA/US, Shanghai, CN, Antwerp, 13 14 BE, Buckinghamshire, GB, Villejuif Cedex, FR
14:24 - 14:36 784O - Docetaxel (D) with androgen suppression (AS) for high-risk localized prostate cancer (HrPC) patients (pts) who relapsed PSA after radical prostatectomy (RP) and/or radiotherapy (RT): A randomized phase III trial 1 2 3 4 5 6 7 S. Oudard , I. Latorzeff , A. Caty , L. Miglianico , E. Sevin , A.-C. Hardy Bessard , R. Delva , F. 8 2 9 10 11 12 13 Rolland , C. Chevreau , F. Priou , P. Beuzeboc , G. Gravis , C. Linassier , P. Gomez , E. Voog 14 1 15 16 1 17 1 2 , P. Chinet , X. Muracciole , C. Abraham Jaillon , R. Elaidi , S. Culine ; Paris, FR, Toulouse, 3 4 5 6 7 8 FR, Lille Cedex, FR, St. Grégoire, FR, Caen, FR, Plérin, FR, Angers, FR, Saint-Herblain, 9 10 11 12 CEDEX/FR, La Roche Sur Yon, CEDEX 9/FR, Paris, CEDEX 5/FR, Marseille, CEDEX 9/FR, 13 14 15 16 17 Tours, CEDEX 9/FR, Rouen, FR, Le Mans, FR, Marseille, FR, Le Chesnay, FR, Paris, CEDEX 10/FR
14:36 - 14:51 Invited Discussant LBA31, 783O and 784O C. Sternberg, Roma, IT
14:51 - 15:03 785O - Lutetium-177 PSMA (LuPSMA) theranostics phase II trial: Efficacy, safety and QoL in patients with castrate-resistant prostate cancer treated with LuPSMA 1 2 2 2 2 2 2 2 M. Hofman , S. Sandhu , P. Eu , J. Price , T. Akhurst , A. Iravani , G. Kong , A. Ravi-Kumar , S. 2 2 2 2 2 2 1 2 Williams , S.-P. Thang , D. Murphy , M. Scalzo , R. Hicks , J. Violet ; Melbourne, AU, Melbourne, VIC/AU
15:03 - 15:15 LBA32 - PROREPAIR-B: A prospective cohort study of DNA repair defects in metastatic castration resistant prostate cancer (mCRPC)
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 3 1 4 E. Castro Marcos , N. Romero Laorden , J.M. Piulats Rodriguez , A. del Pozo , M.I. Sáez , A. Medina 1 1 1 5 6 1 Colmenero , J. Puente , J.C. Silla-Castro , R. Lozano Mejorada , I. Garcia-Carbonero , L. Rivera , 7 8 9 1 10 M.J. Mendez Vidal , R. Morales Barrera , E.M. Fernandez Parra , Y. Cendón Flórez , P. Borrega , 11 12 1 1 1 M.A. Gonzalez Del Alba Baamonde , C. Pritchard , P. Lapunzina , D. Olmos Hidalgo ; Madrid, ES, 2 3 4 5 6 7 Madrid, Madrid/ES, Barcelona, Barcelona/ES, Malaga, ES, Salamanca, ES, Toledo, ES, 8 9 10 11 12 Cordoba, ES, Barcelona, ES, Sevilla, ES, Caceres, Cáceres/ES, Palma De Mallorca, ES, Washington, US
15:15 - 15:30 Invited Discussant 785O and LBA32 J. Mateo, Sutton, GB
14:00 - 15:30 Type: Proffered Paper session Pamplona Auditorium Title: Breast cancer, early stage Chair(s): N. Harbeck, DE; E. Senkus-Konefka, PL
14:00 - 14:12 LBA9 - Letrozole and palbociclib versus 3rd generation chemotherapy as neoadjuvant treatment of luminal breast cancer. Results of the UNICANCER-NeoPAL study 1 2 1 3 4 5 6 7 P. cottu , V. D'Hondt , S. Dureau , F. Lerebours , I. Desmoulins , P.-E. Heudel , F. Duhoux , C. Levy 8 9 10 11 12 13 , M.-A. Mouret-Reynier , F. Dalenc , J.-S. Frenel , C. Jouannaud , L. Venat-Bouvet , S. Nguyen , 14 15 16 1 1 17 1 J.-M. Ferrero , J.-L. Canon , J. Grenier , J. Lemonnier , A. Vincent-Salomon , S. Delaloge ; 2 3 4 5 6 7 Paris, FR, Montpellier, CEDEX 5/FR, Saint Cloud, FR, Dijon, Cedex/FR, Lyon, FR, Brussels, BE, 8 9 10 Caen, CEDEX 5/FR, Clermont-Ferrand, FR, Toulouse, CEDEX 3/FR, Saint-Herblain, CEDEX/FR, 11 12 13 14 15 Reims, CEDEX/FR, Limoges, FR, Beauvais, CEDEX/FR, Nice, CEDEX 2/FR, Charleroi, BE, 16 17 Avignon, CEDEX 2/FR, Villejuif, FR
14:12 - 14:24 LBA10_PR - Primary results of LORELEI: a phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+/HER2-negative early breast cancer (EBC) 1 2 3 1 2 3 C. Saura , E. de Azambuja , D. Hlauschek , M. Oliveira , D. Zardavas , A. Jallitsch-Halper , L. de la 4 1 5 6 7 8 9 10 Pena , P. Nuciforo , A. Ballestrero , M. Fornier , K. Boer , E. Ciruelos , V. Valero , T. Wilson , T. 10 10 10 2 3 6 1 2 3 Stout , J. Hsu , Y. Shi , M. Piccart , M. Gnant , J. Baselga ; Barcelona, ES, Brussels, BE, 4 5 6 7 8 9 Vienna, AT, Barcelona, Spain/ES, Genova, IT, New York, NY/US, Budapest, HU, Madrid, ES, 10 Houston, TX/US, South San Francisco, CA/US
14:24 - 14:36 148O - Phase III evaluating the addition of fulvestrant (F) to anastrozol (A) as adjuvant therapy in postmenopausal women with hormone receptor positive HER2 negative (HR+/HER2-) early breast cancer (EBC): Results from the GEICAM/2006-10 study 1 2 3 4 5 6 M. Ruíz-Borrego , M. Martin Jimenez , A. Ruiz , A. Lluch , M. Ramos , J. Cruz Jurado , J.M. 7 8 9 10 2 Baena-Canada , B. Cirauqui , A. Rodriguez-Lescure , E. Alba Conejo , N. Martínez Jañez , M. Muñoz 11 12 13 14 2 15 , S. Antolin , I. Álvarez López , S. Del Barco , L. Garcia-Estevez , J.I. Chacon Lopez-Muniz , A. 16 2 1 2 3 4 5 Anton Torres , E. Carrasco ; Sevilla, ES, Madrid, ES, Valencia, ES, Valencia, Valencia/ES, A 6 7 8 Coruña, ES, San Cristobal De La Laguna, Santa Cruz de Tenerife, Canary Islands/ES, Cadiz, ES, 9 10 11 12 13 14 Badalona, ES, Elche Alicante, ES, Malaga, ES, Barcelona, ES, Coruña, ES, Donostia, ES, 15 16 Girona, ES, Toledo, ES, Zaragoza, ES
Last update: 02-09-2017 06:01:33pm esmo.org
14:36 - 14:51 Invited Discussant LBA9, LBA10_PR and 148O S. Johnston, London, GB
14:51 - 15:03 149O - Neratinib after trastuzumab (T)-based adjuvant therapy in early-stage HER2+ breast cancer (BC): 5-year analysis of the phase III ExteNET trial 1 2 3 4 5 6 7 M. Martin Jimenez , F.A. Holmes , B. Ejlertsen , S. Delaloge , B. Moy , H. Iwata , G. von Minckwitz , 8 9 10 11 12 13 14 S. Chia , J. Mansi , C. Barrios , M. Gnant , Z. Tomasevic , N. Denduluri , R. Separovic , S.-B. 15 16 17 17 18 19 1 2 3 Kim , E. Jakobsen , R. Bryce , F. Xu , M. Buyse , A. Chan ; Madrid, ES, Houston, TX/US, 4 5 6 7 8 Copenhagen, DK, Villejuif, FR, Boston, MA/US, Chikusa-Ku, Nagoya, JP, Neu-Isenburg, DE, 9 10 11 12 13 Vancouver, BC/CA, London, GB, Porto Alegre, BR, Vienna, AT, Belgrade, RS, Arlington, 14 15 16 17 18 19 VA/US, Zagreb, HR, Seoul, KR, Vejle, DK, Los Angeles, CA/US, San Francisco, CA/US, Perth, AU
15:03 - 15:15 150O_PR - Not all small node negative (pT1abN0) breast cancers are similar: Outcome results from an EORTC 10041/BIG 3-04 (MINDACT) trial substudy 1 1 1 2 3 1 4 3 K. Tryfonidis , C. Poncet , L. Slaets , G. Viale , F. de Snoo , K. Aalders , L. Van'T Veer , E. Rutgers , 1 1 5 1 2 3 4 M. Piccart , J. Bogaerts , F. Cardoso ; Brussels, BE, Milan, IT, Amsterdam, NL, San Francisco, 5 US, Lisbon, PT
15:15 - 15:30 Invited Discussant 149O and 150O_PR H. Rugo, San Francisco, CA/US
14:00 - 15:30 Type: Educational session Cordoba Auditorium Title: Optimal therapy in localised rectal cancer Chair(s): A. Cervantes, ES; J. Taieb, FR
14:00 - 14:25 Imaging and re-imaging R. Beets-Tan, Maastricht, NL
14:25 - 14:50 What treatment should be skipped or intensified? B. Glimelius, Uppsala, SE
14:50 - 15:15 Adjuvant therapy A. Cervantes, Valencia, Valencia/ES
15:15 - 15:30 Discussion
Last update: 02-09-2017 06:01:33pm esmo.org 14:00 - 15:30 Type: Joint Symposium Granada Auditorium Title: ESMO-EACR: Preclinical models for developing combination therapeutics Chair(s): F. Ciardiello, IT; A. Berns, NL
14:00 - 14:05 Introduction F. Ciardiello, Naples, IT
14:05 - 14:25 Tumour organoids to test drug responses M. Garnett, Cambridge, GB
14:25 - 14:45 The Achilles heel of acquired drug resistance R. Bernards, Amsterdam, NL
14:45 - 15:05 Optimising drug combinations to overcome resistance R. Corcoran, Boston, MA/US
15:05 - 15:25 Accelerated clinical evaluation of drug combinations based on biological insight E. Garralda, Barcelona, ES
15:25 - 15:30 Conclusions A. Berns, Amsterdam, NL
14:00 - 15:30 Type: Joint Symposium Valencia Auditorium Title: ESMO-ESP: The evolution of pathological reporting - GI focus Chair(s): D. Arnold, PT; P. Bedossa, FR
14:00 - 14:05 Introduction P. Bedossa, Clichy, FR
14:05 - 14:25 The clinician’s perspective: What is expected from the pathologist? D. Arnold, Lisbon, PT
14:25 - 14:45 Pathologist: From descriptive to synoptic reports I. Nagtegaal, Nijmegen, NL
14:45 - 15:05 Molecular pathology in GI cancer: What is useful and how to integrate it into the pathological report T. Kirchner, Munich, DE
15:05 - 15:25 Immunology in GI cancer: What is useful and how to integrate it into the pathological report C. Badoual, Paris, FR
15:25 - 15:30 Conclusions D. Arnold, Lisbon, PT
Last update: 02-09-2017 06:01:33pm esmo.org 14:00 - 15:30 Type: Educational session Tarragona Auditorium Title: Standard of diagnosis and care in brain tumours Chair(s): P. Wen, US; E. Le Rhun, FR
14:00 - 14:25 The new WHO classification G. Reifenberger, Dusseldorf, DE
14:25 - 14:50 How do I use the Response Assessment in Neuro-Oncology (RANO) criteria? P. Wen, Boston, MA/US
14:50 - 15:15 How to manage complications of radiotherapy and chemotherapy? E. Le Rhun, Lille, CEDEX/FR
15:15 - 15:30 Discussion
14:00 - 15:30 Type: Joint Symposium Bilbao Title: ESMO-ESOP: The growing need for collaboration between clinicians and oncology Auditorium pharmacists Chair(s): S. Rauh, LU; K. Meier, DE
14:00 - 14:05 Introduction S. Rauh, Esch Sur Alzette, LU
14:05 - 14:25 Access to anti-cancer medicines: How Germany is tackling the issue B. Woermann, Berlin, DE
14:25 - 14:45 Contamination with cytotoxic drugs in the workplace - MASHA project E. Korczowska, Poznan, PL
14:45 - 15:05 Challenges in adherence to oral cancer therapies: The clinician’s perspective S. Rauh, Esch Sur Alzette, LU
15:05 - 15:25 Challenges in adherence to oral cancer therapies: The oncology pharmacist’s perspective K. Meier, Hamburg, DE
15:25 - 15:30 Conclusions K. Meier, Hamburg, DE
Last update: 02-09-2017 06:01:33pm esmo.org 14:00 - 15:30 Type: Joint Symposium Alicante Title: ESMO-WHO: Workforce optimisation: a WHO-ESMO study on health workforce Auditorium requirements, using the example of breast cancer care Chair(s): A. Eniu, RO; J. Campbell, CH
14:00 - 14:15 What works in workforce optimisation: The WHO perspective J. Campbell, Geneva, CH
14:15 - 14:30 Predicting the future: How many oncology professionals will your country need? M. Boniol, Lyon, CEDEX 8/FR
14:30 - 14:45 It’s about the people: Assessing the gaps and planning the workforce. The example of breast cancer care G. Curigliano, Milan, IT
14:45 - 15:00 Workforce strategies: Which ones work best? C. Rodriguez, Salamanca, ES
15:00 - 15:25 Participant discussion and Q&A J. Campbell, Geneva, CH
15:25 - 15:30 Conclusions A. Eniu, Cluj-Napoca, RO
14:00 - 15:30 Type: Special Session Cartagena Auditorium Title: Primary and secondary prevention of cancer: Where do we stand? Chair(s): A. Costa, CH; J.-Y. Douillard, CH
14:00 - 14:05 Introduction A. Costa, Bellinzona, CH
14:05 - 14:30 The concept and achievements of therapeutic prevention A. De Censi, Genova, IT
14:30 - 14:55 Aspirin for prevention and adjuvant treatment of cancer R. Langley, London, GB
14:55 - 15:20 Tobacco cessation and cancer incidence and recurrence E. Quoix, Chambéry, CEDEX/FR
15:20 - 15:30 Conclusions J.-Y. Douillard, Lugano - Viganello, CEDEX/CH
Last update: 02-09-2017 06:01:33pm esmo.org 14:00 - 15:30 Type: Educational session Madrid Auditorium Title: Immunotherapy: The next steps Chair(s): J. Larkin, GB; P. Nathan, GB
14:00 - 14:25 Combination of drugs acting on the immune system S. Topalian, Baltimore, Md, US
14:25 - 14:50 How to sequence immunotherapy J. Larkin, London, GB
14:50 - 15:15 When to discontinue immunotherapy C. Robert, Villejuif, FR
15:15 - 15:30 Discussion
14:00 - 14:30 Type: Patient Advocacy Track Palma Auditorium Title: Welcome
14:00 - 14:10 Welcome by ESMO P.G. Casali, Milan, IT
14:10 - 14:20 Welcome by the ESMO PAWG Chair B. Ryll, SE
14:20 - 14:30 Welcome by EACR R. Marais, Manchester, GB
Last update: 02-09-2017 06:01:33pm esmo.org 14:45 - 15:45 Type: Patient Advocacy Track Palma Auditorium Title: Science by patients for patients Chair(s): B. Ryll, SE; C. Roffiaen, IT
14:45 - 14:50 Introduction B. Ryll, SE
14:50 - 15:05 Science and advocacy: Why care about science? How to involve patients in research J. Geissler, DE
15:05 - 15:20 How to run clinical trials that matters to patients E. Low, London, GB
15:20 - 15:35 The citizen scientist: Statistics for citizen D. Dahly, Cork, IE
15:35 - 15:45 Discussion
16:00 - 17:30 Type: Educational session Sevilla Auditorium Title: What is new in germ cell tumours Chair(s): A. López-Beltran, PT; A. Bamias, GR
16:00 - 16:25 What is new in the biology of germ cell tumours A. López-Beltran, Lisbon, PT
16:25 - 16:50 Refining prognosis assessment in germ cell tumours J. Oldenburg, Eiksmarka, NO
16:50 - 17:15 The role of high dose chemotherapy in refractory resistant germ cell tumours J. Beyer, Zurich, CH
17:15 - 17:30 Discussion
Last update: 02-09-2017 06:01:33pm esmo.org 16:00 - 17:30 Type: Educational session Pamplona Auditorium Title: Genome instability, its relevance to cancer and therapeutic potential Chair(s): S. Nik-Zainal, GB; J. Bartek, DK
16:00 - 16:25 What is DNA replication stress and what is its relevance to cancer? J. Bartek, Copenhagen, DK
16:25 - 16:50 Aneuploidy and cancer T. Watkins, London, GB
16:50 - 17:15 Kateagis and Apobec- relevance to cancer S. Nik-Zainal, Cambridge, GB
17:15 - 17:30 Discussion
16:00 - 17:30 Type: Proffered Paper session Cordoba Auditorium Title: Gynaecological cancers Chair(s): D. Lorusso, IT; S. Pignata, IT
16:00 - 16:12 929O_PR - ICON8: A GCIG Phase III randomised trial evaluating weekly dose- dense chemotherapy integration in first-line Epithelial Ovarian/ Fallopian Tube/ Primary Peritoneal Carcinoma (EOC) treatment: Results of Primary Progression- Free Survival (PFS) analysis 1 2 3 4 5 6 7 8 A. Clamp , I. McNeish , A. Dean , D. Gallardo , J. Weon- Kim , D. O'Donnell , J. Hook , C. Coyle , S. 9 10 11 7 12 8 8 13 Blagden , J. Brenton , R. Naik , T. Perren , S. Sundar , A. Cook , E. James , A.M. Swart , S. 8 14 8 1 2 3 4 Stenning , R. Kaplan , J. Ledermann ; Manchester, GB, Glasgow, GB, Subiaco, AU, Mexico, MX, 5 6 7 8 9 10 11 Seoul, KR, Dublin, IE, Leeds, Yorkshire/GB, London, GB, Oxford, GB, Cambridge, GB, 12 13 14 Gateshead, GB, Birmingham, GB, No City Provided, NA, Leeds, GB
16:12 - 16:24 LBA40_PR - ARIEL3: A Phase 3, Randomised, Double-Blind Study of Rucaparib vs Placebo Following Response to Platinum-Based Chemotherapy for Recurrent Ovarian Carcinoma (OC) 1 2 3 4 5 6 3 J. Ledermann , A. Oza , D. Lorusso , C. Aghajanian , A. Oaknin , A. Dean , N. Colombo , J. 7 8 9 10 11 12 13 Weberpals , A. Clamp , G. Scambia , A. Leary , R. Holloway , D. O'Malley , T. Cameron , L. 14 15 15 16 17 18 1 2 Maloney , S. Goble , K. Lin , J. Sun , H. Giordano , R. Coleman ; London, GB, Toronto, 3 4 5 6 7 8 Ontario/CA, Milan, IT, New York, NY/US, Barcelona, ES, Subiaco, AU, Ottawa, Ontario/CA, 9 10 11 12 13 Manchester, GB, Roma, IT, Villejuif, FR, Orlando, FL/US, Columbus, OH/US, Cambridge, GB, 14 15 16 17 18 Boulder, Colorado/US, Boulder, CO/US, Cambridge, MA/US, San Francisco, California/US, Houston, TX/US
16:24 - 16:36 930O - Quality of life in patients with recurrent ovarian cancer (OC) treated with niraparib: Results from the ENGOT-OV16/NOVA Trial
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 3 4 5 6 7 A. Oza , U. Matulonis , S. Malander , J. Sehouli , J. del Campo , D. Berthon-Rigaud , S. Banerjee , G. 8 9 10 11 12 13 6 Scambia , J. Berek , B. Lund , A. Tinker , F. Hilpert , I. Palacio Vázquez , V. D’hondt , B. 14 15 16 16 17 18 1 Benigno , D. Provencher , J. Buscema , S. Hudgens , S. Agarwal , M.R. Mirza ; Toronto,
2 3 4 5 6 7 Ontario/CA, Boston, MA/US, Lund, SE, Berlin, DE, Barcelona, ES, Montpellier, FR, London, GB, 8 9 10 11 12 13 14 Roma, IT, Palo Alto, CA/US, Aalborg, DK, Vancouver, BC/CA, Hamburg, DE, Oviedo, ES, 15 16 17 18 Atlanta, GA/US, Montreal, CA, Tuscon, AZ/US, Waltham, MA/US, Copenhagen, DK
16:36 - 16:51 Invited Discussant 929O, 930O and LBA40 S. Pignata, Napoli, IT
16:51 - 17:03 LBA41 - A Double-blind, placebo-controlled, randomized, phase 2 study to evaluate the efficacy and safety of switch maintenance therapy with the anti-TA-MUC1 antibody PankoMab-GEX after chemotherapy in patients with recurrent epithelial ovarian carcinoma 1 2 3 4 5 1 6 J. Ledermann , J. Sehouli , B. Zurawski , F. Raspagliesi , U. De Giorgi , S. Banerjee , J. Arranz Arija , 7 8 9 10 11 12 M. Romeo Marin , A. Lisyanskaya , R.L. Póka , S. Mihutiu , J. Markowska , C. Cebotaru , A. 6 4 13 14 15 16 2 1 Casado Herraez , N. Colombo , N. Kovalenko , E. Kutarska , M. Hall , R. Belli , A. Zurlo ;
2 3 4 5 6 7 London, GB, Berlin, DE, Bydgoszcz, PL, Milan, IT, Meldola, Forlì-Cesena/IT, Madrid, ES, 8 9 10 11 12 Badalona, Barcelona/ES, St.-Petersburg, RU, Debrecen, HU, Oradea, RO, Poznan, PL, 13 14 15 16 Cluj-Napoca, RO, Volzhskiy, RU, Lublin, PL, Middlesex, GB, Royston, GB
17:03 - 17:15 931O - A phase IIa study of tisotumab vedotin (HuMax®-TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer 1 2 3 4 5 6 7 4 I. Vergote , E. Dean , U. Lassen , J. de Bono , Y. Drew , J.-P. Machiels , D. Nielsen , H.-T. Arkenau , 8 9 10 4 11 12 13 M. Forster , R. Jones , B. Slomovitz , J. Spicer , M. Johnson , N. Cornez , C. Gennigens , B. 14 3 3 15 16 1 2 3 Fulton , S. Lisby , L. Basse , R. Coleman , D. Hong ; Leuven, BE, Manchester, GB,
4 5 6 7 8 Copenhagen, DK, London, GB, Newcastle Upon Tyne, GB, Brussels, BE, Herlev, DK, London, 9 10 11 12 13 14 London/GB, Cardiff, GB, Miami, US, Nashville, TN/US, Mons, BE, Liège, BE, Glasgow, GB, 15 16 Houston, TX/US, Houston, US
17:15 - 17:30 Invited Discussant LBA41 and 931O M.R. Mirza, Copenhagen, DK
Last update: 02-09-2017 06:01:33pm esmo.org 16:00 - 17:30 Type: Joint Symposium Granada Auditorium Title: ESMO-KACO: Molecular targets in breast cancer Chair(s): C. Zielinski, AT; Y.-H. Im, KR
16:00 - 16:05 Introduction Y.-H. Im, Seoul, KR
16:05 - 16:25 Molecular targets in overcoming treatment resistance C. Zielinski, Vienna, AT
16:25 - 16:45 Optimising treatment for luminal breast cancer: Luminal A vs. Luminal B S.-B. Kim, Seoul, KR
16:45 - 17:05 Developing strategies for overcoming drug resistance in HER2–positive breast cancer S.-A. Im, Seoul, KR
17:05 - 17:25 Molecular divergence in an ‘entity’?: Triple-negative breast cancer F. André, Villejuif, CEDEX/FR
17:25 - 17:30 Conclusions C. Zielinski, Vienna, AT
16:00 - 17:30 Type: Joint Symposium Valencia Auditorium Title: ESMO-ASCO: Evidence from single-arm trials Chair(s): F. Ciardiello, IT; B. Johnson, US
16:00 - 16:05 Introduction F. Ciardiello, Naples, IT
16:05 - 16:25 The settings and the challenges of single-arm trials P.G. Casali, Milan, IT
16:25 - 16:45 Evidence from single-arm trials that lead to regulatory approval B. Johnson, Boston, NJ/US
16:45 - 17:05 Early clinical data for new drug approval in Europe: Help or hindrance? F. Pignatti, London, GB
17:05 - 17:25 Generating evidence outside the traditional randomized controlled trial G. Blumenthal, Silver Spring, US
17:25 - 17:30 Conclusions B. Johnson, Boston, NJ/US
Last update: 02-09-2017 06:01:33pm esmo.org 16:00 - 17:30 Type: Joint Symposium Tarragona Title: ESMO-JSMO: Combinations with immuno-oncology agents for gastrointestinal Auditorium cancer: Which ones make the best partners? Chair(s): J. Tabernero, ES; H. Minami, JP
16:00 - 16:05 Introduction J. Tabernero, Barcelona, ES
16:05 - 16:25 Combinations with immune-oncology agents for GI cancers: Their scientific rationales K. Shitara, Kashiwa, Chiba/JP
16:25 - 16:45 Combinations of checkpoint inhibitors and immunostimulation for immune-ignorant tumours I. Melero, Pamplona, ES
16:45 - 17:05 Combinations with immune-oncology agents for upper GI cancers: Update of clinical trial results K. Muro, Nagoya, Aichi/JP
17:05 - 17:25 Combinations with immune-oncology agents for colorectal cancer: Current status of clinical development J. Tabernero, Barcelona, ES
17:25 - 17:30 Conclusions H. Minami, Kobe, Hyogo/JP
16:00 - 17:30 Type: Joint Symposium Bilbao Auditorium Title: ESMO-EONS: Promoting patient safety at clinical and organisational levels Chair(s): G. Pentheroudakis, GR; D. Kelly, GB
16:00 - 16:05 Introduction G. Pentheroudakis, Ioannina, GR
16:05 - 16:25 Patient safety at the clinical and organisational level D. Kelly, Cardiff, GB
16:25 - 16:45 Promoting safety for cancer patients: The ESMO EONS Guidelines for the management of extravasation J.A. Perez Fidalgo, Valencia, Valencia/ES
16:45 - 17:05 Ethical and financial dimensions of patient safety S. Rauh, Esch Sur Alzette, LU
17:05 - 17:25 Evidence of the impact of nursing interventions on patients with cancer: Results from a systematic review M. Wells, Stirling, GB
17:25 - 17:30 Conclusions D. Kelly, Cardiff, GB
Last update: 02-09-2017 06:01:33pm esmo.org 16:00 - 17:30 Type: Proffered Paper session Alicante Auditorium Title: CNS tumours Chair(s): M. Weller, CH; M. van den Bent, NL
16:00 - 16:12 325O - Nivolumab (nivo) in combination with radiotherapy (RT) ± temozolomide (TMZ): Updated safety results from CheckMate 143 in pts with methylated or unmethylated newly diagnosed glioblastoma (GBM) 1 2 3 4 5 6 7 M. Lim , A. Omuro , G. Vlahovic , D. Reardon , S. Sahebjam , T. Cloughesy , J. Baehring , N. 8 9 9 9 9 10 11 1 Butowski , V. Potter , R. Zwirtes , P. Paliwal , M. Carleton , J. Sampson , A. Brandes ; Baltimore,
2 3 4 5 6 7 US, Miami, US, Durham, US, Boston, MA/US, Tampa, FL/US, Los Angeles, US, New Haven, 8 9 10 11 CT/US, San Francisco, US, Princeton, US, Durham, NC/US, Bologna, IT
16:12 - 16:24 326O - The association of programmed death-ligand 1 (PD-L1), programmed cell death (PD-1), tumor infiltrating lymphocytes(TILs) and isocitrate dehydrogenase (IDH-1) mutation in glioblastome multiforme(GBM) D. sener dede, H. Tatli Dogan, F. Asan, B. Gumuskaya Ocal, S. Ayik, M. Sendur, A. Ulas, B. Bilgin, M.
Hizal, M. Akinci, K. Silay, B. Yalçın; Ankara, TR
16:24 - 16:39 Invited Discussant 325O and 326O M. van den Bent, Rotterdam, NL
16:39 - 16:51 LBA16 - REGOMA: a randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib activity in relapsed glioblastoma patients 1 2 3 4 5 6 7 8 G. Lombardi , G.L. De Salvo , A. Brandes , M. Eoli , R. Rudà , M. Faedi , I. Lolli , A. Pace , S. 9 10 11 2 2 2 2 Rizzato , D. Germano , F. Pasqualetti , M. Farina , G. Magni , A. Pambuku , E. Bergo , G. Cabrini 12 2 2 2 1 2 3 4 5 , S. Indraccolo , M. Gardiman , V. Zagonel ; Padua, IT, Padova, IT, Bologna, IT, Milano, IT, 6 7 8 9 10 11 12 Torino, IT, Cesena, IT, Castellana Grotte, IT, Roma, IT, Udine, IT, Benevento, IT, Pisa, IT, Verona, IT
16:51 - 17:03 327O - Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized clinical trials in glioblastoma 1 2 3 4 5 2 3 2 M. van den Bent , L. Roberts-Rapp , P. Ansell , J. Lee , J. Looman , E. Bain , C. Ocampo , K. Holen 2 6 1 2 3 4 , E. Gomez , A. Lassman ; Rotterdam, NL, North Chicago, IL/US, North Chicago, US, Des Plaines, 5 6 IL/US, Amsterdam, NL, New York, NY/US
17:03 - 17:15 328O - Low grade glioma patients with IDH mutation and 1p19q codeletion: What to do after surgery? 1 1 1 1 1 1 1 E. Franceschi , A. Mura , A. Mandrioli , S. Minichillo , A. Tosoni , A. Pession , D. De Biase , D. 2 3 1 2 1 1 1 1 1 Danieli , S. Pizzolitto , A. Fioravanti , L. Volpin , R. Agati , S. Bartolini , A. Paccapelo , A. Brandes ; 2 3 Bologna, IT, Vicenza, IT, Udine, IT
17:15 - 17:30 Invited Discussant LBA16, 327O and 328O J. Sepulveda Sanchez, Madrid, ES
Last update: 02-09-2017 06:01:33pm esmo.org 16:00 - 17:30 Type: Special Symposium Cartagena Auditorium Title: Cancer stem cell properties Chair(s): A. Trumpp, DE; A. Berns, NL
16:00 - 16:05 Introduction A. Trumpp, Heidelberg, DE
16:05 - 16:25 Stem cell re-programming in cancer tissues A. Behrens, London, GB
16:25 - 16:45 Clonal tracking of stem cells L. Shlush, Rehovot, IL
16:45 - 17:05 Stem and progenitor cells in epithelial cancer R. Toftgård, Tockholm, SE
17:05 - 17:25 Normal and malignant stem cells A. Trumpp, Heidelberg, DE
17:25 - 17:30 Conclusions and clinical perspectives A. Berns, Amsterdam, NL
16:00 - 17:30 Type: Proffered Paper session Madrid Auditorium Title: NSCLC, metastatic 1 Chair(s): R. Dziadziuszko, PL; S. Peters, CH
16:00 - 16:12 1295O - Blood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in 2L+ NSCLC (POPLAR and OAK) 1 2 3 4 5 6 6 D. Gandara , M. Kowanetz , T.S.K. Mok , A. Rittmeyer , L. Fehrenbacher , D. Fabrizio , G. Otto , C. 6 6 2 2 2 2 2 2 Malboeuf , D. Lieber , S. Paul , L. Amler , T. Riehl , E. Schleifman , C. Cummings , P. Hegde , W.
2 2 2 2 1 2 3 Zou , A. Sandler , M. Ballinger , D. Shames ; Sacramento, CA/US, South San Francisco, US, 4 5 6 Shatin, HK, Immenhausen, DE, Vallejo, US, Cambridge, US
16:12 - 16:24 1296O - Clinical efficacy of atezolizumab (Atezo) in PD-L1 subgroups defined by SP142 and 22C3 IHC assays in 2L+ NSCLC: Results from the randomized OAK study 1 2 2 3 4 5 6 7 S. Gadgeel , M. Kowanetz , W. Zou , F. Hirsch , K. Kerr , D. Gandara , F. Barlesi , K. Park , M. 2 2 2 2 2 8 1 2 McCleland , H. Koeppen , M. Ballinger , A. Sandler , P. Hegde , A. Rittmeyer ; Ann Arbor, US,
3 4 5 6 7 South San Francisco, US, Aurora, US, Aberdeen, GB, Sacramento, CA/US, Marseille, FR, Seoul, 8 KR, Immenhausen, DE
16:24 - 16:39 Invited Discussant 1295O and 1296O J. Jassem, Gdańsk, PL
16:39 - 16:51 1297O - Randomized results of fixed-duration (1-yr) vs continuous nivolumab in patients (pts) with advanced non-small cell lung cancer (NSCLC)
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 3 4 5 6 7 8 D. Spigel , M. McLeod , M. Hussein , D. Waterhouse , L. Einhorn , L. Horn , B. Creelan , S. Babu , 9 10 11 12 13 14 15 N. Leighl , F. Couture , J. Chandler , G. Goss , G. Keogh , E. Garon , K. Blankstein , D. 16 17 18 18 19 1 2 3 Daniel , M. Mohamed , A. Li , N. Aanur , R. Jotte ; Nashville, TN/US, Cape Coral, US, Lady
4 5 6 7 8 9 Lake, US, Cincinnati, US, Indianapolis, US, Nashville, US, Tampa, US, Fort Wayne, US, Toronto, 10 11 12 13 14 15 CA, Quebec, CA, Southaven, US, Ottawa, CA, Charleston, US, Santa Monica, US, 16 17 18 19 Flemington, US, Chattanooga, US, Greensboro, US, Princeton, US, Denver, US
16:51 - 17:03 LBA48 - ABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC) 1 2 3 4 5 6 7 D. Morgensztern , T.J. Ong , M. Cobo Dols , S. Ponce Aix , P. Postmus , C. Lewanski , J. Bennouna 8 9 10 11 12 2 13 , J. Fischer , O.J. Vidal , D. Stewart , G. Fasola , A. Ardizoni , J. Weaver , M. Wolfsteiner , D. 14 15 1 2 3 4 5 Talbot , R. Govindan ; St Louis, US, Summit, NJ/US, Malaga, ES, Madrid, ES, Wirral, 6 7 8 9 Merseyside/GB, London, GB, Nantes, CEDEX/FR, Löwenstein, Baden-Württemberg, DE, Valencia, 10 11 12 13 14 15 ES, Ottawa, ON/CA, Udine, IT, Bologna, IT, Lenexa, KS/US, Oxford, Oxfordshire/GB, St. Louis, MO/US
17:03 - 17:15 LBA49 - Updated results from KEYNOTE-021 cohort G: a randomized, phase 2 study of pemetrexed and carboplatin (PC) with or without pembrolizumab (pembro) as first-line therapy for advanced nonsquamous NSCLC 1 2 3 4 5 6 7 H. Borghaei , C. Langer , S. Gadgeel , V. Papadimitrakopoulou , A. Patnaik , S. Powell , R. Gentzler , 8 9 10 11 12 13 14 R. Martins , J. Stevenson , S. Jalal , A. Panwalkar , J.C.-H. Yang , M. Gubens , L. Sequist , M. 15 16 16 16 17 1 2 Awad , J. Fiore , S. Saraf , H. Raftopoulos , L. Gandhi ; Philadelphia, US, Philadelphia,
3 4 5 6 7 PA/US, Detroit, US, Houston, US, San Antonio, TX/US, Sioux Falls, SD/US, Charlottesville, 8 9 10 11 12 13 VA/US, Seattle, US, Cleveland, OH/US, Indianapolis, IN/US, Fargo, ND/US, Taipei, TW, San 14 15 16 17 Francisco, CA/US, Boston, MA/US, Boston, US, Kenilworth, NJ/US, New York, NY/US
17:15 - 17:30 Invited Discussant LBA48, LBA49 and 1297O M. Reck, Grosshansdorf, DE
Last update: 02-09-2017 06:01:33pm esmo.org 16:15 - 17:15 Type: Patient Advocacy Track Palma Auditorium Title: Health services research in cancer Chair(s): K. Apostolidis, GR; G. Mountzios, GR
16:15 - 16:30 Health services research in Europe and its use for informing cancer policy T. Albreht, Ljubljana, SI
16:30 - 16:45 Cancer patient experience from referral to hospital performance G. Lyratzopoulos, London, GB
16:45 - 16:55 What cancer patients want K. Benn, Milan, IT
16:55 - 17:05 The importance of healthcare systems research for improving health in CEE V. Voiculescu, RO
17:05 - 17:10 Discussion
17:30 - 19:00 Type: Patient Advocacy Track Palma Auditorium Title: Debate: Working with industry: Inherent conflicts of interest? Chair(s): J. Geissler, DE; D. Haerry, CH
17:30 - 17:37 Introduction on the opportunities and controversies of the collaboration J. Geissler, DE
17:37 - 17:44 A medical society’s perspective on disclosure and conflict of interest P.G. Casali, Milan, IT
17:44 - 17:51 Does industry collaboration with clinicians and patient advocates compromise their objectivity? N. Moll, Brussels, BE
17:51 - 17:58 The impartial patient voice when advising regulators and industry D. Haerry, Bern, CH
17:58 - 18:05 A regulatory perspective on disclosure of interests of clinicians, patient experts and their organisations J. Garcia Burgos, London, GB
18:05 - 18:12 The media perspective on disclosure and conflict of interests A. Wagstaff, Oxford, OXON/GB
18:12 - 19:00 Moderated panel discussion
Last update: 02-09-2017 06:01:33pm esmo.org 18:00 - 20:00 Type: Industry Satellite Symposium Barcelona Auditorium Title: Industry Satellite Symposium 1
18:00 - 20:00 Type: Industry Satellite Symposium Sevilla Auditorium Title: Industry Satellite Symposium 2
18:00 - 20:00 Type: Industry Satellite Symposium Pamplona Auditorium Title: Industry Satellite Symposium 3
18:00 - 20:00 Type: Industry Satellite Symposium Cordoba Auditorium Title: Industry Satellite Symposium 4
18:00 - 20:00 Type: Industry Satellite Symposium Granada Auditorium Title: Industry Satellite Symposium 5
18:00 - 20:00 Type: Industry Satellite Symposium Valencia Auditorium Title: Industry Satellite Symposium 6
18:00 - 20:00 Type: Industry Satellite Symposium Tarragona Auditorium Title: Industry Satellite Symposium 7
18:00 - 20:00 Type: Industry Satellite Symposium Bilbao Auditorium Title: Industry Satellite Symposium 8
18:00 - 20:00 Type: Industry Satellite Symposium Alicante Auditorium Title: Industry Satellite Symposium 9
18:00 - 20:00 Type: Industry Satellite Symposium Cartagena Auditorium Title: Industry Satellite Symposium 10
18:00 - 20:00 Type: Industry Satellite Symposium Salamanca Auditorium Title: Industry Satellite Symposium 11
18:00 - 20:00 Type: Industry Satellite Symposium Jerez Auditorium Title: Industry Satellite Symposium 12
09-09-2017
Last update: 02-09-2017 06:01:33pm esmo.org 08:00 - 09:00 Type: Controversy session Granada Auditorium Title: Is trastuzumab single agent obsolete in early breast cancer Chair(s): F. Cardoso, PT
08:00 - 08:10 Introduction and 1st vote F. Cardoso, Lisbon, PT
08:10 - 08:30 Yes H. Bonnefoi, Bordeaux, CEDEX/FR
08:30 - 08:50 No G. Bianchini, Milano, IT
08:50 - 09:00 2nd vote and conclusions F. Cardoso, Lisbon, PT
08:00 - 09:00 Type: Challenge Your Expert (CYE) session Bilbao Auditorium Title: Germline aberrations and prostate cancer Chair(s): R. Eeles, GB
08:00 - 08:10 Germline aberrations and prostate cancer E. Castro Marcos, Madrid, ES
08:10 - 09:00 Discussion led by Chair R. Eeles, London, GB
08:00 - 09:00 Type: Challenge Your Expert (CYE) session Alicante Auditorium Title: Multimodality therapy of early stage mesothelioma Chair(s): P. Van Schil, BE
08:00 - 08:10 Multimodality therapy of early stage mesothelioma P. Baas, Amsterdam, NL
08:10 - 09:00 Discussion led by Chair P. Van Schil, Edegem, BE
Last update: 02-09-2017 06:01:33pm esmo.org 08:00 - 09:00 Type: Challenge Your Expert (CYE) session Cartagena Auditorium Title: Practical management of toxicities of immunotherapy in cancer patients Chair(s): P. Ascierto, IT
08:00 - 08:10 Practical management of toxicities of immunotherapy in cancer patients B. Besse, Villejuif, FR
08:10 - 09:00 Discussion P. Ascierto, Napoli, IT
08:00 - 09:00 Type: Challenge Your Expert (CYE) session Salamanca Auditorium Title: Progress in pancreatic cancer Chair(s): A. Berns, NL
08:00 - 08:10 Progress in pancreatic cancer D. Tuveson, New York, NY/US
08:10 - 09:00 Discussion led by Chair A. Berns, Amsterdam, NL
08:00 - 09:00 Type: Challenge Your Expert (CYE) session Palma Auditorium Title: How to use molecular biology in neuro-oncology Chair(s): M. Weller, CH
08:00 - 08:10 How to use molecular biology in neuro-oncology M. van den Bent, Rotterdam, NL
08:10 - 09:00 Discussion led by Chair M. Weller, Zürich, CH
08:15 - 09:00 Type: Keynote Lecture Barcelona Auditorium Title: Clinical implications of tumour evolution Chair(s): A. Bardelli, IT
08:15 - 09:00 Clinical implications of tumour evolution C. Swanton, London, GB
09:00 - 10:45 Type: Proffered Paper and Poster Discussion session Pamplona Auditorium Title: Translational research Chair(s): J. Seoane, ES; R. Marais, GB
09:00 - 09:12 LBA59_PR - Expanding the use of approved drugs: The CPCT’s Drug Rediscovery Protocol (DRUP)
Last update: 02-09-2017 06:01:33pm esmo.org 1 1 1 2 3 1 D. van der Velden , L. Hoes , H. van der Wijngaart , H. Bloemendal , K. Grunberg , A. Huitema , E. 4 5 3 6 4 1 5 1 Lugtenburg , F. De Vos , C. Herpen , D.J. de Groot , P. Hamberg , E. Smit , E. Cuppen , N. Steeghs
4 1 7 1 1 2 3 , S. Sleijfer , H. Verheul , H. Gelderblom , E. Voest ; Amsterdam, NL, Amersfoort, NL, Nijmegen, 4 5 6 7 NL, Rotterdam, NL, Utrecht, NL, Groningen, NL, Leiden, NL
09:12 - 09:24 1628O - Development of the Manchester Cancer Research Centre Molecular Tumour Board for matching patients to clinical trials based on tumour and ctDNA genetic profiling A. Gupta, M. Ayub, C. Miller, D. Rothwell, A. Wallace, A. Jordan, N. Cook, F. Thistlethwaite, L. Carter, C. O’brien, S. Aruketty, E. Dean, A. Hudson, K. Frese, J. Dransfield, A. Hughes, R. Marais, C. Dive, G. Brady, M. Krebs; Manchester, GB
09:24 - 09:36 1629O - A systematic rapid autopsy program tracks temporal and spatial heterogeneity of human tumors and identifies mechanisms of resistance to targeted therapies 1 2 3 2 2 2 2 2 C. Walmsley , D. Juric , A. Bardia , L. Henderson , J. Gurski , J. Stone , C. Pinto , S. Isakoff , D.
2 2 2 2 1 2 3 Fitzgerald , J. Gainor , L. Goyal , M. Broudo ; Boston, US, Boston, Ma, US, Boston, MA/US
09:36 - 09:51 Invited Discussant LBA59, 1628O and 1629O J. Seoane, Barcelona, ES
09:51 - 09:51 84PD - Relationship of PD-L1 and a T-cell inflamed gene expression profile (GEP) to clinical response in a multicohort trial of solid tumors (KEYNOTE [KN]028) 1 2 3 4 5 6 7 8 P. Ott , Y.-J. Bang , A. Razak , J. Bennouna , J.-C. Soria , H. Rugo , R. Cohen , B. O'Neil , J. 9 10 11 12 13 14 13 Mehnert , J. Lopez , T. Doi , E. van Brummelen , D. Levitan , G. Zhao , K. Emancipator , K. 13 13 13 13 15 1 2 3 Stein , A. Joe , M. Ayers , J. Lunceford , S. Piha-Paul ; Boston, MA/US, Seoul, KR, Toronto,
4 5 6 7 8 CA, Nantes, CEDEX/FR, Villejuif, FR, San Francisco, CA/US, Philadelphia, PA/US, Indianapolis, 9 10 11 12 13 IN/US, New Brunswick, US, Sutton, Surrey/GB, Kashiwa, Chiba/JP, Amsterdam, NL, 14 15 Kenilworth, NJ/US, Beijing, CN, Houston, TX/US
09:51 - 09:51 1630PD - Association of programmed cell death 1 ligand (PD-L1) expression with molecular alterations in non-small cell lung cancer (NSCLC) patients (pts): Results from the European Thoracic Oncology Platform (ETOP) Lungscape cohort 1 2 3 4 5 6 7 K. Kerr , E. Thunnissen , U. Dafni , A. Soltermann , S. Finn , L. Bubendorf , E. Verbeken , W. Biernat 8 9 10 11 12 13 2 14 , A. Warth , A. Marchetti , E.-J. Speel , S. Pokharel , A.M. Quinn , K. Monkhorst , A. Navarro , 15 16 17 18 16 1 V. Polydoropoulou , R. Kammler , S. Peters , R.A. Stahel , O. Lungscape Consortium ;
2 3 4 5 6 7 Aberdeen, GB, Amsterdam, NL, Athens, Attica/GR, Zürich, CH, Dublin, IE, Basel, CH, Leuven, 8 9 10 11 12 13 BE, Gdansk, PL, Heidelberg, DE, Chieti, IT, Maastricht, NL, Buffalo, US, Wythenshawe, GB, 14 15 16 17 18 Valencia, ES, Athens, GR, Bern, CH, Lausanne, CH, Zurich, CH
09:51 - 09:51 1631PD - Prominent immune suppressive tumor microenvironment in female never-smoker lung cancer patients with EGFR mutations B. Park, D.-E. Ryu, H.K. Kim, J.H. Cho, J. Lee, J. Lee, H.-O. Lee, J.-G. Joung, W.-Y. Park, J. Kim; Seoul,
KR
09:51 - 09:51 1632PD - A novel radiomic based imaging tool to monitor tumor lymphocyte infiltration and outcome of patients treated by anti-PD-1/PD-L1
Last update: 02-09-2017 06:01:33pm esmo.org 1 1 1 2 1 1 3 1 R. Sun , E.J. Limkin , L. Dercle , S. Champiat , S. Reuzé , D. Brandao , L. Verlingue , S. Ammari , S. 1 3 1 1 1 1 Aspeslagh , A. Schernberg , S. Postel-Vinay , A. Hollebecque , C. Massard , A. Marabelle , C. Robert 1 1 2 1 1 2 3 , J.-C. Soria , E. Deutsch , C. Ferté ; Villejuif, FR, Villejuif, CEDEX/FR, Paris, FR
09:51 - 10:06 Invited Discussant 84PD, 1630PD, 1631Pd and 1632PD S. Singh, Hamilton, CA
10:06 - 10:16 Questions to discussant
10:16 - 10:16 85PD - Ultrasensitive detection of EGFR T790M mutation by droplet digital PCR (ddPCR) in TKI naïve non-small cell lung cancer (NSCLC) harboring EGFR mutation: Results of the nationwide program Biomarkers France of the French Cooperative Thoracic Intergroup (IFCT) 1 2 3 4 5 6 7 C. Leduc , E. Pencreach , J.-P. Merlio , P.-P. Bringuier , F. de Fraipont , F. Escande , A. Lemoine , 8 9 10 11 9 12 9 9 O. L'Houcine , H. Blons , M. Denis , P. Hofman , R. Lacave , S. Melaabi , A. Langlais , P. missy , 9 8 5 9 2 1 2 F. Morin , F. Barlesi , D. Moro-Sibilot , J. Cadranel , M. Beau-Faller ; Strasbourg, CEDEX/FR, 3 4 5 6 7 8 9 Strasbourg, FR, Pessac, FR, Lyon, FR, La Tronche, FR, Lille, FR, Villejuif, FR, Marseille, FR, 10 11 12 Paris, FR, Nantes, CEDEX 1/FR, Nice, FR, France, FR
10:16 - 10:16 86PD - Biomarker prevalence study and phase I trial of afatinib in children with malignant tumours 1 2 3 4 5 6 7 K. Nysom , P. Leblond , D. Frappaz , I. Aerts , P. Varlet , F. Giangaspero , M. Gambart , D. Hargrave 8 9 10 11 12 13 14 15 , L. Marshall , P. Kearns , G. Makin , S. Gallego , M. Kieran , M. Casanova , A. Lahogue , S. 16 16 17 18 19 1 2 Wind , B. Stolze , D. Roy , M. Uttenreuther-Fischer , B. Geoerger ; Copenhagen, DK, No City 3 4 5 6 7 8 9 Provided, NA, Lyon, FR, Paris Cédex, FR, Paris, FR, Roma, IT, Toulouse, FR, London, GB, 10 11 12 13 14 15 Sutton, GB, Birmingham, GB, Manchester, GB, Barcelona, ES, Boston, US, Milano, IT, 16 17 18 19 Woluwe-Saint-lambert, BE, Biberach, DE, Ridgefield, CT/US, Ingelheim Am Rhein, DE, Villejuif, FR
10:16 - 10:16 87PD - Prospective study assessing the expression of angiogenesis-related genes as markers of anti-VEGFR2 response in advanced renal cell carcinoma 1 2 1 1 1 1 J. Garcia-Donas , N. Lainez , M. Santos-Romero , J. Puente , D. Castellano , J.F. Rodriguez-Moreno 3 1 4 5 6 , E. Esteban , E. Grande Pulido , E.M. Fernandez Parra , L. Rodriguez Lajusticia , M. Domenech , E. 7 8 9 10 1 Gonzalez Billalabeitia , M.I. Sáez , E. Gallardo Diaz , S. Hernando Polo , A. Herrador , L. 1 1 1 1 2 3 4 Inglada-Pérez , M. Robledo , C. Rodriguez-Antona ; Madrid, ES, Pamplona, ES, Oviedo, ES, 5 6 7 8 9 10 Sevilla, ES, Fuenlabrada, ES, Manresa, ES, Murcia, ES, Malaga, ES, Sabadell, ES, Alcorcon, Madrid/ES
10:16 - 10:31 1633PD - Co-amplification of KIT/KDR/PDGRA in over 100,000 advanced cancer cases 1 2 2 3 4 4 4 5 U. Disel , R. Madison , J. Chung , M. Gounder , A. Oztan , A. Benson , J. Webster , S. Klempner , 6 7 8 2 9 4 2 4 1 S.-H. Ou , S. Ganesan , K. Janeway , P. Stephens , J. Ross , A. Schrock , V. Miller , S. Ali ; Adana,
2 3 4 5 6 7 TR, Cambridge, MA/US, New York, US, Cambridge, US, Los Angeles, CA/US, Orange, CA/US, 8 9 New Brunswick, US, Boston, US, Albany, NY/US
10:31 - 10:41 Invited Discussant 85PD, 86PD, 87PD and 1633PD R. Marais, Manchester, GB
Last update: 02-09-2017 06:01:33pm esmo.org
09:15 - 10:45 Type: Special Symposium Barcelona Auditorium Title: Immunotherapy in thoracic malignancies: What can we expect in 2017? Chair(s): P. Garrido Lopez, ES; J. Vansteenkiste, BE
09:15 - 09:20 Introduction P. Garrido Lopez, Madrid, ES
09:20 - 09:40 The role of immunotherapy in non-metastasic NSCLC J. Vansteenkiste, Leuven, BE
09:40 - 10:00 Upfront immune strategies in advanced NSCLC N. Rizvi, New York, Ny, US
10:00 - 10:20 Present and future of immunotherapy in small cell lung cancer J. Brahmer, Baltimore, Md, US
10:20 - 10:40 Is immunotherapy an option in mesothelioma? J. Aerts, Rotterdam, NL
10:40 - 10:45 Conclusions and clinical perspectives J. Vansteenkiste, Leuven, BE
09:15 - 10:45 Type: Educational session Sevilla Auditorium Title: Controversial issues in the neoadjuvant approach to early breast cancer Chair(s): N. Harbeck, DE; J. Cortes Castan, ES
09:15 - 09:40 Luminal C. Thomssen, Halle, DE
09:40 - 10:05 Triple Negative Breast Cancer (TNBC) A. Tutt, London, GB
10:05 - 10:30 HER2 J. Cortes Castan, Madrid, ES
10:30 - 10:45 Discussion
Last update: 02-09-2017 06:01:33pm esmo.org 09:15 - 10:45 Type: Special Symposium Cordoba Auditorium Title: Predictive biomarkers for response to immunotherapy Chair(s): D. Speiser, CH; F. Thistlethwaite, GB
09:15 - 09:20 Introduction F. Thistlethwaite, Manchester, GB
09:20 - 09:40 New biomarkers for response to immunotherapy C. Blank, Amsterdam, NL
09:40 - 10:00 Biomarkers from biological basis to clinical relevance D. Speiser, Lausanne, CH
10:00 - 10:20 Can microbiota be a biomarker for immunotherapy? L. Zitvogel, Villejuif, FR
10:20 - 10:40 Tumour microenvironment: The role of the innate cell M. Colombo, Milan, IT
10:40 - 10:45 Conclusions and clinical perspectives D. Speiser, Lausanne, CH
09:15 - 10:15 Type: Controversy session Granada Auditorium Title: Prostate cancer liquid biopsies: Ready for prime time? Chair(s): H. Beltran, US
09:15 - 09:25 Introduction and 1st vote H. Beltran, New York, NY/US
09:25 - 09:45 Yes G. Attard, Sutton, Surrey/GB
09:45 - 10:05 No D. Waugh, Belfast, GB
10:05 - 10:15 2nd vote and conclusions H. Beltran, New York, NY/US
Last update: 02-09-2017 06:01:33pm esmo.org 09:15 - 10:45 Type: Proffered Paper session Madrid Auditorium Title: Genitourinary tumours, non-prostate Chair(s): B. Escudier, FR; M. Staehler, DE
09:15 - 09:30 845O - Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of metastatic renal cell carcinoma (SWITCH-II) 1 2 3 4 5 6 7 8 M. Retz , J. Bedke , E. Herrmann , M.-O. Grimm , U. Zimmermann , L. Müller , C. Leiber , D. Teber , 9 10 11 12 13 7 1 1 M. Wirth , C. Bolenz , R. van Alphen , M. De Santis , A. Beeker , M. Frank , J. Gschwend ;
2 3 4 5 6 7 8 München, DE, Tübingen, DE, Münster, DE, Jena, DE, Greifswald, DE, Leer, DE, Freiburg, DE, 9 10 11 12 13 Heidelberg, DE, Dresden, DE, Ulm, DE, Tilburg, NL, Coventry, GB, Hoofddorp, NL
09:30 - 09:45 LBA35 - Immediate versus deferred cytoreductive nephrectomy (CN) in patients with synchronous metastatic renal cell carcinoma (mRCC) receiving sunitinib (EORTC 30073 SURTIME). 1 2 3 4 5 1 6 A. Bex , P. Mulders , M. Jewett , J. Wagstaff , R. van Velthoven , P. Laguna Pes , L. Wood , H. van 7 8 5 9 9 10 5 5 Melick , P. Soetekouw , J.B. Lattouf , T. Powles , E. Boleti , I.-J. de Jong , S. Rottey , B. Tombal , 5 5 5 1 1 1 2 3 S. Marreaud , L. Collette , S. Collette , C. Blank , J. Haanen ; Amsterdam, NL, Nijmegen, NL, 4 5 6 7 8 9 Toronto, CA, Swansea, GB, Brussels, BE, Halifax, CA, Nieuwegein, NL, Maastricht, NL, London, 10 GB, Groningen, NL
09:45 - 10:00 Invited Discussant 845O and LBA35 M. Staehler, Munich, DE
10:00 - 10:15 846O - Final results of a phase I study of cabozantinib (cabo) plus nivolumab (nivo) and cabonivo plus ipilimumab (Ipi) in patients (pts) with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies 1 2 3 4 5 5 5 5 R. Nadal , A. Mortazavi , M. Stein , S. Pal , N. Davarpanah , H.L. Parnes , Y.M. Ning , L.M. Cordes , 5 5 5 5 5 4 2 J. Lin , M. Bagheri , L. Linderberg , M. Berniger , S.M. Steinberg , T. Moore , T. Lancaster , M. Aviles
3 5 5 5 1 1 2 3 , R. Costello , D.P. Bottaro , W.L. Dahut , A. Apolo ; Bethesda, US, Columbus, OH/US, New 4 5 Brunswick, US, Duarte, CA/US, Bethesda, MD/US
10:15 - 10:30 847O - A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with renal cell carcinoma 1 1 2 3 4 5 6 7 C.-H. Lee , V. Makker , D. Rasco , M. Taylor , C. Dutcus , R. Shumaker , E. Schmidt , D. Stepan , D. 5 8 1 2 3 4 Li , R. Motzer ; New York, US, San Antonio, TX/US, Portland, US, Woodcliff Lake, New Jersey/US, 5 6 7 8 Woodcliff Lake, US, North Wales, PA/US, Woodcliff Lake, CA/US, New York, NY/US
10:30 - 10:45 Invited Discussant 846O and 847O L. Albiges, Villejuif, CEDEX/FR
Last update: 02-09-2017 06:01:33pm esmo.org 09:15 - 10:45 Type: Special Session Tarragona Auditorium Title: Access to novel targeted therapies and clinical trials in Europe Chair(s): J. Tabernero, ES; T. Cufer, SI
09:15 - 09:20 Introduction J. Tabernero, Barcelona, ES
09:20 - 09:40 Access to molecular diagnosis: The French model F. Barlesi, Marseille, FR
09:40 - 10:00 Inequalities in access to treatment T. Cufer, Golnik, SI
10:00 - 10:20 The patient’s view B. Ryll, SE
10:20 - 10:40 Drug repurposing: New tricks for old drugs R. Bernards, Amsterdam, NL
10:40 - 10:45 Conclusions T. Cufer, Golnik, SI
09:15 - 10:45 Type: Poster Discussion session Bilbao Auditorium Title: Supportive and palliative care Chair(s): A. Charalambous, CY; P. Gascon, ES; J. Herrstedt, DK
09:15 - 09:15 1542PD - Anticipative approach to improve safety: An innovative daily hospital organisation 1 1 1 1 2 3 1 1 F. Scotté , R.T. Elaidi , H. Haboudagga , C. Thibault , J. Stevens , B. Bonan , S. Oudard ; Paris, FR,
2 3 Boulogne, FR, Suresnes, FR
09:15 - 09:15 1387PD - Prevalence and recent time trend in aggressiveness of cancer care near the end of life: an expanded assessment in a cohort study 1 1 2 1 3 4 5 1 D. Martins Branco , S. Lopes , R. Canario , J. Freire , G. Sousa , N. Lunet , B. Gomes ; Lisbon, PT,
2 3 4 5 Porto, PT, Coimbra, PT, Oporto, PT, London, GB
09:15 - 09:15 LBA54_PR - Proactive Referral to Palliative Care: Model of a new Integrated Palliative Care and Oncology Service J. Wood, A.-M. Stevens, Y. Kano, J. Nevin, S. Popat, T. Wiseman, J. Droney; London, GB
09:15 - 09:35 Invited Discussant 1542PD, 1387PD and LBA54 A. Charalambous, Limassol, CY
09:35 - 09:45 Q&A led by Discussant
Last update: 02-09-2017 06:01:33pm esmo.org 09:45 - 09:45 1388PD - Open-label randomized study of individualized pharmacokinetically (PK)-guided dosing versus body surface area (BSA) dosing of paclitaxel (PTX) in advanced Non-Small Cell Lung Cancer (NSCLC) NCT02058433 1 2 2 2 3 3 2 1 2 S. Salamone , J. Zhang , H. Qi , H. Ni , Y. Li , J. Courtney , C. Zhou ; Bethlehem, US, Shanghai,
3 CN, Bethlehem, PA/US
09:45 - 09:45 1389PD - Prognostic impact of drug interactions in patients with advanced cancer 1 2 3 3 1 1 1 M. Joerger , A. Hömme , M. Haschke , S. Krähenbühl , F. Strasser , C. Lehner , A. von Kameke , T.
4 1 1 1 1 2 3 4 Wälti , B. Thürlimann , M. Früh , C. Driessen ; St. Gallen, CH, Ulm, DE, Basel, CH, Bern, CH
09:45 - 09:45 1544PD - Development of an online drug-drug interaction resource to support prescribing of oncolytics 1 2 3 1 3 3 4 1 N. Lankheet , F. Jansman , S. Gibbons , D. Burger , K. McAllister , S. Khoo , N. Van Erp ;
2 3 4 Nijmegen, NL, Deventer, NL, Liverpool, GB, Leiden, NL
09:45 - 09:45 1545PD - The effect of cannabis use on tumor response to nivolumab in patients with advanced malignancies T. Taha, S. Talhamy, M. Wollner, A. Peer, G. Bar-Sela; Haifa, IL
09:45 - 09:45 1546PD - Impact of sarcopenia on dose limiting toxicities in metastatic colorectal cancer patients (mCRC pts) receiving palliative systemic treatment 1 1 1 1 1 2 3 S. Kurk , P. Peeters , R. Stellato , B. Dorresteijn , M. Jourdan , G.-J. Creemers , F. Erdkamp , F. de 4 5 6 7 8 9 10 Jongh , P. Kint , B. Poppema , S. Radema , L. Simkens , B. Tanis , M. Tjin-A-Ton , A. Van der 11 8 1 1 1 2 3 4 Velden , C. Punt , M. Koopman , A. May ; Utrecht, NL, Eindhoven, NL, Sittard, NL, Rotterdam, 5 6 7 8 9 10 Zuid-Holland/NL, Breda, NL, Groningen, NL, Nijmegen, NL, Amsterdam, NL, Gouda, NL, Tiel, 11 NL, Hilversum, NL
09:45 - 10:05 Invited Discussant 1388PD, 1389PD, 1544PD, 1545Pd and 1546PD P. Gascon, Barcelona, ES
10:05 - 10:15 Q&A led by Discussant
10:15 - 10:15 1547PD - Phase 3 safety evaluation of an intravenous formulation of NEPA, a novel fixed antiemetic combination of fosnetupitant and palonosetron 1 2 3 4 4 5 1 2 L. Schwartzberg , Z. Andric , D. Kowalski , D. Voisin , G. Rizzi , M. Karthaus ; Teheran, TN/IR,
3 4 5 Belgrade, RS, Warsaw, PL, Pazzallo - Lugano, CH, Munich, DE
10:15 - 10:15 1548PD - Quality of life (QOL) evaluation of patients in a phase 3 study comparing NEPA with an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) 1 2 3 4 5 5 6 7 1 L. Zhang , S. Lu , J. Feng , A. Dechaphunkul , S. Chessari , C. Lanzarotti , K. Jordan , M. Aapro ; 2 3 4 5 6 Guangzhou, Guangdong/CN, Shanghai, CN, Nanjing, CN, Hat Yai, TH, Lugano, CH, Heidelberg, 7 DE, Genolier, CH
10:15 - 10:15 1549PD - Multicenter randomized controlled trial to evaluate the efficacy of frozen gloves for the prevention of chemotherapy-induced peripheral neuropathy
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 1 3 3 4 5 A. Beijers , F. Mols , J. Ophorst , J. Pijs , J. de Vos-Geelen , E. Jacobs , L.V. van de Poll-Franse , G.
1 1 2 3 4 5 Vreugdenhil ; Veldhoven, NL, Tilburg, NL, Maastricht, NL, Helmond, NL, Eindhoven, NL
10:15 - 10:35 Invited Discussant 1547PD, 1548PD and 1549PD J. Herrstedt, Odense, DK
10:35 - 10:45 Q&A led by Discussant
09:15 - 10:45 Type: Poster Discussion session Cartagena Auditorium Title: Gynaecological cancers Chair(s): I. Ray-Coquard, FR; A. Gonzalez Martin, ES; C. Sessa, CH
09:15 - 09:15 932PD - Efficacy of olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by lines of prior chemotherapy: Phase III SOLO2 trial (ENGOT Ov-21) 1 2 3 4 5 6 7 R. Penson , M.-C. Kaminsky-Forrett , J. Ledermann , C. Brown , M. Plante , J. Korach , T. Huzarski , 8 9 10 11 12 13 A. Gomez de Liano Lista , C. Pisano , M. Friedlander , N. Colombo , M. Gropp-Meier , H. Nakai , 14 15 16 17 18 1 2 G. Sonke , J.-W. Kim , I. Vergote , A. Allen , E. Pujade-Lauraine ; Boston, US, Vandoeuvre
3 4 5 6 7 8 Les Nancy, CEDEX/FR, London, GB, Sydney, AU, Quebec, CA, Tel Hashomer, IL, Szczecin, PL, 9 10 11 12 13 14 Barcelona, ES, Napoli, IT, Randwick, AU, Milan, IT, Ravensburg, DE, Osaka, JP, 15 16 17 18 Amsterdam, NL, Seoul, KR, Leuven, BE, Gaithersburg, MD/US, Paris, CEDEX 4/FR
09:15 - 09:15 933PD - The exposure-response relationship of niraparib in patients with gBRCAmut and non-gBRCAmut: Results from the ENGOT-OV16/NOVA Trial 1 1 2 3 4 5 1 6 J. Wang , Z.-Y. Zhang , M.R. Mirza , L. Gilbert , M. Fabbro , A. Tinker , X. Wang , A. Redondo , J. 7 8 9 10 11 12 13 14 Berek , L. Woelber , H. Pentikis , K. Moore , D. Lorusso , B. Benigno , S. Hazard , P. Follana , 15 16 1 1 1 2 3 B. Rimel , U. Matulonis , S. Agarwal , V. Kansra ; Waltham, MA/US, Copenhagen, DK, Montreal,
4 5 6 7 8 QC/CA, Montpellier, CEDEX 5/FR, Vancouver, BC/CA, Madrid, ES, Palo Alto, CA/US, Hamburg, 9 10 11 12 13 DE, Baltimore, MD/US, Oklahoma City, Oklahoma/US, Milan, IT, Atlanta, GA/US, Waltham, 14 15 16 US, Nice, CEDEX 2/FR, West Hollywood, CA/US, Boston, MA/US
09:15 - 09:15 934PD - Safety and Efficacy of Niraparib in Elderly Patients (Pts) with Recurrent Ovarian Cancer (OC) 1 2 3 4 5 6 7 8 M. Fabbro , K. Moore , A. Dørum , A. Tinker , S. Mahner , I. Bover , S. Banerjee , G. Tognon , F. 9 10 11 12 13 14 Goffin , R. Shapira-Frommer , R. Wenham , K. Hellman , D. Provencher , P. Harter , I. Palacio 15 16 17 18 19 20 1 Vázquez , P. Follana , M. Pineda , M.R. Mirza , S. Hazard , U. Matulonis ; Montpellier, 2 3 4 5 6 CEDEX 5/FR, Oklahoma City, Oklahoma/US, Oslo, NO, Vancouver, BC/CA, Munich, DE, Palma 7 8 9 10 11 12 De Mallorca, ES, London, GB, Brescia, IT, Liege, BE, Ramat Gan, IL, Tampa, FL/US, 13 14 15 16 17 Stockholm, SE, Montreal, CA, Essen, DE, Oviedo, ES, Nice, CEDEX 2/FR, Chicago, IL/US, 18 19 20 Copenhagen, DK, Waltham, US, Boston, MA/US
09:15 - 09:15 LBA42 - Disruptive mutations in TP53 associate with survival benefit in a PARPi trial in Ovarian Cancer
Last update: 02-09-2017 06:01:33pm esmo.org 1 1 2 1 3 3 A. Martinez Bueno , M.A. Molina , A. Fielding , J. Bertran-Alamillo , B. Dougherty , Z. Lai , D. 2 1 2 1 4 1 5 6 Hodgson , C. Mayo de las Casas , P. Rowe , M. Gil , S. Spencer , S. Viteri , J. Lobera , R. Rosell ,
5 1 2 3 4 5 A. Gasco Hernandez ; Barcelona, ES, Macclesfield, GB, Waltham, MA/US, Cambridge, GB, 6 Madrid, ES, Badalona, Barcelona/ES
09:15 - 09:35 Invited Discussant 932PD, 933PD, 934PD and LBA42 I. Ray-Coquard, Lyon, CEDEX/FR
09:35 - 09:45 Q&A led by Discussant
09:45 - 09:45 935PD - BRCA1&2 tumoral and germline status for ovarian cancer patients in first line setting within the PAOLA-01 trial 1 2 3 4 1 1 1 2 C. Callens , D. Vaur , I. Soubeyran , E. Rouleau , P.-A. Just , E. Guillerm , L. Golmard , N. Goardon , 5 6 7 8 9 10 11 N. Sevenet , O. Cabaret , P. Harter , A. Gonzalez Martin , K. Fujiwara , S. Pignata , N. Colombo , 12 13 14 15 16 1 2 C. Marth , I. Vergote , J. Mäenpää , E. Pujade-Lauraine , I. Ray-Coquard ; Paris, FR, Caen,
3 4 5 6 7 8 FR, Bordeaux, FR, Paris, CEDEX 5/FR, Bordeaux Cedex, FR, Villejuif Cedex, FR, Essen, DE, 9 10 11 12 13 14 15 Madrid, ES, Saitama, JP, Napoli, IT, Milan, IT, Innsbruck, AT, Leuven, BE, Tampere, FI, 16 Paris, CEDEX 4/FR, Lyon, CEDEX/FR
09:45 - 09:45 936PD - Actionable molecular alterations in advanced gynecologic malignancies: First results from the ProfiLER program (NCT01774409) in France 1 2 1 1 1 1 1 R. Varnier , I. Ray-Coquard , V. Corset , C. Baudet , D. Pissaloux , V. Attignon , M. Ezzalfani , O. Le 1 2 1 3 2 4 3 2 3 Saux , P. Heudel , O. Derbel , B. You , O. Tredan , P. Cassier , N. Bonnin , P. Biron , G. Freyer , V.
3 2 2 1 1 2 3 Trillet-Lenoir , T. Bachelot , D. Perol , J.-Y. Blay ; Lyon, FR, Lyon, CEDEX/FR, Pierre Bénite, 4 CEDEX/FR, La Défense, FR
09:45 - 09:45 937PD - PD-L1 expression and prognosis significance in advanced ovarian cancer 1 1 2 3 4 1 4 E. Høgdall , C. Høgdall , T. Vo , W. Zhou , M. Busch-Sørensen , S. Soerensen , D. Chappell , J. 5 5 1 6 1 2 3 Georgsen , E. Mejlgaard , L. Nedergaard , T. Steiniche ; Copenhagen, DK, Kenilworth, US, North 4 5 6 Wales, US, Kenilworth, NJ/US, Aarhus, DK, Aarhus C, DK
09:45 - 09:45 938PD - Prognostic relevance of immune-related gene expression signatures (irGES) in patients (pts) with ovarian clear cell carcinomas (OCCC) V. Heong, D. Lim, T.Z. Tan, J. Ye, Y.W. Lim, S.E. Lim, J. Ng, A. Ilancheran, J. Loh, R. Soong, D. Tan, R.
Huang; Singapore, SG
09:45 - 09:45 939PD - An increased ratio of cytotoxic to suppressive T cells after neoadjuvant chemotherapy (NACT) is prognostic in advanced ovarian cancer 1 1 1 1 2 1 1 A. Khairallah , A. Auguste , A. Leary , C. Genestie , P. Pautier , J. Michels , P. Morice , E. Bentivegna
1 1 1 1 1 1 2 , A. Maulard , F. Drusch , S. Mesnage , S. Gouy ; Villejuif, FR, Villejuif, CEDEX/FR
09:45 - 10:05 Invited Discussant 935PD, 936PD, 937PD, 938PD, 939PD and 939PD A. Gonzalez Martin, Madrid, ES
Last update: 02-09-2017 06:01:33pm esmo.org 10:05 - 10:15 Q&A led by Discussant
10:15 - 10:15 940PD - Long term quality of life among epithelial ovarian cancer patients: The GINECO case/control VIVROVAIRE Study 1 2 3 4 5 6 7 F. Joly Lobbedez , A. Floquet , E. Kalbacher , N. Heutte , D. Berton-Rigaud , O. Tredan , M. Fabbro , 8 9 10 11 12 2 A.M. Savoye , J.E. Kurtz , J. Alexandre , P. Follana , V. Delecroix , N. Dohollou , C. 13 14 15 16 4 Roemer-Becuwe , A. Lesoin , A. Lortholary , G. De Rauglaudre , J.-M. Grellard , D. 4 17 1 2 3 Ahmed-Lecheheb , C. Lhomme ; Caen, CEDEX 5/FR, Bordeaux, CEDEX/FR, Besançon, 4 5 6 7 8 CEDEX/FR, Caen, FR, Saint-Herblain, CEDEX/FR, Lyon, CEDEX/FR, Montpellier, CEDEX 5/FR, 9 10 11 12 13 Reims, CEDEX/FR, Strasbourg, FR, Paris, FR, Nice, CEDEX 2/FR, Saint-Nazaire, FR, 14 15 16 17 Nancy, FR, Lille, FR, Nantes, CEDEX 2/FR, Avignon, FR, Villejuif, CEDEX/FR
10:15 - 10:15 LBA43 - Health-related quality of life after Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for stage III ovarian cancer: results of the phase III OVHIPEC study 1 1 1 1 2 3 S. Koole , W. van Driel , J. Kieffer , K. Sikorska , J. Schagen van Leeuwen , H. Schreuder , R. 4 4 1 5 6 1 7 Hermans , I. de Hingh , J. van der Velden , H. Arts , L. Massuger , A. Aalbers , V. Verwaal , K. Van
1 1 1 1 2 3 4 de Vijver , N. Aaronson , G. Sonke ; Amsterdam, NL, Nieuwegein, NL, Utrecht, NL, Eindhoven, 5 6 7 NL, Groningen, NL, Nijmegen, NL, Aarhus, DK
10:15 - 10:15 941PD - An investigator initiated, open label, randomized, controlled, multicentric study, to assess the safety and efficacy of nimotuzumab (BIOMAb-EGFR) concurrent with cisplatin and radiotherapy (RT) in histologically documented squamous cell carcinoma of the cervix 1 1 1 1 1 2 B. Ajaikumar , K. Swamy , N. Radheshyam , S. Patil , H.P. Shashidhara , M.S.A. Vishweshwara , N. 1 3 4 1 1 1 1 2 Rao , Y. Madhavi , N. Ravi , R. Bilimagga , R. Rao , D. Pawar ; Bangalore, IN, Mysore, 3 4 Karnataka/IN, Mysore, IN, Shimoga, IN
10:15 - 10:15 942PD - Vanucizumab (VAN) in combination with atezolizumab (ATEZO) for platinum-resistant recurrent ovarian cancer (PROC): Results from a single arm extension phase of the phase I study BP28179 1 2 3 4 1 5 6 A. Oaknin , I. Vergote , I. Ray-Coquard , A. Leary , V. Rodriguez Freixinos , N. Concin , P. Toussaint 7 1 5 8 8 9 , C. Massard , L. Fariñas-Madrid , E. Van Nieuwenhuysen , A. Lahr , I. Franjkovic , S. Rossomanno , 9 9 8 9 10 9 8 1 2 P. Gerber , T. Nayak , F. Heil , C. Boetsch , A. Sahbi , K. Longauer , O. Krieter ; Barcelona, ES, 3 4 5 6 7 8 Leuven, BE, Lyon, CEDEX/FR, Villejuif, FR, Leuven, NL, Lyon, FR, Villejuif, CEDEX/FR, 9 10 Penzberg, DE, Basel, CH, Welwyn, GB
10:15 - 10:35 Invited Discussant 940PD, LBA43, 941PD and 942PD C. Sessa, Bellinzona, CH
10:35 - 10:45 Q&A led by Discussant
Last update: 02-09-2017 06:01:33pm esmo.org 09:30 - 10:30 Type: Multidisciplinary Session Valencia Title: Midgut neuroendocrine tumour progressing on 1st line somatostatin analog: What Auditorium treatment approach? Chair(s): J. Strosberg, US
09:30 - 09:35 Presentation of case/condition J. Strosberg, Tampa, US
09:35 - 09:45 Systemic therapies for tumour and syndrome control J. Strosberg, Tampa, US
09:45 - 09:55 Peptide receptor radionuclide therapy G. Nicolas, Basel, CH
09:55 - 10:05 Hepatic transarterial embolisation: When should it be recommended and which product should be selected? T. de Baere, Villejuif, FR
10:05 - 10:30 General Discussion
09:30 - 10:30 Type: Challenge Your Expert (CYE) session Alicante Auditorium Title: Adjuvant systemic therapy in STS and GIST for whom? Chair(s): R. Jones, GB
09:30 - 09:40 Adjuvant systemic therapy in STS and GIST for whom? S. Stacchiotti, Milan, IT
09:40 - 10:30 Discussion led by Chair R. Jones, London, GB
Last update: 02-09-2017 06:01:33pm esmo.org 09:30 - 10:30 Type: Young Oncologist Special session Room 1&2 Title: Clinical cases of solid tumours: Discussion forum for practicing and young oncologists
09:30 - 09:50 Metastatic colorectal cancer clinical case discussion E. Martinelli, Naples, IT
09:50 - 09:50 Table coordinator C. Cardone, Naples, IT
09:50 - 10:10 Unknown primary carcinoma clinical case discussion G. Pentheroudakis, Ioannina, GR
10:10 - 10:10 Table coordinator M. Karamouzis, Athens, GR
10:10 - 10:30 Breast Cancer, adjuvant setting, clinical case discussion O. Pagani, Bellinzona, CH
10:30 - 10:30 Table coordinator R. Vidra, Cluj-Napoca, RO
11:00 - 12:30 Type: Special Symposium Barcelona Auditorium Title: Oligometastatic NSCLC Chair(s): S. Senan, NL; S. Popat, GB
11:00 - 11:05 Introduction S. Popat, London, GB
11:05 - 11:25 Definitions and implications of oligometastatic disease W. Eberhardt, Essen, DE
11:25 - 11:45 Management of oligometastasis in patients with driver oncogenes L. Sequist, Boston, MA/US
11:45 - 12:05 Pro-cons of choice of ablative modality S. Senan, Amsterdam, NL
12:05 - 12:25 Controversies and ongoing clinical trials A.-M. Dingemans, Maastricht, NL
12:25 - 12:30 Conclusions and clinical perspectives S. Senan, Amsterdam, NL
Last update: 02-09-2017 06:01:33pm esmo.org 11:00 - 12:30 Type: Proffered Paper session Madrid Auditorium Title: Breast cancer, metastatic Chair(s): F. André, FR; V. Guarneri, IT
11:00 - 11:15 237O - A phase II trial of pan-HER inhibitor Poziotinib, in patients with HER2-positive metastatic breast cancer who have received at least two prior HER2-directed regimens: The results of NOV120101-203 trial 1 1 1 2 3 4 5 1 1 Y.H. Park , K.-H. Lee , J. Sohn , K.S. Lee , K.H. Jung , J.H. Kim , K.H. Lee , J.S. Ahn , T.-Y. Kim , 1 6 1 4 5 1 1 2 1 G.M. Kim , I.H. Park , S.-B. Kim , S.H. Kim , H.S. Han , Y.-H. Im , J.H. Ahn , J.-Y. Kim , J. Kang , 1 1 2 3 4 5 6 S.-A. Im ; Seoul, KR, Goyang, KR, Seoul, KP, Seongnam, Gyeonggi-do/KR, Cheongju, KR, Gyeonggi-Do, KR
11:15 - 11:30 217O - A gene signature of chemo-immunization to predict outcome in patients with triple negative breast cancer treated with anthracycline-based neoadjuvant chemotherapy 1 2 1 3 4 5 3 C. Criscitiello , M.A. Bayar , G. Curigliano , F. Symmans , C. Desmedt , H. Bonnefoi , B. Sinn , G. 1 2 6 7 8 4 2 9 1 Pruneri , C. Vicier , J.-Y. Pierga , C. Denkert , S. Loibl , C. Sotiriou , S. Michiels , F. André ; Milan,
2 3 4 5 6 7 8 IT, Villejuif, FR, Houston, TX/US, Brussels, BE, Bordeaux, CEDEX/FR, Paris, FR, Berlin, DE, 9 Neu-Isenburg, DE, Villejuif, CEDEX/FR
11:30 - 11:45 Invited Discussant 237O and 217O V. Guarneri, Padua, IT
11:45 - 12:00 LBA13 - Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): results from KEYNOTE-086 1 2 3 4 5 6 7 8 S. Loi , S. Adams , P. Schmid , J. Cortés , D. Cescon , E. Winer , D. Toppmeyer , H. Rugo , M. De 9 10 11 12 13 14 14 14 Laurentiis , R. Nanda , H. Iwata , A. Awada , A. Tan , A. Wang , G. Aktan , V. Karantza , R. 15 1 2 3 4 5 6 Salgado ; Melbourne, VIC/AU, New York, NY/US, London, GB, Barcelona, ES, Toronto, CA, 7 8 9 10 11 Boston, MA/US, New Brunswick, US, San Francisco, CA/US, Naples, IT, Chicago, IL/US, 12 13 14 15 Nagoya, JP, Brussels, BE, Charlotte, NC/US, Kenilworth, NJ/US, Melbourne, AU
12:00 - 12:15 LBA14 - Adaptive phase II randomized non-comparative trial of nivolumab after induction treatment in triple negative breast cancer: TONIC-trial 1 1 1 1 1 1 1 M. Kok , H. Horlings , K. van de Vijver , T. Wiersma , N. Russell , L. Voorwerk , K. Sikorska , E. van 1 1 1 1 2 1 1 Werkhoven , I. Mandjes , I. Kemper , J. Foekema , S. Wilgenhof , M. Chalabi , J. Stouthard , G.
1 3 2 1 1 1 1 2 Sonke , D. Cullen , R. Salgado , T. Schumacher , C. Blank , S. Linn ; Amsterdam, NL, Brussels, 3 BE, Princeton, US
12:15 - 12:30 Invited Discussant LBA13 and LBA14 G. Curigliano, Milan, IT
Last update: 02-09-2017 06:01:33pm esmo.org 11:00 - 12:30 Type: Proffered Paper session Sevilla Auditorium Title: Gastrointestinal tumours, colorectal 1 Chair(s): P. Pfeiffer, DK; D. Arnold, PT
11:00 - 11:12 474O - Treatment outcome according to tumor RAS mutation status in TRICOLORE trial: A randomized phase 3 trial of S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment for metastatic colorectal cancer 1 2 3 4 5 6 7 Y. Komatsu , A. Takashima , T. Denda , M. Gamoh , I. Iwanaga , H. Shimodaira , M. Nakamura , T. 2 8 9 10 11 12 13 Yamaguchi , H. Takahashi , K. Kobayashi , M. Tsuda , Y. Kobayashi , H. Baba , M. Kotake , C. 6 14 1 15 6 2 1 2 Ishioka , A. Sato , S. Yuki , S. Morita , S. Takahashi , K. Shimada ; Sapporo, Hokkaido/JP,
3 4 5 6 7 Tokyo, JP, Chiba, Chiba/JP, Osaki, Miyagi/JP, Kitami, Hokkaido Prefecture/JP, Sendai, JP, 8 9 10 11 12 Matsumoto, JP, Ishinomaki, JP, Yokohama, JP, Akashi, JP, Kushiro, Hokkaido/JP, Kumamoto, 13 14 15 JP, Takaoka, JP, Hirosaki, JP, Kyoto, JP
11:12 - 11:24 475O - mFOLFOXIRI + panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer m(CRC): A randomized phase II VOLFI trial of the AIO (AIO-KRK0109) 1 2 3 4 5 6 M. Geissler , U. Martens , R. Knorrenschield , J. Greeve , A. Florschuetz , A. Tannapfel , S. 1 7 8 9 10 6 1 Wessendorf , T. Seufferlein , S. Kanzler , V. Heinemann , S. Held , A. Reinacher-Schick ;
2 3 4 5 6 7 Esslingen, DE, Heilbronn, DE, Marburg, DE, Paderborn, DE, Dessau, DE, Bochum, DE, Ulm, DE, 8 9 10 Schweinfurt, DE, Munich, DE, Leverkusen, DE
11:24 - 11:39 Invited Discussant 474O and 475O D. Arnold, Lisbon, PT
11:39 - 11:51 476O - Neoadjuvant FOLFOX 4 versus FOLFOX 4 plus cetuximab versus immediate surgery for high-risk stage II and III colon cancers: A phase II multicentre randomised controlled trial (PRODIGE 22) 1 2 3 4 5 6 7 6 M. Karoui , A. Rullier , C. Mariette , E. Maillard , A. Bardier , F. Poizat , A. Luciani , A. Sarran , J.-L. 8 6 2 9 10 7 11 Legoux , C. De Chaisemartin , C. Lecaille , O. Bouche , F. Mauvais , F. Brunetti , M. Prudhomme , 12 13 5 1 2 3 4 J.-F. Seitz , C. Lepage , J. Taieb ; Paris Cedex, FR, Bordeaux, FR, Lille, CEDEX/FR, Dijon, FR, 5 6 7 8 9 10 11 12 Paris, FR, Marseille, FR, Créteil, FR, Orleans, FR, Reims, FR, Beauvais, FR, Nîmes, FR, 13 Marseille, CEDEX 5/FR, Dijon, Cedex/FR
11:51 - 12:03 477O - Bevacizumab (Bev) or cetuximab (Cet) plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Final analysis of a French randomized, multicenter, phase II study (PRODIGE 18) 1 2 3 4 5 6 7 8 J. Bennouna , S. Hiret , C. Borg , A. Bertaut , O. Bouche , G. Deplanque , E. Francois , T. Conroy , 9 10 11 12 10 13 14 F. Ghiringhelli , G. des Guetz , J.-F. Seitz , P. Artru , T. Stanbury , S. Charpentier , M. Denis , 15 1 2 3 4 5 A. Adenis ; Nantes, CEDEX/FR, Saint-Herblain, CEDEX/FR, Besançon, FR, Dijon, FR, Reims, 6 7 8 9 10 11 FR, Vevey, CH, Nice, FR, Vandoeuvre Les Nancy, CEDEX/FR, Dijon, Cedex/FR, Paris, FR, 12 13 14 15 Marseille, CEDEX 5/FR, Lyon, CEDEX 8/FR, Nantes, FR, Nantes, CEDEX 1/FR, Lille, CEDEX/FR
12:03 - 12:18 Invited Discussant 476O and 477O R. Adams, Cardiff, GB
Last update: 02-09-2017 06:01:33pm esmo.org
11:00 - 12:30 Type: Special Symposium Pamplona Auditorium Title: Immuno-oncology in upper GI cancer: PD1 and beyond Chair(s): S.A. Quezada, GB; F. Lordick, DE
11:00 - 11:05 Introduction F. Lordick, Leipzig, DE
11:05 - 11:25 Relationship between microbiota and immunotherapy L. Zitvogel, Villejuif, FR
11:25 - 11:45 The role of the environment and stroma S.R. Hingorani, Seattle, Wa, US
11:45 - 12:05 Biomarkers to predict the effects of immunotherapy S.A. Quezada, London, GB
12:05 - 12:25 Overview of clinical activity of immunomodulating agents in upper GI cancer C. Borg, Besançon, FR
12:25 - 12:30 Conclusions and clinical perspectives S.A. Quezada, London, GB
11:00 - 12:30 Type: Special Symposium Cordoba Auditorium Title: Mechanisms of intrinsic and acquired resistance to current treatment strategies Chair(s): D. Peeper, NL; R. Marais, GB
11:00 - 11:05 Introduction D. Peeper, Amsterdam, NL
11:05 - 11:25 Intrinsic in immuno G. McArthur, Melbourne, AU
11:25 - 11:45 Intrinsic in targeted R. Marais, Manchester, GB
11:45 - 12:05 Acquired in immuno A. Ribas, Los Angeles, CA/US
12:05 - 12:25 Acquired in targeted D. Peeper, Amsterdam, NL
12:25 - 12:30 Conclusions and clinical perspectives R. Marais, Manchester, GB
Last update: 02-09-2017 06:01:33pm esmo.org
11:00 - 12:30 Type: Proffered Paper session Granada Auditorium Title: Sarcoma Chair(s): S. Bauer, DE; R. Jones, GB
11:00 - 11:15 1473O - Encouraging activity of novel pan-KIT and PDGFRα inhibitor DCC-2618 in patients (pts) with Gastrointestinal Stromal Tumor (GIST) 1 2 3 4 4 5 4 1 F. Janku , A. Razak , M. Gordon , D. Flynn , M. Kaufman , J. Pitman , B. Smith , N. Somaiah , J. 6 2 5 5 5 7 8 1 Jennings , S. Salah , D. Westwood , D. Greensmith , J. Jacobson , O. Rosen , S. George ; Houston,
2 3 4 5 6 7 TX/US, Toronto, CA, Scottsdale, AZ/US, Lawrence, US, Waltham, US, Boston, US, New York, 8 MA/US, Boston, MA/US
11:15 - 11:30 LBA55 - Time to definitive failure to the first tyrosine kinase inhibitor in localized gastrointestinal stromal tumors (GIST) treated with imatinib as an adjuvant: final results of the EORTC STBSG, AGITG, UNICANCER, FSG, ISG, and GEIS randomized trial 1 2 3 4 5 6 1 P.G. Casali , A. Le Cesne , A. Poveda , D. Kotasek , P. Rutkowski , P. Hohenberger , E. Fumagalli , 7 8 9 10 11 12 13 I. Judson , A. Italiano , H. Gelderblom , N. Penel , H.-G. Kopp , D. Goldstein , J. Martin Broto , 1 14 15 16 15 17 1 2 A. Gronchi , E. Wardelmann , S. Marreaud , J. Zalcberg , S. Litière , J.-Y. Blay ; Milan, IT,
3 4 5 6 7 8 Villejuif, FR, Valencia, ES, Adelaide, SA/AU, Warsaw, PL, Mannheim, DE, London, GB, 9 10 11 12 13 Bordeaux, FR, Leiden, NL, Lille, CEDEX/FR, Tübingen, DE, Sydney, NSW/AU, Seville, ES, 14 15 16 17 Münster, DE, Brussels, BE, Melbourne, VIC/AU, Lyon, FR
11:30 - 11:45 Invited Discussant 1473O and LBA55 S. Bauer, Essen, DE
11:45 - 12:00 1474O - Improved overall and progression free survival after surgery in expert sites for sarcoma patients: A nationwide study of FSG-GETO/NETSARC 1 2 2 3 4 5 6 J.-Y. Blay , E. Stoeckle , A. Italiano , R.A. Rochwerger , F. Duffaud , S. Bonvalot , C. Honore , G. 7 7 5 8 9 10 11 12 Decanter , C. Maynou , P. Anract , G. Ferron , F. Guillemin , F. Gouin , M. Rios , J.E. Kurtz , P. 13 14 13 15 6 1 2 3 Meeus , J.M. Coindre , I. Ray-Coquard , N. Penel , A. Le Cesne ; Lyon, FR, Bordeaux, FR,
4 5 6 7 8 9 Marseille, FR, Marseille, CEDEX 5/FR, Paris, FR, Villejuif, FR, Lille, FR, Toulouse, CEDEX 3/FR, 10 11 12 13 Reims, FR, Nantes, FR, Vandoeuvre Les Nancy, CEDEX/FR, Strasbourg, FR, Lyon, 14 15 CEDEX/FR, Bordeaux, CEDEX/FR, Lille, CEDEX/FR
12:00 - 12:15 LBA56 - Long-term efficacy of denosumab in giant cell tumor of bone: results of an open-label phase 2 study 1 2 3 4 5 6 7 E. Palmerini , J.-Y. Blay , A. Le Cesne , P. Reichardt , P. Rutkowski , H. Gelderblom , R. Grimer , A. 8 8 9 1 2 3 4 5 Feng , D. Jandial , S. Chawla ; Bologna, IT, Lyon, FR, Villejuif, FR, Berlin-Buch, DE, Warsaw, PL, 6 7 8 9 Leiden, NL, Birmingham, GB, Thousand Oaks, US, Santa Monica, CA/US
12:15 - 12:30 Invited Discussant 1474O and LBA56 W. van der Graaf, Sutton, GB
Last update: 02-09-2017 06:01:33pm esmo.org 11:00 - 12:00 Type: Multidisciplinary Session Valencia Auditorium Title: Lymph involvement in GU cancer Chair(s): P. Bono, FI
11:00 - 11:05 Presentation of case/condition P. Bono, Helsinki, FI
11:05 - 11:15 The medical oncology perspective P. Bono, Helsinki, FI
11:15 - 11:25 The radiation therapy perspective V. Khoo, London, GB
11:25 - 11:35 The surgery perspective A. Bex, Amsterdam, NL
11:35 - 12:00 General Discussion
11:00 - 12:30 Type: Special Symposium Tarragona Auditorium Title: Immunotherapy and targeted therapies in lymphomas Chair(s): M. Provencio Pulla, ES; A. Ferreri, IT
11:00 - 11:05 Introduction A. Ferreri, Milan, IT
11:05 - 11:30 Immune checkpoint inhibition T.A. Eyre, Oxford, GB
11:30 - 11:55 Bispecific T-cell engager A. Viardot, Ulm, DE
11:55 - 12:20 CAR T cell therapy in lymphoma G. Enblad, Uppsala, SE
12:20 - 12:30 Conclusions and clinical perspectives M. Provencio Pulla, Majadahonda, Madrid/ES
Last update: 02-09-2017 06:01:33pm esmo.org 11:00 - 12:30 Type: Joint Symposium Bilbao Title: ESMO-IPOS: Working together to prevent professional burnout and improve Auditorium patient care Chair(s): S. Banerjee, GB; L. Travado, PT
11:00 - 11:05 Introduction L. Travado, Lisbon, PT
11:05 - 11:20 Burnout: The scale of the problem facing oncology professionals S. Banerjee, London, GB
11:20 - 11:35 Communication skills with cancer patients: Improving patient experience L. Fallowfield, Brighton, GB
11:35 - 11:50 The value of psychosocial care for cancer patients L. Travado, Lisbon, PT
11:50 - 12:05 Psychosocial interventions to reduce professional burnout M. Die-Trill, Madrid, ES
12:05 - 12:30 Panel discussion led by 1 2 1 2 M. Preusser , J. Geissler ; Vienna, AT, DE
Last update: 02-09-2017 06:01:33pm esmo.org 11:00 - 12:30 Type: Special Session Alicante Auditorium Title: Women 4 Oncology Chair(s): S. Peters, CH; F. Shepherd, CA
11:00 - 11:05 Numbers and perspectives: The situation of women medical oncologist S. Peters, Lausanne, CH
11:05 - 11:30 Round-table: Gender disparities in the medical field: the Basic Researches and Surgeon perspective 1 2 3 4 5 1 2 3 M. Casiraghi , S. Peters , J. Tabernero , F. Shepherd , C. Dive ; Milan, IT, Lausanne, CH,
4 5 Barcelona, ES, Toronto, ON/CA, Manchester, GB
11:30 - 11:55 How to address equal gender opportunities at a political level? What politicians can do 1 2 3 4 5 6 1 2 C. Diaz , S. Peters , J. Tabernero , F. Shepherd , C. Dive , P. Cornet ; Valencia, ES, Lausanne,
3 4 5 6 CH, Barcelona, ES, Toronto, ON/CA, Manchester, GB, Lawrenceville, US
11:55 - 12:15 Discussion: Step by step: How could ESMO drive changes? 1 2 3 4 1 2 3 4 S. Peters , F. Ciardiello , J. Tabernero , F. Shepherd ; Lausanne, CH, Naples, IT, Barcelona, ES, Toronto, ON/CA
12:15 - 12:17 W4O Award Presentation F. Ciardiello, Naples, IT
12:17 - 12:25 W4O Award Recipient lecture F. Shepherd, Toronto, ON/CA
12:25 - 12:30 Q&A and closing remarks 1 2 1 2 S. Peters , F. Shepherd ; Lausanne, CH, Toronto, ON/CA
Last update: 02-09-2017 06:01:33pm esmo.org 11:00 - 12:00 Type: Multidisciplinary Session Cartagena Auditorium Title: Diagnosis and management of leptomeningeal metastasis Chair(s): E. Le Rhun, FR
11:00 - 11:05 Presentation of case/condition E. Le Rhun, Lille, CEDEX/FR
11:05 - 11:15 Systemic versus intrathecal chemotherapy E. Le Rhun, Lille, CEDEX/FR
11:15 - 11:25 Is there a role for surgery? J.-C. Tonn, Munich, DE
11:25 - 11:35 Treatment concepts in radiation oncology S. Villà, Barcelona, ES
11:35 - 12:00 General Discussion
11:00 - 11:45 Type: Young Oncologist Brunch Salamanca Auditorium Title: Communicating with cancer patients in the era of personalised medicine Chair(s): C. Cardone, IT; M.A. Ozturk, TR
11:00 - 11:45 Communicating with cancer patients in the era of personalised medicine G. Prager, Vienna, AT
Last update: 02-09-2017 06:01:33pm esmo.org 12:30 - 14:30 Type: Patient Advocacy Track Palma Auditorium Title: Managing side effects from immunotherapy Chair(s): G. Spurrier-Bernard, FR; A.-M. Forsea, RO
12:30 - 12:45 Immuno-oncology: Overview of existing therapies and what is coming next? J. Haanen, Amsterdam, NL
12:45 - 13:00 Predicting response to immune therapies T. Kirchhoff, New York, NY/US
13:00 - 13:15 Managing side effects on Immune therapies P. Ascierto, Napoli, IT
13:15 - 13:30 The patient advocate's perspective G. Spurrier, Clermont-Ferrand, FR
13:30 - 14:00 Discussion
13:00 - 14:30 Type: Industry Satellite Symposium Sevilla Auditorium Title: Industry Satellite Symposium 13
13:00 - 14:30 Type: Industry Satellite Symposium Pamplona Auditorium Title: Industry Satellite Symposium 14
13:00 - 14:30 Type: Industry Satellite Symposium Cordoba Auditorium Title: Industry Satellite Symposium 15
13:00 - 14:30 Type: Industry Satellite Symposium Granada Auditorium Title: Industry Satellite Symposium 16
13:00 - 14:30 Type: Industry Satellite Symposium Valencia Auditorium Title: Industry Satellite Symposium 17
13:00 - 14:30 Type: Industry Satellite Symposium Tarragona Auditorium Title: Industry Satellite Symposium 18
13:00 - 14:30 Type: Industry Satellite Symposium Bilbao Auditorium Title: Industry Satellite Symposium 19
13:00 - 14:30 Type: Industry Satellite Symposium Alicante Auditorium Title: Industry Satellite Symposium 20
13:15 - 14:15 Type: Poster Display session Hall 8 Title: Poster display session
Last update: 02-09-2017 06:01:33pm esmo.org
13:15 - 13:15 GASTROINTESTINAL TUMOURS, COLORECTAL 1 2 1 2 R. Adams , R. Glynne-Jones ; Cardiff, GB, Northwood, Middlesex/GB
13:15 - 13:15 487P - International comparison of stage-specific treatment of and survival from colorectal cancer: England, Norway and Sweden, 2010-2012 S. Benitez Majano, C. Di Girolamo, M. Morris, B. Rachet, M. Coleman, S. Walters; London, GB
13:15 - 13:15 488P - Early postoperative PET-CT in patients with pathological stage III colon cancer may change their outcome: Results from a large single institution study 1 2 2 2 2 2 2 2 A. Moore , I. Ben-Aharon , O. Purim , G. Perl , O. Ulitsky , L. Amit , Y. Kundel , R. Lewin , N.
2 2 2 1 2 Wasserberg , H. Kashtan , B. Brenner ; Petah Tikva, IL, Petach Tikva, IL
13:15 - 13:15 489P - Role of body composition in early stage colorectal cancer (CRC) outcomes 1 1 1 2 1 1 2 J. Hopkins , D. Bigam , D. Eurich , V. Baracos , M. Sawyer ; Edmonton, CA, Alberta, CA
13:15 - 13:15 490P - North Japan multicenter phase II study of FOLFOX as adjuvant chemotherapy for stage III colon cancer (NORTH/HGCSG1003): Analysis of tumor location 1 2 2 2 1 1 1 A. Ishiguro , S. Yuki , Y. Kawamoto , H. Nakatsumi , N. Takahashi , T. Shichinohe , T. Kusumi , I. 3 4 5 6 1 7 8 Iwanaga , T. Miyagishima , K. Hatanaka , K. Oomori , M. Nakamura , N. Senmaru , K. Iwai , M. Koike 1 1 1 1 1 2 1 2 , N. Sakamoto , A. Taketomi , S. Hirano , Y. Ito , Y. Komatsu ; Sapporo, JP, Sapporo, 3 4 5 6 7 Hokkaido/JP, Kitami, Hokkaido Prefecture/JP, Kushiro, JP, Hakodate, Hokkaido/JP, Ebetsu, JP, 8 Muroran, JP, Tomakomai, JP
13:15 - 13:15 491P - Factors predicting adherence to a tailored-dose adjuvant treatment based on geriatric assessment in elderly people with colorectal cancer: A prospective study 1 2 3 1 1 2 1 1 M. Antonio , J. Saldaña , A. Carmona-Bayonas , R. Salazar , V. Navarro , C. Tebé , J. Borras ;
2 3 Barcelona, ES, L'hospitalet De Llobregat, Barcelona, ES, Murcia, ES
13:15 - 13:15 492P - Benefits of upfront primary tumour resection (UPTR) according to sidedness in mCRC: Retrospective analyses of TTD MACRO-2 and PLANET randomised trials 1 2 3 3 4 5 M. Benavides , A. Abad , A. Carrato , C. Gravalos , A. Fernández-Montes , E. Falcó , E. 6 7 3 8 9 González-Flores , T. Garcia Garcia , J. Martin-Valades , J. Gallego Plazas , M. Valladares-Ayerbes , 10 11 12 13 14 15 C. García-Girón , R. Dueñas , A. García-Tapiador , C. Pericay , F. Losa , A. Viudez , P. 16 3 17 1 2 3 García-Teijido , E. Diaz Rubio , E. Aranda Aguilar ; Malaga, ES, Badalona, Barcelona/ES, 4 5 6 7 8 9 Madrid, ES, Orense, ES, Palma De Mallorca, ES, Granada, ES, Murcia, ES, Elche, Alicante/ES, 10 11 12 13 14 15 A Coruna, ES, Burgos, ES, Jaén, ES, Ciudad Real, ES, Sabadell, ES, Hospitalet, ES, 16 17 Pamplona, ES, Avilés, ES, Cordoba, ES
13:15 - 13:15 493P - Surgical quality and the impact of liver resection on outcome in the new EPOC study 1 2 3 4 2 5 2 S. Pugh , J. Bridgewater , M. Finch-Jones , M. Rees , D. O'Reilly , M. Peterson , B. Davidson , R. 2 2 2 2 1 1 1 6 Hutchins , N. Heaton , L. Jiao , S. Mudan , A. Allen , J. Mellor , G. Griffiths , D. Cunningham , T.
7 8 1 1 2 3 4 Maughan , J. Garden , J. Primrose ; Southampton, GB, London, GB, Bristol, GB, Basingstoke, GB, 5 6 7 8 Sheffield, GB, Sutton, GB, Oxford, GB, Edinburgh, GB
Last update: 02-09-2017 06:01:33pm esmo.org 13:15 - 13:15 494P - Short-term clinical outcome from a randomized controlled trial of the conventional technique versus the no-touch isolation technique for primary tumor resection in patients with colon cancer: Japan Clinical Oncology Group study JCOG1006 1 2 3 4 5 6 7 8 Y. Takii , K. Komori , M. Shiozawa , M. Ohue , Y. Nishimura , S. Ikeda , N. Takiguchi , T. Kobatake , 3 9 10 11 11 12 11 1 H. Ike , T. Sato , N. Tomita , J. Mizusawa , H. Katayama , Y. Shimada , Y. Kanemitsu ;
2 3 4 5 6 7 Niigata-Shi, JP, Nagoya, JP, Yokohama, JP, Osaka, JP, Kitaadachi, JP, Hiroshima, JP, Chiba, 8 9 10 11 12 Chiba/JP, Matsuyama, JP, Yamagata, JP, Nishinomiya, JP, Tokyo, JP, Kochi, Kochi/JP
13:15 - 13:15 495P - Prognostic impact of tumor deposits in colorectal cancer with lymph nodes metastasis F. Liu, J. Zhao, L. Yang, Y. Xu; Shanghai, CN
13:15 - 13:15 496P - Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer 1 1 1 1 2 1 1 2 S. Zunder , G. van Pelt , H. Gelderblom , R. Tollenaar , C. Mancao , W. Mesker ; Leiden, NL, Basel, CH
13:15 - 13:15 497P - Tumor-stroma interactions and response to targeted agents in preclinical models of colorectal cancer (CRC) 1 2 2 2 2 1 1 2 C. Bazzichetto , F. Conciatori , I. Falcone , F. Cognetti , L. Ciuffreda , M. Milella ; Roma, IT, Rome, IT
13:15 - 13:15 498P - Molecular profiling of colorectal tumors stratified by the histological tumor-stroma ratio T. Sandberg, J. Oosting, G. van Pelt, H. Putter, J.T. van Wezel, R. Tollenaar, J. Morreau, W. Mesker;
Leiden, NL
13:15 - 13:15 499P - The characteristics and prognostic factors in colorectal cancer containing signet ring cell X.Q. Kong, X.Q. Zhang, J.L. Li, Y.P. Dong, J.X. Wu; Fuzhou, CN
13:15 - 13:15 500P - Effect of lateral lymph node dissection for lower rectal cancer: An ad hoc analysis of the ACTS-RC randomized clinical trial 1 1 2 3 4 1 5 E. Oki , M. Shimokawa , A. Murata , T. Takahashi , K. Maeda , T. Kusumoto , Y. Munemoto , K. Ando 1 1 1 1 1 6 1 1 2 , R. Nakanishi , M. Sugiyama , Y. Nakashima , H. Saeki , S. Saji , Y. Maehara ; Fukuoka, JP, 3 4 5 6 Aomori, JP, Gifu, JP, Osaka, JP, Fukui, Fukui/JP, Tokyo, JP
13:15 - 13:15 502P - Effects of mesorectal fascia (MRF) status for locally advanced rectal cancer: Results of a multicenter, randomized, controlled, phase II trial (FDRT-002) J. Zhu, C. Li; Shanghai, CN
13:15 - 13:15 503P - Planned organ preservation for selected T2, T3 rectal cancer: French experience using chemo radiotherapy and contact X ray boost 1 2 1 3 1 1 1 1 J.-P. Gérard , N. Barbet , K. Benezery Sanna , R. Coquard , Y. Chateau , J. Gal , J. Doyen ; Nice,
2 3 FR, Macon, FR, Lyon Villeurbanne, FR
13:15 - 13:15 504P - Comparison between magnetic resonance imaging (MRI) and pathology in the assessment of tumour regression grade (TRG) in rectal cancer (RC)
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 2 2 2 2 F. Sclafani , G. Brown , D. Cunningham , A. Wotherspoon , L. Sena Teixeira Mendes , J. Evans , C. 2 2 1 3 4 5 2 2 Peckitt , R. Begum , D. Tait , J. Capdevila , B. Glimelius , S. Roselló , J. Thomas , J. Oates , I. Chau 6 1 2 3 4 5 6 ; London, GB, Sutton, GB, Barcelona, ES, Uppsala, SE, Valencia, ES, Sutton, Surrey/GB
13:15 - 13:15 505P - FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases (RCSM): Final results of the FFCD 1102 phase II trial 1 2 3 4 5 6 7 J.-B. BACHET , O. Lucidarme , C.B. Levache , E. Maillard , J.L. Raoul , T. Lecomte , C. Desauw , F. 8 9 10 11 12 13 14 Brocard , S. Pernot , G. Breysacher , J.-P. Lagasse , F. Di Fiore , P.L. Etienne , O. Dupuis , A. 15 16 1 1 2 3 4 Aleba , C. Lepage , J. Taieb ; Paris, FR, Paris, CEDEX 13/FR, Périgueux, 24004/FR, Dijon, FR, 5 6 7 8 9 Marseille, FR, Chambray-Lès-tours, FR, Lille, CEDEX/FR, Nancy, FR, Boulogne-Billancourt, FR, 10 11 12 13 14 15 16 Colmar, FR, Orleans, FR, Rouen, FR, St. Brieuc, FR, Le Mans, FR, Niort, CEDEX/FR, Dijon, Cedex/FR
13:15 - 13:15 506P - Neoadjuvant treatment with mFOLFOXIRI alone versus chemoradiotherapy in locally advanced rectal cancer: A propensity score analysis from two prospective trials 1 2 1 1 1 1 1 1 1 1 J. Zhang , Y. Cai , H. Hu , D. Chen , J. Xiao , W. Wang , P. Lan , M. Huang , L. Wang , X. Wu , L.
1 1 1 1 2 Kang , J. Wang , Y. Deng ; Guangzhou, CN, Guangzhou, Guangdong/CN
13:15 - 13:15 507P - Updated survival results of FACT trial: Multicenter phase II trial of neoadjuvant chemotherapy with mFOLFOX6 for stage II/III rectal cancer with a T3/T4 tumor. 1 1 1 1 1 1 1 H. Hasegawa , K. Okabayashi , M. Tsuruta , J. Koike , K. Funahashi , H. Yokomizo , K. Yoshimatsu , 1 1 2 2 1 1 1 3 H. Kan , T. Yamada , H. Ishida , K. Ishibashi , Y. Saida , T. Enomoto , K. Katsumata , K. Koda , T. 1 1 1 1 1 1 2 3 Ochiai , K. Sakamoto , S. Ogawa , M. Itabashi , S. Kameoka ; Tokyo, JP, Saitama, JP, Ichihara, Chiba/JP
13:15 - 13:15 508P - Phase II randomized trial of capecitabine + radiation therapy with/without bevacizumab as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: Final results of 3 and 5-year disease free survival, distant relapse free survival and overall survival 1 2 3 4 2 5 C. Gravalos , J. Capdevila , L. Layos , C. Pericay , M. Martínez-Villacampa , C. López López , F. 2 6 7 8 8 9 1 Losa , M.J. Safont , A. Gómez-España , V. Alonso , P. Escudero , J. Gallego , B. García-Paredes , A. 10 2 2 7 1 2 3 Palacios , S. Biondo , R. Salazar , E. Aranda Aguilar ; Madrid, ES, Barcelona, ES, Badalona, ES, 4 5 6 7 8 9 10 Sabadell, ES, Santander, ES, Valencia, ES, Cordoba, ES, Zaragoza, ES, Alicante, ES, Córdoba, ES
13:15 - 13:15 509P - Immunological features of resected tumor after neoadjuvant chemotherapy (NAC) and chemoradiotherapy (CRT) become the superior prediction markers for recurrence in rectal cancer K. Imaizumi, T. Suzuki, M. Shimomura, Y. Tsukada, T. Sasaki, Y. Nishizawa, M. Kojima, M. Ito, T.
Nakatsura; Kashiwa, JP
13:15 - 13:15 510P - The ADC value of post-RT might predict TRG after neoadjuvant radiotherapy for local advanced rectal cancer W. Junxin, L. Jinluan, D. Kaixin; Fuzhou, CN
13:15 - 13:15 511P - Polyethylene glycol embolics loaded with irinotecan for chemoembolization of refractory liver metastases from colorectal cancer
Last update: 02-09-2017 06:01:33pm esmo.org 1 1 2 3 1 1 4 G. Fiorentini , D. Sarti , R. Carandina , M. Nardella , L. Mulazzani , A. Felicioli , D. Barnes Navarro , 5 6 2 1 2 3 4 5 F. Mugnos Gomez , O. Zoras , C. Aliberti ; Pesaro, IT, Padova, IT, Matera, IT, Barcelona, ES, 6 Valencia, ES, Crete, GR
13:15 - 13:15 512P - Neoadjuvant systemic chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis from colorectal cancer N. Asher, G. Lahat, R. Geva; Tel Aviv, IL
13:15 - 13:15 513P - Efficacy and tolerability of chronomodulated FOLFIRINOX (chronoIFLO) as 1st or 2nd line treatment in patients (pts) with metastatic colorectal cancer (MCC): Final results from an international trial (EORTC 05011) 1 2 3 4 5 6 2 1 C. Garufi , F. Levi , A. Karaboué , A. Torsello , C. Focan , P. Chollet , P. INNOMINATO ; Pescara,
2 3 4 5 6 IT, Coventry, GB, Vitry-Sur-seine, FR, Roma, IT, Liège, BE, Clermont-Ferrand, CEDEX 1/FR
13:15 - 13:15 514P - A multicentre, randomized phase 3 study on the optimization of the combination of bevacizumab with mFOLFOX/OXXEL in patients with metastatic colorectal cancer (mCRC) 1 1 2 1 1 2 1 A. Avallone , G. Nasti , G. Rosati , C. Carlomagno , C. Romano , D. Bilancia , A. De Stefano , A. 1 1 1 1 1 1 1 1 Ottaiano , A. Cassata , L. Silvestro , S. Tafuto , F. Bianco , P. Delrio , F. Izzo , E. Di Gennaro , S. 1 3 1 1 1 1 2 3 Lastoria , C. Gallo , F. Perrone , A. Budillon , M.C. Piccirillo ; Napoli, IT, Potenza, IT, Naples, IT
13:15 - 13:15 515P - First-in-human Phase I study of bacterial RNA interference therapeutic CEQ508 in patients with familial adenomatous polyposis (FAP) 1 2 3 3 3 3 1 2 V. Trieu , L. Hwang , K. Ng , O. D'Cruz , S. Qazi , A. Fong ; Costa Mesa, CA/US, City Of Industry,
3 CA/US, Costa Mesa, US
13:15 - 13:15 516P - A Multicentre Phase I/II Study of TAS-102 with nintedanib in patients with metastatic colorectal cancer refractory to standard therapies (N-task force: EPOC1410) 1 2 2 3 4 5 2 4 K. Yamazaki , Y. Kuboki , E. Shinozaki , H. Hara , Y. Komatsu , T. Nishina , K. Yamaguchi , S. Yuki , 6 7 8 1 4 5 9 H. Bando , M. Asayama , T. Tsushima , S. Hamauchi , H. Nakatsumi , T. Kajiwara , M. Wakabayashi 2 9 6 6 6 1 2 3 , S. Nomura , A. Sato , T. Doi , A. Ohtsu , T. Yoshino ; Shizuoka, Shizuoka/JP, Tokyo, JP, 4 5 6 7 8 9 Saitama, JP, Sapporo, Hokkaido/JP, Matsuyama, JP, Kashiwa, Chiba/JP, Ina, JP, Shizuoka, JP, Chiba, JP
13:15 - 13:15 517P - BEACON CRC: safety lead-in (SLI) for the combination of binimetinib (BINI), encorafenib (ENCO), and cetuximab (CTX) in patients (pts) with BRAF-V600E metastatic colorectal cancer (mCRC) 1 1 2 3 4 5 6 S. Huijberts , J. Schellens , E. Elez , P.-J. Cuyle , E. Van Cutsem , R. Yaeger , M. Fakih , C. 2 7 8 9 10 11 12 Montagut , M. Peeters , J. Desai , T. Yoshino , F. Ciardiello , H. Wasan , A. Grothey , K. Maharry 13 14 15 1 2 3 4 5 , A. Gollerkeri , S. Kopetz ; Amsterdam, NL, Barcelona, ES, Bonheiden, BE, Leuven, BE, 6 7 8 9 10 New York, US, Duarte, CA/US, Edegem, BE, Melbourne, VIC/AU, Kashiwa, Chiba/JP, Naples, IT, 11 12 13 14 15 London, GB, Rochester, MN/US, Boulder, US, Cambridge, US, Houston, US
13:15 - 13:15 518P - Sequential therapy with bevacizumab and epidermal growth factor receptor-directed agents for metastatic colorectal carcinoma: A retrospective, registry-based analysis
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 3 4 3 5 2 6 T. Buchler , R. Chloupkova , A. Poprach , O. Fiala , I. Kiss , K. Kopeckova , L. Dusek , L. Slavicek , 7 4 2 8 9 1 2 3 M. Kohoutek , J. Finek , M. Svoboda , L. Petruzelka , B. Melichar ; Prague, 4/CZ, Brno, CZ, Brno,
4 5 6 7 8 South Moravian/CZ, Plzen, Plzen/CZ, Prague, 5/CZ, Jihlava, Vysocina/CZ, Zlin, Zlin/CZ, Prague, 9 2/CZ, Olomouc, CZ
13:15 - 13:15 519P - Outcomes in patients receiving maintenance therapy in two panitumumab (Pmab) first-line trials for metastatic colorectal cancer (mCRC) 1 2 3 4 4 5 F. Rivera Herrero , J.-B. Bachet , D. Modest , F. de Braud , F. Pietrantonio , R. Koukakis , G. 6 7 1 2 3 4 5 Demonty , J.-Y. Douillard ; Santander, ES, Paris, CEDEX 13/FR, Munich, DE, Milan, IT, Uxbridge, 6 7 GB, Zug, CH, Lugano - Viganello, CEDEX/CH
13:15 - 13:15 520P - AMALTHEA: A prospective, single-arm study of the Hellenic Cooperative Oncology Group evaluating the efficacy and safety of 1st line FOLFIRI+Aflibercept in patients with metastatic colorectal cancer 1 2 2 2 2 2 G. Pentheroudakis , V. Kotoula , G.-A. Koliou , I. Tikas , V. Karavasilis , E. Samantas , G. Aravantinos 2 2 3 2 2 2 2 2 , E. Daskalaki , I. Souglakos , G. Koumakis , I. Efstratiou , C. Petraki , C. Poulios , D. Bafaloukos , 2 2 2 1 2 3 D. Pectasides , E. Vrettou , G. Fountzilas ; Ioannina, GR, Athens, GR, Heraklion, GR
13:15 - 13:15 521P - Multicenter phase II study of biweekly XELIRI plus bevacizumab as a second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study) 1 2 1 1 3 4 5 6 Y. Mori , N. Suzuki , T. Nagasaka , H. Tanioka , Y. Iwamoto , Y. Neki , T. Yamatsuji , M. Kobayashi , 2 7 7 8 7 9 10 8 M. Nakajima , Y. Ojima , S. Ikeda , K. Kawamoto , K. Shinozaki , A. Tsuji , T. Hinoi , Y. Yamaguchi 1 11 7 2 1 2 3 , K. Yamashita , M. Shimokawa , M. Okajima , S. Hazama ; Okayama, JP, Ube, JP, Hiroshima, 4 5 6 7 8 9 Hiroshima/JP, Kochi, JP, Okayama, Okayama/JP, Nangoku, JP, Hiroshima, JP, Kurashiki, JP, 10 11 Kagawa, JP, Kure, JP, Fukuoka, JP
13:15 - 13:15 522P - Sex-related differences in circadian-dependent tolerance of Irinotecan (I) added to chronomodulated (chrono) 5-Fluorouracil (F), Leucovorin (L) and Oxaliplatin (O): Final results from international randomised time-finding study in patients with metastatic colorectal cancer (MCC) 1 2 3 4 5 6 1 1 F. Levi , C. Garufi , A. Karaboué , C. Focan , P. Chollet , X.-M. Li , P. INNOMINATO ; Coventry, GB,
2 3 4 5 6 Pescara, IT, Vitry-Sur-seine, FR, Liège, BE, Clermont-Ferrand, CEDEX 1/FR, Villejuif, FR
13:15 - 13:15 523P - Mechanism of pelareorep (Pel)-mediated cell death in a Phase I study in combination with irinotecan/fluorouracil/leucovorin/bevacizumab (FOLFIRI/B) in patients with KRAS mutant metastatic colorectal cancer (mCRC) 1 2 3 3 3 3 4 4 S. GOEL , A. Ocean , I. Chaudhary , M. Ghalib , E. Kaledzi , U. Shah , A. GUTIERREZ , M. Coffey ,
4 3 1 2 3 4 G. Gill , R. Maitra ; Bronx, US, New York, NY/US, Bronx, NY/US, Calgary,, CA
13:15 - 13:15 524P - Bevacizumab first line and impact on subsequent anti-EGFR activity 1 2 3 4 4 3 4 5 T. Price , J. Hardingham , C. Karapetis , E. Smith , R. Padbury , A. Roy , D. Roder , M. Burge , A. 1 1 2 3 4 5 Townsend ; Woodville, SA/AU, Adelaide, AU, Bedford Park, SA/AU, Adelaide, SA/AU, Brisbane, QLD/AU
13:15 - 13:15 525P - Efficacy of anti-EGFR antibodies combined with chemotherapy for elderly patients with RAS wild-type metastatic colorectal cancer: A systematic review and metanalysis
Last update: 02-09-2017 06:01:33pm esmo.org L. Belluomini, I. Carandina, F. Bonetti, B. Urbini, F. Daniel, F. Lancia, L.R. Martella, I. Toma, A. Moretti,
E. Bannò, C. Nisi, L. Da Ros, A. Frassoldati; Ferrara, IT
13:15 - 13:15 526P - Efficacy of panitumumab and cetuximab in elderly patients (aged ≥75) with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC): Retrospective analysis of data from nationwide drug-reimbursement-access program M. Swierkowski, A. Ptak-Chmielewska, A. Sliwczynski, T. Czeleko, Z. Teter, C. Szczylik; Warsaw, PL
13:15 - 13:15 527P - Toxicity and efficacy of flat-dosed versus body-surface area (BSA)-dosed capecitabine F. Man, G. Veerman, E. Oomen-De Hoop, E. Meerten, T. van Gelder, R. Mathijssen; Rotterdam, NL
13:15 - 13:15 528P - Efficacy of panitumumab and cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC): Retrospective analysis of data from nationwide drug-reimbursement-access program M. Swierkowski, A. Ptak-Chmielewska, A. Sliwczynski, T. Czeleko, Z. Teter, C. Szczylik; Warsaw, PL
13:15 - 13:15 529P - Multicenter randomized phase II trial (BEVATOMOX) assessing the raltitrexed, oxaliplatin and bevacizumab combination versus FOLFOX6 bevacizumab as 2nd line treatment in metastatic colorectal cancer (mCRC) 1 2 3 4 5 5 6 E. Samalin , H. Senellart , S. Thezenas , S. Jacquot , S. Ellis , F. Khemissa , M. Ramdani , F. 3 3 3 7 1 1 2 Portales , E. Assenat , T. Mazard , L. Mineur , M. Ychou ; Montpellier, CEDEX 5/FR, Saint-Herblain, 3 4 5 6 7 CEDEX/FR, Montpellier, FR, Teheran, IR, Perpignan, FR, Béziers, CEDEX/FR, Avignon, FR
13:15 - 13:15 530P - Safety analysis of phase Ib study of FOLFOXIRI plus ramucirumab as first-line therapy for patients with metastatic colorectal cancer 1 2 3 4 5 6 7 8 H. Taniguchi , Y. Kito , H. Satake , Y. Horie , T. Yamada , T. Esaki , T. Denda , K. Mori , K. 9 1 2 3 4 5 6 Yamazaki ; Nagoya, Aichi/JP, Kanazawa, JP, Kobe, JP, Kawasaki, JP, Tsukuba, JP, Fukuoka, 7 8 9 JP, Chiba, Chiba/JP, Shizuoka, JP, Shizuoka, Shizuoka/JP
13:15 - 13:15 531P - Prognostic factors and specific populations in the pharmacogenetic randomized phase II trial of FOLFIRI with high-dose (HD) of irinotecan vs standard doses in metastatic colorectal cancer (mCRC) patients (pts) according to UGT1A1 genotype 1 1 1 2 1 1 3 M. Tobeña , D. Paez , A. Sebio Garcia , J. Fernandez-Plana , M. Martín , A. Virgili , L. Cirera , P.
1 1 1 1 2 3 Riera , I. Sullivan , J. Salazar ; Barcelona, ES, Terrassa, ES, Terrassa, Barcelona/ES
13:15 - 13:15 532P - Analysis of efficacy and prognostic factors in second-line chemotherapy for BRAF V600E mutant metastatic colorectal cancer 1 1 2 1 1 1 2 2 S. Mitani , H. Taniguchi , K. Honda , T. Masuishi , Y. Narita , S. Kadowaki , T. Ura , M. Ando , M.
1 1 1 2 Tajika , K. Muro ; Nagoya, Aichi/JP, Nagoya, JP
13:15 - 13:15 533P - A large retrospective multicenter study evaluating prognosis and chemosensitivity of metastatic colorectal cancer with microsatellite instability
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 3 4 4 5 6 D. Tougeron , R. Cohen , B. Sueur , D. Sefrioui , L. Gentilhomme , T. Lecomte , T. Aparicio , G. Des 7 8 9 10 11 12 13 Guetz , P. Artru , C. de la Fouchardiere , V. Moulin , V. Hautefeuille , R. Coriat , Y. Touchefeu , 14 2 3 2 15 2 1 2 C. Lecaille , G. Goujon , A. Ferru , J. Taieb , T. André , A. Zaanan ; Poitiers, CEDEX/FR, Paris,
3 4 5 6 7 8 FR, Poitiers, FR, Rouen, FR, Chambray-Lès-tours, FR, Bobigny, CEDEX/FR, Limoges, FR, Lyon, 9 10 11 12 CEDEX 8/FR, Lyon, CEDEX/FR, La Rochelle, FR, Amiens, CEDEX/FR, Paris, CEDEX 14/FR, 13 14 15 Nantes, CEDEX 1/FR, Bordeaux, FR, Paris, CEDEX 12/FR
13:15 - 13:15 534P - Exploratory analysis of baseline microsatellite instability (MSI) status in patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) or placebo in the phase 3 CORRECT trial 1 1 2 1 2 K. Köchert , G. Beckmann , M. Teufel ; Berlin, DE, Whippany, NJ/US
13:15 - 13:15 535P - Investigation of MSI status in acquired resistance to 5-fluorouracil treatment in colorectal cancer using a SILAC-based quantitative proteomic analysis method M. Ortega Duran, S. Shnyder, C. Sutton, S.-U. Shaheed; Bradford, GB
13:15 - 13:15 536P - Docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: A phase II study of French interdisciplinary GERCOR and FFCD Groups (Epitopes-HPV02 study) 1 2 3 4 5 3 6 S. Kim , E. Francois , F.-C. Bidard , E. Samalin , F. El Hajbi , N. Baba-Hamed , S. Dumont , S. 7 8 9 10 11 12 13 14 Pernot , D. Peiffert , F. Ghiringhelli , O. Bouche , J. Desrame , M. Zoubir , A. Parzy , D. Smith , 15 16 14 1 17 1 C. de la Fouchardiere , B. Buecher , V. Vendrely , F. Bonnetain , C. Borg ; Besançon, 2 3 4 5 6 7 CEDEX/FR, Nice, FR, Paris, FR, Montpellier, FR, Lille, FR, Paris, CEDEX 12/FR, 8 9 10 11 12 Boulogne-Billancourt, FR, Nancy, FR, Dijon, Cedex/FR, Reims, FR, Lyon, CEDEX 8/FR, La 13 14 15 16 17 Défense, FR, Caen, FR, Bordeaux, FR, Lyon, CEDEX/FR, Paris, CEDEX 5/FR, Besançon, FR
13:15 - 13:15 537P - P2 study of ADXS11-001 Immunotherapy in patients with persistent/recurrent, surgically unresectable locoregional, or metastatic squamous cell anal cancer 1 2 3 1 4 5 6 1 2 C. Eng , M. Fakih , M. Amin , V. Morris , H. Hochster , P. Boland , H. Uronis ; Houston, TX/US,
3 4 5 6 Duarte, CA/US, St. Louis, MO/US, New Haven, CT/US, Buffalo, NY/US, Durham, NC/US
13:15 - 13:15 538P - Relationship between pretreatment levels of circulating DNA, circulating tumor cells, CEA, CA19.9 and tumor burden on CT scan in patients treated for a metastatic colorectal cancer M. Hassine, C. Savoye-Collet, D. Sefrioui, L. Beaussire, A. Gillibert, A. Gangloff, N. Sarafan-Vasseur, P.
Michel, F. Di Fiore; Rouen, FR
13:15 - 13:15 539P - Circulating tumor cells (CTCs), molecular alterations and their correlation with characteristics of patients (pts) with metastatic colorectal cancer (mCRC) treated in the Spanish TTD VISNÚ Program 1 1 2 1 3 4 5 J. Sastre , V. de la Orden , A. Martínez , I. Bando , I. Santamaría , B. Bellosillo Paricio , S. Palanca , 1 1 1 2 3 1 6 I. Peligros , B. Mediero , P. Llovet , V. Moreno , J.M. Viéitez , P. Garcia-Alfonso , S. Gil , M.J. Ortiz 2 5 7 8 2 1 1 Morales , M.A. Salud Salvia , G. Quintero , F.A. Gesto , E. Aranda Aguilar , E. Diaz Rubio ; Madrid, 2 3 4 5 6 7 8 ES, Cordoba, ES, Oviedo, ES, Barcelona, ES, Valencia, ES, Malaga, ES, No City Provided, NA, Santander, ES
13:15 - 13:15 540P - Analysis of liquid biopsies from metastatic colorectal carcinoma (mCRC) patients (pts) enrolled in the CAPRI GOIM clinical trial
Last update: 02-09-2017 06:01:33pm esmo.org 1 1 1 1 1 1 N. Normanno , R. Esposito Abate , M. Lambiase , L. Forgione , C. Cardone , A. Iannaccone , A. 1 1 2 3 4 1 5 1 Sacco , A. Rachiglio , E. Martinelli , D. Rizzi , S. Pisconti , G. Cartenì , R. Bordonaro , T. Troiani , F.
3 6 7 8 9 2 1 2 3 Giuliani , S. Leo , S. Romito , A. Rinaldi , E. Maiello , F. Ciardiello ; Napoli, IT, Naples, IT, Bari, IT, 4 5 6 7 8 9 Statte, IT, Catania, IT, Lecce, IT, Foggia, IT, Castellaneta, IT, San Giovanni Rotondo, IT
13:15 - 13:15 541P - Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemoradiotherapy before surgery in patients with locally advanced rectal cancer 1 2 1 2 3 1 1 J. Schou , B. Sørensen , F. Larsen , R. Abrantes , A. Boysen , J. Johansen , B. Vittrup Jensen , D.
1 3 1 2 3 Nielsen , K.-L. Spindler ; Herlev, DK, Århus, DK, Aarhus C, DK
13:15 - 13:15 542P - Circulating tumor (ct) DNA captures intrapatient heterogeneity in metastatic colorectal (mCRC) patients (pts) progressing to FOLFIRI+panitumumab 1 2 1 1 3 4 5 J. Vidal , J.M. Viéitez , D. Paez , C. Santos , E. Falcó , C. López López , M. Valladares-Ayerbes , L. 6 7 6 1 1 1 Robles , P. Garcia-Alfonso , G. Duran Ogaya , D. Azuara , A. Dalmeses , B. Bellosillo Paricio , G.
1 1 8 1 1 2 3 CAPELLA , R. Salazar , E. Aranda Aguilar , C. Montagut ; Barcelona, ES, Oviedo, ES, Palma De 4 5 6 7 8 Mallorca, ES, Santander, ES, A Coruna, ES, Malaga, ES, Madrid, ES, Cordoba, ES
13:15 - 13:15 543P - Dynamic changes in levels of gene mutations using circulating tumor DNA (ctDNA) and efficacy of 1st-line modified (m)-FOLFOXIRI plus bevacizumab (bev) for metastatic colorectal cancer (mCRC) harboring RAS mutation (mt) (JACCRO CC-11) 1 1 2 3 2 4 5 Y. Sunakawa , T. Sekikawa , J. Usher , H. Satake , Y. Jaimes , Y. Miyamoto , M. Nakamura , H. 6 1 7 8 9 10 11 Nakayama , K. Kazama , A. Takagane , A. Makiyama , K. Kobayashi , Y. Kubota , M. Mori , M. 3 10 10 12 2 1 1 2 Kotaka , M. Takeuchi , M. Fujii , K. Danenberg , H.-J. Lenz , W. Ichikawa ; Yokohama, JP, Los 3 4 5 6 7 8 Angeles, CA/US, Kobe, JP, Kumamoto, JP, Matsumoto, JP, Nagoya, JP, Hakodate, JP, 9 10 11 12 Kita-Kyusyu, JP, Nagasaki, JP, Tokyo, JP, Shimotsuke, JP, New York, CA/US
13:15 - 13:15 544P - The frequency of RAS mutation in circulating tumor DNA predicts worse survival in patients with mCRC L. Yang, Y. Cai, J. Zhang, H. Hu, Z. Wu, R. Deng, Y. Deng; Guangzhou, CN
13:15 - 13:15 545P - Epidermal growth factor receptor (EGFR) copy number (CN) as a biomarker of prognosis and panitumumab (Pan) benefit in RAS-wt advanced colorectal cancer (aCRC) 1 2 2 2 2 2 2 J. Seligmann , H. Wood , S. Richman , F. Elliott , M. Taylor , E. Tinkler-Hundal , J. Barrett , M.
1 2 1 2 Seymour , P. Quirke ; Leeds, Yorkshire/GB, Leeds, GB
13:15 - 13:15 546P - Survival analysis of KRAS, NRAS, BRAF, PIK3CA wild type (wt) metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI plus cetuximab in the CAPRI- GOIM trial 1 2 2 2 3 4 2 E. Martinelli , C. Cardone , T. Troiani , N. Normanno , S. Pisconti , R. Bordonaro , A. Nappi , F. 5 2 6 2 2 7 5 8 Giuliani , M. Biglietto , C. Barone , A. Rachiglio , V. Montesarchio , S. Cinieri , D. Rizzi , A. Febbraro 9 10 5 9 1 1 2 3 , T.P. Latiano , G. Modoni , G. Colucci , E. Maiello , F. Ciardiello ; Naples, IT, Napoli, IT, Statte, 4 5 6 7 8 9 10 IT, Catania, IT, Bari, IT, Roma, IT, Brindisi, IT, Benevento, IT, San Giovanni Rotondo, IT, Taranto, IT
13:15 - 13:15 547P - ULTRA clinical trial: Prospective comparative clinical outcome analysis of three different RAS/BRAF sensitivity mutational cut-offs. A Phase II study of the Spanish TTD Group
Last update: 02-09-2017 06:01:33pm esmo.org 1 1 2 1 1 3 1 4 R. Salazar , D. Azuara , J.M. Viéitez , D. Paez , C. Santos , E. Falcó , E. Elez , C. López López , M. 5 6 7 8 6 9 Valladares-Ayerbes , L. Robles , P. Garcia-Alfonso , C. Buges , G. Duran Ogaya , M.A. Salud Salvia , 1 1 10 1 2 3 V. Navarro , G. CAPELLA , E. Aranda Aguilar ; Barcelona, ES, Oviedo, ES, Palma De Mallorca, 4 5 6 7 8 9 ES, Santander, ES, A Coruna, ES, Malaga, ES, Madrid, ES, Badalona, Barcelona/ES, Valencia, 10 ES, Cordoba, ES
13:15 - 13:15 548P - Prognostic impact of BRAF and KRAS mutations according to the consensus molecular subtypes of colorectal cancer 1 1 1 1 2 1 1 1 J. Smeby , A. Sveen , C. Bergsland , J. Bruun , M. Merok , S. Danielsen , M. Hektoen , M. Eknæs , I.
1 1 1 1 1 2 Eilertsen , M. Grønlie Guren , A. Nesbakken , R. Lothe ; Oslo, NO, Lørenskog, NO
13:15 - 13:15 549P - Gene expression signatures in BRAF V600E mutant colorectal cancer in relation to WNT signaling cascade 1 1 1 1 1 1 1 1 K. YASUI , T. Nagasaka , A. Nyuya , T. Toshima , T. Kawai , K. Shigeyasu , S. Yano , Y. Mori , J.
1 1 1 2 1 1 2 Haraga , K. Nakamura , Y. Umeda , A. Goel , T. Fujiwara ; Okayama, JP, Texas, TX/US
13:15 - 13:15 550P - Prognostic significance of BRAF mutation-associated gene signature in colorectal cancer 1 2 3 1 4 1 1 1 2 J.E. Hwang , W.K. Bae , H.-J. Shim , S.H. Cho , I.J. Chung , K. Kim , E.C. Hwang ; Hwasun, KR,
3 4 Hwasun-Gun, KR, Hwasun, Jeollanam-do/KR, Hwasun, Jeonnam/KR
13:15 - 13:15 551P - Comparative and multimodal analysis of the EGFR, HER2, c-MYC, and MET copy number alteration using in situ hybridization in Korean colorectal cancer patients with integration of array-based copy number data from The Cancer Genome Atlas 1 1 2 3 2 2 2 2 1 Y. Kwak , S. Yun , S.K. Nam , A.N. Seo , K.S. Lee , H.-K. Oh , D.W. Kim , S.B. Kang , W.H. Kim ,
2 1 2 3 H.S. Lee ; Seoul, KR, Sungnamsi, KR, Daegu, KR
13:15 - 13:15 552P - Mutational status and metastatic patteRn in a cohort Of ADvanced colorectal cancer (aCRC) patients (pts): The ROAD study E. Ongaro, G. De Maglio, L. Gerratana, M. Bonotto, S.K. Garattini, D. Basile, M. Cattaneo, V. Andreotti, F. Cortiula, A. Parnofiello, V. Fanotto, S. Pizzolitto, G. Cardellino, M. Casagrande, F. Puglisi, G. Aprile, N. Pella, G. Fasola; Udine, IT
13:15 - 13:15 553P - First-line panitumumab (P) plus capecitabine (C) for the treatment of elderly patients (pts) with wild-type KRAS metastatic colorectal cancer (mCRC): Preliminary results of the phase II, PANEL GITuD-2011-01 study 1 1 2 2 3 J.C. Méndez Méndez , M. Ramos , J.C. De la Cámara Gómez , M.L. Pellón , M. Covela , G.A. 3 4 5 6 Quintero Aldana , M. Salgado Fernandez , A. Fernández-Montes , M. Reboredo , M. 6 7 8 8 1 Valladares-Ayerbes , M. Jorge Fernandez , P. González Villarroel , C. Romero Reinoso ; A Coruña, 2 3 4 5 6 7 8 ES, Ferrol, ES, Lugo, ES, Ourense, ES, Orense, ES, A Coruna, ES, Vigo, Pontevedra/ES, Vigo, ES
13:15 - 13:15 554P - Prevalence of KRAS/NRAS/BRAF mutations detected by massive parallel sequencing and differential outcomes in MCRC patients (pts) treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy 1 2 2 2 1 1 2 1 G. Bruera , F. Pepe , U. Malapelle , P. Pisapia , A. Dal Mas , G. Calvisi , G. Troncone , E. Ricevuto ;
1 2 L'aquila, IT, Napoli, IT
Last update: 02-09-2017 06:01:33pm esmo.org
13:15 - 13:15 555P - Analysis of angiogenesis biomarkers for ramucirumab (RAM) efficacy in patients with metastatic colorectal cancer (mCRC) from RAISE, a global, randomized, double-blind, Phase 3 study 1 2 3 4 5 6 J. Tabernero , R. Hozak , T. Yoshino , A. Cohn , R. Obermannova , G. Bodoky , R. Garcia-Carbonero 7 8 9 10 2 11 12 13 , T.-E. Ciuleanu , D. Portnoy , K. Muro , H. Ouyang , S. Melemed , D. Ferry , F. Nasroulah , E. 14 1 2 3 4 5 Van Cutsem ; Barcelona, ES, Indianapolis, IN/US, Kashiwa, Chiba/JP, Somerset, NJ/US, Brno, 6 7 8 9 10 South Moravian/CZ, Budapest, HU, Madrid, ES, Cluj-Napoca, RO, Memphis, TN/US, Nagoya, 11 12 13 14 Aichi/JP, New York, IN/US, Bridgewater, NJ/US, Buenos Aires, AR, Leuven, BE
13:15 - 13:15 556P - A novel CpG panel is independently associated with colorectal cancer survival 1 1 1 1 1 1 2 2 M. Jia , Y. Zhang , L. Jansen , V. Walter , D. Edelmann , M. Maierthaler , K. Tagscherer , W. Roth , 1 1 1 1 1 3 1 M. Bewerunge-Hudler , E. Herpel , M. Kloor , A. Ulrich , B. Burwinkel , H. Bläker , J. Chang-Claude , 1 1 1 2 3 H. Brenner , M. Hoffmeister ; Heidelberg, DE, Mainz, DE, Berlin, DE
13:15 - 13:15 557P - Predictive factors for early progression during induction chemotherapy (IC) and chemotherapy-free interval (CFI): Analysis from PRODIGE 9 trial 1 2 3 4 5 6 7 T. Aparicio , J. Bennouna , K. Le Malicot , V. Boige , J. Taieb , O. Bouche , E. Francois , J.-M. Phelip 8 9 10 11 12 13 14 , C. Borel , R. Faroux , L. Dahan , J.-B. Bachet , J. Egreteau , M.-C. Kaminsky-Forrett , J.-M. 15 16 17 18 19 19 1 Gornet , O. Cojocarasu , M. Gasmi , V. Guerin-Meyer , F. Ghiringhelli , C. Lepage ; Bobigny, 2 3 4 5 6 7 8 CEDEX/FR, Nantes, CEDEX/FR, Dijon, FR, Villejuif, FR, Paris, FR, Reims, FR, Nice, FR, 9 10 11 Saint-Etienne, FR, Strasbourg, CEDEX/FR, La Roche Sur Yon, CEDEX 9/FR, Marseille, CEDEX 12 13 14 15 5/FR, Paris, CEDEX 13/FR, Lorient, FR, Vandoeuvre Les Nancy, CEDEX/FR, Paris, CEDEX 16 17 18 19 10/FR, Le Mans, FR, Marseille, FR, Angers, FR, Dijon, Cedex/FR
13:15 - 13:15 558P - High PD-L1 expression and high CD8+ T-cell infiltration identifies a new subpopulation of colorectal cancer with high risk of relapse and poor outcome 1 1 1 1 1 2 1 1 1 2 M. Fakih , C. Ouyang , C. Wang , T. Tu , M. Cho , M. Sy , J. Longmate , P. Lee ; Duarte, CA/US, Duarte, US
13:15 - 13:15 559P - Clinical impact of molecular positive lymph node status in colorectal cancer 1 2 3 4 5 6 7 5 N. Matsuura , N. Tomita , M. Inomata , K. Murata , S. Hayashi , Y. Miyake , S. Igarashi , M. Itabashi , 8 9 10 7 10 11 6 T. Kato , S. Noura , T. Furuhata , H. Ozawa , I. Takemasa , M. Yasui , H. Takeyama , O. 12 12 1 2 3 4 5 Okamura , H. Yamamoto ; Osaka, JP, Nishinomiya, JP, Yufu, Oita/JP, Amagasaki, JP, Tokyo, 6 7 8 9 10 11 JP, Minoh, JP, Utsunomiya, JP, Amagasaki, Hyogo/JP, Sakai, JP, Sapporo, JP, Kaizuka, JP, 12 Suita, JP
13:15 - 13:15 560P - Impact of Immune response-associated gene polymorphisms on tumor response in rectal cancer patients treated with capecitabine +/- oxaliplatine and radiation in the ACCORD-12/PRODIGE-2 phase III trial 1 2 3 2 4 5 1 6 1 B. Valerie , C. Mollevi , N. Chaput , S. Gourgou , D. Azria , J.F. Seitz , L. Bigot , B. Juzyna , I. Miran 7 6 1 2 3 4 , J.-P. Gérard , P. Laurent-Puig ; Villejuif, FR, Montpellier, FR, Villejuif, CEDEX/FR, Montpellier, 5 6 7 CEDEX 5/FR, Marseille, CEDEX 5/FR, Paris, FR, Nice, FR
13:15 - 13:15 561P - Improving treatment decisions in colon cancer: The tumor-stroma ratio (TSR) additional to the TNM classification
Last update: 02-09-2017 06:01:33pm esmo.org 1 1 1 2 3 4 5 W. Mesker , G. van Pelt , A. Huijbers , J. van der Laak , E. Dequeker , J.-F. Fléjou , R. Al Dieri , D. 6 2 1 1 2 3 4 5 Kerr , J. Van Krieken , R. Tollenaar ; Leiden, NL, Nijmegen, NL, Leuven, BE, Paris, FR, Brussels, 6 BE, Oxford, Oxfordshire/GB
13:15 - 13:15 562P - Development and validation of multiplex biomarker assay to stratify colorectal cancer (CRC) patient samples into subtypes 1 1 2 3 4 5 5 A. Sadanandam , K. Eason , E. Fontana , G. Nyamundanda , M. Del Rio , K. Si-Lin , T. Siew , P. 4 5 1 1 2 3 4 5 Martineau , I. Tan , C. Ragulan ; London, GB, Sutton, Surrey/GB, Sutton, GB, Montpellier, FR, Singapore, SG
13:15 - 13:15 563P - HER2 overexpression and amplification in patients with colorectal cancer (HOLIC): A large-scale retrospective study in Chinese population S. NI, J. Peng, D. Huang, H. Sun, L. Wang, C. Tan, J. Cai, W. Sheng; Shanghai, CN
13:15 - 13:15 564P - The inflamed immune phenotype can be induced by systemic treatment in angiogenic colorectal liver metastases in contrast to non-angiogenic liver metastases 1 2 2 3 4 5 6 6 S. Stremitzer , P. Vermeulen , M. Kockx , L. Dirix , S. Graver , S. Scherer , D. Yang , W. Zhang , J. 1 1 1 6 1 2 3 4 Stift , F. Wrba , T. Gruenberger , H.-J. Lenz ; Vienna, AT, Antwerp, BE, Wilrijk, BE, Wuerzburg, 5 6 DE, East Hanover, New Jersey/US, Los Angeles, CA/US
13:15 - 13:15 565P - Whole-exome sequencing of matched germline and plasma cell-free DNA portrays the somatic mutation landscape of refractory metastatic colorectal cancer and identifies mutated KDR/VEGFR2 as new cause of therapy resistance 1 2 1 1 1 1 1 R. TOLEDO , E. Garralda , T. Pons , J. Monsech , E. Vega , R. Alvarez , A. Cubillo , C. 1 1 1 3 1 2 3 Blanco-Aparicio , O. Dominguez , J.L. Martinez , M. Hidalgo ; Madrid, ES, Barcelona, ES, Boston, MA/US
13:15 - 13:15 566P - The nationwide cancer genome screening project in Japan, SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced colorectal cancer 1 2 3 4 5 6 7 8 S. Yuki , T. Kato , H. Taniguchi , T. Hamaguchi , K. Akagi , T. Denda , T. Mizukami , E. Oki , T. 9 7 10 11 12 13 14 4 Yamada , M. Shiozawa , T. Kudo , T. Tamura , T. Esaki , D. Naruge , T. Kajiwara , S. Nomura 15 16 16 16 1 2 3 , S. Fujii , K. Shitara , A. Ohtsu , T. Yoshino ; Sapporo, Hokkaido/JP, Amagasaki, Hyogo/JP,
4 5 6 7 8 Nagoya, Aichi/JP, Tokyo, JP, Saitama, JP, Chiba, Chiba/JP, Kanagawa, JP, Fukuoka, Fukuoka/JP, 9 10 11 12 13 14 Tsukuba, JP, Suita, Osaka/JP, Osaka, JP, Fukuoka, JP, Mitaka, Tokyo, JP, Matsuyama, 15 16 JP, Kashiwa, JP, Kashiwa, Chiba/JP
13:15 - 13:15 567P - Clinical utility of quasi-monomorphic variation range (QMVR) on the determination of microsatellite instability (MSI) status in patients (pts) with colorectal cancer (CRC): GI-SCREEN-CRC-MSI sub-study 01 1 2 3 4 5 2 1 2 W. Okamoto , H. Bando , T. Fukui , T. Yamanaka , K. Akagi , T. Yoshino ; Kashiwa, JP, Kashiwa,
3 4 5 Chiba/JP, Kyoto, JP, Yokohama, JP, Saitama, JP
13:15 - 13:15 568P - The impact of antithrombotics on immunochemical fecal occult blood testing for colorectal cancer screening 1 2 2 2 3 2 1 V. Van der Voort , L. Wauters , P. Dobbels , K. Hendrickx , V. Casneuf , J. Vandervoort ; Utrecht,
2 3 NL, Aalst, BE, Aalst, Oost Vl/BE
Last update: 02-09-2017 06:01:33pm esmo.org 13:15 - 13:15 569P - miR-93 regulates epithelial-to-mesenchymal transition process in metastatic colorectal cancer by targeting EphA4 S. Gao, Taiyuan, CN
13:15 - 13:35 571P - Multiplatform assay to classify formalin-fixed paraffin-embedded (FFPE) colorectal cancer (CRC) samples into molecular subtypes with mutational profiles 1 2 2 2 3 2 E. Fontana , C. Ragulan , D. Cunningham , S. Hulkki-Wilson , F. Sclafani , G. Nyamundanda , K. 3 2 3 2 2 2 1 3 2 Eason , R. Begum , I. Chong , C. Peckitt , M. Bali , J. Oates , D. Watkins , S. Rao , M. Hubank , A. 2 2 1 3 2 1 2 3 Wotherspoon , N. Valeri , I. Chau , N. Starling , A. Sadanandam ; Sutton, Surrey/GB, Sutton, GB, London, GB
13:35 - 13:35 572P - A robust gene signature for the detection of early relapse in stage I-III colon cancer W. Dai, Y. Li, S. Mo, G. Cai; Shanghai, CN
13:35 - 13:35 573P - microRNA(miR) subtypes correlates with colorectal cancer(CRC) molecular subtypes: Validation of miR-30b interaction with genes up-regulated in the high-stroma subtype B. Perez-Villamil, M. Paz-Cabezas, T. Calvo-López, J. Ogando-Castro, J. Sastre, S. Mañes, E.
Díaz-Rubio; Madrid, ES
13:35 - 13:35 575P - Prognostic value of microsatellite instability status in stage II/III rectal cancer patients who received upfront surgery 1 1 2 1 1 1 2 C.R. Oh , J.E. Kim , Y.S. Hong , S.Y. Kim , T.W. Kim ; Seoul, KR, Seoul, Songpa-gu/KR
13:35 - 13:35 570P - Array based profiling of emerging molecules in colorectal cancer E. Shinozaki, S. Sakata, T. Konishi, H. Osumi, M. Ueno, K. Yamaguchi, K. Takeuchi; Tokyo, JP
13:35 - 13:35 574P - Gene expression changes in the immunotherapy targets CTLA4 and LAG3 in right- and left-sided colorectal cancer tissues during preoperative oral uracil and tegafur/leucovorin chemotherapy 1 1 1 1 2 2 3 1 S. Sadahiro , T. Suzuki , A. Tanaka , K. Okada , G. Saito , H. miyakita , H. Nagase ; Isehara,
2 3 Kanagawa/JP, Isehara, JP, Tokushima, JP
13:35 - 13:35 576P - Biomarker testing practices in the SECURE (proSpective obsErvational clinical practiCe stUdy in the first-line management of metastatic colorectal cancer [mCRC] with eRbitux in combination with chemothErapy) study 1 2 3 4 5 6 7 G. Aravantinos , A. Shahrasbi , M. Oukkal , B. Larbaoui , P. Ronga , D. Messinger , J. Hamad , W. 8 1 2 3 4 5 6 Benbrahim ; Athens, GR, Tehran, IR, Algiers, DZ, Oran, DZ, Maisons-Alfort, FR, Mannheim, DE, 7 8 Dubai, AE, Batna, DZ
13:35 - 13:35 577P - Exosomal ECM1 protein expression in plasma from the tumor-draining vein (mesenteric vein) and time to relapse in colon cancer patients 1 1 2 2 2 1 1 S. Santasusagna , A. Navarro , I. Moreno , R. Ibeas , F. Martinez , J.J. Castellano , C. Muñoz , J.
1 1 2 2 1 1 2 Canals , S. Morales , R. Hernandez , J. Moreno , M. Monzo ; Barcelona, ES, Badalona, ES
13:35 - 13:35 578P - LAG-3 expression in tumor infiltrating immune cells is associated with poor prognosis in patients with microsatellite instability high colon cancer 1 1 1 1 1 1 1 1 2 1 I. Lee , S.J. Lee , B.W. Kang , Y.S. Chae , H.J. Kim , S.Y. Park , J.S. Park , G.S. Choi , J.G. Kim ;
2 Daegu, KR, Seoul, KR
Last update: 02-09-2017 06:01:33pm esmo.org
13:35 - 13:35 579P - Primary efficacy results and clinical impact of UGT1A1 genotype on safety from a Phase II study of FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer: The QUATTRO study 1 2 3 4 5 6 7 8 H. Bando , T. Kato , T. Yoshino , K. Muro , K. Yamazaki , T. Yamaguchi , E. Oki , S. Iwamoto , A. 9 4 10 11 12 13 14 Tsuji , G. Nakayama , Y. Emi , T. Touyama , M. Nakamura , M. Kotaka , Y. Kagawa , H. 4 15 16 17 1 2 3 Taniguchi , H. Sakisaka , T. Yamanaka , A. Kanazawa ; Kashiwa, JP, Amagasaki, Hyogo/JP,
4 5 6 7 8 Kashiwa, Chiba/JP, Nagoya, Aichi/JP, Shizuoka, Shizuoka/JP, Tokyo, JP, Fukuoka, Fukuoka/JP, 9 10 11 12 13 Hirakata, Osaka/JP, Kagawa, JP, Fukuoka, JP, Okinawa, JP, Matsumoto, JP, Kobe, 14 15 16 17 Hyogo/JP, Amagasaki, JP, Osaka, JP, Yokohama, JP, Izumo, JP
13:35 - 13:35 580P - The expression of interleukin 17 receptor A is associated with poor prognosis in patients with colorectal cancer and its knockdown inhibits tumor growth and modulates tumor-infiltrating immune cells in mice tumor C.-Y. Yang, C.-H. Lin, J.-K. Jiang; Taipei, TW
13:35 - 13:35 588P - Differences in prescribing attitudes and treatment patterns between right-sided and left-sided mCRC in EU5 and the US F. Bermudez, A. Franceschetti; London, GB
13:35 - 13:35 584P - Predictive value of primary tumor location: Results from randomized phase II study of panitumumab + irinotecan versus cetuximab + irinotecan in patients with KRAS exon2 wild-type metastatic colorectal cancer (WJOG6510G) 1 2 1 1 3 4 5 6 T. Tamura , D. Sakai , N. Sugimoto , S. Tokunaga , A. Tsuji , H. Ishida , S. Otsu , T. Moriwaki , H. 7 8 9 8 10 11 8 12 Satake , K. Uchino , S. Matsumoto , E. Baba , M. Sato , H. Taniguchi , J. Kishimoto , N. Boku , I. 6 11 1 2 3 4 5 6 Hyodo , K. Muro ; Osaka, JP, Suita, Osaka/JP, Kagawa, JP, Higashi Ibaraki-Gun, JP, Oita, JP, 7 8 9 10 11 12 Tsukuba, Ibaraki/JP, Kobe, JP, Fukuoka, JP, Kyoto, JP, Ryugasaki, JP, Nagoya, Aichi/JP, Kawasaki, Kanagawa/JP
13:35 - 13:35 582P - Comparison of performances of three technologies for detection of RAS mutations in cfDNA (NGS strategy, BEAMing assay and ddPCR BioRAD assay) 1 1 1 1 1 1 J. Garcia , J. Forestier , E. Dusserre , C. Rodriguez-Lafrasse , V. Cheynet , A.S. Wosny , C. Ferraro 1 1 1 2 2 3 4 Peyret , K. Brengel-Pesce , M. Guillet , M. Chauvenet , S. Couraud , M. Brevet , T. Walter , L. Payen 1 1 2 3 4 ; Lyon, FR, Pierre Bénite, CEDEX/FR, Bron, CEDEX/FR, Hamburg, DE
13:35 - 13:35 587P - Survival by sidedness of metastatic colorectal cancer (mCRC) treated with epidermal growth factor receptor antibodies (EGFR-Ab) in the refractory setting: A population-based study of 1509 patients 1 2 3 2 2 4 1 2 E. Segelov , C. Earle , A. Venook , R. Saskin , L. Mofid , S. Singh ; Melbourne, NSW/AU, Toronto,
3 4 ON/CA, San Francisco, CA/US, Toronto, Ontario/CA
13:35 - 13:35 583P - Impact of tumor location on the efficacy of first-line anti-EGFR monoclonal antibody plus chemotherapy in patients (pts) with metastatic colorectal cancer (mCRC): Retrospective analyses of the randomized MACRO-2 and PLANET trials from TTD Group
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 3 2 2 1 M. Benavides , A. Carrato , A. Abad , C. Guillen-Ponce , P. Garcia-Alfonso , S. Gil , M.T. Cano Osuna 4 5 2 6 7 8 9 , M.J. Safont , C. Gravalos , J.L. Manzano-Mozo , A. Sanchez , J. Alcaide-Garcia , R. López , B. 10 2 11 12 2 Massuti Sureda , J. Sastre , E. Martinez de Castro , P. Escudero , M. Méndez-Ureña , E. Diaz
2 4 1 2 3 4 5 Rubio , E. Aranda Aguilar ; Malaga, ES, Madrid, ES, Badalona, Barcelona/ES, Cordoba, ES, 6 7 8 9 Valencia, ES, Badalona, ES, Majadahonda, ES, Marbella, Málaga/ES, Santiago De Compostela, 10 11 12 ES, Alicante, ES, Santander, ES, Zaragoza, ES
13:35 - 13:35 586P - The prognostic value of sidedness of the primary tumor after local treatment for oligometastatic colorectal cancer: A Danish population based study 1 1 1 1 1 2 1 2 A. Boysen , K.-L. Spindler , M. Høyer , F. Mortensen , T. Christensen , A. Ording ; Aarhus C, DK, Aarhus, DK
13:35 - 13:35 589P - Tumor sidedness and enriched gene groups for efficacy of 1st-line cetuximab (cet) treatment in metastatic colorectal cancer (mCRC) 1 1 2 2 3 1 4 1 W. Ichikawa , K. Mogushi , H.-J. Lenz , W. Zhang , A. Tsuji , T. Takahashi , T. Denda , K. Shimada , 1 5 6 7 8 8 8 2 M. Kochi , M. Nakamura , M. Kotaka , Y. Segawa , B. Lafleur , J. Luecke , D. Thompson , M. Moran , 9 2 1 10 1 2 3 4 S.H. Astrow , J. Hsiang , M. Fujii , Y. Sunakawa ; Tokyo, JP, Los Angeles, CA/US, Miki, JP, 5 6 7 8 9 10 Chiba, Chiba/JP, Matsumoto, JP, Kobe, JP, Hidaka, JP, Tucson, AZ/US, Santa Monica, CA/US, Yokohama, JP
13:35 - 13:35 590P - Correlation between RECIST-criteria, morphologic response by CT and pathologic regression in hepatic metastasis secondary to colorectal cancer: The AVAMET study 1 1 2 3 4 4 5 R. Vera , M. Gómez , J.R. Ayuso , J. Figueras , P. Garcia-Alfonso , V. Martinez , A. Lacasta , A. Ruiz 4 6 6 6 6 7 2 8 , M.J. Safont , J. Aparicio , J. Campos , J. Cámara , M. Martin , C. Montagut , C. Pericay , J.M. 9 10 11 12 13 1 2 Viéitez , E. Falcó , M. Jorge , M. Marín Vera , M. Salgado Fernandez ; Pamplona, ES, 3 4 5 6 7 8 Barcelona, ES, Gerona, ES, Madrid, ES, San Sabastian, ES, Valencia, ES, Sant Pau, ES, 9 10 11 12 13 Sabadell, ES, Oviedo, ES, Palma De Mallorca, ES, Vigo, ES, Murcia, ES, Ourense, ES
13:35 - 13:35 591P - Tumor staging with magnetic resonance imaging after neoadjuvant chemoradiation for locally advanced rectal cancer and comparison of pathologic staging C. De la Pinta, M. Martin, F. López, E. Fernández, A. Hervás, S. Sancho; Madrid, ES
13:35 - 13:35 592P - Quality of life in patients with liver metastases from colorectal cancer treated with first-line selective internal radiotherapy (SIRT): Results from the FOXFIRE prospective randomized studies 1 1 1 2 1 1 3 A. Gray , J. Wolstenholme , F. Fusco , I. Chau , L. Dunham , S. Love , A. Roberts , J. Moschandreas 1 1 2 4 2 2 5 2 6 , P. Virdee , V. Lewington , G. Wilson , P. Tait , N. Khan , D. Berry , A. Wotherspoon , B. Morgan ,
2 7 8 2 1 2 3 4 H. Wasan , G. Van Hazel , P. Gibbs , R. Sharma ; Oxford, GB, London, GB, Cambridge, GB, 5 6 7 8 Manchester, GB, Cardiff, GB, Leicester, GB, Perth, WA/AU, Footscray, VIC/AU
13:35 - 13:35 593P - Quality of life (QoL) analyses in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) treated with first-line FOLFOX-4 ± cetuximab in the phase 3 TAILOR trial 1 2 3 4 5 3 3 6 7 1 T. Liu , J. Li , J. Xu , L. Wang , Y. Cheng , W. Chen , J. Chen , C. Pescott , S. Qin ; Shanghai, 2 3 4 5 6 7 Changning/CN, Beijing Shi, CN, Beijing, CN, Shanghai, CN, Jilin, CN, Darmstadt, DE, Nanjing, CN
Last update: 02-09-2017 06:01:33pm esmo.org 13:35 - 13:35 594P - Implementation, participation and satisfaction rates of a web-based decision support tool for patients with metastatic colorectal cancer 1 2 2 3 4 5 6 L. Keikes , R. The , K. Karssen , A. Mels , J. De Vos-geelen , J.W. de Groot , M. Koopman , M. van
1 1 2 3 4 5 6 Oijen ; Amsterdam, NL, Delft, NL, Amersfoort, NL, Maastricht, NL, Zwolle, NL, Utrecht, NL
13:35 - 13:35 595P - Quality-of-life in patients with metastatic colorectal cancer (mCRC) treated with aflibercept and FOLFIRI – Interim results of the non-interventional AIO study QoLiTrap 1 2 3 4 5 6 R. von Moos , G. Derigs , F. Scholten , J. Thaler , C. Losem , H. Kroening , C. Windemuth-Kieselbach 7 8 1 2 3 4 5 6 , R.D. Hofheinz ; Chur, CH, Frankfurt, DE, Frankfurt Am Main, DE, Wels, AT, Berlin, DE, 7 8 Magdeburg, DE, Gießen, DE, Mannheim, DE
13:35 - 13:35 596P - Chemotherapy-induced thrombocytopenia (CIT) in metastatic colorectal cancer (mCRC) patients 1 2 2 3 1 2 3 K. Cetin , A. Toler , M. Eisen , G. Soff ; Thousand Oaks, US, Thousand Oaks, CA/US, New York City, NY/US
13:35 - 13:35 597P - Real world use of palliative systemic therapy (tx) in patients (pts) with metastatic early onset colorectal cancer (mEOCRC) within a UK specialist cancer centre 1 1 1 1 1 1 1 A. Georgiou , S. Khakoo , A. Minchom , K. Kouvelakis , R. Kalaitzaki , N. Nobar , V. Calamai , M. 1 1 1 2 2 1 3 1 1 Ifijen , M. Lethby , F. Arouri , I. Chau , D. Watkins , S. Rao , D. Cunningham , N. Starling ; London, 2 3 GB, Sutton, Surrey/GB, Sutton, GB
13:35 - 13:35 585P - Differences in survival (sv) and clinicopathologic characteristics (cpc) between right and left-sided colorectal cancer (CRC): A CARESS-CCR group study 1 2 2 2 2 J. Alcaide-Garcia , I. Zarcos-Pedrinaci , A. Rueda Domínguez , F. Rivas-Ruiz , T. Tellez , M.M. 3 4 5 6 7 4 Morales Suarez-Varela , E. Briones , M. Bare , A. Escobar , C. Sarasqueta , N. Fernández de Larrea , 8 2 9 2 2 1 2 J.M. Quintana , E. Pérez-Ruiz , R. Villatoro , D. Perez , M. Redondo ; Marbella, Málaga/ES, 3 4 5 6 7 8 Marbella, ES, Valencia, ES, Madrid, ES, Sabadell, ES, Bilbao, ES, San Sebastián, ES, Galdakao, 9 ES, Málaga, ES
13:35 - 13:35 599P - Real life registry data of primary localisation of a well-defined colon cancer population of western Austria (Salzburg, Tyrol and Vorarlberg), eastern Switzerland (St. Gallen and Graubünden) and Liechtenstein 1 2 3 4 1 2 3 B. Hartmann , W. Oberaigner , H. Frick , L. Weiss , T. Winder , K. Philipp-Abbrederis , C. Herrmann , 5 2 5 2 1 6 7 4 M. Huynh , G. Spizzo , C. Lang , A. Seeber , J. Schneider , E. Wöll , P. Mosler , R. Greil , M. Rössle
7 8 2 7 1 1 2 3 4 , H. Rumpold , G. Gastl , R. von Moos , A. Lang ; Feldkirch, AT, Innsbruck, AT, St. Gallen, CH, 5 6 7 8 Salzburg, AT, Bregenz, AT, Zams, AT, Chur, CH, Linz, AT
13:35 - 13:35 598P - PD-L1 expression in resected colorectal adenocarcinomas is associated with micrometastais K.U. Park, I. Hwang, H.-M. Ryoo, M.H. Heo; Daegu, KR
13:35 - 13:35 600P - Improving visualization and adherence by converting the Dutch colorectal cancer guidelines into decision trees: The Oncoguide project 1 2 2 3 1 4 M. van Oijen , X. Verbeek , T. van Vegchel , I. Nagtegaal , M. Lahaye , A. Méndez Romero , H. 3 5 1 1 1 1 1 2 3 Rütten , S. de Bruijn , H. Verheul , P. Tanis , C. Punt , L. Keikes ; Amsterdam, NL, Utrecht, NL, 4 5 Nijmegen, NL, Rotterdam, NL, Delft, NL
Last update: 02-09-2017 06:01:33pm esmo.org
13:35 - 13:35 601P - Colon and rectal cancer incidence are rising among young Europeans: Results from the cancer registry of Crete 1 2 1 2 1 1 D. Sifaki-Pistolla , E. Saloustros , G. Pitsoulis , L. Vamvakas , D. Mavroudis , V. Georgoulias , C.
1 1 2 Lionis ; Heraklion, GR, Heraklion, Crete/GR
13:35 - 13:35 602P - Epidemiology of colorectal cancer in Korea: Korean National Health insurance bigdata analysis S.K. Baek, J.S. Lee, H.J. Ha, S.-C. Lee, S.-B. Bae, I.G. Hwang, J.G. Kim, T.W. Kim; Seoul, KR
13:35 - 13:35 603P - Watch and wait versus surgery with pathological complete response: Single institution experience J. Souza, R. Guimarães, M. Siqueira, R. Gil, R. Araujo, M. Valadão; Rio De Janeiro, BR
13:35 - 13:35 604P - A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer [HGCSG1503]: Updated analysis 1 1 2 1 3 4 1 5 S. Yuki , Y. Komatsu , M. Yagisawa , Y. Tsuji , K. Harada , K. Hatanaka , H. Okuda , A. Hosokawa , 6 7 8 2 9 2 1 8 K. Ogawa , K. Furukawa , S. Minami , A. Ishiguro , T. Honda , T. Ohta , M. Dazai , K. Eto , T. Sasaki 1 10 2 11 1 2 3 4 , J. Nakajima , N. Sakamoto , Y. Sakata ; Sapporo, Hokkaido/JP, Sapporo, JP, Kushiro, JP, 5 6 7 8 9 10 Hakodate, Hokkaido/JP, Toyama, JP, Takaoka, JP, Niigata, JP, Tomakomai, JP, Nagasaki, JP, 11 Obihiro, JP, Misawa, Aomori/JP
13:35 - 13:35 605P - Preliminary results on germline and somatic molecular investigations in Romanian Lynch syndrome patients L. Negura, A. Chicos, R. Avadanei, A.M. NEGURA; Iasi, RO
13:35 - 13:35 606P - Clinical manifestations and prognostic factors of bone metastasis in colorectal cancer Y.J. Chun, S.W. Lee, J.H. Kim, E.-A. Choe, H.S. Park, S.H. Beom, S.J. Shin, J.B. Ahn; Seoul, KR
13:35 - 13:35 607P - Outcomes of adjuvant chemotherapy for stage II and III colorectal cancer in Korea, 2011-2014: A nationwide study based on the database of quality assessment and the health insurance 1 1 2 1 3 1 1 2 3 I.G. Hwang , J.S. Lee , S.-C. Lee , S.K. Baek , J.G. Kim , T.W. Kim ; Seoul, KR, Cheonan, KR, Daegu, KR
13:35 - 13:35 608P - Variations in clinicopathological features, treatment patterns, and outcomes of young adults with colorectal cancer in the United States and Egypt 1 2 2 2 2 1 1 3 1 A. Heeke , N. Rashad , H. Khaled , N. Ali Eldin , G. Motaal , H. Wang , B. Weinberg , M. Salem ;
2 3 Washington Dc, US, Cairo, EG, Washington Dc, DC/US
13:35 - 13:35 609TiP - PRODIGE 50 - ASPIK French: French double blind randomised study of aspirin versus placebo in resected stage III or high risk stage II colon cancer with PIK3CA mutation 1 2 3 4 5 5 1 6 7 P. Michel , T. André , V. Boige , T. Aparicio , E. Maillard , J. bez , J. Blot , J.-B. Bachet , L. Dahan , 8 9 10 11 12 13 1 1 R. Guimbaud , S. Manfredi , D. Tougeron , J. Taieb , J. Selves , C. Lepage , F. Di Fiore ; 2 3 4 5 6 Rouen, FR, Paris, CEDEX 12/FR, Villejuif, FR, Bobigny, CEDEX/FR, Dijon, FR, Paris, CEDEX 7 8 9 10 13/FR, Marseille, CEDEX 5/FR, Toulouse, CEDEX 3/FR, Rennes, CEDEX/FR, Poitiers, 11 12 13 CEDEX/FR, Paris, FR, Toulouse, FR, Dijon, Cedex/FR
Last update: 02-09-2017 06:01:33pm esmo.org 13:35 - 13:35 610TiP - A randomized Phase 2 study comparing different dosing approaches of induction treatment (first cycle) of regorafenib in metastatic colorectal cancer (mCRC) patients 1 1 2 3 4 G. Argilés Martinez , E. Sanz-Garcia , M. Valladares-Ayerbes , J.M. Viéitez , P. Garcia-Alfonso , C. 4 1 5 6 4 1 Gravalos , M. Tobeña , G. Duran Ogaya , M.T. Cano Osuna , B. García-Paredes , C. Santos , M. 4 7 8 9 10 11 Rodríguez-Garrote , F. Rivera Herrero , M.J. Safont , A. Falcone , F. Ciardiello , R. Goldberg , J.
12 1 6 1 2 3 4 Bennouna , J. Tabernero , E. Aranda Aguilar ; Barcelona, ES, A Coruna, ES, Oviedo, ES, 5 6 7 8 9 10 11 Madrid, ES, Malaga, ES, Cordoba, ES, Santander, ES, Valencia, ES, Pisa, IT, Naples, IT, 12 Columbus, OH/US, Nantes, CEDEX/FR
13:35 - 13:35 611TiP - Nivolumab, ipilimumab and COX2-inhibition in early stage colon cancer 1 1 1 1 1 1 M. Chalabi , M. Van Leerdam , A. Aalbers , J. Van den Berg , G. Beets , C. Grootscholten , P. 1 1 1 1 1 1 2 Snaebjornsson , M. Kuiper , P. Den Hartog , F. Weeber , K. Dijkstra , M. Kok , D. Cullen , T. 1 1 1 1 2 Schumacher , J. Haanen , E. Voest ; Amsterdam, NL, Princeton, US
13:35 - 13:35 612TiP - TRIUMPH Study: A multicenter Phase II study to evaluate efficacy and safety of combination therapy with trastuzumab and pertuzumab in patients with HER2-positive metastatic colorectal cancer (EPOC1602) 1 2 2 3 4 5 6 7 Y. Nakamura , W. Okamoto , K. Sawada , Y. Komatsu , K. Kato , H. Taniguchi , T. Kato , T. Nishina , 8 1 9 2 2 2 2 9 T. Esaki , H. Nomura , M. Fukutani , M. Fukui , H. Hasegawa , M. Yonemura , N. Fuse , A. Sato , S.
2 1 1 1 2 3 4 Fujii , A. Ohtsu , T. Yoshino ; Kashiwa, Chiba/JP, Kashiwa, JP, Sapporo, Hokkaido/JP, Tokyo, JP, 5 6 7 8 9 Nagoya, Aichi/JP, Amagasaki, Hyogo/JP, Matsuyama, JP, Fukuoka, JP, Chiba, JP
13:35 - 13:35 613TiP - Phase II dose titration study of regorafenib for patients with unresectable metastatic colorectal cancer who are progressed after standard chemotherapy 1 2 3 3 4 5 6 7 T. Kudo , T. Kato , Y. Kagawa , K. Murata , H. Ohta , S. Noura , J. Hasegawa , H. Tamagawa , K. 8 8 7 7 9 9 9 1 Ohta , M. Ikenaga , S. Miyazaki , T. Komori , J. Nishimura , T. Hata , C. Matsuda , T. Satoh , T.
1 9 9 9 1 2 3 Mizushima , H. Yamamoto , Y. Doki , M. Mori ; Suita, Osaka/JP, Amagasaki, Hyogo/JP, 4 5 6 7 8 9 Amagasaki, JP, Ikeda, JP, Sakai, JP, Saki, JP, Osaka, JP, Higashiosaka, JP, Suita, JP
13:35 - 13:35 614TiP - Phase II study of Ccr-based dose-control of S-1 in the first-line chemotherapy of S-1/oxaliplatin (SOX) + bevacizumab regimen for advanced colorectal cancer D. MANAKA, R. Nishitai, S. Konishi, T. Ohta, T. Hattori, H. Ann, K. Kawaguchi, Y. Nishikawa, R. Kudo, S.
Hamasu; Kyoto, JP
13:35 - 13:35 GASTROINTESTINAL TUMOURS, NON-COLORECTAL 1 2 1 2 E. Van Cutsem , T. Seufferlein ; Leuven, BE, Ulm, DE
13:35 - 13:35 628P - Treatment outcome of gastric cancer associated with esophageal cancer N. Mori, T. Tanaka, S. Matono, Y. Akagi; Kurume, JP
13:35 - 13:35 629P - Sarcopenia, myosteatosis, and weight loss as determinants of survival and toxicity in patients with resectable esophageal and gastroesophageal junction (GEJ) cancer receiving preoperative chemoradiotherapy (CRT) 1 2 3 2 2 2 2 2 A.G. Lui , A. Gallivan , M. Iafolla , Z. Abdelaziz , D. Yusuf , S. Ghosh , J. Spratlin , K. Mulder , M.
4 1 2 3 4 Sawyer ; Davao City, PH, Edmonton, AB/CA, Hamilton, CA, Edmonton, CA
Last update: 02-09-2017 06:01:33pm esmo.org 13:35 - 13:35 630P - Optimal extent of abdominal lymph node dissection for advanced Siewert type II and III esophagogastric junction carcinoma J. Lin, H. Chang-Ming, C. Zheng, P. Li, J. Xie; Fuzhou, CN
13:35 - 13:35 631P - Prognostic stratification of pathologic stage in patients with preoperative chemoradiotherapy followed by curative esophagectomy for localized esophageal squamous cell carcinoma J. Kang, S.R. Park, Y.-H. Kim, H.R. Kim, J.H. Kim, H.-Y. Jung, G.-H. Lee, H.J. Song, D.H. Kim, K.D.
Choi, J.-S. Ryu, K.-J. Cho, S.-B. Kim; Seoul, KR
13:35 - 13:35 632P - Thromboembolic complications in patients with oesophagogastric adenocarcinoma undergoing preoperative chemotherapy 1 2 1 1 1 1 T. Germetaki , K. Kamposioras , G. Papaxoinis , J. Weaver , S. Galloway , S. Stamatopoulou , M. 1 1 3 1 1 2 Nasralla , Z. Kordatou , A. Anthoney , W. Mansoor ; Manchester, GB, Wakefield, West 3 Yorkshire/GB, Leeds, GB
13:35 - 13:35 633P - Endoscopic resection for Barrett's esophagus: Uzbekistan experience S. Rasul, Tashkent, UZ
13:35 - 13:35 634P - Risk of second malignancies after definitive therapy for esophageal cancer: A competing risk analysis 1 2 1 1 1 1 2 2 S. Mitani , I. Oze , S. Kadowaki , T. Masuishi , Y. Narita , H. Taniguchi , T. Ura , M. Ando , M. Tajika
1 2 2 2 2 1 1 2 , C. Makita , T. Kodaira , N. Uemura , T. Abe , K. Muro ; Nagoya, Aichi/JP, Nagoya, JP
13:35 - 13:35 635P - Prognostic significance of local immunity factors in esophageal cancer E. Kolesnikov, O. Kit, E. Zlatnik, A. Bazaev, A. Maksimov, I. Novikova, O. Selyutina, E. Bondarenko, V.
Trifanov, L. Kharin, P. Gabrichidze, M. Kozhushko, S. Mezentsev, L. Vladimirova; Rostov-On-don, RU
13:35 - 13:35 636P - Recent advance in enhanced recovery after esophagectomy: A systematic review and meta-analysis Y. Wang, Shijiazhuang, CN
13:35 - 13:35 637P - High thromboembolic event rate in patients with locally advanced esophageal cancer during perioperative therapy: A pre-planned analysis of the intergroup phase III trial SAKK 75/08 1 2 3 4 5 6 7 M. Fehr , H. Hawle , S. Hayoz , P. Thuss-Patience , S. Schacher , J. Riera Knorrenschild , D. Dürr , 8 9 10 3 7 11 12 W. Knoefel , H. Rumpold , M. Bitzer , M. Zweifel , P. Samaras , U. Mey , R. Winterhalden , M. 13 14 2 3 15 1 1 2 Kueng , W. Eisterer , V. Hess , M.-A. Gerard , M. Stahl , T. Ruhstaller ; St. Gallen, CH, Basel, 3 4 5 6 7 8 9 CH, Bern, CH, Berlin, DE, Winterthur, CH, Marburg, DE, Zürich, CH, Duesseldorf, DE, Linz, AT, 10 11 12 13 14 15 Tübingen, DE, Chur, CH, Luzern, CH, Fribourg, CH, Klagenfurt, AT, Essen, DE
13:35 - 13:35 638P - Two year survival and safety update for esophageal squamous cell carcinoma treated with nivolumab (ATTRACTION-01/ONO-4538-07) 1 2 1 3 4 5 6 7 8 Y. Kitagawa , Y. Doki , K. Kato , T. Ura , T. Kojima , T. Tsushima , S. Hironaka , H. Hara , T. Kudo , 1 9 1 5 10 1 11 1 S. Iwasa , K. Muro , Y. Hamamoto , H. Yasui , K. Minashi , K. Yamaguchi , A. Ohtsu ; Tokyo, JP,
2 3 4 5 6 7 8 Suita, JP, Nagoya, JP, Kashiwa, JP, Shizuoka, JP, Chiba, Chiba/JP, Saitama, JP, Suita, 9 10 11 Osaka/JP, Nagoya, Aichi/JP, Chiba, JP, Kashiwa, Chiba/JP
Last update: 02-09-2017 06:01:33pm esmo.org 13:35 - 13:35 643P - The research progress in randomized, multicenter, controlled evaluation of S-1 and oxaliplatin as neoadjuvant chemotherapy for advanced gastric cancer patients X. Wang, L. Chen; Beijing, CN
13:35 - 13:35 639P - A phase II study of TAS-102 for advanced/recurrent esophageal cancer refractory/intolerable to standard therapies 1 2 3 4 2 5 6 7 T. Kojima , H. Kasai , T. Tsushima , H. Hara , Y. Mori , R. Ishihara , K. Kato , S. Hironaka , K. Mukai 2 2 2 2 2 8 2 1 2 , O. Kikuchi , K. Enomoto , H. Tada , R. Uozumi , A. Kawaguchi , M. Muto ; Kashiwa-Shi, JP, 3 4 5 6 7 8 Kyoto, JP, Shizuoka, JP, Saitama, JP, Osaka, JP, Tokyo, JP, Chiba, Chiba/JP, Saga, JP
13:35 - 13:35 640P - Dual CDK 4/6 inhibitor demonstrates potent antitumor efficacy in vitro and in vivo against esophageal adenocarcinoma 1 1 1 1 2 3 1 1 A. Omstead , J. Kosovec , M. Biedka , R. Biederman , R. Kelly , A. Zaidi , B. Jobe ; Pittsburgh,
2 3 PA/US, Baltimore, MD/US, Pittsburgh, US
13:35 - 13:35 641P - The influence of body composition on the systemic exposure of paclitaxel in esophageal cancer patients 1 2 1 2 1 1 2 L. Van Doorn , H. Rier , J. van Vught , C. van Kesteren , S. Bins , R. Mathijssen , M.-D. Levin , S.
1 1 2 Koolen ; Rotterdam, NL, Dordrecht, NL
13:35 - 13:35 642P - Survival in advanced oesophagogastric adenocarcinoma (OGA) improves with the use of multiple lines of therapy: Results from an analysis of over 500 patients (pts) 1 1 1 1 1 1 1 C. Cafferkey , M. Davidson , E. Goode , D. Hughes , P. Reguera , R. Kalaitzaki , K. Kouvelakis , C. 2 3 3 1 2 1 1 2 3 Peckitt , I. Chau , D. Watkins , S. Rao , D. Cunningham , N. Starling ; London, GB, Sutton, GB, Sutton, Surrey/GB
13:35 - 13:35 644P - The N stages for early gastric cancer should differ from those of advanced gastric cancer: Results based on the SEER database J.-X. Lin, H. Chang-Ming, C. Zheng, P. Li, J. Wang; Fuzhou, CN
13:35 - 13:35 645P - Young-onset gastric cancer: The role of microbial factors 1 2 1 2 1 3 3 1 I. Ben-Aharon , A. Moore , E. Hikri , T. Goshen-Lago , T. Lazar , H. Kashtan , B. Brenner ; Tel-Aviv,
2 3 IL, Petah Tikva, IL, Petach Tikva, IL
13:35 - 13:35 646P - Comprehensive complication index (CCI) predicts cancer-specific survival of patients with postoperative complications after curative resection of gastric cancer R. Tu, H. Chang-Ming, J. Lin, P. Li, C. Zheng; Fuzhou, CN
13:35 - 13:35 647P - ATM loss, MSI and survival in the MAGIC trial 1 2 1 1 3 3 3 E. Smyth , M. Fassan , K. Kouvelakis , M. Nankivell , C. Peckitt , A. Wotherspoon , N. Valeri , M.
2 1 1 3 1 2 3 Rugge , W. Allum , R. Langley , D. Cunningham ; London, GB, Padua, IT, Sutton, GB
13:35 - 13:35 648P - Negative lymph node count is a significant prognostic factor in patient with stage IV gastric cancer after palliative gastrectomy 1 2 2 2 2 2 1 2 C. Zhuo , M. Ying , R. Lin , X. Wu , S. Guan , C. Yang ; Fuzhou, Fujian/CN, Fuzhou, CN
Last update: 02-09-2017 06:01:33pm esmo.org 13:35 - 13:35 649P - PD-L1 expression in primary tumours and paired lymph node metastases in chemoradiotherapy-naïve esophageal and gastric adenocarcinoma: Relationship with MSI status and prognosis M. Svensson, D. Borg, C. Hedner, J. Eberhard, B. Nodin, K. Leandersson, K. Jirström; Lund, SE
13:35 - 13:35 650P - Effects of preoperative malnutrition on short- and long-term outcomes of patients with gastric cancer: Can we do better? J. Lu, H. Chang-Ming, H. Huang, C. Zheng, P. Li; Fuzhou, CN
13:35 - 13:35 651P - Is there any relationship between Helicobacter pylori infection and HER2 expression in gastric cancer? 1 2 1 3 1 1 1 1 2 E. Algin , M. Baykara , G. Yilmaz , B. Cetin , O. Ekinci , A. Uner , A. Ozet ; Ankara, TR, Sakarya,
3 TR, Sivas, TR
13:35 - 13:35 652P - Iron deficiency anemia in gastric cancer: A Canadian single site retrospective cohort study C. Brezden-Masley, G. Tang, R. Hart, M. Sholzberg; Toronto, CA
13:35 - 13:35 653P - Is surgical resection beneficial in recurrent or metastatic gastric cancer? Y. Choi, M.S. Ahn, H.W. Lee, S.Y. Kang, J.-H. Choi; Suwon, KR
13:35 - 13:35 654P - Nomograms for pre- and post- operative prediction of long-term survival for patients of proximal gastric cancer: A large-scale, single-centre retrospective study Q. Chen, H. Chang-Ming, C. Zheng, P. Li, J. Xie; Fuzhou, CN
13:35 - 13:35 655P - Safety of neoadjuvant/adjuvant chemotherapy for gastroesophageal cancers: A single cancer centre experience 1 2 2 2 3 4 4 4 4 A. Madi , M. Gore , M. McKay , H. Wong , G. Cave , R. Rao , J. Nicholson , H. Smart , N. Howes , J.
2 1 2 3 4 Wood ; Wirral, Merseyside/GB, Wirral, GB, Prescot, GB, Liverpool, GB
13:35 - 13:35 656P - Peritoneal lavage CEA mRNA levels predict conversion gastrectomy outcomes after induction chemotherapy in gastric cancer patients with peritoneal metastasis 1 2 2 1 2 2 3 1 H. Yamaguchi , Y. Sato , H. Ishigami , H. Oozawa , M. Kurihara , Y. Yatomi , J. Kitayama ;
2 3 Shimotsuke, JP, Tokyo, JP, Tochigi, JP
13:35 - 13:35 657P - Nutritional recovery after open and laparoscopic distal gastrectomy for early gastric cancer: A prospective multicenter comparative trial (CCOG1204) 1 1 1 1 1 2 3 4 C. Tanaka , M. Kanda , K. Misawa , S. Ito , Y. Ito , Y. Mochizuki , K. Ishigure , T. Yaguchi , J. 5 1 6 1 1 1 2 3 Teramoto , H. Nakayama , Y. Kawase , M. Fujiwara , Y. Kodera ; Nagoya, JP, Komaki, JP, Konan, 4 5 6 JP, Yatomi, JP, Yokkaichi, JP, Seto, JP
13:35 - 13:35 658P - Randomized, controlled Phase III trial comparing 3D and 2D laparoscopic gastrcetomy for gastric cancer J. Lu, H. Chang-Ming, C. Zheng, P. Li, J. Xie, J. Lin; Fuzhou, CN
13:35 - 13:35 659P - Anthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in advanced gastric cancer: AGAMENON study data
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 1 3 4 5 I. MACIAS , A. Carmona-Bayonas , M. Ferrer , R. Hernandez , A. Custodio , A. Lacalle , J.E. Lorenzo 6 4 7 7 8 9 Barreto , I. Echavarria Diaz-Guardamino , L. Visa , E. Buxo Orra , M. Mangas Izquierdo , A. Azkarate 4 5 2 10 4 , A. Diaz , A. Viudez , M. Sanchez Canovas , A. Ramchandani Vaswani , F. Longo , E. Martinez de 11 12 13 1 2 3 4 Castro , J. Gallego Plazas , P. Jimenez Fonseca ; Sabadell, ES, Murcia, ES, Santa Cruz, ES, 5 6 7 8 9 Madrid, ES, Pamplona, ES, San Cristobal De La Laguna, ES, Barcelona, ES, Galdakao, ES, 10 11 12 13 Palma De Mallorca, ES, Las Palmas, Canary Islands/ES, Santander, ES, Elche, Alicante/ES, Oviedo, ES
13:35 - 13:35 660P - First-in-human study of IMAB362, an anti-claudin 18.2 monoclonal antibody, in patients with advanced gastroesophageal cancer 1 2 3 4 1 1 1 1 2 U. Sahin , M. Schuler , S. Bauer , A. Krilova , M. Utsch , C. Huber , Ö. Türeci ; Mainz, DE, Essen,
3 4 DE, Lebach, DE, Liepaja, LV
13:35 - 13:35 661P - Bidirectional chemotherapy in gastric cancer (GC) with peritoneal carcinomatosis (PC) combining intravenous chemotherapy with pressurized intraperitoneal aerosol chemotherapy (PIPAC): Results of 103 procedures in 52 patients V. Khomyakov, A. Ryabov, L. Bolotina, A. Utkina, A. Ivanov, O. Kuznetsova; Moscow, RU
13:35 - 13:35 662P - Gastrectomy after response to intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology 1 2 1 1 3 1 2 H. Ishigami , H. Yamaguchi , H. Yamashita , M. Asakage , J. Kitayama ; Tokyo, JP, Shimotsuke,
3 JP, Tochigi, JP
13:35 - 13:35 663P - Change in the molecular profile of tumor tissues during treatment with trastuzumab, as analyzed by next-generation sequencing and immunohistochemistry: A multicenter prospective biomarker study on HER2-positive gastric cancer 1 2 3 4 2 2 5 2 N. Takahashi , S. Iwasa , T. Sawada , Y. Sasaki , H. Taniguchi , I. Oda , T. Honda , Y. Kojima , H. 6 2 2 2 2 7 1 Hara , Y. Honma , A. Takashima , K. Kato , T. Hamaguchi , Y. Yamada ; Ina-Machi, Kita-adachi-gun, 2 3 4 5 6 7 JP, Tokyo, JP, Kanazawa, JP, Hokkaido, JP, Nagasaki, JP, Saitama, JP, Shizuoka, JP
13:35 - 13:35 664P - Phase 1 Study of IMAB362 with immunomodulation in patients with advanced gastric cancer 1 2 3 4 5 6 7 S.-E. Al-Batran , Z. Zvirbule , F. Lordick , P. Thuss-Patience , M. Just , M. Bitzer , V. Brass , A. 8 9 9 9 1 2 3 4 Krilova , D. Maurus , Ö. Türeci , U. Sahin ; Frankfurt Am Main, DE, Riga, LV, Leipzig, DE, Berlin, 5 6 7 8 9 DE, Bielefeld, DE, Tübingen, DE, Freiburg, DE, Liepaja, LV, Mainz, DE
13:35 - 13:35 665P - Modified Glasgow prognostic score, prognostic nutritional index and ECOG score could be new prognostic factors for survival in metastatic gastric cancer B. Demirelli, N. Babacan, S. Koca, B. Uzun, Ö. Ercelep, M. Ozturk, S. Kaya, E. Simsek, S. Khalil, R.
Hasanov, O. Alan, T.A. Telli, M. Arıbal, F. Dane, F. Yumuk; Istanbul, TR
13:35 - 13:35 666P - Accuracy and prognostic significance of oncologists’ estimates and scenarios for survival time in a randomised Phase 2 trial of regorafenib in advanced gastric cancer
Last update: 02-09-2017 06:01:33pm esmo.org 1 1 2 3 1 4 5 6 A. Vasista , A. Martin , N. Pavlakis , K. Sjoquist , S. Snow , D. Jonker , Y.J. Chua , R. Epstein , A. 7 8 9 10 11 12 13 Bonaventura , M. Khasraw , S.C. Varma , N. Singhal , D. Ransom , F. Aubin , R. Burkes , H. 14 15 16 3 3 1 2 3 Lim , F. Lemay , S. Begbie , M. Stockler , B. Kiely ; Camperdown, AU, St Leonards, NSW/AU, 4 5 6 7 Camperdown, NSW/AU, Ottawa, CA, Garran, ACT/AU, Darlinghurst, NSW/AU, Newcastle, 8 9 10 11 12 NSW/AU, Geelong, VIC/AU, Douglas, QLD/AU, Adelaide, SA/AU, Subiaco, WA/AU, Montreal, 13 14 15 16 CA, Toronto, ON/CA, Vancouver, British Columbia/CA, Sherbrooke, CA, Port Macquarie, NSW/AU
13:35 - 13:35 667P - ERBB3 mutations in advanced gastric signet-ring cell carcinoma (SRCC) and the implications for targeted therapy J. Wei, B. XU, S. Jin, L. Yu, B. Liu; Nanjing, CN
13:35 - 13:35 668P - Estimating 12-weeks life expectancy in metastatic gastric cancer (mGC) patients (pts) candidates for second-line treatment: The “Gastric Life” nomogram 1 1 2 1 1 3 4 F. Pietrantonio , F. Barretta , V. Fanotto , M. Niger , F. Morano , F. Bergamo , N. Silvestris , L. 5 6 7 8 9 10 11 Fornaro , R. Bordonaro , M. Baretti , D. Santini , G. Tomasello , L. Antonuzzo , S. Noventa , A. 12 13 14 15 1 2 1 2 3 Avallone , S. Di Donato , E. Maiello , F. De Vita , R. Miceli , G. Aprile ; Milan, IT, Udine, IT, 4 5 6 7 8 9 10 Padova, IT, Bari, IT, Pisa, IT, Catania, IT, Rozzano, (MI)/IT, Roma, IT, Cremona, (CR)/IT, 11 12 13 14 15 Firenze, IT, Brescia, IT, Napoli, IT, Prato, IT, San Giovanni Rotondo, IT, Naples, IT
13:35 - 13:35 669P - TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas 1 2 1 3 2 1 1 1 S. Dueland , J. Valle , K. Bell , O. Faluyi , H. Staiger , T. Gjertsen , A.-S. Møller , A.-K. Aksnes , D.
4 1 2 3 4 Palmer ; Oslo, NO, Manchester, GB, Wirral, Merseyside/GB, Liverpool, GB
13:35 - 13:35 670P - A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC) 1 2 3 4 5 5 C. Pauligk , S. Lorenzen , T. Goetze , J. Riera Knorrenschild , S. Hegewisch Becker , J. Seraphin , P. 5 6 7 8 9 10 11 12 Thuss-Patience , H.-G. Kopp , T. Dechow , A. Vogel , K. Luley , D. Pink , M. Stahl , F. Kullmann , 13 11 14 15 16 3 1 2 H. Hebart , J. Siveke , M. Egger , N. Homann , S. Probst , S.-E. Al-Batran ; Frankfurt, DE,
3 4 5 6 7 8 Munich, DE, Frankfurt Am Main, DE, Marburg, DE, Berlin, DE, Tübingen, DE, Ravensburg, DE, 9 10 11 12 13 Hannover, DE, Lübeck, Schleswig-Holstein/DE, Bad Saarow, DE, Essen, DE, Weiden, DE, 14 15 16 Mutlangen, DE, Lahr, DE, Wolfsburg, DE, Bielefeld, DE
13:35 - 13:35 671P - Interim safety and clinical activity of nivolumab (Nivo) in combination with S-1/capecitabine plus oxaliplatin in patients (pts) with previously untreated unresectable advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: part 1 study of ATTRACTION-04 (ONO-4538-37) 1 2 3 4 5 6 3 7 Y.-K. Kang , K. Kato , H.C. Chung , K. Minashi , K.-W. Lee , H. Cho , W.K. Kang , Y. Komatsu , M. 8 2 9 10 11 12 13 1 Tsuda , K. Yamaguchi , H. Hara , S. Fumita , M. Azuma , N. Boku , L.-T. Chen ; Seoul, 2 3 4 5 6 7 Songpa-gu/KR, Tokyo, JP, Seoul, KR, Chiba, JP, Seongnam, KR, Yokohama, JP, Sapporo, 8 9 10 11 12 13 Hokkaido/JP, Akashi, JP, Saitama, JP, Ikoma, JP, Kanagawa, JP, Kawasaki, Kanagawa/JP, Tainan, TW
13:35 - 13:35 672P - A multicentre, phase II study with cabazitaxel in previously treated patients with advanced or metastatic adenocarcinoma of the oesophagogastric junction and stomach (CABAGAST)
Last update: 02-09-2017 06:01:33pm esmo.org 1 1 2 1 3 4 5 1 T. Götze , S.-E. Al-Batran , T. Zander , A. Reichart , U. Lindig , M. Kleiss , L. Mueller , C. Bolling , T. 6 7 8 9 10 11 12 Seufferlein , P. Reichardt , F. Kullmann , H. Eschenburg , A. Schmittel , M. Egger , A. Block , C. 13 14 1 2 3 4 5 Pauligk , H. Schmalenberg ; Frankfurt Am Main, DE, Cologne, DE, Jena, DE, Kassel, DE, Leer, 6 7 8 9 10 11 12 DE, Ulm, DE, Berlin-Buch, DE, Weiden, DE, Güstrow, DE, Berlin, DE, Lahr, DE, Hamburg, 13 14 DE, Frankfurt, DE, Dresden, DE
13:35 - 13:35 673P - Comparison of cytotoxic backbones for first line trastuzumab-containing regimens in HER2-positive advanced esophagogastric cancer: A meta-analysis E. ter Veer, A. Creemers, L. de Waal, M. van Oijen, H. Van Laarhoven; Amsterdam, NL
13:35 - 13:35 674P - Nivolumab (NIVO) in patients (pts) with advanced (adv) chemotherapy-refractory (CT-Rx) esophagogastric (EG) cancer according to microsatellite instability (MSI) status: checkmate 032 1 2 3 4 5 6 6 7 8 P. Ott , D. Le , J. Kim , P. Ascierto , P. Sharma , P. Bono , K. Peltola , D. Jäger , T.R.J. Evans , F. 9 10 11 12 12 12 13 de Braud , I. Chau , J. Bendell , M. Tschaika , C. Harbison , H. Zhao , E. Calvo , Y. Janjigian 14 1 2 3 4 5 6 ; Boston, MA/US, Baltimore, MD/US, New Haven, US, Napoli, IT, Houston, TX/US, Helsinki, FI, 7 8 9 10 11 12 Heidelberg, DE, Glasgow, GB, Milan, IT, Sutton, Surrey/GB, Nashville, TN/US, Princeton, US, 13 14 Madrid, ES, New York, NY/US
13:35 - 13:35 675P - Involvement of the immunoregulator MZB1 in progression of gastric cancer Y. TANAKA, M. Kanda, C. Tanaka, D. Kobayashi, H. Tanaka, H. Takami, M. Hayashi, N. Iwata, Y. Niwa,
S. Yamada, G. Nakayama, H. Sugimoto, M. Koike, M. Fujiwara, Y. Kodera; Nagoya, JP
13:35 - 13:35 676P - PD-L1 immunohistochemistry (IHC) by three different assays and molecular profiling in tissue microarray (TMA) of gastric cancer 1 2 1 2 2 1 2 1 Y. Narita , E. Sasaki , Y. Yatabe , K. Kato , H. Okano , S. Mitani , K. Honda , T. Masuishi , H. 1 1 2 2 1 2 1 1 2 Taniguchi , S. Kadowaki , T. Ura , M. Ando , M. Tajika , S. Ito , K. Muro ; Nagoya, Aichi/JP, Nagoya, JP
13:35 - 13:35 677P - Treatment of advanced gastric cancer based on Lauren’s histological: Real-world data from the AGAMEMON National Cancer Registry 1 2 3 4 5 6 A. Carmona-Bayonas , P. Jiménez-Fonseca , R. Hernández , A. Custodio , J.M. Cano , A. Lacalle , I. 4 7 8 9 9 Echavarria Diaz-Guardamino , I. MACIAS , M. Mangas Izquierdo , L. Visa , E. Buxo Orra , A. Azkarate 10 11 12 13 4 , A. Ramchandani Vaswani , E. Martínez de Castro , A. Fernández Montes , F. Longo , R. 6 14 15 16 1 2 Sánchez Bayona , M.L. Limón , A. Martín Carnicero , J. Gallego Plazas ; Murcia, ES, Oviedo, 3 4 5 6 7 8 9 ES, Tenerife, ES, Madrid, ES, Ciudad Real, ES, Pamplona, ES, Sabadell, ES, Galdakao, ES, 10 11 12 13 Barcelona, ES, Palma De Mallorca, ES, Las Palmas, Canary Islands/ES, Santander, ES, 14 15 16 Orense, ES, Seville, ES, Logroño, ES, Elche, Alicante/ES
13:35 - 13:35 678P - Comparison of oxaliplatin-related spleen enlargement in patient with gastric cancer who received S-1 versus capecitabine as a combination partner of oxaliplatin 1 2 3 3 3 2 1 2 3 S. Seo , M. Kim , M.J. Kim , M.-J. Kim , Y.I. Park , S.R. Park ; Seoul, Songpa-gu/KR, Seoul, KR, Goyang, KR
13:35 - 13:35 679P - Safety and efficacy of S-1 treatment in elderly patients with advanced or recurrent gastric cancer: A subgroup analysis from the phase III JFMC36-0701 trial
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 3 4 5 6 7 K. Nishikawa , S. Yoshino , S. Morita , T. Takahashi , K. Sakata , J. Nagao , H. Nemoto , N. 8 9 10 7 11 12 13 Murakami , H. Hasegawa , R. Shimizu , T. Yoshikawa , H. Osanai , M. Imano , H. Naitoh , A. 14 6 6 9 1 2 3 4 Tanaka , J. Sakamoto , S. Saji , M. Oka ; Osaka, JP, Ube, Yamaguchi/JP, Kyoto, JP, Suita, JP, 5 6 7 8 9 10 Shimonoseki, JP, Tokyo, JP, Yokohama, JP, Takaoka, JP, Yamaguchi, JP, Sanyo-Onoda, JP, 11 12 13 14 Sapporo, JP, Osakasayama, JP, Maebashi, JP, Mine, JP
13:35 - 13:35 680P - Phase II study of modified docetaxel, cisplatin and S-1 (mDCS) combination chemotherapy in patients with unresectable metastatic gastric cancer 1 1 2 2 1 1 1 Y. Sato , H. Ohnuma , K. Okamoto , H. Miyamoto , M. Hirakawa , N. Uemura , S. Kikuchi , T. 1 1 1 3 3 1 1 2 Sagawa , K. Fujikawa , Y. Takahashi , S. Minami , T. Okuda , M. Takahashi , J. Kato , T. Takayama 1 2 3 ; Sapporo, JP, Tokushima, JP, Tomakomai, JP
13:35 - 13:35 681P - Clinical impact of programmed death ligand-1 and -2 expression after platinum based chemotherapy in metastatic gastric cancer J.H. Yang, S. Park, E.K. Joung, M.A. Lee, S.Y. Roh, I.-H. Kim; Seoul, KR
13:35 - 13:35 682P - Clinical practice observation of trastuzumab (TRA) in patients (pts) with HER2-positive metastatic adenocarcinoma of the stomach (mGC) or the gastro-oesophageal junction (GEJ): Final analysis from the German non-interventional study HerMES 1 2 3 4 3 5 S.-E. Al-Batran , E. Moorahrend , C. Maintz , D. Hempel , P. Thuss-Patience , V. Gaillard , S. 3 1 2 3 4 5 Hegewisch Becker ; Frankfurt Am Main, DE, Porta Westfalica, DE, Berlin, DE, Donauwörth, DE, Grenzach Wyhlen, DE
13:35 - 13:35 683P - Intratumoral PD-L1 expression is associated with worse survival of patients with Epstein-Barr virus-associated gastric cancer 1 1 1 1 1 2 1 2 B.W. Kang , A.N. Seo , I. Lee , S.J. Lee , Y.S. Chae , J.G. Kim ; Daegu, KR, Seoul, KR
13:35 - 13:35 684P - Targeting c-met and DNA double-strand break (DSB) repair pathways for BRCA-mutated gastric carcinomas 1 2 3 2 2 4 1 M. Karamouzis , C. Mihailidou , P. Papakotoulas , A. Anestis , E. Koustas , A. Papavassiliou ;
2 3 4 Kolonaki, Athens/GR, Athens, GR, Thessaloniki, GR, Athens, Attiki/GR
13:35 - 13:35 685P - Clinical efficacy observation for endostar combined with chemotherapy treating gastric cancer peritoneal carcinomatosis H. Ma, A. Huang, J. Yao, T. Zhang; Wuhan, CN
13:35 - 13:35 686P - Modified epirubicin and oxaliplatin plus capecitabine (EOX) Regimen as second-line therapy after failure of modified docetaxel and cisplatin plus fuorouracil (DCF) regimen in advanced gastric cancer Y. Bozkaya, O. Yazici, N. Ozdemir, G. Erdem, N. Demirci, N. Zengin; Ankara, TR
13:35 - 13:35 687P - Phase II clinical trial of second-line weekly paclitaxel plus trastuzumab for patients with HER2-positive metastatic gastric cancer Y. Horita, M. Nishino, S. Sugimoto, A. Kida, A. Mizukami, M. Yano, F. Arihara, K. Matsuda, M. Matsuda,
A. Sakai; Toyama, JP
13:35 - 13:35 688P - Beyond first line treatment for advanced esophagogastric adenocarcinoma (EGAC): A phase 1 dose escalation study of regorafenib (Reg) combined with paclitaxel (PTX) (REPEAT study)
Last update: 02-09-2017 06:01:33pm esmo.org S. Schokker, S. Van der Woude, R. Mathot, M. Bijlsma, M. Van Oijen, C. Punt, H. Van Laarhoven;
Amsterdam, NL
13:35 - 13:35 689P - Phase I dose escalation study with expansion cohort of the addition of nab-paclitaxel (nab-P) to capecitabine and oxaliplatin (CAPOX) as first line treatment of advanced esophagogastric adenocarcinoma (EGAC) (ACTION study) S. Schokker, D. Van Zoen, S. Van der Woude, S. Meijer, R. Mathot, M. Bijlsma, M. Van Oijen, C. Punt, H.
Van Laarhoven; Amsterdam, NL
13:35 - 13:35 690P - KRAS status and HER2 targeted treatment in advanced gastric cancer E. Shinozaki, H. Osumi, K. Chin, M. Ogura, D. Takahari, T. Ichimura, T. Matsushima, T. Wakatsuki, I.
Nakayama, Y. Imamura, M. Watanabe, K. Yamaguchi; Tokyo, JP
13:35 - 13:35 691P - Inter-patient and intra-tumoral heterogeneity of oncogenic copy number alterations (CNAs) in gastric and gastroesophageal junction (GEJ) adenocarcinomas 1 1 1 1 1 2 1 1 2 J. Chao , V. Bedell , M. Li , P. Chu , Y.-C. Yuan , S. Klempner , R.-J. Lin ; Duarte, US, Los Angeles, CA/US
13:35 - 13:35 692P - Identification of an RNF43 mutated gastric cancer patient population with potential sensitivity to porcupine inhibitor RXC004 and development of a complimentary ctDNA liquid biopsy assay for patient screening 1 1 1 1 1 1 1 M. Bingham , I. Bhamra , R. Armer , B. Thompson , S. Woodcock , A. Thomason , C. Phillips , H. 1 2 3 3 2 1 2 3 McKeever , J. Bradford , B. Chaffey , L. Little , G. Clack ; Manchester, GB, Sheffield, GB, Newcastle-Upon-tyne, GB
13:35 - 13:35 693P - Prognostic effect of surgery of metastases in patients with advanced gastric cancer: Real-world data from the AGAMENON registry 1 2 3 4 5 P. Jiménez-Fonseca , R. Hernandez , A. Custodio , A. Ramchandani Vaswani , M. Sánchez Cánovas 6 7 3 8 8 , R. Sánchez Bayona , C. López López , I. Echavarria Diaz-Guardamino , L. Visa , E. Buxo Orra , D. 9 6 10 8 11 12 Arias , A. Viudez , A. Martin Carnicero , P. Cerdà , M. Ferrer , J.E. Lorenzo Barreto , M.L. Limón
13 11 14 1 2 3 4 , I. MACIAS , P. Felices ; Oviedo, ES, Santa Cruz, ES, Madrid, ES, Las Palmas, Canary 5 6 7 8 9 10 Islands/ES, Murcia, ES, Pamplona, ES, Santander, ES, Barcelona, ES, Orense, ES, Logrono, 11 12 13 14 ES, Sabadell, ES, San Cristobal De La Laguna, ES, Seville, ES, Zaragoza, ES
13:35 - 13:35 694P - Comparison of HER2 related molecular expression and its significance for clinical outcomes between the primary and paired liver metastasis in advanced gastric cancer H. Osumi, E. Shinozaki, N. Yamamoto, K. Chin, M. Ogura, D. Takahari, T. Wakatsuki, T. Ichimura, I.
Nakayama, T. Matsushima, A. Saiura, T. Yamaguchi, K. Yamaguchi; Tokyo, JP
13:35 - 13:35 695P - Real world data about clinical efficacy and safety of apatinib in the treatment of advanced gastric cancer 1 1 2 3 4 2 1 5 6 1 7 J. feng , B. Shen , Z. He , L. Deng , A. Dai , X. Shen , L. Chen , H. Jiang , X. Li , G. Zhou , J. Yu , 8 9 10 1 2 3 4 5 L. Yang , P. Chen , M. Zhuang ; Nanjing, CN, Suzhou, CN, Jiangyin, CN, Kunshan, CN, 6 7 8 9 10 Changzhou, CN, Zhenjiang, CN, Xinghua, CN, Nantong, CN, Yancheng, CN, Lianyungang, CN
13:35 - 13:35 696P - Correlation between SPARC expression and efficacy of nab-paclitaxel for advanced gastric cancer refractory to fluoropyrimidine: An exploratory analysis of a phase II trial, CCOG1303
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 3 4 2 5 6 D. Kobayashi , A. Enomoto , Y. Mochizuki , T. Matsui , H. Nakayama , Y. Kawase , K. Ishigure , T. 7 8 2 1 2 3 4 5 Shikano , K. Torii , Y. Kodera ; Nagoya, Aichi/JP, Nagoya, JP, Komaki, JP, Okazaki, JP, Seto, 6 7 8 JP, Konan, JP, Yokkaichi, JP, Nakatsugawa, JP
13:35 - 13:35 697P - Detection of microsatellite instability (MSI) with a novel panel of biomarkers in gastric cancer samples 1 2 1 1 1 1 1 B. De Craene , Z. Feng , E. Rondelez , L. Vandenbroeck , K. Peeters , G. Maertens , E. Sablon , T.
2 1 2 Cai ; Mechelen, BE, Billerica, US
13:35 - 13:35 698P - A dose-response study of ramucirumab treatment in patients with gastric cancer/gastroesophageal junction adenocarcinoma: Primary results of 4 dosing regimens in the phase 2 trial I4T-MC-JVDB 1 2 3 4 5 6 7 8 J. Ajani , A. Udrea , T. Sarosiek , M. Shenker , C. Morgan , J. Pikiel , E. Wojcik , D. Swinson , M. 9 10 11 12 13 13 13 13 Joseph , A. Luft , T. Salek , C. Tournigand , D. Ferry , Y. Zhang , A. Long , W.-L. Kuo , L. 13 13 14 1 2 3 4 5 Gao , J. Kauh , W. Mansoor ; Lyngby, DK, Cluj-Napoca, RO, Warszawa, PL, Craiova, RO, 6 7 8 9 10 11 Cardiff, GB, Gdańsk, PL, Poznań, PL, Leeds, GB, Wolverhamptom, GB, St. Petersburg, RU, 12 13 14 Bratislava, SK, Creteil Cedex, FR, Bridgewater, NJ/US, Manchester, GB
13:35 - 13:35 699P - The effectiveness of the 8th American Joint Committee on Cancer TNM classification in the prognosis evaluation of stage III gastric cancer patients: A comparative study between the 7th and 8th editions J. Lu, H. Chang-Ming, C. Zheng, Q. Chen, R. Tu; Fuzhou, CN
13:35 - 13:35 711P - Selective Internal Radiation Therapy (SIRT) with Yttrium-90-glass-microspheres plus chemotherapy in first-line treatment of advanced cholangiocarcinoma (MISPHEC study) 1 2 3 4 5 6 7 J. Edeline , Y. Touchefeu , B. Guiu , O. Farges , D. Tougeron , P. Compagnon , L. Chone , B. 8 1 8 8 8 8 1 1 Campillo-Gimenez , M. Pracht , A. Lievre , S. Le Sourd , K. Boudjema , E. Garin , E. Boucher ;
2 3 4 5 6 Rennes, CEDEX/FR, Nantes, CEDEX 1/FR, Montpellier, FR, Clichy, FR, Poitiers, CEDEX/FR, 7 8 Creteil, FR, Nancy, FR, Rennes, FR
13:35 - 13:35 700P - Comparison of prognostic models for hepatocellular carcinoma (HCC) in patients treated with the sorafenib: Results from a Canadian multi-center HCC database 1 2 2 3 3 2 4 2 H. Samawi , S. Hao-Wen , K. Chan , M. Alghamdi , R. Lee-Ying , J. Knox , P. Gill , A. Romagnino , 3 2 3 3 1 2 3 4 E. Batuyong , Y.-J. Ko , W. Cheung , V. Tam ; Vancouver, CA, Toronto, ON/CA, Calgary, AB/CA, Vancouver, BC/CA
13:35 - 13:35 701P - Final data from a phase Ib trial of tepotinib in Asian patients with advanced hepatocellular carcinoma (HCC) 1 2 2 2 3 4 5 6 1 S. Qin , T.-Y. Kim , H.Y. Lim , B.-Y. Ryoo , D. Zhou , C. Zhao , A. Becker , A.-L. Cheng ; Nanjing,
2 3 4 5 6 CN, Seoul, KR, Beijing, CN, Billerica, GB, Frankfurt An Der Oder, DE, Taipei, TW
13:35 - 13:35 707P - Network meta-analysis (NMA) of treatments for unresectable hepatocellular carcinoma (uHCC) 1 2 3 3 4 5 6 6 1 G. Tremblay , G. Meier , D. Misurski , M. Baig , T. Tamai , S. Kraljevic , A. Shor , A. Forsythe ; 2 3 4 5 6 Levis, CA, Woodcliff Lake, US, Woodcliff Lake, NJ/US, Tokyo, JP, Hatfield, Herts/GB, New York, US
Last update: 02-09-2017 06:01:33pm esmo.org 13:35 - 13:35 703P - Cost effectiveness of selective internal radiation therapy (SIRT) with Y-90 resin microspheres versus sorafenib in Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma patients in the UK 1 2 3 2 2 4 4 4 1 D. Palmer , P. Ross , T. Shah , D. Yu , S. Shergill , K. Patterson , N. Brereton , D. Lee ; Liverpool,
2 3 4 GB, London, GB, Birmingham, GB, Sheffield, GB
13:35 - 13:35 709P - A Phase II study of sorafenib and yttrium-90 glass microspheres for advanced hepatocellular carcinoma, BCLC stage C A. Kaseb, R. Abdel-Wahab, R. Murthy, M. Hassan, K. Raghav, L. Xiao, J. Morris, R. Avritscher, B. Odisio,
C. Ohaji, R. Wolff, J. Yao, A. Mahvash; Houston, US
13:35 - 13:35 702P - Correlation between overall survival (OS) and time to progression (TTP) and between OS and response rate (RR) by RECIST in advanced hepatocellular carcinoma (HCC) 1 2 2 3 3 4 5 2 L. Huang , Y. De Sanctis , M. Shan , J. Bruix , J. Llovet , A.-L. Cheng , G. Meinhardt , K. Nakajima ;
1 2 3 4 5 Whippany, NJ/US, Whippany, US, Barcelona, ES, Taipei, TW, New York, NJ/US
13:35 - 13:35 704P - Ang-2 polymorphisms in relation to outcome in advanced HCC patients receiving sorafenib 1 1 1 2 1 1 2 A. Casadei Gardini , G. Marisi , F.G. Foschi , M. Scartozzi , G.L. Frassineti ; Meldola, IT, Ancona, IT
13:35 - 13:35 706P - Overall survival (OS) by platelet count at baseline in patients with hepatocellular carcinoma (HCC) treated with sorafenib (SOR) in the SHARP and AP trials and regorafenib (REG) in the RESORCE trial 1 2 3 2 1 2 3 G. Meinhardt , Y. De Sanctis , M.-A. Leberre , K. Nakajima ; New York, NJ/US, Whippany, US, Loos, FR
13:35 - 13:35 705P - Circulating miRNA biomarkers predicting regorafenib (REG) clinical benefit in patients with hepatocellular carcinoma (HCC) in the RESORCE trial 1 2 2 3 4 5 6 1 2 M. Teufel , H. Seidel , K. Köchert , G. Meinhardt , R. Finn , J. Llovet , J. Bruix ; Whippany, NJ/US,
3 4 5 6 Berlin, DE, New York, NJ/US, Los Angeles, CA/US, New York, US, Barcelona, ES
13:35 - 13:35 708P - Epidemiological study of histologically proven advanced hepatocholangiocarcinoma: An AGEO multicenter retrospective study 1 2 3 4 4 1 Y. Touchefeu , C. Prieux-Klotz , D. Tougeron , T. Lecomte , M. Caulet , T. Matysiak Budnik , V. 5 2 2 6 1 2 3 Hautefeuille , M. Tiako-Meyo , A. Zaanan , M. Salimon ; Nantes, CEDEX 1/FR, Paris, FR, Poitiers, 4 5 6 CEDEX/FR, Chambray-Lès-tours, FR, Amiens, CEDEX/FR, Nantes, FR
13:35 - 13:35 710P - Assessing cancer risk in patients with HFE gene variants and type 1 hereditary hemochromatosis 1 1 1 2 1 1 1 1 K. Youkhana , V. Tutaeva , H. Williams , O. Corbali , S. Krishnamurthy , R. Metpally , N. Kip ;
2 Danville, US, Istanbul, TR
13:35 - 13:35 720P - Inoperable carcinoma gallbladder: Comparison of two palliative chemotherapy regimens (gemcitabine-platinum versus CAPEOX) 1 2 2 2 2 2 1 H. Malhotra , A. Daga , D. Gangopadhayay , A. Yadav , A. Mathur , B. Malhotra ; Jaipur,
2 Rajasthan/IN, Jaipur, IN
13:35 - 13:35 712P - Effect of adjuvant chemotherapy and chemoradiotherapy in patients with ampullary carcinoma: A NCDB analysis
Last update: 02-09-2017 06:01:33pm esmo.org 1 1 2 3 1 2 3 G. Westin , B. Huffman , S. Alsidawi , A. Mahipal ; Jacksonville, US, Rochester, MN/US, Tampa, FL/US
13:35 - 13:35 713P - The mutational landscape of periampullary adenocarcinomas in relation to morphological subtype and patient survival S. Lundgren, E. Karnevi, J. Elebro, B. Nodin, J. Eberhard, K. Leandersson, G. Jönsson, K. Jirström;
Lund, SE
13:35 - 13:35 714P - Gemcitabine and platinum- based chemotherapy in first line treatment of hepatocholangiocarcinoma: An AGEO multicenter retrospective study 1 2 3 4 4 5 M. Salimon , C. Prieux-Klotz , D. Tougeron , T. Lecomte , M. Caulet , T. Matysiak Budnik , V. 6 2 2 5 1 2 3 Hautefeuille , M. Tiako-Meyo , A. Zaanan , Y. Touchefeu ; Nantes, FR, Paris, FR, Poitiers, 4 5 6 CEDEX/FR, Chambray-Lès-tours, FR, Nantes, CEDEX 1/FR, Amiens, CEDEX/FR
13:35 - 13:35 715P - Jab1 silencing inhibits proliferation and sensitizes to cisplatin in biliary tract cancer J.-W. Kim, A.-R. Nam, J.E. Park, J.-H. Bang, M.H. Jin, D.-Y. Oh, Y.-J. Bang; Seoul, KR
13:35 - 13:35 716P - The nationwide cancer genome screening project in Japan, SCRUM-Japan GI-screen: Efficient identification of cancer genome alterations in advanced biliary tract cancer 1 2 3 4 5 6 7 M. Ueno , C. Morizane , Y. Kawamoto , H. Takahashi , D. Naruge , S. Shimizu , K. Nakamura , T. 8 9 10 11 12 13 14 7 Nakajima , T. Kato , T. Kudo , N. Mizuno , K. Ohtsubo , S. Itoh , H. Ishii , T. Sudo , S. Nomura 2 15 4 4 4 1 2 3 , S. Fujii , K. Shitara , A. Ohtsu , T. Yoshino ; Yokohama, JP, Tokyo, JP, Sapporo, Hokkaido/JP, 4 5 6 7 8 9 Kashiwa, Chiba/JP, Mitaka, Tokyo, JP, Saitama, JP, Chiba, JP, Kanagawa, JP, Amagasaki, 10 11 12 13 14 15 Hyogo/JP, Suita, Osaka/JP, Nagoya, JP, Kanazawa, JP, Fukuoka, JP, Matsuyama, JP, Kashiwa, JP
13:35 - 13:35 717P - Prognostic implication of inflammation-based prognostic scores in patients with intrahepatic cholangiocarcinoma (iCCA) treated with first-line Gemcitabine plus Cisplatin (GEMCIS) H. Cho, C. Yoo, K.-P. Kim, H.-M. Chang, B.-Y. Ryoo; Seoul, KR
13:35 - 13:35 718P - Phase 2 study of triplet chemotherapy with oxaliplatin, irinotecan and S-1 (OIS) as first-line treatment in patients with advanced biliary tract cancer (BTC) 1 2 3 2 3 3 3 2 1 C. Yoo , B. Han , K.-P. Kim , H.S. Kim , J.H. Kim , H.-M. Chang , B.-Y. Ryoo , D.Y. Zang ; Seoul,
2 3 Songpa-gu/KR, Anyang, KR, Seoul, KR
13:35 - 13:35 719P - Prognostic impact of hepatitis B virus (HBV) infection in advanced intrahepatic cholangiocarcinoma (iCCA) patients (pts) treated with first-line gemcitabine plus cisplatin (GEMCIS) E.J. Kim, H. Cho, C. Yoo, K.-P. Kim, H.-M. Chang, B.-Y. Ryoo; Seoul, KR
13:35 - 13:35 721P - Surgical indication for advanced intrahepatic cholangiocarcinoma according to the optimal preoperative carbohydrate antigen 19-9 cut-off value Y. Yamamoto, T. Sugiura, Y. Okamura, T. Ito, R. Ashida, K. Uesaka; Shizuoka, JP
13:35 - 13:35 722P - A phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: Primary analysis results
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 2 3 2 4 2 2 M. Ikeda , T. Sasaki , C. Morizane , N. Mizuno , F. Nagashima , S. Shimizu , N. Hayata , H. Ikezawa 2 2 5 6 1 2 3 4 , T. Suzuki , R. Nakajima , C. Dutcus , M. Ueno ; Kashiwa, Chiba/JP, Tokyo, JP, Nagoya, JP, 5 6 Saitama, JP, Woodcliff Lake, New Jersey/US, Yokohama, JP
13:35 - 13:35 723P - Genotyping and mRNA profiling reveal actionable targets in biliary tract cancers 1 1 1 1 1 1 1 K. Papadopoulou , S. Murray , K. Manousou , I. Tikas , C. Dervenis , J. Sgouros , D. Rontogianni , S. 1 1 1 1 1 2 1 2 Lakis , C. Poulios , S. Pervana , G. Lazaridis , G. Fountzilas , V. Kotoula ; Athens, GR, Thessaloniki, Central Macedonia/GR
13:35 - 13:35 724P - HER-2/HER-3 pathway as a potentially-actionable target in biliary tract cancers (BTCs): A retrospective analysis A. Lamarca, S. Galdy, S. Moghadam, J. Rogan, M. McNamara, R. Hubner, A. Cramer, J. Valle;
Manchester, GB
13:35 - 13:35 725P - Actionable molecular alterations in advanced biliary tract carcinomas: Preliminary data from the ProfiLER program (NCT01774409) 1 2 1 1 1 2 3 P. Cassier , C. de la Fouchardiere , P. Guibert , D. Pissaloux , C. Pacaux , C. Terret , L. Eberst , M. 2 1 2 1 2 1 2 1 2 Sarabi , V. Attignon , Q. Wang , V. Corset , D. Perol , J.-Y. Blay , F. Desseigne ; Lyon, FR, Lyon, 3 CEDEX/FR, Lyon, Cedex 08/FR
13:35 - 13:35 726P - Precision medicine for patients with advanced biliary tract cancers: Updated results from the prospective MOSCATO trial 1 2 2 2 2 2 3 2 L. Verlingue , D. Malka , A. Allorant , C. Massard , C. Ferté , L. Lacroix , E. Rouleau , N. Auger , J. 2 2 2 2 2 2 2 2 Delahousse , R. Sun , T. de Baere , L. Tselikas , B. Ba , J.-Y. Scoazec , S. Michiels , V. Boige , M. 2 2 2 1 2 3 Ducreux , J.-C. Soria , A. Hollebecque ; Paris, FR, Villejuif, FR, Paris, CEDEX 5/FR
13:35 - 13:35 727P - Preoperative chemoradiotherapy after induction FOLFIRINOX improve R0 resection margins rate and histological response in patients secondary resected in borderline or locally advanced pancreatic adenocarcinoma 1 2 3 3 4 5 D. PIETRASZ , O. Turrini , V. Vendrely , C. Laurent , E. Terrebonne , O. Hentic Dhome , A. Sauvanet 5 1 6 7 8 1 9 10 , J.-M. Simon , R. Coriat , F. Portales , B. Le Roy , A.-L. Pointet , L. Marthey , N. Regenet , D. 11 12 1 2 13 11 1 2 Goere , P. Artru , J.-C. Vaillant , J.-R. Delpero , J.-B. Bachet , A. Sa Cunha ; Paris, FR, 3 4 5 6 7 8 Marseille, FR, Bordeaux, FR, Giround, FR, Clichy, FR, Paris, CEDEX 14/FR, Montpellier, FR, 9 10 11 12 13 Clermont Ferrand, FR, Le Kremlin Bicetre, FR, Nantes, FR, Villejuif, FR, Lyon, CEDEX 8/FR, Paris, CEDEX 13/FR
13:35 - 13:35 728P - Intratumoral heterogeneity of SMAD4 immunohistochemical (IHC) expression and its role in prediction of recurrence patterns in patients with resectable pancreatic cancer (PC) 1 1 2 1 1 1 I. Pokataev , A. Kudaibergenova , A. Artemyeva , D. Podluzhnyi , N. Kudashkin , Y. Patyutko , E. 1 2 1 1 1 1 1 Moroz , E. Kharchenko , A. Popova , M. Fedyanin , A. Rumyantsev , I. Bazin , A. Tryakin , E. 1 1 1 1 1 2 Glukhov , O. Sekhina , D. Chekini , S. Tjulandin ; Moscow, RU, Saint Petersburg, RU
13:35 - 13:35 729P - Outcome of patients with pancreatic adenocarcinoma with complete pathological response following neo-adjuvant therapy
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 3 4 5 6 7 H.R. Kourie , A. Sa Cunha , S. Pernot , R. Coriat , A. Sauvanet , N. Regenet , S. Louafi , J.-B. Bachet 8 9 9 1 2 3 4 , D. Pietrasz , J. Taieb ; Brussels, BE, Villejuif, FR, Boulogne-Billancourt, FR, Paris, CEDEX 5 6 7 8 9 14/FR, Clichy, FR, Nantes, FR, Longjumeau, CEDEX/FR, Paris, CEDEX 13/FR, Paris, FR
13:35 - 13:35 730P - Interim health related quality of life (QoL) from LAPACT, a Phase 2 trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC) 1 2 3 4 5 6 7 F. Portales , P. Philip , P. Hammel , M. Buscaglia , R. Pazo-Cid , J.L. Manzano-Mozo , E. Kim , S. 8 9 10 11 12 13 13 Dowden , A. Zakari , C. Borg , E. Terrebonne , F. Rivera Herrero , J. Shiansong Li , T.J. Ong , 14 15 1 2 3 4 5 6 T. Nydam , J. Lacy ; Montpellier, FR, Detroit, MI/US, Clichy, FR, Genova, IT, Zaragoza, ES, 7 8 9 10 11 Badalona, ES, Charlotte, NC/US, Calgary, Alberta/CA, Orlando, FL/US, Besançon, FR, Giround, 12 13 14 15 FR, Santander, ES, Summit, NJ/US, Summit, US, New Haven, CT/US
13:35 - 13:35 731P - Prognosis of familial pancreatic cancer (FPC): A matched case analysis 1 2 2 3 4 5 5 1 2 3 G. O'Kane , A. Borgida , A. Dodd , K. Aung , S. Holter , J. Knox , S. Gallinger ; Dublin, IE, Z, CA,
4 5 Toronto, NB/CA, Toronto, CA, Toronto, ON/CA
13:35 - 13:35 732P - Should pancreatic cancer be included in BRCA1/2 testing criteria? 1 1 1 1 1 1 1 1 M. Venturelli , A. Toss , S. Pipitone , I. Marchi , E. Tenedini , V. Medici , E. Tagliafico , E. Razzaboni
1 2 1 1 1 2 , F. Spaggiari , E. De Matteis , S. Cascinu , L. Cortesi ; Modena, IT, Lecce, IT
13:35 - 13:35 733P - Sequential chemo-chemoradiation (CCRT) in locally advanced pancreas cancer in an irish high volume centre 1 2 3 1 3 1 R. Abdul Rahman , M.Y. Teo , M. Moriarty , R. McDermott , G. McVey ; Dublin, Belgard Square
2 3 North/IE, New York, NY/US, Rathgar, IE
13:35 - 13:35 735P - The prognostic significance of infiltrating lymphocytes in resectable pancreatic ductal adenocarcinoma in untreated versus neoadjuvant treated patients 1 1 1 1 1 1 1 J. Goldstein , D. Chatterjee , M. Zaid , B. Chaudhury , D. Elganainy , D. Halperin , R. Nejati , H. 1 1 1 1 2 2 2 1 Wang , M. Katz , J. Lee , J. Fleming , J. Rodriguez Canales , J. Blando , I. Wistuba , A. Maitra , R. 1 1 1 1 1 2 Wolff , H. Wang , G. Varadhachary , E. Koay ; Houston, US, Houston, TX/US
13:35 - 13:35 736P - Randomized phase 2 trial of peri- or post-operative chemotherapy in resectable pancreatic adenocarcinoma 1 1 1 1 2 2 3 3 M. Reni , S. Zanon , G. Balzano , R. Castoldi , A. Zerbi , M.C. Tronconi , D. Pinelli , S. Mosconi , C.
1 1 1 1 2 3 Doglioni , M. Falconi , L. Gianni ; Milan, IT, Rozzano, IT, Bergamo, IT
13:35 - 13:35 737P - TP53 mutation predicts sensitivity to adjuvant gemcitabine in pancreatic cancer: Results from the CONKO-001 study 1 1 1 1 1 1 1 1 M. Sinn , J. Budczies , F. Damm , P. Lohneis , R. Schmuck , D. Treue , J. Striefler , M. Bahra , U. 1 1 1 1 2 3 1 4 1 Pelzer , A. Jühling , H. Bläker , S. Bischoff , H. Oettle , C. Denkert , H. Riess , B. Sinn ; Berlin, DE, 2 3 4 Friedrichshafen, DE, Heidelberg, DE, Houston, TX/US
13:35 - 13:35 738P - Strong tumour cytidine deaminase (CDA) staining predicts for improved survival associated with sequential nab-Paclitaxel (nabP) and gemcitabine (GEM) chemotherapy as first line treatment of patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC)
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 2 2 2 3 2 4 5 P. Corrie , W. Qian , A. Gopinathan , M. Williams , R. Brais , J. Valle , B. Basu , S. Falk , C. Iwuji , 6 7 8 9 10 2 2 2 H. Wasan , D. Palmer , M. Scott-Brown , J. Wadsley , S. Arif , L. Bax , P. Bundi , R. Skells , A. 11 12 2 1 2 3 Neesse , D. Tuveson , D. Jodrell ; Cambridge, Cambridgeshire/GB, Cambridge, GB, Manchester, 4 5 6 7 8 9 GB, Bristol, GB, Leicester, GB, London, GB, Liverpool, GB, Coventry, GB, Sheffield, South 10 11 12 Yorkshire/GB, Cardiff, GB, Göttingen, DE, New York, NY/US
13:35 - 13:35 739P - Randomized phase 2 trial of nab-paclitaxel plus gemcitabine, ± capecitabine, cisplatin (PAXG regimen) in metastatic pancreatic adenocarcinoma M. Reni, S. Zanon, C. Pircher, M. Chiaravalli, M. Macchini, U. Peretti, E. Mazza, G. Balzano, P. Passoni,
R. Nicoletti, P.G. Arcidiacono, G. Pepe, C. Doglioni, S. Romi, D. Ceraulo, M. Falconi, L. Gianni; Milan, IT
13:35 - 13:35 740P - The impact of UGT1A1 genetic polymorphism on safety in unresectable pancreatic cancer patients receiving FOLFIRINOX therapy: A subset analysis of JASPAC 06 study 1 2 3 4 5 5 6 7 H. Shirasu , K. Omae , H. Fujii , N. Mizuno , M. Ozaka , H. Ueno , S. Kobayashi , K. Uesugi , N. 6 8 9 10 11 12 3 5 Kobayashi , H. Hayashi , K. Sudo , N. Okano , Y. Horita , K. Kamei , Y. Seigo , H. Takafumi , T. 5 5 2 13 1 2 3 4 Henmi , M. Kobayashi , A. Todaka , A. Fukutomi ; Shizuoka, JP, Sunto-Gun, JP, Tochigi, JP, 5 6 7 8 9 10 11 Nagoya, JP, Tokyo, JP, Yokohama, JP, Matsuyama, JP, Sapporo, JP, Chiba, JP, Mitaka, JP, 12 13 Toyama, JP, Osakasayama, JP, Shizuoka, Shizuoka/JP
13:35 - 13:35 744P - Overall survival and immunologic responses in metastatic pancreatic adenocarcinoma (PDAC) on PEGylated human IL-10 (AM0010) with 5-FU/LV and oxaliplatin (FOLFOX) 1 2 3 4 5 6 1 7 J.R. Hecht , A. Naing , G. Falchook , M. Patel , J. Infante , R. Aljumaily , D. Wong , K. Autio , Z. 1 2 5 6 8 8 9 8 Wainberg , M. Javle , J. Bendell , S. Pant , A. Hung , P. Van Vlasselaer , G. Brown , M. Oft , K. 10 1 2 3 4 5 Papadopoulos ; Los Angeles, CA/US, Houston, TX/US, New York, CO/US, Sarasota, FL/US, 6 7 8 9 10 Nashville, TN/US, Oklahoma City, OK/US, New York, US, Redwood City, US, New York, CA/US, San Antonio, TX/US
13:35 - 13:35 741P - Prognostic value of baseline neutrophil-to-lymphocyte ratio for predicting clinical outcome in metastatic pancreatic ductal adenocarcinoma (mPDAC) patients treated with liposomal irinotecan (nal-IRI) + 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alone 1 2 3 4 5 6 7 8 R. Hubner , L.-T. Chen , C.-P. Li , G. Bodoky , A. Dean , K.-H. Lee , D. Cunningham , J. Siveke , F. 9 10 11 11 11 12 13 1 Braiteh , F. de Jong , B. Belanger , R. Walls , P. Mody , D. von Hoff , A. Wang-Gillam ;
2 3 4 5 6 7 8 Manchester, GB, Tainan, TW, Taipei, TW, Budapest, HU, Subiaco, AU, Seoul, KR, Sutton, GB, 9 10 11 12 13 Essen, DE, Las Vegas, US, Zug, CH, Basking Ridge, US, Phoenix, AZ/US, St. Louis, US
13:35 - 13:35 742P - IDO1 expression as biomarker in erlotinib-treated patients with advanced pancreatic cancer: translational results from the AIO-PK0104 phase III trial 1 1 1 1 1 2 1 S. Kruger , S. Ormanns , V. Roesgen , M.-L. Legenstein , M. Haas , B. Westphalen , P. Duewell , M.
1 1 1 1 1 2 Schnurr , V. Heinemann , T. Kirchner , S. Boeck ; Munich, DE, München, DE
13:35 - 13:35 743P - Tumor hyaluronan (HA) is a novel biomarker: Results of the randomized phase 2 HALO 202 study of PEGPH20 plus nab-paclitaxel/gemcitabine (PAG) vs AG in previously untreated, metastatic pancreatic ductal adenocarcinoma (mPDA)
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 3 4 5 6 7 8 A. Hendifar , A. Bullock , T. Seery , L. Zheng , D. Sigal , P. Ritch , F. Braiteh , M. Zalupski , N. 9 10 11 11 11 12 12 12 Bahary , W. Harris , J. Pu , F. Lian , J. Zhu , W. Wu , D. Chondros , P. Jiang , S.R. 13 1 2 3 4 5 6 Hingorani ; Los Angeles, US, Boston, US, Irvine, US, Baltimore, MD/US, La Jolla, CA/US, 7 8 9 10 11 12 Milwaukee, US, Las Vegas, US, Ann Arbor, US, Pittsuburgh, US, Seattle, US, Tucson, US, 13 San Diego, CA/US, Seattle, Wa, US
13:35 - 13:35 745P - Circulating levels of ADAM12, a stromal activation biomarker, are predictive of survival in pancreatic ductal adenocarcinoma (PDAC) 1 2 1 1 1 1 1 H. van Laarhoven , H. Damhofer , V. Veenstra , C. Waasdorp , L. van Rijssen , F. Dijk , J. Wilmink , 1 1 1 3 3 3 1 1 M. Besselink , O. Busch , J.P. Medema , J. Shiansong Li , R. Jiang , D. Pierce , M. Bijlsma ; 2 3 Amsterdam, NL, København N, NL, Summit, NJ/US
13:35 - 13:35 746P - COnsensus statement on mandatory measurements in PAncreatic cancer trials for systemic treatment of unresectable disease (COMM-PACT) 1 1 1 1 2 3 4 L.B. van Rijssen , E. ter Veer , M. Besselink , R. Mali , J. Berlin , S. Boeck , F. Bonnetain , T. Conroy 5 6 7 8 9 10 11 , G. Deplanque , D. Goldstein , B. Glimelius , J. Neoptolemos , M. Reni , W. Scheithauer , J. van 1 1 1 1 1 1 1 der Meer , J. Wilmink , M. van der Poel , O. Busch , M. van Oijen , H. Van Laarhoven ; Amsterdam, 2 3 4 5 6 NL, Nashville, TN/US, Munich, DE, Besançon, CEDEX/FR, Vandoeuvre Les Nancy, CEDEX/FR, 7 8 9 10 11 Vevey, CH, Sydney, NSW/AU, Uppsala, SE, Liverpool, GB, Milan, IT, Vienna, AT
13:35 - 13:35 747P - Phase I study of resminostat/S-1 combination in patients with pre-treated biliary tract or pancreatic cancer 1 2 1 3 3 1 1 3 C. Morizane , I. Ohno , H. Ueno , S. Mitsunaga , Y. Hashimoto , T. Okusaka , S. Kondo , M. Sasaki , 1 2 1 1 1 2 1 2 Y. Sakamoto , H. Takahashi , R. Hara , S. Kobayashi , O. Nakamura , M. Ikeda ; Tokyo, JP, 3 Kashiwa, Chiba/JP, Kashiwa, JP
13:35 - 13:35 748P - Comparisons of outcomes of patients with advanced pancreatic cancer (APC) treated with FOLFIRINOX (FX) versus gemcitabine and nab-paclitaxel (GN): A population-based cohort study 1 2 3 1 2 2 2 1 2 N. Papneja , C. Olson , H. Chalchal , M. Moser , N. Iqbal , K. Haider , A. Zaidi , J. Shaw , B. Brunet , 2 2 2 1 2 3 D.-A. Dueck , T. Abbas , S. Ahmed ; Saskatoon, SK/CA, Saskatoon, CA, Regina, Saskatchewan/CA
13:35 - 13:35 749P - Musculoskeletal Events (MSEs) with PEGPH20 treatment and management in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDA) 1 2 2 2 3 4 1 2 A. Bullock , P. Vervaet , W. Wu , D. Chondros , S.R. Hingorani , A. Hendifar ; Boston, US, San
3 4 Diego, CA/US, Seattle, Wa, US, Los Angeles, US
13:35 - 13:35 750P - Phase Ib study of PF-04136309 (an oral CCR2 inhibitor) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic adenocarcinoma 1 2 3 3 3 4 5 6 7 M. Noel , M. Lowery , D. Ryan , B. Wolpin , A. Bullock , C. Britten , B. Jin , B. Ganguly , C. Taylor , 7 8 7 1 1 2 3 4 D. Yin , D. Wunderlich , E. Gamelin , D. Linehan ; Rochester, US, New York, US, Boston, US, 5 6 7 8 Charleston, US/US, Cambridge, MA/US, South San Francisco, US, San Diego, CA/US, Groton, US
13:35 - 13:35 751P - Metastatic pancreatic cancer: Real Life data from the german quality of life and translational research on pancreatic cancer study (QoliXane)
Last update: 02-09-2017 06:01:33pm esmo.org 1 1 1 1 2 3 4 S.-E. Al-Batran , A. Reichart , C. Schoenherr , G. zur Hausen , C. Pauligk , B. Schöttger , G. Siegler , 5 6 7 8 1 2 9 S. Doerfel , A. Aldaoud , L. Hahn , J. Schubert , O. Waidmann , J. Trojan , H.-G. Hoeffkes , R. 10 11 12 13 14 1 1 Schnell , M. Koenigsmann , W. Blau , J. Uhlig , N. Homann , T. Götze ; Frankfurt Am Main, 2 3 4 5 6 7 8 DE, Frankfurt, DE, Würzburg, DE, Nürnberg, DE, Dresden, DE, Leipzig, DE, Berlin, DE, Riesa, 9 10 11 12 13 14 DE, Fulda, DE, Frechen, DE, Hannover, DE, Giessen, DE, No City Provided, NA, Wolfsburg, DE
13:35 - 13:35 752P - FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: A subset analysis from the nation-wide multicenter observational study (JASPAC06) 1 2 3 4 5 6 7 4 N. Kobayashi , K. Omae , Y. Horita , H. Ueno , N. Mizuno , K. Uesugi , K. Sudo , M. Ozaka , H. 8 9 10 11 1 12 13 Hayashi , N. Okano , K. Kamei , A. Yamaguchi , S. Kobayashi , S. Suzuki , S. Ishihara , T. 14 2 2 1 2 3 4 5 Uchiyama , A. Todaka , A. Fukutomi ; Yokohama, JP, Sunto-Gun, JP, Toyama, JP, Tokyo, JP, 6 7 8 9 10 11 Nagoya, JP, Matsuyama, JP, Chiba, JP, Sapporo, JP, Mitaka, JP, Osakasayama, JP, Kure, JP, 12 13 14 Yamagata, JP, Toyoake, JP, Kikugawa, JP
13:35 - 13:35 753P - Quality of life (QoL) of patients (pts) with metastatic pancreatic cancer (mPAC) initiating first-line chemotherapy (CT) in routine practice 1 2 3 2 4 5 6 2 B. Laquente , T. Macarulla , C. Bugés , M. Martín , C. García , E. Dotor , S. Merino , L. Visa , T. 7 8 9 10 10 9 1 Martín , M. Pedraza , R. Guardeño , L. Pellín , D. Vilanova , A. García ; L'hospitalet De Llobregat,
2 3 4 5 6 7 8 ES, Barcelona, ES, Badalona, ES, Burgos, ES, Sabadell, ES, Reus, ES, Salamanca, ES, León, 9 10 ES, Girona, ES, Madrid, ES
13:35 - 13:35 754P - Impact of the duration of diabetes mellitus (DM) on the outcomes of metastatic pancreatic cancer (mPC) treated with gemcitabine (G): A retrospective study 1 1 1 2 1 1 1 1 K. OHASHI , S. Iizumi , A. Kuchiba , M. Ikeda , Y. Sakamoto , S. Kondo , C. Morizane , H. Ueno , K. 1 3 2 3 3 2 3 1 Osame , S. Mitsunaga , I. Ohno , H. Imaoka , Y. Hashimoto , H. Takahashi , M. Sasaki , T. Okusaka 1 2 3 ; Tokyo, JP, Kashiwa, Chiba/JP, Kashiwa, JP
13:35 - 13:35 755P - Prognostic value of neutrophil-lymphocyte ratio in first line treatment for metastatic pancreatic adenocarcinoma Y.S. Rho, J. Ranger, S. Hamalova, I. Barrera, A. Mamo, G. Batist, P. Kavan; Montreal, QC/CA
13:35 - 13:35 756P - Treatment patterns, clinical characteristics, and outcomes of patients (pts) with metastatic pancreatic cancer (MPC) treated with nab-paclitaxel (nab-P) plus gemcitabine (GEM) in real-life practice: ANICE-Pac trial 1 1 2 3 4 5 6 7 A. Fernández , M. Salgado , A. García , E. Buxò , R. Vera , J. Adeva , P. Jiménez , G. Quintero , C. 8 9 10 5 11 12 13 Llorca , M. Cañabate , L. López , A. Muñoz , P. Ramírez , P. González , C. López , M. 14 15 16 17 5 1 2 3 Reboredo , E. Gallardo , M. Sánchez , J. Gallego , C. Guillén ; Ourense, ES, Girona, ES,
4 5 6 7 8 9 Barcelona, ES, Pamplona, ES, Madrid, ES, Oviedo, ES, No City Provided, NA, Elda, ES, Xàtiva, 10 11 12 13 14 15 16 ES, Toledo, ES, Cádiz, ES, Vigo, ES, Santander, ES, A Coruna, ES, Pontevedra, ES, 17 Murcia, ES, Elche, ES
13:35 - 13:35 757P - Safety and efficacy of gemcitabine/nabpaclitaxel in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma: a retrospective analysis
Last update: 02-09-2017 06:01:33pm esmo.org 1 1 1 1 1 1 1 J. Ventriglia , M.M. Laterza , B. Savastano , A. Petrillo , G. Tirino , L. Pompella , A. Pappalardo , M.
1 2 2 1 2 Orditura , F. Ciardiello , F. De Vita ; Napoli, IT, Naples, IT
13:35 - 13:35 758P - Updated results of a phase II study of gemcitabine, erlotinib, and S-1 in patients with advanced pancreatic cancer 1 1 1 2 3 4 5 1 1 B. Han , H.S. Kim , D.R. Choi , B.Y. Shim , K.H. Lee , J.W. Kim , J.H. Kim , H.Y. Kim , H. Song ,
1 1 2 3 4 5 D.Y. Zang ; Anyang, KR, Suwon, KR, Daegu, KR, Seongnam, KR, Seoul, KR
13:35 - 13:35 759P - PANOVA: a phase II study of TTFields (150 kHz) with concomitant standard chemotherapy for front-line advanced pancreatic adenocarcinoma: Updated efficacy results 1 2 3 4 2 5 M. Kueng , C. Guillen-Ponce , F. Rivera Herrero , J. Gallego Plazas , J. Lopez-Martin , M. Benavides
1 2 3 4 5 ; Fribourg, CH, Madrid, ES, Santander, ES, Elche, Alicante/ES, Malaga, ES
13:35 - 13:35 760P - Risk factors for febrile neutropenia (FN) in unresectable/recurrent pancreatic cancer(PC) patients(pts) receiving FOLFIRINOX (FFX) from JASPAC06 study 1 1 2 3 4 5 1 6 M. Sasaki , H. Ueno , K. Omae , T. Goto , G. Murohisa , N. Mizuno , M. Ozaka , S. Kobayashi , K. 7 6 8 9 10 11 12 1 Uesugi , N. Kobayashi , H. Hayashi , K. Sudo , N. Okano , Y. Horita , K. Kamei , T. Hosokawa , 1 1 13 13 1 2 3 4 T. Henmi , M. Kobayashi , A. Todaka , A. Fukutomi ; Tokyo, JP, Shizuoka, JP, Asahikawa, JP, 5 6 7 8 9 10 Hamamatsu, JP, Nagoya, JP, Yokohama, JP, Matsuyama, JP, Sapporo, JP, Chiba, JP, Mitaka, 11 12 13 JP, Toyama, JP, Osakasayama, JP, Shizuoka, Shizuoka/JP
13:35 - 13:35 761P - A Phase I study of LDE225 in combination with gemcitabine and nab-paclitaxel in patients with metastasized pancreatic cancer 1 1 1 1 1 1 2 K. Lee , R. Molenaar , R. Klaassen , M. Bijlsma , M. Weterman , D. Richel , M. Wymenga , H. Van
1 1 1 2 Laarhoven , J. Wilmink ; Amsterdam, NL, Enschede, NL
13:35 - 13:35 762P - Impact of advances in systemic chemotherapy for unresectable pancreatic ductal adenocarcinoma (PDAC) in Alberta, Canada 1 2 3 1 1 2 3 R. Lee-Ying , J. Loree , W. Cheung , P. Tang ; Calgary, CA, Vancouver, British Columbia/CA, Calgary, AB/CA
13:35 - 13:35 763P - Randomized phase 2 study of PEGPH20 Plus nab-paclitaxel/gemcitabine (PAG) vs AG in patients (Pts) with untreated, metastatic pancreatic ductal adenocarcinoma (mPDA) 1 2 3 4 5 6 7 8 S.R. Hingorani , A. Bullock , T. Seery , L. Zheng , D. Sigal , P. Ritch , F. Braiteh , M. Zalupski , N. 9 10 11 11 11 12 12 12 Bahary , W. Harris , J. Pu , C. Aldrich , S. Khelifa , W. Wu , D. Chondros , P. Jiang , A. 13 1 2 3 4 5 6 Hendifar ; Seattle, Wa, US, Boston, US, Irvine, US, Baltimore, MD/US, La Jolla, CA/US, 7 8 9 10 11 12 Milwaukee, US, Las Vegas, US, Ann Arbor, US, Pittsuburgh, US, Seattle, US, Tucson, US, 13 San Diego, CA/US, Los Angeles, US
13:35 - 13:35 764P - Crucial relationship of neural wiskott aldrich syndrome protein(N-WASP) and lysyl oxidase-like 2(LOXL2) in the promotion of pancreatic cancer metastasis H. Kim, J.S. Park; Seoul, KR
13:35 - 13:35 765P - The nationwide cancer genome screening project in Japan SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced small intestine cancer
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 3 4 5 1 6 7 K. Takayoshi , W. Okamoto , S. Hironaka , Y. Honma , H. Ebi , R. Nakanishi , T. Kajiwara , T. Kudo , 8 9 10 11 12 2 13 4 T. Tamura , Y. Komatsu , H. Hara , D. Naruge , T. Moriwaki , I. Miki , T. Sudo , S. Nomura , S. 2 14 14 14 1 2 3 4 Fujii , K. Shitara , A. Ohtsu , T. Yoshino ; Fukuoka, JP, Kashiwa, JP, Chiba, Chiba/JP, Tokyo, 5 6 7 8 9 10 JP, Kanazawa, JP, Matsuyama, JP, Suita, Osaka/JP, Osaka, JP, Sapporo, Hokkaido/JP, 11 12 13 14 Saitama, JP, Mitaka, Tokyo, JP, Tsukuba, Ibaraki/JP, Chiba, JP, Kashiwa, Chiba/JP
13:35 - 13:35 766P - Frequent ERBB3 (HER3) activating mutations in small bowel adenocarcinomas 1 2 3 2 2 2 4 5 L. Cabel , I. Bieche , T. Aparicio , M. Svrcek , A. Zaanan , P. Afchain , F. Di Fiore , J.-M. Gornet , D. 2 2 2 2 2 2 1 Le Corre , S. Vacher , C. Callens , V. Bernard , P. Laurent-Puig , F.-C. Bidard ; Paris, CEDEX 2 3 4 5 14/FR, Paris, FR, Bobigny, CEDEX/FR, Rouen, FR, Paris, CEDEX 10/FR
13:35 - 13:35 767TiP - CLASS-05 trial: A randomized controlled phase III trial of cytoreductive surgery + hyperthermic intraperitoneal chemotherapy (HIPEC) + systemic chemotherapy vesus systemic chemotherapy alone for patients with limited peritoneal carcinomatosis of gastric cancer 1 1 1 2 3 4 5 1 1 1 1 1 H. Liu , G. Li , J. Yu , X. Su , Y. Sun , J. Hu , L. Huang , Z. Zhou , Y. Li , J. Yu , H. Wei , J. Peng , 6 7 1 1 1 2 3 4 5 Z. Wu , H. Chen , S. Cui , Y. Hu ; Guangzhou, CN, Beijing, CN, Shanghai, CN, Chengdu, CN, 6 7 Fuzhou, CN, Meizhou, CN, Zhongshan, CN
13:35 - 13:35 768TiP - A prospective multicenter, phase II trial (NAC-GA trial) to evaluate the effect of neoadjuvant nab-paclitaxel plus gemcitabine therapy on overall survival in patients with borderline resectable pancreatic cancer K.-I. Okada, T. Shimokawa, S. Hirono, M. Kawai, M. Miyazawa, Y. Kitahata, H. Yamaue; Wakayama, JP
13:35 - 13:35 769TiP - Randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group Study (JCOG1407) 1 2 2 2 3 4 5 6 A. Fukutomi , J. Mizusawa , H. Katayama , T. Okusaka , T. Ito , N. Okano , N. Mizuno , M. Ikeda , M. 7 8 2 9 2 2 3 2 10 Ueno , K. Shioji , M. Ozaka , S. Shimizu , Y. Sakamoto , S. Kondo , K. Kawabe , J. Eba , H. Ishii ,
2 2 1 2 3 4 5 H. Fukuda , J. Furuse ; Shizuoka, Shizuoka/JP, Tokyo, JP, Fukuoka, JP, Mitaka, JP, Nagoya, JP, 6 7 8 9 10 Kashiwa, Chiba/JP, Yokohama, JP, Niigata, JP, Saitama, JP, Matsuyama, JP
13:35 - 13:35 770TiP - NIFE-trial: Liposomal irinotecan (nal-IRI) plus 5-fluorouracil (5-FU) and leucovorin (LV) or gemcitabine plus cisplatin in advanced biliary-tract cancer: An open label, randomized, multicenter phase II trial of the AIO 1 1 2 1 1 2 T. Ettrich , L. Perkhofer , A. Berger , T. Seufferlein ; Ulm, DE, Halle, DE
13:35 - 13:35 771TiP - A feasibility study of TAS-118 plus oxaliplatin as perioperative chemotherapy for locally advanced gastric cancer 1 2 1 1 3 1 3 A. Takashima , D. Takahari , N. Ishizuka , H. Katai , T. Nakajima , M. Ohashi , S. Mikami , S. 1 1 4 1 1 2 3 4 Takahashi , T. Sano , N. Boku , K. Yamaguchi ; Tokyo, JP, Nagoya, Aichi/JP, Kanagawa, JP, Kawasaki, Kanagawa/JP
13:35 - 13:35 772TiP - A phase 1/2 study of ramucirumab plus nivolumab in patients with previously treated advanced gastric adenocarcinoma
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 3 1 4 5 6 1 H. Shoji , H. Miyamoto , H. Hara , D. Takahari , N. Machida , T. Esaki , K. Nagashima , K. Aoki , K. 1 1 1 7 1 1 2 3 4 Honda , Y. Nagata , T. Miyamoto , N. Boku , K. Kato ; Tokyo, JP, Osaka, JP, Saitama, JP, 5 6 7 Shizuoka, JP, Fukuoka, JP, Chiba, JP, Kawasaki, Kanagawa/JP
13:35 - 13:35 773TiP - PRODIGE 51 - GASTFOX: Phase III randomised trial evaluating FOLFOX with or without DOCETAXEL (TFOX) as 1st line chemotherapy for locally advanced or metastatic oesophago-gastric adenocarcinoma 1 2 1 3 4 5 6 A. Zaanan , E. Samalin , C. Louvet , C. Montérymard , F. Khemissa , O. Bouche , S. Louafi , F. 7 8 9 10 11 1 12 Ghiringhelli , P. Bernard , B. Chibaudel , P. Artru , Y. Molin , N. Baba-Hamed , O. Romano , T. 13 14 1 15 16 1 1 2 Aparicio , P. Michel , P. Rougier , D. Tougeron , S. Manfredi , J. Taieb ; Paris, FR, Montpellier,
3 4 5 6 7 8 9 FR, Dijon, FR, Perpignan, FR, Reims, FR, Corbeil Essonnes, FR, Dijon, Cedex/FR, Hyeres, FR, 10 11 12 13 14 Levallois Perret, FR, Lyon, CEDEX 8/FR, Lyon, FR, Lille, CEDEX/FR, Bobigny, CEDEX/FR, 15 16 Rouen, FR, Poitiers, CEDEX/FR, Rennes, CEDEX/FR
13:35 - 13:35 774TiP - Global phase 3, randomized, double-blind, placebo-controlled study evaluating PEGylated recombinant human hyaluronidase PH20 (PEGPH20) plus nab-paclitaxel and gemcitabine in patients with previously untreated, hyaluronan (HA)-high, stage IV pancreatic ductal adenocarcinoma (PDA) 1 2 3 4 5 6 7 8 E. Van Cutsem , A. Hendifar , M. Reni , L. Zheng , M. Ducreaux , W. Harris , P. Corrie , T. Seery , D. 9 10 1 2 3 4 5 6 Chondros , A. Bullock ; Leuven, BE, Los Angeles, US, Milan, IT, Baltimore, MD/US, Paris, FR, 7 8 9 10 Seattle, US, Cambridge, Cambridgeshire/GB, Irvine, US, San Diego, CA/US, Boston, US
13:35 - 13:35 775TiP - KEYNOTE-240: Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC) 1 2 3 4 5 6 7 8 1 R. Finn , S. Chan , A. Zhu , J. Knox , A.-L. Cheng , A. Siegel , O. Bautista , M. Kudo ; Los Angeles, 2 3 4 5 6 7 CA/US, Shatin, HK, Boston, US, Toronto, ON/CA, Taipei, TW, Kenilworth, US, Kenilworth, NJ/US, 8 Osaka, JP
13:35 - 13:35 776TiP - PACTO: A single center, randomized, phase II study of the combination of nab-paclitaxel and gemcitabine with or without tocilizumab, an IL-6R inhibitor, as first-line treatment in patients with locally advanced or metastatic pancreatic cancer 1 1 2 3 1 1 1 I. Chen , J. Johansen , T. Zimmers , C. Dehlendorff , V. Kirk Parner , B. Vittrup Jensen , D. Nielsen ;
1 2 3 Herlev, DK, Indianapolis, IN/US, Copenhagen, DK
13:35 - 13:35 777TiP - ATTRACTION-04 (ONO-4538-37): A randomized, multicenter, phase 2/3 study of nivolumab (Nivo) plus chemotherapy in patients (Pts) with previously untreated advanced or recurrent gastric (G) or gastroesophageal junction (GEJ) cancer 1 2 3 4 1 2 3 L.-T. Chen , Y.-K. Kang , M. Tanimoto , N. Boku ; Tainan, TW, Seoul, Songpa-gu/KR, Osaka-Shi,
4 JP, Kawasaki, Kanagawa/JP
13:35 - 13:35 778TiP - ATTRACTION-05 (ONO-4538-38/BMS CA209844): a randomized, multicenter, double-blind, placebo- controlled Phase 3 study of Nivolumab (Nivo) in combination with adjuvant chemotherapy in pStage III gastric and esophagogastric junction (G/EGJ) cancer 1 2 3 4 3 5 6 7 M. Terashima , Y.-W. Kim , T.-S. Yeh , H.C. Chung , J.-S. Chen , N. Boku , Y.-K. Kang , L.-T. Chen , 8 1 2 3 4 5 M. Sasako ; Shizuoka, Shizuoka/JP, Goyang, KR, Taoyuan, TW, Seoul, KR, Kawasaki, 6 7 8 Kanagawa/JP, Seoul, Songpa-gu/KR, Tainan, TW, Nishinomiya, JP
Last update: 02-09-2017 06:01:33pm esmo.org 13:35 - 13:35 779TiP - Adjuvant oxaliplatin plus S-1 (SOX) with concurrent radiotherapy versus SOX alone for gastric cancer with D2 lymph node dissection and high risk factors: a randomized phase III trial 1 1 1 1 1 1 1 1 1 1 1 X. Wang , Y. Shen , Q. Li , M. Qiu , Z. Li , J. Liu , H. Gou , Y. Yang , D. Cao , C. Yi , D. Luo , H. 1 1 2 2 3 4 1 1 1 2 3 Zhu , Z. Zhou , S. Tan , W. Wang , X. Ye , X. Su , F. Xu , F. Bi ; Chengdu, CN, Guiyang, CN, 4 Deyang, CN, Leshan, CN
13:35 - 13:35 780TiP - Impact of early palliative care on overall survival of patients with metastatic upper gastrointestinal cancers treated with first-line chemotherapy: Phase III EPIC trial 1 1 1 1 1 1 2 1 E. Hutt , A. Da silva , D. Pannier , E. Bogart , F. El-Hajbi , S. Villet , S. Clisant , M.-C. Le Deley , A.
2 1 2 Adenis ; Lille, FR, Lille, CEDEX/FR
13:35 - 13:35 781TiP - Apatinib and irinotecan combination treatment in first-line chemotherapy refractory esophageal squamous cell carcinoma: A phase I dose escalation study J. Jia, J. Yu, Z. Sun, Y. Yang, C. Liu, Y. Xiao, X. Zhang; Beijing, CN
13:35 - 13:35 782TiP - PANOVA-3: A phase 3 study of TTFields with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (LAPC) 1 2 1 1 1 1 2 O. Farber , U. Weinberg , Z. Bomzon , M. Giladi , E. Kirson ; Haifa, IL, Luzern, CH
13:35 - 13:35 GYNAECOLOGICAL CANCERS A. Gonzalez Martin, Madrid, ES
13:35 - 13:35 943P - Location of mutation in BRCA2 gene and survival in patients with ovarian cancer 1 1 2 3 3 1 1 S.I. Labidi-Galy , T. Olivier , M. Rodrigues , D. Ferraioli , O. Derbel , A. Bodmer , P. Petignat , N. 3 4 4 1 1 1 2 2 Chopin , O. Tredan , P. Heudel , V. Viassolo , A. Ayme , P.O. Chappuis , M.-H. Stern , C. Houdayer
2 3 2 3 4 1 2 , D. Stoppa-Lyonnet , A. Buisson , L. Golmard , V. Bonadona , I. Ray-Coquard ; Geneva, CH, Paris, 3 4 FR, Lyon, FR, Lyon, CEDEX/FR
13:35 - 13:35 944P - POLE mutations and MSI were positive predictive factors for progression free survival in endometrial cancer patients at the risk of recurrence 1 1 1 1 1 1 1 1 A. Nyuya , J. Haraga , T. Nagasaka , K. Nakamura , T. Haruma , T. Nishida , K. YASUI , T. Fujiwara
2 1 1 2 , A. Goel , H. Masuyama ; Okayama, JP, Texas, TX/US
13:35 - 13:35 945P - Evaluation of circulating tumor DNA in patients with ovarian cancer harboring somatic PIK3CA or KRAS mutations 1 2 1 1 1 3 2 A. Ogasawara , T. Hihara , A. Yabuno , S. Shimoyokkaichi , D. Shintani , Y. Ikeda , K. Tai , K.
3 2 1 1 2 3 Fujiwara , K. Watanabe , K. Hasegawa ; Hidaka, JP, Tsukuba, JP, Saitama, JP
13:35 - 13:35 946P - Predictive and prognostic value of tumor cells and circulating plasma free DNA in advanced epithelial ovarian carcinoma 1 1 1 1 J. Martinez-Garcia , A. Minguela Puras , P.A. Cascales Campos , M.V. Martinez Sanchez , J. Gil 1 1 1 1 1 Martinez , F. Barcelo Valcarcel , J.R. Rodriguez Hernandez , M.A. Torroba Caron , A. Soto-Gutierrez , 1 1 1 1 2 P. Sanchez Henarejos , A. Puertes Boix , S. Montenegro Luis , P. Ruiz Carreño , E. Rodriguez Braun , 1 1 1 1 1 M.D. Jimenez Lucas , M. Guirao Marín , M.A. Cuellar Rivas , A. Cano Jimenez , A. Anton Garcia , J.L. 1 1 2 Alonso Romero ; Murcia, ES, Cartagena, ES
Last update: 02-09-2017 06:01:33pm esmo.org
13:35 - 13:35 947P - Circulating tumor cells as prognostic marker in ovarian carcinoma: Results from the ANTHALYA study 1 2 3 4 5 6 7 T. de La Motte Rouge , P. Cottu , P. Pautier , M. Provansal , A. Floquet , F. Selle , M. Fabbro , E. 8 9 10 6 11 11 6 Kalbacher , P. Follana , A.F. Lesoin , J. Medioni , J. Dupin , R.-M. Ferri , F.-C. Bidard , C. Dubot 12 12 13 1 2 3 4 , R. Rouzier , F. Joly Lobbedez ; Rennes, FR, Paris, CEDEX 5/FR, Villejuif, CEDEX/FR, 5 6 7 8 Marseille, FR, Bordeaux, CEDEX/FR, Paris, FR, Montpellier, CEDEX 5/FR, Besançon, CEDEX/FR, 9 10 11 12 13 Nice, CEDEX 2/FR, Lille, CEDEX/FR, Boulogne Billancourt, FR, St. Cloud, FR, Caen, CEDEX 5/FR
13:35 - 13:35 948P - Genomic instability is associated with increased immune infiltration and PDL1 expression in epithelial ovarian cancer 1 1 1 1 1 1 1 A. Leary , C. Genestie , Y. Boursin , J. Adam , A. Leformal-Ensarguex , S. Gouy , P. Morice , E. 1 2 1 1 1 1 1 1 2 Bentivegna , P. Pautier , J. Michels , B. Job , M. Deloger , S. Mesnage , A. Auguste ; Villejuif, FR, Villejuif, CEDEX/FR
13:35 - 13:35 949P - Tumor microenvironment in high serous ovary cancer: Characterization of the infiltration pattern and analysis of its prognostic value 1 1 1 1 1 F. Herrera Cañizares , A. Chipirliu , C. Caballero , A. Herreros Pomares , S. Calabuig Fariñas , L. 1 1 1 1 2 1 1 Valdivieso , M. Mosqueda , J. Marí Alexandre , E. Jantus Lewintre , J. Gilabert , C. Camps Herrero ; 2 Valencia, ES, València, ES
13:35 - 13:35 950P - Gene mutational analyses in 154 ovarian cancer (OC) samples from the ROSiA study of front-line bevacizumab (BEV)-containing therapy for OC 1 2 3 4 5 1 6 R. Deurloo , N. Colombo , C. Mendiola , F. Selle , J. Korach , M. Oestergaard , M. Bylesjo , H.-J. 1 1 7 1 2 3 4 5 6 Urban , Y. Ghazi , A. Oza ; Basel, CH, Milan, IT, Madrid, ES, Paris, FR, Tel Hashomer, IL, 7 Edinburgh, GB, Toronto, CA
13:35 - 13:35 951P - A retrospective study of endocrine therapy in high grade serous ovarian carcinoma 1 2 2 2 3 2 2 2 B. Stanley , R. Hollis , J. Towler , X. Yan , H.D.S.M. Nunes , T. Rye , S. Herrington , M. Churchman ,
1 2 2 1 2 3 M. MacKean , F. Nussey , C. Gourley ; Edinburgh, Midlothian/GB, Edinburgh, GB, Lisbon, PT
13:35 - 13:35 952P - Randomised prospective study of maintenance tamoxifen versus post adjuvant chemotherapy surveillance only in advanced ovarian cancer patients 1 1 1 2 3 3 4 3 1 1 V. Goel , A. Jain , S. Tiwari , M. John , V. Talwar , P. Dash , N. Patnaik , S. Raina , D.C. Doval ;
2 3 4 New Delhi, Rohini/IN, Trissur, IN, New Delhi, IN, Delhi, IN
13:35 - 13:35 953P - A phase 1 study to evaluate the safety and tolerability of bevacizumab-niraparib combination therapy and determine the recommended phase 2 dose (RP2D) in women with platinum-sensitive epithelial ovarian cancer (ENGOT-OV24/AVANOVA1) 1 2 1 3 2 1 2 M.R. Mirza , J. Wang , M. Mau-Sørensen , M. Birrer , X. Wang , M. Jørgensen , Z.-Y. Zhang , H. 1 4 5 6 1 1 5 2 Roed , S. Malander , F. Nielsen , L. Bjørge , U. Lassen , L. Boufercha , K. Brøsen , V. Kansra , J.
7 1 2 3 4 5 6 Mäenpää ; Copenhagen, DK, Waltham, MA/US, Boston, MA/US, Lund, SE, Odense, DK, Bergen, 7 NO, Tampere, FI
Last update: 02-09-2017 06:01:33pm esmo.org 13:35 - 13:35 954P - Prospective cohort study of bevacizumab plus standard platinum based chemotherapy as front-line treatment for advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer: Japanese Gynecologic Oncology Group study (JGOG3022) 1 1 1 2 3 4 5 K. Kato , S. Komiyama , N. Takeshima , H. Takano , A. Inoue , A. Hongo , M. Asai-Sato , A. Arakawa 6 1 7 8 1 2 3 4 , K. Kubushiro , S. Kamiura , T. Sugiyama ; Tokyo, JP, Kashiwa, JP, Ehime, JP, Takamatsu, JP, 5 6 7 8 Yokohama, JP, Nagoya, JP, Osaka, JP, Morioka, Iwate/JP
13:35 - 13:35 955P - A landmark analysis of overall survival in PR-OC patients treated with chemotherapy and bevacizumab using early tumor shrinkage as covariate A. Sostelly, F. Jaminion, F. Mercier; Basel, CH
13:35 - 13:35 956P - Influence of comorbidities on clinical outcome in patients (pts) receiving chemotherapy (CT) + bevacizumab (BEV) for primary advanced ovarian cancer (OC) 1 2 3 1 1 1 4 H. Woopen , P. Wimberger , A. Mustea , G. Oskay-Oezcelik , M. Keller , R. Richter , J. Harde , S. 5 6 7 1 1 2 3 4 Klawitter , A. Wegenaer , O. Tomé , J. Sehouli ; Berlin, DE, Dresden, DE, Greifswald, DE, 5 6 7 Freiburg, DE, Grenzach Wyhlen, DE, Grenzach-Wyhlen, DE, Karlsruhe, DE
13:35 - 13:35 957P - Feasibility and effectiveness of multiple lines of bevacizumab-based therapy in patients with recurrent tuboovarian carcinoma V. Kallage, A.T. Kurbacher, S. Herz, G. Kolberg, C. Schweitzer, J. Kurbacher, C. Kurbacher; Bonn, DE
13:35 - 13:35 958P - Impact of body mass index (BMI) on outcome in 785 patients (pts) receiving systemic chemotherapy (CT) and bevacizumab (BEV) for primary advanced ovarian cancer (OC) (on behalf of the North-Eastern German Society of Gynaecological Oncology, NOGGO) 1 2 1 1 1 1 3 J. Sehouli , A. Mustea , G. Oskay-Oezcelik , J. Grabowski , M. Keller , R. Richter , J. Harde , S. 4 5 6 7 1 2 3 4 Klawitter , A. Wegenaer , O. Tomé , P. Wimberger ; Berlin, DE, Greifswald, DE, Freiburg, DE, 5 6 7 Grenzach Wyhlen, DE, Grenzach-Wyhlen, DE, Karlsruhe, DE, Dresden, DE
13:35 - 13:35 959P - A prospective study to evaluate the role of Cytoreductive surgery (CRS)+ HIPEC in advanced epithelian ovarian malignancy -100 consecutive cases -INDIAN experience 1 2 3 2 2 1 2 R. Kumar C , S. Somashekhar , A. Rauthan , R. Ashwin , Y. Ramya ; Bangalore, IN, Bengaluru, IN,
3 Bangalore, Karnataka/IN
13:35 - 13:35 960P - Role of laparotomy-based parameters in assessment of optimal primary debulking surgery and long-term outcomes in patients with stage iiic epithelial ovarian cancer M. Zhou, X. Wang, L. Li, C. Wang, D. Wang; Shenyang, CN
13:35 - 13:35 961P - ICON7: Ovarian cancer, platinum second-line chemotherapy and overall survival 1 2 3 4 5 6 7 A. Cook , A. Embleton , G. Jayson , R. Kaplan , G. Kristensen , M. Parmar , J. Pfisterer , E. 8 9 10 1 2 3 4 Pujade-Lauraine , A. Oza , T. Perren ; London, GB, London, UK/GB, Manchester, GB, Leeds, 5 6 7 8 9 10 GB, Oslo, NO, London, London/GB, Kiel, DE, Paris, FR, Toronto, Ontario/CA, Leeds, Yorkshire/GB
13:35 - 13:35 962P - Disease burden during the “watchful waiting” period in patients with recurrent ovarian cancer 1 2 3 3 3 2 1 2 B. Harrow , K. Travers , B. Davis , P. Smith , A. Gilligan , M. Bala ; Waltham, US, Waltham,
3 MA/US, Cambridge, MA/US
Last update: 02-09-2017 06:01:33pm esmo.org
13:35 - 13:35 963P - Impact of chemotherapy (CT) in heavily pretreated BRCA1/2 mutation carrier ovarian cancer (BMCOC) patients (pts) 1 1 1 2 3 V. Rodriguez Freixinos , L. Fariñas Madrid , M. Gil Martin , P. Barretina , M. Romeo Marin , G. 1 1 1 2 4 Villacampa Javierre , C. VIAPLANA , B. Pardo , H. Ahmed Ouahid , S. Recalde , J.M. Piulats 5 6 1 2 6 2 6 Rodriguez , M. Gomez , A. Gil-Moreno , E. Sala , S. Martinez-Román , C. Melendez , E. Carballas , 1 1 1 2 3 4 R. Dienstmann , A. Oaknin ; Barcelona, ES, Girona, ES, Badalona, Barcelona/ES, L'hospitalet, ES, 5 6 Barcelona, Barcelona/ES, Badalona, ES
13:35 - 13:35 964P - Modeling and impact of organ function on the population pharmacokinetics (PK) of niraparib, a selective poly (ADP-Ribose) polymerase (PARP)-1 and -2 inhibitor 1 1 1 2 1 1 2 Z.-Y. Zhang , X. Wang , J. Wang , H. Pentikis , V. Kansra ; Waltham, MA/US, Baltimore, MD/US
13:35 - 13:35 965P - Evaluation of tumour responses and olaparib efficacy in platinum-sensitive relapsed ovarian cancer (PSROC) patients (pts) with or without measurable disease in the SOLO2 trial (ENGOT Ov-21) 1 2 3 4 5 6 7 A. Oza , P. Combe , J. Ledermann , S. Marschner , A. Amit , T. Huzarski , N. Lainez Milagro , A. 8 9 10 11 12 13 14 Savarese , C. Scott , M. Nicoletto , P. Harter , T. Enomoto , G. Sonke , J.-W. Kim , I. Vergote 15 16 17 1 2 3 4 5 , A. Allen , E. Pujade-Lauraine ; Toronto, Ontario/CA, Paris, FR, London, GB, Sydney, AU, 6 7 8 9 10 11 12 Haifa, IL, Szczecin, PL, Pamplona, ES, Rome, IT, Melbourne, AU, Padova, IT, Essen, DE, 13 14 15 16 17 Niigata, Niigata/JP, Amsterdam, NL, Seoul, KR, Leuven, BE, Gaithersburg, MD/US, Paris, CEDEX 4/FR
13:35 - 13:35 966P - Outcomes of the combination trabectedin and pegylated liposomal doxorubicin (T-PLD) in recurrent platinum-sensitive ovarian cancer (OC): a GINECO cohort study 1 2 3 4 5 6 7 F. Selle , P.-E. Heudel , Y. Tazi , A. Pozet , A.-C. Hardy-Bessard , J. Meunier , L. Gladieff , J.-P. Lotz 1 8 9 10 11 12 , M. Provansal , P. Augereau , J.-S. Frenel , N. Bonichon-Lamichhane , H. Orfeuvre , F. 13 1 14 15 1 2 3 Pommeret , M. Torres-Macque , E. Kalbacher , C. Roemer-Becuwe ; Paris, FR, Lyon, FR,
4 5 6 7 8 9 Strasbourg, FR, Besançon, FR, Plerin-Sur-mer, FR, Orleans, FR, Toulouse, FR, Marseille, FR, 10 11 12 13 14 Angers, FR, Saint-Herblain, FR, Bordeaux, FR, Bourg-En-bresse, FR, Villejuif, FR, 15 Besançon, CEDEX/FR, Nancy, FR
13:35 - 13:35 967P - An observational, multicenter, prospective study of trabectedin plus pegylated liposomal doxorubicin (PLD) in patients with platinum-sensitive recurrent ovarian cancer (PSROC) 1 2 3 4 5 1 2 3 D. Reichert , P. Wimberger , U. Ringsdorf , M. Krohn , I. Runnebaum ; Berlin, DE, Dresden, DE,
4 5 Wetzlar, DE, Rotenburg, DE, Jena, DE
13:35 - 13:35 968P - PRO-002, a phase Ib dose-escalation study of NUC-1031 with carboplatin for recurrent ovarian cancer 1 2 3 3 1 1 2 S. Blagden , A. Sukumaran , L. Spiers , V. Woodcock , A. Lipplaa , S. Nicum , C. Gnanaranjan , D.
4 2 1 2 3 4 Harrison , E. Ghazaly ; Oxford, GB, London, GB, Oxford, Oxfordshire/GB, Fife, GB
13:35 - 13:35 969P - Phase 1/2 trials of peptides cocktail vaccine for resistant cervical and ovarian cancer: Qol analysis 1 2 2 2 1 1 2 1 S. Takeuchi , M. Kagabu , T. Nagasawa , H. Omi , Y. Nitta , H. Itamochi , T. Sugiyama ; Morioka,
2 Iwate/JP, Morioka, JP
Last update: 02-09-2017 06:01:33pm esmo.org 13:35 - 13:35 970P - A phase 1 study of selinexor (S) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced ovarian (OC) or endometrial cancers (EC) 1 2 2 2 2 2 2 V. Makker , N. Boucicaut , K. Cadoo , R. Grisham , D. Hyman , R. O'Cearbhail , A. Snyder Charen ,
2 2 2 1 2 W. Tew , M. Martin , C. Aghajanian ; New York, US, New York, NY/US
13:35 - 13:35 971P - Pazopanib and oral cyclophosphamide in women with platinum resistant epithelial ovarian cancers S. Gulia, S. Gupta, J. Ghosh, J. Bajpai, A. Maheshwari, R. Kerkar, S. Thumkur, K. Deodhar, M. Thakur;
Mumbai, IN
13:35 - 13:35 972P - Apatinib as a salvage treatment in gynecologic cancer patients failed from two or more lines of prior chemotherapy C. Xie, X. Jin; Wenzhou, CN
13:35 - 13:35 973P - A GINECO phase II study of Navitoclax (ABT 263) in women with platinum resistant/refractory recurrent ovarian cancer (ROC) 1 2 3 4 5 6 7 P.E. Brachet , M. Fabbro , A. Leary , J. Medioni , P. Follana , A. Lesoin , J.-S. Frenel , S. Abadie 8 9 10 11 12 13 1 Lacourtoisie , A. Floquet , L. Gladieff , B. You , C. Gavoille , E. Kalbacher , M. Briand , P.-A. 4 1 1 1 1 1 1 2 Just , C. Blanc-Fournier , A. Leconte , J. Lequesne , L. Poulain , F. Joly Lobbedez ; Caen, FR,
3 4 5 6 7 Montpellier, CEDEX 5/FR, Villejuif, FR, Paris, FR, Nice, CEDEX 2/FR, Lille, FR, Saint-Herblain, 8 9 10 11 CEDEX/FR, Angers, FR, Bordeaux, CEDEX/FR, Toulouse, Haute-Garonne/FR, Pierre Bénite, 12 13 CEDEX/FR, Vandoeuvre Les Nancy, CEDEX/FR, Besançon, CEDEX/FR
13:35 - 13:35 974P - Reproductive function in patients (pts) with malignant ovarian germ cell tumors (MOGCT) following chemotherapy (ChT) 1 1 1 1 2 1 1 D. Chekini , A. Tryakin , M. Fedyanin , I. Pokataev , A. Bulanov , T. Zakharova , K. Zhordania , O.
1 1 1 2 Sekhina , S. Tjulandin ; Moscow, RU, Teheran, IR
13:35 - 13:35 975P - Preoperative MRI versus intra-operative frozen section in surgical management of clinically early endometrial cancer A. Maheshwari, R. Ranade, R. Kerkar, S. Ts, K. Deodhar, B. Rekhi, S. Menon, S. Gupta; Mumbai, IN
13:35 - 13:35 976P - Impact of the adjuvant management and risk factors on survival in FIGO stage 3 endometrial cancer patients 1 2 3 4 5 1 2 J. Ko , G. Gelowitz , A. Tinker , C. Holloway , A. Kumar ; Abbotsford, British Columbia/CA,
3 4 5 Abbotsford, BC/CA, Vancouver, BC/CA, Victoria, BC/CA, Surrey, BC/CA
13:35 - 13:35 977P - Is chemotherapy worthwhile in patients with FIGO stage 1B, lymph nodes negative, grade 3 endometrial cancer? 1 2 2 2 1 2 2 C. Fontanella , S. Lepori , A. Barcellini , G. Maltese , C. Andreetta , E. Tripodi , F. Martinelli , A. 2 2 2 2 2 1 2 2 1 Cerrotta , G. Bogani , A. Ditto , M. Signorelli , C. Scaffa , C. Sacco , F. Raspagliesi , D. Lorusso ; 2 Udine, IT, Milan, IT
13:35 - 13:35 978P - Significance of MSH2 promoter methylation in endometrial cancer with MSH2 deficiency 1 1 1 1 1 1 1 1 J. Haraga , T. Nagasaka , K. Nakamura , T. Haruma , T. Nishida , A. Nyuya , K. YASUI , T. Fujiwara
2 1 1 2 , A. Goel , H. Masuyama ; Okayama, JP, Texas, TX/US
Last update: 02-09-2017 06:01:33pm esmo.org
13:35 - 13:35 979P - Achievement of complete response (CR) in metastatic or recurrent cervical cancer (MRCC): Does it matter? J.F. Grau Béjar, V. Rodriguez Freixinos, L. Fariñas Madrid, G. Villacampa Javierre, A. Gil-Moreno, R.
Verges, M.A. Pérez Benavente, A. García, R. Dienstmann, A. Oaknin; Barcelona, ES
13:35 - 13:35 980P - Factors Negatively Affecting Voluntary Cervical Cancer Screening Among Educated Indians Above Poverty Line 1 2 2 1 2 A. Shukla , R. Dokala , J. Philomen ; Bangalore, Karnataka/IN, Bangalore, IN
13:35 - 13:35 982P - Phase II study of the safety and efficacy of oral capecitabine in patients with platinum-pretreated advanced or recurrent cervical carcinoma 1 2 1 1 1 1 1 1 S. Lepori , C. Fontanella , G. Maltese , E. Tripodi , F. Martinelli , G. Bogani , A. Ditto , M. Signorelli ,
1 1 1 1 2 C. Scaffa , F. Raspagliesi , D. Lorusso ; Milan, IT, Udine, IT
13:35 - 13:35 983P - Investigation of the clinicopathological features of vulva cancer: a retrospective survey of the JGOG Net Work study 1 2 3 4 5 6 7 S. Nishio , T. Shibata , S. Yamaguchi , H. Kanao , A. Kojima , M. Takekuma , A. Tozawa , H. 8 9 9 10 11 12 2 Tokunaga , E. Miyagi , H. Kato , K. Kurihara , T. Yanase , K. Ushijima , M. Mikami , T. Sugiyama
5 1 2 3 4 5 6 7 ; Kurume, Fukuoka/JP, Isehara, JP, Akashi, JP, Tokyo, JP, Morioka, JP, Shizuoka, JP, 8 9 10 11 12 Kawasaki, JP, Sendai, JP, Yokohama, JP, Saitama, JP, Niigata, JP, Kurume, JP
13:35 - 13:35 984TiP - Japan CHARLOTTE: Characterizing the cross-sectional approach to ovarian cancer: Genetic testing of BRCA 1 2 3 2 4 5 5 T. Sugiyama , D. Aoki , T. Enomoto , N. Takeshima , Y. Watanabe , K. Fujikawa , T. Jinnai , J.
6 1 2 3 4 5 6 Kigawa ; Morioka, JP, Tokyo, JP, Niigata, Niigata/JP, Sendai, JP, Osaka, JP, Matsue, JP
13:35 - 13:35 985TiP - IMagyn050 / GOG3015 / ENGOT-ov39: A randomized, double-blind, phase III study of atezolizumab vs placebo combined with chemotherapy + bevacizumab in stage III-IV ovarian, fallopian tube & peritoneal cancers (OC) 1 2 3 4 5 1 2 3 K. Moore , A. Okamoto , F. Wu , Y. Lin , S. Pignata ; Oklahoma City, Oklahoma/US, Tokyo, JP,
4 5 Beijing, CN, South San Francisco, US, Napoli, IT
13:35 - 13:35 986TiP - A randomized, double-blind, placebo-controlled multicenter phase 3 trial of niraparib maintenance treatment in patients with advanced ovarian cancer following frontline chemotherapy 1 2 3 4 5 6 7 8 A. Gonzalez Martin , L. Rojas , P. Braly , J. Barter , D. O'Malley , A. Oza , A. Haggerty , C. Vulsteke , 9 10 11 11 12 8 13 D. Provencher , W. Graybill , Y. Li , I. Malinowska , M.R. Mirza , I. Vergote , B. Pothuri , B. 14 1 2 3 4 5 Monk ; Madrid, ES, Sioux Falls, SD/US, Covington, LA/US, Silver Spring, MD/US, Columbus, 6 7 8 9 10 OH/US, Toronto, Ontario/CA, Philadelphia, PA/US, Leuven, BE, Montreal, CA, Charleston, 11 12 13 14 SC/US, Waltham, MA/US, Copenhagen, DK, New York, NY/US, Phoenix, AZ/US
13:35 - 13:35 987TiP - OReO/ENGOT Ov-38: A phase IIIb trial of olaparib maintenance retreatment in patients with epithelial ovarian cancer
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 3 4 5 6 7 E. Pujade-Lauraine , N. Colombo , R. Glasspool , B. Asselain , T. Huzarski , J. Korach , F. Marme , 8 9 10 11 12 4 13 1 M.R. Mirza , A. Redondo , G. Scambia , C. Blakeley , A. Milner , F. Selle , I. Vergote ; Paris,
2 3 4 5 6 7 CEDEX 4/FR, Milan, IT, Glasgow, GB, Paris, FR, Szczecin, PL, Tel Hashomer, IL, Heidelberg, 8 9 10 11 12 13 DE, Copenhagen, DK, Madrid, ES, Roma, IT, London, GB, Cambridge, GB, Leuven, BE
13:35 - 13:35 988TiP - ARIEL4: An international, randomised phase 3 study of the PARP inhibitor rucaparib vs chemotherapy for the treatment of BRCA-mutated, relapsed, high-grade ovarian cancer 1 2 3 4 5 6 7 8 R. Kristeleit , D. Lorusso , A. Oaknin , T. Safra , E. Swisher , I. Bondarenko , T. Huzarski , J. Klat , V. 9 10 11 12 13 12 12 Moiseyenko , R.L. Póka , L. Viola , C. Tankersley , L. Maloney , S. Goble , C. Unger , A. 12 14 15 1 2 3 4 5 Dowson , H. Giordano , A. Oza ; London, GB, Milan, IT, Barcelona, ES, Tel Aviv, IL, Seattle, 6 7 8 9 10 WA/US, Dnepropetrovsk, UA, Szczecin, PL, Ostrava, CZ, Saint Petersburg, RU, Debrecen, HU, 11 12 13 14 15 Porto Alegre, BR, Boulder, CO/US, Boulder, Colorado/US, San Francisco, California/US, Toronto, Ontario/CA
13:35 - 13:35 989TiP - OCTOVA: A randomised phase II trial of olaparib, chemotherapy, or olaparib and cediranib in patients with BRCA-mutated platinum-resistant ovarian cancer 1 1 1 2 1 3 4 1 1 S. Nicum , V. Strauss , N. McGregor , I. McNeish , R. Roux , M. Hall , A. Michael , C. Roberts ;
2 3 4 Oxford, GB, Glasgow, GB, Middlesex, GB, Surrey, GB
13:35 - 13:35 990TiP - A multicentre phase II study of AZD1775 plus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer 1 2 3 4 5 6 7 K. Moore , K. Cadoo , S. Chambers , S. Ghamande , G. Konecny , A. Oza , L.-M. Chen , P. 8 9 10 11 12 13 14 Konstantinopoulos , J. Lea , D. Spitz , D. Uyar , G. Mugundu , N. Laing , D. Strickland , S. 14 15 14 14 1 2 3 Jones , H. Burris , D. Spigel , E. Hamilton ; Oklahoma City, Oklahoma/US, New York, NY/US,
4 5 6 7 Tucson, AZ/US, Augusta, GA/US, Los Angeles, CA/US, Toronto, Ontario/CA, San Francisco, 8 9 10 11 12 CA/US, Boston, MA/US, Dallas, TX/US, West Palm Beach, FL/US, Milwaukee, WI/US, 13 14 15 Waltham, US, Waltham, MA/US, Nashville, TN/US, Nashville, US
13:35 - 13:35 991TiP - FORWARD I: A phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus chemotherapy in adults with folate receptor alpha (FRa)-positive, platinum-resistant epithelial ovarian cancer, primary peritoneal cancer, or primary fallopian tube cancer 1 2 3 4 5 6 7 8 K. Moore , I. Vergote , A. Oaknin , N. Colombo , S. Banerjee , A. Oza , P. Pautier , C. Kelly , K. 9 10 1 2 3 4 5 Malek , M. Birrer ; Oklahoma City, Oklahoma/US, Leuven, BE, Barcelona, ES, Milan, IT, London, 6 7 8 9 10 GB, Toronto, Ontario/CA, Villejuif, CEDEX/FR, Dublin, IE, Waltham, MA/US, Boston, MA/US
13:35 - 13:35 992TiP - N-DUR: Matched pair pharmacodynamics study of neoadjuvant durvalumab in combination with chemotherapy in frontline ovarian cancer 1 2 1 2 1 1 1 1 J. Taylor , S. Westin , S. Sharafi , A. Jazaeri , M. Frumovitz , P. Soliman , A. Sood , K. Lu , K. 1 1 3 1 1 2 3 Savelieva , G. Mills , A. Vergara-Silva , R. Coleman ; Houston, TX/US, Houston, US, Gaithersburg, US
13:35 - 13:35 993TiP - Comparing doses and fractionation regimens for high dose rate brachytherapy in locally advanced cervical carcinoma: A randomized controlled trial A. Manirakiza, F. Rubagumya, D. Msemo, N. Dharsee; Dar Es Salaam, TZ
13:35 - 13:35 HAEMATOLOGICAL MALIGNANCIES
Last update: 02-09-2017 06:01:33pm esmo.org J. Gomez Codina, Valencia, ES
13:35 - 13:35 1010P - Event free survival at 24 months: A new endpoint in diffuse large B-cell lymphoma 1 2 3 1 3 B. Cantos , J.C. Sanchez , V. Calvo de Juan , M. Mendez Garcia , C. Maximiano Alonso , D. Perez 1 2 3 3 2 3 1 Callejo , F.F. Franco , L. Gutierrez Sanz , A. Gonzaga López , B. Nuñez , M. Provencio Pulla ; 2 3 Madrid, ES, Majadahonda, ES, Majadahonda, Madrid/ES
13:35 - 13:35 1011P - Interpreting progression-free survival and overall survival data in biosimilar clinical studies: considerations based on a recent rituximab biosimilar study 1 2 2 1 1 3 1 2 J. Amersdorffer , Y. Li , S. Alexandrova , A. Zubel , E. Sasse , H. Mellstedt ; Holzkirchen, DE,
3 Princeton, US, Stockholm, SE
13:35 - 13:35 1012P - Role of prephase treatment prior to definitive chemotherapy in diffuse large B -cell lymphoma (DLBCL) 1 2 2 2 3 3 2 A. Rudresha , V. Asati , L. Kuntegowdanahalli , G. Babu , D. Lokanatha , L. Jacob , S. Babu , C. 2 2 1 2 2 1 2 Premalatha , L. Rajeev , K.N. Lokesh , S. Saldanha , R. Patidar ; Bangalore, Karnatka/IN, 3 Bangalore, IN, Bengaluru, IN
13:35 - 13:35 1013P - The role of FDG-PET/CT in detecting bone marrow involvement in diffuse large b-cell lymphoma 1 1 1 1 2 3 4 1 A. Bulbul , E.A. Mino , S. Chouial , A. Bautista , A. Mustafa , H. Abboud , S. Rashad , T. Braik , K.
1 1 2 3 4 Masoud ; Carlsbad, NM/US, Jammu, IN, Monee, IL/US, Chicago, IL/US
13:35 - 13:35 1014P - Evaluation of various prognostic scores and impact of cell of origin on survival in limited stage DLBCL: retrospective study M. Rauf, S. Akhtar, T. Ahmed M. Elhassan, Q. Shaikh, F. A. Almugbel, M. N. Zahir, N. Bakshi, I.
Maghfoor; Riyadh, SA
13:35 - 13:35 1015P - The prognostic impact of serum albumin and absolute neutrophil count in patients with newly diagnosed diffuse large B-cell lymphoma B. Spassov, D. Vassileva, G. Arnaudov, S. Nikolov, G. Mihaylov, G. Balatzenko, M. Guenova; Sofia, BG
13:35 - 13:35 1016P - Autologous stem cell transplantation (ASCT) is safe and effective for the treatment of non-hodgkin lymphoma (NHL) in an elderly population of patients over 65 years old: A single center experience 1 1 1 2 2 1 1 2 M. TARDY , J. Viotti , A. Boscagli Melaine , A. Thyss , F. Peyrade , L. Gastaud ; Nice, FR, Nice, CEDEX 2/FR
13:35 - 13:35 1017P - Phenotypic and functional characterization of tumor infiltrating lymphocytes (TIL) grown from non-hodgkin lymphoma tumors: Implications for the development of novel therapies for lymphoma 1 2 2 3 2 1 2 3 L. Karyampudi , A. Gokuldass , M. Blaskovich , M. Fardis , M. Lotze ; Tampa, US, Tampa, FL/US, San Carlos, CA/US
13:35 - 13:35 1018P - International prognostic scores (IPS-7, IPS-3 and IPS-3 new) for prediction of FFS and OS in cases with Hodgkin Lymphoma. Which is more practical and accurate? 1 2 3 1 1 2 3 S. Paydas , M. Dogan , V. Ercolak , G. Seydaoglu ; Adana, TR, Ankara, TR, Mersin, TR
Last update: 02-09-2017 06:01:33pm esmo.org 13:35 - 13:35 1019P - Evaluation of indoleamine 2,3-dioxygenase expression (IDO), transforming growth factor beta (TGF-β) and interleukin 13 (IL13) expression on clinical outcome in patients with Hodgkin’s lymphoma 1 2 2 1 1 1 T. Skrypets , O. Novosad , Y. Pastushenko , O. Skachkova , O. Gorbach , N. Khranovska , I.
1 1 2 Kryachok ; Kiev, UA, Kyiv, UA
13:35 - 13:35 1020P - Clinical impact of atypical phenotypes in adult t cell lymphoma/leukemia among HTLV carriers D. Enriquez Vera, G. De la Cruz Ku, J. Haro Varas, P. Rioja, Z. Morante Cruz, N.I. Valdiviezo Lama, R. Luque, E. Eyzaguirre, M. Lujan, A. Saavedra, M. Mayuri Monsefu, G. Ferreyros, M. Retamozo Alvarado, J. Vidal Ayllón, S. Neciosup Delgado, L.A. Mas Lopez; Lima, PE
13:35 - 13:35 1021P - Evaluation of the PI3K pathway in peripheral t-cell lymphoma 1 1 1 1 2 2 1 1 2 S.T. Lim , M.-L. Nairismägi , S.H. Tan , E.E. Thit , O. Politz , N. Liu , C.K. Ong ; Singapore, SG, Berlin, DE
13:35 - 13:35 1022P - Safety and tolerability of chemotherapy (CT) containing high doses of methotrexate (HD-MTX) and cytarabine (Ara-C) in patients with primary central nervous system lymphoma (PCNSL) and hepatitis B virus (HBV) infection T. Calimeri, P. Lopedote, M. Repetto, A. Vignati, M. Sassone, C. Cecchetti, S. Perrone, M. Foppoli, G.
Ciboddo, S. Girlanda, J. Peccatori, A. Chiara, M. Memoli, A. Ferreri; Milan, IT
13:35 - 13:35 1023P - Evaluation of safety, tolerability and efficacy of temsirolimus in patients (pts) with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice 1 2 3 1 2 3 M. Dreyling , G. Hess , G. Krekeler ; Munich, DE, Mainz, DE, Berlin, DE
13:35 - 13:35 1024P - Clinical impact of FISH analysis in extramedullary plasmacytomas 1 2 2 2 2 1 2 H.A. Jung , C.H. Maeng , J.H. Jang , C.W. Jung , K. Kim ; Hwanseong-Si, Gyeong-Ki-Do/KR, Seoul, KR
13:35 - 13:35 1025P - Independent predictors of one year mortality in patients with primary systemic immunoglobulin light chain cardiac amyloidosis 1 2 2 2 2 2 2 V. Srinivasalu , M. Subramaniam , A. Shanmugam , A. Philip , A. Susan , R. Prabhu , M. Unni , N.
2 2 2 2 2 2 1 2 Sidharthan , W. Jose , S. N V , H. Ahamed , N. Mathew , P. Keechilat ; Cochin, IN, Kochi, IN
13:35 - 13:35 1026P - Endoscopic evaluation of acute intestinal GVHD after allogeneic hematopoietic cell transplantation? I. Tek, R. Altun, A. Gokmen, E. Soydan, M. Kurt Yuksel; Ankara, TR
13:35 - 13:35 1027P - Surveillance stool culture and its association with febrile neutropenia in patients with acute leukemia (AL) undergoing induction chemotherapy 1 1 1 1 1 2 1 1 N. Jadhav , B. Dubashi , J. Mandal , S. Kayal , J. Pattnaik , P. Madasamy , J. Singh ; Puducherry,
2 IN, Pondicherry, IN
13:35 - 13:35 1028P - L-arginine – targeted for the anthracycline cardiotoxicity prevention in patients with acute leukemia of high cardiological risk T. Lymanets, I. Skrypnyk, G. Maslova; Poltava, UA
13:35 - 13:35 1029P - Multiple myeloma complicated by concomitant cardiac pathology
Last update: 02-09-2017 06:01:33pm esmo.org S. Semochkin, E. Yurova; Moscow, RU
13:35 - 13:35 1030P - Evaluation of dose intensification of cytarabine in postremission therapy in older AML patients within the prospective phase II AMLSG 06-04 study 1 2 3 4 5 6 7 8 L. Häcker , M. Tassara , P. Brossart , G. Held , H. Horst , M. Ringhoffer , C.-H. Köhne , S. Kremers , 9 10 11 12 13 14 1 A. Raghavachar , G. Wulf , H. Kirchen , D. Nachbaur , M. Wattad , A. Benner , D. Weber , V. 1 1 1 1 14 1 2 3 Gaidzik , P. Paschka , K. Döhner , H. Döhner , R. Schlenk ; Ulm, DE, Milan, IT, No City Provided, 4 5 6 7 8 9 10 NA, Homburg, DE, Kiel, DE, Karlsruhe, DE, Oldenburg, DE, Lebach, DE, Wuppertal, DE, 11 12 13 14 Göttingen, DE, Trier, DE, Innsbruck, AT, Essen, DE, Heidelberg, DE
13:35 - 13:35 1031P - The EUROSKI biomarker study: Analyzing the mechanisms of treatment-free remission in chronic myeloid leukemia 1 1 2 1 1 1 1 R. Sébastien , C. Sticht , M. Pfirrmann , D. Nowak , A. Fabarius , W. Seifarth , B. Spiess , P. 3 3 3 4 5 6 7 Panayiotidis , M. Pagoni , M. Dimou , J. Dengler , C. Waller , T. Brümmendorf , A. Burchert , G.
8 1 9 1 1 2 3 4 Freunek , W.-K. Hofmann , F.-X. Mahon , S. Saussele ; Mannheim, DE, Munich, DE, Athens, GR, 5 6 7 8 9 Heilbronn, DE, Freiburg, DE, Aachen, DE, Marburg, DE, Straubing, DE, Bordeaux, FR
13:35 - 13:35 1032P - Pharmacodynamic and pharmacokinetic evaluation of SY-1425 (tamibarotene) in biomarker-selected acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients 1 2 3 4 5 6 7 8 D. Bixby , C. Vigil , J. Jurcic , R. Cook , M. Sekeres , D. Rizzieri , J. Cortes , R. Redner , D. 9 10 11 12 12 12 12 Steensma , G. Roboz , T. Moyo , M. McKeown , N. Waters , K. Stephens , E. di Tomaso , D. 12 3 1 2 3 4 5 Roth , E. Stein ; Ann Arbor, MI/US, Iowa City, IA/US, New York, NY/US, Portland, OR/US, 6 7 8 9 10 Cleveland, US, Durham, US, Houston, US, Pittsburgh, PA/US, Boston, MA/US, New York, 11 12 US/US, Nashville, TN/US, Cambridge, US
13:35 - 13:35 1033P - Quantitative assessment of inotuzumab ozogamicin (InO) response relative to investigator’s choice of chemotherapy (ICC) in adults with relapsed or refractory (R/R) CD22+ B-Cell acute lymphoblastic leukemia (ALL) 1 2 3 4 5 1 2 A. Ruiz-Garcia , E. Vandendries , D. Deangelo , H. Kantarjian , J. Boni ; San Diego, CA/US,
3 4 5 Cambridge, MA/US, Boston, MA/US, Houston, TX/US, Collegeville, PA/US
13:35 - 13:35 1034TiP - Phase III randomized, double-blind, controlled studies of the PI3K inhibitor copanlisib in combination with rituximab or rituximab-based chemotherapy in subjects with relapsed indolent B-cell non-Hodgkin’s lymphoma (iNHL): CHRONOS-3 and CHRONOS-4 1 2 2 2 3 2 2 4 J. Gerecitano , H. Zheng , L. Mongay Soler , R. Ito , D. Reis , C. Lu , J. Shen , B. Childs , P.L.
5 1 2 3 4 5 Zinzani ; New York, US, Whippany, NJ/US, São Paulo, BR, New York, New York/US, Bologna, IT
13:35 - 13:35 1035TiP - A multicenter, randomized, phase 3 study of pomalidomide and dexamethasone (Pom-dex) with or without daratumumab in patients with relapsed or refractory multiple myeloma (RRMM): APOLLO 1 2 2 3 4 5 6 1 E. Terpos , M. Dimopoulos , E. Kastritis , J. Schecter , J. Ukropec , E. Smith , P. Sonneveld ; 2 3 4 5 6 Athens, Neo Psychiko/GR, Athens, GR, Raritan, US, Horsham, PA/US, High Wycombe, GB, Rotterdam, NL
13:35 - 13:35 1036TiP - Phase 2, multicenter, single-arm, open label study evaluating the combination of daratumumab + cyclophosphamide, bortezomib and dexamethasone (Dara-CyBorD) in previously untreated and relapsed patients (pts) with multiple myeloma (MM)
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 3 2 4 5 2 6 1 M. Sharma , L. Ey , H. Parros , S. Murphy , M. Darif , A. Londhe , J. Ukropec , M. Qi , Y. Lutska , T. 1 1 1 2 3 4 5 Lin , S. Gunawardena ; Horsham, US, Horsham, PA/US, Titusville, US, Titusville, PA/US, 6 Titusville, NJ/US, Spring House, US
13:35 - 13:35 1037TiP - A double blind randomized phase 2 PILOT study of ERYASPASE in patients with acute lymphoblastic leukemia/lymphoma 1 2 2 2 2 1 1 2 N. Soule , C. Holford , R. Kay , D. Tilton , N. Biswas-Baldwin , I. El Hariry ; Cambridge, US, Lyon, FR
13:35 - 13:35 1038TiP - Phase 2 randomized study of daratumumab (dara), lenalidomide (R), bortezomib (V), and dexamethasone (d; Dara-RVd) vs. RVd in patients (pts) with newly diagnosed multiple myeloma (MM) eligible for high-dose therapy (HDT) and autologous stem cell transplantation (ASCT) 1 1 2 3 2 4 3 5 1 T. Lin , L. Hydutsky , H. Parros , S. Murphy , H. Pei , A. Londhe , J. Ukropec , M. Qi , Y. Lutska , M.
1 1 2 3 4 5 Sharma ; Horsham, US, Titusville, US, Horsham, PA/US, Titusville, NJ/US, Spring House, US
13:35 - 13:35 1039TiP - Phase 2a study of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of wild-type TP53 in patients with peripheral t-cell lymphoma 1 2 3 4 5 6 7 8 M. Payton , D. Pinchasik , A. Mehta , S. Goel , J. Zain , L. Sokol , E. Jacobsen , M. Patel , S. Horwitz 9 10 11 7 2 2 1 2 , F. Meric-Bernstam , A. Shustov , D. Weinstock , M. Aivado , D. Annis ; Cambridge, US,
3 4 5 6 7 Cambridge, MA/US, Birmingham, US, Bronx, NY/US, Duarte, CA/US, Tampa, FL/US, Boston, 8 9 10 11 MA/US, Sarasota, FL/US, New York, NY/US, Houston, US, Seattle, WA/US
13:35 - 13:35 1040TiP - QuANTUM-First: phase 3, double-blind, placebo-controlled study of quizartinib in combination with induction and consolidation chemotherapy, and as maintenance therapy in patients (pts) with newly diagnosed (NDx) FLT3-ITD acute myeloid leukemia (AML) 1 2 3 4 5 6 7 8 R. Schlenk , H. Dombret , S. Amadori , P. Montesinos , M. Levis , M. Sekeres , J. Cortes , A. Perl , 9 9 9 9 9 9 9 9 O. Zernovak , D. Mires , N. Ge , H. Zhang , J. Hanyok , S. Macintyre , S. Gökmen , K. Kobayashi ,
10 1 2 3 4 5 6 H. Erba ; Heidelberg, DE, Paris, FR, Rome, IT, Valenica, ES, Baltimore, MD/US, Cleveland, US, 7 8 9 10 Houston, US, Philadelphia, US, Edison, US, Birmingham, US
13:35 - 13:35 1041TiP - MP0250 – a dual inhibitor of VEGF and HGF - plus bortezomib + dexamethasone in a phase 2 open-label, single-arm, multicenter trial in patients with refractory and relapsed multiple myeloma (RRMM) 1 2 1 1 3 3 4 4 M. Raab , R. Ria , J. Schlenzka , T. Krahnke , J. Haunschild , F. Herrmann , U. Fiedler , K. Dawson , 3 1 3 2 1 1 2 3 M. Stumpp , K. Tadjalli Mehr , A. Harstrick , A. Vacca , H. Goldschmidt ; Heidelberg, DE, Bari, IT, 4 Schlieren, CH, Zurich, CH
13:35 - 13:35 NSCLC, EARLY STAGE A.-M. Dingemans, Maastricht, NL
13:35 - 13:35 1279P - Factors predicting worse outcomes in patients with N0 lung adenocarcinoma of 3cm or smaller J.-J. Hung, W.-H. Hsu; Taipei, TW
13:35 - 13:35 1280P - Regulatory variants in cancer-related pathway genes predict survival of patients with surgically resected non-small cell lung cancer M.J. Hong, K.M. Shin, S.Y. Lee, J.H. Lee, J.Y. Park; Daegu, KR
Last update: 02-09-2017 06:01:33pm esmo.org
13:35 - 13:35 1281P - Relevance between PD-L1 and radiological invasiveness in pathological stage I lung adenocarcinoma 1 2 2 2 2 2 2 G. Toyokawa , K. Takada , T. Okamoto , Y. Kozuma , T. Matsubara , S. Takamori , T. Akamine , M.
2 2 2 1 2 Katsura , F. Shoji , Y. Maehara ; Fukuoka, Fukuoka/JP, Fukuoka, JP
13:35 - 13:35 1282P - Characterization of cancer stem cell and immune microenvironment interactions in non-small cell lung cancer (NSCLC) S. Torres, R. Sirera, C. Aguilar, S. Calabuig Fariñas, M. Mosqueda, A. Herreros-Pomares, E.
Escorihuela, E. García del Olmo, E. Jantus-Lewintre, C. Camps Herrero; Valencia, ES
13:35 - 13:35 1283P - Non-invasive detection of lung cancer by identifying copy number aberrations in circulating cell-free DNA with next generation sequencing to aid early detection 1 2 3 2 4 1 2 3 F. Taylor , J. Bradford , P. Woll , D. Teare , A. Cox ; Sheffield, S. Yorks/GB, Sheffield, GB,
4 Sheffield, South Yorkshire/GB, Rx, GB
13:35 - 13:35 1284P - HOXA-related long non-coding RNAs impact prognosis in early stage NSCLC patients A. Navarro, S. Santasusagna, N. Vinolas Segarra, J.J. Castellano, J. Moises, S. Morales, J. Canals, C.
Muñoz, J. Ramírez, R. Marrades, L. Molins, M. Monzo; Barcelona, ES
13:35 - 13:35 1285P - Association between polymorphisms in microRNA target sites and survival in early-stage non-small cell lung cancer J.H. Lee, S.S. Yoo, M.J. Hong, J.E. Choi, S.Y. Lee, J.Y. Park; Daegu, KR
13:35 - 13:35 1286TiP - Neo-adjuvant chemo/immunotherapy for the treatment of resectable stage IIIA non-small cell lung cancer (NSCLC): A phase II multicenter exploratory study” NADIM trial 1 2 3 4 5 V. Calvo de Juan , A. Insa Molla , M. Cobo Dols , B. Massuti Sureda , G. Lopez-Vivanco , J. Casal 6 7 8 9 7 Rubio , J. de Castro , M. Majem Tarruella , R. Bernabe Caro , J. Gonzalez-Larriba , I.C. Barneto 10 11 8 8 12 9 Aranda , E. Nadal , A. Martinez Marti , N. Vinolas Segarra , M. Guillot Morales , D. Vicente Baz , 13 7 14 1 1 C. Camps Herrero , M. Domine Gomez , D. Rodriguez Abreu , M. Provencio Pulla ; Majadahonda, 2 3 4 5 6 7 Madrid/ES, Valencia, Valencia/ES, Malaga, ES, Alicante, ES, Bizcaia, ES, Vigo, ES, Madrid, ES, 8 9 10 11 12 Barcelona, ES, Sevilla, ES, Cordoba, ES, Barcelona, Barcelona/ES, Palma De Mallorca, ES, 13 14 Valencia, ES, Las Palmas De Gran Canaria, ES
13:35 - 13:35 NSCLC, LOCALLY ADVANCED P. Garrido Lopez, Madrid, ES
13:35 - 13:35 1290P - DNA repair gene expression in bronchial washing fluid as new molecular tool for clinical outcome decision 1 2 2 2 2 2 1 2 D. Schveigert , R. Askinis , J. Fadejeva , V. Sapoka , A. Krasauskas , S. Cicenas ; Cairo, EG, Vilnius, LT
13:35 - 13:35 1291P - Diagnosis and monitoring of non-small cell ung cancer patients by next generation sequencing and droplet digital PCR on circulating tumor DNA P. Vannuffel, C. De Rop; Gosselies, BE
Last update: 02-09-2017 06:01:33pm esmo.org 13:35 - 13:35 1292P - Safety data from randomized phase II study of cisplatin (CDDP)+S-1 versus CDDP+pemetrexed (PEM) combined with thoracic radiotherapy (TRT) for locally advanced non-squamous (non-sq) non-small cell lung cancer (NSCLC): SPECTRA study 1 2 3 4 5 6 7 7 S. Niho , T. Yoshida , T. Akimoto , K. Sakamaki , T. Takahashi , T. Seto , M. Nishio , N. Yamamoto , 8 9 10 11 3 4 7 1 T. Hida , H. Okamoto , T. Kurata , M. Satouchi , K. Goto , T. Yamanaka , Y. Ohe ; Kashiwa,
2 3 4 5 6 7 Chiba/JP, Aichi, JP, Kashiwa, JP, Yokohama, JP, Shizuoka, JP, Fukuoka, Fukuoka/JP, Tokyo, 8 9 10 11 JP, Nagoya, Aichi/JP, Yokohama, Kanagawa/JP, Hirakata, JP, Akashi, JP
13:35 - 13:35 1293P - Preliminar analysis of the Spanish Lung Cancer Group (SLCG) phase II trial of concurrent chemo-radiotherapy (CT-RT) with cisplatin (P) plus metronomic oral vinorelbine (mOV) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC): NORA trial (GECP 15/02) 1 2 3 4 5 M. Majem Tarruella , L. Isla Casado , M. Guirado , B. Massuti Sureda , A. Ortega Granados , R. 6 7 8 9 10 Marse Fabregat , M. Domine Gomez , R. de las Peñas , M.T. Moran Bueno , S. Vazquez Estevez , 11 12 7 13 M.A. Sala Gonzalez , J. Coves Sarto , J.M. Sánchez-Torres , D. Vicente Baz , J. Gonzalez-Larriba 7 14 1 15 6 16 1 2 , A. Paredes , N. Farré , L. Fernández Fornos , A. Mena , M. Provencio Pulla ; Barcelona, ES, 3 4 5 6 7 8 Zaragoza, ES, Elche, Alicante/ES, Alicante, ES, Jaén, ES, Palma De Mallorca, ES, Madrid, ES, 9 10 11 12 Castellón, ES, Badalona, Barcelona/ES, Lugo, ES, Bilbao, ES, Palma De Mallorca, Islas 13 14 15 16 Baleares/ES, Sevilla, ES, San Sebastián, ES, Elche, ES, Majadahonda, Madrid/ES
13:35 - 13:35 1294P - Real world data of practice patterns and outcomes for pemetrexed plus platinum as neoadjuvant chemotherapy in adenocarcinomas of lung from a tertiary cancer center of India: Looking beyond the usual paradigm 1 2 2 2 2 2 2 2 A. Kapoor , S. Zanwar , A. Joshi , V. Noronha , V. Patil , A. Chougule , A. Mahajan , P. Bhargava ,
2 1 2 K. Prabhash ; Varanasi, Uttar Pradesh/IN, Mumbai, IN
13:35 - 13:35 NSCLC, METASTATIC R. Dziadziuszko, Gdansk, PL
13:35 - 13:35 1309P - Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with stage IV non-small cell lung cancer (NSCLC) 1 2 2 3 2 4 5 B. Besse , P. Garrido Lopez , J. Puente , A. Cortot , M.E. Olmedo Garcia , M. Perol , M. Gil , G. Chao 6 7 8 1 2 3 4 5 6 , J. Shahidi , J. Bennouna ; Villejuif, FR, Madrid, ES, Lille, FR, Lyon, CEDEX/FR, Warsaw, PL, 7 8 Bridgewater, NJ/US, Indianapolis, US, Nantes, CEDEX/FR
13:35 - 13:35 1310P - Survival and safety of atezolizumab by best overall response (BOR) in the phase III NSCLC OAK study 1 2 3 4 5 6 7 F. de Marinis , F. Barlesi , A. Rittmeyer , J. von Pawel , J.-Y. Han , M. Kozloff , A. Spira , L. 8 9 10 11 10 10 10 12 Fehrenbacher , D. Gandara , W. Yu , P. He , C. Yun , M. Ballinger , M. Gandhi , S. Gadgeel ; 1 2 3 4 5 6 7 Milan, IT, Marseille, FR, Immenhausen, DE, Gauting, DE, Goyang, KR, Harvey, US, Fairfax, US, 8 9 10 11 12 Vallejo, US, Sacramento, CA/US, South San Francisco, US, South San Francisco, CA/US, Ann Arbor, MI/US
13:35 - 13:35 1311P - LKB1 loss is a novel genomic predictor of de novo resistance to PD-1/PD-L1 axis blockade in KRAS-mutant lung adenocarcinoma
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 3 4 5 6 6 1 F. Skoulidis , M. Hellman , M. Awad , J. Gainor , H. Rizvi , B. Carter , W. Denning , P. Villalobos , E. 1 1 1 7 5 6 1 Parra , Y. Elamin , J. Zhang , G. Leonardi , D. Halpenny , V. Papadimitrakopoulou , I. Wistuba , J.
5 7 4 2 1 1 2 3 Wolchok , A. Shaw , P. Jänne , C. Rudin , J. Heymach ; Houston, TX/US, New York, NY/US, 4 5 6 7 Boston, US, Boston, Ma, US, New York, US, Houston, US, Boston, MA/US
13:35 - 13:35 1312P - Prediction of survival with durvalumab in locally advanced or metastatic NSCLC using early tumor assessments 1 2 3 1 4 1 4 4 1 X. Zhang , K. Park , N. Rizvi , P. Dennis , R. Narwal , Y. Huang , R. Arani , P. Mukhopadhyay ;
2 3 4 Gaithersburg, US, Seoul, KR, New York, Ny, US, Gaithersburg, MD/US
13:35 - 13:35 1313P - Immune-related adverse events (irAEs) in advanced NSCLC patients treated with atezolizumab: Safety population analyses from the Ph III study OAK 1 2 3 4 5 6 D. Cortinovis , J. von Pawel , K. Syrigos , J. Mazieres , R. Dziadziuszko , L. Fehrenbacher , P. 7 8 9 10 11 12 13 Conkling , J. Goldschmidt , C. Thomas , R. Bordoni , M. Kosty , F. Braiteh , P. He , M. Ballinger 14 14 14 15 1 2 3 4 5 , M. Gandhi , H. Patel , D. Gandara ; Monza, IT, Gauting, DE, Athens, GR, Toulouse, FR, 6 7 8 9 10 11 Gdansk, PL, Vallejo, US, Norfolk, VA/US, Blacksburg, US, Scarborough, ME/US, Marietta, US, 12 13 14 15 La Jolla, US, Las Vegas, US, South San Francisco, CA/US, South San Francisco, US, Sacramento, US
13:35 - 13:35 1314P - Association between immune-related adverse events (irAEs) and atezolizumab efficacy in advanced NSCLC: analyses from the phase III study OAK 1 2 3 4 5 6 7 J. von Pawel , K. Syrigos , J. Mazieres , D. Cortinovis , R. Dziadziuszko , D. Gandara , P. Conkling , 8 9 10 11 12 13 13 J. Goldschmidt , C. Thomas , R. Bordoni , M. Kosty , F. Braiteh , S. Hu , M. Ballinger , H. Patel 13 13 14 1 2 3 4 5 , M. Gandhi , L. Fehrenbacher ; Gauting, DE, Athens, GR, Toulouse, FR, Monza, IT, 6 7 8 9 10 Gdansk, PL, Sacramento, CA/US, Norfolk, VA/US, Blacksburg, US, Scarborough, ME/US, 11 12 13 14 Marietta, US, La Jolla, US, Las Vegas, US, South San Francisco, US, Vallejo, US
13:35 - 13:35 1315P - Efficacy and safety data from patients with advanced non-squamous NSCLC and brain metastases from the nivolumab expanded access programme (EAP) in Italy 1 2 3 4 5 6 7 4 L. Crinò , P. Bidoli , F. Roila , E. Cortesi , M. Garassino , F. Cappuzzo , F. Grossi , G. Tonini , G. 8 9 10 4 11 12 13 Sarobba , G. Pinotti , G. Numico , R. Samaritani , L. Ciuffreda , A. Frassoldati , M. Bregni , A. 14 15 15 5 16 1 2 Santo , F.V. Piantedosi , I. Alfonso , F. De Marinis , A. Delmonte ; Perugia, (PG)/IT, Monza 3 4 5 6 7 8 9 10 (mi), IT, Terni, IT, Roma, IT, Milano, IT, Ravenna, IT, Genova, IT, Nuoro, IT, Varese, IT, 11 12 13 14 15 16 Alessandria, IT, Torino, IT, Ferrara, IT, Busto Arsizio, IT, Verona, IT, Napoli, IT, Meldola, Forlì-Cesena/IT
13:35 - 13:35 1316P - Efficacy and immune activation with PEGylated human IL-10 (AM0010) in combination with an anti-PD1 in advanced NSCLC: Update 1 2 3 4 5 6 7 8 D. Wong , J. Schneider , R. Aljumaily , M. Korn , K. Autio , J. Infante , M. Patel , K. Papadopoulos , 9 10 4 1 11 11 12 A. Naing , N. Gabrail , P. Munster , J. Goldman , P. Van Vlasselaer , A. Hung , G. Brown , M. 11 13 1 2 3 4 Oft , E. Garon ; Los Angeles, CA/US, Mineola, US, Oklahoma City, OK/US, San Francisco, 5 6 7 8 9 CA/US, New York, US, Nashville, TN/US, Sarasota, FL/US, San Antonio, TX/US, Houston, TX/US, 10 11 12 13 Ohio, US, Redwood City, US, New York, CA/US, Santa Monica, US
Last update: 02-09-2017 06:01:33pm esmo.org 13:35 - 13:35 1317P - Multicenter observational study of the efficacy and safety of nivolumab (Nivo) as 2+ line treatment and quality of life (QoL) in advanced refractory non-small cell lung cancer (NSCLC) patients: Interim analysis 1 1 1 1 2 1 3 K. Laktionov , A. Arzumanyan , L. Bolotina , V. Breder , N. Buevich , A. Danilova , E. Filippova , A. 1 3 2 2 3 3 3 Kornietskaya , M. Kramchaninov , E. Kushniruk , D. Latipova , F. Moiseenko , T. Nikitina , S. Orlov ,
3 2 1 4 3 1 2 R. Orlova , S. Protsenko , K. Sarantseva , D. Stroyakovskiy , T. Ionova ; Moscow, RU, 3 4 Saint-Petersburg, RU, Saint Petersburg, RU, Moscow, Krasnogorski District/RU
13:35 - 13:35 1318P - Italian nivolumab expanded access programme in non-squamous non-small cell lung cancer patients: Real-world results in never smokers and EGFR positive patients 1 2 3 4 5 6 2 7 M. Garassino , E. Cortesi , F. Grossi , R. Chiari , H. Soto Parra , S. Cascinu , F. Cognetti , D. Turci , 8 9 10 11 12 13 14 L. Blasi , C. Bengala , E. Mini , E. Baldini , T. Gamucci , G.L. Ceresoli , P. Antonelli , E. Vasile 15 16 17 18 1 1 2 3 , M. Pagano , M. Macerelli , A. Lagroscino , F. De Marinis ; Milano, IT, Roma, IT, Genova, IT,
4 5 6 7 8 9 10 11 Perugia, IT, Catania, IT, Ancona, IT, Ravenna, IT, Palermo, IT, Grosseto, IT, Firenze, IT, 12 13 14 15 16 17 Lucca, IT, Sora, Frosinone/IT, Bergamo, IT, Busto Arsizio, IT, Pisa, IT, Reggio Emilia, IT, 18 Udine, IT, Bari, IT
13:35 - 13:35 1319P - Efficiency of nivolumab in the treatment of second-line advanced non-squamous non-small cell lung cancer (NSCLC) in Spain 1 2 3 1 2 1 2 P. González , N. Ortega-Joaquín , M. Provencio Pulla , C. Garrido , M. Echave ; Madrid, ES,
3 Pozuelo De Alarcón (madrid), ES, Majadahonda, Madrid/ES
13:35 - 13:35 1320P - Use of nivolumab in elderly patients with advanced non-squamous NSCLC: Results from the Italian expanded access program (EAP) 1 2 3 4 5 6 7 2 M.R. Migliorino , A. Gelibter , F. Grossi , D. Fagnani , P. Bordi , T. Franchina , D. Turci , L. Di Lauro , 8 9 10 11 12 13 14 15 S. Cascinu , L. Calabro , M. Brighenti , N. Tedde , A. Bearz , S. Giusti , E. Vasile , G. Surico , 16 1 17 18 1 2 3 4 G. Cartenì , P. Marchetti , F. Verderame , B. Melotti ; Roma, IT, Rome, IT, Genova, IT, 5 6 7 8 9 10 11 Vimercate, IT, Parma, IT, Messina, IT, Ravenna, IT, Ancona, IT, Siena, IT, Cremona, IT, 12 13 14 15 16 17 18 Olbia, IT, Pordenone, IT, Arezzo, IT, Pisa, IT, Lecce, IT, Napoli, IT, Palermo, IT, Bologna, IT
13:35 - 13:35 Survival benefit of immune checkpoint inhibitors according to the histology in non-small-cell lung cancer J.H. Kim, B.J. Kim; Seoul, KR
13:35 - 13:35 1322P - Real life experience with nivolumab in patients (pts) with advanced non-squamous NSCLC (nSq-NSCLC) exhibiting KRAS mutations: The Italian Expanded Access Program (EAP) 1 2 3 4 1 5 6 7 F. Cappuzzo , P. Bidoli , R. Chiari , A. Chirco , D. Turci , A. Ardizzoni , A. Santoro , C. Natoli , G. 8 9 10 11 12 13 14 15 Francini , M. Giordano , G. Borra , C. Defferrari , L. Livi , A. Berruti , M. Minelli , E. Ricevuto , 16 17 18 19 1 2 3 4 A. Illiano , G. Puppo , A. Delmonte , A. Misino ; Ravenna, IT, Monza, IT, Perugia, IT,
5 6 7 8 9 Bergamo, IT, Bologna, IT, Rozzano, (MI)/IT, Chieti, IT, Siena, IT, San Fermo Della Battaglia, 10 11 12 13 14 15 16 CO/IT, Novara, IT, Genova, IT, Florence, IT, Brescia, IT, Roma, IT, L'aquila, IT, Napoli, 17 18 19 IT, Pisa, IT, Meldola, IT, Bari, IT
13:35 - 13:35 1323P - Baseline corticosteroids (CS) could be associated with absence of benefit to immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 3 4 2 2 G. Martínez Bernal , L. Mezquita , E. Auclin , R. Ferrara , D. Planchard , J. Remon Masip , J. Lahmar 2 2 2 2 2 2 2 1 2 , M.-E. Boucher , C. CARAMELLA , J. Adam , A. Gazzah , J.-C. Soria , B. Besse ; Sevilla, ES, 3 4 Villejuif, FR, Paris, FR, Verona, IT
13:35 - 13:35 1324P - Practical effectiveness efficacy and safety of nivolumab for advanced non-small cell lung cancer: A retrospective multicenter analysis 1 2 1 1 1 3 4 K. Kobayashi , I. Nakachi , K. Naoki , Y. Oyamada , M. Nakamura , T. Inoue , H. Tateno , F. 5 6 7 8 2 1 1 1 Sakamaki , K. Sayama , T. Terashima , H. Koh , D. Arai , H. Yasuda , I. Kawada , K. Soejima , T.
1 1 2 3 4 5 6 7 Betsuyaku ; Tokyo, JP, Utsunomiya, JP, Sano, JP, Saitama, JP, Hachiouji, JP, Kawasaki, JP, 8 Ichikawa, JP, Tachikawa, JP
13:35 - 13:35 1325P - Generalization and representativeness of phase III immune checkpoint inhibitor trials in NSCLC S.H. Yoo, M. Kim, B. Keam, T.M. Kim, D.-W. Kim, D.S. Heo; Seoul, KR
13:35 - 13:35 1326P - Long-term follow-up results of stage III-IV non-small-cell lung cancer (NSCLC) patients treated with an epitope derived from Indoleamine 2,3 Dioxygenase (IDO) in a phase I study J. Kjeldsen, T. Iversen, L. Noerregaard, A. Mellemgaard, M. Andersen, I.-M. Svane; Herlev, DK
13:35 - 13:35 1327P - The Lung Immune Prognostic Index (LIPI), a predictive score for immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC) patients 1 2 1 3 1 1 4 L. Mezquita , E. Auclin , M. Charrier , R. Ferrara , J. Remon Masip , D. Planchard , S. Ponce Aix , L. 4 1 5 6 7 4 Paz-Ares , J. Lahmar , L. Leroy , C. Audigier-Valette , J. Zeron-Medina Cuairan , P. Garrido Lopez , 2 8 1 1 9 1 1 1 S. Brosseau , J. Mazieres , C. CARAMELLA , J. Adam , N. Chaput , J.-C. Soria , B. Besse ; Villejuif, 2 3 4 5 6 7 8 FR, Paris, FR, Verona, IT, Madrid, ES, Bordeaux, FR, Toulon, FR, Barcelona, ES, Toulouse, 9 FR, Villejuif, CEDEX/FR
13:35 - 13:35 1328P - Association of single nucleotide polymorphisms with efficacy in nivolumab-treated NSCLC patients 1 1 1 1 1 2 E. Basak , S. Bins , S. El Bouazzaoui , S. Koolen , E. Oomen-De Hoop , C. van der Leest , A. van der
1 1 1 1 1 1 1 2 Veldt , S. Sleijfer , R. Debets , R. van Schaik , R. Mathijssen , J. Aerts ; Rotterdam, NL, Breda, NL
13:35 - 13:35 1329P - Systematic inflammation and histologic grade in non-small cell lung carcinoma 1 2 2 2 1 2 K. Tsapakidis , N. Tsoukalas , C. Giaginis , I. Gioulbasanis , M. Tolia , E. Aravantinou , M. 2 2 2 1 3 1 2 2 Galanopoulos , M. Kiakou , I. Kostakis , I. Litos , M. Liontos , E. Sogka , V. Tzouda , K. Liaskonis , S. 2 1 2 3 Theocharis ; Larissa, GR, Athens, GR, Athens, Attiki/GR
13:35 - 13:35 1330P - Impact of next generation TKI and co-occurring mutations in ALK-positive NSCLC patients: Results of the Network Genomic Medicine 1 1 2 1 2 2 2 2 R. Riedel , A. Kron , S. Michels , J. Fassunke , M. Scheffler , R. Fischer , L. Nogova , D. Abdulla , C. 1 1 1 3 4 5 6 7 Heydt , F. Ueckeroth , B. Pauli , M. Serke , S. Krueger , C. Grohe , M. Sebastian , D. Koschel , K.-O.
8 1 1 2 1 2 3 4 Kambartel , T. Zander , R. Büttner , J. Wolf ; Cologne, DE, Köln, DE, Hemer, DE, Düsseldorf, DE, 5 6 7 8 Berlin, DE, Frankfurt Am Main, DE, Coswig, DE, Moers, DE
13:35 - 13:35 1331P - Detection of EGFR T790M in Asia-Pacific patients (pts) with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): Circulating tumour (ct) DNA analysis across 3 platforms
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 3 4 1 1 5 5 1 6 C. Zhou , M. Wang , Y. Cheng , Y. Chen , X. Ye , Y. Sun , X. Huang , S. Patel , Y. Chen , Y.-L. Wu
1 2 3 4 5 6 ; Shanghai, CN, Beijing, CN, Jilin, CN, Wuhan, CN, Cambridge, GB, Guangzhou, CN
13:35 - 13:35 1332P - Influence of plasma T790M mutation on clinical decision after 1st generation EGFR-TKI resistance in a Real-world study S. Zhang, L. Zhu, B. Xia, X. Chen, S. Ma; Hangzhou, CN
13:35 - 13:35 1333P - Detectability of RET fusions by amplicon-based next generation sequencing in nationwide lung cancer genomic screening project: LC-SCRUM-Japan 1 2 1 3 3 4 5 6 7 Y. Usui , K. Kirita , S. Matsumoto , Y. Ohe , M. Nishio , T. Seto , M. Kodani , K. Taima , Y. Hattori , 3 2 8 1 2 3 4 T. Kohno , K. Yoh , K. Goto ; Kashiwa-Shi, JP, Kashiwa, Chiba/JP, Tokyo, JP, Fukuoka, 5 6 7 8 Fukuoka/JP, Yonago, JP, Hirosaki, JP, Akashi, JP, Kashiwa, JP
13:35 - 13:35 1334P - A comparison of Bronchial Washing Fluid (BWF) and histologic samples in the analysis of EGFR mutation in NSCLC patients 1 1 2 1 1 1 1 1 1 1 1 X. Zhang , M. Ye , C. Li , Q. Hu , M. Du , X. Wang , Z. Gong , D. Zhang , Q. Hong , J. Hu , L. Mei ,
1 1 1 2 Y. Hou , X. Zhang ; Shanghai, CN, Shanghai, Changning/CN
13:35 - 13:35 1335P - EGFR T790M detection in TKI-naïve NSCLCs carrying sensitive EGFR mutations G. Pinotti, R. Cerutti, N. Sahnane, L. Lettig, C. Albeni, A. Tuzi, F. Franzi, A. Pastore, F. Ogliari, F. Sessa,
D. Furlan; Varese, IT
13:35 - 13:35 1336P - ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer 1 2 1 1 1 1 A. Mc Leer , M. Duruisseaux , J. Pinsolle , S. Dubourg , J. Mondet , M. Phillips-Houlbracq , N. Magnat 1 1 1 1 1 1 1 2 , J. Fauré , A. Chatagnon , F. de Fraipont , M. Giaj Levra , A.C. Toffart , G. Ferretti , E. Brambilla , 3 1 1 1 2 3 P. Hainaut , D. Moro-Sibilot , S. Lantuéjoul ; La Tronche, FR, La Tronche, CEDEX 9/FR, Lyon, FR
13:35 - 13:35 1337P - A meta-analysis on epidemiology of ROS1 rearrangement in Asian and non-Asian population 1 2 3 1 2 3 V. Gupta , N. Godre , M. Alam ; Jeddah, SA, Mumbai, IN, West Ryde, AU
13:35 - 13:35 1338P - EGFR mutation detection in plasma cell-free DNA correlates with clinical outcomes in non-small cell lung cancer J. Shi, J. Mong, T.M. Chin, Y.H. Lim, W.L. Tan, C.K. Toh, H.S. Tan, S.-W. Wong, A. Tee, D. Chan, K.
Wong, S. Yeap, L. Ngo, Y.-O. Tan, M.-H. Tan; Singapore, SG
13:35 - 13:35 1339P - A large prospective cohort study of the clinical features of advanced lung cancer harboring HER2 aberrations (HER2-CS STUDY) 1 1 2 3 3 4 5 T. Tanaka , H. Yoshioka , A. Bessho , N. Ishikawa , M. Yamasaki , T. Shibayama , K. Aoe , T. Kozuki 6 4 7 8 9 10 11 4 3 , N. Fujimoto , K. Genba , Y. Ueda , M. Inoue , T. Murakami , S. Kuyama , H. Kawai , K. Fujitaka 6 12 4 4 1 2 3 , K. Inoue , M. Takata , H. Yanai , K. Kiura ; Kurashiki, JP, Okayama, Okayama Prefecture/JP, 4 5 6 7 8 9 Hiroshima, JP, Okayama, JP, Ube, JP, Matsuyama, JP, Fukuyama, JP, Takamatsu, JP, 10 11 12 Shimonoseki, JP, Himeji, JP, Iwakuni, JP, Kyoto, JP
13:35 - 13:35 1340P - Transcriptomic analysis of bronchoalveolar lavage cells from advanced non-small cell lung cancer identifies overexpressed immunoglobulin genes of immunosuppressive implication
Last update: 02-09-2017 06:01:33pm esmo.org C.-H. Kuo, C.-Y. Liu, Y.-L. Lo, Y.-W. Wang, T.-H. Wang, C.-T. Yang; Taipei, TW
13:35 - 13:35 1341P - Assessing response to immunotherapy in patients with non-small cell lung cancer using circulating tumor DNA 1 1 1 1 1 2 1 1 S. Goldberg , A. Narayan , A. Kole , R. Decker , J. Teysir , N. Carriero , A. Lee , R. Nemati , S. Nath 1 1 1 1 1 1 1 3 1 , S. Mane , Y. Deng , N. Sukumar , D. Zelterman , D. Boffa , K. Politi , S. Gettinger , L. Wilson , R. 1 1 1 2 3 Herbst , A. Patel ; New Haven, US, New York, US, New Haven, CT/US
13:35 - 13:35 1342P - Detection of epidermal growth factor receptor mutations in circulating cell-free DNA versus tumor biopsy 1 1 1 1 1 2 1 1 2 I.-J. Oh , H.-W. Seo , H.-J. Cho , C.-K. Park , J.-H. Lim , Y.-C. Kim , Y.-D. Choi ; Hwasun, KR, Hwasun, Jeollanam-do/KR
13:35 - 13:35 1343P - Efficacy and safety of lorlatinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) previously treated with 2nd-generation ALK TKIs 1 2 3 4 5 6 7 8 E. Felip Font , A. Shaw , B. Solomon , T. Bauer , S.-H. Ou , S. Gadgeel , R. Soo , T. Seto , J. Clancy 9 10 11 12 1 2 3 4 , L. James , A. Abbattista , B. Besse ; Barcelona, ES, Boston, MA/US, Melbourne, VIC/AU,
5 6 7 8 9 Nashville, TN/US, Orange, CA/US, Detroit, US, Singapore, SG, Fukuoka, Fukuoka/JP, Princeton, 10 11 12 NJ/US, New York, US, Milan, IT, Villejuif, FR
13:35 - 13:35 1344P - Brigatinib (BRG) in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC): Long-term efficacy and safety results from a phase 1/2 trial 1 2 3 4 1 5 6 7 L. Bazhenova , S. Gettinger , C. Langer , R. Salgia , K. Gold , R. Rosell , A. Shaw , G. Weiss , J. 8 8 8 9 1 2 3 Haney , V. Rivera , D. Kerstein , R. Camidge ; La Jolla, CA/US, New Haven, CT/US, Philadelphia,
4 5 6 7 8 PA/US, Chicago, IL/US, Badalona, Barcelona/ES, Boston, MA/US, Goodyear, AZ/US, Cambridge, 9 MA/US, Aurora, CO/US
13:35 - 13:35 1345P - Intracranial efficacy of brigatinib (BRG) in patients (Pts) With crizotinib (CRZ)-refractory anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) and baseline CNS metastases 1 2 3 4 5 6 4 7 S.-H. Ou , M. Tiseo , R. Camidge , M.-J. Ahn , R. Huber , M. Hochmair , S.-W. Kim , H. West , K. 8 9 10 11 12 13 14 Reckamp , J. Molina , G. Liu , A. Delmonte , S. Viteri , A. Bearz , Y. Summers , W. Reichmann 15 15 16 4 1 2 3 4 , D. Kerstein , S. Gettinger , D.-W. Kim ; Orange, CA/US, Parma, IT, Aurora, CO/US, Seoul,
5 6 7 8 9 10 KR, Munich, DE, Vienna, AT, Seattle, WA/US, Duarte, CA/US, Rochester, US, Toronto, 11 12 13 14 15 Ontario/CA, Meldola, IT, Barcelona, ES, Pordenone, IT, Manchester, GB, Cambridge, 16 MA/US, New Haven, CT/US
13:35 - 13:35 1346P - CNS efficacy results from the phase III ALUR study of alectinib vs chemotherapy in previously treated ALK+ NSCLC 1 2 3 4 5 6 7 J. de Castro , S. Novello , J. Mazieres , I.-J. Oh , M. Migliorino , A. Helland , R. Dziadziuszko , F. 8 9 10 10 10 10 10 Griesinger , F. de Marinis , A. Zeaiter , A. Cardona , B. Balas , H. Johannsdottir , M. Chlistalla ,
10 11 1 2 3 4 5 6 V. Smoljanovic , J. Wolf ; La Pa, ES, Torino, IT, Toulouse, FR, Hwasun, KR, Rome, IT, Oslo, 7 8 9 10 11 NO, Gdansk, PL, Oidenburg, DE, Milan, IT, Basel, CH, Köln, DE
13:35 - 13:35 1347P - Treatment beyond disease progression: ALK inhibitors in ALK-rearranged advanced NSCLC
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 1 1 3 4 1 5 1 N. Leighl , J. Kuo , A. Pavel , M. Prescilla , F. Shepherd , G. Liu , P. Bradbury , M. Moskovits ;
2 3 4 5 Toronto, CA, Melbourne, VIC/AU, Toronto, ON/CA, Toronto, Ontario/CA, Haifa, IL
13:35 - 13:35 1348P - Overall survival (OS) in patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC) treated with osimertinib: Results from two phase II studies 1 2 3 4 5 6 7 T. Mitsudomi , M.-J. Ahn , L. Bazhenova , F. Blackhall , T. Hida , M. Majem Tarruella , S. Vowler , G. 7 8 9 1 2 3 4 5 Laus , P. Jänne , J.C.-H. Yang ; Osaka, JP, Seoul, KR, San Diego, CA/US, Manchester, GB, 6 7 8 9 Nagoya, Aichi/JP, Barcelona, ES, Cambridge, GB, Boston, Ma, US, Taipei, TW
13:35 - 13:35 1349P - Subsequent therapies post-afatinib among patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC in LUX-Lung (LL) 3, 6 and 7 1 2 3 4 5 6 7 8 9 L. Sequist , Y.-L. Wu , M. Schuler , T. Kato , J. Yang , H. Tanaka , T. Hida , S. Lu , K. Park , S. 10 11 12 13 14 14 15 Laurie , J. Bennouna , D. Moro Sibilot , A. Märten , B. Peil , E. Ehrnrooth , N. Yamamoto , K. 16 1 2 3 4 5 6 Nakagawa ; Boston, MA/US, Guangzhou, CN, Essen, DE, Yokohama, JP, Taipei, TW, Nagoya, 7 8 9 10 11 12 JP, Nagoya, Aichi/JP, Shanghai, CN, Seoul, KR, Ottowa, ON/CA, Nantes, FR, Grenoble, FR, 13 14 15 16 Ingelheim Am Rhein, DE, Copenhagen, DK, Wakayama, JP, Osaka, JP
13:35 - 13:35 1350P - Phase I study of TAS-121, a novel third-generation epidermal growth factor receptor (EGFR) inhibitor, in patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC) 1 2 3 4 5 6 7 2 H. Murakami , Y. Ohe , T. Hida , H. Sakai , K. Kasahara , F. Imamura , T. Baba , K. Kubota , Y. 2 8 6 2 2 2 1 Hosomi , T. Shimokawa , H. Hayashi , K. Miyadera , T. Tamura , M. Nishio ; Shizuoka, Shizuoka/JP, 2 3 4 5 6 7 8 Tokyo, JP, Nagoya, Aichi/JP, Ina, JP, Kanazawa, JP, Osaka, JP, Yokohama, JP, Yokohama, Kanagawa/JP
13:35 - 13:35 1351P - The addition of apatinib to gefitinib or icotinib for advanced non-small cell lung cancer with acquired resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitor: An assessment of effectiveness and safety C. Ying, Y. Wu; Hangzhou, CN
13:35 - 13:35 1352P - Leptomeningeal carcinomatosis from EGFR-mutated non-small cell lung cancer 1 2 2 2 2 2 2 1 T. Iuchi , M. Shingyoji , T. Setoguchi , Y. Yoshida , H. Ashinuma , Y. Hasegawa , T. Sakaida ;
2 Chiba, Chiba/JP, Chiba, JP
13:35 - 13:35 1353P - CNS response to osimertinib in Asian-Pacific patients (pts) with T790M-positive advanced NSCLC: data from an open-label Phase II trial (AURA17) 1 2 3 4 5 6 7 1 1 C. Zhou , Y. Cheng , Y. Lu , M. Shi , J.-Y. Han , M. Wang , S.-W. Kim , J. Wang , Y. Chen , Y.-L. 8 1 2 3 4 5 6 7 Wu ; Shanghai, CN, Jilin, CN, Chengdu, CN, Nanjing, CN, Goyang, KR, Beijing, CN, Seoul, KR, 8 Guangzhou, CN
13:35 - 13:35 1354P - Osimertinib in Asia-Pacific patients (pts) with EGFR T790M-positive advanced NSCLC: Updated Phase II study results including progression-free survival (PFS) 1 2 3 4 5 2 6 1 7 C. Zhou , M. Wang , Y. Cheng , Y. Chen , Y. Zhao , Y.-K. Shi , M.-J. Ahn , Y. Chen , X. Huang , M. 8 9 1 2 3 4 5 Cantarini , Y.-L. Wu ; Shanghai, CN, Beijing, CN, Changchun, Jilin/CN, Wuhan, CN, Zhengzhou, 6 7 8 9 CN, Seoul, KR, Cambridge, GB, Macclesfield, Cheshire/GB, Guangzhou, CN
Last update: 02-09-2017 06:01:33pm esmo.org 13:35 - 13:35 1355P - Activity of afatinib in heavily pretreated patients (pts) with HER2 mutation-positive (HER2m+) advanced non-small cell lung cancer (NSCLC): findings from a global named patient use (NPU) program 1 2 3 4 4 5 S. Peters , A. Curioni-Fontecedro , H. Nechushtan , J.-Y. Shih , W.-Y. Liao , O. Gautschi , V. Spataro 6 7 4 8 8 9 10 1 2 , M. Unk , J.C.-H. Yang , R. Lorence , P. Carrière , A. Cseh , G.-C. Chang ; Lausanne, CH,
3 4 5 6 7 8 Zurich, CH, Jerusalem, IL, Taipei, TW, Lucerne, CH, Bellinzona, CH, Ljubljana, SI, Ridgefield, 9 10 CT/US, Vienna, AT, Taichung, TW
13:35 - 13:35 1356P - Octogenarians with EGFR-mutated non-small cell lung Cancer (NSCLC) treated by Tyrosine Kinase Inhibitor (TKI): A multicentric real world study assessing tolerance and efficacy. OCTOMUT study GFPC 07-15 1 2 3 4 5 6 3 7 R. Corre , R. Gervais , L. Tassy , F. Guisier , R. Lamy , G. Fraboulet , L. Greillier , H. Doubre , C. 8 9 1 2 3 4 5 6 chouaid , J.B. Auliac ; Rennes, FR, Caen, CEDEX 5/FR, Marseille, FR, Rouen, FR, Lorient, FR, 7 8 9 Pontoise, FR, Suresnes, FR, Créteil, FR, Mantes La Jolie, FR
13:35 - 13:35 1357P - Prospective evaluation of the relationship between erlotinib concentration and efficacy in patients with non-small cell lung cancer harboring EGFR-activating mutations 1 2 3 3 3 3 3 H. Kenmotsu , C. Imamura , T. Kawamura , T. Oyakawa , S. Omori , K. Nakashima , K. Wakuda , A. 1 1 3 1 4 3 2 1 Ono , T. Taira , T. Naito , H. Murakami , N. Yamamoto , T. Takahashi , Y. Tanigawara ; Shizuoka, 2 3 4 Shizuoka/JP, Tokyo, JP, Shizuoka, JP, Wakayama, JP
13:35 - 13:35 1358P - First-in-human phase I study of PF-06747775, a third-generation mutant selective EGFR tyrosine kinase inhibitor (TKI) in metastatic EGFR mutant NSCLC after progression on a first-line EGFR TKI 1 2 3 4 5 6 7 8 H. Husain , R. Martins , S. Goldberg , P. Senico , W. Ma , J. Masters , N. Pathan , D.-W. Kim , M. 9 10 8 1 2 3 4 Socinski , Z. Goldberg , B.C. Cho ; San Diego, CA/US, Seattle, US, New Haven, US, 5 6 7 8 9 10 Philadelphia, US, New York, US, La Jolla, US, San Diego, US, Seoul, KR, Pittsburgh, PA/US, New London, US
13:35 - 13:35 1359P - Impact on OS and PFS of 2nd and 3rd generation TKI in EGFR mt+ and ALK+ pts: Results of the NOWEL network 1 2 3 4 5 1 6 J. Roeper , A. Lueers , M. Netchaeva , M. Falk , C. Hallas , M. Tiemann , N. Neemann , L. Heukamp 6 5 5 3 3 7 1 2 3 , C. Wesseler , G. Wiest , D. Ukena , S. Sackmann , F. Griesinger ; Berlin, DE, Oldenburg, DE, 4 5 6 7 Bremen, DE, Hamburg, Hamburg/DE, Hamburg, DE, Köln, DE, Oidenburg, DE
13:35 - 13:35 1360P - Phase II trial of AZD9291 in second line treatment after acquired resistance with T790M mutation detected from circulating tumor DNA (LiquidLung-O-Cohort 2) 1 2 2 2 2 2 2 2 2 Y.-C. Kim , C.K. Park , I.-J. Oh , J.-H. Lim , Y.-D. Choi , H. Cho , S.-J. Ahn , S.-Y. Song , J.S. Yun ,
2 1 2 K.-J. Na ; Hwasun, Jeollanam-do/KR, Hwasun, KR
13:35 - 13:35 1362P - Safety and clinical activity of DS-6051b, a ROS1/NTRK inhibitor, in Japanese patients with NSCLC harboring ROS1 fusion gene 1 2 3 3 4 4 3 3 M. Takeda , T. Seto , Y. Fujiwara , N. Yamamoto , K. Nosaki , R. Toyozawa , C. Abe , R. Shiga , K.
3 1 1 2 3 4 Nakamaru , K. Nakagawa ; Osaka, JP, Fukuoka, Fukuoka/JP, Tokyo, JP, Fukuoka, JP
13:35 - 13:35 1363P - Efficacy and safety of abemaciclib combined with either LY3023414 or pembrolizumab in stage IV NSCLC
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 3 4 5 6 7 P. Garrido Lopez , J. Goldman , K. Kelly , E. Kim , T. Beck , M. Alonso Garcia , Z. Yang , K.-J. 7 7 7 8 1 2 3 Ingram , L. Amstutz , W. John , M. Provencio Pulla ; Madrid, ES, Santa Monica, US, Sacramento, 4 5 6 7 8 US, Charlotte, US, Fayetteville, US, Sevilla, ES, Indianapolis, US, Majadahonda, Madrid/ES
13:35 - 13:35 1364P - Final clinical results from SUNRISE: A phase III, randomized, double-blind, placebo-controlled multicenter trial of bavituximab plus docetaxel in patients with previously treated stage IIIb/IV nonsquamous non-small cell lung cancer 1 2 3 4 5 6 7 R. Palmero , P. Bidoli , I. Bondarenko , M. Boyer , P. Germonpre , D. Ghizdavescu , A. Kotsakis , H. 8 9 10 11 12 13 14 15 Lena , G. Losonczy , K. Park , M. Reck , W.-C. Su , N. Kallinteris , M. Tang , J. Lai , J. Shan 13 16 1 2 3 4 5 6 , D. Spigel ; Barcelona, ES, Monza, IT, Dnepropetrovsk, UA, Camperdown, AU, Gent, BE, 7 8 9 10 11 Ploiesti, RO, Heraklion, GR, Rennes, CEDEX/FR, Budapest, HU, Seoul, KR, Grosshansdorf, 12 13 14 15 16 DE, Tainan, TW, New York, CA/US, Tustin, CA/US, New York, US, Nashville, TN/US
13:35 - 13:35 1365P - Effect on quality of life (QOL) of adding cisplatin to single-agent first-line chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC): A joint analysis of the multicentre, randomized, phase 3 MILES-3 and MILES-4 studies 1 1 2 3 4 5 3 6 M.C. Piccirillo , A. Morabito , P. Maione , A. Luciani , L. Cavanna , L. Bonanno , E. Piazza , S. Leo , 7 1 8 9 10 1 1 S. Cinieri , F. Morgillo , M.A. Burgio , D. Bilancia , F. Rosetti , A. Montanino , A. Manzo , L. Arenare 1 11 11 1 2 1 2 3 4 , S. Signoriello , C. Gallo , F. Perrone , C. Gridelli ; Napoli, IT, Avellino, IT, Milano, IT, 5 6 7 8 9 10 11 Piacenza, IT, Padova, IT, Lecce, IT, Brindisi, IT, Meldola, IT, Potenza, IT, Mirano, IT, Naples, IT
13:35 - 13:35 1366P - Effect of nab-paclitaxel/carboplatin (nab-P/C) induction therapy on quality of life (QoL) of patients with squamous (SCC) non-small cell lung cancer (NSCLC) (ABOUND.sqm) 1 2 3 4 5 6 7 S. Ponce Aix , V. Villaflor , J. Knoble , M. Thomas , J. von Pawel , S. Bailey , M. Hussein , M.A. 8 9 10 11 11 12 1 2 3 Razaq , K. Sabbath , P. Staib , T. Chen , N. Trunova , D. Spigel ; Madrid, ES, Chicago, US,
4 5 6 7 8 9 Columbus, US, Heidelberg, DE, Gauting, DE, Hazard, US, Lady Lake, US, Oklahoma City, US, 10 11 12 Waterbury, US, Eschweiler, DE, Summit, US, Nashville, TN/US
13:35 - 13:35 1367P - Quality of life (QoL) in elderly NSCLC patients (pts) treated with nab-paclitaxel/carboplatin (nab-P/C) in the ABOUND.70+ trial 1 2 3 4 5 6 7 8 C. Langer , E. Anderson , R. Jotte , J. Goldman , D. Haggstrom , D. Smith , C. Dahkil , K. Konduri , 9 10 10 11 1 2 3 4 E. Kim , A. Sanford , K. Amiri , J. Weiss ; Philadelphia, PA/US, Portland, US, Denver, US,
5 6 7 8 9 10 Santa Monica, US, Charlotte, US, Vancouver, US, Wichita, US, Dallas, Texas/US, Dallas, US, 11 Summit, US, New York, US
13:35 - 13:35 1368P - Phase I/II trial of weekly nab-paclitaxel as 2nd or 3rd line treatment in NSCLC without driver mutations. (OLCSG1303) 1 1 1 1 2 2 2 3 T. Ninomiya , K. Hotta , K. Ohashi , T. Kubo , D. Harada , T. Kozuki , N. Nogami , I. Oze , S. 1 4 5 6 7 8 8 1 Hosokawa , A. Bessho , H. Yoshioka , K. Kudo , S. Kuyama , S. Harita , I. Takata , N. Fujimoto , T. 2 9 1 1 1 2 3 4 Moritaka , H. Ichikawa , N. Takigawa , K. Kiura ; Okayama, JP, Matsuyama, JP, Nagoya, JP, 5 6 7 8 9 Okayama, Okayama Prefecture/JP, Kurashiki, JP, Tokyo, JP, Iwakuni, JP, Fukuyama, JP, Takamatsu, JP
13:35 - 13:35 1369P - nab-paclitaxel/carboplatin (nab-P/C) induction therapy in squamous (SCC) non-small cell lung cancer (NSCLC): Interim safety results from ABOUND.sqm
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 3 4 5 6 7 8 C. Gridelli , M. McCleod , D. Morgensztern , D. Daniel , R. Page , T. Wehler , O. Juan , B. Levy , A. 9 10 10 10 11 1 2 3 Ardizzoni , T. Berry , T. Chen , N. Trunova , R. Jotte ; Avellino, IT, Cape Coral, US, St Louis,
4 5 6 7 8 9 10 US, Chattanooga, US, Fort Worth, US, Mainz, DE, Valencia, ES, New York, US, Valencia, IT, 11 Summit, US, Denver, US
13:35 - 13:35 1370P - Comparison of platinum agents cisplatin and carboplatin in routine treatment of advanced NSCLC: Results from prospective German TLK cohort study 1 2 3 4 5 1 1 N. Marschner , U. von Verschuer , R. Schnell , M.-O. Zahn , J. Eggert , A. Binninger , L. Spring , M.
1 1 2 3 4 5 Jänicke ; Freiburg, DE, Essen, DE, Frechen, DE, Goslar, DE, Moers, DE
13:35 - 13:35 1371P - Diagnostic and therapeutic strategies for elderly patients with advanced non-small cell lung cancer (NSCLC): Results from an EORTC pan-European survey 1 2 3 4 4 4 5 M. Giaj Levra , J. Menis , A. Luciani , E. De Maio , B. Hasan , T. Berghmans , M.A. Massiani , M. De 6 7 4 8 9 10 1 Waele , A.-M. Dingemans , J. Donckele , C. Faivre-Finn , N. Girard , L. Greillier , S. Lantuéjoul , M. 11 12 4 13 2 14 1 2 O'Brien , M. Reck , K. Tryfonidis , H. Wildiers , B. Besse , S. Novello ; La Tronche, FR, 3 4 5 6 7 8 9 Villejuif, FR, Milano, IT, Brussels, BE, Paris, FR, Edegem, BE, Maastricht, NL, Manchester, GB, 10 11 12 13 14 Bron, FR, Marseille, FR, London, GB, Grosshansdorf, DE, Leuven, BE, Orbassano, IT
13:35 - 13:35 1372P - Diversity of brain metastasis (BM) management in non-small cell lung cancer (NSCLC) in Europe (EU): Results of the Young Investigators European Organisation for Research and Treatment of Cancer Lung Cancer Group (YI EORTC LCG) survey 1 2 3 3 4 1 5 L. Hendriks , C. Faivre-Finn , B. Hasan , E. de Maio , A. Berghoff , A.-M. Dingemans , S. Novello , T. 3 6 6 1 2 3 4 5 Berghmans , B. Besse , A. Levy ; Maastricht, NL, Manchester, GB, Brussels, BE, Vienna, AT, 6 Torino, IT, Villejuif, FR
13:35 - 13:35 1373P - Clinical features of never smoker patients with lung squamous cell carcinoma: A retrospective multicenter study 1 2 3 1 2 1 1 2 S. Frega , M. Macerelli , A. Del Conte , L. Bonanno , M. Bartoletti , V. Polo , G. Zago , A. Follador , I. 1 1 1 4 2 1 1 1 2 3 Attili , A. Pavan , L. Urso , S. Basso , G. Fasola , P.F. Conte , G. Pasello ; Padova, IT, Udine, IT, 4 Aviano, IT, Pordenone, IT
13:35 - 13:35 1374P - Characteristics and prognostic impact of advanced non-small-cell lung cancer patients who were ineligible for clinical trials 1 1 2 1 1 1 1 1 H. Kawachi , D. Fujimoto , T. Morimoto , M. Ito , S. Teraoka , Y. Sato , K. Nagata , A. Nakagawa , K.
1 1 1 1 2 Otsuka , Y. Imai , K. Tomii ; Kobe, JP, Nishinomiya, JP
13:35 - 13:35 1375P - Treatment paradigm shift in NSCLC: Patient data analysis from 2005 to 2016 1 2 2 3 3 1 2 3 L. Mitrofan , M. Sahni , D. Dhingra , H. Mistry , C. Anger ; Paris, FR, Gurgaon, IN, London, GB
13:35 - 13:35 1376TiP - Phase III study of atezolizumab (atezo) vs chemotherapy (chemo) in patients (pts) with treatment-naive advanced, recurrent or metastatic NSCLC unsuitable for platinum (plat)-based chemo 1 2 3 3 4 1 2 3 S.M. Lee , C. Schulz , A. Cardona , P. Bartakova , S. Peters ; London, GB, Regensburg, DE,
4 Basel, CH, Lausanne, CH
Last update: 02-09-2017 06:01:33pm esmo.org 13:35 - 13:35 1377TiP - JAVELIN Lung 100: updated design of a phase 3 trial of avelumab vs platinum doublet chemotherapy as first-line (1L) treatment for metastatic or recurrent PD-L1+ non-small-cell lung cancer (NSCLC) 1 2 3 4 5 6 7 8 M. Reck , C.-H. Yang , P. Postmus , F. Barlesi , E. Font , M. Thomas , T. Kim , M. Cobo Dols , H. 9 7 8 10 11 12 13 Skuladottir , K. Park , R. Sullivan , A. Veatch , N. Pavlakis , L. Dreosti , M. Özgüroğlu , F. 14 15 16 17 18 1 2 Morgillo , M. Schlichting , F. Teofilovici , V. Chand , V. Westeel ; Grosshansdorf, DE, Taipei
3 4 5 6 7 8 9 City, TW, Liverpool, GB, Marseille, FR, Barcelona, ES, Heidelberg, DE, Seoul, KR, Málaga, ES, 10 11 12 13 14 15 Herning, DK, Puyallup, WA/US, Sydney, AU, Pretoria, ZA, Istanbul, TR, Naples, IT, 16 17 18 Darmstadt, DE, Billerica, US, Billerica, MA/US, Besançon Cedex, FR
13:35 - 13:35 1378TiP - A phase 3 study of first-line durvalumab vs platinum-based chemotherapy in patients with advanced NSCLC and high PD-L1 expression: PEARL 1 2 3 4 5 5 2 6 1 Y.-L. Wu , S. Lu , S. Clarke , K. Lactionov , P. Li , M. Kirkby , Y. Xie , P. Stockman ; Guangzhou, 2 3 4 5 6 Guangdong/CN, Shanghai, CN, St Leonards, NSW/AU, Moscow, RU, Beijing, CN, Alderley Park, GB
13:35 - 13:35 1379TiP - Phase I/II study of S 49076, a MET/AXL/FGFR inhibitor, in combination with gefitinib in EGFR-mutated NSCLC patients who progress on EGFR tyrosine kinase inhibitor 1 2 3 4 5 6 7 8 K. Park , F. Ciardiello , T. Hida , W. Lim , C.-C. Lin , H. Murakami , M. Nishio , F. Cantero , V. Cattan 8 8 8 9 1 2 3 4 , C. Gabarroca , E. Gandossi , L. Paz-Ares ; Seoul, KR, Naples, IT, Nagoya, Aichi/JP, Singapore, 5 6 7 8 9 SG, Taipei, TW, Shizuoka, Shizuoka/JP, Tokyo, JP, Suresnes, FR, Madrid, ES
13:35 - 13:35 1380TiP - A randomized, open-label comparison of lorlatinib versus crizotinib as first-line treatment for advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer 1 2 3 4 5 6 7 8 1 A. Shaw , T. Bauer , T. Takahashi , C. Baik , A. Polli , M. Carpentieri , J.-F. Martini , B. Solomon ; 2 3 4 5 6 7 Boston, MA/US, Nashville, TN/US, Shizuoka, JP, Seattle, US, Milan, IT, Milan, Italia/IT, San 8 Diego, CA/US, Melbourne, VIC/AU
13:35 - 13:35 1381TiP - A randomized double-blind phase II trial evaluating maintenance PARP inhibitor Olaparib versus placebo in patients with platinum-sensitive advanced non-small cell lung cancer: PIPSeN trial 1 1 2 1 3 4 S. Postel-Vinay , D. Planchard , A. Ortega Granados , A. Gazzah , M.A. Sala Gonzalez , M. Majem , 5 1 6 7 8 9 C.J. Camps , A. Abou-Lauvergne , J.-P. Pignon , J. Cadranel , J. Bennouna , F. Barlesi , M.R. Garcia 10 4 1 11 12 1 13 1 Campelo , S. Viteri , B. Besse , J. Coves Sarto , B. Massuti Sureda , J.-C. Soria , R. Rosell ;
2 3 4 5 6 7 8 Villejuif, FR, Jaén, ES, Bilbao, ES, Barcelona, ES, Valencia, ES, Villejuif, CEDEX/FR, Paris, FR, 9 10 11 12 Nantes, CEDEX/FR, Marseille, FR, A Coruña, ES, Palma De Mallorca, Islas Baleares/ES, 13 Alicante, ES, Badalona, Barcelona/ES
13:35 - 13:35 1382TiP - Investigation of biomarkers in patients with adenocarcinoma of the lung receiving nintedanib according to approved label: Non-interventional LUME-BioNIS study 1 2 3 4 5 5 5 M. Reck , A. Staal-van den Brekel , A. Mellemgaard , N. Morsli , K. Pietzko , T. Kitzing , J. Braunger ,
6 1 2 3 4 5 6 K. Kerr ; Grosshansdorf, DE, Almelo, NL, Herlev, DK, Paris, FR, Biberach, DE, Aberdeen, GB
13:35 - 13:35 1383TiP - Blood first line ready screening trial (B-F1RST) and blood first assay screening trial (BFAST) enable clinical development of novel blood-based biomarker assays for tumor mutational burden (TMB) and somatic mutations in 1L advanced or metastatic NSCLC
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 3 4 5 5 5 5 6 T.S.K. Mok , S. Gadgeel , E. Kim , V. Velcheti , S. Hu , T. Riehl , E. Schleifman , S. Paul , S. Mocci , 5 5 5 5 5 7 8 1 D. Shames , S. Phan , C. Yun , M. Mathisen , M. Kowanetz , U. Sweere , M. Socinski ; Shatin, HK,
2 3 4 5 6 Ann Arbor, MI/US, Charlotte, US, Cleveland, OH/US, South San Francisco, US, South San 7 8 Francisco, CA/US, Basel, CH, Orlando, FL/US
13:35 - 13:35 1384TiP - Prospective comparison of liquid biopsy to standard of care tissue testing in metastatic, non-squamous, non-small cell lung cancer (NSCLC) patients (pts) 1 2 2 2 3 4 2 R. Palmero , Á. Taus , M. Majem Tarruella , S. Viteri , E. Carcereny Costa , J. Garde , J. Garde , E. 2 5 5 2 3 1 2 3 Felip Font , C. Cassidy , D. Dix , N. Karachaliou , R. Rosell ; L'hospitalet, ES, Barcelona, ES, 4 5 Badalona, Barcelona/ES, Valencia, ES, Redwood City, CA/US
13:35 - 13:35 1385TiP - Clinical Research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients (CRISP): a prospective German Registry in stage IV NSCLC AIO-TRK-0315) 1 2 3 3 3 3 3 F. Griesinger , W. Eberhardt , N. Marschner , M. Jänicke , A. Fleitz , L. Spring , J. Sahlmann , A. 4 4 5 6 7 1 2 3 Karatas , A. Hipper , W. Weichert , M. Sebastian , M. Thomas ; Oidenburg, DE, Essen, DE, 4 5 6 7 Freiburg, DE, Berlin, DE, Munich, DE, Frankfurt Am Main, DE, Heidelberg, DE
13:35 - 13:35 SCLC P. Garrido Lopez, Madrid, ES
13:35 - 13:35 1532P - The role of thoracic radiotherapy on peripheral lymphocyte subsets in patients with limited-stage small cell lung cancer Y. Chen, Y. Jin, M. Chen; Hangzhou, CN
13:35 - 13:35 1534P - Antidepressants simulate enriched environment enhance platinum chemosensitivity of small cell lung cancer Y. Wu, Q. Wang, H. Tang; Zhengzhou, CN
13:35 - 13:35 1535TiP - KEYNOTE-604: Phase 3 trial of pembrolizumab plus etoposide/platinum (EP) for first-line treatment of extensive stage small-cell lung cancer (ES-SCLC) 1 2 3 1 2 3 C. Rudin , L. Shen , M.C. Pietanza ; New York, NY/US, Kenilworth, NJ/US, Rahway, NJ/US
13:35 - 13:35 1536TiP - An open-label study on safety and tolerability of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer 1 2 3 4 4 4 5 4 I. Okamoto , H. Udagawa , S. Kanda , T.H. Han , I. Lakatos , F. Zhang , S. Okubo , C. Scripture , M. 5 6 3 1 2 3 4 Takeda , H. Akamatsu , T. Tamura ; Fukuoka, JP, Chiba, JP, Tokyo, JP, South San Francisco, 5 6 US, Osaka, JP, Wakayama, JP
13:35 - 13:35 1537TiP - A phase 3 trial of rovalpituzumab tesirine vs topotecan in patients with advanced small cell lung cancer following frontline platinum-based chemotherapy 1 2 2 2 2 2 2 P. Komarnitsky , H.-J. Lee , M. Shah , S. Wong , S. Gulbranson , J. Dziubinski , L. Caffrey , P. 2 2 3 1 2 3 Tanwani , M. Motwani , F. Zhang ; Cambridge, MA/US, North Chicago, US, South San Francisco, US
13:35 - 13:35 1538TiP - A phase 1/2 study on safety of rovalpituzumab tesirine in combination with nivolumab or nivolumab + ipilimumab in small cell lung cancer
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 1 1 1 1 3 1 1 C. Scripture , G. Selvaggi , I. Lakatos , K. Boynton , S. Lally , T.H. Han , S. Peng , S.J. Dylla ;
2 3 South San Francisco, US, Lawrenceville, NJ/US, New York, CA/US
13:35 - 13:35 THORACIC MALIGNANCIES, OTHER P. Garrido Lopez, Madrid, ES
13:35 - 13:35 1620P - Outcomes of malignant pleural mesothelioma (MPM) patients (p) treated with immune-oncology drugs (IO) in clinical trials S. Cedres, A. Martinez Marti, A. Navarro, N. Pardo, J. Remon, I. Matos, M. Ochoa de Olza, C. Hierro, J. Martin Liberal, J.M. Miquel, C. VIAPLANA, G. Villacampa Javierre, R. Dienstmann, E. Felip Font; Barcelona, ES
13:35 - 13:35 1621P - Baseline hyperglycemia was predictive of poor outcome in pleural malignant mesothelioma 1 2 1 3 1 1 1 J.C. Ruffinelli , J.C. Pardo , S. Recalde , J.C. Benítez , L. Cancel , R. Palmero , R. Llatjós , M.R. 2 1 1 2 2 1 4 1 2 Escoda , S. Padrones , I. Brao , E. Dalmau , Y. Garcia , F. Cardenal , E. Nadal ; L'hospitalet, ES, 3 4 Sabadell, ES, Terrassa, ES, Barcelona, Barcelona/ES
13:35 - 13:35 1622P - Evaluation of quality of life in survivors with malignant pleural mesothelioma in Japan 1 2 2 3 3 3 3 3 I. Oze , Y. Nagamatsu , K. Aoe , K. Hotta , K. Kato , J. Nakagawa , K. Hara , T. Kishimoto , N.
3 1 2 3 Fujimoto ; Nagoya, JP, Ube, JP, Okayama, JP
13:35 - 13:35 1623P - Staging and assessment of the response to PET-CT treatment in non-small cell lung carcinoma 1 1 1 1 1 1 1 M. Mendez Garcia , M. Brenes , R. Gómez , M. Soriano , M. Torrente , C. Maximiano , G. Díaz , B.
1 1 2 1 2 Rodríguez , M.D.M. Córdoba , M. Provencio Pulla ; Madrid, ES, Majadahonda, Madrid/ES
13:35 - 13:35 1624P - “Liquid Withdarw” technique prominently reduced the incidence of pneumothorax and improved tumor tissue amount of CT-guided cutting needle lung biopsy: A retrospective study R. Li, W. Ren, J. Gao, Y. Zhang, P. Jiang, X. Zhou, H. Zhang, X. Shen, J. Liu, S. Gao, L. Wang, B. Liu;
Nanjing, CN
13:35 - 13:35 1625P - Phase II trial of S-1 treatment as palliative-intent chemotherapy for previously treated advanced thymic carcinoma Y. Okuma, Y. Goto, F. Ohyanagi, K. Sunami, Y. Nakahara, S. Kitazono, Y. Tambo, N. Yanagitani, S. Kanda, H. Horinouchi, A. Horiike, Y. Fujiwara, H. Nokihara, N. Yamamoto, M. Nishio, Y. Ohe, Y. Hosomi; Tokyo, JP
13:35 - 13:35 1626P - Detects esophageal squamous cell carcinoma via liquid biopsy of circulating exosomes 1 2 2 2 2 3 1 2 3 Z. An , A. Chen , J. Zhang , W. Guo , Z. Ling , W. Mao ; Hangzhou, CN, Hangzhou, CN, Hangzhou, Zhejiang/CN
13:35 - 13:35 1627TiP - ONCOS-102 and pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma 1 2 3 4 4 5 5 S. Ponce Aix , S. Viteri , J. Bosch-Borrera , L. Kuryk , T. Hakonen , S. Vetrhus , M. Jäderberg , L.
1 1 2 3 4 5 Paz-Ares ; Madrid, ES, Barcelona, ES, Girona, ES, Helsinki, FI, Oslo, NO
Last update: 02-09-2017 06:01:33pm esmo.org 14:45 - 16:15 Type: Educational session Barcelona Auditorium Title: Molecular targeted therapy of advanced colorectal cancer Chair(s): G. Middleton, GB; R. Glynne-Jones, GB
14:45 - 15:10 BRAF mutant patients M. Ducreux, Villejuif, FR
15:10 - 15:35 MSI G. Middleton, Birmingham, GB
15:35 - 16:00 Rare mutations L. Trusolino, Turin, IT
16:00 - 16:15 Discussion
Last update: 02-09-2017 06:01:33pm esmo.org 14:45 - 16:15 Type: Proffered Paper session Madrid Auditorium Title: Melanoma and other skin tumours Chair(s): R. Dummer, CH; O. Michielin, CH
14:45 - 15:00 1213O - Characterization of complete responses (CRs) in patients with advanced melanoma (MEL) who received the combination of nivolumab (NIVO) and ipilimumab (IPI), NIVO or IPI alone 1 2 3 4 5 6 7 8 C. Robert , J. Larkin , P. Ascierto , G. Long , J. Hassel , D. Schadendorf , F.S. Hodi , C. Lebbé , J.-J. 9 10 11 12 13 14 15 Grob , K. Grossmann , J. Wagstaff , J. Chesney , D. Hogg , O. Bechter , I. Márquez-Rodas , 16 17 17 16 16 1 2 3 A. Pavlick , D. Walker , R. Bhore , M. Postow , J. Wolchok ; Villejuif, FR, London, GB,
4 5 6 7 8 9 10 Napoli, IT, Sydney, AU, Heidelberg, DE, Essen, DE, Boston, US, Paris, FR, Marseille, FR, Salt 11 12 13 14 15 16 Lake City, US, Swansea, GB, Louisville, US, Toronto, CA, Leuven, BE, Madrid, ES, New 17 York, US, Princeton, US
15:00 - 15:15 1214O - Epacadostat plus pembrolizumab in patients with advanced melanoma: Phase 1 and 2 efficacy and safety results from ECHO-202/KEYNOTE-037 1 2 3 4 5 6 1 O. Hamid , T. Gajewski , A. Frankel , T. Bauer , A. Olszanski , J. Luke , A. Balmanoukian , E. 7 8 8 8 5 1 2 3 Schmidt , B. Sharkey , J. Maleski , M. Jones , T. Gangadhar ; Los Angeles, CA/US, Chicago, US, 4 5 6 7 8 Dallas, TX/US, Nashville, TN/US, Philadelphia, PA/US, Chicago, IL/US, Kenilworth, NJ/US, Wilmington, DE/US
15:15 - 15:30 Invited Discussant 1213O and 1314O O. Michielin, Lausanne, CH
15:30 - 15:45 1215O - Results of COLUMBUS Part 2: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus ENCO in BRAF-mutant melanoma 1 2 3 4 5 6 7 R. Dummer , P. Ascierto , H. Gogas , A. Arance , M. Mandala , G. Liszkay , C. Garbe , D. 8 9 10 11 12 13 Schadendorf , I. Krajsová , R. Gutzmer , V. Chiarion Sileni , C. Dutriaux , J.W. de Groot , N. 14 15 16 17 17 18 19 1 Yamazaki , C. Loquai , L. de Parseval , M. Pickard , V. Sandor , C. Robert , K. Flaherty ;
2 3 4 5 6 7 Zürich, CH, Napoli, IT, Athens, Attiki/GR, Barcelona, ES, Bergamo, IT, Budapest, HU, Tuebingen, 8 9 10 11 12 13 14 DE, Heidelberg, DE, Prague, CZ, Hannover, DE, Padua, IT, Bordeaux, FR, Zwolle, NL, 15 16 17 18 19 Tokyo, JP, Mainz, DE, Basel, CH, Boulder, CO/US, Villejuif, FR, Boston, MA/US
15:45 - 16:00 1216O - KEYNOTE-022 update: phase 1 study of first-line pembrolizumab (pembro) plus dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma 1 2 3 4 5 6 7 6 A. Ribas , F.S. Hodi , D. Lawrence , V. Atkinson , S. Agarwal , M. Carlino , R. Fisher , G. Long , W. 8 9 10 11 1 1 2 Miller , Y. Huang , B. Homet Moreno , N. Ibrahim , O. Hamid ; Los Angeles, CA/US, Boston, US,
3 4 5 6 7 8 9 Boston, MA/US, Brisbane, AU, Goshen, IN/US, Sydney, AU, Auckland, NZ, Montreal, CA, East 10 11 Hanover, NJ/US, Kenilworth, NJ/US, Kenilworth, US
16:00 - 16:15 Invited Discussant 1215O and 1216O P. Lorigan, Manchester, GB
Last update: 02-09-2017 06:01:33pm esmo.org 14:45 - 16:15 Type: Educational session Sevilla Auditorium Title: How to manage ovarian cancer in 2017 Chair(s): S. Pignata, IT; I. Vergote, BE
14:45 - 15:05 Biological implications for clinical practice S. Pignata, Napoli, IT
15:05 - 15:25 Front line surgery: Criteria for selection P. Harter, Essen, DE
15:25 - 15:45 Medical management of recurrent disease A. Gonzalez Martin, Madrid, ES
15:45 - 16:05 Is there a role for surgical management of recurrent disease? I. Vergote, Leuven, BE
16:05 - 16:15 Discussion
14:45 - 16:15 Type: Poster Discussion session Pamplona Auditorium Title: Breast cancer, early stage Chair(s): I. Tannock, CA; R. Salgado, BE; L. Gianni, IT; J. Bliss, GB; A. Tutt, GB
14:45 - 14:45 151PD - Efficacy and safety of biosimilar ABP 980 compared with trastuzumab in HER2 positive early breast cancer 1 2 3 4 4 1 2 G. von Minckwitz , O. Ponomarova , S. Morales , N. Zhang , V. Hanes ; Neu-Isenburg, DE, Kiev,
3 4 UA, Lleida, ES, Thousand Oaks, US
14:45 - 14:45 152PD - Double-blind, randomized phase III study to compare the efficacy and safety of trastuzumab and its biosimilar candidate CT-P6 in HER2 positive early breast cancer (EBC) 1 2 2 3 3 4 2 F. Esteva , Y. Baranau , V. Baryash , A. Manikhas , V. Moiseyenko , G. Dzagnidze , E. Zhavrid , D. 5 6 7 8 9 4 8 10 Boliukh , D. Stroyakovskiy , J. Pikiel , A. Eniu , D. Komov , Z. Zautashvili , G. Morar-Bolba , R. Li , I. 11 12 13 13 14 1 2 3 Lifirenko , A. Rusyn , S.J. Lee , S. Yu , J. Stebbing ; Houston, TX/US, Minsk, BY, Saint
4 5 6 7 8 Petersburg, RU, Tbilisi, GE, Vinnytsya, UA, Moscow, Krasnogorski District/RU, Gdańsk, PL, 9 10 11 12 13 Cluj-Napoca, RO, Moscow, RU, Quezon City, PH, Kursk, RU, Uzhorod, Zakarpattia/UA, 14 Incheon, KR, London, GB
14:45 - 14:45 153PD - One-year safety, immunogenicity, and survival results from a phase III study comparing SB3 (a proposed trastuzumab biosimilar) and originator trastuzumab in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment 1 2 3 4 5 6 7 6 X. Pivot , I. Bondarenko , Z. Nowecki , M. Dvorkin , E. Trishkina , J.H. Ahn , Y. Vinnyk , S.-A. Im , T. 8 9 10 5 11 12 Sarosiek , S. Chatterjee , M. Wojtukiewicz , V. Moiseyenko , Y. Shparyk , M. Bello III , V. 5 13 13 1 2 3 4 Semiglazov , L. Younju , J. Lim ; Besançon, CEDEX/FR, Dnepropetrovsk, UA, Warsaw, PL, 5 6 7 8 9 Omsk, RU, Saint Petersburg, RU, Seoul, KR, Kharkiv, UA, Warszawa, PL, Kolkata, West 10 11 12 13 Bengal/IN, Bialystok, Podlaskie/PL, Lviv, UA, Quezon City, PH, Suwon, KR
Last update: 02-09-2017 06:01:33pm esmo.org
14:45 - 14:45 154PD - A randomized, double-blind study of PF-05280014 (a potential biosimilar) vs trastuzumab, both given with docetaxel (D) and carboplatin (C), as neoadjuvant treatment for operable human epidermal growth factor receptor 2-positive (HER2+) breast cancer 1 2 3 4 5 6 6 1 2 P. Lammers , M. Dank , R. Masetti , R. Abbas , F. Hilton , J. Coiro , I. Jacobs ; Nashville, TN/US,
3 4 5 6 Budapest, HU/HU, Rome, IT, Collegeville, PA/US, Groton, CT/US, New York, NY/US
14:45 - 15:00 Invited Discussant 151PD, 152PD, 153PD and 154PD I. Tannock, Toronto, Ontario/CA
15:00 - 15:05 Q&A led by Discussant
15:05 - 15:05 155PD - Tumor-infiltrating lymphocytes (TILs) in HER2-positive (HER2+) early breast cancer treated with neoadjuvant lapatinib and trastuzumab without chemotherapy in the PAMELA Trial 1 1 2 1 1 3 1 3 P. Nuciforo , A. Prat , A. Llombart , R. Fasani , L. Paré , T. Pascual , M. Oliveira , N. Martínez Jañez 4 1 1 5 1 6 3 , B. Bermejo De Las Heras , M. Vidal , S. Pernas Simon , R. López , M. Muñoz , I. Garau , L. Manso , 6 7 1 3 J. Alarcon Company , E. Martinez de Dueñas , P. Villagrasa Gonzalez , J. Cortes Castan , E. Holgado 3 1 2 3 4 5 6 ; Barcelona, ES, Lerida, ES, Madrid, ES, Valencia, Valencia/ES, Santiago De Compostela, ES, 7 Palma De Mallorca, ES, Castellon, ES
15:05 - 15:05 156PD - Targeted NGS profiling identifies genomic alterations associated with high-risk eBC T. Wilson, A. Udyavar, C.-W. Chang, J. Giltnane, J. Spoerke, J. Aimi, H. Savage, A. Daemen, R.
Bourgon, M. Lackner; South San Francisco, CA/US
15:05 - 15:05 157PD - 10 years follow up of the RASTER study; implementing a genomic signature in daily practice 1 1 2 1 1 1 S. Vliek , V. Retel , C. Drukker , E. Rutgers , H. van Tinteren , M.J. van de Vijver , J.M.
1 1 1 1 1 2 Bueno-De-Mesquita , J. Wesseling , W. van Harten , S. Linn ; Amsterdam, NL, Dordrecht, NL
15:05 - 15:05 LBA11 - Prognostic impact of Recurrence Score (RS), grade/Ki67 central pathological review, and anthracycline (A)-free vs. A-containing chemotherapy (CT) on distant and locoregional disease-free survival (DDFS/LRFS) in high clinical risk HER2- early breast cancer (EBC): WSG PlanB trial results 1 1 2 3 4 5 6 7 O. Gluz , U. Nitz , M. Christgen , W. Malter , M. Clemens , T. Reimer , B. Nuding , B. Aktas , A. 8 9 10 11 12 7 13 Stefek , A. Ppllmanns , F. Lorenz-Salehi , C. Uleer , P. Krabisch , S. Kümmel , C. Liedtke , S. 14 1 15 2 15 1 2 Shak , R. Kates , R. Wurstlein , H.H. Kreipe , N. Harbeck ; Mönchengladbach, DE, Hannover,
3 4 5 6 7 8 9 DE, Cologne, DE, Trier, DE, Rostock, DE, Bergisch Gladbach, DE, Essen, DE, Stenadal, DE, 10 11 12 13 14 Oberhausen, DE, Wiesbaden, DE, Hildesheim, DE, Chemnitz, DE, Lübeck, DE, Redwood 15 City, CA/US, Munich, DE
15:05 - 15:20 Invited Discussant 155PD, 156PD, 157PD and LBA11 R. Salgado, Brussels, BE
15:20 - 15:25 Q&A led by Discussant
Last update: 02-09-2017 06:01:33pm esmo.org 15:25 - 15:25 158PD - Adjuvant anti-HER2 therapy, treatment-induced amenorrhea (TIA) and survival in premenopausal patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Analysis from the ALTTO trial (BIG 2-06) 1 2 3 4 5 1 6 M. Lambertini , C. Campbell , J. Bines , L. Korde , M.A. Izquierdo Delso , D. Fumagalli , K. Pritchard , 7 8 9 10 11 12 13 14 A. Wolff , C. Jackisch , I. Lang , M. Untch , I. Smith , F. Boyle , B. Xu , C. Barrios , J. Baselga 15 16 1 17 1 1 2 3 , A. Moreno-Aspitia , M. Piccart , R. Gelber , E. De Azambuja ; Brussels, BE, Kingussie, GB,
4 5 6 7 8 Rio De Janeiro, BR, Bethesda, US, Basel, CH, Toronto, Ontario/CA, Baltimore, MD/US, Offenbach, 9 10 11 12 13 14 15 DE, Budapest, HU, Berlin, DE, London, GB, Sydney, AU, Beijing, CN, Porto Alegre, BR, 16 17 New York, NY/US, Jacksonville, US, Boston, MA/US
15:25 - 15:25 159PD - Neoadjuvant therapy with trastuzumab emtansine and pertuzumab in patients with HER2-positive primary breast cancer (A randomized, phase 2 study; JBCRG-20) 1 2 3 4 5 6 7 3 N. Masuda , S. Ohtani , T. Takano , K. Inoue , E. Suzuki , R. Nakamura , H. Bando , Y. Ito , K. Ishida 8 9 3 1 5 3 5 5 , T. Yamanaka , K. Kuroi , H. Yasojima , H. Kasai , T. Takasuka , T. Sakurai , T. Kataoka , S. Morita
5 3 5 1 2 3 4 5 , S. Ohno , M. Toi ; Osaka, JP, Hiroshima, Hiroshima/JP, Tokyo, JP, Kita-Adachi Ina, JP, Kyoto, 6 7 8 9 JP, Chiba, JP, Tsukuba, Ibaraki/JP, Morioka, JP, Yokohama, JP
15:25 - 15:40 Invited Discussant 158PD and 159PD L. Gianni, Milan, IT
15:40 - 15:45 Q&A led by Discussant
15:45 - 15:45 160PD - Statistical model to predict brain metastasis risk in patients with early-stage breast cancer 1 2 2 1 2 B. Abderrahman , N. Ibrahim , K. Hess ; Houston, US, Houston, TX/US
15:45 - 15:45 161PD - Surrogate endpoints for overall survival in randomized controlled trials evaluating adjuvant treatment for breast cancer: A meta-analysis 1 2 1 3 1 3 1 M. Savina , W. Jacot , S. Mathoulin-Pélissier , Y. Laghzali , C. Bellera , S. Gourgou ; Bordeaux, FR,
2 3 Montpellier, CEDEX 5/FR, Montpellier, FR
15:45 - 15:55 Invited Discussant 160PD and 161PD J. Bliss, Sutton, GB
15:55 - 16:00 Q&A led by Discussant
16:00 - 16:00 162PD - Pathological response in a triple-negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to Lehmann’s refined classification (TNBCtype-4) 1 1 1 1 2 1 I. Echavarria Diaz-Guardamino , A. Picornell , S. López-Tarruella , Y. Jerez , K. Hoadley , E. Alvarez , 1 1 1 1 1 1 M. del Monte-Millán , J. Gayarre , R. Ramos-Medina , T. Massarrah , I. Ocaña , M. Cebollero , F. 1 1 3 3 1 Moreno Antón , J.A. García-Saenz , H. Gomez Moreno , H. Fuentes , A.I. Ballesteros Garcia , U. Bohn 4 2 1 1 2 3 4 Sarmiento , C. Perou , M. Martin Jimenez ; Madrid, ES, Chapel Hill, NC/US, Lima, PE, Las Palmas, Canary Island/ES
Last update: 02-09-2017 06:01:33pm esmo.org 16:00 - 16:00 163PD - Long-term survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative (TNBC) and HER2-positive early breast cancer (GeparSixto) 1 2 3 4 5 1 1 6 M. Untch , A. Schneeweiss , C. Salat , M. Rezai , D.-M. Zahm , P. Klare , J.-U. Blohmer , H. Tesch , 7 8 9 10 10 10 1 F. Khandan , P.A. Fasching , C. Jackisch , V. Nekljudova , G. von Minckwitz , S. Loibl ; Berlin,
2 3 4 5 6 7 DE, Heidelberg, DE, München, DE, Düsseldorf, DE, Gera, DE, Frankfurt Am Main, DE, Frankfurt, 8 9 10 DE, Erlangen, DE, Offenbach, DE, Neu-Isenburg, DE
16:00 - 16:10 Invited Discussant 162PD and 163PD A. Tutt, London, GB
16:10 - 16:15 Q&A led by Discussant
14:45 - 16:15 Type: Special Session Granada Auditorium Title: The incoming wave of biosimilars in oncology Chair(s): J. Tabernero, ES; E. Wolff-Holz, DE
14:45 - 14:55 Introduction E. Wolff-Holz, Langen, DE
14:55 - 15:05 Biosimilars: European Medicines Agency’s plan for healthcare professionals J. Garcia Burgos, London, GB
15:05 - 15:15 Clinician’s perspective: Building confidence to prescribe biosimilars R. Giuliani, Roma, IT
15:15 - 15:25 Collaborative approach key for uptake of biosimilars G. Befrits, Stockholm, SE
15:25 - 15:35 The crucial role of specialist nurses J. De Munter, Gent, BE
15:35 - 15:45 Patient’s perspective: What have we learned and what can be improved? L. Avedano, Brussels, BE
15:45 - 15:55 Oncology: Impact of biosimilars on the sustainability of healthcare systems M. Aitken, Parsippany, US
15:55 - 16:15 Discussion
Last update: 02-09-2017 06:01:33pm esmo.org 14:45 - 16:15 Type: Joint Symposium Tarragona Auditorium Title: ESMO-ESTRO: Lung cancer: Recent development of multimodal treatments Chair(s): S. Peters, CH; Y. Lievens, BE
14:45 - 14:50 Introduction S. Peters, Lausanne, CH
14:50 - 15:10 How to integrate radiotherapy innovations in the multimodality treatment of LA-NSCLC? C. Faivre-Finn, Manchester, GB
15:10 - 15:30 Standard and perspectives for systemic treatments in stage 3? P. Garrido Lopez, Madrid, ES
15:30 - 15:50 Oligometastatic NSCLC: What are the treatment paradigms and how does radiotherapy fit in? M. Guckenberger, Zürich, CH
15:50 - 16:10 Oligometastatic NSCLC: When and how to combine systemic therapy and radiotherapy? L. Coate, Dublin, IE
16:10 - 16:15 Conclusions Y. Lievens, Gent, BE
14:45 - 16:15 Type: Joint Symposium Bilbao Title: ESMO-SIOPE: Tumours at the edge of paediatric and adult oncology: Emphasising Auditorium collaboration Chair(s): G. Mountzios, GR; S. Bielack, DE
14:45 - 14:50 Introduction G. Mountzios, Athens, GR
14:50 - 15:10 Bone and soft tissue sarcomas in AYA as models of multidisciplinary management S. Bielack, Stuttgart, DE
15:10 - 15:30 Leukaemias-Lymphomas: New insights from paediatric leukaemia research and clinical trials A. von Stackelberg, Berlin, DE
15:30 - 15:50 CNS tumours in AYA: Overcoming obstacles with multidisciplinary care E. Razis, Athens, GR
15:50 - 16:10 Mapping the cancer care for AYA in Europe: Current status and needs D. Stark, Leeds, GB
16:10 - 16:15 Conclusion S. Bielack, Stuttgart, DE
Last update: 02-09-2017 06:01:33pm esmo.org 14:45 - 16:15 Type: Poster Discussion session Alicante Auditorium Title: Head and neck cancer, excluding thyroid Chair(s): A. Psyrri, GR; S. Oosting, NL; J. Bourhis, CH; J. Guigay, FR
14:45 - 14:45 1045PD - Adjuvant androgen deprivation therapy for high-risk androgen receptor-positive salivary duct carcinoma 1 2 1 1 3 1 1 W. Boxtel , L. Locati , S. Tooten , E. Bos , C. Bergamini , A.C.H. van Engen-van Grunsven , E. Boon 4 2 1 1 2 1 1 2 , E. Fiets , S. Cavalieri , G. Verhaegh , J. Schalken , L. Licitra , C. Herpen ; Nijmegen, NL, Milan, 3 4 IT, Milano, IT, Leeuwarden, NL
14:45 - 14:45 1046PD - Overexpression of the c-MET proto-oncogene in salivary duct carcinoma patients 1 1 1 2 1 1 1 C. Herpen , W. Boxtel , U. Flucke , E. Bloemena , E. Boon , G. Verhaegh , M.W. Aalders , M.A.
1 1 1 1 2 Jonker , J. Schalken , Y.M.H. Versleijen-Jonkers ; Nijmegen, NL, Amsterdam, NL
14:45 - 14:45 1047PD - Mammary analogue secretory carcinoma (MASC): clinical characteristics in 28 ETV6-NTRK3 fusion gene confirmed patients 1 2 3 2 4 5 2 E. Boon , M. Valstar , W. van der Graaf , E. Bloemena , S. Willems , C. Meeuwis , L. Smit , M. Merkx 1 1 1 1 1 2 3 4 5 , R. Takes , U. Flucke , C. Herpen ; Nijmegen, NL, Amsterdam, NL, Sutton, GB, Utrecht, NL, Rotterdam, NL
14:45 - 14:57 Invited Discussant 1045PD, 1046PD and 1047PD J. Guigay, Nice, CEDEX 2/FR
14:57 - 15:07 Q&A led by Discussant
15:07 - 15:07 LBA46 - An Open-label, Multicohort, Phase 1/2 Study in Patients With Virus-Associated Cancers (CheckMate 358): Safety and Efficacy of Neoadjuvant Nivolumab in Squamous Cell Carcinoma of the Head and Neck (SCCHN) 1 2 3 4 5 6 7 R. Ferris , A. Gonçalves , S. Baxi , U. Martens , H. Gauthier , M. Langenberg , W. Spanos , R. 8 9 10 11 12 12 13 9 1 Leidner , H. Kang , J. Russell , S. Chiosea , I. Soumaoro , S. Rao , Z.A. Cao , S. Topalian ; 2 3 4 5 6 7 US, Marseille, FR, New York, US, Heilbronn, DE, Paris, CEDEX 10/FR, Utrecht, NL, Sioux Falls, 8 9 10 11 12 13 US, Portland, US, Baltimore, MD/US, Tampa, FL/US, Pittsburgh, PA/US, Ladeuze, BE, Princeton, US
15:07 - 15:07 1048PD - RetroSpective cohort stUdy of PD-L1 expression in REcurrent and/or MEtastatic squamous cell carcinoma of the head and neck (SUPREME-HN) 1 2 1 3 4 5 6 7 S. Pai , E. Cohen , D. Lin , G. Fountzilas , E. Kim , H. Mehlhorn , N. Baste , D. Clayburgh , L. 8 9 10 11 12 13 14 15 Lipworth , C. Resteghini , N. Shara , T. Fujii , J. Zhang , M. Stokes , D. Lawrence , A. Khaliq , 16 15 1 2 3 4 5 G. Melillo , N. Shire ; Boston, US, La Jolla, IL/US, Thessaloniki, GR, Charlotte, US, Leipzig, 6 7 8 9 10 11 12 DE, Barcelona, ES, Portland, US, Nashville, US, Milan, IT, Hyattsville, US, Osaka, JP, 13 14 15 16 Houston, US, Waltham, US, Cambridge, GB, Gaithersburg, US, Gaithersburg, Maryland/US
15:07 - 15:07 1049PD - Relationship between PD-L1 expression and survival in head and neck squamous cell carcinoma (HNSCC) patients (pts)
Last update: 02-09-2017 06:01:33pm esmo.org 1 1 2 2 2 2 2 2 M. Stokes , R. Wang , S. Wildsmith , M. Secrier , H. Angell , C. Barker , J. Walker , P. Scorer , M.
3 3 1 2 3 Rebelatto , N. Shire ; Waltham, US, Cambridge, GB, Gaithersburg, US
15:07 - 15:19 Invited Discussant LBA46, 1048PD and 1049PD A. Psyrri, Athens, GR
15:19 - 15:29 Q&A led by Discussant
15:29 - 15:29 LBA47 - First line Cetuximab and Cisplatin with or without Paclitaxel in recurrent/metastatic head and neck cancer: a randomized phase IIb trial 1 1 1 1 2 3 4 5 P. Bossi , L. Hollander , R. Miceli , D. Ferrari , S. Vecchio , G. Moretti , M. Merlano , F. Caponigro , 6 7 8 9 10 11 1 1 1 C. Moro , E. Vaccher , O. Alabisio , A. Caldara , A. Russo , F. Ferrau , F. Nolè , L. Licitra ; Milan,
2 3 4 5 6 7 8 9 IT, Genova, IT, Reggio Emilia, IT, Cuneo, IT, Napoli, IT, Bergamo, IT, Aviano, IT, Novara, IT, 10 11 Trento, IT, Palermo, IT, Taormina, IT
15:29 - 15:29 1050PD - The ELAN-ONCOVAL (ELderly heAd and Neck cancer-Oncology eValuation) study: Evaluation of the feasibility of a suited geriatric assessment for use by oncologists to classify patients as fit or unfit 1 2 3 4 5 6 7 8 C. Mertens , H. Le Caer , C. Ortholan , E. Blot , C. Even , H. Rousselot , F. Peyrade , C. Sire , D. 9 10 11 12 13 14 15 Cupissol , Y. Pointreau , P. Debourdeau , F. Rolland , J. Fayette , O. Capitain , X. Sun , M. 5 5 16 5 7 1 2 3 Debbah , D. Schwob , R. Boulahssass , A. Aupérin , J. Guigay ; Bordeaux, FR, Saint Brieux, FR,
4 5 6 7 8 Monaco, MC, Vannes, FR, Villejuif, FR, Vandoeuvre-Lès-nancy, FR, Nice, CEDEX 2/FR, Lorient, 9 10 11 12 13 FR, Montpellier, CEDEX 5/FR, Le Mans, FR, Avignon, FR, Saint-Herblain, CEDEX/FR, Lyon, 14 15 16 FR, Angers, FR, Belfort, FR, Nice, FR
15:29 - 15:29 1051PD - A phase 1, multicenter, open-label, dose-escalation, combination study of RM-1929 and photoimmunotherapy in patients with recurrent head and neck cancer 1 1 2 2 3 3 1 S.T. Kochuparambil , D. McDonald , M. Fidler , K. Stenson , N. Vasan , M.A. Razaq ; Minneapolis,
2 3 US, Chicago, US, Oklahoma City, US
15:29 - 15:41 Invited Discussant LBA47, 1050PD and 1051PD S. Oosting, Groningen, NL
15:41 - 15:51 Q&A led by Discussant
15:51 - 15:51 1052PD - First-line paclitaxel plus carboplatin with/without bevacizumab in recurrent or metastatic nasopharyngeal carcinoma: A multicenter, randomized, open-label, phase II trial 1 2 2 2 2 2 2 3 4 5 L. Zhang , Y. Huang , Y. Yang , S. Ma , X. Lin , L. Lin , T. Zhou , Y. Deng , C. Zhang , X. Ding , S. 6 7 7 8 6 1 2 3 Wang , R. Wang , G. Feng , Y. Chen , R. Xu ; Guangzhou, Guangdong/CN, Guangzhou, CN, 4 5 6 7 8 Foshan, CN, Dongguan, CN, Jiangmen, CN, Shenzhen, CN, Guangxi, CN, Hainan, CN
15:51 - 15:51 1053PD - Refining staging system for nasopharyngeal carcinoma treated with intensity-modulated radiation therapy
Last update: 02-09-2017 06:01:33pm esmo.org 1 1 1 1 2 1 1 1 V. Lee , D. Kwong , T.W. Leung , C.-W. Choi , B. O'Sullivan , K.O. Lam , V. Lai , P.-L. Khong , S.-K. 1 1 1 1 1 1 1 1 1 Chan , C.-Y. Ng , C.C. Tong , P.Y.P. Ho , W.L. Chan , L.-S. Wong , D. Leung , S.-Y. Chan , A. Lee ; 1 2 Hong Kong, HK, Toronto, ON/CA
15:51 - 15:51 1054PD - A New Classification for Nasopharyngeal Carcinoma H.C. Cheng, C.-F. Horng; Taipei, TW
15:51 - 16:03 Invited Discussant 1052PD, 1053PD and 1054PD J. Bourhis, Lausanne, CH
16:03 - 16:13 Q&A led by Discussant
15:00 - 16:00 Type: Multidisciplinary Session Cordoba Auditorium Title: Vomiting: One symptom, many causes Chair(s): S. Kaasa, NO
15:00 - 15:05 Presentation of case/condition S. Kaasa, Oslo, NO
15:05 - 15:15 The general perspective S. Kaasa, Oslo, NO
15:15 - 15:25 The clinical and medical oncology perspective C. Ruhlmann, Odense, DK
15:25 - 15:35 The surgery perspective R. Audisio, Liverpool, GB
15:35 - 16:00 General Discussion
Last update: 02-09-2017 06:01:33pm esmo.org 15:00 - 16:00 Type: Multidisciplinary Session Valencia Auditorium Title: Brain progression on targeted therapies and immunotherapies Chair(s): S. Senan, NL
15:00 - 15:05 Presentation of case/condition S. Senan, Amsterdam, NL
15:05 - 15:15 The radiation therapy perspective S. Senan, Amsterdam, NL
15:15 - 15:25 The neurosurgery perspective H.-S. Gwak, Goyang-Si, KR
15:25 - 15:35 The medical oncology perspective L. Sequist, Boston, MA/US
15:35 - 16:00 General Discussion
Last update: 02-09-2017 06:01:33pm esmo.org 15:00 - 16:00 Type: Multidisciplinary Session Cartagena Auditorium Title: Management of toxicities Chair(s): S. Cousin, FR
15:00 - 15:10 Presentation of melanoma case and the clinical oncology perspective S. Cousin, Lille, FR
15:10 - 15:15 The dermatology perspective H.B. Thio, Rotterdam, NL
15:15 - 15:20 The ophthalmology perspective U. Urner Bloch, Zürich, CH
15:20 - 15:30 Discussion with audience
15:30 - 15:40 Presentation of TKI resistance case and The clinical oncology perspective S. Cousin, Lille, FR
15:40 - 15:45 The dermatology perspective H.B. Thio, Rotterdam, NL
15:45 - 15:50 The ophthalmology perspective U. Urner Bloch, Zürich, CH
15:50 - 16:00 Discussion with audience
15:00 - 16:00 Type: Young Oncologist Special session Room 55 Title: ESMO for medical students and young physicians Chair(s): A. Cervantes, ES; A. Berghoff, AT
15:00 - 15:10 ESMO-ESO Medical Students Course A. Cervantes, Valencia, Valencia/ES
15:10 - 15:20 How to prepare and present your first poster at a congress A. Berghoff, Vienna, AT
15:20 - 16:00 Guided poster walk 1 2 3 1 2 3 M. Petrova , M. Preusser , M. Strijbos ; Sofia, BG, Vienna, AT, Brasschaat, BE
Last update: 02-09-2017 06:01:33pm esmo.org 16:20 - 18:00 Type: Proffered Paper session Cordoba Auditorium Title: Supportive and palliative care Chair(s): M. Aapro, CH; S. Kaasa, NO
16:20 - 16:32 1386O - Cancer cachexia (CAX), anorexia and muscle wasting (sarcopenia) assessment in non-small cell lung cancer (NSCLC): an observational study in 531 patients 1 2 3 4 5 6 7 D. Debieuvre , H. Morel , P.-J. Souquet , V. Surmont , D. Planchard , F. Bonnetain , I. Krakowski , H. 8 5 1 2 3 4 5 Gaudin , S. Antoun ; Mulhouse, FR, Orleans, FR, Pierre Bénite, CEDEX/FR, Gent, BE, Villejuif, 6 7 8 FR, Besançon, CEDEX/FR, Vandoeuvre Les Nancy, CEDEX/FR, Paris, FR
16:32 - 16:44 1539O - Pre-chemotherapy nutritional status and chemotherapy response: An observational study R. Rao, N. Saha, V. Mani, R. Amritanshu, R. Geetha, N. Radheshyam, S. Patil, H.P. Shashidhara, T.
Satheesh, V. Agarwal, B. Ajaikumar; Bangalore, IN
16:44 - 16:59 Invited Discussant 1386O and 1539O S. Kaasa, Oslo, NO
16:59 - 17:11 1540O - Fosaprepitant reduces the impact of nausea on daily function during five weeks of chemo-radiotherapy: A sub-study of the GAND-emesis trial 1 2 3 4 5 6 C. Ruhlmann , T. Christensen , L. Hammer Dohn , M. Paludan , E. Roennengart , F. Hilpert , P. Feyer 7 8 1 9 10 1 2 3 , G. Kristensen , O. Hansen , D. Keefe , J. Herrstedt ; Odense C, DK, Hillerød, DK, Copenhagen, 4 5 6 7 8 9 10 DK, Aarhus, DK, Herlev, DK, Kiel, DE, Berlin, DE, Oslo, NO, Adelaide, AU, Odense, DK
17:11 - 17:23 1422O - CTCA toxicity scoring and EORTC quality of life questionnaire: A comparison of physicians’ and patients’ scoring of toxicity in the “Panther trial” 1 2 1 1 3 3 2 Y. Brandberg , S. Loibl , T. Foukakis , H. Johansson , M. Gnant , C. Singer , G. von Minckwitz , N.-O. 4 5 6 1 3 4 7 8 Bengtsson , E. Karlsson , B. Mlineritsch , M. Hellström , G. Steger , L. Carlsson , D. Egle , R. Greil ,
1 1 2 3 4 5 6 J. Bergh ; Stockholm, SE, Neu-Isenburg, DE, Vienna, AT, Umeå, SE, Karlstad, SE, Saltzburg, 7 8 AT, Innsbruck, AT, Salzburg, AT
17:23 - 17:38 Invited Discussant 1540O and 1422O K. Jordan, Heidelberg, DE
17:38 - 17:50 1541O_PR - Reproductive potential and performance of fertility-preserving procedures in BRCA mutation-positive (BRCA+) breast cancer (BC) patients (pts) 1 1 2 1 1 1 M. Lambertini , O. Goldrat , A. Ferreira , J. Dechene , J. Desir , A. Delbaere , M.-D. t’Kint de
1 1 1 1 1 2 Roodenbeke , E. De Azambuja , M. Ignatiadis , I. Demeestere ; Brussels, BE, Lisbon, PT
17:50 - 18:00 Invited Discussant 1541O O. Pagani, Bellinzona, CH
Last update: 02-09-2017 06:01:33pm esmo.org 16:30 - 18:00 Type: Educational session Barcelona Auditorium Title: CDK4 inhibitors in metastatic breast cancer Chair(s): S. Loibl, DE; S. Loi, AU
16:30 - 16:55 Rationale to target CDK4 B. O'Leary, London, AF
16:55 - 17:20 Efficacy of CDK4 inhibitors: Data from clinical trials S. Loibl, Neu-Isenburg, DE
17:20 - 17:45 Triple combination with PI3K D. Juric, Boston, Ma, US
17:45 - 18:00 Discussion
Last update: 02-09-2017 06:01:33pm esmo.org 16:30 - 18:00 Type: Presidential Symposium Madrid Auditorium Title: Presidential Symposium I Chair(s): F. Ciardiello, IT; R. Stahel, CH
16:30 - 16:45 LBA1_PR - PACIFIC: A double-blind, placebo-controlled Phase III study of durvalumab after chemoradiation therapy (CRT) in patients with Stage III, locally advanced, unresectable NSCLC 1 2 3 4 5 6 7 8 L. Paz-Ares , A. Villegas , D. Daniel , D. Baz , S. Murakami , R. Hui , T. Yokoi , A. Chiappori , K.H. 9 10 11 12 13 14 15 Lee , M. de Wit , B.C. Cho , M. Bourhaba , X. Quantin , T. Tokito , T. Mekhail , D. Planchard 16 17 17 17 18 1 2 3 , H. Jiang , Y. Huang , P. Dennis , M. Özgüroğlu ; Madrid, ES, Jacksonville, FL/US,
4 5 6 7 8 9 Chattanooga, US, Seville, ES, Yokohama, JP, Sydney, AU, Hirakata, JP, Tampa, US, Cheongju, 10 11 12 13 14 15 16 KR, Berlin, DE, Seoul, KR, Liège, BE, Montpellier, FR, Kurume, JP, Orlando, US, 17 18 Villejuif, FR, Gaithersburg, US, Istanbul, TR
16:45 - 17:00 Invited Discussant LBA1_PR J. Vansteenkiste, Leuven, BE
17:00 - 17:15 1273O - Results of the phase III IFCT-0302 trial assessing minimal versus CT-scan-based follow-up for completely resected non-small cell lung cancer (NSCLC) 1 2 3 4 5 6 6 6 V. Westeel , F. Barlesi , P. Foucher , J.-J. Lafitte , J. Domas , P. Girard , J. Tredaniel , M. Wislez , P. 7 8 9 10 11 12 13 14 Dumont , E. Quoix , O. Raffy , D. Braun , M. Derollez , F. Goupil , J. Hermann , E. Devin , E. 15 16 6 17 1 2 3 Pichon , J.-P. Gury , F. Morin , P.-J. Souquet ; Besançon, CEDEX/FR, Marseille, FR, Dijon,
4 5 6 7 8 9 Cedex/FR, Lille, FR, Perpignan, FR, Paris, FR, Chauny, CEDEX/FR, Chambéry, CEDEX/FR, 10 11 12 13 14 15 Chartres, FR, Briey, FR, Maubeuge, FR, Le Mans, FR, Metz, FR, Evreux, FR, Tours, 16 17 CEDEX 9/FR, Vesoul, FR, Pierre Bénite, CEDEX/FR
17:15 - 17:30 Invited Discussant 1273O E. Smit, Amsterdam, NL
17:30 - 17:45 LBA2_PR - Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA 1 2 3 4 5 S. Ramalingam , T. Reungwetwattana , B. Chewaskulyong , A. Dechaphunkul , K.H. Lee , F. Imamura 6 7 8 9 10 11 12 13 , N. Nogami , Y. Ohe , Y. Cheng , B.C. Cho , E.K. Cho , J. Vansteenkiste , P.J. Voon , C. Zhou 14 15 16 17 18 1 2 3 , J. Gray , R. Hodge , Y. Rukazenkov , J.-C. Soria ; Atlanta, GA/US, Bangkok, TH, Chiang
4 5 6 7 8 9 10 Mai, TH, Hat Yai, TH, Cheongju, KR, Osaka, JP, Matsuyama, JP, Tokyo, JP, Jilin, CN, Seoul, 11 12 13 14 15 16 KR, Incheon, KR, Leuven, BE, Kuching, MY, Shanghai, CN, Tampa, FL/US, Cambridge, 17 18 GB, Macclesfield, Cheshire/GB, Villejuif, FR
17:45 - 18:00 The winner takes it all - Invited Discussion of LBA2_PR T.S.K. Mok, Shatin, HK
Last update: 02-09-2017 06:01:33pm esmo.org 16:30 - 18:00 Type: Educational session Sevilla Auditorium Title: Pancreatic cancer Chair(s): E. Van Cutsem, BE; T. Seufferlein, DE
16:30 - 16:55 New approaches in genetic classification and translational studies G. Tortora, Verona, IT
16:55 - 17:20 Neoadjuvant vs adjuvant T. Seufferlein, Ulm, DE
17:20 - 17:45 New treatment combinations in metastatic disease E. O'Reilly, New York, Ny, US
17:45 - 18:00 Discussion
Last update: 02-09-2017 06:01:33pm esmo.org 16:30 - 18:00 Type: Proffered Paper session Granada Auditorium Title: Basic science Chair(s): A. Berns, NL; C. Isacke, GB
16:30 - 16:42 1700O - Genomic profiling of 114,200 advanced cancers identifies recurrent kinase domain duplications (KDD) and oncogenic rearrangements (RE) across diverse tumor types 1 2 2 2 2 2 2 3 L. Gay , D. Pavlick , J. Chung , S. Ramkissoon , S. Daniel , J. Elvin , E. Severson , T. Bivona , K. 4 5 6 7 2 2 8 9 Reckamp , S. Klempner , S.-H. Ou , A. Schrock , V. Miller , P. Stephens , J. Ross , S. Ganesan , C. 10 11 2 1 2 3 4 Lovly , A. Mansfield , S. Ali ; Cambridge, CA, Cambridge, MA/US, San Francisco, US, Duarte, 5 6 7 8 9 CA/US, Los Angeles, US, Orange, CA/US, Cambridge, US, Albany, NY/US, New Brunswick, US, 10 11 Nashville, TN/US, Rochester, MN/US
16:42 - 16:54 1701O - Comprehensive Genomic Profiling (CGP) of Thymic Gland Carcinomas 1 2 2 3 2 2 2 J. Ross , P. Vanden Borre , N. Almog , A. Schrock , J. Chung , J.-A. Vergilio , J. Suh , S. 2 2 2 2 2 2 2 2 1 Ramkissoon , E. Severson , S. Daniel , S. Ali , V. Miller , P. Stephens , J. Elvin , L. Gay ; Albany, 2 3 NY/US, Cambridge, MA/US, Cambridge, US
16:54 - 17:06 1702O - Clinical implications of genomic variants identified in over 30,000 advanced-stage cancer patients by next-generation sequencing of circulating tumor DNA 1 2 3 3 4 4 3 3 S. Pal , C. Brooks , D. Chudova , J. Odegaard , D. Gandara , P. Mack , S. Mortimer , K. Banks , R. 2 3 3 3 3 1 2 3 Nagy , A. Baca , R. Lanman , H. Eltoukhy , A. Talasaz ; Duarte, CA/US, Redwood City, US, 4 Redwood City, CA/US, Sacramento, CA/US
17:06 - 17:21 Invited Discussant 1700O, 1701O and 1702O U. McDermott, Cambridge, GB
17:21 - 17:33 1O - Wild-type KRAS mediates growth inhibition and resistance to MEK inhibitors through dimerization with mutant KRAS in lung adenocarcinoma 1 2 3 4 2 2 2 2 4 C. Ambrogio , J. Kohler , Z. Zhou , H. Wang , R. Paranal , M. Capelletti , C. Caffarra , S. Li , Q. Lv , 5 3 6 1 2 3 4 D. Santamaria , K. Westover , P. Jänne ; Madrid, ES, Boston, MA/US, Dallas, TX/US, Shanghai, 5 6 CN, Pessac, FR, Boston, Ma, US
17:33 - 17:45 2O - CDCP1 initiates tumorigenesis and cooperates with PTEN loss to promote senescence evasion and prostate cancer progression A. Alajati, J. Chen, A. Alimonti; Bellinzona, CH
17:45 - 18:00 Invited Discussant 1O and 2O C. Isacke, London, GB
Last update: 02-09-2017 06:01:33pm esmo.org 16:30 - 18:00 Type: Special Symposium Valencia Auditorium Title: State of the science of targeted treatment in sarcoma Chair(s): G.D. Demetri, US; R. Jones, GB
16:30 - 16:35 Introduction G.D. Demetri, Boston, MA/US
16:35 - 16:55 Managing GIST resistance to standard TKI therapy H. Joensuu, Helsinki , FI
16:55 - 17:15 Inhibitors of MDM2, CDK4 and other approaches in MDM2 amplified sarcomas O. Mir, Villejuif, FR
17:15 - 17:35 Immuno-oncology approaches to sarcomas R. Maki, New York, Ny, US
17:35 - 17:55 Next generation targets and combinations in sarcomas G.D. Demetri, Boston, MA/US
17:55 - 18:00 Conclusions and clinical perspectives R. Jones, London, GB
16:30 - 17:45 Type: Poster Discussion session Tarragona Auditorium Title: Public health policy and health economics Chair(s): J. Martin-Moreno, ES; R. Giuliani, IT; F. Perrone, IT
16:30 - 16:30 1440PD - The European Cancer Patient Coalition’s white policy paper on the value of innovation in oncology 1 2 3 4 1 5 L. Makaroff , F. De Lorenzo , K. Apostolidis , J. Pelouchova , A. Winterbottom , S. Chrostowski , D. 1 6 1 1 1 1 1 Cimpoeru , N. Bolanos Fernandez , A. Rek , I. Manneh-Vangramberen , L. Baker , F. Florindi ; 2 3 4 5 6 Brussels, BE, Roma, IT, GR, Prague, 2/CZ, Warsaw, PL, Madrid, ES
16:30 - 16:30 1441PD - Magnitude of clinical benefit of randomized controlled trials supporting US Food and Drug Administration approval of drugs for solid tumours 1 2 3 4 1 C. Molto Valiente , E. Amir , A. Ocana Fernandez , A. Templeton , L. del Carpio Huerta , J. Del Paggio 5 1 6 1 1 2 3 4 , A. Barnadas , C. Booth , A. Tibau ; Barcelona, ES, Toronto, Ontario/CA, Albacete, ES, Basel, 5 6 CH, Kingston, CA, Kingston, Ontario/CA
16:30 - 16:30 1442PD - Review on adherence to breast cancer guidelines in Europe 1 1 2 3 1 1 L. Neamtiu , L. Pylkkanen , C. Freeman , Z. Saz Parkinson , S. Deandrea , A. Uluturk Tekin , N.
1 1 1 2 3 Dimitrova , D. Lerda ; Ispra, IT, Barcelona, ES, Ispra, Varese/IT
16:30 - 16:45 Invited Discussant 1440PD, 1441PD and 1442PD R. Giuliani, Roma, IT
Last update: 02-09-2017 06:01:33pm esmo.org 16:45 - 16:55 Q&A led by Discussant
16:55 - 16:55 1443PD - Analysis of compliance factors for colorectal cancer screening using a Bayesian network 1 2 3 4 5 6 7 8 F. Eisinger , J. Viguier , J.-Y. Blay , A. Cortot , C. Touboul , C. Lhomel , L. Greillier , S. Couraud , 9 1 2 3 4 5 6 J.-F. Morere ; Marseille, CEDEX 9/FR, Tours, FR, Lyon, FR, Lille, FR, Paris, FR, 7 8 9 Neuilly-Sur-seine, FR, Marseille, FR, Pierre Bénite, CEDEX/FR, Villejuif, CEDEX/FR
16:55 - 16:55 1401PD - Fluctuating cancer screening uptake in France: results of the 5th EDIFICE survey 1 2 3 4 5 6 7 8 J. Viguier , S. Couraud , L. Greillier , J.-Y. Blay , C. Touboul , C. Lhomel , A. Cortot , J.-F. Morere , 9 1 2 3 4 5 F. Eisinger ; Boulogne-Billancourt, FR, Pierre Bénite, CEDEX/FR, Marseille, FR, Lyon, FR, Paris, 6 7 8 9 FR, Neuilly-Sur-seine, FR, Lille, FR, Villejuif, CEDEX/FR, Marseille, CEDEX 9/FR
16:55 - 17:05 Invited Discussant 1443PD and 1401PD J. Martin-Moreno, Valencia, Valencia/ES
17:05 - 17:10 Q&A led by Discussant
17:10 - 17:10 1110PD_PR - Factors associated with reduced work ability in a nation-wide cohort of long-term cancer survivors treated in young adulthood (19-39 years) – the NOR-CAYACS study C. Kiserud, H. Lie, A. Finset, S. Fosså, J.H. Loge, E. Ruud, A. Dahl; Oslo, NO
17:10 - 17:10 1111PD - Economic burden of cancer patients and the job assistance from the society N. Koinuma, Sendai, JP
17:10 - 17:10 1112PD_PR - Real-World Productivity, Healthcare Resource Utilization (HRU), and Quality of Life (QOL) in Patients with Advanced Gastric Cancer (GC) in Canada and Europe 1 2 3 2 2 4 1 2 G. Maglinte , A. Rider , M. Contente , A. Boyers , B. Clarke , E. Calvo ; Princeton, US, Manchester,
3 4 GB, Ladeuze, BE, Madrid, ES
17:10 - 17:20 Invited Discussant 1110PD, 1111PD and 1112PD F. Perrone, Napoli, IT
17:20 - 17:25 Q&A led by Discussant
17:25 - 17:25 1113PD - Using the ASCO’s quality oncology practice initiative (QOPI) metrics and standards to improve value, meaningful use of resources and reduce waste C. Pinto, F. Loiola, T. Garcia, E. Romano, L. Altoe, L. Garcia, D. Oliveira, A. Rodrigo, H. Fernandes; Sao
Jose Dos Campos, BR
17:25 - 17:25 1444PD - Cancer Clinical Practice Guidelines: Evaluation of ESMO, NICE and SIGN diversity E. Pallari, A. Fox, G. Lewison; London, GB
17:25 - 17:35 Invited Discussant 1113PD and 1444PD
Last update: 02-09-2017 06:01:33pm esmo.org M. Aapro, Genolier, CH
17:35 - 17:40 Q&A led by Discussant
16:30 - 17:30 Type: Poster Discussion session Bilbao Auditorium Title: CNS tumours Chair(s): P. French, NL; J.-C. Tonn, DE
16:30 - 16:30 329PD - Prognostic factors for IDH mutant molecular astrocytomas 1 1 1 1 1 1 1 S. Minichillo , E. Franceschi , A. Mura , A. Mandrioli , A. Tosoni , G. Tallini , A. Pession , M.P. 1 1 2 3 1 1 1 1 Foschini , C. Bortolotti , D. Danieli , A. Talacchi , L. Cirillo , S. Bartolini , A. Paccapelo , A. Brandes ; 1 2 3 Bologna, IT, Vicenza, IT, Verona, IT
16:30 - 16:30 330PD - Galectin-1 (Gal-1) expression as a prognostic factor in a homogenous cohort of glioblastoma (GB) (Gliocat study) 1 1 2 1 2 1 N. VilariÑo Quintela , N. Martinez Bosch , C. Balana , F. Alameda , A. Estival , E. Pineda , S. Del 3 1 4 1 5 1 1 1 Barco , M. Gil-Gil , C. Mesia , O. Gallego , C. Carrato , T. Ribalta , N. Vidal , N. Dela Iglesia , O. Arpi
1 1 5 5 1 1 1 2 , J. Capellades , N. Garcia , J.M. Velarde , P. Navarro , M. Martinez-Garcia ; Barcelona, ES, 3 4 5 Badalona, Barcelona/ES, Girona, ES, Barcelona, Barcelona/ES, Badalona, ES
16:30 - 16:30 331PD - Impact of WHO 2016 update and molecular markers in pleomorphic xanthoastrocytoma R. Tonse, T. Gupta, E. Sridhar, J. Shastri, A. Jain, N. Bano, R. Jalali; Mumbai, IN
16:30 - 16:30 332PD - Change of PD-L1 expression status of high grade glial tumors at recurrence and its effect on survival B. Oyan, S. Eren, O. Sonmez, F. Ozkan, K. Yaltırak, U. Ture; Istanbul, TR
16:30 - 16:50 Invited Discussant 329PD, 330PD, 331PD and 332PD P. French, Rotterdam, NL
16:50 - 17:00 Q&A led by Discussant
17:00 - 17:00 333PD - Meta-analysis of the effect of rituximab in the treatment of primary central nervous system lymphoma 1 2 3 4 1 1 2 3 4 S. Yavuz , M. Yildirim , G. Yazıcı , V. Kaya , S. Paydas ; Adana, TR, Gaziantep, TR, Ankara, TR, Antalya, TR
17:00 - 17:00 334PD - Tumor Treating Fields (TTFields) – A novel cancer treatment modality: Translating preclinical evidence and engineering into a survival benefit with delayed decline in quality of life
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 3 4 5 6 7 8 R. Stupp , M. Taphoorn , L. Dirven , S. Taillibert , J. Honnorat , T. Chen , J. Sroubek , S.H. Paek , J. 9 10 11 12 13 14 15 16 Bruna Escuder , J. Easaw , C. David , C.Y. Kim , R. Desai , Y. Kew , A. Olivi , A. Hottinger , 17 17 16 18 1 2 3 4 E. Kirson , G. Lavy-Shahaf , M. Hegi , Z. Ram ; Zürich, CH, The Hague, NL, Leiden, NL,
5 6 7 8 9 10 Paris, FR, Lyon, FR, Los Angeles, CA/US, Prague, CZ, Seoul, KR, Barcelona, ES, Calgary, CA, 11 12 13 14 15 Burlington, MA/US, Bundang, KR, Scarborough, ME/US, Houston, TX/US, Baltimore, 16 17 18 MD/US, Lausanne, CH, Haifa, IL, Tel Aviv, IL
17:00 - 17:00 335PD - Early platelet variation during concomitant chemo-radiotherapy predicts adjuvant temozolomide-induced thrombocytopenia in newly-diagnosed glioblastoma 1 2 2 1 1 1 1 M. Fontanilles , F. Clatot , C. Alexandru , O. Langlois , O. Veresezan , F. Marguet , M. David , A.
1 2 2 1 1 2 Laquerriere , C. Hanzen , I. Tennevet Bouilly , F. Di Fiore ; Rouen, FR, Rouen, CEDEX 1/FR
17:00 - 17:00 336PD - Treatment of recurrent glioblastoma (GB) after radiotherapy (RT) and temozolomide (TMZ): A retrospective analysis of the GLIOCAT study 1 2 1 1 3 1 4 M. Gil-Gil , J.M. Velarde , M. Martinez-Garcia , O. Gallego , S. del Barco , E. Pineda , C. Mesia , A. 5 1 3 1 1 2 1 1 Estival , N. Vilariño , J. Marruecos , E. Verger , J. Craven , R. Fuentes , A. Lucas , M. Macià , C.
2 6 1 2 5 1 2 3 4 Carrato , N. Vidal , R. Velasco , S. Villa , C. Balana ; Barcelona, ES, Badalona, ES, Girona, ES, 5 6 Barcelona, Barcelona/ES, Badalona, Barcelona/ES, L'hospitalet, ES
17:00 - 17:20 Invited discussant 333PD, 334PD, 335PD and 336Pd J.-C. Tonn, Munich, DE
17:20 - 17:30 Q&A led by Discussant
16:30 - 18:00 Type: Poster Discussion session Alicante Auditorium Title: Developmental therapeutics Chair(s): C. Massard, FR; S. Sleijfer, NL; U. Lassen, DK
16:30 - 16:30 LBA20 - Safety and immunobiological activity of intratumoral (IT) double-stranded RNA (dsRNA) BO-112 in solid malignancies: first in human clinical trial 1 2 1 2 I. Marquez Rodas , M. Rodriguez Ruiz , S. Lopez-Tarruella Cobo , J.L. Perez Gracia , M. Ponz Sarvise 2 1 1 1 1 1 1 , R. Alvarez , E. de Miguel , Y. Jerez , A. Calvo Ferrandiz , M. Blanco Codesido , J. Gayarre , R.
1 1 2 3 3 2 Ramos Medina , A. Calles , M.A. Aznar , L. Planelles , M. Quintero , S. Martin Algarra , M. Martin 1 2 1 2 3 Jimenez , I. Melero ; Madrid, ES, Pamplona, ES, Valencia, ES
16:30 - 16:30 366PD - Oncolytic herpesvirus therapy for mesothelioma: A phase I/IIa trial of intrapleural administration of HSV1716 (NCT01721018) 1 1 2 3 1 4 4 4 S. Danson , P. Woll , J. Edwards , K. Blyth , P. Fisher , J. Roman , K. Simpson , R. Spavin , K. 4 4 1 2 3 4 Learmonth , J. Conner ; Sheffield, South Yorkshire/GB, Sheffield, GB, Glasgow, GB, Newhouse, GB
16:30 - 16:30 367PD - Early FDG-PET response correlates with dose and clinical efficacy in patients with microsatellite stable (MSS) metastatic CRC (mCRC) treated with the CEA-CD3 T-cell bispecific antibody plus atezolizumab
Last update: 02-09-2017 06:01:33pm esmo.org 1 1 1 2 1 2 1 1 F. Sandoval , D. Sabanes Bove , S. Bouseida , V. Karanikas , A. Keelara , J. Saro , T. Nayak ;
2 Basel, CH, Schlieren, CH
16:30 - 16:30 368PD - Dose escalation/expansion study to investigate the safety, pharmacokinetics, food effect, and antitumor activity of BGB-290 in patients with advanced solid tumors 1 2 1 3 2 3 4 J. Lickliter , L. Mileshkin , M. Voskoboynik , M. Millward , A. Freimund , T. Meniawy , T. Tang , R. Wei 4 5 6 1 2 3 4 5 , M. Li , V. Paton ; Melbourne, AU, Melbourne, VIC/AU, Nedlands, WA/AU, Emeryville, CA/US, 6 Beijing, CN, Emeryville, US
16:30 - 16:50 Invited Discussant LBA20, 366PD, 367PD and 368PD C. Massard, Villejuif, FR
16:50 - 17:00 Q&A led by Discussant
17:00 - 17:00 370PD - Phase I dose escalation study of M2698, a p70S6K/AKT inhibitor, in patients with advanced cancer 1 2 3 4 5 6 A. Tsimberidou , C. Verschraegen , A. Weise , J. Sarantopoulos , G. Lopes , J. Nemunaitis , A. Victor 7 7 8 9 1 2 3 4 , J. Shaw , R. Kaleta , R. Kurzrock ; Houston, TX/US, Cincinnati, US, Detroit, US, San Antonio, 5 6 7 8 9 US, Miami, FL/US, Dallas, US, Darmstadt, DE, Billerica, US, San Diego, US
17:00 - 17:00 371PD - A Phase 1 PK/PD Study of ASN003, a novel highly selective BRAF and PI3K inhibitor, in patients with advanced solid tumors 1 2 3 4 4 5 1 2 1 D. Rasco , R. Sullivan , N. Lakhani , S. Reddy , N. Rao , L. Denis , A. Tolcher , K. Flaherty ; San 2 3 4 5 Antonio, TX/US, Boston, MA/US, Grand Rapids, MI/US, Lawrenceville, NJ/US, Bridgewater, New Jersey/US
17:00 - 17:00 372PD - First-in-human (FIH) study of TAS-120, a highly selective covalent oral fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced solid tumors 1 2 2 2 2 3 2 2 Y. Kuboki , N. Matsubara , H. Bando , K. Shitara , K. Yoh , T. Kojima , I. Ohno , H. Takahashi , K. 4 1 1 1 2 1 2 3 Harano , S. Kondo , H. HIRAI , C. Morizane , T. Doi ; Tokyo, JP, Kashiwa, Chiba/JP, Kashiwa, JP, 4 Kawasaki, Kanagawa/JP
17:00 - 17:20 Invited Discussant 370PD, 371PD and 372PD S. Sleijfer, Rotterdam, NL
17:20 - 17:30 Q&A led by Discussant
17:30 - 17:30 373PD - Phase 1 Study of E7046, a PGE2 Receptor EP-4 inhibitor that targets immunosuppressive myeloid cells in the tumor microenvironment 1 2 3 3 4 5 6 5 D. Hong , A. Varga , A. Parikh , G. Shapiro , L. Reyderman , M. Ren , S. Dayal , T. Binder , C.E. Ooi 5 6 2 1 2 3 4 5 , O. Ataman , A. Marabelle ; Houston, US, Villejuif, FR, Boston, US, Woodcliff Lake, NJ/US, 6 Woodcliff Lake, US, Hatfield, GB
Last update: 02-09-2017 06:01:33pm esmo.org 17:30 - 17:30 374PD - A first in human phase 1 study of KPT-9274, a first in class dual inhibitor of PAK4 and NAMPT, in patients with advanced solid malignancies or NHL 1 2 3 4 5 6 7 8 A. Naing , S. Leong , M. Pishvaian , A. Razak , A. Mahipal , J. Berlin , D. Cho , W. Senapedis , S. 9 10 11 9 12 1 2 3 Shacham , M. Kauffman , J. Ellis , J. Meade , E. Baloglu ; Houston, TX/US, Aurora, CO/US,
4 5 6 7 8 Washington, DC/US, Toronto, CA, Tampa, FL/US, Nashville, TN/US, New York, NY/US, Natick, 9 10 11 12 MA/US, Newton, US, Natick, US, Newton, MA/US, Rotterdam, NL
17:30 - 17:30 375PD - Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine (gem) in patients (pts) with refractory solid tumors 1 2 3 4 5 6 7 A. Italiano , J. Infante , G. Shapiro , K. Moore , P. Lorusso , S. Postel-Vinay , S. Cousin , M. 8 1 9 9 9 9 9 9 Toulmonde , C. Lucchesi , E. Blackwood , S. Mahrus , X. Lu , M. Tagen , J. Schutzman , J. Lauchle ,
6 1 2 3 4 5 J.-C. Soria ; Bordeaux, FR, Nashville, TN/US, Boston, US, Oklahoma City, Oklahoma/US, New 6 7 8 9 Haven, CT/US, Villejuif, FR, Lille, FR, Bordeaux, CEDEX/FR, South San Francisco, US
17:30 - 17:50 Invited Discussant 373PD, 374PD and 375PD U. Lassen, Copenhagen, DK
17:50 - 18:00 Q&A led by Discussant
18:00 - 19:30 Type: Patient Advocacy Track Palma Title: Bio-ethical controversies and what they mean to research and European Auditorium inequalities Chair(s): A. Plate, BE; G. Henning, GB
18:00 - 18:15 The regulatory perspective K. Steig, Oslo, NO
18:15 - 18:30 The academic perspective I. De Lecuona, Barcelona, ES
18:30 - 18:45 The clinical researcher perspective B. Woermann, Berlin, DE
18:45 - 19:00 Why an oncologist should care G. Morgan, Lund, SE
19:00 - 19:15 The patient perspective L. Bayne, London, GB
19:15 - 19:30 Discussion
Last update: 02-09-2017 06:01:33pm esmo.org 18:30 - 20:00 Type: Industry Satellite Symposium Sevilla Auditorium Title: Industry Satellite Symposium 21
18:30 - 20:00 Type: Industry Satellite Symposium Pamplona Auditorium Title: Industry Satellite Symposium 22
18:30 - 20:00 Type: Industry Satellite Symposium Cordoba Auditorium Title: Industry Satellite Symposium 23
18:30 - 20:00 Type: Industry Satellite Symposium Granada Auditorium Title: Industry Satellite Symposium 24
18:30 - 20:00 Type: Industry Satellite Symposium Valencia Auditorium Title: Industry Satellite Symposium 25
18:30 - 20:00 Type: Industry Satellite Symposium Tarragona Auditorium Title: Industry Satellite Symposium 26
18:30 - 20:00 Type: Industry Satellite Symposium Bilbao Auditorium Title: Industry Satellite Symposium 27
10-09-2017
08:00 - 09:00 Type: Challenge Your Expert (CYE) session Cordoba Auditorium Title: Management of patients on immunotherapy Chair(s): I.-M. Svane, DK
08:00 - 08:10 Management of patients on immunotherapy P. Lorigan, Manchester, GB
08:10 - 09:00 Discussion led by Chair I.-M. Svane, Herlev, DK
Last update: 02-09-2017 06:01:33pm esmo.org 08:00 - 09:00 Type: Controversy session Granada Auditorium Title: Which is the best TKI upfront in ALK + NSCLC patients? Chair(s): E. Felip Font, ES
08:00 - 08:10 Introduction and 1st vote E. Felip Font, Barcelona, ES
08:10 - 08:30 New generation TKI upfront J. Wolf, Köln, DE
08:30 - 08:50 Crizotinib upfront B. Besse, Villejuif, FR
08:50 - 09:00 2nd vote and conclusions E. Felip Font, Barcelona, ES
08:00 - 09:00 Type: Challenge Your Expert (CYE) session Valencia Auditorium Title: Locoregional challenges with neoadjuvant systemic therapy Chair(s): E. Senkus-Konefka, PL
08:00 - 08:10 Locoregional challenges with neoadjuvant systemic therapy M. Gnant, Vienna, AT
08:10 - 09:00 Discussion led by Chair E. Senkus-Konefka, Gdańsk, PL
08:00 - 09:00 Type: Challenge Your Expert (CYE) session Tarragona Auditorium Title: Multidisciplinary management of localised high risk bladder cancer Chair(s): A. Bamias, GR
08:00 - 08:10 Multidisciplinary management of localised high risk bladder cancer A. Necchi, Milan, IT
08:10 - 09:00 Discussion led by Chair A. Bamias, Athens, Attiki/GR
Last update: 02-09-2017 06:01:33pm esmo.org 08:00 - 09:00 Type: Challenge Your Expert (CYE) session Bilbao Auditorium Title: GE junction tumours Chair(s): H. van Laarhoven, NL
08:00 - 08:10 GE junction tumours D. Cunningham, Sutton, GB
08:10 - 09:00 Discussion led by Chair H. Van Laarhoven, Amsterdam, NL
08:00 - 09:00 Type: Challenge Your Expert (CYE) session Cartagena Auditorium Title: How a tumour's microenvironment may affect therapeutic response Chair(s): S.A. Quezada, GB
08:00 - 08:10 How a tumour's microenvironment may affect therapeutic response J.W. Pollard, Edinburgh, GB
08:10 - 09:00 Discussion led by Chair S.A. Quezada, London, GB
08:00 - 09:00 Type: Challenge Your Expert (CYE) session Salamanca Auditorium Title: Secondary MDS and AML Chair(s): J. De La Serna, ES
08:00 - 08:10 Secondary MDS and AML M. Dennis, Manchester, GB
08:10 - 09:00 Discussion led by Chair J. De La Serna, Madrid, ES
08:15 - 09:00 Type: Keynote Lecture Barcelona Auditorium Title: Coping with escalating healthcare costs in 2017 and beyond Chair(s): P.G. Casali, IT
08:15 - 09:00 Coping with escalating healthcare costs in 2017 and beyond J. Tabernero, Barcelona, ES
Last update: 02-09-2017 06:01:33pm esmo.org 09:15 - 10:45 Type: Proffered Paper session Barcelona Auditorium Title: Mesothelioma and SCLC Chair(s): P. Garrido Lopez, ES; S. Popat, GB
09:15 - 09:30 1615O - Pembrolizumab as second or further line treatment in relapsed malignant pleural mesothelioma: A Swiss registry 1 2 3 4 5 6 7 L. Mauti , D. Klingbiel , S. Schmid , H. Bouchaab , T. Bartnick , O. Gautschi , S. Rothschild , M. 8 9 10 11 12 10 Loeffler , P. Froesch , U. Petrausch , S. Wolleb Schild , W. Mingrone , S. Pratsch Peter , S. 7 1 13 13 1 2 3 Savic Prince , M. Pless , R. von Moos , Y. Metaxas ; Winterthur, CH, Berne, CH, St. Gallen, CH, 4 5 6 7 8 9 10 11 Lausanne, CH, Baden, CH, Luzern, CH, Basel, CH, Aarau, CH, Locarno, CH, Zürich, CH, 12 13 Uster, CH, Olten, Solothurn/CH, Chur, CH
09:30 - 09:45 LBA58_PR - Second or 3rd line Nivolumab (Nivo) versus Nivo plus Ipilimumab (Ipi) in Malignant Pleural Mesothelioma (MPM) patients: updated results of the IFCT-1501 MAPS2 randomized phase 2 trial. 1 2 3 4 5 6 7 8 G. Zalcman , J. Mazieres , L. Greillier , S. Lantuejoul , P. Dô , O. Bylicki , I. Monnet , R. Corre , C. 9 10 11 12 13 14 Audigier-Valette , M. Locatelli-Sanchez , O. Molinier , L. Thiberville , T. Urban , D. Planchard , 15 16 16 17 18 1 C. Ligeza-Poisson , E. Amour , F. Morin , D. Moro-Sibilot , A. Scherpereel ; Paris, CEDEX
2 3 4 5 6 7 18/FR, Toulouse, FR, Marseille, FR, La Tronche, CEDEX 9/FR, Caen, FR, Clamart, FR, Créteil, 8 9 10 11 12 13 FR, Rennes, CEDEX/FR, Toulon, FR, Pierre-Bénite, FR, Le Mans, FR, Rouen, FR, Angers, 14 15 16 17 18 CEDEX 9/FR, Villejuif, FR, Saint-Nazaire, FR, Paris, FR, La Tronche, FR, Lille, FR
09:45 - 10:00 Invited Discussant 1615O and LBA58_PR P. Baas, Amsterdam, NL
10:00 - 10:15 1616O - Multicenter, nonrandomized, open-label Phase 1b study of FP-1039/GSK3052230 with chemotherapy: results in malignant pleural mesothelioma (MPM) 1 2 3 4 5 6 J. Trigo Perez , E. van Brummelen , E. Levchenko , M. Domine Gomez , D. Fennell , H. Kindler , S. 7 8 4 9 10 3 11 Viteri , S. Gadgeel , P. Garrido Lopez , V. Kostorov , D. Morgensztern , S. Orlov , P. Paik , J. 12 13 13 14 15 13 13 1 Vansteenkiste , X. Wang , A. Sharabidze , M. Deyoung , K. Baker , L. Yan , I. Mitrica ;
2 3 4 5 6 7 Malaga, ES, Amsterdam, NL, St. Petersburg, RU, Madrid, ES, Leicester, GB, Chicago, IL/US, 8 9 10 11 12 Barcelona, ES, Detroit, US, Kuzmolovsky, RU, St Louis, US, New York, NY/US, Leuven, BE, 13 14 15 Collegeville, PA/US, Abbotsford, AU, South San Francisco, US
10:15 - 10:30 1527O - Top-line data from the randomized phase 2 IMPULSE study in small-cell lung cancer (SCLC): Immunotherapeutic maintenance treatment with lefitolimod 1 2 3 4 5 5 M. Thomas , S. Ponce-Aix , A. Navarro Mendivil , J. Riera Knorrenschild , M. Schmidt , M. Krikow , E. 5 2 5 6 7 8 9 1 Wiegert , M. Domine Gomez , J. Kollmeier , P. Sadjadian , K. Fröhling , R. Huber , M. Wolf ;
2 3 4 5 6 7 Heidelberg, DE, Madrid, ES, Barcelona, ES, Marburg, DE, Berlin, DE, Minden, DE, Koblenz, DE, 8 9 Munich, DE, Kassel, DE
10:30 - 10:45 Invited Discussant one LBA TBC and 1616O S. Popat, London, GB
Last update: 02-09-2017 06:01:33pm esmo.org 09:15 - 10:45 Type: Special Symposium Cordoba Auditorium Title: Innovative therapies in head and neck cancer Chair(s): J.-P. Machiels, BE
09:15 - 09:20 Introduction J.-P. Machiels, Brussels, BE
09:20 - 09:40 Sense and non-sense of TransOral Robotic Surgery (TORS) P. Ceruse, Lyon, FR
09:40 - 10:00 Proton therapy D. Weber, Villigen, CH
10:00 - 10:20 Precision medicine in head and neck cancer: Myth or reality? L. Siu, Toronto, On, CA
10:20 - 10:40 Window of opportunity in clinical trials for biomarker discovery in head and neck cancer C. Le Tourneau, Paris, FR
10:40 - 10:45 Conclusions and clinical perspectives
09:15 - 10:15 Type: Controversy session Granada Title: Supportive and palliative care improve patient outcomes and decrease treatment Auditorium costs Chair(s): F. Scotté, FR
09:15 - 09:25 Introduction and 1st vote F. Scotté, Paris, FR
09:25 - 09:45 Yes B. Rapoport, Sandton, ZA
09:45 - 10:05 No A. Charalambous, Limassol, CY
10:05 - 10:15 2nd vote and conclusions F. Scotté, Paris, FR
09:15 - 10:30 Type: Poster Discussion session Bilbao Auditorium Title: Genitourinary tumours, prostate Chair(s): D. Olmos Hidalgo, ES; S. Oudard, FR; R. de Wit, NL
09:15 - 09:15 786PD - DNA repair gene panel mutations in young onset and aggressive vs non aggressive prostate cancer cases in the UK
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 2 2 2 2 2 R. Eeles , E. Saunders , S. Wakerell , I. Whitmore , C. Cieza-Borrella , K. Govindasami , T. Dadaev ,
2 3 1 2 3 Z. Kote-Jarai , D. Leongamornlert ; Sutton, Surrey/GB, Sutton, GB, Cambridge, GB
09:15 - 09:15 787PD - Prognostic associations of prostate-specific antigen (PSA) decline with survival, radiographic response and progression in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide 1 2 3 4 5 6 7 2 A. Armstrong , P. Lin , C. Higano , P. Iversen , C. Sternberg , B. Tombal , D. Phung , T. Parli , A. 8 9 1 2 3 4 5 Krivoshik , T. Beer ; Durham, US, San Francisco, US, Seattle, WA/US, Copenhagen, DK, Roma, 6 7 8 9 IT, Brussels, BE, Leiden, NL, Chicago, US, Portland, OR/US
09:15 - 09:25 Invited Discussant 786PD and 787PD D. Olmos Hidalgo, Madrid, ES
09:25 - 09:30 Q&A led by Discussant
09:30 - 09:30 788PD - Randomized controlled trial comparing radiotherapy +/- endocrine therapy versus endocrine therapy alone for PSA failure after radical prostatectomy: Japan Clinical Oncology Group Study JCOG0401 1 2 3 4 5 6 7 A. Yokomizo , T. Satoh , K. Hashine , T. Inoue , K. Fujimoto , S. Egawa , T. Habuchi , K. Kawashima 8 9 10 11 12 6 6 , O. Ishizuka , N. Shinohara , M. Sugimoto , Y. Yoshino , M. Wakabayashi , K. Nihei , H. Fukuda 6 6 11 1 1 2 3 4 , K.-I. Tobisu , Y. Kakehi , S. Naito ; Fukuoka, JP, Sagamihara, JP, Matsuyama, JP, Kyoto, JP, 5 6 7 8 9 10 11 Nara, JP, Tokyo, JP, Akita, JP, Utsunomiya, JP, Matsumoto, JP, Sapporo, JP, Kagawa, JP, 12 Nagoya, JP
09:30 - 09:30 LBA33 - What are the optimal systemic treatments for men with metastatic, hormone-sensitive prostate cancer? A STOPCaP systematic review and network meta-analysis 1 2 2 2 1 3 4 5 6 C. Vale , D. Fisher , J. Carpenter , I. White , S. Burdett , N. Clarke , K. Fizazi , G. Gravis , N. James 7 8 2 9 10 1 2 1 , M. Mason , M. Parmar , L. Rydzewska , C. Sweeney , M. Spears , M. Sydes , J. Tierney ;
2 3 4 5 6 7 London, UK/GB, London, GB, M Hd, GB, Villejuif, FR, Marseille, CEDEX 9/FR, Birmingham, GB, 8 9 10 Cardiff, GB, London, London/GB, Boston, MA/US, Wcb Nh, GB
09:30 - 09:30 LBA34 - Adding abiraterone for patients (pts) with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Outcomes in non-metastatic (M0) patients from STAMPEDE (NCT00268476) 1 2 3 4 5 6 2 7 N. James , J. de Bono , M. Spears , N. Clarke , M. Mason , D. Dearnaley , A. Ritchie , M. Russell , 2 7 8 3 9 10 2 11 C. Gilson , R. Jones , S. Gillessen , D. Matheson , S. Aung , A. Birtle , S. Chowdhury , J. Gale , Z. 12 13 14 15 1 2 3 4 Malik , J. O'Sullivan , M. Parmar , M. Sydes ; Birmingham, GB, London, GB, Wcb Nh, GB, M 5 6 7 8 9 10 11 Hd, GB, Cardiff, GB, Sutton, GB, Glasgow, GB, St. Gallen, CH, Devon, GB, Preston, GB, 12 13 14 15 Portsmouth, GB, Clatterbridge, GB, Belfast, GB, London, London/GB, London, UK/GB
09:30 - 09:30 789PD - Abiraterone acetate (AA) + prednisolone (P) for metastatic castration-resistant prostate cancer (mCRPC) with early progression or non-response to androgen deprivation therapy (ADT) 1 2 3 3 2 2 2 1 G. Arai , M. Ogi , K. Kobayashi , N. Okuno , T. Takahara , K. Fukushima , K. Yoshizawa ; Saitama,
2 3 JP, Tokyo, JP, Kanagawa, JP
Last update: 02-09-2017 06:01:33pm esmo.org 09:30 - 09:50 Invited Discussant 788PD, LBA33, LBA34 and 789PD S. Oudard, Paris, FR
09:50 - 10:00 Q&A led by Discussant
10:00 - 10:00 790PD - Safety and immunogenicity of a DNA-vaccine immunotherapy in men with biochemically (PSA) relapsed prostate cancer 1 2 3 4 5 6 6 6 N. Shore , E. Heath , L. Nordquist , H. Cheng , K. Bhatt , M. Morrow , T. McMullan , K. Kraynyak , J. 6 6 6 6 7 8 9 10 Lee , B. Sacchetta , L. Liu , S. Rosencranz , S. Tagawa , R. Parikh , R. Tutrone , J. Garcia , Y. 11 12 5 5 1 2 3 4 Whang , W. Kelly , I. Csiki , M. Bagarazzi ; Myrtle Beach, US, Detroit, US, Omaha, US, Seattle, 5 6 7 8 9 WA/US, Plymouth Meeting, US, Plymouth Meeting, PA/US, New York, US/US, Pittsburg, PA/US, 10 11 12 Towson, MD/US, Cleveland, OH/US, Chapel Hill, NC/US, Philadelphia, PA/US
10:00 - 10:00 791PD - Re-education of tumor-associated macrophages by CXCR2 blockade drives senescence enhancement and tumor inhibition in advanced prostate cancer 1 1 1 2 2 1 3 4 D. Di Mitri , J. Vasilevska , A. Calcinotto , V. Gil , G. Boysen , A. Revandkar , D. Waugh , S. Barry ,
5 1 1 2 3 4 5 J. de Bono , A. Alimonti ; Bellinzona, CH, Sutton, GB, Belfast, GB, Cambridge, GB, London, GB
10:00 - 10:00 792PD - Phase I, open-label, dose-finding study of GSK2636771, a phosphoinositide 3-kinase (PI3K)β inhibitor, in combination with enzalutamide in male subjects with metastatic castration-resistant prostate cancer (mCRPC) 1 2 3 2 4 5 P. Rescigno , J. de Bono , A. Aparicio , S. Chowdhury , P. Twardowski , N. Dawson , U. 6 7 8 8 9 10 11 12 Vaishampayan , A. Pantuck , Y. Zhou , D. Fecteau , G. Ganji , J. Tolson , D. Smith , J. Medina , 12 1 2 3 4 5 6 L. Yan ; Napoli, IT, London, GB, Houston, TX/US, Duarte, CA/US, Washington D.c., DC/US, 7 8 9 10 11 Detroit, MI/US, Los Angeles, CA/US, Collegeville, US, King Of Prussia, PA/US, Rtp, NC/US, 12 Durham, NC/US, Collegeville, PA/US
10:00 - 10:00 793PD - Phase 1 study of the PSMA-targeted small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC) 1 2 3 4 5 6 7 M. Morris , N. Vogelzang , O. Sartor , A. Armour , M. Groaning , R. Messmann , A. Robarts , D. 8 9 10 11 1 2 3 Petrylak , A. Tolcher , M. Gordon , H. Babiker ; New York, NY/US, Las Vegas, NV/US, New
4 5 6 7 8 Orleans, LA/US, Indianapolis, IN/US, Indianapolis, US, West Lafayette, US, New York, US, New 9 10 11 Haven, CT/US, San Antonio, TX/US, Scottsdale, AZ/US, Tucson, US
10:00 - 10:20 Invited Discussant 790PD, 791PD, 792PD and 793PD R. de Wit, Rotterdam, NL
10:20 - 10:30 Q&A led by Discussant
Last update: 02-09-2017 06:01:33pm esmo.org 09:15 - 10:45 Type: Special Symposium Madrid Auditorium Title: Optimal treatment of RAS mutated patients Chair(s): C.-H. Koehne, DE; A. Falcone, IT
09:15 - 09:20 Introduction A. Falcone, Pisa, IT
09:20 - 09:40 Liquid biopsies M. Ychou, Montpellier, CEDEX 5/FR
09:40 - 10:00 Molecular heterogeneity F. Ciardiello, Naples, IT
10:00 - 10:20 New ways of targeting RAS R. Corcoran, Boston, MA/US
10:20 - 10:40 Immunotherapy: MSI and beyond J. Bendell, Nashville, TN/US
10:40 - 10:45 Conclusions and clinical perspectives C.-H. Koehne, Oldenburg, DE
09:15 - 10:45 Type: Poster Discussion session Sevilla Auditorium Title: Breast cancer, metastatic Chair(s): A. Prat, ES; M.V. Dieci, IT; A. Gennari, IT
09:15 - 09:15 239PD - A phase II trial of dasatinib (D) in combination with trastuzumab (T) and paclitaxel (P) in the first line treatment of HER2 positive metastatic breast cancer (MBC) patients (pts): GEICAM/2010-04 1 2 3 4 2 2 A. Ocana Fernandez , M. Ruíz-Borrego , M. Gil Martin , S. Antolin , M. Atienza , A. Montaño , N. 5 6 3 7 3 2 Ribelles , A. Guerrero , M. Muñoz , I. Fernández-Pérez , A. Urruticoechea , A. Falcon Gonzalez , S. 3 8 9 9 9 10 10 Pernas Simon , J. Prato Varela , M.J. Escudero , S. Benito , R. Caballero , E. Carrasco , F. Rojo , 11 1 2 3 4 5 6 A. Pandiella ; Albacete, ES, Sevilla, ES, Barcelona, ES, Coruña, ES, Malaga, ES, Valencia, ES, 7 8 9 10 11 Vigo, ES, A Coruna, ES, San Sebastian De Los Reyes, ES, Madrid, ES, Salamanca, ES
09:15 - 09:15 LBA12 - Genomic analyses reveal potential recurrence markers of locally advanced triple negative breast cancer treated by combined neoadjuvant EGFR targeting and chemotherapy 1 2 2 2 1 3 3 N. Radosevic-Robin , E. Cocco , H. Won , M. Berger , M. Privat , C. Abrial , F. Penault-Llorca , M.
2 1 2 3 Scaltriti ; Clermont-Ferrand, FR, New York, NY/US, Clermont-Ferrand, CEDEX 1/FR
09:15 - 09:15 240PD - Comprehensive genomic profiling of primary and metastatic CDH1 mutated classic and pleomorphic invasive lobular breast carcinomas reveals markers of hormonal therapy resistance and opportunities for targeted therapies 1 2 2 2 2 2 2 2 J. Ross , L. Gay , J. Elvin , J. Suh , J.-A. Vergilio , S. Ramkissoon , E. Severson , S. Daniel , G. 2 2 3 2 2 4 2 1 2 Frampton , D. Fabrizio , A. Schrock , S. Ali , V. Miller , P. Stephens , J. Chung ; Albany, NY/US, 3 4 Cambridge, MA/US, Cambridge, US, Cambridge, Massachusetts/US
Last update: 02-09-2017 06:01:33pm esmo.org
09:15 - 09:15 LBA15 - SToRM: a clinical cohort to identify genetic variability related to metastatic phenotypes 1 1 2 3 4 5 6 7 D. Cox , E. Blanc , G. Romieu , M. Rios , C. Becuwe , C. Jouannaud , L. Chaigneau , M. Arnedos , 8 9 10 11 12 13 H. Orfeuvre , T. Petit , N. Quenel Tueux , J.-P. Jacquin , J.-M. Ferrero , S. Abadie Lacourtoisie , 14 1 1 15 16 1 2 F. Penault-Llorca , C. Segura-Ferlay , I. Moullet , T. Bachelot , X. Pivot ; Lyon, FR, Montpellier, 3 4 5 6 CEDEX 5/FR, Vandoeuvre Les Nancy, CEDEX/FR, Nancy, FR, Reims, CEDEX/FR, Besancon, FR, 7 8 9 10 11 Villejuif, FR, Bourg-En-bresse, FR, Strasbourg, CEDEX/FR, Bordeaux, CEDEX/FR, Saint Priest 12 13 14 15 En Jarez, FR, Nice, CEDEX 2/FR, Angers, FR, Clermont-Ferrand, CEDEX 1/FR, Lyon, 16 CEDEX/FR, Besançon, CEDEX/FR
09:15 - 09:35 Invited Discussant 239PD, LBA12, 240PD and LBA15 A. Prat, Barcelona, ES
09:35 - 09:45 Q&A led by discussant
09:45 - 09:45 241PD - BEECH: A randomised Phase 2 study assessing the efficacy of AKT inhibitor AZD5363 combined with paclitaxel in patients with ER+ve advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population 1 2 3 4 5 6 7 N. Turner , E. Alarcón , A. Armstrong , M. Philco , Y.A. López Chuken , M.-P. Sablin , K. Tamura , A. 8 9 10 11 10 10 Gomez Villanueva , J.A. Pérez-Fidalgo , A. Foxley , J. Lindemann , R. Maudsley , E. Outhwaite , 10 10 10 12 1 2 3 4 M. Pass , P. Rugman , G. Schiavon , M. Oliveira ; London, GB, Lima, PE, Manchester, GB, 5 6 7 8 9 10 Bellavista, PE, Monterrey, MX, Paris, FR, Tokyo, JP, Toluca, MX, Ciberonc, ES, Cambridge, 11 12 GB, Melbourn, UK/GB, Barcelona, ES
09:45 - 09:45 242PD - Initial results of a phase 1 dose expansion cohort of M6620 (formerly VX-970), an ATR inhibitor, in combination with cisplatin in patients with advanced triple-negative breast cancer NCT02157792) 1 2 3 4 5 6 7 7 M. Telli , S. Lord , E. Dean , V. Abramson , H.-T. Arkenau , C. Becerra , S. Tolaney , R. Tang , M. 7 7 7 7 8 1 2 3 Penney , J. Pollard , G. Conboy , S. Fields , G. Shapiro ; Stanford, CA/US, Oxford, GB, 4 5 6 7 8 Manchester, GB, Nashville, TN/US, London, GB, Dallas, TX/US, Boston, MA/US, Boston, US
09:45 - 09:45 243PD - OlympiAD: Further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice 1 2 3 4 5 6 7 8 S. Delaloge , P.F. Conte , S.-A. Im , E. Senkus-Konefka , B. Xu , S. Domchek , N. Masuda , W. Li , 9 10 11 12 13 14 1 2 N. Tung , A. Armstrong , W. Wu , C. Goessl , S. Runswick , M. Robson ; Villejuif, FR, 3 4 5 6 7 8 9 Padova, IT, Seoul, KR, Gdańsk, PL, Beijing, CN, Philadelphia, US, Osaka, JP, Changchun, CN, 10 11 12 13 Boston, MA/US, Manchester, GB, Gaithersburg, MD/US, Gaithersburg, US, Macclesfield, GB, 14 New York, NY/US
09:45 - 10:05 Invited Discussant 241PD, 242PD and 243PD M.V. Dieci, Padova, IT
10:05 - 10:15 Q&A led by discussant
Last update: 02-09-2017 06:01:33pm esmo.org
10:15 - 10:15 238PD - A randomized, double-blind study of PF-05280014 (a potential trastuzumab biosimilar) vs trastuzumab, both in combination with paclitaxel, as first-line treatment for HER2-positive metastatic breast cancer 1 2 3 4 5 3 3 1 M. Pegram , E. Tan-Chiu , A. Freyman , A. Vana , F. Hilton , C. Zacharchuk , R. Ewesuedo ;
2 3 4 5 Stanford, CA/US, Plantation, FL/US, Cambridge, MA/US, San Diego, CA/US, Groton, CT/US
10:15 - 10:15 244PD - Everolimus (EVE) + letrozole (LET) in patients (pts) with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): Progression-free survival (PFS) subgroup analyses in BOLERO-4 1 2 3 4 5 6 7 T. Bachelot , M. Royce , C. Villanueva , F. Melo Cruz , R. Hegg , C. Falkson , J. Jeong , V. 8 9 10 9 11 12 13 Srimuninnimit , C. Arce , A. Ridolfi , C. Lin , W. Gradishar , M. Ozguroglu , F. Cardoso , S. 14 1 2 3 4 5 Azevedo ; Lyon, CEDEX/FR, Albuquerque, US, Besançon, CEDEX/FR, Mooca, BR, Sao Paulo, 6 7 8 9 10 SP/BR, Birmingham, AL/US, Seoul, KR, Bangkok, TH, East Hanover, US, Rueil-Malmaison, FR, 11 12 13 14 Chicago, IL/US, Istanbul, TR, Lisbon, PT, Porto Alegre, BR
10:15 - 10:15 245PD - Duration of response and tumor shrinkage with first-line ribociclib + letrozole in postmenopausal women with HR+, HER2– ABC 1 2 3 4 5 6 7 8 9 W. Janni , E. Alba Conejo , T. Bachelot , S. Diab , M. Gil-Gil , T. Beck , L. Ryvo , R. López , M. Tsai 10 11 12 13 14 15 16 , F. Esteva , M.P. Zamora Aunon , Z. Kral , P. Ward , P. Richards , T. Pluard , S. Sutradhar , 17 18 1 2 3 4 5 M. Miller , M. Campone ; Ulm, DE, Malaga, ES, Lyon, CEDEX/FR, Aurora, ON/CA, Barcelona,
6 7 8 9 10 ES, Fayetteville, US, Tel Aviv, IL, Santiago De Compostela, ES, Minneapolis, MN/US, Houston, 11 12 13 14 15 16 TX/US, Madrid, ES, Brno, CZ, Kenwood, OH/US, Salem, VA/US, Kansas City, MO/US, 17 18 East Hanover, US, East Hanover, New Jersey/US, Saint-Herblain, CEDEX/FR
10:15 - 10:15 246PD - Efficacy of two times four versus continuous eight cycles of paclitaxel/bevacizumab as first-line chemotherapy in metastatic breast cancer: The Stop&Go study of the Dutch Breast Cancer Research Group (BOOG) 1 2 3 3 3 4 A. Claessens , M. Bos , S. de Groot , E. van Leeuwen - Stok , M. Lopez-Yurda , A. Honkoop , H. de 5 2 6 6 7 8 1 Graaf , E. van Druten , L. van Warmerdam , M. van der Sangen , V. Tjan-Heijnen , F. Erdkamp ;
2 3 4 5 6 7 Sittard-Geleen, NL, Delft, NL, Amsterdam, NL, Zwolle, NL, Leeuwarden, NL, Eindhoven, NL, 8 Maastricht, NL, Sittard, NL
10:15 - 10:35 Invited Discussant 238PD, 244PD, 245PD and 246PD A. Gennari, Genova, IT
10:35 - 10:45 Q&A led by discussant
Last update: 02-09-2017 06:01:33pm esmo.org 09:15 - 10:45 Type: Educational session Pamplona Auditorium Title: Immunotherapy beyond checkpoint inhibitors Chair(s): M. Maus, US; R. Plummer, GB
09:15 - 09:40 Biomarkers for personalised immunotherapy A. Marabelle, Villejuif, FR
09:40 - 10:05 Modulation of tumour microenvironments L. Akkari, Amsterdam, NL
10:05 - 10:30 CAR-T and beyond M. Maus, Charleston, US
10:30 - 10:45 Discussion
09:30 - 10:30 Type: Special Session Valencia Auditorium Title: Oligometastatic disease: Immunotherapy and /or local treatment Chair(s): B. Neyns, BE
09:30 - 09:50 Is immunotherapy first choice? B. Neyns, Brussels, BE
09:50 - 10:10 Radiotherapy is it the treatment and/or the adjuvant? P. Nathan, Northwood, Middlesex/GB
10:10 - 10:30 Does surgery still have a role? A. van Akkooi, Amsterdam, NL
09:30 - 10:30 Type: Challenge Your Expert (CYE) session Tarragona Auditorium Title: Personalised and stratified management of non-epithelial ovarian cancer Chair(s): I. Ray-Coquard, FR
09:30 - 09:40 Personalised and stratified management of non-epithelial ovarian cancer J. Ledermann, London, GB
09:40 - 10:30 Discussion led by Chair I. Ray-Coquard, Lyon, CEDEX/FR
Last update: 02-09-2017 06:01:33pm esmo.org 09:30 - 10:30 Type: Multidisciplinary Session Alicante Auditorium Title: Challenges and opportunities in the treatment of Hodgkin's lymphoma Chair(s): U. Ricardi, IT
09:30 - 09:35 Presentation of case/condition U. Ricardi, Turin, IT
09:35 - 09:45 The radiation therapy perspective U. Ricardi, Turin, IT
09:45 - 09:55 The nuclear medicine perspective S. Barrington, London, GB
09:55 - 10:05 The medical oncology perspective A. Rueda Domínguez, Marbella, ES
10:05 - 10:30 General Discussion
09:30 - 10:30 Type: Special Session Cartagena Auditorium Title: The “macro-economics” of cancer Chair(s): A. Eniu, RO; Y. Lievens, BE
09:30 - 09:50 Global discrepancies in cancer outcomes P. Boyle, Ecully, FR
09:50 - 10:10 Access to essential medicines A. Eniu, Cluj-Napoca, RO
10:10 - 10:30 Cancer macroeconomics, policy and politics J. Martin-Moreno, Valencia, Valencia/ES
Last update: 02-09-2017 06:01:33pm esmo.org 10:45 - 12:45 Type: ESMO Clinical Practice Guidelines session Granada Auditorium Title: ESMO Clinical Practice Guidelines 1 Chair(s): C. Sessa, CH; G. Pentheroudakis, GR
10:45 - 10:55 Introduction to the ESMO Clinical Practice Guidelines G. Pentheroudakis, Ioannina, GR
10:55 - 11:05 Questionnaire C. Sessa, Bellinzona, CH
11:05 - 11:15 Resectable locally advanced oesophagogastric cancer case presentation E. Smyth, London, GB
11:15 - 11:25 Discussant F. Lordick, Leipzig, DE
11:25 - 11:30 Q&A
11:30 - 11:40 Renal cancer: Sequence of therapies, immunotherapy case presentation L. Derosa, Villejuif, FR
11:40 - 11:50 Discussant B. Escudier, Villejuif, FR
11:50 - 11:55 Q&A
11:55 - 12:05 Management of carcinomatous meningitis in patient with advanced lung adenocarcinoma case presentation E. Le Rhun, Lille, CEDEX/FR
12:05 - 12:15 Discussant M. Preusser, Vienna, AT
12:15 - 12:20 Q&A
12:20 - 12:30 Early stage NSCLC case presentation A. Curioni, Zürich, CH
12:30 - 12:40 Discussant P. Postmus, Wirral, Merseyside/GB
12:40 - 12:45 Q&A
Last update: 02-09-2017 06:01:33pm esmo.org
11:00 - 12:30 Type: Proffered Paper session Barcelona Auditorium Title: Gastrointestinal tumours, non-colorectal 2 Chair(s): M. Hidalgo, US; L. Rimassa, IT
11:00 - 11:15 LBA29 - Adjuvant GEMOX for biliary tract cancer: updated relapse-free survival and first overall survival results of the randomized PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial. 1 2 3 4 5 6 7 J. Edeline , F. Bonnetain , J.-M. Phelip , J. Watelet , P. Hammel , J.-P. Joly , M. Benabdelghani , L. 8 9 10 11 12 13 Fartoux , K. Bouhier-Leporrier , J.-L. Jouve , R. Faroux , V. Guerin-Meyer , E. Assenat , J.-F. 14 15 8 16 8 8 1 1 Seitz , D. Malka , C. Louvet , A. Bertaut , B. Juzyna , T. Stanbury , E. Boucher ; Rennes,
2 3 4 5 6 7 CEDEX/FR, Besançon, CEDEX/FR, Saint-Etienne, FR, Nancy, FR, Clichy, FR, Amiens, FR, 8 9 10 11 12 Strasbourg, FR, Paris, FR, Caen, FR, Dijon, Cedex/FR, La Roche Sur Yon, CEDEX 9/FR, 13 14 15 16 Angers, FR, Montpellier, FR, Marseille, CEDEX 5/FR, Villejuif, FR, Dijon, FR
11:15 - 11:30 619O - JET-HCC: A phase 3 randomized, double-blind, placebo-controlled study of tivantinib as a second-line therapy in patients with c-Met high hepatocellular carcinoma 1 2 3 4 5 6 7 8 S. Kobayashi , K. Ueshima , M. Moriguchi , T. Takayama , N. Izumi , H. Yoshiji , K. Hino , T. Oikawa 9 10 11 12 13 14 15 16 , T. Chiba , K. Motomura , J. Kato , K. Yasuchika , A. Ido , J. Kinoshita , T. Sato , M. Ikeda , 15 17 18 15 1 2 3 4 T. Okusaka , M. Kudo , K. Tamura , J. Furuse ; Yokohama, JP, Sayama, JP, Kyoto, JP,
5 6 7 8 9 10 Tokushima, JP, Musashino, JP, Kashihara, JP, Kurashiki, JP, Morioka, JP, Chiba, JP, Iizuka, 11 12 13 14 15 16 JP, Bunkyo, JP, Sakyo, JP, Kagoshima, JP, Chiyodaku, JP, Tokyo, JP, Kashiwa, 17 18 Chiba/JP, Osaka, JP, Fukuoka, JP
11:30 - 11:45 Invited Discussant LBA29 and 619O C. Verslype, Leuven, BE
11:45 - 12:00 LBA30 - Analysis of serum biomarkers (BM) in patients (pts) from a phase 3 study of lenvatinib (LEN) vs sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC) 1 2 3 4 5 6 7 8 9 R. Finn , M. Kudo , A.-L. Cheng , L. Wyrwicz , R. Ngan , J.-F. Blanc , A. Baron , A. Vogel , M. Ikeda 10 11 12 13 14 15 16 , F. Piscaglia , K.-H. Han , S. Qin , Y. Minoshima , Y. Funahashi , M. Ren , R. Dairiki , P. 17 16 17 18 1 2 3 Sachdev , T. Tamai , C. Dutcus , T.R.J. Evans ; Los Angeles, CA/US, Osaka, JP, Taipei City,
4 5 6 7 8 9 TW, Warsaw, PL, Kowloon, HK, Pessac, FR, San Fransisco, US, Hannover, DE, Kashiwa, 10 11 12 13 14 15 Chiba/JP, Bologna, IT, Seoul, KR, Nanjing, CN, Tsukuba, Ibaraki, JP, Andover, US, 16 17 18 Woodcliff Lake, US, Tokyo, JP, Woodcliff Lake, New Jersey/US, Glasgow, GB
12:00 - 12:15 618O - Health-related quality of Life (HRQOL) and disease symptoms in patients with unresectable hepatocellular carcinoma (HCC) treated with lenvatinib (LEN) or sorafenib (SOR) 1 2 3 4 5 6 7 8 A. Vogel , S. Qin , M. Kudo , S. Hudgens , T. Yamashita , J.-H. Yoon , L. Fartoux , K. Simon , C. 9 10 11 12 13 14 15 López López , M. Sung , C. Dutcus , S. Kraljevic , T. Tamai , N. Grunow , G. Meier , V. 16 1 2 3 4 5 Breder ; Hannover, DE, Nanjing, CN, Osaka, JP, New York, Arizona/US, Kanazawa, 6 7 8 9 10 11 Ishikawa/JP, Seoul, KR, Paris, FR, Wroclaw, PL, Santander, ES, New York, NY/US, Woodcliff 12 13 14 15 16 Lake, New Jersey/US, Hatfield, Herts/GB, Tokyo, JP, Tucson, US, Woodcliff Lake, US, Moscow, RU
12:15 - 12:30 Invited Discussant one LBA30 and 618O
Last update: 02-09-2017 06:01:33pm esmo.org L. Rimassa, Rozzano, (MI)/IT
11:00 - 12:40 Type: Special Symposium Madrid Auditorium Title: How to manage luminal breast cancer Chair(s): F. Cardoso, PT; M. Colleoni, IT
11:00 - 11:20 How to classify luminal breast cancer J. Reis-Filho, New York, Ny, US
11:20 - 11:40 Who benefits from chemotherapy? F. Cardoso, Lisbon, PT
11:40 - 12:00 Early response assessment N. Harbeck, Munich, DE
12:00 - 12:20 How much endocrine therapy is long enough? M. Colleoni, Milan, IT
12:20 - 12:40 Is there an optimal chemotherapy? A. Di Leo, Prato, IT
11:00 - 12:30 Type: Educational session Sevilla Auditorium Title: Optimising treatment of metastatic prostate cancer Chair(s): N. James, GB; S. Gillessen, CH
11:00 - 11:25 Why switch treatment? Response biomarkers H. Scher, New York, Ny, US
11:25 - 11:50 When to treat? How do we define best sequence? N. James, Birmingham, GB
11:50 - 12:15 Who to treat? Molecular stratification predictive biomarkers J. Mateo, Sutton, GB
12:15 - 12:30 Discussion
Last update: 02-09-2017 06:01:33pm esmo.org 11:00 - 12:30 Type: Joint Symposium Pamplona Title: ESMO-EORTC-EACR: Tumours with rare oncogenic lesions: From pre-clinical to Auditorium clinical validation Chair(s): R. Stahel, CH; A. Berns, NL; R. Stupp, CH
11:00 - 11:05 Introduction A. Berns, Amsterdam, NL
11:05 - 11:25 Targeting the stem of cancer: Inhibition of the WNT pathway in colorectal tumours A. Bardelli, Candiolo, (TO)/IT
11:25 - 11:45 Using rare mutations to guide treatment options for drug resistant melanoma R. Marais, Manchester, GB
11:45 - 12:05 Vulnerabilities of gliomas with IDH1 mutations D. Cahill, Boston, US
12:05 - 12:25 Biomarkers for PARP responders L. Van'T Veer, San Francisco, US
12:25 - 12:30 Conclusions R. Stupp, Zürich, CH
11:00 - 12:30 Type: Special Symposium Cordoba Auditorium Title: Targeted therapy in neuro-oncology Chair(s): P. Wen, US; P. French, NL
11:00 - 11:05 Introduction P. French, Rotterdam, NL
11:05 - 11:25 What can we learn from patient-derived models? J. Seoane, Barcelona, ES
11:25 - 11:45 Is IDH a valid therapeutic target in neuro-oncology? M. Platten, Heidelberg, DE
11:45 - 12:05 Targeting EGFR in glioblastoma: Beyond TKI and ACT IV M. Weller, Zürich, CH
12:05 - 12:25 Basket & umbrella trials in neuro-oncology W. Wick, Heidelberg, DE
12:25 - 12:30 Conclusions and clinical perspectives P. Wen, Boston, MA/US
Last update: 02-09-2017 06:01:33pm esmo.org 11:00 - 12:30 Type: Joint Symposium Valencia Auditorium Title: ESMO-CSCO: Liquid biopsy in the clinic: From myth to reality Chair(s): F. Ciardiello, IT; Y.-L. Wu, CN
11:00 - 11:05 Introduction F. Ciardiello, Naples, IT
11:05 - 11:25 Technologic advances in liquid biopsy: East meets West X.-C. Zhang, Guangzhou, CN
11:25 - 11:45 Next generation sequencing and liquid biopsy N. Normanno, Napoli, IT
11:45 - 12:05 Clinical application of liquid biopsy in management of advanced NSCLC S. Wang, Beijing, CN
12:05 - 12:25 Clinical application of liquid biopsy in management of colorectal cancer
12:25 - 12:30 Conclusions Y.-L. Wu, Guangzhou, CN
11:00 - 12:00 Type: Multidisciplinary Session Tarragona Auditorium Title: Challenges and complex presentations: Non resectable bone sarcoma Chair(s): A.P. Dei Tos, IT
11:00 - 11:05 Presentation of case/condition A.P. Dei Tos, Treviso, IT
11:05 - 11:15 The pathology perspective A.P. Dei Tos, Treviso, IT
11:15 - 11:25 The radiation therapy perspective R.L. Haas, Amsterdam, NL
11:25 - 11:35 The surgery perspective A. Leithner, Graz, AT
11:35 - 11:45 The medical oncology perspective W. van der Graaf, Sutton, GB
11:45 - 12:00 General Discussion
Last update: 02-09-2017 06:01:33pm esmo.org 11:00 - 12:30 Type: Special Session Bilbao Title: How to conciliate the fast moving genetic landscape with everyday practice and Auditorium resources Chair(s): S. Rauh, LU; G. Lakatos, HU
11:00 - 11:05 Introduction G. Lakatos, Budapest, HU
11:05 - 11:25 Overview of genetic testing: Evolution in the last 5 years I. Peták, Budapest, HU
11:25 - 11:45 What has been included in present guidelines: Impact of inclusion on oncology practice C. Rolfo, Edegem, BE
11:45 - 12:05 Integrating personalised medicine into oncology practice: The French experience J.-C. Soria, Villejuif, FR
12:05 - 12:25 Panel discussion: What are the benefits of personalised medicine for oncology practice? How can it be integrated into everyday practice?
12:25 - 12:30 Conclusions S. Rauh, Esch Sur Alzette, LU
11:00 - 12:00 Type: Multidisciplinary Session Alicante Auditorium Title: Multidisciplinary approach to the management of stage III thymoma Chair(s): M. Garassino, IT
11:00 - 11:05 Presentation of case/condition M. Garassino, Milan, IT
11:05 - 11:15 The medical oncology perspective M. Garassino, Milan, IT
11:15 - 11:25 The surgery perspective R.J. Korst, Paramus, Nj, US
11:25 - 11:35 The radiation therapy perspective C. Le Pechoux, Villejuif, CEDEX/FR
11:35 - 12:00 General Discussion
Last update: 02-09-2017 06:01:33pm esmo.org 11:00 - 12:15 Type: Proffered Paper session Cartagena Auditorium Title: Haematological malignancies Chair(s): M. Provencio, ES; M. Ghielmini, CH
11:00 - 11:15 994O - Equivalent efficacy of a biosimilar rituximab and reference rituximab in previously untreated advanced follicular lymphoma: Extended results of ASSIST-FL, a confirmatory phase III study 1 2 3 4 5 6 7 W. Jurczak , I. Moreira , K. Setty Govindbabu , E. Munhoz , M.-A. Echeveste , P. Giri , N. Castro , J. 7 8 9 10 11 11 12 12 Pereira , A. Luiza , S. Alexeev , D. Osmanov , P. Zhu , S. Alexandrova , A. Zubel , O. Harlin , 12 1 2 3 4 5 6 J. Amersdorffer ; Kraków, PL, Porto, PT, Bangalore, IN, Curitiba, BR, San Sebastian, ES, 7 8 9 10 11 12 Adelaide, AU, Sao Paulo, BR, Naharyia, IL, St. Petersburg, RU, Moscow, RU, Princeton, US, Holzkirchen, DE
11:15 - 11:30 Invited Discussant 994O M. Ghielmini, Bellinzona, CH
11:30 - 11:45 995O - Interim results from a phase 1 first-in-human study of flotetuzumab, a CD123 x CD3 bispecific DART molecule, in AML/MDS 1 2 3 4 5 6 7 8 N. Vey , J. Davidson-Moncada , G. Uy , M. Foster , D. Rizzieri , J. Godwin , M. Topp , F. Ciceri , M. 8 9 10 11 12 12 12 12 Carrabba , G. Martinelli , G. Huls , A. Wegener , M. Shannon , K. Tran , J. Sun , E. Bonvini , 13 2 3 1 2 3 4 B. Löwenberg , J. Wigginton , J. Dipersio ; Marseille, FR, Rockville, US, St. Louis, MO/US, 5 6 7 8 9 10 Chapel Hill, US, Durham, US, Portland, US, Wurzburg, DE, Milano, IT, Milan, IT, Groningen, NL, 11 12 13 Paris, FR, Rockville, MD/US, Rotterdam, NL
11:45 - 12:00 996O - Risk of developing acute myeloid leukemia (AML) in well-differentiated thyroid cancer (WDTC) patients treated with radioactive iodine (RAI): a population-based study 1 2 2 2 3 2 1 R. Molenaar , T. Radivoyevitch , H. Carraway , J. Maciejewski , M. Sekeres , S. Mukherjee ;
2 3 Amsterdam, NL, Cleveland, OH/US, Cleveland, US
12:00 - 12:15 Invited Discussant 995O and 996O T. Somervaille, Manchester, GB
11:00 - 11:45 Type: Young Oncologist Brunch Salamanca Auditorium Title: Burn out in young oncologists: How can we combat it? Chair(s): T. Amaral, PT; M. Strijbos, BE
11:00 - 11:20 Introduction to psychological stress and burn-out F. Fiore, Napoli, IT
11:20 - 11:45 Prevalence and prevention of burn-out in young oncologists S. Banerjee, London, GB
Last update: 02-09-2017 06:01:33pm esmo.org 12:30 - 14:30 Type: Patient Advocacy Track Palma Auditorium Title: Patient outcomes research Chair(s): I. Banks, IE; B. Ryll, SE
12:30 - 12:45 How to integrate qualitative research into clinical trials A. Nelson, Cardiff, GB
12:45 - 13:00 What are meaningful patient outcomes and how to implement them E. Low, London, GB
13:00 - 13:15 Risk benefit assessment tool B. Ryll, SE
13:15 - 13:30 Measuring Quality of Life - and deltas of perceptions between HCPs and patients L. Cannella, Napoli, IT
13:30 - 14:00 Discussion
13:00 - 14:30 Type: ESMO Colloquium Sevilla Title: ESMO COLLOQUIUM - Systemic treatment of unresectable hepatocellular Auditorium carcinoma Chair(s): A. Vogel, DE; J.L. Raoul, FR
13:00 - 13:05 Introduction J.L. Raoul, Marseille, FR
13:05 - 13:30 The increasing epidemics of HCC world-wide J.L. Raoul, Marseille, FR
13:30 - 13:55 First-line systemic treatment: Can we do better than sorafenib? A. Vogel, Hannover, DE
13:55 - 14:20 Second and later line treatments: Anti-angiogeneic? MET inhibitors? Immunotherapy? Or just best supportive care? J. Trojan, Frankfurt, DE
14:20 - 14:30 Summary and conclusion
13:00 - 14:30 Type: Industry Satellite Symposium Pamplona Auditorium Title: Industry Satellite Symposium 29
13:00 - 14:30 Type: Industry Satellite Symposium Cordoba Auditorium Title: Industry Satellite Symposium 30
Last update: 02-09-2017 06:01:33pm esmo.org
13:00 - 14:30 Type: Industry Satellite Symposium Valencia Auditorium Title: Industry Satellite Symposium 31
13:00 - 14:30 Type: Industry Satellite Symposium Tarragona Auditorium Title: Industry Satellite Symposium 32
13:00 - 14:30 Type: Industry Satellite Symposium Bilbao Auditorium Title: Industry Satellite Symposium 33
13:00 - 14:30 Type: Industry Satellite Symposium Alicante Auditorium Title: Industry Satellite Symposium 34
13:00 - 14:30 Type: Industry Satellite Symposium Jerez Auditorium Title: Industry Satellite Symposium 59
13:15 - 14:15 Type: Poster Display session Hall 8 Title: Poster display session
13:15 - 13:15 CNS TUMOURS 1 2 1 2 P. Wen , P. French ; Boston, MA/US, Rotterdam, NL
13:15 - 13:15 337P - Molecular subtypes of gliomas defined by gene expression profiling 1 2 3 2 2 2 2 E. Deluche , F. Caire , V. Rigau , S. Durand , S. Robert , B. Bessette , F. Labrousse , M.-O.
2 2 2 1 2 3 Jauberteau , K. Durand , F. Lalloue ; Limoges, CEDEX/FR, Limoges, FR, Montpellier, FR
13:15 - 13:15 338P - Chitosan-capped gold nanoparticles impair radioresistant glioblastoma stem-like cells M. Aldea, M. Potara, O. Soritau, I.S. Florian, G. Kacso; Cluj-Napoca, RO
13:15 - 13:15 339P - Hypoxia, Inflammation and redox status as determinants of malignant progression of cancer stem cells M. Papale, Roma, IT
13:15 - 13:15 340P - The prognostic role of high mobility group box protein-1 in glioblastoma and its relationship with the inflammatory response 1 2 2 2 2 2 2 1 1 M. Yildirim , D. Süren , A. Alikanoğlu , Ö. Çakın , İ. Karacay , C. Sezer , V. Kaya , A. Güzel ;
2 Gaziantep, TR, Antalya, TR
13:15 - 13:15 341P - Impact of hyperbaric oxygenation on the expression of PKD1 protein forms in T98G glioblastoma cell line treated with selected pentabromobenzylisothiourea (ZKK-3) K. Stepien, R. Ostrowski, E. Pucko, E. Grzywaczewska, E. Matyja; Warsaw, PL
13:15 - 13:15 (Withdrawn)
13:15 - 13:15 343P - The role of clinical characteristics in low grade gliomas in molecular era
Last update: 02-09-2017 06:01:33pm esmo.org 1 1 1 1 1 1 2 A. Mura , E. Franceschi , S. Minichillo , A. Mandrioli , A. Tosoni , A. Fioravanti , A. Talacchi , L. 3 1 1 1 4 1 1 1 1 Volpin , G. Tallini , D. De Biase , R. Agati , S. Pizzolitto , S. Bartolini , A. Paccapelo , A. Brandes ; 2 3 4 Bologna, IT, Verona, IT, Vicenza, IT, Udine, IT
13:15 - 13:15 344P - IDH wild type low grade gliomas: Who seeks shall find 1 1 1 1 1 1 2 A. Mandrioli , E. Franceschi , S. Minichillo , A. Mura , A. Tosoni , D. De Biase , E. Zunarelli , G. 3 4 5 1 1 1 6 1 Lanza , D. Bartolini , E.M. Silini , G. Tallini , L. Cirillo , C. Bortolotti , D. Danieli , S. Bartolini , A. 1 1 1 2 3 4 5 6 Paccapelo , A. Brandes ; Bologna, IT, Modena, IT, Ferrara, IT, Cesena, IT, Parma, IT, Vicenza, IT
13:15 - 13:15 345P - Effect of ADM alone or combined with monoclonal anti-programmed death ligand-1 antibody on glioma cell lineU251 and T lymphocytes S. Zheng, H. Zhang; Nanjing, CN
13:15 - 13:15 346P - Prognostic Impact of neutrophil to lymphocyte ratio (NLR) in patients (pts) with recurrent primary malignant brain tumours (PMBT) in phase I (Ph1) trials: The Royal Marsden (RMH) Experience 1 2 2 2 2 2 3 N. Coleman , V. Michalarea , S. Alken , R. Perez Lopez , N. Tunariu , A. Petruckevitch , U. Banerji ,
2 2 2 3 1 2 3 J. de Bono , L. Welsh , F. Saran , J. Lopez ; Dublin, IE, London, GB, Sutton, Surrey/GB
13:15 - 13:15 347P - Prognostic value of pre-operative neutrophil-to-lymphocyte ratio in patients with glioblastoma multiforme Y. Kemal, O. Oltulu, E. Odabasi, O. Ozdemir, I. Yucel; Samsun, TR
13:15 - 13:15 348P - The prognostic role of gender and MGMT methylation status in glioblastoma patients: The female power 1 1 2 3 4 5 6 5 A. Tosoni , E. Franceschi , R. Depenni , B. Urbini , M. Faedi , M. Michiara , C. Biasini , E. Giombelli , 2 7 3 4 1 2 3 4 G. Pavesi , F. Zanelli , M.A. Cavallo , L. Tosatto , A. Fioravanti , E. Zunarelli , G. Lanza , D. Bartolini
5 1 1 2 3 4 5 6 , E.M. Silini , A. Brandes ; Bologna, IT, Modena, IT, Ferrara, IT, Cesena, IT, Parma, IT, 7 Piacenza, IT, Reggio Emilia, IT
13:15 - 13:15 349P - Reduced-intensity bevacizumab in progressive glioblastoma multiforme (GBM) is associated with similar overall survival versus standard-dosing 1 1 1 2 1 1 1 1 J. Gleeson , N. Keegan , E. Harrold , D. Kamel , N. Karadawi , E. Mammadov , D. Kelly , C. O'Leary 1 1 1 1 1 1 1 , P. O'Halloran , K. Egan , S. Molloy , S. Mac Nally , B. Hennessy , O. Breathnach , W. Grogan , P. 1 1 2 Morris ; Dublin, IE, Kingston, ON/CA
13:15 - 13:15 350P - An individualized-approach to second-line systemic anti-cancer therapy for glioblastoma 1 1 2 1 2 P. Gkogkou , K.(. Geropantas , T. Ajithkumar ; Norwich, GB, Cambridge, GB
13:15 - 13:15 351P - Levetiracetam offers a survival advantage in patients with epilepsy related to MGMT-unmethylated glioblastoma 1 1 1 2 3 1 2 L. Rojas , A. Ruiz-Patiño , A. Cardona , O. Arrieta , Z. Zatarain-Barrón ; Bogotá, CO, Ciudad De
3 México, Tlalpan. D.F./MX, Cd De Mexico, MX
13:15 - 13:15 352P - The prognostic role of indicators of systemic inflammatory response in patients with glioblastoma
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 3 4 2 2 1 2 3 V. Kaya , M. Yildirim , G. Yazıcı , A. Yalçın , N. Orhan , A. Güzel ; Antalya, TR, Gaziantep, TR,
4 Ankrar, TR, Isparta, TR
13:15 - 13:15 353P - Which patients with recurrent glioblastoma will require a second surgery during their treatment? A machine learning solution 1 1 1 2 3 1 2 A. Ruiz-Patiño , A. Cardona , L. Rojas , O. Arrieta , Z. Zatarain-Barrón ; Bogotá, CO, Ciudad De
3 México, Tlalpan. D.F./MX, Cd De Mexico, MX
13:15 - 13:15 354P - The prognostic role of age in salvage re-irridiation applied patients with recurrent glioblastoma: A meta-analysis 1 2 3 4 1 2 3 4 E. Dereağzı , V. Kaya , G. Yazıcı , M. Yildirim ; İstanbul, TR, Antalya, TR, Ankara, TR, Gaziantep, TR
13:15 - 13:15 355P - Temozolomide combined with fractionated stereotactic radiotherapy for large brain metastases: A propensity-matched Study Y. Ma, J. Xiao, N. Bi, Q. Liu, Y. Zhang, R. Zhao, S. Yang, Y. Li; Beijing, CN
13:15 - 13:15 356P - Worsening of quality of life (QoL), cognitive functions (CF) and psychological status (PSY) can predict radiologic progressive disease (RPD) in glioblastoma (GBM) patients (PTS) treated with radiation therapy (RT) and temozolomide (TMZ): A mono-institutional prospective study E. Bergo, G. Lombardi, P. Del Bianco, S. Dal Pos, F. Berti, L. Bellu, A. Pambuku, V. Zagonel; Padova, IT
13:15 - 13:15 357P - Dose distribution after tumor cavity injection in brain glioma patients M. Zhao, X. Fu; Beijing, CN
13:15 - 13:15 358P - Retrospective analysis to ascertain whether thromboembolic events, patient gender and tumour size have prognostic implications for glioblastoma multiforme D. Parslow, S. Pascoe; Plymouth, GB
13:15 - 13:15 359P - The standard and high dose chemotherapy dose intensity and their effect on the survival of medulloblastoma using nation-wide treatment protocol J.Y. Lim, L.M.-J. Cha, S.M. Hahn, C.-O. Suh, D.-S. Kim, C.J. Lyu, J.W. Han; Seoul, KR
13:15 - 13:15 360P - Primary central nervous system germ cell tumours: A single institution retrospective study J. Silva, M. Ramos, A. Azevedo, D. Salgado, I. Costa, J. Marques; Lisbon, PT
13:15 - 13:15 361P - Effect of silibinin nutraceutical supplementation in brain metastases of patients with advanced lung cancer 1 1 1 1 1 1 1 J. Bosch-Barrera , E. Sais , A. Izquierdo , A. Hernández , D. Roa , E. Cuyas , S. Pedraza , N. Priego 2 1 1 1 1 3 1 2 , P. Ortuño , G. Sánchez , N. Cañete , A. Roselló , R. Soffietti , J. Brunet , M. Valiente , J.A. 1 1 2 3 Menendez ; Girona, ES, Madrid, ES, Torino, IT
13:15 - 13:15 362P - Melanoma with V600 BRAF mutations and brain metastases: Experience of targeted therapy in a single center D. Naskhletashvili, L. Demidov; Moscow, RU
13:15 - 13:15 363P - Radioprotective effect of xenon in radiation treatment for brain metastases
Last update: 02-09-2017 06:01:33pm esmo.org M. Zinkovich, T. Protasova, A. Shikhlyarova, L. Rozenko, Y. Arapova; Rostov-On-don, RU
13:15 - 13:15 ENDOCRINE AND NEUROENDOCRINE TUMOURS J. Strosberg, Tampa, US
13:15 - 13:15 442P - Long-term survival of patients with carcinoid syndrome in clinical trials of telotristat ethyl 1 2 3 4 5 6 7 8 P. Lapuerta , M.H. Kulke , M. Caplin , E. Bergsland , L. Anthony , K. Öberg , M. Pavel , D. Hörsch , 9 10 11 11 1 2 3 T. O'Dorisio , J. Dillon , K. Kassler-Taub , W. Jiang ; Princeton, US, Boston, Ma, US, London,
4 5 6 7 8 9 GB, San Francisco, CA/US, Lexington, US, Uppsala, SE, Berlin, DE, Bad Berka, DE, Iowa City, 10 11 US, Iowa City, IA/US, The Woodlands, US
13:15 - 13:15 443P - Identifying symptom and quality of life improvements in patients with carcinoid syndrome treated with telotristat ethyl: Qualitative patient exit interviews from the TELESTAR Trial 1 2 1 2 1 2 F. Marteau , P. Williams , M. Feuilly , B. Arnould ; Boulogne-Billancourt, FR, Lyon, FR
13:15 - 13:15 444P - Carcinoid syndrome: Patient outcomes from a European Neuroendocrine Tumour Society (ENETs) centre of excellence 1 2 1 1 1 1 1 1 P. d'Arienzo , E. Amir , A. Lewis , L. Magdalani , W. Mansoor , R. Hubner , J. Valle , M. McNamara ;
1 2 Manchester, GB, Toronto, Ontario/CA
13:15 - 13:15 445P - Relationship between symptoms and health-related quality of life benefits in patients with carcinoid syndrome: Post-hoc analyses from TELESTAR 1 2 2 3 4 4 4 4 M. Pavel , D. Cella , J. Beaumont , S. Hudgens , F. Marteau , M. Feuilly , S. Gabriel , A. Houchard , 5 6 7 1 2 3 4 J. Ramage , D. Hörsch , M.H. Kulke ; Berlin, DE, Chicago, Il, US, New York, Arizona/US, 5 6 7 Boulogne-Billancourt, FR, Basingstoke, GB, Bad Berka, DE, Boston, Ma, US
13:15 - 13:15 446P - Benefit of oral monotherapy with pazopanib in metastatic gastroenteropancreatic neuroendocrine tumours 1 2 2 1 2 D. Katalinic , I. Aleric , A. Vcev ; Zagreb, HR, Osijek, HR
13:15 - 13:15 447P - High hepatic tumor burden and cardiovascular comorbidities linked to carcinoid heart disease M. Mesquita, C. Silva, C. Silva, M. Feres Almeida Soeiro, L. Hajjar, P. Gehm Hoff, R. Riechelmann; Sao
Paulo, BR
13:15 - 13:15 448P - Bone metastases in patients with neuroendocrine neoplasms: A survey of natural history and clinical management 1 1 1 2 3 4 1 N. Fazio , P. Maisonneuve , A.M. Frezza , T. Ibrahim , A. La Salvia , S. Tafuto , S. Pusceddu , R. 5 6 7 8 9 1 10 Marconcini , F. Silvestris , D. Campana , D. Santini , A. Faggiano , S. Massironi , L. De Marinis , G. 6 8 11 12 13 1 1 2 3 Rubini , E. Merola , L. Antonuzzo , V. Amoroso , I. Puliafito , F. Spada ; Milan, IT, Meldola, IT, 4 5 6 7 8 9 10 11 Orbassano, IT, Napoli, IT, Pisa, IT, Bari, IT, Bologna, IT, Roma, IT, Naples, IT, Rome, IT, 12 13 Firenze, IT, Brescia, IT, Viagrande, IT
13:15 - 13:15 449P - Financial toxicity in patients with neuroendocrine tumors: Impact of a chronic disease on patients’ economic situation
Last update: 02-09-2017 06:01:33pm esmo.org 1 1 1 2 1 2 1 1 L. Apostolidis , K. Mehlis , M. Kudlich , J. Witte , J. Walther , W. Greiner , E. Winkler ; Heidelberg,
2 DE, Bielefeld, DE
13:15 - 13:15 450P - Pancreatic exocrine insufficiency (PEI) in patients (pts) with well-differentiated neuroendocrine tumours (wd-NETs) treated with somatostatin analogues (SSAs): Incidence and impact on quality of life A. Lamarca, L. McCallum, C. Nuttall, J. Barriuso, M. Frizziero, R. Leon, W. Mansoor, M. McNamara, R.
Hubner, J. Valle; Manchester, GB
13:15 - 13:15 451P - Final analysis of time to subsequent disease progression/death in patients with metastatic enteropancreatic neuroendocrine tumours progressing under placebo and switched to lanreotide autogel/depot 120mg in the CLARINET open-label extension 1 2 3 4 5 6 7 8 J. Cwikla , E. Wolin , M. Pavel , A. Phan , M. Raderer , E. Sedláčková , G. Cadiot , J. Capdevila , G. 9 10 11 11 12 13 1 Rindi , C. Lombard-Bohas , N. Liyanage , X.-M. Truong Thanh , P. Ruszniewski , M. Caplin ;
2 3 4 5 6 7 Olsztyn, PL, New York, US, Erlangen, DE, Albuquerque, NM/US, Vienna, AT, Prague, CZ, Reims, 8 9 10 11 12 13 FR, Barcelona, ES, Roma, IT, Lyon, FR, Les Ulis, FR, Clichy, FR, London, GB
13:15 - 13:15 452P - Temozolomide-capecitabine (TemCap) chemotherapy for neuroendocrine neoplasms (NENs): Time to maximum response and optimal treatment duration A. Lamarca, J. Barriuso, L. McCallum, G. Papaxoinis, M. Nasralla, C. Nuttall, M. Frizziero, Z. Kordatou,
M. McNamara, R. Hubner, P. Manoharan, W. Mansoor, J. Valle; Manchester, GB
13:15 - 13:15 453P - Efficacy of recombinant human endostatin combined with chemotherapy in advanced pancreatic neuroendocrine tumors Y. Cheng, Beijing, CN/CN
13:15 - 13:15 454P - Comparison of clinical efficacy of SST analogues therapy (lanreotide autogel vs. octreotide LAR) in treatment of patients with advance, non-resectable pancreatic neuroendocrine tumours (pNETs) 1 2 1 1 1 3 A. Kolasinska-Cwikla , A. Lewczuk , J. Palucki , L. Sawicki , K. Roszkowska-Purska , M. Kidd , L. 4 5 6 1 2 3 4 5 Bodei , I. Modlin , J. Cwikla ; Warsaw, PL, Gdansk, PL, Branford, CT/US, Milan, IT, New Haven, 6 CT/US, Olsztyn, PL
13:15 - 13:15 455P - Metastatic neuroendocrine neoplasia (mNEN) treatments in over 70 years (y) old patients: A retrospective outcome analysis 1 2 3 1 4 5 6 2 A. Bongiovanni , F. Foca , F. Recine , V. Fausti , N. Riva , E. Setola , M. Faedi , A. Ianniello , F. Pieri 7 2 7 7 7 7 2 1 , R. Galassi , D. Cavaliere , A. Gardini , A. Tartaglia , V. Lunedei , L. Mercatali , D. Amadori , T.
2 1 2 3 4 5 6 Ibrahim ; Meldola, Forlì-Cesena/IT, Meldola, IT, Roma, IT, Meldola (fc), IT, Milan, IT, Cesena, IT, 7 Forli, IT
13:15 - 13:15 456P - Modified staging classification for gastric neuroendocrine carcinomas on the basis of the American Joint Committee on cancer J. Xie, H. Chang-Ming, C. Zheng, P. Li, J. Lin; Fuzhou, CN
13:15 - 13:15 457P - Predictive factors in GEP-NEN: The integrated role of Ki67, beta-catenin and morphology 1 1 1 1 1 1 2 M. MILIONE , R. Miceli , A. Pellegrinelli , G. Centonze , F. Barretta , S. Pusceddu , L. Giacomelli , J.
1 1 1 3 1 1 2 3 Coppa , V. Mazzaferro , G. Sozzi , A. Anichini , F. de Braud ; Milan, IT, Genoa, IT, Milano, IT
Last update: 02-09-2017 06:01:33pm esmo.org 13:15 - 13:15 458P - The preoperative blood lymphocyte-to-monocyte ratio acts as a superior prognostic factor and predicts tumor metastasis in gastric neuroendocrine neoplasms after surgery L. Cao, H. Chang-Ming, J. Lin, J. Lu, C. Zheng; Fuzhou, CN
13:15 - 13:15 459P - Follow-up and recurrence in resected gastroenteropancreatic neuroendocrine tumours: A population-based study 1 2 3 3 3 3 4 1 2 D. Chan , E. Segelov , L. Moody , N. Liu , H. Fischer , P. Austin , S. Singh ; St Leonards, AU,
3 4 Melbourne, NSW/AU, Toronto, CA, Toronto, Ontario/CA
13:15 - 13:15 460P - Elevated levels of 5-HIAA and CgA in patients with PanNETs from the CLARINET Study 1 2 3 4 4 5 6 A. Phan , E. Wolin , N. Liyanage , B. Mirakhur , S. Pitman Lowenthal , A. Vinik , G. Fisher, Jr , M. 7 1 2 3 4 5 Pavel ; Albuquerque, NM/US, Bronx, NY/US, Les Ulis, FR, Basking Ridge, NJ/US, Norfolk, VA/US, 6 7 Stanford, CA/US, Berlin, DE
13:15 - 13:15 461P - An open-label, multicenter Phase 1b study of radium-223 + paclitaxel in cancer patients with bone metastases L. Gurevich, N. Korsakova, I. Voronkova, I. Kazantseva, V. Ashevskaya, A. Titov, L. Kogoniya, M.
Byakhova; Moscow, RU
13:15 - 13:15 462P - A nomogram based on tumor-associated neutrophil-to-lymphocyte ratio to predict survival prognosis for patients with gastric neuroendocrine neoplasms L.-L. Cao, H. Chang-Ming, J. Lu, J. Xie, P. Li; Fuzhou, CN
13:15 - 13:15 463P - Plasma protein fingerprinting and machine learning for the diagnosis of small intestinal neuroendocrine tumors: The nordic NET biomarker group EXPLAIN study 1 2 3 4 5 6 M. Kjellman , S. Welin , U. Knigge , H. Gronbaek , H. Sorbye , E. Thiis-Evensen , M. Thyregod 7 8 9 10 1 1 10 1 Jørgensen , V. Johanson , C. Schalin-Jäntti , P. Myrenfors , T. Ström , K. Becker , R. Belusa ;
2 3 4 5 6 7 Stockholm, SE, Uppsala, SE, Copenhagen, DK, Aarhus, SE, Bergen, NO, Oslo, SE, Odense, DK, 8 9 10 Gothenburg, SE, Helsinki, FI, Kista, SE
13:15 - 13:15 464P - CXCR4 inhibition by ulocuplumab prevents EMT of pNET cells in vitro 1 2 1 1 1 1 1 1 E. Pellé , M. Cives , D. Quaresmini , D. Lovero , C. Felici , P. Cafforio , R. Palmirotta , F. Silvestris ;
1 2 Bari, IT, Tampa, FL/US
13:15 - 13:15 465P - Interim baseline characteristics from RIFTOS MKI, a global non-interventional study assessing the use of multikinase inhibitors (MKIs) in the treatment of patients with asymptomatic radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC): A European subgroup analysis 1 2 3 4 5 6 7 8 9 J. Smit , M. Brose , F. Pitoia , C.-C. Lin , I. Sugitani , M. Alevizaki , Y. Godbert , J. Aller , R. Peeters 10 11 12 12 13 1 , K. Pazaitou-Panayiotou , L. Leenhardt , M. Fellous , Y. De Sanctis , M. Schlumberger ; 2 3 4 5 6 7 Nijmegen, NL, Philadelphia, PA/US, Buenos Aires, AR, Taipei, TW, Tokyo, JP, Athens, GR, 8 9 10 11 12 13 Bordeaux, FR, Madrid, ES, Rotterdam, NL, Thessaloniki, GR, Paris, FR, Whippany, US, Villejuif, CEDEX/FR
13:15 - 13:15 466P - Mixed adeno-neuroendocrine carcinoma (MANEC) of the gastroenteropancreatic (GEP) tract: A multicentre retrospective study
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 2 3 4 5 6 6 M. Frizziero , X. Wang , B. Chakrabarty , A. Childs , T.V. Luong , T. Walter , M. Elshafie , T. Shah , 2 2 2 4 2 2 2 1 P. Fulford , A. Minicozzi , W. Mansoor , T. Meyer , R. Hubner , J. Valle , M. McNamara ; Vipiteno, 2 3 4 5 6 Bolzano/IT, Manchester, GB, Bt, GB, London, GB, Hamburg, DE, Birmingham, GB
13:15 - 13:15 467P - Incidence of adrenal gland tumor as a second primary malignancy: SEER based database 1 1 1 1 1 1 1 2 1 W. Rashed , A. Saad , M. Al-Husseini , A. Galal , A. Al-Tayep , A. El Shafie , M. Ali , A. Alfaar ;
2 Cairo, EG, Berlin, DE
13:15 - 13:15 468P - Activity of temozolomide (TMZ) in patients (PTS) with malignant pheochromocytoma or paraganglioma (MPP): A mono-institutional retrospective study G. Lombardi, M. Ferrara, A. Pambuku, M. Lorusso, F. Boaretto, F. Schiavi, L. Biasini, F. Azzolin, G.
Opocher, S. Zovato, V. Zagonel; Padova, IT
13:15 - 13:15 469P - Neuroendocrine carcinoma of the uterine cervix: A retrospective monocentric study 1 1 1 1 2 1 1 1 M. Creoff , S. Thezenas , A. Lapierre , A. Ducteil , D. Azria , C. Bourgier , C. Kerr ; Montpellier, FR,
2 Montpellier, CEDEX 5/FR
13:15 - 13:15 470TiP - AGITG NABNEC: A randomised phase II study of nab-paclitaxel in combination with carboplatin as first line treatment of gastrointestinal neuroendocrine carcinomas 1 2 3 4 5 5 6 5 M. Khasraw , M. Hofman , L. Chantrill , N. Pavlakis , V. Gebski , A. Gill , B. Markman , S. Yip , E. 5 7 1 8 2 5 5 6 1 Gibbs , C. Karapetis , S.F. Wong , D. Ransom , M. MICHAEL , K. Wilson , J. Simes , L. Lipton ;
2 3 4 5 6 Geelong, VIC/AU, Melbourne, AU, Darlinghurst, NSW/AU, St Leonards, NSW/AU, Sydney, AU, 7 8 Melbourne, VIC/AU, Bedford Park, SA/AU, Subiaco, WA/AU
13:15 - 13:15 471TiP - A multicentre, randomised, double-blind, parallel-group, placebo-controlled trial of apatinib in local progressive or metastatic radioactive iodine-refractory differentiated thyroid cancer 1 2 1 2 Y. Lin , S. Qin ; Beijing, CN, Nanjing, CN
13:15 - 13:15 472TiP - Phase 2 clinical investigation of BPM31510 (ubidecarenone) alone and in combination with gemcitabine in patients with advanced pancreatic cancer 1 2 2 3 4 5 1 A. Niewiarowska , R. Sarangarajan , D. Lucius , N. Narain , R. Raminathan , M. Hidalgo ;
2 3 4 5 Bethlehem, PA/US, Framingham, MA/US, Natick, MA/US, Phoenix, AZ/US, Madrid, ES
13:15 - 13:15 GENITOURINARY TUMOURS, PROSTATE 1 2 1 2 K. Fizazi , D. Lorente Estelles ; Villejuif, FR, Valencia, ES
13:15 - 13:15 794P - EPI-506 (ralaniten acetate), a novel androgen receptor (AR) N-terminal domain (NTD) inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC): Phase 1 update on safety, tolerability, pharmacokinetics and efficacy 1 2 3 4 5 6 U. Vaishampayan , R. Montgomery , M. Gordon , D. Smith , K. Barber , A. de Haas-Amatsaleh , N. 5 5 5 7 1 2 3 4 Thapar , C. Chandhasin , F. Perabo , K. Chi ; Detroit, MI/US, Seattle, US, Scottsdale, AZ/US, Ann 5 6 7 Arbor, US, Houston, US, Houston, TX/US, Vancouver, CA
13:15 - 13:15 795P - An innovative Dendritic Cell Vaccine for Castration-Resistant Prostate Cancer Patients: radiological PFS results
Last update: 02-09-2017 06:01:33pm esmo.org 1 1 1 1 2 1 H. Westdorp , I.M. van Oort , G. Schreibelt , A.L. de Goede , N. Mehra , C.A. Hulsbergen-van de Kaa 1 1 1 1 1 1 1 , C.G. Figdor , F. Witjes , E. Aarntzen , R.D.M. Mus , M. Gotthardt , J.O. Barentsz , I.J.M. de Vries , 1 1 2 W. Gerritsen ; Nijmegen, NL, Nijmegen, Surrey/NL
13:15 - 13:15 796P - Phase I expansion cohort of TAS-115, a novel oral MET/VEGFR/FMS inhibitor, for castration-resistant prostate cancer patients (CRPC pts) with bone metastases 1 2 2 2 2 3 1 1 N. Matsubara , Y. Naito , M. Sasaki , N. Yamamoto , S. Takahashi , H. Uemura , T. Doi ; Kashiwa,
2 3 Chiba/JP, Tokyo, JP, Yokohama, JP
13:15 - 13:15 797P - Phase II trial of SM88 in non-metastatic biochemical recurrent prostate cancer 1 2 2 3 4 1 2 3 G. Del Priore , W.-T. Chen , H. Dong , S. Hoffman , G. Sokol ; Atlanta, US, Stony Brook, NY/US,
4 New York, NY/US, Bethesda, MD/US
13:15 - 13:15 798P - Impact of the addition of metformin (Met) to abiraterone (Abi) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) progressing on Abi treatment: A phase II pilot study 1 2 1 3 4 4 1 M. Mark , D. Klingbiel , U. Mey , R. Winterhalder , C. Rothermundt , S. Gillessen , R. von moos , G.
1 1 1 2 3 4 Manetsch , R. Cathomas ; Chur, CH, Berne, CH, Luzern, CH, St. Gallen, CH
13:15 - 13:15 799P - Steroid switch: Reversal of resistance to abirateron acetate (AA) and prednisolone (P) combination in metastatic castration-resistant prostate cancer (mCRPC) patients F. Gyergyay, B. Budai, K. Biro, Z. Küronya, K. Nagyivanyi, L. Geczi; Budapest, HU
13:15 - 13:15 800P - Phase II study of prednisone-dexamethasone switch in metastatic castration resistant prostate cancer (mCRPC) patients treated with abiraterone and prednisone (AA+P) 1 2 3 4 5 6 R. Lozano Mejorada , N. Romero Laorden , A. Jayaram , F. López , M.I. Sáez , R. Villatoro , A. 6 5 6 4 4 4 Montesa , I. Moreno , M. Ruiz Vico , M. García Ferrón , J. Rogado , Y. Cendón Flórez , P. Nombela 4 4 6 1 7 8 Blanco , L. Rivera , G. Grau , J.J. Cruz Hernandez , D. Lorente Estelles , G. Attard , E. Castro Marcos 4 4 1 2 3 4 5 , D. Olmos Hidalgo ; Salamanca, ES, Madrid, Madrid/ES, London, GB, Madrid, ES, Malaga, ES, 6 7 8 Málaga, ES, Valencia, ES, Sutton, Surrey/GB
13:15 - 13:15 801P - Effect of sequence on outcome of prostate cancer patients: retrospective study of a French cohort R. Elaidi, Y. Belhadj, S. Oudard; Paris, FR
13:15 - 13:15 802P - Patient preference between Cabazitaxel and Docetaxel for first-line chemotherapy in metastatic castrate-resistant prostate cancer (mCRPC): Results from the CABADOC randomized trial 1 2 3 4 5 6 7 K. Fizazi , R. Delva , G. Gravis , G. Baciarello , C. Theodore , M. Gross-Goupil , E. Bompas , F. Joly 8 9 10 11 12 13 Lobbedez , Y. Tazi , T. L'Haridon , T. Nguyen Tan Hon , P. Barthelemy , S. Culine , J.-F. Berdah 14 15 16 17 18 1 1 1 , M. Deblock , P. Beuzeboc , A. Fléchon , C. Cheneau , G. Martineau , I. Borget ; Villejuif, 2 3 4 5 6 7 FR, Angers, FR, Marseille, CEDEX 9/FR, Villejuif, CEDEX/FR, Suresnes, FR, Bordeaux, FR, 8 9 10 Saint-Herblain, CEDEX/FR, Caen, CEDEX 5/FR, Strasbourg, FR, La Roche Sur Yon, CEDEX 9/FR, 11 12 13 14 15 Besançon, CEDEX/FR, Strasbourg, CEDEX/FR, Paris, CEDEX 10/FR, Hyeres, FR, 16 17 18 Vandoeuvre Les Nancy, CEDEX/FR, Paris, CEDEX 5/FR, Lyon, FR, Lorient, CEDEX/FR
13:15 - 13:15 803P - Indirect comparison of abiraterone acetate and docetaxel for treatment of metastatic “hormone-sensitive” prostate cancer
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 3 4 2 2 5 6 S. Feyerabend , F. Saad , T. Li , T. Ito , J. Diels , S. Van Sanden , P. De Porre , J. Roïz , S. 6 7 1 2 3 4 5 Abogunrin , K. Fizazi ; Reutlingen, DE, Beerse, BE, Raritan, NJ/US, Buckinghamshire, GB, 6 7 Antwerp, BE, London, GB, Villejuif Cedex, FR
13:15 - 13:15 804P - Practice patterns in metastatic castration-resistant prostate cancer (mCRPC): Evidence from the veterans health administration 1 1 2 1 3 3 3 A. Halwani , Z. Burningham , K. Rasmussen , V. Patil , S. Narayanan , S.-W. Lin , S. Carroll , L.-I. 3 4 5 2 1 1 1 2 Hsu , J. Graff , R. Dreicer , S. Gupta , C. Low , B. Sauer ; Salt Lake City, UT/US, Salt Lake City, 3 4 5 US, South San Francisco, CA/US, Portland, US, Charlottesville, VA/US
13:15 - 13:15 805P - Efficacy and safety of first-line combined androgen blockade in advanced prostate cancer: A meta-analysis Y. Sun, Y. Yang, R. Chen, L. Zhao, F. Liu, S. Ren, H. Wang, X. Lu, X. Gao, C. Xu; Shanghai, CN
13:15 - 13:15 806P - Outcomes of prechemotherapy (pCRx) abiraterone acetate (AA) or enzalutamide (E) for metastatic castration-resistant prostate cancer (mCRPC) after ADT + Docetaxel (D) or ADT alone for metastatic hormone sensitive prostate cancer (mHSPC) in a multi-institution hospital-based registry 1 2 2 2 3 1 1 1 E. Francini , S. Yip , N. Ahmed , H. Li , L. Ardolino , C. Evan , M. Kaymakcalan , G. Shaw , P. 1 4 5 6 5 1 1 2 Kantoff , M.E. Taplin , N. Alimohamed , A. Joshua , D. Heng , C. Sweeney ; Boston, MA/US, 3 4 5 6 Calgary, AB/CA, Sydney, NSW/AU, Boston, US, Calgary, CA, Sydney, AU
13:15 - 13:15 807P - First interim results of the radium-223 (Ra-223) REASSURE observational study: Analysis of patient (Pt) characteristics and safety by use of abiraterone and/or enzalutamide (Abi/Enza) 1 2 3 4 5 6 7 L. Harshman , J. Logue , C. Sternberg , S. Sundar , D. Schrijvers , M. Schostak , J. Sylvester , S. 8 9 10 11 12 13 14 15 George , M. Tucci , C. Mantz , P. Borrega , P. Ziem , R. Concepcion , K. Miller , O. Sartor , J. 16 17 18 1 2 3 4 Kalinovsky , Y. De Sanctis , B. Tombal ; Boston, MA/US, Manchester, GB, Roma, IT, 5 6 7 8 Nottingham, Nottinghamshire/GB, Antwerp, BE, Magdeburg, DE, Lakewood Ranch, FL/US, Buffalo, 9 10 11 12 13 US, Orbassano, TO/IT, Fort Myers, FL/US, Caceres, Cáceres/ES, Neubrandenburg, DE, 14 15 16 17 18 Nashville, TN/US, Berlin, DE, New Orleans, LA/US, Bratislava, SK, Whippany, NJ/US, Brussels, BE
13:15 - 13:15 808P - A phase II study of enzalutamide (Enz) with dutasteride (Dut) or finasteride (Fin) in men ≥ 65 years with hormone-naive systemic prostate cancer (HNSPCa) 1 2 2 1 2 2 1 D. KILARI , E. Guancial , D. Sahasrabudhe , K. Bylow , L. Sievert , K. Schaffer , M. Riese , J. 1 1 2 2 2 2 1 2 Burfeind , K. Musto , C. Feng , E. Messing , S. Mohile , C. Fung ; Milwaukee, US, Rochester, NY/US
13:15 - 13:15 809P - Cabazitaxel plus prednisone and prophylaxis of neutropenia complications in the treatment of metastatic castration-resistant prostate cancer after failure to docetaxel: A multicenter, non-comparative, open-label, phase IV study 1 2 3 4 5 6 7 1 F. Maluf , D. Cubero , F. de Oliveira , P. Liedke , L. Brust , C. Inocêncio , F. Monteiro ; Sao Paulo,
2 3 4 5 6 7 BR, Santo Andre, SP/BR, Curitiba, BR, Porto Alegre, BR, Lageado, BR, Cuiaba, BR, Brasilia, BR
13:15 - 13:15 810P - Assessment of health-related quality of life (HRQL) in PROSELICA: A Phase 3 trial assessing cabazitaxel 20 &
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 3 4 5 6 7 M. Eisenberger , A.-C. Hardy-Bessard , C.S. Kim , L. Géczi , D. Ford , L. Mourey , J. Carles , P. 8 9 10 11 12 12 11 13 1 Parente , A. Font , G. Kacsó , G. Barnes , H. Wang , W. Zhang , A. Ozatilgan , J. de Bono ; 2 3 4 5 6 7 Baltimore, US, Plerin-Sur-mer, FR, Seoul, KR, Budapest, HU, Birmingham, GB, Toulouse, FR, 8 9 10 11 12 Barcelona, ES, Box Hill, AU, Badalona, ES, Cluj-Napoca, RO, Cambridge, MA/US, 13 Bridgewater, NJ/US, London, GB
13:15 - 13:15 811P - Cabazitaxel followed by androgen deprivation therapy (ADT) significantly improves time to progression in patients with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC): A randomized, open label, phase III, multicenter trial 1 2 1 1 1 2 O. Andrén , A. Widmark , A. Falt , E. Ulvskog , S. Davidsson , C. Thellenberg Karlsson , M.
3 1 2 3 Hjalm-Eriksson ; Orebro, SE, Umea, SE, Stockholm, SE
13:15 - 13:15 812P - Health-related quality of life (HRQL) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel (CBZ) in a prospective observational study (CAPRISTANA) 1 2 3 4 5 6 6 A. Pichler , G. Barnes , J. Katolicka , H. Korunkova , A. Tomova , M. Ghosn , F. El Karak , I. Koroleva 7 6 8 9 10 1 2 3 4 , J. Makdessi , A. Ozatilgan , S. Hitier , J. Carles ; Leoben, AT, Cambridge, MA/US, Brno, CZ, 5 6 7 8 9 10 Plzen, CZ, Plovdiv, BG, Beirut, LB, Samara, RU, Istanbul, TR, Chilly-Mazarin, FR, Barcelona, ES
13:15 - 13:15 813P - Real-world use of docetaxel for metastatic castration-resistant prostate cancer in China: Results from a large observational study 1 2 2 3 4 5 5 5 2 3 6 D. He , Z. Sun , J. Guo , Z. Zhang , Y. Shan , L. Ma , H. Li , J. Jin , Y. Huang , J. Xiao , Q. Wei , D.
2 1 2 3 4 5 6 Ye ; Xi'an, CN, Shanghai, CN, Hangzhou, CN, Suzhou, CN, Beijing, CN, Chengdu, CN
13:15 - 13:15 814P - Longer time from diagnosis to docetaxel treatment results in a shorter survival in metastatic hormonosensitive prostate cancer (mHSPC) patients treated with chemotherapy+androgen deprivation therapy (ADT) 1 2 3 4 1 5 M.A. Climent Duran , B. Mellado , J.M. Piulats Rodriguez , L. Heras Lopez , M.J. Juan , M.I. Sáez , O. 2 6 2 4 2 1 2 6 Reig , A. Montesa , J.F. Suarez , R. Hajianfar , M.J. Ribal , J. Rubio , M. Castells , R. Villatoro , S.
1 7 1 2 3 4 Sandiego , D. Olmos Hidalgo ; Valencia, ES, Barcelona, ES, Barcelona, Barcelona/ES, Sant Joan 5 6 7 Despí, ES, Malaga, ES, Málaga, ES, Madrid, ES
13:15 - 13:15 815P - Prognostic value of systemic inflammatory biomarkers in patients with mCRPC treated with abiraterone in pre-docetaxel setting 1 1 2 1 2 2 1 R. Ratta , E. Verzoni , F. Pantano , P. Grassi , D. De Lisi , A. Onorato , M. Prisciandaro , R. Montone
3 1 4 1 1 2 3 4 , F. de Braud , D. Santini , G. Procopio ; Milan, IT, Rome, IT, Milano, IT, Roma, IT
13:15 - 13:15 816P - 68Ga-PSMA-PET/CT as a changing practice tool in biochemically recurrent prostate cancer P. Domingues, T. Abreu, M. Siqueira, G. Marinho, D. Rosa, H. Cottas, L. Araujo, D. Herchenhorn, F.
Peixoto; Rio De Janeiro, BR
13:15 - 13:15 817P - Prostascore: A simplified tool for predicting outcomes among patients with treatment-naïve advanced prostate cancer O. Abdel-Rahman, Cairo, EG
Last update: 02-09-2017 06:01:33pm esmo.org 13:15 - 13:15 818P - PSA doubling time (PSADT) and proximal PSA predict metastasis-free survival (MFS) in men with biochemically recurrent prostate cancer (BRPC) after radical prostatectomy (RP): Implications for patient counseling and clinical trial design 1 2 3 3 4 3 3 1 M. Markowski , Y. Chen , Z. Feng , B. Trock , J. Cullen , D. Suzman , E. Antonarakis , C. Paller , M. 3 3 1 1 2 3 4 Han , A. Partin , M. Eisenberger ; Baltimore, US, Rockville, MD/US, Baltimore, MD/US, Rockville, US
13:15 - 13:15 819P - PSA kinetics impact on CT-PET PSMA uptake in prostate cancer 1 2 3 1 2 3 A. Sella , S. Kovel , T. Sella ; Zerifin, IL, Beer Jacob, IL, Ramat Gan, IL
13:15 - 13:15 820P - Combining functional imaging with circulating biomarker analysis to improve prognostication of metastatic castration-resistant prostate cancer (mCRPC) 1 2 2 2 1 1 3 2 V. Conteduca , S. Salvi , P. Caroli , E. Scarpi , G. Schepisi , C. Lolli , D. Wetterskog , S.L. Burgio , 1 2 4 1 5 1 1 C. Menna , V. Casadio , F. Matteucci , G. Paganelli , G. Attard , U. De Giorgi ; Meldola, 2 3 4 5 Forlì-Cesena/IT, Meldola, IT, Sutton, GB, Meldola (fc), IT, Sutton, Surrey/GB
13:15 - 13:15 821P - A polymorphism in the promoter of the FRAS1 gene is associated with metastatic prostate cancer 1 2 1 1 1 3 1 C. Sweeney , M. Geybels , S. Coseo-Markt , V. Wang , K. Penney , T. Gerke , M. Pomerantz , 1 4 1 1 1 2 3 G.-S.M. Lee , D. Nitsch , C. Huttenhower , L. Mucci ; Boston, MA/US, Seattle, WA/US, Tampa, 4 FL/US, Hamburg, DE
13:15 - 13:15 822P - Phenotypic circulating tumor cell (CTC) classifier of genomic instability (GI) associates with improved overall survival (OS) for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) receiving platinum agents in addition to taxanes 1 2 2 3 3 3 2 2 H. Scher , R. Graf , A. Jendrisak , B. McLaughlin , E. Barnett , N. Schreiber , J. Lee , J. Kelvin , Y. 2 4 5 1 2 3 4 Wang , M. Landers , R. Dittamore ; New York, Ny, US, San Diego, CA/US, New York, NY/US, San 5 Diego, US, New York, US
13:15 - 13:15 823P - Expression of steroid hormone transporter, SLCO1B3, is mediated by a CBP/p300 regulatory mechanism in prostate cancer 1 2 2 2 2 2 2 2 1 E. McCrea , P. Huang , E. Harris , J. Strope , T. Sissung , D. Price , C. Chau , W. Figg ; Cairo, EG,
2 Bethesda, MD/US
13:15 - 13:15 824P - ARV7 status and CTC count: A combined biomarker for the baseline therapeutic decision in each line of mCRPC treatment E. Bournakis, E. Lianidou, A. Strati, M. Zavridou, A. Sfika, A. Bournakis, C. Papadimitriou; Athens, GR
13:15 - 13:15 825P - Limited value of currently used germline brca mutations predictive tools in prostate cancer 1 2 3 1 1 L. Oliva Fernández , M.A. Márquez-Aragonés , N. Romero-Laorden , B.I. Pajares Hachero , I. Moreno 2 1 2 1 2 , M. Ruiz Vico , G. Duran Ogaya , C. Muriel , J. Pascual , C. Fernández de Souza , M.E. Dominguez
1 2 1 2 2 3 1 2 Recio , G. Grau , M.I. Sáez , A. Montesa , R. Correa , D. Olmos Hidalgo ; Malaga, ES, Málaga, ES, 3 Madrid, ES
13:15 - 13:15 826P - Prevalence and baseline clinico-pathological associations of germline deleterious mutations in DNA repair genes (gmDDR) in a metastatic castration resistant prostate cancer (mCRPC) prospective spanish cohort (PROREPAIR-B study)
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 3 4 5 N. Romero Laorden , R. Lozano Mejorada , J.M. Piulats Rodriguez , E. Vallespín , A. Montesa , D. 6 7 5 8 4 Lorente Estelles , J.C. Villaguzmán , G. Grau , A. Rodriguez-Vida , K. Ibañez , E. 9 4 6 10 4 5 Gonzalez-Billalabeitia , L. Magraner , J. Garde , S. Hernando Polo , J. Arranz Arija , R. Villatoro , B.
11 4 4 4 1 2 Pérez Valderrama , P. Lapunzina , E. Castro Marcos , D. Olmos Hidalgo ; Madrid, Madrid/ES, 3 4 5 6 7 Salamanca, ES, Barcelona, Barcelona/ES, Madrid, ES, Málaga, ES, Valencia, ES, Ciudad Real, 8 9 10 11 ES, Barcelona, ES, Murcia, ES, Alcorcon, Madrid/ES, Sevilla, ES
13:15 - 13:15 827P - Comprehensive characterization of BRCA1 and BRCA2 alterations in circulating tumor DNA and tumor tissue in men with prostate cancer: Implications for clinical care 1 1 1 2 1 2 2 1 P. Lara , J. McPherson , W. Heyer , R. Hartmaier , R. Devere White , J. Chung , S. Ali , M. Dall'Era ;
1 2 Sacramento, CA/US, Cambridge, MA/US
13:15 - 13:15 828P - Durable prostate cancer control in a randomized trial of optimal timing of dose escalated (76 Gy) radiation and 6 months ADT in prostate cancer 1 1 1 1 1 1 1 2 1 S. Malone , L. Eapen , C. E , W. Kendal , J. Craig , R. Macrae , G. Perry , J. Bowen , S. Morgan , O.
1 1 1 2 Holmes , S. Grimes ; Ottawa, CA, Sudbury, CA
13:15 - 13:15 829P - Initial results from AQUARiUS, a prospective, observational, multi-centre phase IV study assessing patient-reported outcomes (PROs) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate plus prednisone (AAP) or enzalutamide (ENZ) 1 2 3 4 5 6 7 A. Thiery-Vuillemin , M.H. Poulsen , A. Reid , E. Lagneau , G. Ploussard , A. Birtle , L.M. Dourthe , D. 8 9 10 11 12 13 1 Beal-Ardisson , E. Pintus , R. Trepiakas , M. Lukac , S. Van Sanden , L. Dearden ; Besançon,
2 3 4 5 6 7 8 FR, Odense, DK, Sutton, Surrey/GB, Dijon, FR, Toulouse, FR, Preston, GB, Strasbourg, FR, 9 10 11 12 13 Lyon, FR, Reading, GB, Naestved, DK, Prague, CZ, Beerse, BE, High Wycombe, GB
13:15 - 13:15 830P - Assessment of association between clinical characteristics and prostate specific antigen (PSA) progression in men with prostate cancer (PCa) receiving a leuprorelin acetate implant: Results from the non-interventional German cohort LEAN study 1 2 3 3 1 2 3 B. Schmitz-Dräger , S. Mühlich , B. Ottillinger , M. Studen ; Fürth, DE, Bamberg, DE, Holzkirchen, DE
13:15 - 13:15 831P - Neuropsychiatric adverse events of enzalutamide and abiraterone acetate plus prednisone treatment: Contrasting a meta-analysis of randomized clinical trials with real world reporting patterns from EUDRA 1 1 1 1 1 2 1 M. Sanchez Iznaola , R. Parra , G. Angela , J. Casariego , J. MuÑoz Del Toro , P. Robinson ;
2 Madrid, ES, High Wycombe, GB
13:15 - 13:15 832P - Influence of an international consensus conference on practice patterns in advanced prostate cancer (APC) 1 1 2 3 4 5 5 1 2 J. Gong , S. Pal , J. Hsu , B. Tombal , M. Sydes , A. Omlin , S. Gillessen ; Duarte, CA/US, Duarte,
3 4 5 US, Brussels, BE, London, UK/GB, St. Gallen, CH
13:15 - 13:15 833P - Postoperative radiation therapy after radical prostatectomy A. Hervás, C. Vallejo, J. Domínguez, F. López, M. Martin, D. Candini, E. Carrasco, S. Sancho; Madrid,
ES
Last update: 02-09-2017 06:01:33pm esmo.org 13:15 - 13:15 834TiP - Randomized phase III trial of ipatasertib vs. placebo, plus abiraterone and prednisone/prednisolone, in men with asymptomatic or mildly symptomatic previously untreated metastatic castrate-resistant prostate cancer (mCRPC) 1 2 3 4 5 6 7 J. de Bono , S. Bracarda , K. Chi , C. Massard , D. Olmos Hidalgo , S. Sandhu , C. Sternberg , S. 8 9 9 10 11 1 2 3 Gendreau , N. Xu , T. Baney , D. Maslyar , C. Sweeney ; London, GB, Arezzo, IT, Vancouver,
4 5 6 7 8 British Columbia/CA, Villejuif, FR, Madrid, ES, Melbourne, VIC/AU, Roma, IT, South San 9 10 11 Francisco, US, South San Francisco, CA/US, South San Francisco, California/US, Boston, MA/US
13:15 - 13:15 835TiP - A phase 2 trial of ODM-201 maintenance therapy in patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with a AR targeting agent and non-progressive on a second line taxane (SAKK 08/16) 1 2 2 2 3 4 5 1 S. Gillessen , S. Hayoz , A. Fuhrer , C. Biaggi Rudolf , A. Pedrazzini , G. Procopio , R. Cathomas ;
2 3 4 5 St. Gallen, CH, Bern, CH, Basel, CH, Milan, IT, Chur, CH
13:15 - 13:15 836TiP - The TRITON clinical trial programme: Evaluation of the PARP inhibitor rucaparib in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD) 1 2 3 4 5 6 7 S. Chowdhury , W. Abida , J. Arranz Arija , G. Daugaard , K. Fizazi , E. Gez , A. Heidenreich , F. Joly 8 9 10 11 12 13 Lobbedez , R. McDermott , A. Merseburger , J.M. Piulats Rodriguez , B. Sautois , S. Sridhar , C. 14 15 16 17 18 16 19 1 Sternberg , S. Watkins , A. Simmons , S. Shetty , A. Golsorkhi , C. Ryan , H. Scher ; 2 3 4 5 6 7 London, GB, New York, NY/US, Madrid, ES, Copenhagen, DK, Villejuif, FR, Tel Aviv, IL, Aachen, 8 9 10 11 DE, Caen, CEDEX 5/FR, Dublin, Belgard Square North/IE, Lübeck, DE, Barcelona, 12 13 14 15 16 Barcelona/ES, Liège, BE, Toronto, Ontario/CA, Roma, IT, Cambridge, GB, San Francisco, 17 18 19 CA/US, Boulder, CO/US, Boulder, US, New York, Ny, US
13:15 - 13:15 837TiP - Phase I study of apalutamide (ARN) plus abiraterone acetate (AA), docetaxel (D) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) 1 2 3 4 1 2 2 2 A. Molina , P. Christos , Y. Whang , L. Nordquist , A. Hackett , H. Beltran , B. Faltas , D. Nanus , P. 2 5 1 2 3 4 Giannakakou , S. Tagawa ; New York, US, New York, NY/US, Chapel Hill, NC/US, Omaha, 5 NE/US, New York, US/US
13:15 - 13:15 838TiP - ARASENS: A phase 3 trial of darolutamide in males with metastatic hormone-sensitive prostate cancer (mHSPC) 1 2 3 4 5 6 7 8 B. Tombal , F. Saad , M. Hussain , C. Sternberg , K. Fizazi , E. Crawford , K. Yamada , C. Kappeler 8 9 1 2 3 4 5 6 , I. Kuss , M. Smith ; Brussels, BE, Montreal, QC/CA, Chicago, IL/US, Roma, IT, Villejuif, FR, 7 8 9 Boston, MA/US, Whippany, NJ/US, Berlin, DE, Boston, US
13:15 - 13:15 839TiP - A phase II clinical trial of radium-223 activity in patients (pts) with metastatic castration-resistant prostate cancer (mcrpc) with asymptomatic progression while on abiraterone acetate or enzalutamide besides AR-V7 mutational status (EXCAAPE) 1 2 3 4 5 J. Carles Galceran , T. Bonfill Abella , P. Borrega , R. Collado , J. Garde , M.A. Gonzalez Del Alba 6 7 1 8 9 Baamonde , E. Grande Pulido , B. Mellado , M.J. Mendez Vidal , J.M. Piulats Rodriguez , R. Morales 1 2 1 1 1 10 1 Barrera , E. Gallardo Diaz , P. Paredes , C. Suarez Rodriguez , O. Reig , S. Vazquez Estevez ; 2 3 4 5 6 Barcelona, ES, Sabadell, ES, Caceres, Cáceres/ES, CÁceres, ES, Valencia, ES, Palma De 7 8 9 10 Mallorca, ES, Madrid, ES, Cordoba, ES, Barcelona, Barcelona/ES, Lugo, ES
Last update: 02-09-2017 06:01:33pm esmo.org 13:15 - 13:15 840TiP - Stereotactic ablative radiotherapy (SABR) for oligoprogressive metastatic castration-resistant prostate cancer (mCRPC) during abiraterone therapy: A phase I study 1 2 3 2 1 2 3 U. Emmenegger , S. Cheng , K. Zukotynski , P. Cheung ; Toronto, Ontario/CA, Toronto, ON/CA, Hamilton, ON/CA
13:15 - 13:15 841TiP - A randomized phase II study comparing cabazitaxel/prednisone to cabazitaxel alone for second-line chemotherapy in men with metastatic castrate resistant prostate cancer (mCRPC): CABACARE 1 1 1 2 1 2 C. Buonerba , D. Bosso , S. De Placido , G. Di Lorenzo ; Napoli, IT, Naples, IT
13:15 - 13:15 842TiP - PROSABI: Prospective multi-centre study of prognostic factors in castration resistant prostate cancer (CRPC) patients treated with abiraterone acetate (AA) 1 2 3 4 2 2 D. Lorente Estelles , J. Puente , A. Medina , R. Lozano Mejorada , L. Rivera , M.I. Pacheco , M.I. 5 6 7 8 7 Sáez , J.M. Piulats Rodriguez , E.M. Fernandez Parra , P. Borrega García , B. Pérez Valderrama , E. 9 10 11 12 2 Gallardo Diaz , R. Villatoro , R. Morales Barrera , S. Vazquez Estevez , A. Pinto Marin , J.A.
13 14 2 1 2 3 Contreras Ibañez , N. Romero Laorden , E. Castro Marcos ; Valencia, ES, Madrid, ES, A Coruña, 4 5 6 7 8 9 ES, Salamanca, ES, Malaga, ES, Barcelona, Barcelona/ES, Sevilla, ES, Cáceres, ES, Sabadell, 10 11 12 13 14 ES, Málaga, ES, Barcelona, ES, Lugo, ES, Cadiz, ES, Madrid, Madrid/ES
13:15 - 13:15 843TiP - PRORADIUM: Prospective multicentre study of prognostic factors in castration resistant prostate cancer (CRPC) patients treated with radium-223 1 2 3 4 5 R. Morales Barrera , M.I. Sáez , N. Romero-Laorden , R. Lozano Mejorada , D. Lorente Estelles , G. 6 7 8 9 de Velasco , M.A. Gonzalez Del Alba Baamonde , E. Gonzalez Billalabeitia , A. Medina , P. Borrega 10 1 11 12 4 García , A. Rodriguez-Vida , U. Ferrandiz Brotons , O. Fernandez Calvo , R. García Domínguez , 3 13 14 3 3 1 J. Puente , J.M. Piulats Rodriguez , R. Villatoro , E. Castro Marcos , D. Olmos Hidalgo ; 2 3 4 5 6 7 Barcelona, ES, Malaga, ES, Madrid, ES, Salamanca, ES, Valencia, ES, Boston, US, Palma De 8 9 10 11 12 13 Mallorca, ES, Murcia, ES, A Coruña, ES, Cáceres, ES, Badalona, ES, Ourense, ES, 14 Barcelona, Barcelona/ES, Málaga, ES
13:15 - 13:15 844TiP - PROSENZA: Prospective multi-centre study of prognostic factors in castration resistant prostate cancer (CRPC) patients treated with enzalutamide (ENZ) 1 2 3 4 5 A. Medina , A. Montesa , N. Romero Laorden , E. Gonzalez-Billalabeitia , A. Rodriguez-Vida , G. Grau 2 6 5 7 2 , T. Garcés , R. Morales Barrera , F.J. Vazquez Mazon , R. Villatoro , M.A. Gonzalez Del Alba 8 6 9 10 11 12 Baamonde , F. López , S. Hernando Polo , M. Domenech , G. de Velasco , P. Borrega , R. Querol 13 14 6 6 1 2 3 , E. Velez , E. Castro Marcos , D. Olmos Hidalgo ; A Coruña, ES, Málaga, ES, Madrid, 4 5 6 7 8 9 Madrid/ES, Murcia, ES, Barcelona, ES, Madrid, ES, Elche, Alicante/ES, Palma De Mallorca, ES, 10 11 12 13 14 Alcorcon, Madrid/ES, Manresa, ES, Boston, US, Caceres, Cáceres/ES, Mataró, ES, Logroño, ES
13:15 - 13:15 GENITOURINARY TUMOURS, NON-PROSTATE 1 2 1 2 A. Necchi , V. Khoo ; Milan, IT, London, GB
13:15 - 13:15 856P - Avelumab treatment of metastatic urothelial carcinoma (mUC) in the phase 1b JAVELIN solid Tumor study: updated analysis with ≥6 months of follow-up in all patients
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 3 4 5 6 7 8 A. Apolo , J. Ellerton , J. Infante , M. Agrawal , M. Gordon , R. Aljumaily , C. Britten , L. Dirix , K.-W. 9 10 11 12 13 14 14 15 Lee , M. Taylor , P. Schöffski , D. Wang , A. Ravaud , A. Gelb , J. Xiong , G. Rosen , M. 16 1 2 3 4 5 Patel ; Bethesda, US, Las Vegas, NV/US, Nashville, TN/US, Rockville, MD/US, Scottsdale, 6 7 8 9 10 AZ/US, Oklahoma City, OK/US, Charleston, SC/US, Antwerpen, BE, Seongnam, KR, Portland, 11 12 13 14 15 16 OR/US, Leuven, BE, Detroit, MI/US, Bordeaux Cedex, FR, Billerica, US, Billerica, MA/US, Sarasota, FL/US
13:15 - 13:15 857P - Pembrolizumab (pembro) as first-line therapy in cisplatin-ineligible advanced urothelial cancer (UC): Outcomes from KEYNOTE-052 in senior patients (pts) with poor performance status 1 2 3 4 5 6 7 8 P. Grivas , E. Plimack , A. Balar , D. Castellano , P. O'Donnell , J. Bellmunt , T. Powles , N. Hahn , 9 3 10 10 10 11 1 2 R. de Wit , D. Bajorin , M. Ellison , T. Frenkl , S. Keefe , J. Vuky ; Cleveland, US, Philadelphia,
3 4 5 6 7 8 PA/US, New York, US, Madrid, ES, Chicago, US, Boston, MA/US, London, GB, Indianapolis, 9 10 11 IN/US, Rotterdam, NL, Kenilworth, US, Portland, US
13:15 - 13:15 858P - Sacituzumab govitecan (IMMU-132) for patients with pretreated metastatic urothelial uancer (UC): interim results 1 2 3 4 5 6 7 8 S. Tagawa , B. Faltas , E. Lam , P. Saylor , A. Bardia , J. Hajdenberg , A. Morgans , E. Lim , K. 8 9 10 8 11 11 11 Kalinsky , D. Petrylak , M. Guarino , M. Galsky , P. Maliakal , B. Mudenda , R. Sharkey , W. 11 11 1 2 3 4 5 Wegener , D. Goldenberg ; New York, US/US, New York, NY/US, Denver, US, Boston, US, 6 7 8 9 10 Boston, MA/US, Orlando, FL/US, Nashville, US, New York, US, New Haven, CT/US, Newark, US, 11 Morris Plains, US
13:15 - 13:15 859P - Anti-tumor activity of the pan-FGFR inhibitor rogaratinib in patients with advanced urothelial carcinomas selected based on tumor FGFR mRNA expression levels 1 2 3 4 5 1 6 7 M. Schuler , L. Nogova , A. Heidenreich , D. Tai , P. Cassier , H. Richly , B.C. Cho , C.M. Sayehli , 8 9 10 10 10 11 9 A. Navarro , S. Bender , M. Ocker , H. Nogai , A. Wagner , S. Ince , P. Ellinghaus , M. Joerger
12 1 2 3 4 5 6 7 ; Essen, DE, Köln, DE, Aachen, DE, Singapore, SG, La Défense, FR, Seoul, KR, Würzburg, 8 9 10 11 12 DE, Barcelona, ES, Wuppertal, DE, Berlin, DE, Whippany, US, St. Gallen, CH
13:15 - 13:15 860P - Phase II California cancer consortium trial of gemcitabine-eribulin combination (ge) in cisplatin ineligible patients (pts) with metastatic urothelial carcinoma (mUC): Efficacy report (NCI-9653; 1UM1CA186717, NO1-CM-2011-00038) 1 2 3 4 1 5 6 1 S. Sadeghi , S. Groshen , R. Parikh , A. Mortazavi , T. Dorff , C. Hoimes , L. Doyle , D. Quinn , E. 7 8 1 2 3 4 Newman , P. Lara ; Los Angeles, CA/US, Los Angeles, US, Pittsburg, PA/US, Columbus, OH/US, 5 6 7 8 Cleveland, OH/US, Bethesda, US, Duarte, US, Sacramento, CA/US
13:15 - 13:15 861P - Expression of long non-coding RNA MFI2-AS1 is a strong predictor of recurrence in sporadic localized clear-cell renal cell carcinoma 1 1 2 1 1 1 1 R. Flippot , R. Mouawad , J.-P. Spano , M. Rouprêt , E. Compérat , M.-O. Bitker , J. Parra , C. 1 1 1 3 2 3 2 1 2 Vaessen , F. Allanic , Q. Manach , N. Tannir , D. Khayat , X. Su , G. Malouf ; Paris, FR, Paris, 3 CEDEX 13/FR, Houston, TX/US
13:15 - 13:15 862P - Treatment and outcome after Immune checkpoint inhibitors (ICI) in metastatic Urothelial Carcinoma (mUC): A European perspective
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 3 1 4 5 A. Gomez de Liano Lista , A. Necchi , P. Lavaud , J. Carles Galceran , D. Castellano , A. Ravaud , I. 6 7 2 8 1 9 Duran , N. van Dijk , P. Giannatempo , Y. Loriot , R. Morales Barrera , G. De Velasco Oria De Rueda 5 6 2 5 10 7 1 , F. Lefort , G. Martínez Bernal , D. Raggi , M. Gross-Goupil , T. Powles , M. Van der Heijden ; 2 3 4 5 6 7 Barcelona, ES, Milan, IT, Paris, CEDEX 14/FR, Madrid, ES, Bordeaux, FR, Sevilla, ES, 8 9 10 Amsterdam, NL, Villejuif, FR, Boston, US, London, GB
13:15 - 13:15 863P - Phase 2 study of pembrolizumab alone or combined with acalabrutinib in platinum-refractory metastatic urothelial carcinoma (mUC) 1 1 2 3 4 5 6 7 T. Zhang , M. Harrison , P. O'Donnell , A. Alva , N. Hahn , L. Appleman , J. Cetnar , J. Burke , M. 8 9 10 11 12 13 13 Fleming , M. Milowsky , A. Mortazavi , N. Shore , E. Schmidt , C. Kresja , T. Chen , B. Bitman 13 13 13 1 1 2 3 4 , R. Izumi , A. Hamdy , D. George ; Durham, NC/US, Chicago, IL/US, Ann Arbor, MI/US, 5 6 7 8 9 Indianapolis, IN/US, Pittsburgh, PA/US, Portland, OR/US, Aurora, CO/US, Norfolk, VA/US, Chapel 10 11 12 13 Hill, NC/US, Columbus, OH/US, Myrtu Beach, US, North Wales, PA/US, Redwood City, CA/US
13:15 - 13:15 864P - Long non-coding RNAs are differentially expressed between bladder cancer subtypes 1 2 1 3 1 1 4 3 R. Sébastien , E. Rempel , T. Worst , M. Eckstein , A. Steidler , C. Weiss , C. Bolenz , A. Hartmann ,
1 1 2 3 4 P. Erben ; Mannheim, DE, Heidelberg, DE, Erlangen, DE, Ulm, DE
13:15 - 13:15 865P - Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: A joint study of the EAU-Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration 1 1 1 2 3 4 5 A. Necchi , S. Lo Vullo , L. Mariani , M. Moschini , K. Hendricksen , M. Rink , R. Sosnowski , J. 6 7 8 9 10 11 1 10 Dobruch , J. Raman , C. Wood , V. Margulis , M. Rouprêt , A. Briganti , F. Montorsi , E. Xylinas ,
12 1 2 3 4 5 6 7 S. Shariat ; Milan, IT, Luzern, CH, Amsterdam, NL, Eppendorf, DE, Otwock, PL, Warsaw, PL, 8 9 10 11 12 Hershey, PA/US, Houston, US, Dallas, US, Paris, FR, Milano, IT, Vienna, AT
13:15 - 13:15 866P - Impact of cisplatin-based therapy on long-term survival in advanced urinary tract cancer (aUTC). A retrospective international study of invasive/advanced cancer of the urothelium (RISC) 1 2 2 3 4 5 6 7 A. Bamias , K. Tzannis , C. Bamia , L. Harshman , S. Crabb , Y.-N. Wong , S. Pal , U. De Giorgi , S. 8 9 10 11 12 13 14 Ladoire , N. Agarwal , E. Yu , G. Niegisch , C. Sternberg , A. Srinivas , U. Vaishampayan , A. 15 16 17 18 19 1 2 Necchi , J. Rosenberg , T. Powles , J. Bellmunt , M. Galsky ; Athens, Attiki/GR, Athens, GR, 3 4 5 6 7 8 Boston, MA/US, Southampton, GB, Philadelphia, US, Duarte, CA/US, Meldola, Forlì-Cesena/IT, 9 10 11 12 13 Dijon, Cedex/FR, Salt Lake City, UT/US, Seattle, US, Düsseldorf, DE, Roma, IT, Stanford, 14 15 16 17 18 19 US, Detroit, MI/US, Milan, IT, New York, NY/US, London, GB, Boston, Ma, US, New York, US
13:15 - 13:15 867P - Correlation of circulating tumor DNA (ctDNA) assessment with tissue-based comprehensive genomic profiling (CGP) in metastatic urothelial cancer (mUC) 1 2 3 4 2 2 2 2 5 1 B. McGregor , S. Ali , P. Grivas , J. Ross , P. Stephens , V. Miller , B. Forcier , J. Chung , S. Pal ;
2 3 4 5 Boston, US, Cambridge, MA/US, Cleveland, US, Albany, NY/US, Duarte, CA/US
13:15 - 13:15 868P - Comparison of circulating tumor DNA (ctDNA) profile in metastatic urothelial carcinoma (mUC) derived from the upper tract (UT) and lower tract (LT)
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 3 4 4 5 5 6 1 N. Agarwal , S. Pal , G. Sonpavde , L. Kiedrowski , R. Nagy , K. Banks , R. Lanman , P. Grivas ; 2 3 4 5 Salt Lake City, US, Duarte, CA/US, Birmingham, AL/US, Redwood City, US, Redwood City, CA/US, 6 Cleveland, US
13:15 - 13:15 869P - Modeling of Tumor Kinetics and Overall Survival to Identify Predictive Factors for Efficacy of Durvalumab in Patients with Urothelial Carcinoma (UC) 1 2 2 3 2 4 2 2 Y. Zheng , X. Jin , R. Narwal , C.-Y.D. Jin , A. Gupta , Y. Ben , P. Mukhopadhyay , B. Higgs , L.
2 1 2 3 4 Roskos ; Mountain View, US, Gaithersburg, MD/US, Mountain View, CA/US, Gaithersburg, US
13:15 - 13:15 870P - Expression of Galectin-1 Determines Tumor Recurrence and Cancer-specific Survival in Patients with pT3 Upper Urinary Tract Urothelial Carcinoma H.Y.-L. Su, H.-L. Luo, C.-C. Huang, M.-C. Hsieh; Kaohsiung, TW
13:15 - 13:15 871P - Identification of genomic features underlying response of muscle-invasive bladder cancer (MIBC) to neoadjuvant sorafenib, gemcitabine, and cisplatin (SGC) in an open-label, single-arm, phase 2 study 1 2 2 1 2 2 1 D. Raggi , A. Paoli , M. Dugo , P. Giannatempo , L. De Cecco , M. Colecchia , M.G. Daidone , A.
1 2 1 2 Necchi , M.L. Sensi ; Milan, IT, Milano, IT
13:15 - 13:15 872P - Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib (c) vs everolimus (e) in advanced renal cell carcinoma (rcc) 1 2 3 4 5 4 6 7 T. Powles , R. Motzer , D. George , E. Jonasch , S. Pal , N.M. Tannir , S. Signoretti , T. Mai , C. 8 8 8 9 10 1 2 3 Scheffold , E. Wang , D. Aftab , B. Escudier , T. Choueiri ; London, GB, New York, NY/US,
4 5 6 7 8 Durham, NC/US, Houston, TX/US, Duarte, CA/US, Boston, MA/US, Ann Arbor, MI/US, South San 9 10 Francisco, CA/US, Villejuif, FR, Boston, US
13:15 - 13:15 873P - RX-3117, an oral hypomethylating agent to treat advanced solid tumors (st): Interim results from an ongoing phase 2a study in advanced urothelial cancer 1 1 2 1 3 4 5 5 5 M. Maia , S. Pal , S. Tagawa , V. Chung , J. Picus , S. Gupta , J. Poore , C. Peterson , E. Benaim ;
1 2 3 4 5 Duarte, CA/US, New York, US/US, St. Louis, US, Salt Lake City, US, Rockville, MD/US
13:15 - 13:15 874P - Immune correlates for the efficacy of PEGylated Human IL-10 (AM0010) with nivolumab in renal cell cancer 1 2 3 4 5 6 7 5 A. Naing , J. Infante , D. Wong , M. Korn , R. Aljumaily , K. Papadopoulos , K. Autio , S. Pant , T. 2 8 1 9 9 10 9 1 1 Bauer , A. Drakaki , N. Daver , A. Hung , P. Van Vlasselaer , G. Brown , M. Oft , N. Tannir ; 2 3 4 5 Houston, TX/US, Nashville, TN/US, Los Angeles, CA/US, San Francisco, CA/US, Oklahoma City, 6 7 8 9 10 OK/US, San Antonio, TX/US, New York, US, Los Angeles, US, Redwood City, US, New York, CA/US
13:15 - 13:15 875P - Outcomes of patients with metastatic urothelial carcinoma (mUC) with exclusive bone metastases: Focus on a special patient population
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 3 4 5 6 7 8 9 A. Necchi , G. Pond , S. Pal , N. Agarwal , D. Bowles , E. Plimack , E. Yu , S. Ladoire , J. Baniel , S. 10 11 12 13 14 15 16 Crabb , G. Niegisch , A.R. Golshayan , S. Sridhar , D. Berthold , J. Rosenberg , T. Powles , 17 18 19 20 1 2 3 4 A. Bamias , L. Harshman , J. Bellmunt , M. Galsky ; Milan, IT, Hamilton, CA, Duarte, CA/US, 5 6 7 8 9 Salt Lake City, UT/US, South Aurora, CO/US, Philadelphia, PA/US, Seattle, US, Dijon, Cedex/FR, 10 11 12 13 14 Petach Tikva, IL, Southampton, GB, Düsseldorf, DE, Charleston, US, Toronto, Ontario/CA, 15 16 17 18 19 Lausanne, CH, New York, NY/US, London, GB, Athens, GR, Boston, MA/US, Boston, Ma, 20 US, New York, US
13:15 - 13:15 876P - Efficacy of cabozantinib (C) after PD-1/PD-L1 checkpoint inhibitors in metastatic renal cell carcinoma (mRCC): The Gustave Roussy experience 1 1 1 2 1 2 1 1 L. Derosa , J. Rouche , E. Colomba , G. Baciarello , B. Routy , L. Albiges , B. Escudier ; Villejuif,
2 FR, Villejuif, CEDEX/FR
13:15 - 13:15 877P - Second-line treatment patterns and outcomes of metastatic bladder cancer patients in clinical practice 1 2 2 3 4 1 2 K. Flannery , J. Black-Shinn , M. Boyd , N. Robert , A. Kamat ; West Point, US, The Woodlands,
3 4 TX/US, Fairfax, US, Houston, TX/US
13:15 - 13:15 878P - Comparing ITC results from lenvatinib plus everolimus for second-line treatment of advanced/metastatic renal cell carcinoma: Crossover versus no crossover 1 1 2 3 4 1 2 3 S. Garib , G. Tremblay , G. Meier , H. McElroy , M. Guo ; New York, US, Woodcliff Lake, US, The
4 Synergy, SG, London, GB
13:15 - 13:15 879P - Urine-derived lymphocytes (UDLs) as a non-invasive surrogate marker of tumour infiltrating lymphocytes (TILs) in patients with muscle invasive bladder cancer (MIBC) 1 1 1 1 1 1 1 Y.N.S. Wong , K. Joshi , P. Khetrapal , M. Ismail , J. Linares , A.U. Akarca , J.L. Reading , A. 2 1 1 1 1 1 1 1 Furness , A. Feber , U. McGovern , C. Swanton , A. Freeman , T.P. Briggs , J. Kelly , T. Marafioti , 1 1 1 1 1 1 2 K.S. Peggs , T. Powles , B.M. Chain , M. Linch , S.A. Quezada ; London, GB, London, London/GB
13:15 - 13:15 880P - Biomarkers before and after nephrectomy of locally advanced or metastatic renal cell carcinoma (RCC) treated with everolimus: Neorad phase 2 trial (PREDICT consortium) 1 1 2 3 4 5 6 S. Oudard , A. Mejean , D. Topart , R. Thuret , C. Tournigand , L. Salomon , A. Thiery-Vuillemin , G. 7 1 1 8 9 10 1 Guichard , S. Le Moulec , A. Houlgatte , A. Guillot , N. Mottet , A. Cessot , N. Barry-Delongchamps , 1 11 11 12 13 14 1 2 R. Elaidi , S. Turajlic , C. Swanton , B. Escudier , J.J. Patard , L. Albiges ; Paris, FR,
3 4 5 6 Montpellier, CEDEX 5/FR, Montpellier, FR, Créteil, CEDEX/FR, Creteil, FR, Besançon, CEDEX/FR, 7 8 9 10 11 Besançon, FR, St. Priest En Jarez, FR, St. Etienne, cédex 2/FR, Paris, CEDEX 14/FR, London, 12 13 14 GB, Villejuif, FR, Le Kremlin Bicetre, FR, Villejuif, CEDEX/FR
13:15 - 13:15 881P - Predicted benefits of adjuvant sorafenib after nephrectomy for renal cell carcinoma (RCC) in SORCE: an international, placebo-controlled, randomised phase 3 trial 1 2 3 4 5 6 6 7 N. Lawrence , A. Martin , I. Davis , S. Troon , S. Sengupta , E. Hovey , X. Coskinas , R. Kaplan , A. 8 8 9 6 1 1 2 Ritchie , A. Meade , T. Eisen , P. Blinman , M. Stockler ; Camperdown, NSW/AU, Camperdown,
3 4 5 6 7 8 AU, Box Hill, AU/AU, Perth, WA/AU, Melbourne, AU, Sydney, NSW/AU, Leeds, GB, London, GB, 9 Cambridge, Cambridgeshire/GB
Last update: 02-09-2017 06:01:33pm esmo.org 13:15 - 13:15 882P - Potential impact of avelumab+axitinib (A+Ax) on tumor size (TS) compared with historical data of sunitinib (S) as evaluated by a modeling and simulation (MS) approach 1 2 3 4 2 5 2 6 J. Zheng , A. Chang , J. Larkin , R. Motzer , M. Amantea , C. Bello , D. Pavlov , M. Geraldes , M. 7 7 2 1 2 3 4 Martignoni , A. Di Pietro , G. Andrews ; New London, US, San Diego, CA/US, London, GB, New 5 6 7 York, NY/US, New York, US, Collegeville, US, Milan, IT
13:15 - 13:15 883P - Synchronous vs metachronous metastatic disease: Impact of time to metastasis on outcome in metastatic renal cell carcinoma patients treated with targeted therapy 1 2 3 4 5 6 3 7 F. Donskov , W. Xie , J.C. Wells , A.P. Fraccon , F. Pasini , C. Porta , I. Stukalin , J.L. Lee , A. 8 9 10 11 12 13 13 Bamias , T. Yuasa , I. Davis , C. Pezaro , R. Kanesvaran , G. Bjarnason , H.-W. Sim , N. 14 15 16 17 3 1 2 Agarwal , C. Kollmannsberger , C. Canil , T. Choueiri , D. Heng ; Aarhus C, DK, Boston,
3 4 5 6 7 8 9 MA/US, Calgary, CA, Padova, IT, Rovigo, RO/IT, Pavia, IT, Seul, KP, Athens, Attiki/GR, Tokyo, 10 11 12 13 14 JP, Box Hill, AU/AU, Box Hill, AU, Singapore, SG, Toronto, Ontario/CA, Salt Lake City, 15 16 17 UT/US, Vancouver, British Columbia/CA, Ottawa, CA, Boston, US
13:15 - 13:15 884P - SPAZO2 (SOGUG): Comparative effectiveness of pazopanib in metastatic renal carcinoma (mRC): Ineligible (I) vs eligible (E) patients for clinical trials 1 2 3 4 J. Arranz Arija , B. Pérez Valderrama , Á. Rodríguez Sánchez , I. Chirivella González , U. Anido 5 6 7 4 8 Herranz , J.P. Maroto Rey , M.J. Miranda Pallares , M.A. Climent Duran , G. Crespo Herrero , J.A. 9 6 10 11 1 Meana Garcia , A. Rodriguez-Vida , R. Fernandez-Rodriguez , C. Santander , G. Rubio Romero , S. 12 13 14 15 Vazquez Estevez , O. Fernandez Calvo , M.B. Gonzalez Gragera , E. Almagro Casado , S. Perez 1 16 1 2 3 4 5 Ramirez , P. Borrega García ; Madrid, ES, Sevilla, ES, Leon, ES, Valencia, ES, Santiago De 6 7 8 9 10 11 Compostela, ES, Barcelona, ES, Reus, ES, Burgos, ES, Alicante, ES, Bilbao, Bizkaia/ES, 12 13 14 15 16 Zaragoza, ES, Lugo, ES, Ourense, ES, Palma De Mallorca, ES, Majadahonda, Madrid/ES, Cáceres, ES
13:15 - 13:15 885P - Sunitinib versus pazopanib for patients with metastatic renal cell carcinoma: Two Turkish hospital experience, a retrospective comparative case series study M. Ekenel, E. Aydin, I. Cil, A. Zirtiloglu, D. Tural, S. Karabulut; Istanbul, TR
13:15 - 13:15 886P - SPAZO2 (SOGUG): Comparative effectiveness of everolimus (Ev) vs axitinib (Ax) as second-line after first-line pazopanib (1stPz) in metastatic renal carcinoma (mRC) 1 2 3 4 1 J. Arranz Arija , B. Pérez-Valderrama , A. Rodriguez Sanchez , J. Puertas Alvarez , A. Pinto Marin , C. 5 6 2 7 Maximiano Alonso , J.C. Villa Guzman , E.M. Fernandez Parra , E. Gallardo Diaz , J. Gonzalez-Larriba 1 1 8 9 10 , J. Tafalla García , J. Lambea , M. Constenla Figueiras , M.J. Mendez Vidal , J.A. Virizuela 2 11 12 13 14 Echaburu , F.J. Vazquez Mazon , O. Etxaniz Ulazia , M.T. Abad Villar , J. Cassinello , J.M. 15 1 2 3 4 5 Jurado García ; Madrid, ES, Sevilla, ES, Leon, ES, Valladolid, ES/ES, Majadahonda, Madrid/ES, 6 7 8 9 10 11 Ciudad Real, Ciudad Real/ES, Sabadell, ES, Zaragoza, ES, Pontevedra, ES, Cordoba, ES, 12 13 14 15 Elche, Alicante/ES, Badalona, Barcelona/ES, Bilbao, ES, Guadalajara, ES, Granada, ES
13:15 - 13:15 887P - Negative prognostic factors and resulting clinical outcome in patients (pts) with metastatic renal cell carcinoma (mRCC) included in the Italian nivolumab expanded access program (EAP)
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 3 4 5 6 7 8 S. Bracarda , L. Galli , M. Maruzzo , G. Lo Re , S. Buti , A. Favaretto , F. Costanzo , C. Sacco , M. 9 10 11 12 13 14 Merlano , C. Mucciarini , E. Zafarana , S. Romito , A. Maestri , C. Giannitto Giorgio , M.T. Ionta 15 16 17 18 19 20 1 2 3 , D. Turci , U. De Giorgi , G. Procopio , E. Cortesi , C. Porta ; Arezzo, IT, Pisa, IT,
4 5 6 7 8 9 10 Padova, IT, Pordenone, IT, Parma, IT, Treviso, IT, Firenze, IT, Udine, IT, Cuneo, IT, Carpi 11 12 13 14 15 16 (modena), IT, Prato, IT, Foggia, IT, Bologna, IT, Caltagirone, IT, Monserrato, (CA)/IT, 17 18 19 20 Ravenna, IT, Meldola, Forlì-Cesena/IT, Milan, IT, Roma, IT, Pavia, IT
13:15 - 13:15 888P - Change in neutrophil-to-lymphocyte ratio (NLR) in response to immunotherapy for metastatic renal cell carcinoma (mRCC) 1 2 2 2 2 3 4 2 A.-K. Lalani , W. Xie , D. Martini , C. Norton , J. Steinharter , D. Bossé , J. Bellmunt , E. Van Allen , 2 2 1 1 2 3 4 B. McGregor , L. Harshman , T. Choueiri ; Boston, US, Boston, MA/US, Ottawa, Ontario/CA, Boston, Ma, US
13:15 - 13:15 889P - Broad immunomodulating effect of first-line pazopanib in metastatic renal cell carcinoma patients 1 2 2 3 4 1 1 2 E. Verzoni , L. De Cecco , M. Dugo , D. Rinchai , D. Bedognetti , P. Grassi , R. Ratta , A. Cova , P. 2 2 2 2 1 2 1 2 Squarcina , V. Huber , R. Montone , M. Sorrentino , G. Procopio , L. Rivoltini ; Milan, IT, Milano, IT, 3 4 Doha, QA, Didra, QA
13:15 - 13:15 890P - Prospective comparison of RECIST and alternative response assessment criteria in the evaluation of metastatic renal cell cancer patients from phase II of the multi-centre randomised STAR trial 1 2 1 2 2 3 4 5 C. Kelly-Morland , J. Zhong , V. Goh , T. Wah , C. Ralph , F. Thistlethwaite , P. Patel , P. Nathan , T. 6 2 2 2 2 2 2 2 Eisen , W. Gregory , L. McParland , H. Cool , K.-L. Royle , E. Best , L. Whincup , F. Collinson , J.
7 1 2 3 4 5 6 Brown ; London, GB, Leeds, GB, Manchester, GB, Nottingham, GB, Northwood, Middlesex/GB, 7 Cambridge, Cambridgeshire/GB, Sheffield, GB
13:15 - 13:15 891P - Outcomes of patients with metastatic renal cell carcinoma (mRCC) who were treated with second-line (2L) vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKI) after first-line (1L) immune checkpoint inhibitor (ICI) therapy 1 2 2 2 2 2 1 A. Shah , E. Lemke , G. Jianjun , A. Chandamohan , M. Campbell , A. Zurita Saavedra , L. Xiao , J.
2 2 2 2 2 1 2 Wang , P. Corn , E. Jonasch , P. Sharma , N. Tannir ; Houston, US, Houston, TX/US
13:15 - 13:15 892P - Treatment beyond progression in patients with advanced RCC participating in the expanded access programme (EAP) 1 2 3 4 5 6 7 8 E. Cortesi , F. Cappuzzo , L. Galli , A. Bearz , S. Pignata , A. Berruti , G. Tortora , D. Tassinari , S. 9 10 11 12 13 14 15 16 Panni , A. Pazzola , G. Surico , M. Maio , L. Latini , G. Schinzari , V. Adamo , E. Ricevuto , 14 17 5 18 1 2 3 4 F. Cognetti , U. de giorgi , G. Cartenì , U. Basso ; Roma, IT, Ravenna, IT, Pisa, IT, 5 6 7 8 9 10 11 Pordenone, IT, Napoli, IT, Brescia, IT, Verona, IT, Rimini, IT, Cremona, IT, Sassari, IT, Lecce, 12 13 14 15 16 17 18 IT, Siena, IT, Macerata, IT, Rome, IT, Messina, IT, L'aquila, IT, Meldola (fc), IT, Padova, IT
13:15 - 13:15 893P - Improved long-term clinical outcomes and safety profile of sunitinib dosing schedule with 4/2 switched to 2/1 in patients with metastatic renal cell carcinoma X. Zhang, G. Sun, J. Zhao, K. Shu, P. Zhao, J. Liu, Y. Yang, Q. Tang, J. Chen, P. Shen, H. Zeng;
Chengdu, CN
13:15 - 13:15 894P - A retrospective study of the management of metastatic renal cell carcinoma brain tumors
Last update: 02-09-2017 06:01:33pm esmo.org 1 1 2 1 1 1 1 G. Klausner , I. Troussier , G. Malouf , L. Feuvret , J. Jacob , J.-M. Simon , C.H. Canova , I. 1 1 1 1 1 1 2 Lamproglou , P.-Y. Borius , C. Valery , P. Cornu , M. Rouprêt , J.-J. Mazeron , J.-P. Spano , P. 1 1 2 Maingon ; Paris, FR, Paris, CEDEX 13/FR
13:15 - 13:15 895P - SPAZO2 (SOGUG): Validation of the international metastatic database consortium (IMDC) prognostic classification for targeted therapies as 2nd-line after 1st-line pazopanib (1stPz) in metastatic renal cell carcinoma (mRC) 1 2 3 4 5 B. Pérez-Valderrama , J. Arranz Arija , I. Chirivella González , U. Anido Herranz , J.M. Jurado García , 6 7 2 8 C. Suarez Rodriguez , I. García Carbonero , G. de Velasco , R. García Domínguez , R.D. García 9 10 3 11 3 Marrero , M.A. Gonzalez Del Alba Baamonde , C. Molins Palau , M.E. Lazaro , J. Munoz-Langa , E. 12 13 14 2 Martinez Ortega , A. Hernández Jorge , M. Campayo Guillaumes , M. Sereno Moyano , R. Luque 5 15 1 2 3 4 5 Caro , Á. Rodríguez Sánchez ; S, ES, Madrid, ES, Valencia, ES, Santiago De Compostela, ES, 6 7 8 9 10 Granada, ES, Barcelona, ES, Toledo, ES, Salamanca, ES, Santa Cruz De Tenerife, ES, Palma 11 12 13 14 15 De Mallorca, ES, Vigo, Pontevedra/ES, Jaen, ES, Donostia, ES, Terrassa, ES, Leon, ES
13:15 - 13:15 896P - A Phase (Ph) 1 dose finding study of X4P-001 (an oral CXCR4 inhibitor) and axitinib in patients with advanced renal cell carcinoma (RCC) 1 2 3 4 5 6 7 8 D. McDermott , R. Joseph , T. Ho , U. Vaishampayan , S. Ali , M. Matrana , R. Alter , J. Edenfield , 9 9 10 1 2 3 4 S. Blanchette , L. Gan , M. Atkins ; Boston, MA/US, Jacksonville, US, Phoenix, AZ/US, Detroit,
5 6 7 8 9 MI/US, Indianapolis, IN/US, New Orleans, LA/US, Hackensack, NJ/US, Greensville, SC/US, 10 Cambridge, MA/US, Washington Dc, US
13:15 - 13:15 897P - Efficacy and safety data in elderly patients (pts) with metastatic renal cell carcinoma (mRCC) included in the nivolumab expanded access program (EAP) in Italy 1 2 3 4 5 6 7 8 R. sabbatini , L. Galli , S. Pignata , G. Lo Re , F. Valcamonico , C. Defferrari , M. Spada , D. Santini , 9 10 11 12 13 14 15 C. Masini , L. Ciuffreda , E.M. Ruggeri , A. Chioni , L. Livi , D. Fagnani , A. Bonetti , L. Giustini 16 17 18 19 3 1 2 3 4 , S. Duranti , G. Procopio , C. Caserta , G. Cartenì ; Modena, IT, Pisa, IT, Napoli, IT,
5 6 7 8 9 10 11 Pordenone, IT, Brescia, IT, Genova, IT, Cefalù, IT, Roma, IT, Reggio Emilia, IT, Torino, IT, 12 13 14 15 16 17 Viterbo, IT, Grosseto, IT, Florence, IT, Vimercate, IT, Legnago (vr), IT, Fermo, IT, Arezzo, 18 19 IT, Milan, IT, Terni, IT
13:15 - 13:15 898P - Immune expression profile and sunitinib benefit in metastatic clear cell renal cell carcinoma (ccRCC) O. Reig Torras, M. Marín_aguilera, N. Jimenez, L. Paré, P. Galvan, C. Mallofre, A. Prat, B. Mellado
Gonzalez; Barcelona, ES
13:15 - 13:15 899P - Interim results from PAZOREAL: A non-interventional study to assess effectiveness and safety of pazopanib and everolimus in the changing mRCC treatment landscape 1 2 3 4 5 6 7 J. Bedke , M. Welslau , M. Boegemann , M. Schostak , C. Hering-Schubert , A. Petzoldt , T. Wolf , J. 8 9 10 11 12 13 14 Schleicher , C. Doehn , C. Grüllich , V. Grünwald , T. Steiner , R. Ehness , D. Klein , T. 14 15 1 2 3 4 5 Medinger , P. Goebell ; Tübingen, DE, Berlin, DE, Münster,, DE, Magdeburg, DE, Eisenach, 6 7 8 9 10 11 DE, Fürth, DE, Dresden, DE, Stuttgart, DE, Lübeck, DE, Heidelberg, Baden Württemberg/DE, 12 13 14 15 Hannover, DE, Erfurt, DE, Munich, DE, Freiburg, DE, Erlangen, DE
13:15 - 13:15 900P - Phase II study of individualized sunitinib (SUN) as first-line therapy for metastatic renal cell cancer: Pharmacokinetic data
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 3 4 5 6 7 G. Bjarnason , J. Knox , C. Kollmannsberger , D. Soulieres , D.S. Ernst , P. Zalewski , C. Canil , E. 8 9 10 11 12 10 9 2 Winquist , S. Hotte , S. North , D. Heng , R. Macfarlane , P. Venner , A. Kapoor , A. Hansen , P. 13 2 14 15 1 2 3 Czaykowski , B. Boyd , L. Wang , N. Basappa ; Toronto, Ontario/CA, Toronto, ON/CA,
4 5 6 7 Vancouver, British Columbia/CA, Montreal, CA, London, Ontario/CA, Oshawa, ON/CA, Ottawa, CA, 8 9 10 11 12 13 London, ON/CA, Hamilton, Ontario/CA, Edmonton, AB/CA, Calgary, CA, Halifax, NS/CA, 14 15 Winnipeg, CA, Toronto, CA, Edmonton, CA
13:15 - 13:15 901P - Safety and efficacy of Cabozantinib for metastatic renal cell carcinoma (mRCC): real world data from an Italian Expanded Access Program (EAP) 1 1 2 2 3 4 4 G. Procopio , M. Prisciandaro , R. Iacovelli , M. Mancini , G. Fornarini , G. Facchini , G. Cartenì , M. 5 2 6 7 8 9 10 11 Napolitano , C. Sternberg , C. Caserta , M. Bregni , F. Massari , S. Buti , E. Biasco , U. De Giorgi , 12 1 13 14 1 1 2 3 4 F. Zustovich , R. Ratta , C. Ortega , G. Tortora , E. Verzoni ; Milan, IT, Roma, IT, Genova, IT, 5 6 7 8 9 10 11 Napoli, IT, Modena, IT, Terni, IT, Busto Arsizio, IT, Bologna, IT, Parma, IT, Pisa, IT, Meldola, 12 13 14 Forlì-Cesena/IT, Belluno, IT, Candiolo, (TO)/IT, Verona, IT
13:15 - 13:15 902P - Prognostic factors for overall survival of patients with advanced renal cell carcinoma – data from the German prospective RCC-Registry 1 2 3 4 5 5 5 5 1 P. Goebell , L. Müller , M. Staehler , M. Müller , M. Frank , L. Kruggel , M. Jänicke , N. Marschner ;
2 3 4 5 Erlangen, DE, Leer, DE, Munich, DE, Offenburg, DE, Freiburg, DE
13:15 - 13:15 903P - The efficacy and safety of sorafenib in patients with renal insufficiency of advanced renal cell carcinoma: Real- world data of sorafenib in Japan 1 2 2 2 1 2 K. Tatsugami , M. Oya , K. Kabu , H. Akaza ; Fukuoka, JP, Tokyo, JP
13:15 - 13:15 904P - Inflammatory indexes strongly predict clinical outcome in patients (pts) with metastatic renal cell cancer (mRCC) treated with nivolumab: results from the Italian expanded access program (EAP) 1 2 3 4 5 6 7 8 U. De Giorgi , G. Procopio , A. Guida , A. Bearz , S. Buti , U. Basso , M. Mitterer , C. Ortega , P. 9 10 11 12 13 14 13 Bidoli , F. Ferrau , L. Crinò , A. Frassoldati , P. Marchetti , E. Mini , A. Scoppola , C. Verusio 15 16 17 18 13 1 2 3 , G. Fornarini , G. Cartenì , C. Caserta , C. Sternberg ; Meldola, Forlì-Cesena/IT, Milan, IT,
4 5 6 7 8 9 Modena, IT, Pordenone, IT, Parma, IT, Padova, IT, Merano, IT, Candiolo, (TO)/IT, Monza (mi), IT, 10 11 12 13 14 15 16 Taormina, IT, Perugia, (PG)/IT, Ferrara, IT, Roma, IT, Firenze, IT, Saronno, (VA)/IT, 17 18 Genova, IT, Napoli, IT, Terni, IT
13:15 - 13:15 905P - CORE-URO-01 study: comparison of safety and efficacy of pazopanib in first-line metastatic renal cell carcinoma (mRCC) with or without renal failure 1 1 2 3 4 5 6 7 C. Masini , M.G. Vitale , M. Maruzzo , G. Procopio , U. De Giorgi , S. Buti , S. Rossetti , R. Iacovelli , 8 9 10 6 11 12 13 A. Guida , F. Atzori , C. Mucciarini , S. Scagliarini , F. Vignani , G. Prati , L. Cosmai , A. Berselli 1 1 1 2 3 4 5 6 , C. Pinto ; Reggio Emilia, IT, Padova, IT, Milano, IT, Meldola, Forlì-Cesena/IT, Parma, IT, 7 8 9 10 11 12 Napoli, IT, Verona, IT, Modena, IT, Cagliari, IT, Carpi (modena), IT, Torino, IT, Guastalla, IT, 13 Cremona, IT
13:15 - 13:15 906P - Impact of haptoglobin polymorphism on survival of renal cell carcinoma patients 1 2 2 3 1 2 3 T. Vermassen , N. Lumen , J. Delanghe , S. Rottey ; Gent, BE, Ghent, BE, Brussels, BE
Last update: 02-09-2017 06:01:33pm esmo.org 13:15 - 13:15 907P - Impact of CYP3A4*22 on pazopanib pharmacokinetics in cancer patients 1 2 1 1 2 3 3 1 S. Koolen , A. Huitema , P. Laven , S. El Bouazzaoui , H. Yu , N. Erp , C. Herpen , P. Hamberg , H. 4 2 1 1 1 1 1 2 Gelderblom , N. Steeghs , S. Sleijfer , R. van Schaik , R. Mathijssen , S. Bins ; Rotterdam, NL, 3 4 Amsterdam, NL, Nijmegen, NL, Leiden, NL
13:15 - 13:15 908P - Association between biopsychosocial distress (BPSD) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) 1 2 2 2 1 2 2 2 C. Bergerot , K. Clark , K. Ashing , L. Almeida , P. Bergerot , R. Obenchain , N. Dizman , J. Hsu , M.
2 3 2 2 1 2 3 Maia , E. Philip , M. Loscalzo , S. Pal ; Duarte, US, Duarte, CA/US, Notre Dame, IL/US
13:15 - 13:15 909P - Treatment reality and outcome data of patients with advanced papillary renal cell carcinoma: Data from the German prospective RCC-Registry 1 2 3 4 5 5 5 L. Müller , M. Staehler , P. Goebell , F. Overkamp , M. Frank , L. Kruggel , M. Jänicke , N. Marschner
5 1 2 3 4 5 ; Leer, DE, Munich, DE, Erlangen, DE, Recklinghausen, DE, Freiburg, DE
13:15 - 13:15 910P - Exome sequencing of tumor samples from S1107 “Randomized phase II evaluation of tivantinib and tivantinib in combination with erlotinib in patients with papillary renal cell carcinoma (pRCC)” 1 1 2 2 3 4 5 1 P. Twardowski , X. Wu , M. Plets , C. Tangen , E. Plimack , N. Agarwal , N. Vogelzang , J. Wang , S. 1 6 7 1 2 3 4 Tao , I. Thomson , P. Lara ; Duarte, CA/US, Seattle, WA/US, Philadelphia, PA/US, Salt Lake City, 5 6 7 UT/US, Las Vegas, NV/US, San Antonio, TX/US, Sacramento, CA/US
13:15 - 13:15 911P - Patients (pts) with metastatic non-clear cell renal cell carcinoma (mnccRCC) treated with Nivolumab (Nivo) based immunotherapy as advanced treatment (ATL) line: analysis of a national early access program (EAP) 1 1 2 3 3 4 5 A. Peer , K. Savion , K. Rouvinov , R. Leibowitz-Amit , R. Berger , A. Sella , V. Neiman , E. 5 2 1 1 1 6 1 2 Rosenbaum , W. Mermershtain , A. Neumann , M. Kolin , R. Perets , D. Keizman ; Haifa, IL, Beer 3 4 5 6 Sheva, IL, Ramat Gan, IL, Zerifin, IL, Petah Tikva, IL, Kfar Saba, IL
13:15 - 13:15 912P - Cabozantinib for the treatment of patients with metastatic variant histology renal cell carcinoma (vhRCC): a retrospective study 1 2 3 1 3 3 3 3 1 M. Campbell , M. Bilen , C. Duran , E. Altinmakas , Z. Lim , A. Shah , E. Jonasch , N. Tannir ;
2 3 Houston, US, Atlanta, GA/US, Houston, TX/US
13:15 - 13:15 913P - Avelumab in patients with metastatic adrenocortical carcinoma (mACC): Results from the JAVELIN solid tumor trial 1 2 3 4 5 6 7 C. Le Tourneau , C. Zarwan , C. Hoimes , D. Wong , S. Bauer , M. Wermke , H.J. Grote , A. von 7 8 9 1 2 3 4 Heydebreck , K. Chin , J. Gulley ; Paris, FR, Burlington, MA/US, Cleveland, OH/US, Los Angeles, 5 6 7 8 9 CA/US, Essen, DE, Dresden, DE, Darmstadt, DE, Billerica, MA/US, Bethesda, Md, US
13:15 - 13:15 914P - Do patients (pts) with advanced nonseminomatous germ cell tumors (aNSGCT) and unfavorable time to normalization (TTN) of tumor markers benefit with prolongation of 1-st line chemotherapy (ChT)? 1 1 1 2 1 1 1 A. Tryakin , M. Fedyanin , J. Sergeev , A. Bulanov , B. Akhmedov , T. Zakharova , V. Matveev , I.
1 1 1 1 2 Fainstein , A. Garin , S. Tjulandin ; Moscow, RU, Teheran, IR
Last update: 02-09-2017 06:01:33pm esmo.org 13:15 - 13:15 915P - The prognostic role of neutrophil-to-lymphocyte ratio (NLR) in patients with metastatic germ cell tumors 1 2 3 3 3 3 3 D. Ribnikar , P. Bedard , R. Hamilton , M. Jewett , P. Warde , P. Chung , L. Anson Cartwright , A. 4 2 5 6 1 2 3 4 Templeton , E. Amir , A. Hansen , J. Lewin ; Ljubljana, SI, Toronto, Ontario/CA, Toronto, CA, 5 6 Basel, CH, Toronto, ON/CA, Nassau, BS
13:15 - 13:15 916P - Biological assessment of viable germ cell tumor (VT) in patients (pts) with seminoma (S) and non-seminoma (S) using miR371 1 1 1 2 2 3 1 2 1 L. Nappi , M. Thi , L. Fazli , K. Chi , B. Eigl , C. Nichols , M. Gleave , C. Kollmannsberger ;
2 3 Vancouver, BC/CA, Vancouver, British Columbia/CA, Salt Lake City, UT/US
13:15 - 13:15 917P - A single centre retrospective review of testosterone deficiency in germ cell cancer patients L. Gibbs, G. Gullick, E. Allison, S. Brand, A. Addeo, A. Kuchel, J. Braybrooke; Bristol, GB
13:15 - 13:15 918TiP - Pembrolizumab and nanoparticle albumin bound paclitaxel (nab-paclitaxel) for metastatic urothelial carcinoma (UC) after chemotherapy failure: the open-label, single-arm, phase 2 PEANUT study 1 1 2 1 1 2 2 1 A. Necchi , L. Mariani , A. Anichini , P. Giannatempo , D. Raggi , G. Calareso , R. Salvioni ; Milan,
2 IT, Milano, IT
13:15 - 13:15 919TiP - Pembrolizumab ± chemotherapy versus chemotherapy in advanced urothelial cancer: Phase 3 KEYNOTE-361 trial 1 2 3 4 5 6 7 T. Powles , J. Gschwend , Y. Loriot , J. Bellmunt , L. Geczi , C. Vulsteke , M. Abdelsalam , R. 8 9 10 11 12 13 14 Gafanov , W.K. Bae , J. Revesz , Y. Yamamoto , U. Anido , W.-P. Su , M. Fleming , M. Markus 15 16 17 18 1 2 3 4 5 , D. Feng , C. Poehlein , A. Alva ; London, GB, Munich, DE, Villejuif, FR, Boston, Ma, US,
6 7 8 9 10 11 Budapest, HU, Leuven, BE, Moncton, NB/CA, Moscow, RU, Hwasun-Gun, KR, Miskolc, HU, 12 13 14 15 Ube, JP, Santiago De Compostela, ES, Tainan, TW, Norfolk, VA/US, Colorado Springs, 16 17 18 CO/US, Kenilworth, NJ/US, Kenilworth, US, Ann Arbor, MI/US
13:15 - 13:15 920TiP - Afatinib in patients with advanced or metastatic urothelial carcinoma (UC) with genetic alterations in ErbB receptors 1–3 who failed on platinum-based chemotherapy: The Phase II LUX-Bladder 1 trial 1 2 2 3 4 5 1 A. Font , F. Real , J. Puente , F.J. Vazquez Mazon , N. Sala , J. Virizuela , A. Rodriguez-Vida , E. 2 2 6 1 7 8 Grande Pulido , D. Castellano , M. Climent , E. Gallardo , A. González del Alba , P. Fernandez , P. 8 1 9 1 10 11 1 1 Jares , I. Aldecoa , N. Gibson , J. Serra , E.R. Imedio , E. Ehrnrooth , B. Mellado ; Barcelona, ES, 2 3 4 5 6 7 8 Madrid, ES, Elche, Alicante/ES, Girona, ES, Seville, ES, Valencia, ES, Palma De Mallorca, ES, 9 10 11 Barcelon, ES, Biberach, DE, Bracknell, GB, Copenhagen, DK
13:15 - 13:15 921TiP - A Phase III, randomized, double-blind, multicenter study of adjuvant nivolumab vs placebo in patients (pts) with high-risk invasive urothelial carcinoma (UC; CheckMate 274) 1 1 2 3 4 5 1 2 D. Bajorin , M. Galsky , J. Gschwend , Y. Tomita , A. Azrilevich , F. Witjes ; New York, US,
3 4 5 München, DE, Yamagata, JP, Princeton, US, Nijmegen, NL
13:15 - 13:15 922TiP - KEYNOTE-564: Phase 3 trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma (RCC)
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 3 4 5 6 7 1 2 T. Choueiri , T. Powles , T. Zhang , D. Quinn , J. Gschwend , S. Wan , C. Poehlein ; Boston, US,
3 4 5 6 7 London, GB, Durham, NC/US, Los Angeles, CA/US, Munich, DE, North Wales, US, Kenilworth, US
13:15 - 13:15 923TiP - A phase 2 BIOmarker driven trial with Nivolumab and Ipilimumab or VEGFR tKi in naïve metastatic Kidney cancer: the BIONIKK trial R.T. Elaidi, S. Oudard, E. Braychenko, C.-M. Sun, C. Sautès-Fridman, Y.-A. Vano; Paris, FR
13:15 - 13:15 924TiP - Savolitinib versus sunitinib in patients with MET-driven, unresectable and locally advanced or metastatic papillary renal cell carcinoma: SAVOIR, a randomised, phase III trial 1 2 3 3 3 4 3 1 T. Choueiri , R. Jakacki , D. Ghiorghiu , V. Haddad , A. Kohlmann , M. Frigault , L. Ottesen ; Boston,
2 3 4 US, Gaithersburg, MD/US, Cambridge, GB, San Francisco, CA/US
13:15 - 13:15 925TiP - A phase 2 study of investigational TORC1/2 inhibitor TAK-228 and TAK-228 plus investigational PI3Kα-selective inhibitor TAK-117 vs everolimus in adults with advanced or metastatic clear-cell renal cell carcinoma (ccRCC) that has progressed on VEGF-targeted therapy 1 2 3 4 5 5 6 T. Choueiri , C. Porta , C. Suarez Rodriguez , R. Alter , P. Czaykowski , I. Duran , M. Gross-Goupil , 7 8 9 9 9 9 10 1 E. Kalinka-Warzocha , B. Melichar , C. Patel , R. Neuwirth , A. Enke , F. Zohren , T. Powles ;
2 3 4 5 6 7 Boston, US, Pavia, IT, Barcelona, ES, Hackensack, NJ/US, Seville, ES, Bordeaux, FR, Lodz, PL, 8 9 10 Olomouc, CZ, Cambridge, US, London, GB
13:15 - 13:15 926TiP - Phase Ib/II trial of interleukin-2 (IL-2) and nivolumab in metastatic clear cell renal cell cancer (RCC) 1 2 1 2 S. Yentz , A. Alva ; Ann Arbor, US, Ann Arbor, MI/US
13:15 - 13:15 927TiP - Cabozantinib in patients with advanced penile squamous cell carcinoma (PSCC): the open-label, single-arm, single-center, phase 2, CaboPen trial 1 1 2 1 1 2 2 A. Necchi , L. Mariani , M. Colecchia , P. Giannatempo , D. Raggi , G. Calareso , N. Nicolai , M.
2 2 2 2 1 2 Catanzaro , T. Torelli , F. Perrone , R. Salvioni ; Milan, IT, Milano, IT
13:15 - 13:15 HEAD AND NECK CANCER, EXCLUDING THYROID 1 2 1 2 J.-P. Machiels , M. Merlano ; Brussels, BE, Cuneo, IT
13:15 - 13:15 1055P - Nivolumab vs investigator’s choice (IC) in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): treatment effect on clinical outcomes by best overall response in checkmate 141 1 2 3 4 5 6 7 L. Licitra , R. Ferris , G. Blumenschein Jr , K. Harrington , J. Guigay , S. Kasper , N. Saba , R. 8 9 10 10 10 11 12 1 2 Haddad , N. Kiyota , M. Monga , M. Lynch , L. Li , M. Gillison , J. Fayette ; Milan, IT,
3 4 5 6 7 8 Pittsburgh, PA/US, Houston, US, London, GB, Nice, CEDEX 2/FR, Essen, DE, Atlanta, GA/US, 9 10 11 12 Boston, MA/US, Kobe, Hyogo/JP, Princeton, US, Columbus, US, Lyon, CEDEX/FR
13:15 - 13:15 1056P - Estimated costs of treatment-related adverse events (TRAEs) for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the checkmate 141 trial 1 2 3 1 2 4 5 1 M. Venkatachalam , S. Bobiak , J. Shaw , I. Santi , M. Contente , B. Korytowsky , D. Stenehjem ;
2 3 4 5 Waltham, MA/US, Princeton, NJ/US, New York, US, Princeton, US, Salt Lake City, US
Last update: 02-09-2017 06:01:33pm esmo.org 13:15 - 13:15 1057P - Phase I trial of cetuximab, intensity modulated radiotherapy (IMRT), and ipilimumab in previously untreated, locally advanced head and neck squamous cell carcinoma (PULA HNSCC) 1 1 2 1 1 1 1 1 1 R. Ferris , D. Clump , J. Ohr , W. Gooding , S. Kim , B. Karlovits , U. Duvvuri , J. Johnson , D. Petro
1 3 1 2 3 , D. Heron , J. Bauman ; Pittsburgh, PA/US, Pittsburgh, US, Tucson, PA/US
13:15 - 13:15 1058P - Does hyper-progression exist among head and neck cancer patients treated with immunotherapy? 1 2 2 2 1 2 A. Ortega Franco , M. Plana , I. Braña , M. Taberna Sanz , M. Oliva Bernal , S. Vázquez , M. 2 2 2 1 2 2 1 Domenech Vinyolas , G. Berenguer , E. Vilajosana , M. Bergamino , N. Baste , R. Mesia Nin ; 2 Barcelona, Barcelona/ES, Barcelona, ES
13:15 - 13:15 1059P - PD-L1 Detection and Assay Performance in Squamous Cell Carcinoma of the Head and Neck Using PD-L1 IHC 28-8 pharmDx 1 1 2 1 2 2 2 2 S. Alvarez , J. Chan , J. William , C. Felten , D.A. Hanks , A. Northrup , D. Jaiswal , M. Jansson , T. 2 2 2 2 2 2 2 2 Phillips , A. Segal , I. Satnick , H. McDonald , H. Little , C. Pierce , B. Wynne , J. Carnahan , S. 2 3 2 1 2 3 Reddy , H.D. Inzunza , E. Oroudjev ; Carpinteria, US, Carpinteria, CA/US, San Diego, US
13:15 - 13:15 1060P - Programmed death ligand-1overexpression is a poor prognostic factor for Human papillomavirus-positive tonsillar squamous cell carcinoma 1 2 2 1 2 M.J. Kwon , M. Hong , S.Y. Kang ; Anyang, KR, Seoul, KR
13:15 - 13:15 1061P - The prognostic role of PD-L1 expression in tumor and immune cells in oral cavity squamous cell carcinoma 1 1 2 3 4 1 1 S. Kutukova , N. Beliak , G. Manikhas , G. Raskin , Y. Ivaskova , N. Popova ; Saint Petersburg, RU,
2 3 4 No City Provided, NA, St.-Petersburg, RU, Saint-Petersburg, RU
13:15 - 13:15 1062P - Immune profile analysis of head and neck squamous cell carcinoma before and after neoadjuvant treatment with the IRX-2 regimen 1 2 3 4 1 5 6 1 G. Wolf , J. Newman , N. Berinstein , M. McNamara , A. Nguyen , J. Egan , M. Kaplan ; Ann Arbor,
2 3 4 5 6 US, Philadelphia, PA/US, Toronto, CA, Portland, OR/US, New York, NY/US, Stanford, CA/US
13:15 - 13:15 1063P - Phenotyping of the immune infiltrate in oropharyngeal squamous cell carcinoma: Focus on materials and methods 1 1 2 3 1 2 3 A. De Meulenaere , T. Vermassen , S. Rottey , L. Ferdinande ; Gent, BE, Brussels, BE, Ghent, BE
13:15 - 13:15 1064P - High-dose versus low-dose cisplatin with definitive concurrent radiotherapy for squamous cell carcinoma of the head and neck (SCC): An analysis of veteran’s health registry data 1 2 2 2 2 3 2 3 J. Bauml , R. Vinnakota , Y.-H. Park , S. Bates , T. Fojo , C. Aggarwal , S. Lunate , N. Damjanov , R. 3 3 3 2 1 2 3 Mamtani , C. Langer , R. Cohen , K. Sigel ; Philadelphia, US, New York, NY/US, Philadelphia, PA/US
13:15 - 13:15 1065P - 3-weekly or weekly cisplatin concurrently with radiotherapy for patients with locally advanced squamous cell carcinoma of the head and neck: A multicentre, retrospective analysis 1 1 2 3 1 1 3 S. Rothschild , S. Helfenstein , O. Riesterer , U. Meier , A. Papachristofilou , B. Kasenda , M. Pless ;
1 2 3 Basel, CH, Zürich, CH, Winterthur, CH
Last update: 02-09-2017 06:01:33pm esmo.org 13:15 - 13:15 1066P - Hyperfractionated twice daily re-irradiation (bid re-RT) and chemotherapy (CT) for locoregionally recurrent head and neck squamous cell carcinoma (LR HNSCC): A systematic review (SR) 1 2 2 2 1 2 2 1 2 D. Day , G. Locke , K. Chan , S. Cheng , L. Wang , B. O'Sullivan , A. Hansen ; Toronto, CA, Toronto, ON/CA
13:15 - 13:15 1067P - Raltitrexed versus 5-fluorouracil with cisplatin and concurrent radiotherapy (CCRT) for locally advanced head and neck squamous cell carcinoma (LA-HNSCC): A randomized controlled multi-centered trial 1 2 1 2 2 1 1 1 1 3 4 X. He , H. Yin , W. Guo , X. Sun , X. Hu , P. Yan , F. Li , S. Huang , H. Zhou , F. Zhang , B. Wang , 1 1 1 1 1 1 1 1 2 3 X. Bian , Q. Wei , J. Wu , F. Wang , D. Song , J. Liu , B. Zhou ; Nanjing, CN, Xuzhou, CN, Wuxi, 4 CN, Yangzhou, CN
13:15 - 13:15 1068P - The observational ENCORE study: Cetuximab + platinum-based therapy (PBT) for first-line (1L) treatment of patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) 1 2 2 3 4 5 6 C. Le Tourneau , M. Ghiani , M. Cau , R. Depenni , G. Ronzino , L. Livi , V. Montesarchio , M. 1 7 8 9 10 11 1 2 Bretagne , M. Saint-Ghislain , J. Schulten , D. Messinger , A. Sbrana , M. Ghi ; Paris, FR,
3 4 5 6 7 8 9 Cagliari, IT, Modena, IT, Lecce, IT, Florence, IT, Napoli, IT, Rouen, FR, Darmstadt, DE, 10 11 Mannheim, DE, Pisa, IT, Venice, IT
13:15 - 13:15 1069P - Primary surgery versus chemoradiotherapy for advanced oropharyngeal and hypopharyngeal cancer: A propensity-score matched study using a nationwide database C. Cheng, Taipei, TW
13:15 - 13:15 1070P - Comparison of carboplatin with 5-fluorouracil (carbo-5FU) versus cisplatin as concomitant chemoradiotherapy (CRT) for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) 1 1 1 1 1 1 1 S. Hanemaaijer , I. Kok , R. Fehrmann , B. van der Vegt , J. Gietema , B. Plaat , M. Vugt , M. 2 2 2 2 1 1 1 2 Vergeer , J. Voortman , C.R. Leemans , J. Buter , J. Langendijk , S. Oosting ; Groningen, NL, Amsterdam, NL
13:15 - 13:15 1071P - Postoperative radiotherapy with weekly cisplatin in locally advanced head and neck cancer A. Hervás, J. Domínguez, D. Candini, M. Martín, C. Vallejo; Madrid, ES
13:15 - 13:15 1072P - Effectiveness and toxicities of cetuximab in combination with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A propensity score-matched analysis L.-R. Wu, J.-H. Xu, W.-J. Guo, X. He; Nanjing, CN
13:15 - 13:15 1073P - Safety and efficacy of nimotuzumab with concurrent chemoradiotherapy in unresectable locally advanced squamous cell carcinoma of head and neck: Indian rural hospital experience 1 2 1 1 2 1 2 S. Rawat , D. Pawar , H. Tandon , S. Patel , S. Chaudhari ; Jabalpur, IN, Bangalore, IN
13:15 - 13:15 1074P - A phase II study of combination chemotherapy with cetuximab/S-1/low dose cisplatin as neoadjuvant manner for oral squamous cell carcinoma patients 1 2 2 3 4 5 6 M. Nakazawa , T. Imai , Y. Matsumiya , M. Suematsu , Y. Ohta , T. Ohnishi , M. Ohmae , H. Chisoku 7 2 3 8 1 2 3 4 5 , I. Kato , S.-Y. Tada , A. Takeshita ; Suita, Osaka/JP, Suita, JP, Nishinomiya, JP, Itami, JP, 6 7 8 Ikeda, JP, Izumisano, Osaka/JP, Higashiosaka, JP, Suita, Osaka, JP
Last update: 02-09-2017 06:01:33pm esmo.org 13:15 - 13:15 1075P - Role of induction chemotherapy in locally advanced T4b oral cavity cancers: A single Institute experience 1 2 3 2 4 4 2 K.N. Lokesh , T. Chaudhuri , K.C. Lakshmaiah , G. Babu , D. Lokanatha , L. Jacob , S. Babu , A.
1 2 1 2 3 4 Rudresha , L. Rajeev ; Bangalore, Karnatka/IN, Bangalore, IN, Beijing, CN, Bengaluru, IN
13:15 - 13:15 1076P - Concurrent chemoradiotherapy (CCRT) versus induction docetaxel, cisplatin and 5-fluorouracil (TPF) followed by CCRT in locally advanced hypopharyngeal and base of tongue cancer: A randomized phase II study 1 2 2 2 2 2 2 2 2 S.H. Lim , J.-M. Sun , J. Hong , D. Oh , Y.C. Ahn , M.K. Chung , H.-S. Jeong , Y.-I. Son , M.-J. Ahn
2 2 1 2 , C.-H. Baek , K. Park ; Hwanseong-Si, Gyeong-Ki-Do/KR, Seoul, KR
13:15 - 13:15 1077P - Do patients over 70 years with advanced head and neck squamous cell carcinoma tolerate curative intent concurrent chemo-radiation? Predictors of oncological outcomes 1 2 3 2 2 2 V. Srinivasalu , N. Subramaniam , N. Kumar , D. Balasubramaniam , A. Philip , A. Susan , A. 2 2 2 2 2 2 2 1 Remesan Nair , C. G Prameela , K.U. Pushpaja , K. Thankappan , W. Jose , S. Iyer , P. Keechilat ; 2 3 Cochin, IN, Kochi, IN, Cambridge, GB
13:15 - 13:15 1078P - Multidisciplinary team management in head and neck cancer: The real life experience 1 1 1 1 1 1 1 J.-B. Guy , Y. Xia , A. Vallard , S. Espenel , J.-C. Trone , J. Langrand-Escure , A. Hamrouni , M. Ben 1 1 1 1 2 2 1 2 Mrad , C. Rancoule , S. Ouni , T. Muron , P. Fournel , N. Magne ; Saint-Etienne, FR, St. Priest En Jarez, FR
13:15 - 13:15 1079P - Long-term response to second-line afatinib in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Analysis of the LUX-Head & Neck 1 (LHN1) trial 1 2 2 3 4 2 J.-P. Machiels , G. de Castro Jr , L. de Souza Viana , R. Galiulin , M. Tahara , U. Nicolau , C. Le 5 6 7 8 9 10 11 Tourneau , K. Okami , V. Vladimirov , A. Izmailov , K. Hoermann , L. Licitra , R. Haddad , E. 12 13 14 15 16 17 1 2 Cohen , N. Dupuis , J. Love , E. Zografos , E. Ehrnrooth , J. Fayette ; Brussels, BE, São
3 4 5 6 7 8 9 Paulo, BR, Omsk, RU, Kashiwa, Chiba/JP, Paris, FR, Isehara, JP, Pyatigorsk, RU, Ufa, RU, 10 11 12 13 14 Mannheim, DE, Milan, IT, Boston, MA/US, La Jolla, IL/US, Boulder, CO/US, Ridgefield, 15 16 17 CT/US, Athens, GL, Copenhagen, DK, Lyon, FR
13:15 - 13:15 (Withdrawn)
13:15 - 13:15 1081P - Benefit of cetuximab addition to a platinum-fluorouracil-based chemotherapy in an unselected population of metastatic head and neck cancer patients and effect of KRAS Lcs6 variation on cetuximab response 1 1 1 1 2 1 1 V. Bastit , N. Bon-Mardion , J.-M. Picquenot , V. Rainville , C. Moldovan , A. François , F. El Ouakif ,
1 1 1 3 1 2 3 F. Jardin , J.-P. Marie , F. Di Fiore , F. Clatot ; Rouen, FR, Paris, FR, Rouen, CEDEX 1/FR
13:15 - 13:15 1082P - A pilot study of apatinib in heavily pretreated metastatic adenocarcinoma of the head and neck L. Gui, X. He; Beijing, CN
13:15 - 13:15 1083P - Natural history and prognostic factors of head and neck cancer patients with bone metastases: A retrospective Italian study
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 1 1 3 4 5 6 S. Grisanti , C. Bergamini , S. Bianchi , A. Baiguini , S. Vecchio , L. Locati , A. Bonetta , P.F. Conte , 7 8 9 10 11 1 1 5 M. Airoldi , M. Merlano , P. Carlini , T. Ibrahim , C. Rossetto , P. Nicolai , R. Maroldi , S. Tonoli , P. 12 1 4 1 1 2 3 4 5 Pronzato , S. Magrini , L. Licitra , A. Berruti ; Brescia, IT, Milano, IT, Genova, IT, Milan, IT, 6 7 8 9 10 11 12 Cremona, IT, Padova, IT, Torino, IT, Cuneo, IT, Rome, IT, Meldola, IT, Udine, IT, La Spezia, IT
13:15 - 13:15 1084P - Prognostic impact of the neutrophil-to-lymphocyte ratio (NLR) on overall survival in patients treated with chemoradiotherapy for head and neck cancer 1 2 1 1 1 2 1 1 S. Makhloufi , G. Lefebvre , I. Sakji , F. Feutry , T. Leroy , N. Penel , B. Coche , J. Fourquet , F.
1 1 1 2 1 2 Ghestem , M. Julieron , D. Chevalier , E. Tresch ; Lille, FR, Lille, CEDEX/FR
13:15 - 13:15 1085P - Association of ERP29 genetic polymorphism in microRNA-binding site with oropharynx cancer risk and prognosis 1 2 1 1 1 1 J. Carron , E. Costa , L. Lopes-Aguiar , B. Sá Carvalho , J.A. Rinck-Junior , A. Dalla Costa , M.
3 1 1 1 2 3 Ortega , C. Lima , G. Lourenço ; Campinas, BR, Campinas, SP/BR, Bragança Paulista, BR
13:15 - 13:15 1086P - Diagnostic and prognostic impact of plasma osteopontin in nasopharyngeal carcinoma J.-C. Lin, W.-Y. Wang, Y.C. Liu; Taichung, TW
13:15 - 13:15 1087P - Head and neck cancer (HNC) and synchronic lung cancer: Impact of the lung cancer on the management and prognosis of these patients. Data from the SYNCHRON GFPC 15-04 Study 1 1 2 3 4 5 6 N. Paleiron , L. SARAMON , G. Robinet , R. Gervais , P. Fournel , H. Le Caer , H. Berard , G. Valette 1 1 7 1 2 3 4 , R. Marianowski , C. Chouaid ; Brest, FR, Brest, Cedex 2/FR, Caen, CEDEX 5/FR, St. Priest En 5 6 7 Jarez, FR, St Brieuc, FR, Toulon, FR, Paris, CEDEX 12/FR
13:15 - 13:15 1088P - An estimation of the population survival benefit of first-course chemotherapy for head and neck cancers 1 2 2 3 4 1 2 3 V. Do , W. Ng , S. Jacob , G. Delaney , M. Barton ; Westmead, NSW/AU, Sydney, NSW/AU,
4 Liverpool, NSW/AU, Liverpool, AU
13:15 - 13:15 1089P - GSTP1 c.313A>G, XPD c.934G>A, XPF c.2505T>C and CASP9 c.-1339A>G polymorphisms and severity of vomiting in head and neck cancer patients treated with cisplatin chemoradiation 1 2 2 2 2 2 2 2 C. Lima , J. Carron , L. Lopes-Aguiar , E. Costa , G. Nogueira , T. Lima , E. Pincinato , M. Visacri , J.
2 2 2 1 2 Quintanilha , P. Moriel , G. Lourenço ; Campinas, SP/BR, Campinas, BR
13:15 - 13:15 1090P - Analysis of the impact of the tumours committee on the multidisciplinary approach to head and neck epidermoid cancer in our institution 1 1 2 1 3 1 1 M.J. Martínez-Ortiz , P. Cerezuela , G. Marin Zafra , J. Balsalobre , J. Díaz-Manzano , J. Trujillo ;
2 3 Cartagena, ES, Murcia, ES, El Palmar, ES
13:15 - 13:15 1091P - Prognostic nutritional index (PNI) is an independent prognostic factor in locoregionally advanced squamous cell head and neck cancer (LAHNSCC) 1 2 3 3 2 1 1 G. Bruixola , J. Caballero , F. Papaccio , A. Petrillo , M. Pastor , A. Cervantes ; Valencia,
2 3 Valencia/ES, Valencia, ES, Napoli, IT
Last update: 02-09-2017 06:01:33pm esmo.org 13:15 - 13:15 1092P - CASP9 c.-1339A>G and CASP3 c.-1191A>G polymorphisms in susceptibility and outcome of head and neck squamous cell carcinoma E. Costa, L. Lopes-Aguiar, G. Nogueira, T. Lima, V. Liutti, F. Leal, V. Santos, J.A. Rinck-Junior, G.
Lourenço, C. Lima; Campinas, BR
13:15 - 13:15 1093P - Resource-stratification of national comprehensive cancer network (NCCN®) head and neck cancers guideline 1 2 3 2 2 4 1 2 R. Carlson , E. Nardi , J. Bacigalupo , S. Darlow , J. McClure , D. Pfister ; New York, CA/US, Fort
3 4 Washington, PA/US, Fort Washington, US, New York, NY/US
13:15 - 13:15 1094P - Long-term results of chemoradiotherapy for stage III nasopharyngeal carcinoma patients and risk grouping by pretreatment EBV viral load P.-J. Lin, W.-Y. Wang, Y.C. Liu, J.-C. Lin; Taichung, TW
13:15 - 13:15 1095P - Nasopharyngeal cancer in children: Long term results the experience of the university hospital of Sfax (Tunisia) L. Ghorbal, N. Toumi, H. Ben Salah, S. Charfi, A. Ghorbel, A. Khanfir, M. Frikha, J. Daoud; Sfax, TN
13:15 - 13:15 (Withdrawn)
13:15 - 13:15 1098P - Incidence and impact of DPD mutation on neoadjuvant chemotherapy in head and neck cancers S. Turkar, A. Chougule, V. Patil, V. Noronha, A. Joshi, N. Pande, A. Chandrashekharan, K. Prabhash;
Mumbai, IN
13:15 - 13:15 1099P - Radiotherapy related xerostomia in head and neck oncology: A systematic review D. Johns, Kozhikode, IN
13:15 - 13:15 1100P - The phase II study of HMB/Arg/Gln against oral mucositis induced by chemoradiotherapy for head and neck cancer patients 1 1 2 2 2 2 2 2 T. Yokota , S. Hamauchi , Y. Yoshida , T. Yurikusa , M. Suzuki , A. Yamashita , H. Ogawa , T. Onoe
2 2 1 2 , K. Mori , T. Onitsuka ; Shizuoka, Shizuoka/JP, Shizuoka, JP
13:15 - 13:15 1101P - Oral mucosa dose parameters predicting grade ≥3 acute toxicity in locally advanced nasopharyngeal carcinoma patients treated with concurrent intensity-modulated radiation therapy and chemotherapy 1 2 3 3 1 2 3 K. Li , L. Yang , Y.-Y. Chen , M. Chen ; Quanzhou, CN, Xinyu, CN, Hangzhou, CN
13:15 - 13:15 1102P - Sinonasal non-glandular cancers relapsing after multimodal treatments 1 1 1 2 1 1 1 S. Cavalieri , R. Granata , L. Locati , C. Bergamini , S. Alfieri , C. Resteghini , D. Galbiati , E. Orlandi
1 1 2 1 1 1 1 1 2 , N. Iacovelli , G. Calareso , M. Guzzo , P. Quattrone , L. Licitra , P. Bossi ; Milan, IT, Milano, IT
13:15 - 13:15 1103P - Survival outcome and optimal treatment of intermediate-grade salivary gland carcinoma G. PARK, Changwon, KR
13:15 - 13:15 1104P - Incidence and survival of secondary malignances (SM) in oropharingeal squamous cell carcinoma (OPSCC): A homogeneous single report institution
Last update: 02-09-2017 06:01:33pm esmo.org 1 1 1 1 1 1 1 M. Napolitano , F. Bertolini , E. D'Angelo , A. Spallanzani , S. Tassi , B. Meduri , S. Bettelli , R.
1 1 1 1 2 1 2 Depenni , A. Ghidini , F. Lohr , L. Presutti , S. Cascinu ; Modena, IT, Ancona, IT
13:15 - 13:15 1105TiP - Pembrolizumab plus chemoradiation (CRT) for the treatment of locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Phase 3 KEYNOTE-412 trial 1 2 3 4 5 1 6 6 J.-P. Machiels , L. Licitra , D. Rischin , J. Waldron , B. Burtness , V. Grégoire , T. Shekar , H. Brown 7 8 1 2 3 4 5 , J. Cheng , L. Siu ; Brussels, BE, Milan, IT, East Melbourne, VIC/AU, Toronto, ON/CA, New 6 7 8 Haven, CT/US, Kenilworth, NJ/US, North Wales, PA/US, Toronto, On, CA
13:15 - 13:15 1106TiP - Hope for salivary gland cancer (SGC): EORTC HNCG/UKCRN 1206 randomized phase II study to evaluate the efficacy and safety of Chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic androgen receptor (AR) expressing SGC 1 2 2 3 1 4 2 1 L. Locati , C. Caballero , C. Fortpied , F. Perrone , S. Pilotti , K. Harrington , V. Grégoire , L. Licitra ;
1 2 3 4 Milan, IT, Brussels, BE, Milano, IT, London, GB
13:15 - 13:15 1107TiP - Phase II trial of abiraterone acetate in patients with relapsed and/or metastatic, castration resistant AR expressing salivary glands carcinomas (SGCs) L. Locati, A. Gambaro, L. Licitra; Milan, IT
13:15 - 13:15 1108TiP - Chemoradiotherapy versus radiotherapy in the treatment of salivary glands and nasal tumors: The GORTEC 2016-02 study 1 2 3 4 5 6 7 8 F.R. Ferrand , J. Thariat , N. Vulquin , V. Calugaru , O. Malard , C. Murariu , F. Janot , F. Louat , C. 2 9 1 2 3 4 5 Michel , J. Bourhis ; Saint-Mandé, CEDEX 5/FR, Nice, FR, Dijon, Cedex/FR, Paris, FR, Nantes, 6 7 8 9 FR, Reims, FR, Villejuif, FR, Tours, FR, Lausanne, CH
13:15 - 13:15 1109TiP - MEDINDUCTION: Phase I trial evaluating the safety of durvalumab in combination with Docetaxel, Cisplatin and 5-FU (DCF) in induction for locally advanced squamous cell carcinoma of the head and neck (SCCHN) 1 1 2 1 3 1 1 1 C. Even , M. Texier , C. Le Tourneau , A. Marabelle , N. Chaput , J. Adam , A. Paci , S. Broutin , C. 1 1 4 5 1 2 3 4 Ferté , I. Breuskin , D. Cupissol , J. Fayette ; Villejuif, FR, Paris, FR, Villejuif, CEDEX/FR, 5 Montpellier, CEDEX 5/FR, Lyon, FR
13:15 - 13:15 HEALTH ECONOMICS M. Ijzerman, Enschede, NL
13:15 - 13:15 1114P - All.Can initiative: improving efficiency in cancer care 1 2 3 4 5 6 7 M. Aapro , S. Chrostowski , F. Florindi , B. Gandouet , S. Hanna , R. Hazarika , R. Hess , F. de 3 6 6 8 9 10 11 Lorenzo , V. Muthu , K. Oliver , A. Roediger , T. Rosvall-Puplett , B. Ryll , G. Spurrier , K. 12 13 6 3 3 1 2 3 Steinmann , T. Szucs , S. Wait , L. Wierinck , W. Yared ; Genolier, CH, Warsaw, PL, Brussels, 4 5 6 7 8 9 10 BE, Toulouse, FR, Laval, CA, London, GB, Cologne, DE, Luzer, CH, Braine L'alleud, BE, SE, 11 12 13 Clermont-Ferrand, FR, Zug, CH, Basel, CH
13:15 - 13:15 1115P - Cost-effectiveness of nivolumab+ipilimumab in first-line treatment of advanced melanoma: Analysis using 28-month overall survival from CheckMate 067
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 2 3 4 4 3 3 J. Sabater , T. Baker , V. Paly , K. Gupte-Singh , M. Lorenzi , A. Jeffers , H. Beyhaghi , S. Kotapati , 3 5 1 2 3 4 5 S. Rao , A. Briggs ; Madrid, ES, Philadelphia, PA/US, Princeton, NJ/US, San Francisco, CA/US, Glasgow, GB
13:15 - 13:15 1116P - Palbociclib in advanced breast cancer: A cost-utility analysis 1 2 2 1 2 J. Raphael , J. Helou , D. Naimark ; Toronto, Ontario/CA, Toronto, ON/CA
13:15 - 13:15 1117P - Real-world survival outcomes in patients with advanced urothelial cancer in Germany 1 2 3 4 5 5 6 5 G. Niegisch , H. Gerullis , S.-W. Lin , J. Pavlova , A. Gondos , A. Rudolph , G. Haas , N. Hennies , 7 1 2 3 4 5 M. Kramer ; Düsseldorf, DE, Oldenburg, DE, South San Francisco, US, Basel, CH, Frankfurt, DE, 6 7 Frankfurt Am Main, DE, Lübeck, DE
13:15 - 13:15 1118P - Health related quality of life and utility weights of medical oncology inpatients M.A. Vicente Conesa, M. Zafra Poves, M.A. Ivars, I. Ballester, A. Carmona-Bayonas, F. Ayala de la
Peña; Murcia, ES
13:15 - 13:15 1119P - A trial-based EUROQOL EQ-5D health utility analysis in patients with classical Hodgkin's lymphoma 1 2 2 1 2 E. Wu , J. Liao , A. Balakumaran ; West Point, US, North Wales, US
13:15 - 13:15 1120P - Real world comparison of common patient reported symptoms with health utility scores in cancer outpatients 1 2 3 4 5 6 3 4 3 6 M. Moskovits , K. Jao , C. Brown , S. Su , H. Naik , L. Eng , T. Wang , Y. Leung , W. Xu , G. Liu , 4 4 4 1 2 3 4 5 M. Li , G. Devins , D. Howell ; Haifa, IL, Montreal, QC/CA, Toronto, CA, Toronto, ON/CA, 6 Vencouver, CA, Toronto, Ontario/CA
13:15 - 13:15 1121P - Costs of dacomitinib versus placebo in pretreated unselected patients (pts) with advanced NSCLC: CCTG BR.26 1 1 2 3 2 1 4 5 S. Karim , K. Ding , P. Bradbury , P. Ellis , N. Mittman , X. Xiaoqun Sun , M. Millward , G. Liu , S. 6 7 8 9 10 11 12 13 Sun , M. Stockler , V. Cohen , N. Blais , R. Sangha , M. Boyer , R. Sasidharan , C. Lee , F. 14 15 16 2 1 2 3 4 Shepherd , G. Goss , L. Seymour , N. Leighl ; Kingston, CA, Toronto, CA, Hamilton, CA,
5 6 7 8 Nedlands, WA/AU, Toronto, Ontario/CA, Vancouver, CA, Camperdown, NSW/AU, Montreal, QC/CA, 9 10 11 12 13 14 Montreal, CA, Edmonton, Alberta/CA, Camperdown, AU, Auckland, NZ, Surrey, CA, 15 16 Toronto, ON/CA, Ottawa, CA, Kingston, Ontario/CA
13:15 - 13:15 1122P - Feasibility of routine collection of health state utilities using EQ-5D in a breast cancer outpatient clinic 1 2 1 2 2 2 1 2 S. Torres , M. Trudeau , K. Pritchard , N. Mitsakakis , N. Li , M. Krahn ; Toronto, Ontario/CA, Toronto, ON/CA
13:15 - 13:15 1123P - The cost of expensive breast cancer drugs 1 1 1 2 1 1 2 S. Berghuis , H. Koffijberg , L. Terstappen , S. Sleijfer , M. Ijzerman ; Enschede, NL, Rotterdam, NL
13:15 - 13:15 1124P_PR - Impact of licensing and reimbursement discrepancies on patient access to cancer treatments across Europe and Canada
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 3 1 1 1 1 2 J. McKendrick , B. Malcolm , K. Sheahan , I. Katsoulis , X. Song , J. van Loon ; Fleet, GB,
3 Wallingford, GB, Uxbridge, GB
13:15 - 13:15 1125P - The cost-effectiveness of EndoPredict to inform adjuvant chemotherapy decisions in early breast cancer 1 2 3 3 3 3 3 1 2 S. Hinde , C. Theriou , S. May , L. Matthews , A. Arbon , L. Fallowfield , D. Bloomfield ; York, GB,
3 Nottingham, GB, Brighton, GB
13:15 - 13:15 1126P - The evolution of value with filgrastim in oncology 1 2 1 2 P. Cornes , A. Krendyukov ; Bs Da, GB, Holzkirchen, DE
13:15 - 13:15 1127P - Tyrosine kinase inhibitors (TKI): Awareness of drug-drug interaction N. Ozdemir, S. Toptas, M. Sendur, O. Yazici, B. Öksüzoğlu, K. Silay, N. Zengin; Ankara, TR
13:15 - 13:15 1128P - Anti-PD1 inhibitors: Assessment of proper use, efficacy and economic impact in daily practice 1 1 1 1 2 1 1 1 A. Gobert , A. Jaeger , L. Taillade , N. Osman , D. Lassoued , C. Mateescu , P. Maingon , P. Tilleul ,
2 1 1 2 J.-P. Spano , A. Bellanger ; Paris, FR, Paris, CEDEX 13/FR
13:15 - 13:15 1129P - Real world treatment costs and resource utilization among patients with metastatic bladder cancer 1 2 2 2 3 4 1 2 K. Flannery , X. Cao , J. He , Y. Zhong , A. Shah , A. Kamat ; West Point, US, North Wales,
3 4 PA/US, Houston, US, Houston, TX/US
13:15 - 13:15 1130P - Investigating discrepancies in assessments of PFS by study investigators and independent review C. Jones, J. Soto Barrientos, G. Monnickendam; Fleet, GB
13:15 - 13:15 1131P - Medical costs and health care resource use (HCRU) in elderly us patients (pts) with newly diagnosed metastatic or surgically unresectable urothelial carcinoma (mUC) using surveillance, epidemiology, and end results (SEER) medicare data 1 1 2 3 1 4 1 2 3 A. Aly , C. Johnson , S. Yang , S. Rao , M. Botteman , A. Hussain ; Bethesda, US, Princeton, US,
4 Princeton, NJ/US, Baltimore, US
13:15 - 13:15 1132P - Chasing the survival curve tail: The effect on cost-effectiveness of nivolumab for second-line treatment of advanced renal cell carcinoma M. Sarfaty, A. Moore, V. Neiman, E. Rosenbaum, D. Goldstein; Petah Tikva, IL
13:15 - 13:15 1133P - Non-elective admissions in cancer care - A review of acute oncology services (AOS) implementation in a north-west region of England S. Chow, R. Leach, C. Mitchell; Manchester, GB
13:15 - 13:15 1134P - Changing treatment patterns in metastatic colorectal cancer in EU5 countries from 2014 to 2016 N. Schmidt, L. Hoyer; Frankfurt Am Main, DE
13:15 - 13:15 IMMUNOTHERAPY OF CANCER 1 2 1 2 F. Thistlethwaite , D. Speiser ; Manchester, GB, Lausanne, CH
Last update: 02-09-2017 06:01:33pm esmo.org
13:15 - 13:15 1149P - Results of the randomized, placebo-controlled phase I/IIB trial of CV9104, an mRNA based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC) 1 2 3 4 5 6 7 A. Stenzl , S. Feyerabend , I. Syndikus , T. Sarosiek , H. Kübler , A. Heidenreich , R. Cathomas , C. 8 9 10 11 11 Grüllich , Y. Loriot , J.L. Perez Gracia , U. Klinkhardt , A. Schroeder , O. Schönborn-Kellenberger 12 13 13 14 14 13 9 13 1 , V. Reus , V. Reus , S.D. Koch , H.S. Hong , T. Seibel , K. Fizazi , U. Gnad-Vogt ;
2 3 4 5 6 Grenzach, DE, Reutlingen, DE, Bebington, Merseyside/GB, Warsaw, PL, Würzburg, DE, Aachen, 7 8 9 10 11 DE, Chur, CH, Heidelberg, Baden Württemberg/DE, Villejuif, FR, Pamplona, ES, Frankfurt Am 12 13 14 Main, DE, Heidelberg, DE, Frankfurt, DE, Tübingen, DE
13:15 - 13:15 1150P - Phase II clinical trial of peptide vaccination for advanced head and neck cancer patients induced immune responses and prolonged OS 1 2 2 2 2 2 1 Y. YOSHITAKE , D. Fukuma , M. Hirayama , H. Nakayama , H. Ogi , M. Shinohara ; Kumamoto
2 City, JP, Kumamoto, JP
13:15 - 13:15 1151P - Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors 1 2 2 2 2 2 2 1 A. Hosono , T. Yoshikawa , N. Tsuchiya , N. Fujinami , K. Saito , S. Mizuno , T. Nakatsura ;
2 Kashiwa, Chiba/JP, Chiba, JP
13:15 - 13:15 1152P - Phase 1 study of HSP105-derived peptide vaccine for patients with advanced esophageal cancer/colo- rectal cancer 1 2 2 2 1 2 2 S. Wada , T. Kojima , T. Nakatsura , H. Bando , O. Motohashi , M. Shimomura , T. Yoshikawa , K. 3 1 2 2 2 4 2 1 Kohashi , A. Hori , H. Ono , M. Fukutani , M. Wakabayashi , S. Nomura , A. Sato , T. Sasada , A. 2 1 2 3 4 Ohtsu ; Yokohama, JP, Chiba, JP, Fukuoka, JP, Tokyo, JP
13:15 - 13:15 1153P - An observational clinical study with RAS peptide vaccine TG01 evaluating immune response, safety and overall survival in patients with non-resectable pancreatic cancer 1 1 2 1 1 1 2 J.A. Eriksen , I. Gladhaug , A. Rosseland , K. Risberg Handeland , T. Buanes ; Oslo, NO, Lillestrøm, NO
13:15 - 13:15 1154P - Telomerase peptide vaccine combined with ipilimumab in metastatic melanoma: Reports from a phase I trial 1 1 1 2 1 1 1 1 E. Aamdal , G. Gaudernack , E. Inderberg , W. Rasch , J. Bjørheim , S. Aamdal , T.K. Guren ; Oslo,
2 NO, Oslo, NO/NO
13:15 - 13:15 1155P - Results of an open label randomized phase II trial of CV9104, an mRNA-based multivalent cancer immunotherapy in patients (pts) with intermediate or high risk localized prostate cancer (PC) undergoing radical prostatectomy (RPE) 1 2 3 4 5 6 7 6 A. Stenzl , S. Feyerabend , H. Kübler , M. Retz , C. Grüllich , M. Hipp , U. Klinkhardt , H.S. Hong , F. 6 6 6 6 7 8 9 Doener , S.D. Koch , M. Scholl , S. Brutlach , A. Schroeder , T. Seibel , N. Halama , O. 9 6 8 1 2 3 Schönborn-Kellenberger , M. Fotin-Mleczek , U. Gnad-Vogt ; Grenzach, DE, Reutlingen, DE, 4 5 6 7 Würzburg, DE, München, DE, Heidelberg, Baden Württemberg/DE, Tübingen, DE, Frankfurt Am 8 9 Main, DE, Frankfurt, DE, Heidelberg, DE
Last update: 02-09-2017 06:01:33pm esmo.org 13:15 - 13:15 1156P - Italian nivolumab expanded access programme: real-world results in non-squamous non-small cell lung cancer patients 1 2 3 4 5 5 6 F. Grossi , L. Crinò , A. Delmonte , D. Turci , G. Lo Russo , F. De Marinis , H. Soto Parra , D. Galetta 7 4 8 9 10 11 12 12 , F. Cappuzzo , F. Sperandi , M. Tiseo , G. Puppo , F. Roila , M.R. Migliorino , G. Tonini , F. 13 5 14 12 12 1 2 3 Cognetti , A. Santoro , D. Tassinari , A. Scoppola , E. Cortesi ; Genova, IT, Perugia, (PG)/IT, 4 5 6 7 8 9 10 11 Meldola, IT, Ravenna, IT, Milano, IT, Catania, IT, Bari, IT, Bologna, IT, Parma, IT, Pisa, IT, 12 13 14 Terni, IT, Roma, IT, Rome, IT, Rimini, IT
13:15 - 13:15 1157P - Correlation and differences in Effect sizes between Progression Free Survival (PFS) and Overall Survival (OS) among PD-1 inhibitors B. Gyawali, T. Shimokata, Y. Ando; Nagoya, Aichi/JP
13:15 - 13:15 1158P - Is objective response rate (ORR) a valid primary endpoint in phase 2 trials (Ph2t) of immune checkpoint inhibitors (ICI) for advanced solid cancers? 1 2 2 2 2 3 4 1 2 G. Ritchie , H. Gasper , J. Man , S. Lord , M. Friedlander , C. Lee , I. Marschner ; Randwick, AU,
3 4 Sydney, AU, Kogarah, NSW/AU, Sydney, NSW/AU
13:15 - 13:15 1159P - Long term survival in patients responding to an Anti-PD-1/PD-L1 therapy and disease outcome upon treatment discontinuation 1 2 3 2 2 3 3 M.-L. Gauci , E. Lanoy , S. Champiat , J.-M. Michot , A. Varga , R. Bahleda , E. Angevin , A. Gazzah 2 1 2 2 2 4 2 2 , L. Verlingue , F. Bigot , S. Aspeslagh , E. Castanon , C. Baldini , S. Postel-Vinay , C. Massard , A. 2 2 2 1 2 3 4 Hollebecque , J.-C. Soria , A. Marabelle ; Paris, FR, Villejuif, FR, Villejuif, CEDEX/FR, Lille, CEDEX/FR
13:15 - 13:15 1160P - Meta-Analysis of Anti-PD-1/PD-L1 Therapy Related Adverse Events in Clinical Trials 1 2 2 2 3 3 3 Y. Wang , X. Wang , F. Yang , X. Guan , N. Duma , J. Vera Aguilera , G. Nowakowski , A. 3 3 3 3 4 3 1 Chintakuntlawar , K. Price , J. Molina , T. Halfdanarson , A. Grothey , S. Markovic ; Jacksonville, US, 2 3 4 Nanjing, CN, Rochester, US, Rochester, MN/US
13:15 - 13:15 1161P - A standardized comparison of outcomes in patients (pts) with refractory, aggressive non-hodgkin Lymphoma (rNHL) from the SCHOLAR-1 analysis and the ZUMA-1 study of axicabtagene ciloleucel (axi-cel) 1 2 3 4 5 6 7 S. Neelapu , F. Locke , N. Bartlett , L. Lekakis , P. Reagan , D. Miklos , C. Jacobson , I. 8 9 10 11 12 12 13 Braunschweig , O. Oluwole , T. Siddiqi , Y. Lin , M. Crump , J. Kuruvilla , E. Van den Neste , B. 14 11 15 15 16 13 1 2 Link , U. Farooq , L. Navale , W. Go , J. Wiezorek , C. Gisselbrecht ; Houston, US, Tampa,
3 4 5 6 7 8 US, Saint Louis, MO/US, Miami, FL/US, Rochester, NY/US, Stanford, CA/US, Boston, MA/US, 9 10 11 12 13 14 Bronx, US, Nashville, TN/US, Duarte, US, Rochester, US, Kingston, CA, Paris, FR, Iowa 15 16 City, US, Santa Monica, CA/US, Thousand Oaks, CA/US
13:15 - 13:15 1162P - Predictive factors for poor progression-free survival in patients with non-small-cell lung cancer treated with nivolumab 1 2 1 1 1 3 4 5 Y. Taniguchi , A. Tamiya , S.-I. Isa , K. Nakahama , K. Okishio , T. Shiroyama , H. Suzuki , T. Inoue , 3 5 5 3 5 2 1 2 M. Tamiya , K. Nishino , T. Kumagai , T. Hirashima , F. Imamura , S. Atagi ; Sakai, JP, Sakai, 3 4 5 Osaka/JP, Habikino, Osaka/JP, Habikino, JP, Osaka, JP
Last update: 02-09-2017 06:01:33pm esmo.org 13:15 - 13:15 1163P - Immunotherapy phase I trials in patients over 70 years with advanced solid tumours: The Gustave Roussy experience 1 2 2 2 2 2 2 H. Herin , E. Castanon , V. Dyevre , S. Aspeslagh , A. Marabelle , S. Postel-Vinay , A. Varga , A. 2 2 3 2 2 2 2 2 Gazzah , V. Ribrag , R. Bahleda , J.-M. Michot , O. Mir , C. Massard , A. Hollebecque , J.-C. Soria , 4 1 2 3 4 C. Baldini ; Paris, FR, Villejuif, FR, Villejuif, CEDEX/FR, Lille, CEDEX/FR
13:15 - 13:15 1164P - Patterns of progression under antiPD1/PDL1 in advanced NSCLC patients allow discriminating pseudo-progression from real progression 1 1 1 1 2 1 1 C. CARAMELLA , M. Tazdait , L. Mezquita , J. Lahmar , R. Ferrara , A. Marabelle , C. Balleyguier ,
1 1 1 1 1 2 D. Planchard , A. Gazzah , J.-C. Soria , B. Besse ; Villejuif, FR, Verona, IT
13:15 - 13:15 1165P - Immune checkpoint inhibitors following targeted therapies in MITF family translocation renal cell carcinomas 1 2 3 1 4 2 5 A. Boileve , M. Carlo , P. Barthelemy , S. Oudard , D. Borchiellini , M. Voss , S. George , C. 6 1 1 7 8 9 10 Chevreau , J. Landman-Parker , M.-D. Tabone , D. Chism , A. Amin , M. Bilen , D. Bosse , T. 11 12 13 1 2 3 4 Choueiri , N. Tannir , G. Malouf ; Paris, FR, New York, US, Strasbourg, CEDEX/FR, Nice, 5 6 7 8 9 10 CEDEX 2/FR, Buffalo, NY/US, Toulouse, FR, Nashville, US, Charlotte, NC/US, Atlanta, GA/US, 11 12 13 No City Provided, NA, Boston, US, Houston, TX/US, Paris, CEDEX 13/FR
13:15 - 13:15 1166P - Tumor flare reaction (TFR) in cancer treatments: a systematic review A. Taleb, Paris, FR
13:15 - 13:15 1167P - Melanoma brain metastases patients treated with stereotactic radiosurgery and ipilimumab versus stereotactic radiosurgery alone: a systematic review with meta-analysis 1 2 3 4 1 2 3 S. Nguyen , A. Castrellon , O. Vaidis , A. Johnson ; Orlando, US, Hollywood, FL/US, Tampa,
4 FL/US, Houston, TX/US
13:15 - 13:15 1168P - Estimation of benefice to anti-PD-(L)1 for metastatic patients by real-time quantitative and functional estimation of immune infiltrate with RNAseq 1 2 2 2 3 2 2 L. Verlingue , L. Mahjoubi , D. Brandao , S. Michiels , S. Champiat , S. Aspeslagh , Y. Loriot , Y. El 2 2 2 2 2 2 2 Dakdouki , S. Postel-Vinay , C. Nicotra , H. Zouhri , G. Chartier , E. Solary , O. Bernard , D.
2 3 2 2 3 2 1 2 Gautheret , E. Angevin , A. Hollebecque , A. Marabelle , F. André , J.-C. Soria ; Paris, FR, Villejuif, 3 FR, Villejuif, CEDEX/FR
13:15 - 13:15 1169P - Topography of Tumor Mutational Burden (TMB) and Immune-related Genomic Alterations (GA) Across Gastrointestinal Malignancies (GIm): A Study of 22,570 Cases 1 2 3 4 5 6 2 2 S. Klempner , G. Frampton , J. Chao , M. Bailey , P. Stephens , J. Ross , V. Miller , S. Ali , A. 4 1 2 3 4 5 Schrock ; Los Angeles, CA/US, Cambridge, MA/US, Duarte, US, Cambridge, US, Cambridge, 6 Massachusetts/US, Albany, NY/US
13:15 - 13:15 1170P - Analysis of POLE mutation and tumor mutational burden (TMB) across 80,853 tumors: Implications for immune checkpoint inhibitors (ICPIs) 1 1 1 2 3 2 4 2 A. Schrock , D. Fabrizio , Y. He , J. Chung , M. Resnick , P. Stephens , J. Ross , V. Miller , S. 2 2 2 5 6 1 2 3 Ramkissoon , J. Elvin , S. Ali , M. Fakih , S. Klempner ; Cambridge, US, Cambridge, MA/US, 4 5 6 Providence, RI/US, Albany, NY/US, Duarte, CA/US, Los Angeles, US
Last update: 02-09-2017 06:01:33pm esmo.org
13:15 - 13:15 1171P - Checkpoint inhibitors in MSI tumors: Lessons from a monocentric experience 1 2 1 1 1 3 1 Y. El Dakdouki , L. Verlingue , C. Massard , A. Leary , L. Lacroix , E. Rouleau , J.-Y. Scoazec , O. 1 1 1 1 1 1 1 1 Caron , P. Benusiglio , P. Kannouche , A. Hollebecque , D. Malka , J.-C. Soria , A. Marabelle ; 2 3 Villejuif, FR, Paris, FR, Paris, CEDEX 5/FR
13:15 - 13:15 1172P - Single nucleotide polymorphisms in PD-L1 and outcome in nivolumab-treated advanced non-small-cell lung cancer patients T. Nomizo, T. Funazo, H. Ozasa, T. Tsuji, Y. Yasuda, H. Yoshida, Y. Sakamori, H. Nagai, T. Hirai, Y.H.
Kim; Kyoto, JP
13:15 - 13:15 1173P - Efficient identification of neoantigens for personalized cancer immunotherapy in advanced refractory epithelial cancer patients F. Chen, Z. Zou, J. Du, J. Wei, J. Shao, F. Meng, N. ding, B. Liu; Nanjing, CN
13:15 - 13:15 1174P - KRAS mutations (KRAS-mut) and antiPD1/PDL1 therapy in a cohort of non-small cell lung cancer (NSCLC) patients (p): Experience from a single institution 1 2 3 3 3 3 3 C. Erasun Lecuona , M.T. Moran Bueno , L. Vila , I. Teruel , L. Angelats , A. Ferrando , A. Plaja , P. 3 3 3 3 3 3 2 1 Torres , E. Lopez , R. Muriel , A.M. Muñoz-Marmol , J.L. Mate , J.M. Velarde , E. Carcereny Costa ; 2 3 Barcelona, ES, Badalona, Barcelona/ES, Badalona, ES
13:15 - 13:15 1175P - Comparability of programmed death-ligand 1 (PD-L1) expression on tumor-infiltrating immune cells (IC) and tumor cells (TC) in advanced urothelial bladder cancer (UBC) using clinically relevant immunohistochemistry (IHC) assays 1 2 3 4 5 5 K. Schwamborn , R. Knüchel , A. Hartmann , G. Baretton , F. Lasitschka , P. Schirmacher , T. 2 6 6 7 7 6 1 Braunschweig , R. Tauber , F. Erlmeier , S. Hieke-Schulz , J. Ammann , W. Weichert ; Munich, DE, 2 3 4 5 6 7 Nürnberg, DE, Erlangen, DE, Dresden, DE, Heidelberg, DE, München, DE, Basel, CH
13:15 - 13:15 1176P - IDO-1 and PD-L1 predict response to immunotherapy in advanced non small cell lung cancer: An NGS and multiplex IHC analysis 1 1 2 1 2 1 1 1 L. Leroy , J. Massé , J. Adam , V. Brouste , N. Signolle , I. Soubeyran , V. Velasco , E. Khalifa , B.
1 1 2 3 1 2 3 Lortal , A. Italiano , B. Besse , S. Le Moulec ; Bordeaux, FR, Villejuif, FR, Paris, CEDEX 5/FR
13:15 - 13:15 1177P - Undiscovered immune heterogeneity in pancreatic adenocarcinoma (PDAC) 1 1 2 1 3 3 1 1 C. Ragulan , P. Poudel , K. Young , G. Nyamundanda , R. Lawlor , A. Scarpa , A. Sadanandam ;
2 3 Sutton, GB, London, GB, Verona, IT
13:15 - 13:15 1178P - Optimized protocols to determine PD-L1 expression on tumor tissue and cytology samples from non–small cell lung cancer (NSCLC) patients using the 22C3 antibody with various immunohistochemistry (IHC) autostainers 1 2 3 2 2 2 1 M. Ilie , S. Khambata-Ford , C. Copie-Bergman , L. Huang , R. Mogg , J. Juco , V. Hofman , P.
1 1 2 3 Hofman ; Nice, FR, Kenillworth, NJ/US, Créteil, FR
13:15 - 13:15 1179P - Tumor-infiltrating lymphocytes expression in stage IIIc/IV of high-grade serous ovarian cancer: Variation with neoadjuvant chemotherapy and prognostic value C. Bárcena, K. Rojas, L. Lema, L. Manso Sánchez, J. Rios, R. García-Martín, A. Maroto, J.L.
Rodríguez-Peralto, E.M. Ciruelos Gil, D.C. Mendiola, L. Paz-Ares; Madrid, ES
Last update: 02-09-2017 06:01:33pm esmo.org
13:15 - 13:15 1180P - Development of OAT-1746, a novel arginase 1 and 2 inhibitor for cancer immunotherapy P. Stanczak, M. Grzybowski, P. Wolska, A. Zdziarska, M. Mazurkiewicz, R. Blaszczyk, J. Nowicka, A.
Sosnowska, K. Ramji, D. Nowis, J. Golab, A. Golebiowski, P. Dobrzanski, K. Dzwonek; Warsaw, PL
13:15 - 13:15 1181P - Pharmacokinetics (PK) and Pharmacodynamics (PD) of cergutuzumab amunaleukin (CA), a carcinoembryonic antigen (CEA)-targeted interleukin 2 variant (IL2v) with abolished binding to CD25 1 2 3 4 5 6 7 E. van Brummelen , U. Lassen , I. Melero , J. Tabernero , K. Homicsko , E. Angevin , V. Teichgräber 8 9 10 11 10 11 , L. Jukofsky , E. Rossmann , G. Babitzki , A. Patricia Silva , M. Canamero , C. Boetsch , S. 7 12 4 1 2 3 4 Evers , J. Charo , G. Argiles ; Amsterdam, NL, Copenhagen, DK, Pamplona, ES, Barcelona, ES, 5 6 7 8 9 10 Lausanne, Vaud/CH, Villejuif, CEDEX/FR, Schlieren, CH, New York, US, Basel, Solna/CH, 11 12 Penzberg, DE, Basel, CH, Schlieren, Zurich/CH
13:15 - 13:15 1182P - A first-in-human study of a novel monoclonal antibody INCSHR01210 directed against programmed cell death protein 1 (PD-1) in patients with advanced or metastatic cancer 1 2 3 4 5 6 6 6 7 J. Lickliter , H. Gan , B. Gao , P. Grimison , J. Zou , H. Kallender , K. Sun , X. Chen , A. Behren , P. 8 3 1 7 9 9 1 Fernandez-Penas , A. Nagrial , M. Voskoboynik , K. Woods , M. Millward , T. Meniawy ; Melbourne,
2 3 4 5 6 7 AU, Heidelberg, VIC/AU, Blacktown, AU, Camperdown, AU, Shanghai, CN, Wilmington, US, 8 9 Heidelberg, AU, Westmead, NSW/AU, Nedlands, WA/AU
13:15 - 13:15 1183P - Safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of PF 06801591, an anti-PD1 antibody administered intravenously (IV) or subcutaneously (SC) 1 2 3 4 5 6 7 5 M. Johnson , S. Hu-Lieskovan , F. Braiteh , J. Grilley-Olson , J. Chou , J. Davda , B. Jin , A. Forgie , 5 5 1 2 3 4 D. Rassam , S. Youssef ; Nashville, TN/US, Los Angeles, CA/US, Las Vegas, US, Chapel Hill, 5 6 7 NC/US, South San Francisco, CA/US, La Jolla, CA/US, Cambridge, MA/US
13:15 - 13:15 1148P - A phase I/II safety study of tisotumab vedotin (HuMax®-TF-ADC) in patients with solid tumors 1 2 3 4 5 1 5 M. Chenard-Poirier , D. Hong , R. Coleman , J. de Bono , M. Mau-Sorensen , D. Collins , S. Lisby , L.
5 5 1 2 3 4 5 Basse , U. Lassen ; Sutton, GB, Houston, US, Houston, TX/US, London, GB, Copenhagen, DK
13:15 - 13:15 1185P - Safety, pharmacodynamic, and pharmacokinetic profile of TSR-042, an anti–PD–1 monoclonal antibody, in patients (pts) with advanced solid tumors 1 2 3 4 2 5 5 5 J. Sachdev , A. Patnaik , J. Waypa , J. Pelusi , M. Beeram , E. Im , D. Jenkins , K. McEachern , S. 5 5 5 5 5 5 3 1 2 Lu , W. Guo , R. Tran , V. Reichert , D. Bobilev , V. Kansra , G. Weiss ; Scottsdale, US, San 3 4 5 Antonio, TX/US, Goodyear, AZ/US, Scottsdale, AZ/US, Waltham, MA/US
13:15 - 13:15 1186P - Phase Ia study of a humanized anti-PD-1 monoclonal antibody (JS001) in Chinese patients with refractory solid tumors 1 1 1 2 2 2 2 1 1 F.-H. Wang , C. Ren , Y. Zhang , S. Yao , H. Feng , H. Wu , H.-F. Song , R. Zhang , X.-L. Wei , 1 1 1 1 1 1 1 3 1 X.-J. Xia , Q. Zhao , J.-P. Yun , B.-Y. Zou , M. Qiu , Z.-Q. Wang , Y.-H. Li , R. Xu ; Guangzhou, CN, 2 3 Shanghai, CN, Guangzhou, Guangdong/CN
13:15 - 13:15 1187P - A Phase 1/2 trial of intratumoral (i.t.) IMO-2125 (IMO) in combination with checkpoint inhibitors (CPI) in PD-(L)1-refractory melanoma
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 2 1 2 3 3 3 A. Diab , C. Haymaker , M. Uemura , R. Murthy , M. James , J. Geib , M. Cornfeld , S. Swann , C. 2 2 2 2 2 2 2 2 2 Yee , J. Wargo , R. Amaria , S. Patel , H. Tawbi , I. Glitza , S. Woodman , W.-J. Hwu , M. Davies , 2 2 1 1 2 3 W. Overwijk , C. Bernatchez , P. Hwu ; Houston, US, Houston, TX/US, Exton, PA/US
13:15 - 13:15 1188P - Clinical and immune effects patients with progressive disease treated with low dose of anti-CTLA-4, bortezomib, gemcitabine, naproxen and meloxicam 1 2 3 3 3 3 J. Marquez-Manriquez , J.A. Briseno , K. Quayle , L. Fernandez , I. Barajas , G. Torres-Montano , F. 2 2 3 3 Durazo-Bustamante , A. Durazo-Acuna , L.-A. Rangel-Reyna , D. Lopez-Hernandez , A.
2 3 2 2 2 1 Rodriguez-Jasso , M.-A. Trujillo-Acosta , E. Ramos-Garcia , S. Icedo-Zamora , P.A. Diaz ; Ciudad 2 3 Obregon, Washington/MX, Ciudad Obregon, MX, Seattle, WA/US
13:15 - 13:15 1189P - 4SC-202 plus anti-PD1: Breaking PD1-refractoriness to increase efficacy of checkpoint inhibition in patients with advanced melanoma F. Hermann, Munich, DE
13:15 - 13:15 (Withdrawn)
13:15 - 13:15 1192P - Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitis 1 1 1 1 1 1 1 2 C. Franklin , I. Rooms , M. Fiedler , H. Reis , L. Milsch , S. Herz , E. Livingstone , L. Zimmer , K.W.
1 1 1 1 1 2 Schmid , U. Dittmer , D. Schadendorf , B. Schilling ; Essen, DE, Duisburg, DE
13:15 - 13:15 1193P - Pooled data analysis of the safety and tolerability of intravenous pelareorep in combination with chemotherapy in 500 + cancer patients A. GUTIERREZ, C. Reid, M. Crawford, K. Cheetham, A. Dzugalo, M. Parsi, A. Penman, N. Noronha, D.
Galindez, R. O'Flynn, M. Coffey; Calgary,, CA
13:15 - 13:15 1194P - Impact of prior immune checkpoint inhibitors on haematological toxicity in phase I patients receiving chemotherapy 1 2 3 2 2 4 3 A. Ingles Garces , J.E. Ang , M. Ameratunga , M. Chenard-Poirier , D. Dolling , R. Sundar , S. Kaye , 3 5 5 1 2 3 4 J. de Bono , U. Banerji , J. Lopez ; Rio De Janeiro, RJ/BR, Sutton, GB, London, GB, Lyngby, DK, 5 Sutton, Surrey/GB
13:15 - 13:15 1195P - Compromised efficacy of PD-L1 blockade therapy in axenic (germ-free) mice with syngeneic tumors A. Mansfield, X. Liu, S. Cao, W. Bindeman, P. Yin, L. Till, S. Harrington, H. Dong; Rochester, MN/US
13:15 - 13:15 1197P - iRGD enhances T cells infiltration and augments response to PD-1 gene knockout immunotherapy in gastric cancer N. ding, S. Su, F. Meng, H. Sha, F. Chen, J. Wei, S. du, B. Liu; Nanjing, CN
13:15 - 13:15 1198P - Immunomodulation by regorafenib alone and in combination with anti PD1 antibody on murine models of colorectal cancer 1 1 1 2 1 2 S. Hoff , S. Grünewald , L. Röse , D. Zopf ; Berlin, DE, No City Provided, NA
13:15 - 13:15 1199P - Effect of MEK inhibition on PD-L1 and MCH-1 expression and on cytokines production profile in NSCLC cells and in human lymphocites
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 1 1 1 1 1 C.M. Della Corte , G. Barra , V. Ciaramella , F. Papaccio , G. Viscardi , G. Esposito , R. Di Liello , M.
1 1 1 2 1 1 2 Orditura , T. Troiani , R. De Palma , F. Ciardiello , F. Morgillo ; Napoli, IT, Naples, IT
13:15 - 13:15 1200P - Exploring personalized immunotherapy opportunities in colorectal cancer 1 1 1 1 1 1 B. Navarro Rodrigo , S. Bobisse , S. Viganò , P. Baumgartner , T. Nguyen-Ngoc , P. Gannon , R. 1 1 1 1 1 1 1 Genolet , B. Stevenson , C. Sempoux , M.-O. Sauvain , M. Hubner , D. Hahnloser , N. Demartines , 1 1 1 1 2 1 2 M. Montemurro , L. Kandalaft , S. Rusakiewicz , A. Harari , G. Coukos ; Lausanne, CH, Epalinges, CH
13:15 - 13:15 (Withdrawn)
13:15 - 13:15 1203P - Functional screening of B7H6-based chimeric antigen receptor (CAR) designs 1 1 1 1 1 1 1 B. Demoulin , L. Springuel , D. Daro , J. Bolsée , J. Houssa , F. Huberty , C. Jacques-Hespel , C. 1 1 1 1 1 2 2 Marchand , J. Marijsse , T.L.T. Nguyen , N. Ramelot , B. Violle , C. Lonez , D. Gilham , V. 1 1 2 Steenwinckel ; Mont Saint Guibert, BE, Mont-Saint-guibert, BE
13:15 - 13:15 1204P - Concurrent immuno-radiotherapy in lung and renal cancer- a new treatment paradigm 1 2 2 2 2 2 2 2 J. Ansari , M. Ali , A. Alomair , A. Mohammed Ali , E. Murshid , A. Shaukat , E. Batubara , F. Bashir ,
2 2 2 1 2 A. Farrag , K. Hussein , A. Alhamad ; Glasgow, GB, Riyadh, SA
13:15 - 13:15 1205P - Optimum fractionation of radiation dose to combine anti-PD-1 mAb in MC38 mice model 1 1 1 2 1 2 F. TENG , X. Wang , J. Yu , L. Kong ; Jinan, CN, Jinan, Shandong/CN
13:15 - 13:15 1206P - Efficacy of tumor treating fields (TTFields) and anti-PD-1 in non-small-cell lung cancer (NSCLC) preclinical models 1 1 1 2 1 1 2 M. Giladi , T. Voloshin , O. Talyitzhaki , U. Weinberg , E. Kirson ; Haifa, IL, Luzern, CH
13:15 - 13:15 1207TiP - An open-label, Phase IB study of NEO-PV-01 + Adjuvant with Nivolumab in Patients with Melanoma, Non-Small Cell Lung Carcinoma, or Transitional Cell Carcinoma of the Bladder 1 2 3 4 5 6 5 P. Ott , A. Naing , G. Ramaswamy , K. Margolin , M. Moles , R. Gaynor , M. Goldstein , S. 7 1 2 3 4 5 6 Hu-Lieskovan ; Boston, MA/US, Houston, TX/US, St. Louis, US, Duarte, CA/US, Boston, US, 7 Cambridge, US, Los Angeles, CA/US
13:15 - 13:15 1208TiP - A phase II exploratory study of durvalumab (MEDI4736) in HIV-1 patients with advanced solid tumors 1 2 3 2 4 2 M. Gonzalez-Cao , J. Martinez-Picado , M. Provencio Pulla , B. Clotet , O. Juan , J. Dalmau , T. 2 1 5 2 1 6 1 Moran , A. Mayerhans , J. De Castro , J. Blanco , R. Blanco , R. Bernabe Caro , N. Karachaliou , J.
1 1 2 7 1 2 3 Garcia-Corbacho , M.A. Molina , C. Brander , R. Rosell ; Barcelona, ES, Badalona, ES, 4 5 6 7 Majadahonda, Madrid/ES, Valencia, ES, Madrid, ES, Sevilla, ES, Badalona, Barcelona/ES
13:15 - 13:15 1209TiP - A first-in-human, open-label, multicenter phase 1/2a study to evaluate the safety and efficacy of increased repeated doses of the first in class RORγ agonist LYC-55716 in treating locally advanced or metastatic solid tumors 1 2 3 1 2 3 H. Wilkins , E. Hamilton , D. Mahalingam ; San Diego, US, Nashville, US, San Antonio, US
Last update: 02-09-2017 06:01:33pm esmo.org
13:15 - 13:15 1210TiP - A phase I global trial targeting multiple solid and hematologic malignancies through a NKG2D receptor-based CAR-T immunotherapy 1 2 2 2 2 2 3 B. VERMA , A. Awada , P. Aftimos , P. Lewalle , N. Meuleman , J.-P. Machiels , G. Catala , E. 2 4 4 4 5 2 6 6 Vandenneste , J. Brayer , D. Sallman , S. Sahebjam , T. Kerre , S. Rottey , K. Odunsi , E. Wang , U.
7 8 8 8 1 2 3 Santanam , C. Lonez , D. Gilham , F. Lehmann ; Boston, US, Brussels, BE, Woluwe-Saint-lambert, 4 5 6 7 8 BE, Tampa, FL/US, Ghent, BE, Buffalo, NY/US, Boston, MA/US, Mont-Saint-guibert, BE
13:15 - 13:15 1211TiP - FAK-PD1: a phase I/IIa trial of FAK (defactinib) & PD-1 (pembrolizumab) inhibition 1 2 3 4 2 2 2 2 S. Symeonides , T.R.J. Evans , V. Coyle , A. Serrels , F. Thomson , D. Currie , S. Dillon , J. Paul , D. 5 6 1 2 3 4 Fennell , C. Ottensmeier ; Edinburgh, Midlothian/GB, Glasgow, GB, Belfast, UK/GB, Edinburgh, 5 6 GB, Leicester, GB, Southampton, GB
13:15 - 13:15 1212TiP - PIVOT-02: A phase 1/2, open-label, multicenter, dose escalation and dose expansion study of NKTR-214 and nivolumab in patients with select, locally advanced or metastatic solid tumor malignancies 1 2 3 3 3 3 4 3 A. Diab , M. Hurwitz , N. Tannir , C. Bernatchez , C. Haymaker , S. Bentebibel , B. Curti , M. Wong , 5 6 6 6 6 6 7 8 I. Gergel , M. Tagliaferri , J. Zalevsky , U. Hoch , S. Aung , M. Imperiale , D. Cho , S. Tykodi , I. 9 10 1 10 1 2 3 4 Puzanov , H. Kluger , P. Hwu , M. Sznol ; Houston, US, New Haven, CT/US, Houston, TX/US, 5 6 7 8 9 Portland, OR/US, San Francisco, CA/US, San Francisco, US, New York, NY/US, Seattle, WA/US, 10 Buffalo, NY/US, New Haven, US
13:15 - 13:15 MELANOMA AND OTHER SKIN TUMOURS S. Martin Algarra, Pamplona, ES
13:15 - 13:15 1227P - Avelumab treatment in chemotherapy-naïve patients with distant metastatic Merkel cell carcinoma (mMCC) 1 2 3 4 5 6 7 S. D'Angelo , J. Russell , J. Hassel , C. Lebbé , B. Chmielowski , G. Rabinowits , P. Terheyden , I. 8 9 10 11 12 1 2 Brownell , I. Zwiener , M. Bajars , M. Hennessy , H. Kaufman ; New York, NY/US, Tampa,
3 4 5 6 7 8 FL/US, Heidelberg, DE, Paris, FR, Los Angeles, CA/US, Boston, MA/US, Lübeck, DE, Bethesda, 9 10 11 12 MD/US, Darmstadt, DE, Riga, LV, Billerica, MA/US, New Brunswick, NJ/US
13:15 - 13:15 1228P - Long-term effects of sonidegib on tumor burden: 30-month results from the phase 2 randomized bolt trial 1 2 1 2 R. Dummer , M. Migden ; Zurich, CH, Houston, TX/US
13:15 - 13:15 1230P - Modulation of Risk and Prognosis of Cutaneous Melanoma Patients by Genetic Polymorphisms on PDCD1 Gene G. Gomez, J.A. Rinck-Junior, D. Da Silva, R. Mamoni, G. Lourenço, A. Moraes, C. Lima; Campinas, BR
13:15 - 13:15 1231P - Role of an intronic polymorphism in the CREB1 gene, involved in melanogenesis, with the risk and the aggressiveness of cutaneous melanoma 1 2 1 1 1 1 1 J. Silva , C. Oliveira , B. Sá Carvalho , C. Torricelli , G. Gomez , W. Oliveira , J. Rinck-Junior , A. 1 3 1 1 1 2 3 Moraes , M. Ortega , C. Lima , G. Lourenço ; Campinas, BR, Campinas, SP/BR, Bragança Paulista, BR
Last update: 02-09-2017 06:01:33pm esmo.org 13:15 - 13:15 1232P - Investigation of AMBRA1 as a melanoma susceptibility gene V. Hoeiom, M. Yang, K. Nosrati, A. Azimi, S. Egyhazi Brage, R. Tuominen; Stockholm, SE
13:15 - 13:15 1233P - Influence of an intronic polymorphism in the MITF gene, of melanogenic pathway, in the risk and the prognosis of cutaneous melanoma 1 2 1 1 1 1 1 C. Torricelli , C. Oliveira , B. Sá Carvalho , J. Silva , G. Gomez , W. Oliveira , J.A. Rinck-Junior , A. 1 3 1 1 1 2 3 Moraes , M. Ortega , C. Lima , G. Lourenço ; Campinas, BR, Campinas, SP/BR, Bragança Paulista, BR
13:15 - 13:15 1234P - Hybrid-capture based genomic profiling identifies BRAF V600 and non-V600 alterations in melanoma samples negative by prior testing 1 2 3 4 2 2 5 6 L. Boussemart , A. Wang , M. Wong , J. Ross , P. Stephens , S. Ali , J. Sosman , J. Mehnert , G. 7 8 9 2 1 2 3 4 Daniels , K. Kendra , A. Schrock , V. Miller ; Rennes, FR, Cambridge, MA/US, Houston, TX/US, 5 6 7 8 9 Albany, NY/US, Chicago, US, New Brunswick, US, La Jolla, US, Columbus, US, Cambridge, US
13:15 - 13:15 1235P - Post-transcriptional regulation of immune checkpoint genes by mir-16 in melanoma 1 1 2 1 1 2 1 2 R. Leibowitz-Amit , A. Layani , J. Roszik , Y. Sidi , D. Avni , E. Grimm ; Ramat Gan, IL, Houston, US
13:15 - 13:15 1236P - Does melanoma or other skin cancers belong to the BRCA2 phenotype? 1 1 1 2 1 1 1 1 R. Vitorino , F. Vaz , A.L. Carvalho , S. Bento , A. Luís , A. Opinião , A. Clara , J. Dupont , S. Santos 1 1 1 1 1 1 1 2 , P. Machado , S. Fragoso , P. Rodrigues , J. Parreira , C. Moura ; Lisbon, PT, Santarem, Santarem/PT
13:15 - 13:15 1237P - Resected malignant melanoma at high risk of recurrence in SEER-Medicare 1 1 1 2 1 1 2 N. Sadetsky , J. Yi , A. Hernandez , D. Colburn , G. Goodman ; South San Francisco, US, South San Francisco, California/US
13:15 - 13:15 1238P - Independent prognostic impact of lympho-vascular invasion in cutaneous melanoma patients with sentinel lymph node biopsy R. Luca, M. Rizzo, P. Mando, C. Perez de La Puente, A. Blanco, S. Rivero, G. Lutter, F. Cappuccio, M.
Amat, J. Kaplan, R. Chacon, M. Chacon; Caba, AR
13:15 - 13:15 1239P - Validating prognostic models in metastatic uveal melanoma (MUM), an international rare cancers initiative 1 2 3 4 1 2 3 L. Khoja , E. Atenafu , A. Joshua , I.R.C.I. Ocular Melanoma Group ; Melbourn, GB, Toronto, CA,
4 Sydney, AU, London, GB
13:15 - 13:15 1240P - Impact of an active surveillance programme on outcome of patients (pts) with uveal melanoma (UM) after primary curative therapy (PTx): results of a single-institution experience 1 1 1 1 2 1 1 1 1 C.L. Lee , G. Gullo , N. Horgan , C. Baily , R. Abdul Rahman , D. Smith , C. Buckley , J. Crown ;
2 Dublin, IE, Dublin, Belgard Square North/IE
13:15 - 13:15 1241P - Impact of duration of response (DOR) on overall survival (OS) in patients with metastatic melanoma treated with dacarbazine (DTIC), vemurafenib (V), or cobimetinib plus vemurafenib (C+V): a pooled analysis
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 3 4 5 6 7 8 K. Lewis , J. Larkin , A. Ribas , K. Flaherty , G. McArthur , P. Ascierto , B. Dréno , E. McKenna , Q. 9 10 11 1 2 3 4 Zhu , Y. Mun , A. Hauschild ; Aurora, CO/US, London, GB, Los Angeles, CA/US, Boston,
5 6 7 8 9 MA/US, Melbourne, AU, Napoli, IT, Nantes, FR, South San Francisco, CA/US, South San 10 11 Francisco, US, South San Francisco, California/US, Kiel, Schleswig-Holstein/DE
13:15 - 13:15 1242P - Neutrophil to Lymphocyte Ratio (NLR) as an independent prognostic measure in patients receiving targeted therapy or immunotherapy for stage IV melanoma E. Blackley, L.E. Lim, M. Moore, M. Voskoboynik, C. McLean, A. Haydon; Melbourne, AU
13:15 - 13:15 1243P - The prognostic significance of distant metastasis free interval (DMFI) in BRAF mutant advanced melanoma patients treated with first line targeted therapy 1 2 1 1 1 1 D. Bafaloukos , H. Linardou , P. Diamantopoulos , T. Sergentanis , A. Laskarakis , K.-M. Giati , A.
2 3 3 1 2 3 Tarampikou , A. Anastasopoulou , H. Gogas ; Athens, GR, Athens, N. Faliro/GR, Athens, Attiki/GR
13:15 - 13:15 1244P - Hospitalization Rates in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma 1 2 3 4 5 6 7 A. Arance , R. Dummer , P. Ascierto , H. Gogas , M. Mandala , G. Liszkay , C. Garbe , D. 8 9 10 11 12 13 Schadendorf , I. Krajsová , R. Gutzmer , V. Chiarion Sileni , C. Dutriaux , J.W. de Groot , N. 14 15 16 17 17 18 19 1 Yamazaki , C. Loquai , L. de Parseval , M. Pickard , V. Sandor , C. Robert , K. Flaherty ;
2 3 4 5 6 7 Barcelon, ES, Zürich, CH, Napoli, IT, Athens, Attiki/GR, Bergamo, IT, Budapest, HU, Tuebingen, 8 9 10 11 12 13 14 DE, Heidelberg, DE, Prague, CZ, Hannover, DE, Padova, IT, Bordeaux, FR, Zwolle, NL, 15 16 17 18 19 Tokyo, JP, Mainz, DE, Basel, CH, Boulder, CO/US, Villejuif, FR, Boston, MA/US
13:15 - 13:15 1245P - Quality-of-life (QoL) in COLUMBUS part 1: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in braf-mutant melanoma 1 2 3 4 5 6 7 H. Gogas , R. Dummer , P. Ascierto , A. Arance , M. Mandala , G. Liszkay , C. Garbe , D. 8 9 10 11 12 13 Schadendorf , I. Krajsová , R. Gutzmer , V. Chiarion Sileni , C. Dutriaux , J.W. de Groot , N. 14 15 16 17 17 18 19 1 Yamazaki , C. Loquai , L. de Parseval , M. Pickard , V. Sandor , C. Robert , K. Flaherty ;
2 3 4 5 6 7 Athens, Attiki/GR, Zürich, CH, Napoli, IT, Barcelona, ES, Bergamo, IT, Budapest, HU, Tuebingen, 8 9 10 11 12 13 14 DE, Essen, DE, Prague, CZ, Hannover, DE, Padua, IT, Bordeaux, FR, Zwolle, NL, Tokyo, 15 16 17 18 19 JP, Mainz, DE, Basel, CH, Boulder, CO/US, Villejuif, FR, Boston, MA/US
13:15 - 13:15 1246P - Loss of USP28 drives resistance to BRAF targeted therapy in melanoma 1 2 1 1 1 1 1 A. Saei , M. Palafox , T. Benoukraf , N. Kumari , P. Jaynes , P. Iyengar , J.L. Charles Richard , Z.F. 1 1 2 1 1 2 1 1 2 Isa , B. Pang , M. Guzman , H. Yang , W.L. Tam , V. Serra , P. Eichhorn ; Singapore, SG, Barcelona, ES
13:15 - 13:15 1247P - Patterns of progression in metastatic melanoma patients treated with Braf and Mek inhibitors: an Italian Melanoma Intergroup (IMI) study 1 2 3 4 5 2 1 1 R. Marconcini , E. Marra , F. De Rosa , L. Stucci , L. Orgiano , S. Ribero , F. Bloise , A. Antonuzzo ,
1 1 2 3 4 5 A. Falcone ; Pisa, IT, Turin, IT, Meldola, IT, Bari, IT, Monserrato, (CA)/IT
13:15 - 13:15 1248P - Tumor-stroma interactions as a determinant of drug resistance in BRAF-mut melanoma 1 1 1 1 1 1 1 I. Falcone , R. Loria , U. Cesta Incani , L. Ciuffreda , C. Bazzichetto , F. Conciatori , B. Bellei , D.
1 1 1 2 1 2 Kovacs , M. Picardo , R. Falcioni , M. Milella ; Rome, IT, Roma, IT
Last update: 02-09-2017 06:01:33pm esmo.org
13:15 - 13:15 1249P - Extended survival analysis of ipilimumab for the treatment of advanced malignant melanoma in pretreated patients: Five-year long-term follow-up of the South African expanded access program 1 2 3 4 5 6 3 B. Rapoport , D. Vorobiof , L. Dreosti , A. Nosworthy , G. Mcadam , A. Jordaan , M. De Necker , J. 7 8 1 2 3 4 5 De Beer , H. Duvenhage ; Sandton, ZA, Sandton, Gauteng/ZA, Pretoria, ZA, Johannesburg, ZA, 6 7 8 Cape Town, ZA, Durban, Kwazulu Natal/ZA, Centurion, ZA, Woodmead, ZA
13:15 - 13:15 1250P - Real-world use of ipilimumab and nivolumab monotherapy or in combination in patients with advanced melanoma: results from a retrospective chart review 1 2 3 4 3 4 1 2 A. Tarhini , C. Macahilig , C. Atzinger , K. Gupte-Singh , C. Solem , S. Rao ; Pittsburgh, PA/US,
3 4 Parsippany, NJ/US, Bethesda, MD/US, Princeton, NJ/US
13:15 - 13:15 1251P - Baseline neutrophil-to-lymphocyte ratio and its values monitored over time is associated with outcome of metastatic melanoma patients treated with immunotherapy 1 2 1 1 3 I. Lugowska , B. Cybulska-Stopa , P. Jagodzinska-Mucha , P. Teterycz , H. Koseła-Paterczyk , K. 1 3 2 1 2 1 1 2 Kozak , K. Szamotulska , K. Roman , T. Switaj , M. Ziobro , P. Rutkowski ; Warsaw, PL, Krakow, 3 PL, Warszawa, PL
13:15 - 13:15 1252P - Early safety from phase 1b/3, multicenter, open-label, randomized trial of talimogene laherparepvec (T-VEC) + pembrolizumab (pembro) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): MASTERKEY-232 1 2 3 4 5 6 7 8 9 K. Harrington , A. Kong , N. Mach , T. Rordorf , J. Corral , V. Espeli , S. Treichel , J. Cheng , J. Kim 10 1 2 3 4 5 6 , J. Chesney ; London, GB, Birminghan, GB, Geneva, CH, Zürich, CH, Seville, ES, Bellinzona, 7 8 9 10 CH, South San Francisco, US, North Wales, PA/US, Thousand Oaks, US, Louisville, US
13:15 - 13:15 1253P - Characteristics of metastatic melanoma (MM) patients with leptomeningeal disease (LMD) and survival of & I. Glitza, J. Ma, S. Ferguson, R. Bassett Jr, L. Haydu, M. Davies; Houston, TX/US
13:15 - 13:15 1254P - Tolerance and outcomes of stereotactic radiosurgery combined with anti-PD1 (pembrolizumab) for melanoma brain metastases 1 1 1 1 1 1 1 2 C. Nardin , C. Mateus , M. Texier , E. Lanoy , S. Hibat-Allah , S. Ammari , C. Robert , F. Dhermain ;
1 2 Villejuif, FR, Villejuif, CEDEX/FR
13:15 - 13:15 1255P - Dabrafenib and Trametinib combination in real life patients including brain metastases: French experience within MelBase 1 2 3 4 5 6 7 C. Allayous , B. Guillot , S. Dalac Rat , L. Mortier , C. Dutriaux , M.-T. Leccia , J.-P. Lacour , S. Dalle 8 9 10 11 12 13 14 , P. Saiag , M. Beylot-Barry , C. Lok , J. De Quatrebarbes , F. Aubin , T. Lesimple , B. Dreno 15 1 1 1 1 1 2 3 4 , R. Porcher , A. Ballon , B. Oriano , C. Lebbe ; Paris, FR, Montpellier, FR, Dijon, Cedex/FR,
5 6 7 8 9 Lille, CEDEX/FR, Bordeaux, FR, La Tronche, CEDEX 9/FR, Nice, FR, Pierre Bénite, CEDEX/FR, 10 11 12 13 14 Boulogne-Billancourt, FR, Pessac, FR, Amiens, FR, Metz-Tessy, FR, Besançon, FR, 15 Rennes, FR, Nantes, CEDEX 1/FR
13:15 - 13:15 1256TiP - A Phase II, Randomised, Open Label Study of Neoadjuvant Pembrolizumab with/without Dabrafenib and Trametinib (D+T) in BRAF V600 Mutant Resectable Stage IIIB/C/D Melanoma (NeoTrio Trial)
Last update: 02-09-2017 06:01:33pm esmo.org 1 1 2 2 2 2 2 2 M. Gonzalez , A. Menzies , R. Saw , J. Thompson , A. Spillane , J. Howle , O. Nieweg , K. Shannon 1 3 2 4 2 2 5 2 1 , S. Ch'Ng , J. Stretch , M. Carlino , A. Guminski , L. Emmett , H. Rizos , R. Scolyer , G. Long ; 2 3 4 5 North Sydney, AU, Sydney, AU, Wollstonecraft, AU, St Leonards, NSW/AU, Camperdown, AU
13:15 - 13:15 1257TiP - KEYNOTE 029: Phase 1/2 randomized study of pembrolizumab (pembro) plus 2 dose regimens of ipilimumab (ipi) for advanced melanoma 1 2 3 2 4 5 6 7 M. Atkins , M. Carlino , A. Hill , C. McNeil , A. Ribas , V. Atkinson , J. Cebon , M. Jameson , W.-J. 8 9 10 10 11 2 1 Hwu , J. Thompson , J. Anderson , B. Homet Moreno , N. Ibrahim , G. Long ; Washington Dc,
2 3 4 5 6 7 US, Sydney, AU, Southport, AU, Los Angeles, CA/US, Brisbane, AU, Heidelberg, AU, Hamilton, 8 9 10 11 NZ, Houston, TX/US, Seattle, WA/US, Kenilworth, NJ/US, Kenilworth, US
13:15 - 13:15 1258TiP - Phase 2 Study Comparing Pembrolizumab with Intermittent/short-term dual MAPK pathway inhibition plus Pembrolizumab(PEM) in patients harboring the BRAFV600 mutation (IMPemBra Trial) E. Rozeman, M. Deken, J. Gadiot, M. Geukes Foppen, L. Pronk, J. Thienen, J. Haanen, C. Blank;
Amsterdam, NL
13:15 - 13:15 1259TiP - A randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600–mutant melanoma (COMBI-i) 1 2 3 4 5 6 7 E. Gasal , A.M. Arance Fernandez , P. Ascierto , V. Atkinson , R. Dummer , K. Flaherty , J.-J. Grob , 8 9 10 11 12 13 14 15 J. Hansson , J. Hassel , J. Larkin , C. Lebbé , G. Long , P. Lorigan , W. Miller , P. Nathan , A. 16 17 18 19 20 1 2 Ribas , C. Robert , D. Schadendorf , H. Tawbi , A. Upalawanna ; East Hanover, US, 3 4 5 6 7 8 Barcelona, ES, Napoli, IT, Woolloongabba, AU, Zürich, CH, Boston, MA/US, Marseille, FR, 9 10 11 12 13 14 Stockholm, SE, Heidelberg, DE, London, GB, Paris, FR, Sydney, AU, Manchester, GB, 15 16 17 18 19 Montreal, QC/CA, Northwood, Middlesex/GB, Los Angeles, CA/US, Villejuif, FR, Essen, DE, 20 Houston, TX/US, Basel, CH
13:15 - 13:15 1260TiP - Late physical, psychological and social consequences of ipilimumab treatment in advanced melanoma 1 1 1 2 3 4 A. Boekhout , M. Hauptmann , A. van den Eertwegh , G. Hospers , J.W. de Groot , M. Aarts , E. 5 6 7 8 9 10 11 Kapiteijn , A. Ten Tije , D. Piersma , W. Kruit , K. Suijkerbuijk , F. Berkmortel , G. Vreugdenhil , R. 12 13 14 9 1 1 1 Koornstra , E. Fiets , M. Lees , K. Janssen , L. van den Poll-Franse , C. Blank ; Amsterdam, NL, 2 3 4 5 6 7 8 Groningen, NL, Zwolle, NL, Maastricht, NL, Leiden, NL, Breda, NL, Enschede, NL, Rotterdam, 9 10 11 12 13 14 NL, Utrecht, NL, Sittard, NL, Eindhoven, NL, Nijmegen, NL, Leeuwarden, NL, Rueil-Malmaison, FR
13:15 - 13:15 PALLIATIVE CARE F. Scotté, Paris, FR
13:15 - 13:15 1390P - Efficacy of anamorelin in advanced non-small cell lung cancer (NSCLC) patients with anorexia/cachexia and modified Glasgow Prognostic Score (mGPS) of 2: Pooled analysis of two phase 3 trials 1 2 2 3 2 4 5 1 2 S. Kaasa , B. Laird , M. Fallon , D. McMillan , R. Skipworth , D. Currow , R. Giorgino ; Oslo, NO,
3 4 5 Edinburgh, GB, Glasgow, GB, Sydney, NSW/AU, Lugano Pazzallo, CH
Last update: 02-09-2017 06:01:33pm esmo.org 13:15 - 13:15 1391P - Prognostic Nutritional Index (PNI) for cost effective utilisation of newer, expensive radiation technology for palliative treatment of all cancer patients with limited life expectancy 1 2 2 2 2 1 2 S. Sundar , J. Price , T. Wolfe , D. Thurairasa , E. Shawcroft ; Nottingham, Nottinghamshire/GB, Nottingham, GB
13:15 - 13:15 1392P - Characterization of cachectic patients with non-small cell lung cancer (NSCLC) according to their modified Glasgow Prognostic Score (mGPS) 1 2 3 1 1 4 5 1 B. Laird , D. McMillan , S. Kaasa , M. Fallon , R. Skipworth , D. Currow , R. Giorgino ; Edinburgh,
2 3 4 5 GB, Glasgow, GB, Oslo, NO, Sydney, NSW/AU, Lugano Pazzallo, CH
13:15 - 13:15 1393P - Chemotherapy in advanced cancer patients with poor performance status (PS) initiated in an integrated oncology and palliative care (PC) setting: an observational comparative study 1 2 1 1 3 1 2 F. Strasser , N. Kalbermatten Magaya , D. Hehli , M. Früh , D. Blum ; St. Gallen, CH,
3 Münsterlingen, CH, Hamburg, DE
13:15 - 13:15 1394P - Previous palliative care encounter is associated with lower total hospital charge and shorter length of stay in patients with metastatic cancer Y. Liu, New York, US
13:15 - 13:15 1395P - Specialized ambulatory palliative care: (SAPV) 5-year results of a multi-professional care model by HomeCare linker Niederrhein gGmbH (HC) in the Lower Rhine region U. Grabenhorst, Viersen, DE
13:15 - 13:15 1396P - Increasing palliative interventions at the end of life: patterns in metastatic colorectal cancer (mCRC) 1 1 1 1 1 1 2 1 R. Prince , A. Easson , S. Liang , M. Brar , S. Ramkumar , A. Scheer , R. Wong , J. Hallet , C.
1 1 2 Zimmermann ; Toronto, CA, Toronto, ON/CA
13:15 - 13:15 1397P - Chronic pleural effusion in malignancy: A single center’s ten years expertise with indwelling pleural catheters N. Frost, M. Brünger, B. Temmesfeld-Wollbrück, D. Schürmann, N. Suttorp; Berlin, DE
13:15 - 13:15 1398P - Aggressiveness of care at the end of life in children with cancer: A nationwide cohort study 1 2 2 3 2 1 2 3 A. Cardoso , D. Martins Branco , A. Lacerda , B. Gomes , S. Lopes ; Penafiel, PT, Lisbon, PT, London, GB
13:15 - 13:15 (Withdrawn)
13:15 - 13:15 PREVENTION AND SCREENING M. Ijzerman, Enschede, NL
13:15 - 13:15 (Withdrawn)
13:15 - 13:15 1403P - Community-based lung cancer screening of high-risk population with low-dose computed tomography in China F. Qian, W. Yang, H. Wang, J. Teng, Y. Zhang, Q. Chen, J. Ye, J. Lou, R. Shi, L. Jiang, A. Gu, Y. Zhao,
B. Jin, X. Zhang, J. Xu, Y. Lou, B. Han; Shanghai, CN
Last update: 02-09-2017 06:01:33pm esmo.org
13:15 - 13:15 1404P - Colon cancer screening by fecal immunochemical testing in Iran 1 2 3 4 4 4 4 H. Salimzadeh , F. Bishehsari , C. Sauvaget , M. Amani , R. Hamzeloo , A. Nikfarjam , M. Maziar , S.
4 4 4 1 2 3 4 Merat , A. Delavari , R. Malekzadeh ; Teheran, IR, Chicago, US, Lyon, FR, Tehran, IR
13:15 - 13:15 1405P - Diagnostic analysis of patients referred from general practitioner with serious non-organ-specific symptoms and signs of cancer: A retrospective cohort study 1 1 2 2 2 2 1 B. Jørgensen , C. Dehlendorff , C. Kistorp , S. Bojesen , J. Johansen , C. Feltoft ; Copenhagen, DK,
2 Herlev, DK
13:15 - 13:15 1406P - Increased mutation burden in high-risk lung tissues: Toward precision cancer risk diagnosis E. Kubo, H. Takeshima, S. Yamashita, N. Motoi, T. Ushijima; Tokyo, JP
13:15 - 13:15 1407P - Change of natural history of hereditary diffuse gastric cancer after identification of a novel CDH1 mutation 1 2 2 2 2 2 2 N. Stjepanovic , S. Castro , N. Gadea , E. Carrasco , M. Codina , A. Lopez , M.E. Semidey , I.M. De 2 2 3 3 3 2 2 1 Torres , M. Alsina , M. Urioste , L. Pena , F. Mercadillo , S. Landolfi , J. Balmana ; Toronto, 2 3 Ontario/CA, Barcelona, ES, Madrid, ES
13:15 - 13:15 1408P_PR - A study of body fat composition, derived from DXA-scans, in association with cancer incidence in postmenopausal women. 1 2 1 1 1 1 1 2 L. Staunstrup , J. Christensen , J. Blair , H. Nielsen , C. Christiansen , C. Bager ; Herlev, DK, København, DK
13:15 - 13:15 1409P - Cervical cancer screening in France: recent change in behaviors 1 2 3 4 5 6 T. de La Motte Rouge , J. Viguier , J.-F. Morere , L. Brignoli-Guibaudet , J.-Y. Blay , C. Lhomel , F. 7 1 2 3 4 5 6 Eisinger ; Rennes, FR, Tours, FR, Villejuif, CEDEX/FR, Paris, FR, Lyon, FR, Neuilly-Sur-seine, 7 FR, Marseille, CEDEX 9/FR
13:15 - 13:15 1410P_PR - The role of tumour marker testing in earlier diagnosis of cancer C. Barrington, R. Frazer, E. Higgins, A. Shore; Swansea, GB
13:15 - 13:15 1411P - Genetic counseling, screening and risk reducing practices in patients with BRCA mutations 1 1 1 1 2 1 1 2 R. Saroufim , S. Daouk , I. Abou Dalle , F. Kreidieh , Y. Bidet , N. El Saghir ; Beirut, LB, Clermont-Ferrand, FR
13:15 - 13:15 1412P_PR - Ischemic stroke as cancer predecessor and associated predictors 1 1 2 1 1 1 1 J. Rogado , V. Pacheco , R. Mondejar , S. Quintas , P. Gullón , J. Dotor , M.D. Fenor de la Maza , B. 1 1 1 1 1 1 Obispo , G. Reig-Roselló , T. Pascual , A.I. Ballesteros Garcia , O. Donnay , J.M. Sánchez-Torres , R. 1 1 1 1 2 López Ruiz , J. Vivancos , R. Colomer Bosch ; Madrid, ES, Cuenca, ES
13:15 - 13:15 1413P - Gastric cancer detected after Helicobacter pylori eradication at one private screening center in Japan 1 2 2 2 2 2 2 2 T. Nakamura , Y. Kon , K. Konuma , T. Sanada , S. Shibata , H. Gonda , Y. Suto , Y. Amagasa , A.
2 2 2 1 2 Suzuki , M. Fukuda , C. Aoyagi ; Ota, Gunma/JP, Ota, JP
Last update: 02-09-2017 06:01:33pm esmo.org
13:15 - 13:15 (Withdrawn)
13:15 - 13:15 1415P - NGS and Sanger screening for BRCA1/BRCA2, CHEK2 and TP53 in Argentinian high-risk breast/ovarian cancer families and bioinformatic studies: Initial results 1 1 1 1 2 2 2 2 L. Bruno , P. Jablonski , M. Ozkul , G. Mercado , J. Sendoya , A. Llera , L. Núñez , R. Valdez , D. 2 2 2 2 2 2 1 2 Mansilla , V. Cólica , P. Kalfayan , C. Ruggiero , M. Reyes , R. Cerretini ; Capital Federal, AR, Ciudad Autónoma De Buenos Aires, AR
13:15 - 13:15 1416P - The change in self-perceived characteristics of health and lifestyle due to colorectal cancer screening invitation and attendance M. Jäntti, S. Heinävaara, N. Malila, T. Sarkeala; Helsinki, FI
13:15 - 13:15 1417P - Multi-gene panels: new clinical experience in hereditary breast and ovarian cancer 1 1 1 1 2 1 1 1 T. Ramon y Cajal , A. Lasa , G. Llort , C. Lopez , C. Yagüe , M. Cornet , A. Gisbert , D. Fisas , N. 1 1 1 1 1 1 1 2 Calvo , A. Vethencourt , A. Barba , S. Quero , E. Martinez , I. Hernan , A. Ruiz , A. Arcusa , E. Saigi 1 1 1 1 2 , A. Barnadas , J. Surralles ; Barcelona, ES, Terrassa, ES
13:15 - 13:15 1418P - Clinical features and outcomes of reversible posterior encephalopathy syndrome following bevacizumab treatment M. Iwamoto, H. Fujioka, K. Kimura, K. Uchiyama, R. Terasawa; Osaka, JP
13:15 - 13:15 1419P - Deliberative democracy and cancer screening. The use of citizens' s juries in health policy decision-making 1 2 2 1 1 A. Cutillas , P. Rosado-Varela , V. Luque-Ribelles , S. Márquez Calderón , E. Benitez-Rodríguez ,
1 1 1 2 J.M. Ribera-Bautista , J.M. Baena-Canada ; Cadiz, ES, Puerto Real, ES
13:15 - 13:15 1420P - Genetic landscape in HBOC families from Brazil: A mutational analysis 1 2 2 3 4 2 E. Dos Santos , B. Rossi , E.M.M. Santos , E. Rouleau , S. Caputo , C. Urbeteli de Sa , M. F. Sa 2 2 2 1 2 3 4 Ribeiro , N. Vaz , B. Garicochea ; Sao Paulo, SP/BR, Sao Paulo, BR, Paris, CEDEX 5/FR, Paris, FR
13:15 - 13:15 1421P - Recommended cancer screening and vulnerable populations: results from the EDIFICE 5 survey 1 2 3 4 5 6 7 J.-F. Morere , F. Eisinger , J.-Y. Blay , S. Couraud , L. Brignoli-Guibaudet , C. Lhomel , A. Cortot , L. 8 9 1 2 3 4 Greillier , J. Viguier ; Villejuif, CEDEX/FR, Marseille, CEDEX 9/FR, Lyon, FR, Pierre Bénite, 5 6 7 8 9 CEDEX/FR, Paris, FR, Neuilly-Sur-seine, FR, Lille, FR, Marseille, FR, Tours, FR
13:15 - 13:15 PSYCHO-ONCOLOGY K. Tamura, Fukuoka, JP
13:15 - 13:15 1423P - Loneliness and cognitive dysfunction in elderly cancer patients 1 2 2 2 2 2 2 2 2 A. Alkan , H. Selvi Öztorun , E. Karcı , G. Tuncay , A. Yaşar , E. Çınar , Y. Ürün , S. Aras , M. Varlı ,
2 1 2 F. Çay Şenler ; Osmaniye, TR, Ankara, TR
13:15 - 13:15 1424P - The study of emotional distress in oncology patients
Last update: 02-09-2017 06:01:33pm esmo.org K. Kondrateva, C. Valentina, T. Semiglazova, M. Vagaitseva, A. Karitskiy, E. Pestereva, A. Belyaev;
Saint-Petersburg, RU
13:15 - 13:15 1425P - Risk of mood disorders in long-term cancer survivors: A population-based cohort study W.-K. Huang, Taoyuan, TW
13:15 - 13:15 1426P - What oncologists should know about the screening of psychological distress: One example of pilot study in Ancona M. Romeo, R. Giampieri, L. Burattini, M. Di Pietro Paolo, A. Bittoni, S. Rinaldi, M. Torniai, R. Berardi;
Ancona, IT
13:15 - 13:15 1427P - Biopsychosocial factors underlying older patients treated for an incurable cancer in a two-tiered health care system in Brazil 1 2 3 1 2 2 2 1 2 C. Bergerot , K. Ashing , E. Philip , P. Bergerot , N. Dizman , S. Pal , W. Dale ; Duarte, US,
3 Duarte, CA/US, Notre Dame, IL/US
13:15 - 13:15 1428P - Family-associated factors influence the postoperative prognosis in patients with non-small cell lung cancer 1 2 3 3 3 3 3 S. Takamori , G. Toyokawa , H. Ueo , F. Kinoshita , Y. Kozuma , T. Matsubara , N. Haratake , T. 3 3 3 3 3 3 1 2 Akamine , F. Hirai , T. Tagawa , F. Shoji , T. Okamoto , Y. Maehara ; Fukuoka-Shi, JP, Fukuoka, 3 Fukuoka/JP, Fukuoka, JP
13:15 - 13:15 1429P - (Withdrawn)
13:15 - 13:15 1430P - Sexual functioning and quality of life in Egyptian premenopausal patients receiving treatment for breast cancer H. Elghazaly, M. Kelany, O. Abdel-Rahman, N. Naguib, S. Alsirafy; Cairo, EG
13:15 - 13:15 1431P - Primary results of a study to evaluate a decision aid for women offered neoadjuvant systemic therapy for breast cancer 1 2 2 1 1 1 2 1 N. Zdenkowski , P. Butow , A. Spillane , C. Douglas , C. Beckmore , M. Jones , F. Boyle ;
2 Newcastle, AU, Sydney, AU
13:15 - 13:15 (Withdrawn)
13:15 - 13:15 1433P - Burnout syndrome: What impact on clinical research? 1 2 3 4 5 1 6 C. Cagnazzo , S. Campora , S. Pirondi , A. Guarrera , A. Nuzzo , G. Gentili , C. Taverniti , M. 1 7 1 2 3 4 5 6 7 Manuela , R. Filippi ; Meldola, IT, Milan, IT, Sassuolo, IT, Firenze, IT, Candiolo, IT, Torino, IT, Torino, (TO)/IT
13:15 - 13:15 1434TiP - Effectiveness of the HuCare Quality Improvement Strategy on health-related quality of life in patients with cancer: Study protocol of a stepped wedge cluster randomized controlled trial (HuCare2 study) 1 2 2 1 2 R. Passalacqua , C. Caminiti , E. Iezzi ; Cremona, (CR)/IT, Parma, IT
13:15 - 13:15 PUBLIC HEALTH J. Martin-Moreno, Valencia, Valencia/ES
Last update: 02-09-2017 06:01:33pm esmo.org
13:15 - 13:15 1445P - Inclusion of older patients with colorectal cancer in clinical trials: the SAGE prospective multicenter cohort study 1 2 1 3 1 3 F. Canouï-Poitrine , A. Lievre , F. Dayde , D. Lopez-Trabada-Ataz D , I. Baumgartner , O. Dubreuil , 1 4 5 3 3 6 1 F. Brunetti , T. Aparicio , R. Coriat , K. Maley , O. Colussi , C. Tournigand , E. Paillaud , S. 1 1 2 3 4 5 6 Bastuji-Garin ; Créteil, FR, Rennes, FR, Paris, FR, Bobigny, CEDEX/FR, Paris, CEDEX 14/FR, Creteil Cedex, FR
13:15 - 13:15 1446P - Risk of second primary cancers and competing mortality in survivors of adult-onset cancer: changing pattern over three decades Y. Ye, P. Otahal, K. Wills, A. Neil, A. Venn; Hobart, AU
13:15 - 13:15 1447P - Reporting of results of randomized trials in common cancers in the lay media 1 2 3 4 1 5 1 D. Ribnikar , H. Goldvaser , A. Ocana Fernandez , A. Templeton , B. Seruga , E. Amir ; Ljubljana,
2 3 4 5 SI, Toronto, CA, Albacete, ES, Basel, CH, Toronto, Ontario/CA
13:15 - 13:15 1448P - Effect of rural residence (RD) and distance travel to the cancer center (DTC) on neoadjuvant chemoradiation (NCRT) in localized rectal cancer 1 2 3 2 2 3 1 2 3 A. Suo , A. Talat , D. Le , N. Iqbal , S. Kanthan , S. Ahmed ; Calgary, CA/CA, Saskatoon, SK/CA, Saskatoon, CA
13:15 - 13:15 (Withdrawn)
13:15 - 13:15 1450P - European survey of 907 people with cancer about the importance of nutrition 1 2 3 1 1 1 1 M. Muscaritoli , A. Molfino , F. Scala , F. De Lorenzo , K. Christoforidi , I. Manneh-Vangramberen ;
2 3 Brussels, BE, Roma, IT, Salerno, IT
13:15 - 13:15 1451P - Breast cancer specific survival (BCSS) in young women <40 years with node negative luminal breast cancer (BC) treated based on tumor gene expression 1 2 1 3 4 1 2 3 S. Shak , M. Roberts , D. Miller , A. Kurian , V. Petkov ; Redwood City, CA/US, Bethesda, US,
4 Stanford, US, Bethesda, MD/US
13:15 - 13:15 1452P - Risk of malignant mesothelioma in Spain from environmental asbestos exposure 1 2 2 1 2 J. Torres-Roman , G. Lopez-Abente , J. Sanz-Anquela ; Ica, PE, -, ES
13:15 - 13:15 1453P - Tobacco exposure and adverse pathological features in oral cancer: Does age impact survival? 1 2 2 3 2 2 2 V. Srinivasalu , N. Subramaniam , D. Balasubramaniam , N. Kumar , S. Murthy , A. Susan , A. Philip
2 2 2 1 2 3 , K. Thankappan , S. Iyer , P. Keechilat ; Cochin, IN, Kochi, IN, Cambridge, GB
13:15 - 13:15 (Withdrawn)
13:15 - 13:15 1455P - Initiation of systemic anti-cancer treatment in the inpatient setting in a tertiary hospital in London J. Lam, K. Ng, T. Emms, R. Gillmore; London, GB
13:15 - 13:15 1456P - Young-age onset colorectal cancer: Analysis of incidence, clinical features and outcomes
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 2 2 2 2 F.K. Fujiki , M.F.B. Vicentini , A.C.B. Silva , E. Zambrano , L.G. Fonseca , M.I. Braghiroli , J. Sabbaga
3 2 1 2 3 , P.M. Hoff ; São Paulo, BR, Sao Paulo, BR, Sao Paulo, SP/BR
13:15 - 13:15 1457P - Improved provision of written information on metastatic spinal cord compression to at-risk cancer patients at a tertiary referral centre P. Mahaligam, K. Ng, A. McLaren, K. Fordham, J. King; London, GB
13:15 - 13:15 1458P - Impact of mastectomy on the social well-being and family dynamics of breast cancer female patients in the Gaza Strip M. Elshami, E. Alaloul, E. Khader, I. Awad, A. Alhelu, H. Baraka, H. Abu Nemer, B. Böttcher, K. Elessi;
Gaza, PS
13:15 - 13:15 1459P - Cancer incidence and mortality trends in Crete, Greece during the last two decades (1992-2013): Results from the cancer registry of Crete 1 1 1 2 2 1 V.-E. Chatzea , D. Sifaki-Pistolla , F. Koinis , E. Saloustros , L. Vamvakas , G. Pitsoulis , N. Tzanakis
1 1 1 1 1 2 , D. Mavroudis , V. Georgoulias , C. Lionis ; Heraklion, GR, Heraklion, Crete/GR
13:15 - 13:15 1460P - Robotic anticancer drug compounding assist system for the preparation of injectable antineoplastic drugs S. Masuda, H. Watanabe, T. Irisa, K. Hata, A. Kumagai, C. Tanaka, N. Ozawa, K. Nakashima; Fukuoka,
JP
13:15 - 13:15 1461P - Monitoring of contamination with cytostatics in pharmacies and hospitals in the Czech Republic S. Kozakova, Brno, CZ
13:15 - 13:15 1462P - New treatments in Oncology: Clinical practice regarding the management of Adverse Events (AEs). Results from a survey conducted by the Hellenic Group of Young Oncologists (HeGYO) 1 2 2 2 2 2 2 M. Liontos , F. Koinis , G. Chatsidis , K. Kamposioras , G. Papaxoinis , M. Nikolaou , K. Tsigaridas , 2 2 3 2 2 4 5 E. Voulgaris , E. Pantavou , G. Aravantinos , A. Ardavanis , I. Boukovinas , E. Galani , S. Angelaki ,
2 2 2 6 1 2 3 G. Mountzios , Z. Saridaki , I. Varthalitis , N. Tsoukalas ; Athens, Attiki/GR, Athens, GR, Kifisia, 4 5 6 Attica/GR, Athens, N. Faliro/GR, Heraklion, Crete/GR, Kolonaki, GR
13:15 - 13:15 1463P - Oncologists’ perspectives on biologic substitution M. Reilly, A. Spiegel; Washington Dc, US
13:15 - 13:15 1464P - Ukrainian Association for helping patients with lymphoproliferative diseases: Patients support care program 1 2 1 2 1 1 1 I. Kryachok , O. Novosad , T. Skrypets , T. Kadnikova , I. Titorenko , O. Aleksik , K. Filonenko , A. 1 2 1 1 1 1 Martynchyk , Y. Pastushenko , Y. Stepanishina , E. Kushchevyy , K. Ulianchenko , M. Surkis , V. 1 1 1 2 Jurchishina , E. Gingsburg ; Kiev, UA, Kyiv, UA
13:15 - 13:15 1465P_PR - Do Oncology Patients Understand Clinical Trials? A Nationwide Study By Cancer Trials Ireland
Last update: 02-09-2017 06:01:33pm esmo.org 1 1 1 1 1 2 3 4 C. Kelly , R. Feighery , J. McCaffrey , M. Higgins , M. Smith , S. O'Reilly , C. Murphy , A. Horgan , J. 1 5 1 1 6 7 8 1 Walshe , R. McDermott , D. O'Donnell , P. Morris , M. Keane , M. Martin , K. Duffy , A. Mihai , J.
1 1 1 1 1 2 3 4 Armstrong , E. Mulroe , V. Murphy , C. Kelly ; Dublin, IE, Cork, Cork/IE, Cork, IE, Waterford, 5 6 7 8 CO/IE, Dublin, Belgard Square North/IE, Galway, IE, Sligo, IE, Letterkenny, Donegal/IE
13:15 - 13:15 1466P - Feasibility and barriers to optimal oncological treatment in solid organ transplant patients with de novo cancer 1 2 2 3 2 2 2 B. Rousseau , A. Jobard , C. Duvoux , C. Neuzillet , P. Compagnon , D. Azoulay , A. de la Taille , L. 2 2 2 2 4 1 2 Salomon , I. Cholley , M. Matignon , P. Grimbert , C. Tournigand ; Créteil, CEDEX/FR, Creteil, FR, 3 4 Clichy, FR, Creteil Cedex, FR
13:15 - 13:15 1467P - Generating patient reported outcome norms for an EU cancer population using real world data (FACT-G) 1 2 3 2 2 2 2 1 A. Rider , S. Simpson , B. Bennett , K. Byrne , P. Hallworth , T. Desai , K. Cocks ; Manchester, GB,
2 3 Jb, GB, Bollington, GB
13:15 - 13:15 1468P - Development of a web-based application using machine learning algorithms to facilitate systematic literature reviews 1 2 3 4 4 5 6 H.-L. Wong , T. Luechtefeld , A. Prawira , Z. Patterson , J. Workman , D. Day , N. Chooback , L. 7 6 6 8 8 9 10 11 Nappi , H. Samawi , J.-M. Lavoie , A. Spreafico , A. Hansen , S. Sahebjam , L. Siu , S. Ivy , C. 2 6 1 2 3 4 5 Paller , D. Renouf ; Parkville, AU/AU, Baltimore, US, Toronto, Ontario/CA, Washington Dc, US, 6 7 8 9 10 Toronto, CA, Vancouver, CA, Vancouver, BC/CA, Toronto, ON/CA, Tampa, FL/US, Toronto, On, 11 CA, Bethesda, US
13:15 - 13:15 1469P - Survival patterns for different types of cancers in the United States (1973-2012) M. Gouda, Shebin El Kom, Menoufia Governorate/EG
13:15 - 13:15 1470P - Decisions and supports around clinical trial participation: A national study by Cancer Trials Ireland 1 1 1 1 1 2 3 1 C. Kelly , R. Feighery , J. McCaffrey , M. Higgins , M. Smith , S. O'Reilly , A. Horgan , J. Walshe , R. 4 1 1 5 6 7 8 1 McDermott , D. O'Donnell , P. Morris , M. Keane , M. Martin , C. Murphy , K. Duffy , A. Mihai , J.
1 1 1 1 1 2 3 4 Armstrong , E. Mulroe , V. Murphy , C. Kelly ; Dublin, IE, Cork, Cork/IE, Waterford, CO/IE, Dublin, 5 6 7 8 Belgard Square North/IE, Galway, IE, Sligo, IE, Cork, IE, Letterkenny, Donegal/IE
13:15 - 13:15 1471P - Academic clinical research: Enough players to get out there? 1 2 3 1 4 5 1 1 C. Cagnazzo , S. Campora , S. Pirondi , G. Gentili , A. Guarrera , C. Taverniti , M. Manuela ;
2 3 4 5 Meldola, IT, Milan, IT, Sassuolo, IT, Firenze, IT, Torino, IT
13:15 - 13:15 1472P_PR - Change of patient perceptions of chemotherapy side effects in breast and ovarian cancer patients B. Ataseven, J. Frindte, P. Harter, G. Göke, J. Holtschmidt, C. Vogt, A. Traut, B. Vincenzo, M. Vincent, H.
Florian, S. Kuemmel, S. Prader, M. Sporkmann, S. Schneider, A. du Bois; Essen, DE
13:15 - 13:15 SUPPORTIVE CARE J. Herrstedt, Odense, DK
Last update: 02-09-2017 06:01:33pm esmo.org
13:15 - 13:15 1550P - Primary prevention of nausea and vomiting induced by moderately emetogenic chemotherapies: findings from the French CONVINCE-ME survey 1 2 2 1 2 F. Scotté , R. Chevrier , H. Bertucat ; Paris, FR, Clermont-Ferrand, FR
13:15 - 13:15 1551P - Risk factors of chemotherapy-induced nausea and vomiting during cisplatin regimen in antiemetic triplet regimen including palonosetron or granisetron: TRIPLE study (phase lll) 1 2 2 3 4 1 5 6 K. SUZUKI , D. Tsuji , K. Ito , Y. Kawasaki , T. Yamanaka , H. Hashimoto , K. Goto , R. Matsui , N. 1 1 7 1 2 3 4 5 Seki , T. Hama , N. Yamamoto ; Tokyo, JP, Shizuoka, JP, Kyoto, JP, Yokohama, JP, Kashiwa, 6 7 JP, Kashiwa, Chiba/JP, Wakayama, JP
13:15 - 13:15 1552P - Evaluation of Antiemetic Practices for Prevention of Chemotherapy-induced Nausea and Vomiting (CINV): Results of a European Oncology Nurse Survey 1 2 3 4 5 1 2 3 P. DIELENSEGER , S. Borjeson , C. Vidall , A. Young , P. Jahn ; Villejuif, FR, Linköping, SE,
4 5 Northampton, GB, Coventry, GB, Halle, DE
13:15 - 13:15 1553P - A pooled analysis evaluating the combination antiemetic therapy on chemotherapy-induced nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy of moderate emetic risk 1 2 3 4 5 1 6 7 M. Shimokawa , T. Kogawa , J. Nishimura , T. Satoh , K. Nakata , T. Hayashi , R. Matsui , K. Aiba , 1 1 2 3 4 5 6 K. Tamura ; Fukuoka, JP, Kashiwa, JP, Suita, JP, Suita, Osaka/JP, Sakai, JP, Kashiwa, 7 Chiba/JP, Tokyo, JP
13:15 - 13:15 1554P - Efficacy of neurokinin-1 receptor antagonists in the prevention of Chemotherapy-Induced Nausea and Vomiting in patients receiving carboplatin-based chemotherapy: a systematic review and meta-analysis 1 2 3 2 4 5 2 6 1 M. Di Maio , C. Baratelli , P. Bironzo , F. Vignani , E. Bria , E. Sperti , M. Marcato , F. Roila ; Napoli,
2 3 4 5 6 IT, Turin, IT, Orbassano, TO/IT, Verona, IT, Torino, IT, Terni, IT
13:15 - 13:15 1555P - Pharmacokinetic (PK) study of a single oral dose of NEPA in Chinese healthy volunteers (HVs) 1 2 3 3 1 1 2 3 R. Chen , S. Chessari , C. Lanzarotti , A. Bernareggi , P. Hu ; Beijing, CN, Pazzallo, CH, Lugano, CH
13:15 - 13:15 1556P - Iron deficiency anaemia in oncology: an epidemiological prospective study 1 2 3 3 4 2 2 J. BARRIERE , J.-M. Ferrero , B. Hoch , R. Largillier , C. Hebert , D. Borchiellini , P. Follana , V. Mari 4 2 4 4 4 4 4 1 , L. Evesque , E. Saada-Bouzid , R. Schiappa , V. Raimondi , E. Chamorey , J. Viotti ; 2 3 4 Cagnes-Sur-mer, FR, Nice, CEDEX 2/FR, Mougins, FR, Nice, FR
13:15 - 13:15 1557P - Nutritional risk as a predictor of short-term outcomes in a prospective cohort of elderly patients with cancer 1 2 3 1 1 1 1 L. Sales , J. Oliveira Lima , A. Bergmann , M.J. Mello , M. Rebello , Z. Cavalcanti , D. Sales , N. Cruz
1 3 1 2 3 , L.C. Thuler ; Recife, BR, Recife, PE/BR, Rio De Janeiro, BR
13:15 - 13:15 1558P - A patient-centered approach to the re-development of supportive care services for oncology adolescent and young adult (AYA) patients (pt(s)) across McGill University hospitals (Rossy Cancer Network-RCN)
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 2 1 2 1 2 2 P. Kavan , R. Fox , G. Raskovic , I. Barrera , W. Sateren , G. Batist , M. Palumbo , T. Muanza , N.
2 1 2 2 2 1 2 Johnson , A. Mamo , T. Alcindor , R. Turcotte , A. Meguerditchian ; Montreal, QC/CA, Montreal, CA
13:15 - 13:15 1559P - Multidimensional telemonitoring of cancer patients (pts) receiving chronomodulated (chrono) Irinotecan (I), 5-fluorouracil (F), leucovorin (L) and oxaliplatin (O; chronoIFLO4) combination at home 1 2 3 3 3 4 2 P. Innominato , S. Komarzynski , M. Bouchahda , A. Ulusakarya , M. Haydar , A. Karaboué , F. Levi ;
1 2 3 4 Villejuif, CEDEX/FR, Coventry, GB, Villejuif, FR, Vitry-Sur-seine, FR
13:15 - 13:15 1560P - A pilot study to evaluate the feasibility, usability, and perceived satisfaction with eCO (eCediranib-Olaparib), a mobile application for side effect monitoring and reporting, in women with recurrent ovarian cancer 1 1 1 1 2 2 3 4 J. Liu , C. Whalen , S. Morrissey , E. Komatsu , J.-M. Lee , N. Houston , R. Wenham , D. O'Malley , 5 6 7 2 8 1 2 3 4 E. Strock , R. Phillips , K. Mari , S. Ivy , B. Killam ; Boston, MA/US, Bethesda, US, Tampa, US, 5 6 7 8 Columbus, OH/US, Boston, US, Cambridge, US, Lyon, FR, Ashburn, US
13:15 - 13:15 1561P - Study of the satisfaction level of an education program for cancer patients 1 1 1 2 1 1 1 2 Y. Kim , H.Y. Lee , B.G. Seo , Y.H. Choi , K.A. Kwon , E.J. Son ; Busan, KR, Seoul, KR
13:15 - 13:15 1562P - Factors influencing the use of thromboprophylaxis in cancer outpatients: CAT AXIS, a case-vignette study on clinical practice 1 1 2 1 1 2 F. Scotté , I. Elalamy , D. Mayeur , G. Meyer ; Paris, FR, Le Chesnay, FR
13:15 - 13:15 1563P - Literature review of TPOR agonists for CIT 1 2 3 4 4 4 5 1 G. Soff , I. Ray-Coquard , L.J. Marfil-Rivera , J. Fryzek , M. Mullins , L. Bylsma , J. Park ; New York,
2 3 4 5 US, Lyon, CEDEX/FR, Nuevo León, MX, Ann Arbor, US, Thousand Oaks, US
13:15 - 13:15 1564P - Random optimization interactive system based on Kernel learning (RISK) for venous thromboembolism risk assessment in chemotherapy-treated cancer patients 1 2 2 2 2 1 1 2 P. Ferroni , F. Zanzotto , N. Scarpato , S. Riondino , F. Guadagni , M. Roselli ; Roma, IT, Rome, IT
13:15 - 13:15 1565P - Association between systemic inflammation and symptoms in advanced cancer patients D. Viñal Lozano, A. Alonso-Babarro, Y. Vilches-Aguirre, L. Diez-Porres, M. Varela-Cerdeira, J. Villamayor
Sanchez, L. Gutierrez Sainz, R. Madero-Jarabo; Madrid, ES
13:15 - 13:15 1566P - Outcomes of patients with malignancy admitted to the intensive care units (ICU): A prospective study H. Assi, V. Nohra, F. Sukhon, N. Moukalled, I. Bou Akl, D. Mukherji, M. Charafeddine, N. Abdul Halim, C.
El Mouhayyar, Y. Medlej, P. Bou Khalil; Beirut, LB
13:15 - 13:15 (Withdrawn)
13:15 - 13:15 1568P - Management of thrombosis in cancer patients in Greece
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 2 2 2 2 2 N. Tsoukalas , E. Bournakis , A. Adamidis , C. Andreadis , K. Arvaniti , A. Christopoulou , S. Douna , 2 2 2 2 2 2 J.D. Moreno , G. Goumas , L. Kostadima , P. Makaronis , T. Makatsoris , D. Doufexis , G.
2 2 2 2 2 2 Papatsimpas , I. Sgouros , E. Stergiou , P. Thalassinou , I. Boukovinas , P. Papakotoulas , I. 2 1 2 Varthalitis ; Kolonaki, GR, Athens, GR
13:15 - 13:15 1569P - Incidence and outcome of Incidental Pulmonary Embolism (IPE) in oncology patients with current macroscopic disease M.M.M. Moe, London, Greater London/GB
13:15 - 13:15 1570P - Immune related adverse events associated with ipilimumab and nivolumab 1 2 2 1 2 B. Rapoport , R. Van Eeden , T. Smit ; Sandton, ZA, Johannesburg, ZA
13:15 - 13:15 1571P - Febrile Neutropenia: a systematic review of the first 5 years of a cancer unit 1 2 1 1 3 1 3 3 3 J. Pinto , I. Leão , F. Branco , J. Godinho , P. Simões , F. Lopes , A. Escária , F. Costa , I. Galvão ,
4 1 2 3 4 J. Passos-Coelho ; Loures, Lisboa/PT, V. N. Gaia, PT, Loures, PT, Lisbon, PT
13:15 - 13:15 1572P - G-CSF and G-CSF biosimilars: a meta-analysis of randomized clinical trials in breast cancer patients 1 2 3 1 2 3 E. Botteri , A. Krendyukov , G. Curigliano ; Oslo, NO, Holzkirchen, DE, Milan, IT
13:15 - 13:15 1573P - Pharmacokinetic and pharmacodynamic comparability of B12019: A proposed pegfilgrastim biosimilar K. Roth, H. Wessels, J. Hoefler, R. Jankowsky; Munich, DE
13:15 - 13:15 1574P - Efficacy and safety of RGB-02, a proposed biosimilar pegfilgrastim to prevent chemotherapy-induced neutropenia: Results of a randomized, double-blind, phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving docetaxel/doxorubicin 1 2 3 1 4 1 2 3 K. Horvat-Karajz , D. Grecea , M. Smakal , A. Illes , Z. Kahan ; Budapest, HU, Cluj-Napoca, RO,
4 Horovice, CZ, Szeged, HU
13:15 - 13:15 1575P - Impact of resistance exercise on metabolic syndrome (MetS) parameters in men receiving androgen deprivation therapy (ADT) for prostate cancer 1 1 1 1 2 2 2 2 T. Dorff , M. Gross , D. Quinn , J. Pinski , T. Schroeder , S. Groshen , C. Dieli-Conwright , J. Kiwata ;
1 2 Los Angeles, CA/US, Los Angeles, US
13:15 - 13:15 1576P - Body mass index (BMI), lifestyle behaviors, and perceptions in cancer survivors 1 2 2 2 2 3 2 2 2 L. Eng , S. Su , D. Pringle , M. Mahler , C. Niu , H. Naik , R. Mohan , K. Tiessen , H. Hon , C. Brown 4 4 2 4 4 4 1 1 2 , J. Jones , D. Howell , P. Selby , S. Alibhai , W. Xu , G. Liu ; Toronto, Ontario/CA, Toronto, 3 4 ON/CA, Vencouver, CA, Toronto, CA
13:15 - 13:15 1577P - Barriers to improving awareness of the importance on exercise and dietary intervention, impact of it on lung cancer survivors’ behavior J.-A. Sim, Y.H. Yun, S.H. Yoo; Seoul, KR
13:15 - 13:15 1578P - Current perspectives of healthcare providers on weight loss and supportive nutritional care in cancer patients
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 3 4 5 6 7 1 F. Strasser , J. Arends , A. Laviano , N. Georgiou , R. Audisio , M. Sawyer , S. Kaasa ; St. Gallen,
2 3 4 5 6 7 CH, Freiburg, DE, Rome, IT, Schiphol Airport, NL, St. Helens, GB, Edmonton, CA, Oslo, NO
13:15 - 13:15 1579P - A survey of patient acceptance of skin toxicities from cetuximab-based therapy 1 1 2 3 1 2 3 B. Tischer , M. Bilang , P. Ronga , M. Lacouture ; Munich, DE, Maisons-Alfort, FR, New York, NY/US
13:15 - 13:15 1580P - Increase in cetuximab-induced skin rash and hypomagnesemia in patients receiving concomitant treatment with proton pump inhibitors (PPIs): A possible drug interaction? M. Abu Amna, G. Bar-Sela; Haifa, IL
13:15 - 13:15 (Withdrawn)
13:15 - 13:15 1582P - NeuroCog-FX study: A multicenter cohort study on cognitive dysfunction in patients with early breast cancer 1 2 3 4 5 6 7 8 O. Rick , M. Reuß-Borst , T. Dauelsberg , H. Hass , V. König , R. Caspari , G. Götz-Keil , J. Pfitzner , 9 10 10 1 2 3 C. Kerschgens , K. Fliessbach , C. Hoppe ; Bad Wildungen, DE, Bad Kissingen, DE, Nordrach,
4 5 6 7 8 9 DE, Scheidegg, DE, Bad Oeynhausen, DE, Cham, DE, Bad Nauheim, DE, Graal Müritz, DE, 10 Berlin, DE, Bonn, DE
13:15 - 13:15 1583P - Autonomic neuropathy in geriatric patients with gynecologic cancer receiving taxanes and platinum chemotherapy 1 2 3 4 5 6 1 G.S. Bhattacharyya , G. Babu , P. Parikh , A. Vora , G. Biswas , H. Malhotra ; Kolkata, West
2 3 4 5 6 Bengal/IN, Bangalore, IN, Mumbai, IN, New Delhi, IN, Bhubaneshwar, IN, Jaipur, Rajasthan/IN
13:15 - 13:15 (Withdrawn)
13:15 - 13:15 (Withdrawn)
13:15 - 13:15 1586P - Potential drug interactions in older patients with cancer: Updated data from the ELCAPA cohort survey 1 2 2 2 3 4 G. Beinse , D. Reitter , L. Segaux , M. Carvalho-Verlinde , C. Tournigand , B. Rousseau , T. 5 2 2 2 1 2 3 Cudennec , E. Paillaud , F. Canouï-Poitrine , P. Caillet ; Créteil, FR/FR, Créteil, FR, Creteil Cedex, 4 5 FR, Créteil, CEDEX/FR, Boulogne-Billancourt, FR
13:15 - 13:15 1587P - How do Spanish medical oncologists manage breakthrough pain? A national study 1 2 3 4 5 6 E. Aranda , C. Camps Herrero , P. Khosravi , M. Feyjoo , A. Anton Torres , P. Gascon , J. Garcia 4 4 2 4 7 Foncillas , E. Diaz Rubio , V. Guillem Porta , A. Carrato , M. Constenla Figueiras , J.J. Cruz
8 9 1 2 3 4 5 Hernandez , R. López ; Cordoba, ES, Valencia, ES, Torrejón De Ardoz, ES, Madrid, ES, 6 7 8 9 Zaragoza, ES, Barcelona, ES, Pontevedra, ES, Salamanca, ES, Santiago De Compostela, ES
13:15 - 13:15 1588P - Enhanced supportive care in early phase clinical trials N. Cook, L. Carter, S. Aruketty, C. O'Brien, F. Thistlethwaite, E. Dean, M. Krebs, M. Warren, R. Berman;
Manchester, GB
Last update: 02-09-2017 06:01:33pm esmo.org 13:15 - 13:15 1589P - Cancer patient interest and perceptions of lifestyle behavior programs 1 2 2 2 2 2 2 3 2 L. Eng , S. Liu , Q. Zhang , D. Farzanfar , S. Yeung , C. Brown , W. Xu , D. Howell , D. Goldstein ,
2 2 2 1 1 2 3 J. Jones , P. Selby , M. Giuliani , G. Liu ; Toronto, Ontario/CA, Toronto, CA, Toronto, ON/CA
13:15 - 13:15 1590P - The investigate relationship between severe neutropenia and ABCB1and ABCG2 gene polymorphisms with esophageal cancer patients receiving docetaxel, cisplatin and 5-fluorouracil chemotherapy 1 2 3 3 3 3 4 3 H. Nomura , D. Tsuji , K. Demachi , S. Suzuki , N. Mochizuki , T. Yano , H. Daiko , S. Fujii , T.
3 2 3 1 2 3 4 Kojima , K. Ito , M. Yamaguchi ; Kashiwa, Chiba/JP, Shizuoka, JP, Kashiwa, JP, Chu-O, JP
13:15 - 13:15 1591P - Hepatitis B and C reactivation rates due to cytotoxic chemotherapy in patients with solid tumors 1 2 2 1 3 1 1 2 3 M. Karaca , D. Tural , I. Cil , G. Ozet , O.K. Yucel , A. Ozet ; Ankara, TR, Istanbul, TR, Antalya, TR
13:15 - 13:15 1592P - Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab 1 2 3 4 5 6 7 8 D. Arnold , C. Fuchs , J. Tabernero , A. Ohtsu , A. Zhu , E. Garon , L. Paz-Ares , A. Baron , T. 9 4 10 11 12 12 11 12 Okusaka , T. Yoshino , H. Yoon , M. Das , D. Ferry , Y. Zhang , Y. Lin , P. Binder , A. 13 14 1 2 3 4 5 Sashegyi , I. Chau ; Lisbon, PT, New Haven, CT/US, Barcelona, ES, Kashiwa, Chiba/JP, 6 7 8 9 10 Boston, US, Santa Monica, US, Madrid, ES, San Francisco, CA/US, Tokyo, JP, Rochester, 11 12 13 14 MN/US, Indianapolis, US, Bridgewater, NJ/US, Indianapolis, IN/US, Sutton, Surrey/GB
13:15 - 13:15 1593P - The preventive role of intravenous L-alanyl L-glutamine in reducing the incidence of oral mucositis in head and neck cancer patients receiving radiotherapy with or without chemotherapy A. Elfeky, N. Sabry, A. Barakat; Tanta, EG
13:15 - 13:15 1594P - Biosimilar epoetin alfa (HX575) for the treatment of chemotherapy-induced anaemia: Development, approval and 10 years’ clinical experience 1 2 2 3 4 1 2 3 M. Aapro , A. Krendyukov , N. Höbel , A. Seidl , P. Gascón ; Genolier, CH, Holzkirchen, DE,
4 Overhaching, DE, Barcelona, ES
13:15 - 13:15 1595P - Experience with the implant of vascular access devices by medical oncologist in a non-surgical scenery 1 1 2 3 1 A. Revuelta , D. Rodríguez Rubí , M.L. Sánchez Lorenzo , L. Ruiz Echeverria , W. Li , M.P. Solís 1 1 1 1 1 Hernández , L. Fáez García , S. Fernández Arrojo , C. Iglesias Gómez , N. Villanueva Palicio , P.
1 1 1 4 1 1 Jimenez Fonseca , M. Luque Cabal , C. Álvarez Fernández , M. Izquierdo , J.M. Viéitez , E. Esteban ; 1 2 3 4 Oviedo, ES, Madrid, ES, Burgos, ES, Gijón, ES
13:15 - 13:15 1596P - Management of chemotherapy-related side effects- do patients know where to get help? 1 2 1 1 1 1 1 R. Prince , E. Amir , S. Blacker , S. McEwen , M. Morey-Hollis , C. Mothersill , U. Saha , L. Wayment
1 1 1 2 , M. Wyatt ; Toronto, CA, Toronto, Ontario/CA
13:15 - 13:15 1597P - The effects of nurses’ empathy skills on attitudes towards patients with cancer A. Alkan, Osmaniye, TR
Last update: 02-09-2017 06:01:33pm esmo.org 13:15 - 13:15 1598P - Can postponement of death be used in shared decision making in patients treated with adjuvant chemotherapy? N. Trabjerg, T. Hansen, K. Steffensen, A. Jakobsen, L.H. Jensen; Vejle, DK
13:15 - 13:15 1599P - Cancer patient attitudes and preferences towards smoking status assessment 1 2 2 2 2 2 2 3 2 L. Eng , S. Liu , Q. Zhang , D. Farzanfar , R. Milne , S. Yeung , C. Brown , D. Howell , W. Xu , D. 2 2 2 2 1 1 2 3 Goldstein , J. Jones , P. Selby , M. Giuliani , G. Liu ; Toronto, Ontario/CA, Toronto, CA, Toronto, ON/CA
13:15 - 13:15 1600P - Optimizing Physician Surveys in Pharmacovigilance Using ecancer Online Community 1 2 3 4 5 4 6 J.-J. Body , O. Nicolatou-Galitis , J. Sprafka , A. Stepto , R. Gleave , C. Hartley , D. Niepel , A. Liede 7 1 2 3 4 5 6 ; Brussels, BE, Athens, Attica/GR, Thousand Oaks, CA/US, Bristol, GB, Cambridge, GB, Vienna, 7 AT, South San Francisco, CA/US
13:15 - 13:15 1601P - Ideal cardiovascular health (ICVH) in patients with a recent diagnosis of colorectal cancer (CRC) 1 1 1 2 1 1 1 1 J. Ramos , A. Álvarez-Bustos , M. Soriano , B. Nuñez , J. Ros , P. Osorio , L. Gutierrez , R. Gómez , 1 1 1 1 2 1 1 1 F. Hidalgo , A. Leon , M. Mendez , C. González , A. Sanchez , S. Martínez , I. Pagola , L. Brea , C. 1 1 1 1 2 Fiuza-Luces , A. Lucia , A. Ruiz-Casado ; Madrid, ES, Majadahonda, ES
13:15 - 13:15 1602P - Additive effect of vinca alkaloids as the risk factor for hearing impairments in the childhood cancer survivors L.M.-J. Cha, M. Huh, J.Y. Lim, S.M. Hahn, C.J. Lyu, J.W. Han; Seoul, KR
13:15 - 13:15 1603P - Development and validation of chewing swallowing inventory (CSI) in head and neck cancer patients Y.-H. Lai, Taipei, TW
13:15 - 13:15 1604P - The Relationship between Oral Supportive Care and Oral Complications in Cancer Patients Receiving Chemotherapy: A Retrospective Study T. Kataoka, Kobe, JP
13:15 - 13:15 1605P - Safety and effectiveness of sensor-controlled scalp cooling in women receiving chemotherapy for primary breast cancer C. Kurbacher, S. Herz, G. Kolberg, N. Kettelhoit, A.T. Kurbacher, C. Schweitzer, J. Kurbacher; Bonn, DE
13:15 - 13:15 1606P - Pharmacokinetics and safety of FOLFOX therapy in patients undergoing hemodialysis 1 2 2 2 3 4 5 T. Funakoshi , T. Horimatsu , A. Yamada , T. Kirishima , T. Mizukami , Y. Harada , M. Nakajima , S. 2 2 2 2 1 2 3 Nakagawa , T. Matsubara , M. Yanagita , M. Muto ; Kyoto, Shizuoka/JP, Kyoto, JP, Kawasaki, JP, 4 5 Saga, JP, Ibaraki, JP
13:15 - 13:15 1607TiP - J-FORCE study: A randomized, double-blind, placebo-controlled phase III study evaluating olanzapine (5 mg) combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based, highly emetogenic chemotherapy 1 1 2 1 3 4 1 1 H. Hashimoto , S. Iwasa , M. Abe , T. Yanai , S. Zenda , T. Yamaguchi , H. Kaba , H. Fukuda , H.
1 1 1 2 3 4 Terakado , Y. Ohe ; Tokyo, JP, Shizuoka, JP, Chiba, JP, Sendai, JP
Last update: 02-09-2017 06:01:33pm esmo.org 13:15 - 13:15 1608TiP - Heath related quality of life (HRQOL) assessment for patients with advanced renal cell carcinoma (mRCC) treated with tyrosine kinase inhibitor (TKI) using electronic patient reported outcome (PRO) in daily clinical practice 1 2 2 2 2 2 2 1 G. Mouillet , A. Pozet , J. Fritzsch , I. Es-Saad , S. Paget-Bailly , A. Foubert , D. Berthod , A. Anota ,
1 1 1 2 F. Bonnetain , A. Thiery-Vuillemin ; Besançon, CEDEX/FR, Besançon, FR
13:15 - 13:15 1609TiP - Impact of a cancer care coordination program based on health information technologies for patients treated by oral anticancer therapy: The CAPRI randomized trial 1 1 1 1 1 2 M. Ferrua , M. Di Palma , F. Lemare , A. Fourcade , B. Lalloue , F. Daumas - Yatim , M. Guillet -
1 1 1 2 Lacaze , E. Minvielle ; Villejuif, FR, Rennes, FR
13:15 - 13:15 1610TiP - Oncological Home-Hospitalization: Prospective randomized trial to evaluate its implications for patient and society 1 1 1 1 1 2 3 1 L. Cool , J. Missiaen , P. Debruyne , K. Geldhof , T. Lefebvre , M. Desmedt , V. Foulon , H. Pottel ,
4 1 1 2 3 4 D. Vandijck , K. Van Eygen ; Kortrijk, BE, Hasselt, BE, Leuven, BE, Gent, BE
13:15 - 13:15 1611TiP - A novel multimodal treatment strategy for cancer cachexia; rationale and motivation for the MENAC (Multimodal – Exercise, Nutrition and Anti-inflammatory medication for Cachexia) trial 1 2 3 3 4 1 5 2 2 S. Kaasa , B. Laird , T. Balstad , G. Stene , V. Baracos , A. Bye , F. Strasser , M. Fallon , K. Fearon
1 2 3 4 5 ; Oslo, NO, Edinburgh, GB, Trondheim, NO, Alberta, CA, St. Gallen, CH
13:15 - 13:15 1612TiP - Multicenter prospective cohort study to evaluate of eye disorder induced by chemotherapy including S-1 (EyeDropS study/HGCSG1604) 1 1 2 2 2 2 2 M. Yagisawa , M. Nakamura , T. Muranaka , Y. Kawamoto , H. Nakatsumi , S. Yuki , T. Sasaki , T. 1 2 1 3 4 5 4 6 Meguro , M. Dazai , A. Ishiguro , K. Eto , K. Harada , Y. Kobayashi , T. Miyagishima , I. Iwanaga , M. 7 8 1 9 2 1 2 Uebayashi , K. Hatanaka , N. Sakamoto , Y. Sakata , Y. Komatsu ; Sapporo, JP, Sapporo, 3 4 5 6 7 Hokkaido/JP, Tomakomai, JP, Kushiro, JP, Kushiro, Hokkaido/JP, Kitami, Hokkaido Prefecture/JP, 8 9 Kitami, JP, Hakodate, Hokkaido/JP, Misawa, Aomori/JP
13:15 - 13:15 1613TiP - Outpatient monitoring with an eTool: self managed or with pro active intervention? 1 2 3 4 3 1 2 S. Rauh , L. Hoechstenbach , C. Schmitz , A. Hagemann , I. Denine ; Esch Sur Alzette, LU,
3 4 Maastricht, NL, Esch, LU, Sittard, NL
13:15 - 13:15 1614TiP - A Phase I safety study of topical Calcitriol (BPM 31543) for the prevention of chemotherapy-induced alopecia (CIA) 1 2 3 4 3 3 4 4 4 B. Berman , J. Konner , V. Belum , H. Dion , K. Ciccolini , S. Kitts , R. Ye , S. Ravipaty , V. Akmaev 4 1 5 3 3 1 2 , R. Sarangarajan , J. Jimenez , N. Narain , S. Goldfarb , M. Lacouture ; Miami, FL/US, New York, 3 4 5 US, New York, NY/US, Framingham, MA/US, Natick, MA/US
Last update: 02-09-2017 06:01:33pm esmo.org 14:15 - 17:15 Type: Young Oncologist Masterclass Cartagena Title: Young oncologists and excellence in clinical research: ESMO YOC meets Methods in Auditorium Clinical Cancer Research Workshop – MCCR Chair(s): M. Preusser, AT; L. De Mattos-Arruda, ES
14:15 - 14:40 Understanding the design of clinical trials: Where to start? J. de Bono, London, GB
14:40 - 14:40 Session Shooter J. Corral, Seville, ES
14:40 - 14:55 Discussion
14:55 - 15:20 Incorporation of immuno-biomarkers and immunotherapy in clinical trials I. Melero, Pamplona, ES
15:20 - 15:20 Session Shooter T. Amaral, Lisbon, PT
15:20 - 15:35 Discussion
15:35 - 15:55 Break
15:55 - 16:20 Incorporation of genomics in clinical trials F. André, Villejuif, CEDEX/FR
16:20 - 16:20 Session Shooter L. Poulsen, Aalborg, US
16:20 - 16:35 Discussion
16:35 - 17:00 Perspectives in clinical trials for the next decade S. Sleijfer, Rotterdam, NL
17:00 - 17:00 Session Shooter A. Tyulyandina, Moscow, RU
17:00 - 17:15 Discussion
Last update: 02-09-2017 06:01:33pm esmo.org 14:30 - 16:30 Type: ESMO Clinical Practice Guidelines session Granada Auditorium Title: ESMO Clinical Practice Guidelines 2 Chair(s): C. Sessa, CH; G. Pentheroudakis, GR
14:30 - 14:40 Introduction to the ESMO Clinical Practice Guidelines G. Pentheroudakis, Ioannina, GR
14:40 - 14:50 Questionnaire C. Sessa, Bellinzona, CH
14:50 - 15:00 Patient with metastatic breast cancer: Sequence of therapies case presentation C. Criscitiello, Milan, IT
15:00 - 15:10 Discussant N. Harbeck, Munich, DE
15:10 - 15:15 Q&A
15:15 - 15:25 BRCA mutation carrier patient: How to manage? Case presentation K. Sosinska-Mielcarek, Gdansk, PL
15:25 - 15:35 Discussant S. Paluch-Shimon, Ramat Gan, IL
15:35 - 15:40 Q&A
15:40 - 15:50 Hodgkin lymphoma case presentation J. Longley, Southampton, GB
15:50 - 16:00 Discussant S. Luminari, Modena, IT
16:00 - 16:05 Q&A
16:05 - 16:15 Immunotherapy in melanoma, pseudoprogression, management of toxicities case presentation E. Romano, Paris, CEDEX 5/FR
16:15 - 16:25 Discussant U. Keilholz, Berlin, DE
16:25 - 16:30 Q&A
Last update: 02-09-2017 06:01:33pm esmo.org
14:45 - 16:15 Type: Special Symposium Barcelona Auditorium Title: Immunotherapy and targeted therapies in gynaecological malignancies Chair(s): S. Banerjee, GB; J. Jonkers, NL
14:45 - 14:50 Introduction S. Banerjee, London, GB
14:50 - 15:10 Immunology of gynaecological tumours G. Coukos, Epalinges, CH
15:10 - 15:30 Immunotherapy in gynaecological malignancies E. Pujade-Lauraine, Paris, FR
15:30 - 15:50 Clinical implications of HRD beyond BRCA J. Jonkers, Amsterdam, NL
15:50 - 16:10 How to integrate PARP inhibitors into clinical practice S. Banerjee, London, GB
16:10 - 16:15 Conclusions and clinical perspectives J. Jonkers, Amsterdam, NL
14:45 - 16:15 Type: Poster Discussion session Cordoba Auditorium Title: Genitourinary tumours, non-prostate Chair(s): P. Grivas, US; M. De Santis, GB; C. Porta, IT
14:45 - 14:45 848PD - Impact of zumor mutation burden on nivolumab efficacy in second-line urothelial carcinoma patients: Exploratory analysis of the phase ii checkmate 275 study 1 2 2 2 3 4 5 6 M. Galsky , A. Saci , P. Szabo , A. Azrilevich , C. Horak , A. Lambert , A. Siefker-Radtke , A. Necchi 5 1 2 3 4 5 , P. Sharma ; New York, US, Princeton, US, Pennington, NJ/US, Braine-L'alleud, BE, Houston, 6 TX/US, Milan, IT
14:45 - 14:45 849PD - Comparison of tumor mutational burden (TMB) in relevant molecular subsets of metastatic urothelial cancer (MUC) 1 2 3 4 5 4 4 4 6 1 S. Pal , N. Agarwal , T. Choueiri , P. Stephens , J. Ross , V. Miller , S. Ali , J. Chung , P. Grivas ; 2 3 4 5 6 Duarte, CA/US, Salt Lake City, UT/US, Boston, US, Cambridge, MA/US, Albany, NY/US, Cleveland, US
14:45 - 14:45 850PD - Epithelial-mesenchymal transition (EMT), T cell infiltration, and outcomes with nivolumab (nivo) in urothelial cancer (UC) 1 2 3 3 2 2 1 2 3 M. Galsky , L. Wang , A. Saci , P. Szabo , Y. Gong , J. Zhu ; New York, US, New York, NY/US, Princeton, US
14:45 - 15:05 Invited Discussant 848PD, 849PD and 850PD P. Grivas, Cleveland, US
Last update: 02-09-2017 06:01:33pm esmo.org
15:05 - 15:15 Q&A led by Discussant
15:15 - 15:15 851PD - Subgroup analyses from KEYNOTE-045: Pembrolizumab (pembro) versus individual investigator’s choice of chemotherapy (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (uc) 1 2 3 4 5 6 7 8 D. Petrylak , N. Vogelzang , Y. Fradet , D. Bajorin , R. de Wit , D. Vaughn , J.-L. Lee , L. Fong , M. 9 10 11 12 13 14 15 Climent , A. Necchi , W. Gerritsen , H. Gurney , D. Quinn , S. Culine , C. Sternberg , E. 16 17 18 19 20 1 2 Jensen , M. Puhlmann , R. Perini , J. Bellmunt , T. Choueiri ; New Haven, US, Las Vegas, 3 4 5 6 7 8 NV/US, Quebec City, CA, New York, US, Rotterdam, NL, Philadelphia, US, Seoul, KR, San 9 10 11 12 13 Francisco, CA/US, Valencia, ES, Milan, IT, Nijmegen, NL, Macquarie Park, NSW/AU, Los 14 15 16 17 Angeles, CA/US, Paris, CEDEX 10/FR, Roma, IT, Kenilworth, US, New York, New Jersey/US, 18 19 20 North Wales, US, Boston, MA/US, Boston, US
15:15 - 15:15 852PD - Atezolizumab (atezo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Post-progression outcomes from the phase 2 IMvigor210 study 1 2 3 4 5 6 7 A. Necchi , R. Joseph , Y. Loriot , J. Hoffman-Censits , J.L. Perez Gracia , D. Petrylak , Q. Zhu , B. 7 7 8 1 2 3 4 5 Ding , C. Kaiser , J. Rosenberg ; Milan, IT, Jacksonville, US, Villejuif, FR, Philadelphia, US, 6 7 8 Pamplona, ES, New Haven, CT/US, South San Francisco, US, New York, NY/US
15:15 - 15:15 LBA37_PR - Pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine for recurrent, advanced urothelial cancer (UC): mature results from the phase 3 KEYNOTE-045 trial 1 2 3 4 5 6 7 8 R. de Wit , D. Vaughn , Y. Fradet , J.-L. Lee , L. Fong , N. Vogelzang , M. Climent , D. Petrylak , T. 9 10 11 12 13 14 15 Choueiri , A. Necchi , W. Gerritsen , H. Gurney , D. Quinn , S. Culine , C. Sternberg , Y. Mai 16 17 18 19 20 1 2 3 , M. Puhlmann , R. Perini , J. Bellmunt , D. Bajorin ; Rotterdam, NL, Philadelphia, PA/US, 4 5 6 7 8 Quebec City, CA, Seoul, KR, San Francisco, CA/US, Las Vegas, NV/US, Valencia, ES, New 9 10 11 12 13 Haven, CT/US, Boston, US, Milan, IT, Nijmegen, NL, Macquarie Park, NSW/AU, Los Angeles, 14 15 16 17 18 CA/US, Paris, CEDEX 10/FR, Roma, IT, Kenilworth, NJ/US, New York, New Jersey/US, 19 20 North Wales, US, Boston, Ma, US, New York, US
15:15 - 15:35 Invited Discussant 851PD, 852PD and LBA37 M. De Santis, Coventry, GB
15:35 - 15:45 Q&A led by Discussant
15:45 - 15:45 LBA38 - Progression-free survival (PFS) by independent review and updated overall survival (OS) results from Alliance A031203 trial (CABOSUN): cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC) 1 2 3 3 4 5 5 6 T. Choueiri , C. Hessel , S. Halabi , B. Sanford , O. Hahn , M. Michaelson , M. Walsh , T. Olencki , J. 7 8 9 2 3 10 1 2 Picus , E. Small , S. Dakhil , C. Scheffold , D. George , M. Morris ; Boston, US, South San
3 4 5 6 7 Francisco, CA/US, Durham, NC/US, Chicago, IL/US, Boston, MA/US, Columbus, OH/US, St. 8 9 10 Louis, US, San Francisco, CA/US, Wichita, KS/US, New York, NY/US
Last update: 02-09-2017 06:01:33pm esmo.org 15:45 - 15:45 LBA39 - IMmotion150: Novel Radiological Endpoints and Updated Data From a Randomized Phase II Trial Investigating Atezolizumab (atezo) With or Without Bevacizumab (bev) vs Sunitinib (sun) in Untreated Metastatic Renal Cell Carcinoma (mRCC) 1 2 3 4 5 6 7 8 9 T. Powles , D. McDermott , B. Rini , R. Motzer , M. Atkins , L. Fong , R. Joseph , S. Pal , A. Ravaud 10 11 12 1 13 14 15 , S. Bracarda , C. Suarez Rodriguez , M. Maio , M. Gore , V. Grünwald , M. Staehler , J. Qiu , 16 17 17 18 1 2 3 A. Thobhani , M. Huseni , C. Schiff , B. Escudier ; London, GB, Boston, MA/US, Cleveland, 4 5 6 7 8 OH/US, New York, NY/US, Washington Dc, US, San Francisco, CA/US, Jacksonville, US, Duarte, 9 10 11 12 13 14 CA/US, Bordeaux, FR, Arezzo, IT, Barcelona, ES, Siena, IT, Hannover, DE, Munich, DE, 15 16 17 South San Francisco, CA/US, Welwyn Garden City, Hertfordshire/GB, South San Francisco, US, 18 Villejuif, FR
15:45 - 15:45 854PD - Pazopanib (p) or sorafenib (s) + radium-223 (rad) in metastatic renal cell carcinoma (mrcc) with bone metastases (bm) 1 2 3 3 3 3 3 3 D. Bossé , R. McKay , K. Gray , M. Michaelson , C. Sleeper , M. Walsh , K. Krajewski , H. Jacene , 4 3 3 5 1 2 3 J. Bellmunt , M. Pomerantz , L. Harshman , T. Choueiri ; Ottawa, Ontario/CA, San Diego, US, 4 5 Boston, MA/US, Boston, Ma, US, Boston, US
15:45 - 15:45 855PD - Adjuvant sunitinib (SU) in patients (pts) with high risk renal cell carcinoma (RCC): Safety and therapy management in S-TRAC trial 1 2 3 4 5 6 7 8 M. Staehler , R. Motzer , D. George , H. Pandha , F. Donskov , B. Escudier , J. Kliment , A. Pantuck 9 10 2 11 12 13 14 , A. Patel , L. Deannuntis , H. Bhattacharyya , X. Lin , M. Lechuga , L. Serfass , J.-J. Patard , 15 1 2 3 4 5 6 A. Ravaud ; Munich, DE, New York, NY/US, Durham, NC/US, Surry, GB, Aarhus, DK, Villejuif, 7 8 9 10 11 12 FR, Martin, SK, Los Angeles, CA/US, London, GB, Collegeville, PA/US, La Jolla, CA/US, 13 14 15 Milan, IT, Paris, FR, Mont-De-marsan, FR, Bordeaux, FR
15:45 - 16:05 Invited Discussant LBA38, LBA39, 854PD and 855PD C. Porta, Pavia, IT
16:05 - 16:15 Q&A led by Discussant
Last update: 02-09-2017 06:01:33pm esmo.org 14:45 - 16:15 Type: Educational session Bilbao Auditorium Title: State of the art in the treatment of soft tissue sarcoma: ESMO guidelines Chair(s): R.L. Haas, NL; H. Joensuu, FI
14:45 - 15:10 Histological and molecular classification A.P. Dei Tos, Treviso, IT
15:10 - 15:35 Local treatment and strategy S. Bonvalot, Paris, FR
15:35 - 16:00 Systemic treatment: What the patient needs to know J. Martin Broto, Seville, ES
16:00 - 16:15 Discussion
14:45 - 16:15 Type: Special Symposium Alicante Auditorium Title: Recent advances in endocrine malignancies Chair(s): J. Capdevila, ES
14:45 - 14:50 Introduction
14:50 - 15:10 Medullary thyroid cancer J. Capdevila, Barcelona, ES
15:10 - 15:30 Malignant pheochromocytoma and paraganglioma J. Crona, Uppsala, SE
15:30 - 15:50 Adrenocortical tumours A. Berruti, Brescia, IT
15:50 - 16:10 Differentiated thyroid carcinoma B. Jarzab, Warsaw, PL
16:10 - 16:15 Conclusions and clinical perspectives J. Capdevila, Barcelona, ES
Last update: 02-09-2017 06:01:33pm esmo.org 14:45 - 16:15 Type: Special Symposium Madrid Auditorium Title: Precision medicine for metastatic breast cancer Chair(s): C. Sotiriou, BE; T. Bachelot, FR
14:45 - 15:05 Targeting PI3K S. Loi, Melbourne, VIC/AU
15:05 - 15:25 The genomic landscape of metastatic breast cancer L. Yates, Cambridge, Kent/GB
15:25 - 15:45 Clinical utility of large panel of genes M. Arnedos, Villejuif, FR
15:45 - 16:05 Clinical utility of circulating DNA N. Turner, London, GB
16:05 - 16:15 Clinical perspectives: Which genomic tests should be used in mBC? C. Sotiriou, Brussels, BE
14:45 - 16:15 Type: Educational session Tarragona Auditorium Title: Immunotherapy in head and neck cancer Chair(s): A. Psyrri, GR; J. Guigay, FR
14:45 - 15:10 State of the art of immunotherapy in head and neck cancer U. Keilholz, Berlin, DE
15:10 - 15:35 How to target immuno escape after anti PD-1 R. Ferris, US
15:35 - 16:00 Rationale to combine with classical or novel therapies A. Psyrri, Athens, GR
16:00 - 16:15 Discussion
15:00 - 16:00 Type: Poster Discussion session Sevilla Auditorium Title: Gastrointestinal tumours, colorectal Chair(s): T. Gruenberger, AT; G. Folprecht, DE
15:00 - 15:00 482PD - Robot-assisted vs laparoscopic vs open abdominoperineal resections for low rectal cancer: Short-term outcomes of a single-center prospective randomized controlled trial J. Xu, Y. Wei, L. Ren, Q. Feng, J. Chen, D. Zhu, W. Chang, T. Yi, L. Yang, X. Qin; Shanghai, CN
Last update: 02-09-2017 06:01:33pm esmo.org 15:00 - 15:00 483PD - Perioperative chemotherapy with or without cetuximab in patients (pts) with resectable colorectal liver metastasis (CRLM): Mature analysis of overall survival (OS) in the New EPOC randomised controlled trial 1 2 2 2 2 2 2 J. Bridgewater , S. Pugh , A. Whitehead , L. Stanton , Z. Eminton , J. Mellor , A. Allen , M. 3 3 2 4 5 6 7 8 Finch-Jones , S. Falk , T. Iveson , M. Rees , J. Valle , J. Hornbuckle , T. Hickish , D. Cunningham , 9 10 2 2 1 2 3 4 T. Maughan , J. Garden , G. Griffiths , J. Primrose ; London, GB, Southampton, GB, Bristol, GB, 5 6 7 8 9 Basingstoke, GB, Manchester, GB, Sheffield, South Yorkshire/GB, Bournemouth, GB, Sutton, GB, 10 Oxford, GB, Edinburgh, GB
15:00 - 15:00 LBA26 - FOXFIRE-SIRFLOX-FOXFIRE Global prospective randomised studies of first-line selective internal radiotherapy (SIRT) in patients with liver metastases from colorectal cancer: KRAS mutation and tumour site analysis 1 1 2 3 4 5 6 7 H. Wasan , R. Sharma , V. Heinemann , N. Sharma , J. Taieb , J. Ricke , M. Peeters , M. Findlay , 8 8 8 8 9 8 10 10 P. Virdee , S. Love , J. Moschandreas , P. Dutton , V. Gebski , A. Gray , D. Price , G. Bower , A. 11 12 10 1 2 3 4 5 Montazeri , P. Gibbs , G. Van Hazel ; London, GB, Munich, DE, Hershey, US, Paris, FR, 6 7 8 9 10 11 Magdeburg, DE, Edegem, BE, Auckland, NZ, Oxford, GB, Sydney, AU, Perth, WA/AU, Wirral, 12 Merseyside/GB, Footscray, VIC/AU
15:00 - 15:20 Invited Discussant 482PD, 483PD and LBA26 T. Gruenberger, Vienna, AT
15:20 - 15:30 Q&A led by Discussant
15:30 - 15:30 481PD - Sidedness influences prognosis in stage III but not in stage II colon cancer patients receiving an adjuvant therapy: A GISCAD analysis from three randomized trials including 5234 patients 1 2 3 4 5 6 1 2 3 S. Cascinu , D. Poli , A. Zaniboni , R. Labianca , A. Sobrero , V. Torri ; Modena, IT, Milano, IT,
4 5 6 Brescia, IT, Bergamo, IT, Genova, IT, Milan, IT
15:30 - 15:30 484PD - Analysis of tumor PD-L1 expression and biomarkers in relation to clinical activity in patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) + ipilimumab (IPI): CheckMate 142 1 2 3 4 5 6 7 T. André , M. Overman , S. Lonardi , M. Aglietta , R. McDermott , K.Y.M. Wong , M. Morse , A. 8 9 10 10 10 11 1 2 Hendlisz , R. Moss , J.-M. Ledeine , H. Tang , Z.A. Cao , S. Kopetz ; Paris, CEDEX 12/FR,
3 4 5 6 7 Houston, TX/US, Padova, IT, Candiolo, (TO)/IT, Dublin, Belgard Square North/IE, Sydney, AU, 8 9 10 11 Durham, US, Brussels, BE, New Brunswick, NJ/US, Princeton, US, Houston, US
15:30 - 15:30 485PD - Randomized phase III study of adjuvant chemotherapy with S-1 versus capecitabine in patients with stage III colorectal cancer: Updated results of Japan Clinical Oncology Group study (JCOG0910) 1 1 1 2 3 1 1 1 T. Hamaguchi , Y. Shimada , J. Mizusawa , T. Sato , T. Kato , K. Takahashi , K. Sugihara , Y. Saida 4 5 1 6 6 7 8 9 , H. Ike , K. Hase , T. Masaki , M. Shiozawa , A. Sugita , J. Nishimura , Y. Munakata , S. Ikeda , K.
1 1 1 2 3 4 5 Nakamura , H. Fukuda ; Tokyo, JP, Yamagata, JP, Amagasaki, Hyogo/JP, Yokohama, JP, 6 7 8 9 Saitama, JP, Kanagawa, JP, Niigata, JP, Nagano, JP, Hiroshima, JP
15:30 - 15:50 Invited Discussant 481PD, 484PD and 485PD G. Folprecht, Dresden, DE
Last update: 02-09-2017 06:01:33pm esmo.org
15:50 - 16:00 Q&A led by Discussant
15:00 - 16:00 Type: Multidisciplinary Session Pamplona Auditorium Title: Management of locally advanced gastric and oesophageal adenocarcinoma Chair(s): F. Lordick, DE
15:00 - 15:05 Presentation of case/condition F. Lordick, Leipzig, DE
15:05 - 15:15 The medical oncology perspective F. Lordick, Leipzig, DE
15:15 - 15:25 The radiation therapy perspective T. Leong, Melbourne, AU
15:25 - 15:35 The surgery perspective M. Pera, Barcelona, ES
15:35 - 16:00 General Discussion
15:00 - 16:00 Type: Multidisciplinary Session Valencia Auditorium Title: Treating patients with melanoma brain metastases Chair(s): M. Guckenberger, CH
15:00 - 15:10 Patient with BRAF mutation under kinase inhibitor therapy and controlled systemic disease developing 3 asymptomatic 1-2cm large brain metastases P. Ascierto, Napoli, IT
15:10 - 15:20 Patient under treatment with immunotherapy developing one single 2.5cm large symptomatic brain metastasis M. Guckenberger, Zürich, CH
15:20 - 15:30 Primary diagnosis of malignant melanoma with 7 symptomatic brain without other visceral metastases R. Dummer, Zürich, CH
15:30 - 16:00 Discussion
16:30 - 18:00 Type: Poster Discussion session Barcelona Auditorium Title: NSCLC, metastatic Chair(s): R. Dziadziuszko, PL; J. Bar, IL
Last update: 02-09-2017 06:01:33pm esmo.org
16:30 - 16:30 1301PD - Three-year follow-up from CheckMate 017/057: Nivolumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC) 1 2 3 4 5 6 7 E. Felip Font , S. Gettinger , M.A. Burgio , S. Antonia , E. Holgado , D. Spigel , O. Arrieta , M. 5 8 9 10 11 12 13 Domine Gomez , O. Aren Frontera , J. Brahmer , L. Chow , L. Crinò , C. Butts , B. Coudert , L. 14 15 16 17 18 19 1 2 Horn , M. Steins , W. Geese , A. Li , D. Healey , E. Vokes ; Barcelona, ES, New Haven, 3 4 5 6 7 8 CT/US, Meldola, IT, Tampa, FL/US, Madrid, ES, Nashville, TN/US, Mexico City, MX, Santiago, 9 10 11 12 13 CL, Baltimore, Md, US, Seattle, WA/US, Perugia, (PG)/IT, Edmonton, CA, Dijon, Cedex/FR, 14 15 16 17 18 19 Nashville, US, Heidelberg, DE, Princeton, NJ/US, Princeton, US, Wallingford, GB, Chicago, IL/US
16:30 - 16:30 1302PD - IFCT-1502 CLINIVO: Real-life experience with nivolumab in 600 patients (pts) with advanced non-small cell lung cancer (NSCLC): Efficacy and safety of nivolumab and post-nivolumab treatment in the French Expanded Access Program (EAP) 1 2 3 4 5 6 7 N. Girard , C. Audigier Valette , J. Cadranel , I. Monnet , J. Hureaux , W. HILGERS , E. Fauchon , E. 3 8 9 10 11 12 13 Fabre , B. Besse , P. Brun , D. Coëtmeur , E. Quoix , P. Mourlanette , F. Barlesi , S. 14 15 3 3 16 17 1 2 Bordenave-Caffre , T. Egenod , P. missy , F. Morin , D. Moro-Sibilot , O. Molinier ; Bron, FR,
3 4 5 6 7 Toulon, CEDEX/FR, Paris, FR, Créteil, FR, Angers, CEDEX 9/FR, Avignon, FR, Saint Julien En 8 9 10 11 12 Genevois, FR, Villejuif, FR, Valence, FR, Saint Brieuc, FR, Chambéry, CEDEX/FR, 13 14 15 16 17 Cornebarrieu, FR, Marseille, FR, Nantes, FR, Limoges, FR, La Tronche, FR, Le Mans, FR
16:30 - 16:30 1303PD - Nivolumab in previously treated patients with metastatic squamous NSCLC: Results of a European single-arm, phase 2 trial (CheckMate 171) including patients aged ≥70 years and with poor performance status 1 2 3 4 5 6 7 S. Popat , A. Ardizzoni , T. Ciuleanu , M. Cobo Dols , K. Laktionov , M. Szilasi , R. Califano , E. 8 9 10 11 12 13 14 Carcereny Costa , R. Griffiths , L. Paz-Ares , C. Szczylik , J. Corral , D. Isla , J. Jassem , W. 15 16 17 18 18 8 1 2 Appel , J. Van Meerbeeck , J. Wolf , J. Jiang , L.R. Molife , E. Felip Font ; London, GB,
3 4 5 6 7 8 Bologna, IT, Cluj-Napoca, RO, Malaga, ES, Moscow, RU, Debrecen, HU, Manchester, GB, 9 10 11 12 13 14 Barcelona, ES, Bebington, GB, Madrid, ES, Warsaw, PL, Seville, ES, Zaragoza, ES, 15 16 17 18 Gdańsk, PL, Preston, GB, Edegem, BE, Köln, DE, Princeton, NJ/US
16:30 - 16:50 Invited Discussant 1301PD, 1302PD and 1303PD R. Dziadziuszko, Gdansk, PL
16:50 - 17:00 Q&A led by Discussant
17:00 - 17:00 1304PD - Correlation of radiation pneumonitis history before nivolumab and onset risk of interstitial lung disease or progression free survival of nivolumab in patients with non-small cell lung cancer 1 2 1 1 3 1 2 A. Tamiya , M. Tamiya , K. Nakahama , Y. Taniguchi , T. Shiroyama , S.-I. Isa , T. Inoue , K. Nishino 2 2 4 3 2 5 1 2 3 , T. Kumagai , H. Suzuki , T. Hirashima , F. Imamura , S. Atagi ; Sakai, JP, Osaka, JP, Habikino, 4 5 Osaka/JP, Habikino, JP, Sakai, Osaka/JP
17:00 - 17:00 1305PD - Whole body PD-1 and PD-L1 PET in pts with NSCLC
Last update: 02-09-2017 06:01:33pm esmo.org 1 1 1 1 1 1 1 A.-L. Niemeijer , E. Smit , I. Bahce , O. Hoekstra , M. Huisman , G.A. van Dongen , B. Windhorst , N. 1 1 1 2 2 2 2 1 Hendrikse , A. Poot , D. Vugts , D. Leung , W. Hayes , R. Smith , L. Wilson , E. Thunnissen , J. De 1 1 2 Langen ; Amsterdam, NL, Princeton, NJ/US
17:00 - 17:00 1306PD - Hyperprogressive disease (HPD) is frequent in non-small cell lung cancer (NSCLC) patients (pts) treated with anti PD1/PD-L1 monoclonal antibodies (IO) 1 2 2 3 4 2 R. Ferrara , C. CARAMELLA , M. Texier , C. Audigier Valette , L. Tessonnier , L. Mezquita , J. 2 5 6 7 8 9 9 Lahmar , J. Mazieres , G. Zalcman , S. Brosseau , V. Westeel , S. Le Moulec , L. Leroy , B. 10 11 2 2 2 2 2 1 Duchemann , R. Veillon , D. Planchard , M.-E. Boucher , S. Koscielny , J.-C. Soria , B. Besse ; 2 3 4 5 6 7 Verona, IT, Villejuif, FR, Toulon, CEDEX/FR, Toulon, FR, Toulouse, FR, Paris, CEDEX 18/FR, 8 9 10 11 Paris, FR, Besançon, CEDEX/FR, Bordeaux, FR, Bobigny, CEDEX/FR, Pessac, FR
17:00 - 17:00 LBA52 - Randomized double blind phase IIb trial in advanced NSCLC patients who did not progress after first line platinum based chemotherapy : Vx-001, a therapeutic cancer vaccine, vs placebo as maintenance therapy. 1 2 3 4 5 6 C. Gridelli , T. Ciuleanu , M. Domine Gomez , A. Szczesna , I. Bover , M. Cobo Dols , N. Kentepozidis 7 8 9 10 11 12 13 1 , S. Viteri , C. Manegold , D. Khayat , J.-Y. Douillard , K. Kosmatopoulos , V. Georgoulias ; 2 3 4 5 6 7 Avellino, IT, Cluj-Napoca, RO, Madrid, ES, Otwock, PL, Palma De Mallorca, ES, Malaga, ES, 8 9 10 11 Athens, GR, Barcelona, ES, Mannheim, DE, Paris, CEDEX 13/FR, Lugano - Viganello, 12 13 CEDEX/CH, Paris, FR, Heraklion, GR
17:00 - 17:20 Invited Discussant 1304PD, 1305PD, 1306PD and LBA52 J. Bar, Ramat Gan, IL
17:20 - 17:30 Q&A led by Discussant
17:30 - 17:30 1300PD - Impact of co-occurring genomic alterations on overall survival of BRAF V600E and non-V600E mutated NSCLC patients: Results of the Network Genomic Medicine 1 1 2 1 1 2 2 A. Kron , R. Riedel , S. Michels , J. Fassunke , S. Merkelbach-Bruse , M. Scheffler , L. Nogova , R. 2 1 2 1 1 3 4 5 Fischer , F. Ueckeroth , D. Abdulla , F. Kron , B. Pauli , B. Kaminsky , J. Braess , U. Graeven , C.
6 7 1 2 1 2 3 4 Grohe , S. Krueger , R. Büttner , J. Wolf ; Cologne, DE, Köln, DE, Solingen, DE, Regensburg, DE, 5 6 7 Mönchengladbach, DE, Berlin, DE, Düsseldorf, DE
17:30 - 17:30 LBA53 - A Phase II, randomised, open-label study of Gemcitabine/Carboplatin first-line chemotherapy in combination with or without the antisense oligonucleotide Apatorsen (OGX-427) in advanced squamous cell lung cancers 1 2 3 4 5 6 7 8 P. Schmid , F. Blackhall , D. Muthukumar , J. Lester , S. Khan , J. Adams , M. Illsley , C. Macgregor 9 1 1 1 1 1 1 1 , W. Owadally , S.-J. Sarker , L. Smith , A. Prendergast , C. Ackerman , K. Mousa , L. Lim Farah ;
2 3 4 5 6 7 London, GB, Manchester, GB, Colchester, GB, Wales, GB, Nottingham, GB, Reading, GB, 8 9 Guildford, GB, Inverness, GB, Bristol, GB
17:30 - 17:30 1307PD - Detection of driver and resistance mutations in leptomeningeal metastases of NSCLC by next-generation sequencing of cerebrospinal fluid circulating tumor cells
Last update: 02-09-2017 06:01:33pm esmo.org 1 1 1 1 1 2 1 1 Y.-S. Li , B.-Y. Jiang , W.-B. Guo , X.-C. Zhang , J.-J. Yang , Y. Shao , B. Huang , Y.-H. Liu , Y.-L.
1 1 2 Wu ; Guangzhou, CN, Nanjing, CN
17:30 - 17:30 1308PD - Preliminary efficacy and safety of lorlatinib in patients (Pts) with ROS1-positive non-small cell lung cancer (NSCLC) 1 2 3 4 5 6 7 8 B. Besse , A. Shaw , B. Solomon , T. Bauer , R. Chiari , C.-C. Lin , M. Satouchi , J. Clancy , L. 9 10 11 1 2 3 4 James , A. Abbattista , E. Felip Font ; Villejuif, FR, Boston, MA/US, Melbourne, VIC/AU,
5 6 7 8 9 10 Nashville, TN/US, Perugia, IT, Taipei, TW, Akashi, JP, Princeton, NJ/US, New York, US, Milan, 11 IT, Barcelona, ES
17:30 - 17:50 Invited Discussant 1300PD, LBA53, 1307PD and 1308PD J. Mazieres, Toulouse, FR
17:50 - 18:00 Q&A led by Discussant
Last update: 02-09-2017 06:01:33pm esmo.org 16:30 - 18:00 Type: Proffered Paper session Cordoba Auditorium Title: Developmental therapeutics Chair(s): J. Schellens, NL; U. Banerji, GB
16:30 - 16:45 LBA17 - Anti-CC-chemokine receptor 4 (CCR4) antibody mogamulizumab (Moga) and nivolumab (Nivo) combination phase I study in patients with advanced or metastatic solid tumors 1 2 3 4 5 6 7 N. Yamamoto , K. Muro , H. Ishii , T. Kato , T. Tsushima , M. Takenoyama , S. Oizumi , T. Kawakami 8 9 1 2 3 4 5 6 , T. Doi ; Tokyo, JP, Nagoya, Aichi/JP, Matsuyama, JP, Yokohama, JP, Shizuoka, JP, Fukuoka, 7 8 9 JP, Sapporo, Hokkaido/JP, Chiyodaku, JP, Kashiwa, Chiba/JP
16:45 - 17:00 LBA18 - Efficacy of BMS-986016, a Monoclonal Antibody That Targets Lymphocyte Activation Gene-3 (LAG-3), in Combination With Nivolumab in Pts With Melanoma Who Progressed During Prior Anti–PD-1/PD-L1 Therapy (mel prior IO) in All-Comer and Biomarker-Enriched Populations 1 2 3 4 5 6 7 8 P. Ascierto , P. Bono , S. Bhatia , I. Melero , M. Nyakas , I.-M. Svane , J. Larkin , C. Gomez-Roca , 9 10 11 12 13 14 13 D. Schadendorf , R. Dummer , A. Marabelle , C. Hoeller , M. Maurer , C. Harbison , P. Mitra , 13 13 15 1 2 3 4 S. Suryawanshi , K. Thudium , E. Muñoz Couselo ; Napoli, IT, Helsinki, FI, Seattle, WA/US, 5 6 7 8 9 10 Pamplona, ES, Oslo, NO, Herlev, DK, London, GB, Toulouse, Haute-Garonne/FR, Essen, DE, 11 12 13 14 15 Zürich, CH, Villejuif, FR, Vienna, AT, Princeton, NJ/US, Princeton, US, Barcelona, ES
17:00 - 17:15 Invited Discussant LBA17 and LBA18 A. Italiano, Bordeaux, FR
17:15 - 17:30 LBA19 - A Phase 1b study of RXDX-105, a VEGFR-sparing potent RET inhibitor, in RETi-naïve patients with RET fusion-positive NSCLC 1 2 3 4 5 5 6 7 A. Drilon , S. Liu , R. Doebele , C. Rodriguez , M. Fakih , K. Reckamp , L. Bazhenova , B.C. Cho , E. 8 8 8 7 1 2 3 Kowack , J. Oliver , P. Multani , M.-J. Ahn ; New York, NY/US, Washington Dc, US, Aurora, 4 5 6 7 8 CO/US, Seattle, WA/US, Duarte, CA/US, San Diego, US, Seoul, KR, San Diego, CA/US
17:30 - 17:45 365O - Phase 1 safety and clinical activity of BLU-554 in advanced hepatocellular carcinoma (HCC) 1 2 3 4 5 2 6 7 R. Kim , D. Sarker , T. Macarulla , T. Yau , S.P. Choo , T. Meyer , A. Hollebecque , J. Whisenant , 8 9 9 10 11 12 13 14 M. Sung , J.-H. Yoon , H.Y. Lim , A. Zhu , J.-W. Park , S. Faivre , V. Mazzaferro , H. Shi , O. 14 14 14 15 1 2 3 4 Schmidt-Kittler , C. Clifford , B. Wolf , Y.-K. Kang ; Tampa, US, London, GB, Barcelona, ES, 5 6 7 8 9 10 Hong Kong, HK, Singapore, SG, Villejuif, FR, Salt Lake City, US, New York, NY/US, Seoul, KR, 11 12 13 14 15 Boston, US, Goyang, KR, Paris, FR, Milan, IT, Cambridge, US, Seoul, Songpa-gu/KR
17:45 - 18:00 Invited Discussant LBA19 and 365O J. Rodon, Barcelona, ES
16:30 - 17:45 Type: Poster Discussion session Bilbao Auditorium Title: Basic science Chair(s): C. Isacke, GB; D. Tuveson, US; C. Dive, GB
16:30 - 16:30 1703PD - Landscape of DNA damage response (DDR) genes alterations in the prospective MOSCATO and MATCH R trials
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 1 3 1 1 4 Y. El Dakdouki , L. Verlingue , C. Massard , R. Bahleda , A. Hollebecque , L. Mahjoubi , E. Rouleau , 1 1 1 1 1 3 1 L. Lacroix , N. Auger , J.-Y. Scoazec , E. Solary , A. Marabelle , F. André , J.-C. Soria , S. 1 1 2 3 4 Postel-Vinay ; Villejuif, FR, Paris, FR, Villejuif, CEDEX/FR, Paris, CEDEX 5/FR
16:30 - 16:30 1704PD - Tumor microenvironment biomarkers as therapeutic strategies for TNBC 1 2 3 4 3 5 6 F. Rojo , M. Ruíz-Borrego , M. Hui , J. Trigo Perez , A. Cazet , M. Karsdal , A. Urruticoechea , S. 7 1 3 8 8 8 Antolin , J.A. García-Saenz , S. O’toole , A. Blach , L. Perez-Ramos , S. Bezares , M. Sánchez-Aragó 8 8 5 3 1 1 2 3 , R. Caballero , C. Bager , A. Swarbrick , M. Martin Jimenez ; Madrid, ES, Sevilla, ES, New South 4 5 6 7 8 Wales, AU, Malaga, ES, Herlev, DK, Barcelona, ES, Coruña, ES, San Sebastian De Los Reyes, ES
16:30 - 16:30 1705PD - Detection of therapeutic targets in carcinomas of unknown primary 1 2 2 2 2 2 1 B. Clynick , B. Dessauvagie , G. Strerrett , N. Harvey , S. Subramaniam , J. Herron , R. Allcock , B.
1 2 2 2 1 2 Guo , C. Saunder , W. Erber , K. Meehan ; Perth, AU, Perth, WA/AU
16:30 - 16:45 Invited Discussant 1703PD, 1704PD and 1705PD C. Dive, Manchester, GB
16:45 - 16:55 Q&A led by Discussant
16:55 - 16:55 3PD - New targets in triple negative breast cancer: Role of oncostatin M receptor pathway 1 1 1 2 1 1 1 M. Muñoz Caffarel , A. Araujo , C. Lawrie , I. Álvarez López , R. Rezola , A. Abaurrea ; San
2 Sebastian, ES, Donostia, ES
16:55 - 16:55 4PD - GGNBP2 suppresses tumor growth and cancer stem cell load of triple negative breast cancer by controlling STAT3 pathway J. Zhang, Tianjin, CN
16:55 - 16:55 5PD - The acquired resistance to the combination of the anti-EGFR cetuximab and the MEK-inhibitor refametinib in KRAS mutated colorectal cancer cell lines depends on PI3K-signalling 1 1 2 1 1 1 1 1 P.P. Vitiello , G. Martini , C. Cardone , D. Ciardiello , V. Belli , N. Matrone , T. Troiani , S. Napolitano 1 1 1 1 1 1 1 , V. Sforza , G. Papaccio , V. Desiderio , V. De Falco , E. Giunta , F. Morgillo , M.R. Diadema , P. 1 1 2 2 1 2 Vitale , N. Zanaletti , F. Ciardiello , E. Martinelli ; Napoli, IT, Naples, IT
16:55 - 17:10 Invited Discussant 3PD, 4PD and 5PD C. Isacke, London, GB
17:10 - 17:20 Q&A led by Discussant
17:20 - 17:20 6PD - FPA150, a novel B7-H4 therapeutic antibody with checkpoint blockade and ADCC activities 1 1 1 2 1 1 1 1 1 C. Kaplan , D. Houser , F. Kemp , N. Nielson , A. Hsu , K. Legris , G. Brattich , H. Xiang , A. Ahene ,
1 1 1 1 2 U. Jeffry , D. Bellovin , L. Borges ; San Francisco, US, Lebanon, NH/US
Last update: 02-09-2017 06:01:33pm esmo.org 17:20 - 17:20 1706PD - Analysis of stroma and immune-related gene expression patterns during breast cancer (BC) progression 1 2 3 4 5 6 L. Molinero , J. Albanell , H. Koeppen , E. Martinez de Dueñas , D. Halligan , A. Guerrero , J.I. 7 8 9 10 2 11 Chacón López-Muñiz , R. Perez , S. Antolin , I. Blancas , M. Muñoz , A. Oltra , M.H. LÓpez de 12 13 13 8 14 6 Ceballos , M. Sánchez-Aragó , R. Caballero , E. Carrasco , A.M. González-Angulo , A. Lluch , E.
14 8 1 2 3 4 Mittendorff , F. Rojo ; South San Francisco, CA/US, Barcelona, ES, South San Francisco, US, 5 6 7 8 9 10 Castellon, ES, Edinburgh, GB, Valencia, ES, Toledo, ES, Madrid, ES, Coruña, ES, Granada, 11 12 13 14 ES, Alicante, ES, CÁceres, ES, San Sebastian De Los Reyes, ES, Texas, US
17:20 - 17:20 1707PD - Orthotopic versus subcutaneous NET: tumor tissue characteristics result in different answers when ADC is used to validate early therapy response following Peptide Receptor Radionuclide Therapy (PRRT) E. Koziolek, J. Albrecht, S. Exner, V. Prasad, C. Grötzinger, W. Brenner; Berlin, DE
17:20 - 17:35 Invited Discussant 6PD, 1706PD and 1707PD D. Tuveson, New York, NY/US
17:35 - 17:45 Q&A led by Discussant
16:30 - 18:00 Type: Special Session Alicante Auditorium Title: Cost, value and assessment tools of therapies in modern oncology Chair(s): E.G.E. de Vries, NL; N. Cherny, IL
16:30 - 16:35 Introduction N. Cherny, Jerusalem, IL
16:35 - 16:50 Principles and reflections on cost, value and sustainability of anticancer therapies I. Tannock, Toronto, Ontario/CA
16:50 - 17:05 ESMO Magnitude of Clinical Benefit Scale (MCBS): New version: 1.1 N. Cherny, Jerusalem, IL
17:05 - 17:20 Integrating MCBS in ESMO Guidelines G. Pentheroudakis, Ioannina, GR
17:20 - 17:35 Implementation of the ESMO-MCBS scale E.G.E. de Vries, Cluj-Napoca, RO
17:35 - 18:00 Discussion and conclusions, led by E.G.E. de Vries, Cluj-Napoca, RO
16:30 - 18:20 Type: Presidential Symposium Madrid Auditorium Title: Presidential Symposium II
Last update: 02-09-2017 06:01:33pm esmo.org Chair(s): F. Ciardiello, IT; A. Cervantes, ES
16:30 - 16:45 236O_PR - MONARCH 3: Abemaciclib as initial therapy for patients with HR+/HER2- advanced breast cancer 1 2 3 4 5 6 7 8 A. Di Leo , M. Toi , M. Campone , J. Sohn , S. Paluch-Shimon , J. Huober , I.H. Park , O. Tredan , 9 10 11 12 13 14 15 S.-C. Chen , L. Manso , O. Freedman , G. Jaliffe , T. Forrester , M. Frenzel , S. Barriga , I. 14 16 17 1 2 3 4 Smith , N. Bourayou , M. Goetz ; Prato, IT, Kyoto, JP, Saint-Herblain, CEDEX/FR, Seoul, KR,
5 6 7 8 9 10 11 Ramat Gan, IL, Ulm, DE, Gyeonggi-Do, KR, Lyon, CEDEX/FR, Taipei, TW, Madrid, ES, 12 13 14 15 16 Oshawa, CA, Mexico City, MX, Indianapolis, IN/US, Indianapolis, US, Windlesham, GB, 17 Neuilly-Sur-seine, FR, Rochester, US
16:45 - 17:00 Invited Discussant 236O N. Turner, London, GB
17:00 - 17:15 928O_PR - Neoadjuvant chemotherapy followed by surgery (NACT-surgery) versus concurrent cisplatin and radiation therapy (CTRT) in patients with stage IB2 to IIB squamous carcinoma of cervix: A randomized controlled trial (RCT) S. Gupta, P. Parab, R. Kerkar, U. Mahantshetty, A. Maheshwari, S. Sastri, R. Engineer, R. Hawaldar, J. Ghosh, S. Gulia, S. Godbole, N. Kumar, J. Malliga, R. Dalvi, Y. Kembhavi, M. Gaikar, R. Ranade, H. Tongaonkar, R. Badwe, S. Shrivastava; Mumbai, IN
17:15 - 17:30 Invited Discussant 928O_PR D. Lorusso, Milan, IT
17:30 - 17:45 LBA4_PR - RANGE: a randomized, double-blind, placebo-controlled phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma 1 2 3 4 5 6 7 8 D. Petrylak , K. Chi , A. Drakaki , C. Sternberg , R. de Wit , H. Nishiyama , E. Yu , D. Castellano , S. 9 10 11 12 13 14 Hussain , I. Percent , A. Fléchon , A. Bamias , M. van der Heijden , N. Matsubara , B. Alekseev 15 16 16 16 16 17 1 , R. Walgren , O. Hamid , A. Zimmermann , K. Bell-Mcguinn , T. Powles ; New Haven,
2 3 4 5 6 7 8 CT/US, Vancouver, CA, Los Angeles, US, Roma, IT, Rotterdam, NL, Tsukuba, JP, Seattle, US, 9 10 11 12 13 14 Madrid, ES, Liverpool, GB, Port Charlotte, US, Lyon, FR, Athens, GR, Amsterdam, NL, 15 16 17 Kashiwa, Chiba/JP, Moscow, RU, Indianapolis, US, London, GB
17:45 - 17:55 Invited Discussant LBA4_PR Y. Loriot, Villejuif, FR
17:55 - 18:10 LBA5 - CheckMate 214: Efficacy and safety of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naïve advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups 1 2 3 4 5 6 7 B. Escudier , N. Tannir , D. McDermott , O. Frontera , B. Melichar , E. Plimack , P. Barthelemy , S. 8 9 10 11 12 13 4 George , V. Neiman , C. Porta , T. Choueiri , T. Powles , F. Donskov , P. Salman , C. 14 15 16 16 17 18 1 Kollmannsberger , B. Rini , S. Mekan , M.B. McHenry , H. Hammers , R. Motzer ; Villejuif, 2 3 4 5 6 7 FR, Houston, TX/US, Boston, MA/US, Santiago, CL, Olomouc, CZ, Philadelphia, PA/US, 8 9 10 11 12 13 Strasbourg, CEDEX/FR, Buffalo, US, Petah Tikva, IL, Pavia, IT, Boston, US, London, GB, 14 15 16 17 Aarhus C, DK, Vancouver, British Columbia/CA, Cleveland, OH/US, Princeton, NJ/US, Dallas, 18 MD/US, New York, NY/US
Last update: 02-09-2017 06:01:33pm esmo.org
18:10 - 18:20 Invited Discussant LBA5 M. Schmidinger, Vienna, AT
16:30 - 18:00 Type: Educational session Sevilla Auditorium Title: State of the art of melanoma therapy Chair(s): D. Schadendorf, DE; R. Dummer, CH
16:30 - 16:50 Is there still a role for surgery? A. Testori, Milan, IT
16:50 - 17:10 Adjuvant therapy: Still a role for interferon? A.M.M. Eggermont, Villejuif, FR
17:10 - 17:30 Targeted therapy: Still a role in 1st line? D. Schadendorf, Essen, DE
17:30 - 17:50 Immunotherapy: Still a role for ipilimumab? O. Michielin, Lausanne, CH
17:50 - 18:00 Discussion
16:30 - 18:00 Type: Educational session Pamplona Auditorium Title: Complications and toxicities: Tips for daily practice Chair(s): J. Herrstedt, DK; K. Tamura, JP
16:30 - 16:50 Skin toxicities: Prevention and management C. Robert, Villejuif, FR
16:50 - 17:10 Management of opioid induced nausea and vomiting D. Walsh, Dublin, OH/IE
17:10 - 17:30 Bone metastases: How to evaluate the fracture risk: Surgery? Cementoplasty? Radiation? H. Shibata, Akita, JP
17:30 - 17:50 Rehabilitation and nutritional support for patients with advanced cancer J. Arends, Freiburg, DE
17:50 - 18:00 Discussion
Last update: 02-09-2017 06:01:33pm esmo.org 16:30 - 17:30 Type: Multidisciplinary Session Valencia Auditorium Title: Managing colorectal cancer evolution Chair(s): A. Bardelli, IT
16:30 - 16:35 Presentation of case/condition A. Bardelli, Candiolo, (TO)/IT
16:35 - 16:45 Colorectal cancer evolution in response to treatment: Evolving intra-tumour heterogeneity A. Bardelli, Candiolo, (TO)/IT
16:45 - 16:55 Classification and molecular diagnosis of colorectal cancer: Inter-tumour heterogeneity R. Dienstmann, Barcelona, ES
16:55 - 17:05 Clinical implications of inter- and intra-tumour heterogeneity S. Tejpar, Leuven, BE
17:05 - 17:30 General Discussion
Last update: 02-09-2017 06:01:33pm esmo.org 16:30 - 18:00 Type: Proffered Paper session Tarragona Auditorium Title: Endocrine and neuroendocrine tumours Chair(s): M. Ducreux, FR; I. Chau, GB
16:30 - 16:42 427O - Pembrolizumab for patients with PD-L1–positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study 1 2 3 4 5 6 7 8 J. Mehnert , H. Rugo , B. O'Neil , A. Santoro , J. Schellens , R. Cohen , T. Doi , P. Ott , M. Pishvaian 9 10 11 12 13 14 15 16 , I. Puzanov , K. Aung , C. Hsu , C. Le Tourneau , J.-C. Soria , E. Elez , K. Tamura , M. 17 17 17 18 1 2 3 Gould , G. Zhao , K. Stein , S. Piha-Paul ; New Brunswick, US, San Francisco, CA/US,
4 5 6 7 Indianapolis, IN/US, Rozzano-Milano, IT, Amsterdam, NL, Philadelphia, PA/US, Kashiwa, Chiba/JP, 8 9 10 11 12 13 Boston, MA/US, Washington, DC/US, Buffalo, NY/US, Toronto, NB/CA, Taipei, TW, Paris, 14 15 16 17 18 FR, Villejuif, FR, Barcelona, ES, Tokyo, JP, Kenilworth, NJ/US, Houston, TX/US
16:42 - 16:54 428O - Immune landscape of pancreatic neuroendocrine tumours (PanNETs) 1 2 2 2 3 2 1 K. Young , C. Ragulan , G. Nyamundanda , Y. Patil , R. Lawlor , D. Cunningham , N. Starling , A.
3 2 1 2 3 Scarpa , A. Sadanandam ; London, GB, Sutton, GB, Verona, IT
16:54 - 17:06 429O - A phase II trial of palbociclib in metastatic grade 1/2 pancreatic neuroendocrine tumors: The PALBONET study on behalf of the Spanish Taskforce Group of Neuroendocrine Tumors (GETNE) 1 2 1 3 4 2 E. Grande Pulido , A. Teule , T. Alonso-Gordoa , P. Jiménez-Fonseca , M. Benavent , J. Capdevila , 1 5 6 7 1 1 2 A. Custodio , R. Vera , J. Munarriz , A. La Casta-Muñoa , R. Garcia-Carbonero ; Madrid, ES, 3 4 5 6 7 Barcelona, ES, Oviedo, ES, Sevilla, ES, Pamplona, ES, Castellón, ES, San Sebastian, ES
17:06 - 17:21 Invited Discussant 427O, 428O and 429O I. Chau, Sutton, Surrey/GB
17:21 - 17:33 430O - Different RNA expression profile defines prognosis in grade 1/2 neuroendocrine neoplasms of small intestine origin: The GETNE-NETSEQ study 1 1 1 1 2 2 J. Capdevila , F. Mancuso , S. Landolfi , F. Salva , C. Miguel , P. Jiménez-Fonseca , R. 3 4 1 1 1 1 Garcia-Carbonero , C. López López , A. Casteras , T. Sauri Nadal , P. Nuciforo , A. Vivancos , I. 1 1 2 3 4 Matos ; Barcelona, ES, Oviedo, ES, Madrid, ES, Santander, ES
17:33 - 17:45 431O - Genomic subtypes of pulmonary large cell neuroendocrine carcinoma (LCNEC) may predict chemotherapy outcome 1 2 3 4 5 6 4 J. Derks , N. Leblay , R.J. van Suylen , E. Thunnissen , M. den Bakker , H.J.M. Groen , E. Smit , R. 7 7 2 2 2 2 1 Damhuis , E. van den Broek , A. Charbrier , M. Foll , J. McKay , L. Fernandez-Cuesta , E.-J. Speel ,
1 1 2 3 4 5 A.-M. Dingemans ; Maastricht, NL, Lyon, FR, S'hertogenbosch, NL, Amsterdam, NL, Rotterdam, 6 7 NL, Groningen, NL, Utrecht, NL
17:45 - 18:00 Invited Discussant 430O and 431O M. Cives, Tampa, FL/US
Last update: 02-09-2017 06:01:33pm esmo.org 16:30 - 18:30 Type: Special Session Salamanca Title: 4th ESMO Integrated Oncology & Palliative Care Community Session and Auditorium Awards Chair(s): F. Strasser, CH; G. Kreye, AT
16:30 - 16:35 Introduction and current developments in cancer palliative care F. Strasser, St. Gallen, CH
16:35 - 16:45 Proactive Referral to Palliative Care: Model of a new Integrated Palliative Care and Oncology Service J. Wood, London, GB
16:45 - 16:50 Discussion
16:50 - 17:00 2017 WHO Cancer Resolution: Timely access, treatment and Palliative Care A. Ilbawi, Geneva, CH
17:00 - 17:05 Discussion
17:05 - 17:20 What does ESMO offer in Palliative Care R. Canario, Porto, PT
17:20 - 17:30 Invited discussion on selected abstracts from ESMO 2017 produced in ESMO Designated Centres of Integrated Oncology & Palliative Care G. Kreye, Krems, AT
17:30 - 18:00 Audience discussion
18:00 - 18:05 Conclusions F. Strasser, St. Gallen, CH
18:05 - 18:30 Designated Centre and Palliative Care Fellowship Awards 1 2 1 2 F. Strasser , G. Kreye ; St. Gallen, CH, Krems, AT
Last update: 02-09-2017 06:01:33pm esmo.org 16:45 - 17:45 Type: Controversy session Granada Title: Single agent or combination chemotherapy in the adjuvant therapy for pancreatic Auditorium cancer Chair(s): T. Seufferlein, DE
16:45 - 16:55 Introduction and 1st vote T. Seufferlein, Ulm, DE
16:55 - 17:15 Monotherapy M. Hidalgo, Madrid, ES
17:15 - 17:35 Combination T. Conroy, Vandoeuvre Les Nancy, CEDEX/FR
17:35 - 17:45 2nd vote and conclusions T. Seufferlein, Ulm, DE
17:30 - 18:30 Type: Young Oncologist Vesalius Talk Foyer Ibiza Title: How active participation in ESMO has impacted my career Chair(s): C. Zielinski, AT
17:30 - 17:35 Introduction C. Zielinski, Vienna, AT
17:35 - 18:00 Discussion 1 2 3 1 2 3 E. Martinelli , R. Califano , E. De Azambuja ; Naples, IT, Manchester, GB, Brussels, BE
Last update: 02-09-2017 06:01:33pm esmo.org 18:00 - 19:30 Type: Patient Advocacy Track Palma Auditorium Title: Rare cancers: More common than you think, more difficult to serve Chair(s): K. Oliver, GB; J.-Y. Blay, FR
18:00 - 18:15 The EURORDIS table: Similarities and differences of rare cancers and rare diseases K. Oliver, GB
18:15 - 18:30 Joint actions on rare cancers P.G. Casali, Milan, IT
18:30 - 18:45 What EUROCAN, the European Reference Network for Rare Cancers, will do for patients J.-Y. Blay, Lyon, FR
18:45 - 19:00 The importance of adaptive pathways in rare cancers F. Pignatti, London, GB
19:00 - 19:30 Discussion
18:30 - 20:00 Type: Industry Satellite Symposium Sevilla Auditorium Title: Industry Satellite Symposium 35
18:30 - 20:00 Type: Industry Satellite Symposium Pamplona Auditorium Title: Industry Satellite Symposium 36
18:30 - 20:00 Type: Industry Satellite Symposium Cordoba Auditorium Title: Industry Satellite Symposium 37
18:30 - 20:00 Type: Industry Satellite Symposium Granada Auditorium Title: Industry Satellite Symposium 38
18:30 - 20:00 Type: Industry Satellite Symposium Valencia Auditorium Title: Industry Satellite Symposium 39
18:30 - 20:00 Type: Industry Satellite Symposium Tarragona Auditorium Title: Industry Satellite Symposium 40
18:30 - 20:00 Type: Industry Satellite Symposium Bilbao Auditorium Title: Industry Satellite Symposium 41
11-09-2017
Last update: 02-09-2017 06:01:33pm esmo.org 08:00 - 09:00 Type: Challenge Your Expert (CYE) session Valencia Auditorium Title: Liver dominant disease Chair(s): G. Folprecht, DE
08:00 - 08:10 Liver dominant disease R. Adam, Paris, FR
08:10 - 09:00 Discussion led by Chair G. Folprecht, Dresden, DE
08:00 - 09:00 Type: Challenge Your Expert (CYE) session Tarragona Auditorium Title: Do we need to test for PD-L1 and how do we choose? Chair(s): M. Reck, DE
08:00 - 08:10 Do we need to test for PD-L1 and how do we choose? K. Kerr, Aberdeen, GB
08:10 - 09:00 Discussion led by Chair M. Reck, Grosshansdorf, DE
08:00 - 09:00 Type: Challenge Your Expert (CYE) session Bilbao Auditorium Title: How to best manage oligometastatic disease Chair(s): R. Rouzier, FR
08:00 - 08:10 How to best manage oligometastatic disease F. Cardoso, Lisbon, PT
08:10 - 09:00 Discussion led by Chair R. Rouzier, Paris, FR
08:00 - 09:00 Type: Challenge Your Expert (CYE) session Alicante Title: Gut microbiota: Will it help to improve immunotherapy in haematological Auditorium malignancies? Chair(s): C. Robert, FR
08:00 - 08:10 Gut microbiota: Will it help to improve immunotherapy in haematological malignancies? T. Gajewski, Chicago, Il, US
08:10 - 09:00 Discussion led by Chair C. Robert, Villejuif, FR
Last update: 02-09-2017 06:01:33pm esmo.org 08:00 - 09:00 Type: Challenge Your Expert (CYE) session Cartagena Auditorium Title: Management of elderly patients with head and neck cancer Chair(s): J. Guigay, FR
08:00 - 08:10 Management of elderly patients with head and neck cancer J. Langendijk, Groningen, NL
08:10 - 09:00 Discussion led by Chair J. Guigay, Nice, CEDEX 2/FR
08:00 - 09:00 Type: Challenge Your Expert (CYE) session Salamanca Auditorium Title: The new EU clinical trials and data protection regulations Chair(s): C. Dittrich, AT
08:00 - 08:10 The new EU clinical trials and data protection regulations A. Negrouk, Brussels, BE
08:10 - 09:00 Discussion led by Chair C. Dittrich, Vienna, AT
08:15 - 09:00 Type: Keynote Lecture Barcelona Auditorium Title: Does immunotherapy cure advanced cancer? Chair(s): I.-M. Svane, DK
08:15 - 09:00 Does immunotherapy cure advanced cancer? J. Haanen, Amsterdam, NL
Last update: 02-09-2017 06:01:33pm esmo.org 09:15 - 10:45 Type: Proffered Paper session Barcelona Auditorium Title: NSCLC, metastatic 2 Chair(s): T. Reungwetwattana, TH; L. Paz-Ares, ES
09:15 - 09:30 LBA50 - Overall Survival (OS) for First-Line Crizotinib Versus Chemotherapy in ALK+ Lung Cancer: Updated Results from PROFILE 1014 1 2 3 4 5 6 7 8 T. Mok , D.-W. Kim , Y.-L. Wu , K. Nakagawa , T. Mekhail , E. Felip , F. Cappuzzo , J. Paolini , T. 8 9 10 11 1 2 3 4 Usari , K. Wilner , F. Blackhall , B. Solomon ; Hong Kong, CN, Seoul, KR, Guangzhou, CN,
5 6 7 8 9 10 Osaka, JP, Orlando, US, Barcelona, ES, Ravenna, IT, Milan, IT, San Diego, CA/US, 11 Manchester, GB, Melbourne, VIC/AU
09:30 - 09:45 1298O_PR - Alectinib vs crizotinib in treatment-naïve ALK+ NSCLC: CNS efficacy results from the ALEX study 1 2 3 4 5 6 7 8 S. Gadgeel , S. Peters , T. Mok , A. Shaw , D.-W. Kim , S.-H.I. Ou , M. Perol , R. Dziadziuszko , J.S. 5 9 10 10 10 10 11 1 Ahn , R. Rosell , A. Zeaiter , E. Mitry , E. Nueesch , B. Balas , R. Camidge ; Ann Arbor,
2 3 4 5 6 7 MI/US, Lausanne, CH, New Territories, HK, Boston, MA/US, Seoul, KR, Orange, US, Lyon, 8 9 10 11 CEDEX/FR, Gdansk, PL, Badalona, Barcelona/ES, Basel, CH, Aurora, CO/US
09:45 - 10:00 1299O_PR - Primary results from the phase III ALUR study of alectinib versus chemotherapy in previously treated ALK+ non-small-cell lung cancer (NSCLC) 1 2 3 4 5 6 7 S. Novello , J. Mazieres , I.-J. Oh , J. de Castro , M. Migliorino , A. Helland , R. Dziadziuszko , F. 8 9 9 9 9 9 9 10 Griesinger , A. Kotb , A. Zeiter , A. Cardona , B. Balas , H. Johannsdottir , A. Das-Gupta , J. Wolf ;
1 2 3 4 5 6 7 8 Torino, IT, Toulouse, FR, Hwasun, KR, Madrid, ES, Rome, IT, Oslo, NO, Gdansk, PL, 9 10 Oidenburg, DE, Basel, CH, Köln, DE
10:00 - 10:20 Invited Discussant LBA50, 1298O and 1299O L. Paz-Ares, Madrid, ES
10:20 - 10:35 LBA51 - Phase 2 Trial (BRF113928) of Dabrafenib (D) Plus Trametinib (T) in Patients (pts) With Previously Untreated BRAF V600E–Mutant Metastatic Non-Small Cell Lung Cancer (NSCLC) 1 2 3 4 1 5 6 D. Planchard , E. Smit , H.J.M. Groen , J. Mazieres , B. Besse , Å. Helland , V. Giannone , A. 6 7 8 9 1 2 3 4 D'Amelio , P. Zhang , B. Mookerjee , B. Johnson ; Villejuif, FR, Amsterdam, NL, Groningen, NL, 5 6 7 8 9 Toulouse, FR, Oslo, NO, East Hanover, NJ/US, East Hanover, US, New Jersey, US, Boston, NJ/US
10:35 - 10:45 Invited discussant LBA51 O.T. Brustugun, Oslo, NO
Last update: 02-09-2017 06:01:33pm esmo.org 09:15 - 10:45 Type: Special Symposium Sevilla Auditorium Title: Immunobiology in prostate cancer Chair(s): A. Alimonti, CH; H. Beltran, US
09:15 - 09:20 Introduction H. Beltran, New York, NY/US
09:20 - 09:40 Basic immunobiology in prostate cancer A. Alimonti, Bellinzona, CH
09:40 - 10:00 Immunogenomics and prostate cancer J. de Bono, London, GB
10:00 - 10:20 Vaccination in prostate cancer J. Gulley, Bethesda, Md, US
10:20 - 10:40 Checkpoint inhibitors in prostate cancer W. Gerritsen, Nijmegen, NL
10:40 - 10:45 Conclusions & clinical perspectives H. Beltran, New York, NY/US
09:15 - 10:45 Type: Special Symposium Cordoba Auditorium Title: Are grade III / IV toxicities the only ones that matter? Chair(s): M. Aapro, CH; S. Kaasa, NO
09:15 - 09:20 Introduction S. Kaasa, Oslo, NO
09:20 - 09:40 Why do grade I/II toxicities matter B. Seruga, Ljubljana, SI
09:40 - 10:00 What toxicities matter to the patients C. Roffiaen, Milan, IT
10:00 - 10:20 How does EMA look at toxicity/benefit ratios in cancer treatment F. Pignatti, London, GB
10:20 - 10:40 Drug interactions that matter T. Lembrecht Jørgensen, Odense, DK
10:40 - 10:45 Conclusions and perspectives M. Aapro, Genolier, CH
Last update: 02-09-2017 06:01:33pm esmo.org 09:15 - 10:45 Type: Educational session Granada Auditorium Title: B cell receptor as a therapeutic target Chair(s): A. Ferreri, IT; L. De La Cruz Merino, ES
09:15 - 09:40 Diagnosis and classification of the pathologic subtypes of large B cell lymphoma: Immunophenotyping, gene expression profiling and mutational analyses S. Montes, Santander, ES
09:40 - 10:05 Current therapies against B cell receptor A. Ferreri, Milan, IT
10:05 - 10:30 Overcoming resistance in B cell receptor therapeutics S. Rule, Plymouth, GB
10:30 - 10:45 Discussion
09:15 - 10:45 Type: Poster Discussion session Bilbao Auditorium Title: Immunotherapy of cancer Chair(s): P. Nathan, GB; F. Thistlethwaite, GB
09:15 - 09:15 1138PD - Immune checkpoint inhibitor (ICPI) efficacy and resistance detected by comprehensive genomic profiling (CGP) in non-small cell lung cancer (NSCLC) 1 2 2 3 4 2 2 2 J. Ross , M. Goldberg , L. Albacker , L. Gay , V. Agarwala , J. Elvin , J.-A. Vergilio , J. Suh , S. 2 2 2 2 5 2 5 2 Ramkissoon , E. Severson , S. Daniel , S. Ali , A. Schrock , G. Frampton , D. Fabrizio , V. Miller , G.
5 4 2 1 2 3 4 Singal , A. Abernethy , P. Stephens ; Albany, NY/US, Cambridge, MA/US, Cambridge, CA, New 5 York, US, Cambridge, US
09:15 - 09:15 1139PD - Analyzing biomarkers of cancer immunotherapy (CIT) response using a real-world clinico-genomic database 1 2 3 1 3 4 4 1 3 G. Singal , P. Miller , V. Agarwala , G. Li , A. Gossai , L. Albacker , M. Goldberg , J. He , S. Frank , 4 3 1 3 1 1 4 4 5 D. Bourque , I. Ivanov , D. Fabrizio , T. Caron , A. Parker , A. Guria , V. Miller , J. Elvin , J. Ross , A. 3 4 1 2 3 4 5 Abernethy , P. Stephens ; Cambridge, US, Boston, US, New York, US, Cambridge, MA/US, Albany, NY/US
09:15 - 09:15 1140PD - Predictive biomarkers for hyper-progression (HP) in response to immune checkpoint inhibitors (ICI) – analysis of somatic alterations (SAs) 1 2 1 2 1 2 2 2 A. Singavi , S. Menon , D. KILARI , A. Alqwasmi , P. Ritch , J. Thomas , A. Martin , C. Oxencis , S.
3 2 1 2 3 Ali , B. George ; Milwaukee, US, Milwaukee, WI/US, Cambridge, US
09:15 - 09:30 Invited Discussant 1138PD, 1139Pd and 1140PD C. Blank, Amsterdam, NL
09:30 - 09:40 Q&A led by Discussant
Last update: 02-09-2017 06:01:33pm esmo.org
09:40 - 09:40 1141PD - CA-170, a first in class oral small molecule dual inhibitor of immune checkpoints PD-L1 and VISTA, demonstrates tumor growth inhibition in pre-clinical models and promotes T cell activation in Phase 1 study 1 2 3 4 5 6 7 J. Powderly , M. Patel , J. Lee , J. Brody , F. Meric-Bernstam , E. Hamilton , S. Ponce Aix , J. 8 9 9 9 9 8 10 Garcia-Corbacho , Y.-J. Bang , M.-J. Ahn , S.Y. Rha , K.-P. Kim , M. Gil Martin , H. Wang , A. 11 12 11 13 14 15 1 2 Lazorchak , T. Wyant , A. Ma , S. Agarwal , D. Tuck , A. Daud ; Huntersville, US, Sarasota,
3 4 5 6 7 8 FL/US, Pitsburgh, PA/US, New York, US, Houston, US, Nashville, TN/US, Madrid, ES, Barcelona, 9 10 11 12 13 14 ES, Seoul, KR, Bridgewater, NJ/US, Lexington, MA/US, Lexington, US, Waltham, MA/US, 15 New York, Massachusetts/US, San Francisco, US
09:40 - 09:40 1142PD - Safety, pharmacokinetics (PK) and pharmacodynamics (PD) data from a phase I dose-escalation study of OX40 agonistic monoclonal antibody (mAb) PF-04518600 (PF-8600) in combination with utomilumab, a 4-1BB agonistic mAb 1 2 3 1 4 5 6 7 O. Hamid , W. Ros , J. Thompson , S. Hu-Lieskovan , F. Eskens , A. Diab , T. Doi , J. Wasser , J.-P. 8 9 10 11 12 13 14 15 Spano , N. Rizvi , E. Angevin , A. Chiappori , P. Ott , B. Ganguly , C. Fleener , V. Dell , K. 15 15 16 1 1 2 3 Liao , T. Joh , J. Chou , A. El-Khoueiry ; Los Angeles, CA/US, Amesterdam, NL, Seattle,
4 5 6 7 8 WA/US, Rotterdam, NL, Houston, US, Kashiwa, Chiba/JP, Farmington, CT/US, Paris, CEDEX 9 10 11 12 13 13/FR, New York, Ny, US, Villejuif, CEDEX/FR, Tampa, FL/US, Boston, MA/US, South San 14 15 16 Francisco, US, Groton, US, La Jolla, US, South San Francisco, CA/US
09:40 - 09:40 1143PD - Dose-finding combination study of niraparib and pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC) or recurrent platinum-resistant epithelial ovarian cancer (OC) (TOPACIO/Keynote-162) 1 2 3 1 4 4 4 P. Konstantinopoulos , J. Sachdev , L. Schwartzberg , U. Matulonis , P. Sun , J.Y. Wang , W. Guo , 4 5 5 6 7 1 2 3 D. Bobilev , G. Aktan , V. Karantza , B. Dezube , S. Vinayak ; Boston, MA/US, Scottsdale, US, 4 5 6 7 Memphis, TN/US, Waltham, MA/US, Kenilworth, NJ/US, Waltham, US, Cleveland, OH/US
09:40 - 09:55 Invited Discussant 1141PD, 1142PD and 1143PD P. Nathan, Northwood, Middlesex/GB
09:55 - 10:05 Q&A led by Discussant
10:05 - 10:05 1145PD - Adoptive cell therapy with tumor-infiltrating lymphocytes for patients with metastatic ovarian cancer: A pilot study 1 2 2 2 2 2 3 M. Pedersen , M. Westergaard , M. Nielsen , T. Borch , L. Poulsen , H. Hendel , T. Juhler-Nøttrup ,
2 2 2 1 2 3 Ö. Met , M. Donia , I.-M. Svane ; Copenhagen, DK, Herlev, DK, Copenhagen Ø, DK
10:05 - 10:05 1146PD - Adjuvant therapy with autologous dendritic cell (DC) vaccine based on cancer-testis antigens (CaTeVac) in melanoma patients 1 2 3 1 1 1 1 A. Novik , I. Baldueva , S. Protsenko , T. Nehaeva , A. Danolova , N. Pipia , N. Olisova , M.
1 1 1 2 3 Kornienko , T. Danilova ; Saint Petersburg, RU, St. Petersburg, RU, Saint-Petersburg, RU
10:05 - 10:20 Invited Discussant 1144PD, 1145PD and 1146PD F. Thistlethwaite, Manchester, GB
Last update: 02-09-2017 06:01:33pm esmo.org
10:20 - 10:30 Q&A led by Discussant
10:30 - 10:30 1147PD - Germline determinants of immune related adverse events (irAEs) in melanoma immunotherapy response 1 2 2 1 2 2 2 T. Kirchhoff , R. Ferguson , D. Simpson , E. Kazlow , C. Martinez , M. Vogelsang , M. Wilson , A.
2 2 2 1 2 Pavlick , J. Weber , I. Osman ; New York, NY/US, New York, US
10:30 - 10:30 1148PD - Immunotherapy in patients with concurrent solid organ transplant, HIV, and Hepatitis B and C 1 2 3 4 5 6 7 1 8 R. Rai , O. Ezeoke , J. McQuade , L. Zimmer , C. Koo , J. Park , L. Ardolino , D. Yip , S. Goldinger , 9 10 11 7 12 13 14 J. Cohen , M. Millward , V. Atkinson , A. Kane , P. Ascierto , C. Garbe , R. Gutzmer , D. 15 2 16 17 1 2 3 Johnson , M. Hellman , G. Long , A. Menzies ; Garran, ACT/AU, New York, NY/US, Houston,
4 5 6 7 8 9 TX/US, Duisburg, DE, Melbourne, VIC/AU, Westmead, AU, Sydney, NSW/AU, Zürich, CH, 10 11 12 13 14 Boston, MA/US, Nedlands, WA/AU, Woolloongabba, AU, Napoli, IT, Tübingen, DE/DE, 15 16 17 Hannover, DE, Nashville, TN/US, Sydney, AU, North Sydney, AU
10:30 - 10:40 Invited Discussant 1147PD and 1148PD J. Haanen, Amsterdam, NL
10:40 - 10:45 Q&A led by Discussant
Last update: 02-09-2017 06:01:33pm esmo.org 09:15 - 10:45 Type: Proffered Paper session Madrid Auditorium Title: Gastrointestinal tumours, colorectal 2 Chair(s): J. Taieb, FR; C.-H. Koehne, DE
09:15 - 09:30 486O - Sequential first-line therapy of metastatic colorectal cancer (mCRC) starting with fluoropyrimidine (FP) plus bevacizumab (BEV) vs. initial FP plus irinotecan (IRI) and BEV: German AIO KRK0110 (ML22011) study 1 2 3 4 5 6 D. Modest , L. Fischer von Weikersthal , T. Decker , U. Vehling-Kaiser , J. Uhlig , M. Schenk , J. 7 8 9 10 11 Freiberg-Richter , B. Peuser , C. Denzlinger , C. Peveling Genannt Reddemann , U. Graeven , G. 12 12 1 13 10 1 1 Schuch , I. Schwaner , A. Stahler , A. Jung , S. Held , S. Stintzing , C. Giessen-Jung , V.
1 1 2 3 4 5 6 Heinemann ; Munich, DE, Amberg, DE, Ravensburg, DE, Landshut, DE, No City Provided, NA, 7 8 9 10 11 Regensburg, DE, Dresden, DE, Leipzig, DE, Stuttgart, DE, Leverkusen, DE, Mönchengladbach, 12 13 DE, Berlin, DE, München, DE
09:30 - 09:45 478O - Efficacy and safety of Sym004 in refractory metastatic colorectal cancer with acquired resistance to anti-EGFR therapy: Results of a randomized phase II study (RP2S) 1 2 1 3 4 5 6 J. Tabernero , F. Ciardiello , C. Montagut , C. Ding , S. Kopetz , T. Tuxen Poulsen , A. Bardelli , L. 7 8 1 9 10 11 12 13 Wyrwicz , A. Cubillo , C. Santos , G. Fumi , V. Zagonel , J. Bennouna , S. Siena , A. Falcone , 14 1 15 5 16 1 2 3 M. Benavent , G. Argiles , M. Kragh , I. Horak , M. Dvorkin ; Barcelona, ES, Naples, IT, 4 5 6 7 8 Somerville, New Jersey, US, Houston, US, Ballerup, DK, Candiolo, (TO)/IT, Warsaw, PL, Madrid, 9 10 11 12 13 14 15 16 ES, Terni, IT, Padova, IT, Nantes, CEDEX/FR, Milan, IT, Pisa, IT, Sevilla, ES, -, DK, Omsk, RU
09:45 - 10:00 Invited Discussant 486O and 478O C.-H. Koehne, Oldenburg, DE
10:00 - 10:15 479O - Consensus molecular subtypes (cms) as predictors of benefit from bevacizumab in first line treatment of metastatic colorectal cancer: Retrospective analysis of the MAX clinical trial 1 2 3 4 5 6 7 8 J. Mooi , P. Wirapati , R. Asher , C. Lee , P. Savas , T. Price , S. Tejpar , J. Mariadason , N. Tebbutt 8 1 2 3 4 5 6 ; Heidelberg, AU, Lausanne, CH, Sydney, NSW/AU, Kogarah, NSW/AU, Melbourne, VIC/AU, 7 8 Woodville, SA/AU, Leuven, BE, Heidelberg, VIC/AU
10:15 - 10:30 480O - Prognostic value of methylator phenotype in stage III colon cancer treated with oxaliplatin-based adjuvant chemotherapy 1 1 1 2 3 1 4 5 C. Gallois , J. Taieb , D. Le Corre , K. Le Malicot , J. Tabernero , C. Mulot , J.-F. Seitz , T. Aparicio , 6 7 8 9 10 1 1 2 G. Folprecht , C. Lepage , E. Mini , J.-L. Van Laethem , J.F. Emile , P. Laurent-Puig ; Paris, FR,
3 4 5 6 7 Dijon, FR, Barcelona, ES, Marseille, CEDEX 5/FR, Bobigny, CEDEX/FR, Dresden, DE, Dijon, 8 9 10 Cedex/FR, Firenze, IT, Brussels, BE, Boulogne-Billancourt, FR
10:30 - 10:45 Invited Discussant 479O and 480O A. Falcone, Pisa, IT
Last update: 02-09-2017 06:01:33pm esmo.org 09:15 - 10:45 Type: Joint Symposium Tarragona Auditorium Title: ESMO-SEOM: Integrating biomarkers into oncology Chair(s): F. Ciardiello, IT; M. Martin Jimenez, ES
09:15 - 09:20 Introduction M. Martin Jimenez, Madrid, ES
09:20 - 09:40 General vision of biomarkers in oncology: Design of clinical studies for biomarker discovery J.L. Perez Gracia, Pamplona, ES
09:40 - 10:00 Biomarkers in breast cancer A. Prat, Barcelona, ES
10:00 - 10:20 Biomarkers in lung cancer S. Peters, Lausanne, CH
10:20 - 10:40 Biomarkers in unknown origin cancer M. Esteller, Barcelona, ES
10:40 - 10:45 Conclusions F. Ciardiello, Naples, IT
09:30 - 10:30 Type: Multidisciplinary Session Pamplona Auditorium Title: Treatment of young women with breast cancer Chair(s): O. Pagani, CH
09:30 - 09:35 Presentation of case/condition O. Pagani, Bellinzona, CH
09:35 - 09:45 Issues on systemic treatment O. Pagani, Bellinzona, CH
09:45 - 09:55 Issues on genetics S. Delaloge, Villejuif, FR
09:55 - 10:05 Issues on fertility F. Peccatori, Milan, IT
10:05 - 10:30 General Discussion
Last update: 02-09-2017 06:01:33pm esmo.org 09:30 - 10:30 Type: Special Session Valencia Auditorium Title: Overcoming drug resistance Chair(s): U. McDermott, GB; R. Marais, GB
09:30 - 09:50 Genome-wide genetic screens: Defining and overcoming the drug resistance landscape U. McDermott, Cambridge, GB
09:50 - 10:10 Cancer evolution as a therapeutic target A. Bardelli, Candiolo, (TO)/IT
10:10 - 10:30 Cell context, mutation and treatment response across ovarian cancer subtypes D. Huntsman, Vancouver, British Columbia/CA
09:30 - 10:30 Type: Challenge Your Expert (CYE) session Alicante Auditorium Title: Integration of molecular imaging into drug development Chair(s): U. Banerji, GB
09:30 - 09:40 Integration of molecular imaging into drug development E.G.E. de Vries, Cluj-Napoca, RO
09:40 - 10:30 Discussion led by Chair U. Banerji, Sutton, Surrey/GB
09:30 - 10:30 Type: Challenge Your Expert (CYE) session Salamanca Auditorium Title: Management of typical and atypical lung neuroendocrine tumours Chair(s): M. Pavel, DE
09:30 - 09:40 Management of typical and atypical lung neuroendocrine tumours M. Caplin, London, GB
09:40 - 10:30 Discussion led by Chair M. Pavel, Berlin, DE
Last update: 02-09-2017 06:01:33pm esmo.org 09:30 - 10:30 Type: Young Oncologist Special session Room 1&2 Title: Your choice of career path in oncology Chair(s): L. Poulsen, US
09:30 - 09:30 Topic 1 - Table 1: Clinical oncology and palliative care S. Rauh, Esch Sur Alzette, LU
09:30 - 09:30 Topic 1 - Table 2: Clinical oncology and palliative care M. Strijbos, Brasschaat, BE
09:30 - 09:30 Topic 2 - Table 1: Clinical and translational research F. Cardoso, Lisbon, PT
09:30 - 09:30 Topic 2 - Table 2: Clinical and translational research G. Argilés Martinez, Barcelona, ES
09:30 - 09:30 Topic 3 - Table 1: Industry as a career path E. Mitry, Basel, CH
09:30 - 09:30 Topic 3 - Table 2: Industry as a career path S. Maier, Plainsboro, US
09:30 - 09:30 Topic 4 - Table 1: Basic science W. Berger, Vienna, AT
09:30 - 09:30 Topic 4 - Table 2: Basic science E. Høgdall, Copenhagen, DK
Last update: 02-09-2017 06:01:33pm esmo.org 11:00 - 12:30 Type: Special Symposium Barcelona Title: Impact of tumour heterogeneity on precision medicine in kidney and bladder Auditorium cancers Chair(s): L. Albiges, FR; C. Porta, IT
11:00 - 11:05 Introduction C. Porta, Pavia, IT
11:05 - 11:25 What is the current status of precision medicine C. Massard, Villejuif, FR
11:25 - 11:45 The impact of tumour heterogeneity on precision medicine M. Gerlinger, London, GB
11:45 - 12:05 Is genomic classification going to help in RCC? L. Albiges, Villejuif, CEDEX/FR
12:05 - 12:25 Is genomic classification going to help in bladder cancer? J. Bellmunt, Boston, Ma, US
12:25 - 12:30 Conclusions and clinical perspectives L. Albiges, Villejuif, CEDEX/FR
Last update: 02-09-2017 06:01:33pm esmo.org 11:00 - 12:30 Type: Proffered Paper session Madrid Auditorium Title: Immunotherapy of cancer Chair(s): I.-M. Svane, DK; T. Powles, GB
11:00 - 11:15 1144O - Phase III randomized controlled trial of adjuvant chemoimmunotherapy in patients with resected primary lung cancer 1 2 3 3 3 1 2 3 H. Kimura , Y. Matsui , T. Nakajima , T. Iizasa , A. Ishikawa ; Chiba, JP, Nitona-Cho -, Chiba, JP, Chu-O-ku,chiba, JP
11:15 - 11:30 1135O - Phase 1b/2 Study (SCORES) assessing safety, tolerability, and preliminary anti-tumor activity of durvalumab plus AZD9150 or AZD5069 in patients with advanced solid malignancies and squamous cell carcinoma of the head and neck (SCCHN) 1 2 3 2 4 5 6 E. Cohen , D. Hong , T. Wise Draper , W. Nassib William , D. Schrijvers , R. Mesia Nin , M. Scott , P. 6 6 6 6 6 7 1 2 Lyne , G. Mugundu , P. McCoon , C. Cook , M. Mehta , U. Keilholz ; La Jolla, IL/US, Houston, US, 3 4 5 6 7 Cincinnati, US, Antwerp, BE, Barcelona, ES, Waltham, US, Berlin, DE
11:30 - 11:45 Invited Discussant 1144O and 1135O T. Powles, London, GB
11:45 - 12:00 1136O - Nivolumab and ISA 101 HPV vaccine in incurable HPV-16+ cancer 1 2 3 3 3 3 3 3 B. Glisson , E. Massarelli , W. William , F. Johnson , M. Kies , R. Ferrarotto , M. Guo , S.A. Peng , 3 3 3 3 3 3 3 J.J. Lee , H. Tran , Y. Kim , C. Haymaker , C. Bernatchez , M. Curran , B. Sanchez Espiridion , J.
3 3 4 3 4 1 2 Rodriguez Canales , I. Wistuba , S. van der Burg , J. Wang , C. Melief ; Houston, US, Duarte, 3 4 CA/US, Houston, TX/US, Leiden, NL
12:00 - 12:15 1137O - Interim analysis of the phase 3 ADAPT trial evaluating rocapuldencel-T (AGS-003), an individualized immunotherapy for the treatment of newly-diagnosed patients with metastatic renal cell carcinoma (mRCC) 1 2 3 4 5 6 7 2 R. Figlin , C. Nicolette , N. Tannir , S. Tykodi , D. Chen , V. Master , B. Lane , M. Debenedette , T. 2 2 2 8 1 2 3 4 Monesmith , W. Tan , S. Leland , C. Wood ; Los Angeles, US, Durham, US, Houston, TX/US, 5 6 7 8 Seattle, WA/US, Philadelphia, US, Atlanta, US, Grand Rapids, US, Houston, US
12:15 - 12:30 Invited Discussant 1136O and 1137O H. Gogas, Athens, Attiki/GR
Last update: 02-09-2017 06:01:33pm esmo.org 11:00 - 12:00 Type: Multidisciplinary Session Sevilla Auditorium Title: Synchronous liver metastases in rectal cancer: Which treatment first? Chair(s): R. Glynne-Jones, GB
11:00 - 11:05 Presentation of case/condition R. Glynne-Jones, Northwood, Middlesex/GB
11:05 - 11:15 The radiation therapy perspective R. Glynne-Jones, Northwood, Middlesex/GB
11:15 - 11:25 The surgical oncology perspective T. Gruenberger, Vienna, AT
11:25 - 11:35 The medical oncology perspective P. Pfeiffer, Odense C, DK
11:35 - 12:00 General Discussion
11:00 - 12:15 Type: Poster Discussion session Pamplona Auditorium Title: Melanoma and other skin tumours Chair(s): D. Schadendorf, DE; C. Hoeller, AT; S. Goldinger, CH
11:00 - 11:00 1217PD - Comprehensive genomic profiling (CGP) and tumor mutational burden (TMB) assessment in subtypes of metastatic melanoma 1 1 2 2 2 2 2 2 J. Ross , J. Carlson , J. Elvin , J.-A. Vergilio , J. Suh , S. Ramkissoon , E. Severson , S. Daniel , S. 2 3 2 2 2 2 2 4 1 Ali , A. Schrock , D. Fabrizio , G. Frampton , V. Miller , P. Stephens , L. Gay , D. Johnson ; Albany, 2 3 4 NY/US, Cambridge, MA/US, Cambridge, US, Nashville, TN/US
11:00 - 11:00 1218PD - Precision medicine for the treatment of metastatic uveal melanoma: A pilot study S. Leyvraz, M. Schuette, D. Rieke, T. Kessler, S. Ochsenreither, V. Amstislavskiy, T. Risch, C. Wierling, K. Joehrens, C.A. Peuker, M. Lamping, S. Burock, G. Poch, F. Kiecker, R. Schaefer, B. Lange, H. Lehrach, A. Joussen, U. Keilholz, M.-L. Yaspo; Berlin, DE
11:00 - 11:00 1219PD - Combined radiofrequency ablation and ipilimumab in uveal melanoma: Results from the SECIRA-UM trial 1 1 1 1 1 1 1 E. Rozeman , W. Prevoo , M. Meier , K. Sikorska , B. van de Wiel , A. Broeks , H. van Tinteren , E.
2 1 1 1 1 2 Kapiteijn , J. Thienen , J. Haanen , C. Blank ; Amsterdam, NL, Leiden, NL
11:00 - 11:15 Invited Discussant 1217PD, 1218PD and 1219PD D. Schadendorf, Essen, DE
11:15 - 11:25 Q&A led by Discussant
Last update: 02-09-2017 06:01:33pm esmo.org 11:25 - 11:25 1220PD - Phase 2 study of neoadjuvant dabrafenib + trametinib (D+T) for resectable stage IIIB/C BRAF V600 mutant melanoma 1 1 2 3 3 3 4 A. Menzies , M. Gonzalez , A. Guminski , O. Nieweg , K. Shannon , J. Thompson , R. Kefford , S. 3 1 3 3 3 3 3 3 3 Ch'Ng , J. Stretch , A. Spillane , J. Lee , H. Lee , R. Kapoor , L. Emmett , H. Rizos , R. Saw , R.
5 3 1 2 3 4 Scolyer , G. Long ; North Sydney, AU, St Leonards, NSW/AU, Sydney, AU, Macquarie Park, 5 NSW/AU, Camperdown, AU
11:25 - 11:25 1221PD - (Neo-)adjuvant ipilimumab + nivolumab (IPI+NIVO) in palpable stage 3 melanoma – updated relapse free survival (RFS) data from the OpACIN trial and first biomarker analyses 1 1 1 1 1 2 3 E. Rozeman , L. Fanchi , A. van Akkooi , P. Kvistborg , J. Thienen , B. Stegenga , B. Lamon , J.
1 1 1 1 2 3 Haanen , T. Schumacher , C. Blank ; Amsterdam, NL, Utrecht, NL, Princeton, New Jersey/US
11:25 - 11:25 1222PD - Regional differences in overall survival (OS) in patients with advanced melanoma (MEL) who received nivolumab (NIVO) combined with ipilimumab (IPI) or NIVO alone in a phase 3 trial (CheckMate 067) 1 2 3 4 5 6 7 J.-J. Grob , D. Schadendorf , J. Wagstaff , I. Márquez-Rodas , C. Lebbé , P. Ascierto , F.S. Hodi , K. 8 9 10 10 11 12 1 2 Grossmann , J. Hassel , D. Walker , R. Bhore , J. Larkin , J. Wolchok ; Marseille, FR, Essen,
3 4 5 6 7 8 9 DE, Swansea, GB, Madrid, ES, Paris, FR, Napoli, IT, Boston, US, Salt Lake City, US, 10 11 12 Heidelberg, DE, Princeton, US, London, GB, New York, US
11:25 - 11:25 1223PD - Quality-adjusted survival of combined nivolumab plus ipilimumab (NIVO+IPI) or NIVO alone vs IPI among treatment-naïve patients (pts) with advanced melanoma (MEL): a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis 1 1 2 3 4 2 5 6 M. Botteman , R. Shah , K. Gupte-Singh , L. Luo , J. Sabater , S. Rao , D. McDermott , M. Atkins , 5 1 2 3 4 5 6 M. Regan ; Bethesda, US, Princeton, NJ/US, Bethesda, MD/US, Princeton, US, Boston, MA/US, Washington Dc, US
11:25 - 11:40 Invited Discussant 1220PD, 1221PD 1222PD and 1223PD C. Hoeller, Vienna, AT
11:40 - 11:50 Q&A led by Discussant
11:50 - 11:50 1224PD - Analysis of response and survival in patients (pts) with ipilimumab (ipi)-refractory melanoma treated with pembrolizumab (pembro) in KEYNOTE-002 1 2 3 4 5 6 7 A. Daud , I. Puzanov , R. Dummer , D. Schadendorf , O. Hamid , C. Robert , F.S. Hodi , J. Schachter 8 9 10 11 12 13 14 15 , J. Sosman , A. Pavlick , R. Gonzalez , C. Blank , L. Cranmer , S. O’day , A. Salama , K. 16 17 18 17 5 1 2 Margolin , J. Yang , B. Homet Moreno , N. Ibrahim , A. Ribas ; San Francisco, US, Buffalo,
3 4 5 6 7 8 9 NY/US, Zurich, CH, Essen, DE, Los Angeles, CA/US, Villejuif, FR, Boston, US, Ramat Gan, IL, 10 11 12 13 14 Nashville, TN/US, New York, US, Aurora, CO/US, Amsterdam, NL, Seattle, US, Santa 15 16 17 18 Monica, US, Durham, US, Duarte, CA/US, Kenilworth, US, Kenilworth, NJ/US
11:50 - 11:50 1225PD - Prognostic impact of early complete metabolic response on FDG-PET, in BRAF V600 mutant metastatic melanoma patients treated with combination vemurafenib & cobimetinib
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 1 3 4 5 3 6 W. Xu , J. Frederickson , J. Callahan , A. Ribas , R. Gonzalez , A. Pavlick , O. Hamid , T. Gajewski , 7 8 9 10 11 1 12 1 I. Puzanov , A. Daud , D. Colburn , N. Choong , M. Wongchenko , R. Hicks , G. McArthur ; 2 3 4 5 Melbourne, VIC/AU, South San Francisco, CA/US, Los Angeles, CA/US, Aurora, CO/US, New York, 6 7 8 9 10 US, Chicago, Il, US, Buffalo, NY/US, San Francisco, US, South San Francisco, California/US, 11 12 South San Francisco, US, Hillsboro, US, Melbourne, AU
11:50 - 11:50 1226PD - Five-year efficacy and safety update from METRIC: Trametinib vs chemotherapy in patients with BRAF V600E/K–mutant advanced or metastatic melanoma 1 2 3 4 5 6 7 8 D. Schadendorf , K. Flaherty , P. Nathan , P. Hersey , C. Garbe , M. Milhem , L. Demidov , P. Mohr , 9 10 11 9 12 13 14 J. Hassel , P. Rutkowski , R. Dummer , J. Utikal , F. Kiecker , J. Larkin , A. D’Amelio Jr , Y. 15 14 16 1 2 3 4 Huang , B. Mookerjee , C. Robert ; Essen, DE, Boston, MA/US, Northwood, Middlesex/GB,
5 6 7 8 9 10 Sydney, AU, Tübingen, DE/DE, Iowa, US, Moscow, RU, Buxtehude, DE, Heidelberg, DE, 11 12 13 14 15 Warsaw, PL, Zürich, CH, Berlin, DE, London, GB, New Jersey, US, East Hanover, NJ/US, 16 Villejuif, FR
11:50 - 12:05 Invited Discussant 1224PD, 1225PD and 1226PD S. Goldinger, Zürich, CH
12:05 - 12:15 Q&A led by Discussant
11:00 - 12:30 Type: Educational session Cordoba Auditorium Title: Treating your patients using epigenetics Chair(s): K. Helin, DK; D. Huntsman, CA
11:00 - 11:25 Targeting epigenetic enzymes in cancer K. Helin, Copenhagen, DK
11:25 - 11:50 Deacetylation of chromatin: A new target for epigenetic therapy? N. La Thangue, Oxford, GB
11:50 - 12:15 Protein methyltransferase inhibitors in preclinical models and clinical studies P. Trojer, Cambridge, US
12:15 - 12:30 Discussion
Last update: 02-09-2017 06:01:33pm esmo.org 11:00 - 12:00 Type: Multidisciplinary Session Granada Auditorium Title: Management of high risk early stage endometrial cancer Chair(s): M.R. Mirza, DK
11:00 - 11:05 Presentation of case/condition M.R. Mirza, Copenhagen, DK
11:05 - 11:15 The medical oncology perspective M.R. Mirza, Copenhagen, DK
11:15 - 11:25 The surgery perspective P. Benedetti Panici, Rome, IT
11:25 - 11:35 The radiation therapy perspective R. Nout, Leiden, NL
11:35 - 12:00 General Discussion
11:00 - 12:30 Type: Joint Symposium Valencia Auditorium Title: ESMO-MASCC: Emerging issues in cancer supportive care and survivorship Chair(s): N. Cherny, IL; I. Olver, AU
11:00 - 11:05 Introduction N. Cherny, Jerusalem, IL
11:05 - 11:25 Safe monitoring of immunotherapy I. Olver, Adelaide, South Australia/AU
11:25 - 11:45 Steroids and supportive care N. Cherny, Jerusalem, IL
11:45 - 12:05 Financial toxicity R. Sullivan, London, GB
12:05 - 12:25 Return to work after cancer F. Pimentel, Lisbon, PT
12:25 - 12:30 Conclusions I. Olver, Adelaide, South Australia/AU
Last update: 02-09-2017 06:01:33pm esmo.org 11:00 - 12:30 Type: Special Symposium Tarragona Auditorium Title: Access to innovative drugs in the EU Chair(s): R. Giuliani, IT; M. Ijzerman, NL
11:00 - 11:05 Introduction M. Ijzerman, Enschede, NL
11:05 - 11:25 Challenges in clinical research methodology P. Bruzzi, Genoa, IT
11:25 - 11:45 Challenges in regulation R. Giuliani, Roma, IT
11:45 - 12:05 Challenges in reimbursement M. Ijzerman, Enschede, NL
12:05 - 12:25 The European cancer patient’s perspective B. Ryll, SE
12:25 - 12:30 Conclusions and clinical perspectives R. Giuliani, Roma, IT
11:00 - 12:30 Type: Poster Discussion session Bilbao Auditorium Title: Sarcoma Chair(s): S. Bonvalot, FR; R. Maki, US; M. Eriksson, SE
11:00 - 11:00 1475PD - A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide and cisplatin (API), followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). Update at 10 years 1 2 3 4 5 6 7 P. Pautier , C. Brard , A. Floquet , L. Gladieff , M. Rios , S. Piperno-Neumann , D. Berton-Rigaud , 8 9 10 11 12 13 J.-Y. Blay , M. Fabbro , J.-P. Lotz , A. Vinceneux , F. Bertucci , T. De La Motte Rouge , C. 14 2 15 1 2 3 4 Guillemet , C. Genestie , F. Duffaud ; Villejuif, CEDEX/FR, Villejuif, FR, Bordeaux, CEDEX/FR,
5 6 7 Toulouse, Haute-Garonne/FR, Vandoeuvre Les Nancy, CEDEX/FR, Paris, CEDEX 5/FR, 8 9 10 11 Saint-Herblain, CEDEX/FR, Lyon, FR, Montpellier, CEDEX 5/FR, Paris, FR, Tours, CEDEX 9/FR, 12 13 14 15 Marseille, CEDEX 9/FR, Rennes, FR, Rouen, FR, Marseille, CEDEX 5/FR
11:00 - 11:00 1476PD - Tumour necrosis and clinical outcomes following neoadjuvant therapy in soft tissue sarcoma (STS) 1 2 3 2 1 2 3 J. Lewin , S. Salah , E. Amir , A. Razak ; Nassau, BS, Toronto, CA, Toronto, Ontario/CA
11:00 - 11:00 1477PD - Prognosis of desmoid tumours initially managed with surveillance only at all anatomical locations 1 1 1 1 1 1 1 1 W. van Houdt , A. Patel , R. Jones , M. Smith , A. Miah , C. Benson , S. Zaidi , C. Messiou , E.
1 1 1 1 2 1 2 Moskovic , D. Strauss , A. Hayes , O. Husson , W. van der Graaf ; London, GB, Sutton, GB
Last update: 02-09-2017 06:01:33pm esmo.org 11:00 - 11:00 1478PD - Adult Translocation-related soft tissue sarcomas (TRS): Presentation, management and outcome of 2,143 cases confirmed by expert pathologists 1 2 2 3 4 5 6 N. Penel , J.-M. Coindre , A. Giraud , P. Terrier , D. Ranchere-Vince , F. Collin , S. Le Guellec , C. 7 8 9 10 8 3 11 Bazille , M. Lae , G. De Pinieux , I. Ray-Coquard , S. Bonvalot , A. Le Cesne , Y.-M. Robin , E. 2 10 12 4 1 2 3 Stoeckle , F. Ducimetiere , M. Toulmonde , J.-Y. Blay ; Lille, CEDEX/FR, Bordeaux, FR, Villejuif, 4 5 6 7 8 9 10 11 FR, Lyon, FR, Dijon, FR, Toulouse, FR, Caen, FR, Paris, FR, Tours, FR, Lyon, CEDEX/FR, 12 Lille, FR, Bordeaux, CEDEX/FR
11:00 - 11:20 Invited Discussant 1475PD, 1476PD, 1477PD and 1478PD S. Bonvalot, Paris, FR
11:20 - 11:30 Q&A led by Discussant
11:30 - 11:30 1479PD - Phase II study of TAS-116, an oral inhibitor of heat shock protein 90 (HSP90), in metastatic or unresectable gastrointestinal stromal tumor refractory to imatinib, sunitinib and regorafenib 1 2 3 4 5 6 5 5 Y. Kurokawa , T. Doi , A. Sawaki , Y. Komatsu , M. Ozaka , T. Takahashi , Y. Naito , S. OKUBO , T. 5 1 2 3 4 5 Nishida ; Suita, Osaka/JP, Kashiwa, Chiba/JP, Kurashiki, Okayama/JP, Sapporo, Hokkaido/JP, 6 Tokyo, JP, Suita, JP
11:30 - 11:30 1480PD - A phase 2 study of CMB305 and atezolizumab in NY-ESO-1+ soft tissue sarcoma: Interim analysis of immunogenicity, tumor control and survival 1 2 3 4 5 6 7 8 9 S. Chawla , B. Van Tine , S. Pollack , K. Ganjoo , A. Elias , R. Riedel , S. Attia , E. Choy , S. Okuno 10 11 12 13 14 15 , M. Agulnik , M. von Mehren , M. Livingston , V. Keedy , C. Verschraegen , T. Philip , C. 16 17 17 18 1 2 3 4 Bohac , H. Lu , M. Chen , R. Maki ; San Francisco, US, St Louis, US, Seattle, US, Palo Alto,
5 6 7 8 9 10 US, Aurora, US, Durham, US, Jacksonville, FL/US, Boston, US, Rochester, US, Chicago, US, 11 12 13 14 15 Philadelphia, PA/US, Charlotte, US, Nashville, US, Cincinnati, US, New Hyde Park, NY/US, 16 17 18 Thousand Oaks, California/US, South San Francisco, CA/US, New York, Ny, US
11:30 - 11:30 1481PD - Efficacy and safety of palbociclib in patients with advanced gastrointestinal stromal tumors refractory to imatinib and sunitinib 1 2 3 4 5 6 7 1 A. Italiano , A. Adenis , J.-Y. Blay , F. Duffaud , M. Rios , E. Bompas , O. Bouche , M. Pulido , A. Le 8 1 2 3 4 5 Cesne ; Bordeaux, FR, Lille, CEDEX/FR, Lyon, FR, Marseille, CEDEX 5/FR, Vandoeuvre Les 6 7 8 Nancy, CEDEX/FR, Saint-Herblain, CEDEX/FR, Reims, FR, Villejuif, FR
11:30 - 11:30 1482PD - Notch pathway inhibition with LY3039478 in soft tissue sarcoma (STS) and gastrointestinal stromal tumours (GIST) 1 2 3 4 5 2 6 7 O. Mir , A. Azaro , J. Merchan , R. Chugh , J.C. Trent , J. Rodon , U. Ohnmacht , C. Smith , G. 8 1 1 9 10 1 2 3 Oakley III , A. Le Cesne , J.-C. Soria , K. Benhadji , C. Massard ; Villejuif, FR, Barcelona, ES,
4 5 6 7 8 Miami, US, Ann Arbor, US, Houston, TX/US, Bad Homburg, DK, Windlesham, GB, Indianapolis, 9 10 US, Neuilly-Sur-seine, FR, Villejuif, CEDEX/FR
11:30 - 11:50 Invited Discussant 1479PD, 1480PD, 1481PD and 1482PD R. Maki, New York, Ny, US
Last update: 02-09-2017 06:01:33pm esmo.org 11:50 - 12:00 Q&A led by Discussant
12:00 - 12:00 1483PD - Imatinib in combination with everolimus in patients with progressive advanced chordoma: results form an Italian phase 2 clinical trial 1 1 1 1 1 2 1 S. Stacchiotti , C. Morosi , A. Casale , E. Palassini , A.M. Frezza , A. Messina , A. Gronchi , G.
1 1 1 2 1 1 2 Garrone , E. Venturelli , S. Pilotti , E. Tamborini , P. Casali ; Milan, IT, Milano, IT
12:00 - 12:00 1484PD - A matching-adjusted indirect comparison of trabectedin and pazopanib for the treatment of advanced, metastatic, leiomyosarcomas 1 2 3 4 5 5 R. Jones , J.-Y. Blay , A. Lecesne , J. Martin-Broto , M.J. Pontes , J.M. Fernandez Santos , B. García 5 6 7 8 9 10 11 1 2 San Andrés , G. Wang , S. Wang , C.R. Shin , R. Maki , S. Patel , G.D. Demetri ; London, GB,
3 4 5 6 7 8 Lyon, FR, Villejuif, FR, Seville, ES, Madrid, ES, Spring House, US, Horsham, PA/US, Horsham, 9 10 11 US, New York, Ny, US, Houston, TX/US, Boston, MA/US
12:00 - 12:00 LBA57 - Results of the LMS03 phase II study evaluating gemcitabine combined with pazopanib as a 2nd-line treatment for metastatic/relapsed leiomyosarcomas (uterine or soft tissue) after failure of anthracycline-based chemotherapy: the UNICANCER SARCOME 11 study. 1 2 3 4 5 6 7 P. Pautier , N. Penel , I. Ray-Coquard , A. Italiano , E. Bompas , C. Delcambre , J.-O. Bay , F. 8 9 10 11 12 13 14 Bertucci , J. Delaye , C. Chevreau , D. Cupissol , L. Bozec Le Moal , J.-C. Eymard , A. Thyss , 15 16 17 18 9 19 1 N. Isambert , C. Guillemet , M. Rios , S. Piperno-Neumann , G. Chenuc , F. Duffaud ; Villejuif, 2 3 4 5 6 CEDEX/FR, Lille, CEDEX/FR, Lyon, CEDEX/FR, Bordeaux, FR, Saint-Herblain, CEDEX/FR, Caen, 7 8 9 10 11 CEDEX 5/FR, Clermont-Ferrand, FR, Marseille, CEDEX 9/FR, Paris, FR, Toulouse, FR, 12 13 14 15 Montpellier, CEDEX 5/FR, St. Cloud, FR, Reims, CEDEX/FR, Nice, CEDEX 2/FR, Dijon, 16 17 18 19 Cedex/FR, Rouen, FR, Vandoeuvre Les Nancy, CEDEX/FR, Paris, CEDEX 5/FR, Marseille, CEDEX 5/FR
12:00 - 12:20 Invited Discussant 1483PD, 1484PD and LBA57 M. Eriksson, Lund, SE
12:20 - 12:30 Q&A led by Discussant
11:00 - 12:00 Type: Poster Discussion session Alicante Auditorium Title: Endocrine and neuroendocrine tumours Chair(s): B. Jarzab, PL; R. Garcia-Carbonero, ES
11:00 - 11:00 432PD - Prognostic impact of RNA expression profile (EP) in the phase III DECISION trial for patients with advanced radioactive-iodine refractory differentiated thyroid cancer (DTC) 1 1 1 1 1 1 1 1 I. Matos , F. Mancuso , C. Iglesias , P. Nuciforo , C. Zafón , H.G. Palmer , Z. Ogbah , L. Muños , G. 1 2 3 4 1 1 1 Villacampa Javierre , C. Peña , M. Brose , M. Schlumberger , A. Vivancos , J. Capdevila ; 2 3 4 Barcelona, ES, Whippany, NJ/US, Philadelphia, PA/US, Villejuif, CEDEX/FR
11:00 - 11:00 433PD - Comprehensive genomic profiling of metastatic and relapsed thyroid gland carcinomas is associated with tumor type and reveals new routes to targeted therapies
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 2 2 3 2 2 2 J. Ross , L. Gay , P. Vanden Borre , N. Almog , A. Schrock , J.-A. Vergilio , J. Suh , S. Ramkissoon , 2 2 2 2 2 2 4 1 2 E. Severson , S. Daniel , S. Ali , V. Miller , P. Stephens , J. Elvin , D. Bowles ; Albany, NY/US, 3 4 Cambridge, MA/US, Cambridge, US, South Aurora, CO/US
11:00 - 11:00 434PD - Impact of duration of dose interruption on the efficacy of lenvatinib (LEN) in a phase 3 sudy in patients (pts) with radioiodine refractory differentiated thyroid cancer (RR-DTC) 1 2 3 4 4 5 6 7 1 M. Tahara , M. Brose , L. Wirth , T. Suzuki , K. Fujino , N. Batty , C. Dutcus , A. Gianoukakis ; 2 3 4 5 6 Kashiwa, Chiba/JP, Philadelphia, PA/US, Boston, MA/US, Tokyo, JP, Woodcliff Lake, US, 7 Woodcliff Lake, New Jersey/US, Torrance, US
11:00 - 11:00 436PD - Preliminary safety and efficacy of rovalpituzumab tesirine in patients with delta-like protein 3-expressing advanced solid tumors 1 2 3 4 5 6 7 8 R. Aggarwal , A. Mansfield , H. Beltran , A. Farago , C.L. Hann , F. Kaye , K. Lewis , J. Niu , S. 9 10 11 12 13 14 15 15 Richey , D. Smith , H.P. Soares , A. Spira , M. Taylor , S.N. Waqar , S. Lally , M. Rossi , L. 15 15 15 16 1 2 3 Saunders , S.J. Dylla , E. Kavalerchik , L. Anthony ; San Francisco, US, Rochester, MN/US,
4 5 6 7 8 9 New York, NY/US, Boston, MA/US, Baltimore, US, Gainesville, US, Aurora, CO/US, Gilbert, US, 10 11 12 13 14 15 Fort Worth, US, Vancouver, US, Tampa, US, Fairfax, US, Portland, US, St. Louis, US, 16 South San Francisco, US, Lexington, US
11:00 - 11:20 Invited Discussant 432PD, 433PD, 434PD and 436PD B. Jarzab, Warsaw, PL
11:20 - 11:30 Q&A led by Discussant
11:30 - 11:30 437PD - Integrative DNA methylome and miRNA transcriptome analysis for new biomarker discovery in entero-pancreatic neuroendocrine tumours (EP-NETS) 1 1 2 2 2 2 J. Barriuso , A. Lamarca , V. Heredia , L. Guerra-Pastrian , C. Alvarez-Escola , J. Castell , A.
2 2 2 2 1 2 Custodio , M. Miguel , M. Mendiola , J. Feliu ; Manchester, GB, Madrid, ES
11:30 - 11:30 438PD - Improved time to quality of life deterioration in patients with progressive midgut neuroendocrine tumors treated with 177Lu-DOTATATE: The NETTER-1 phase III trial 1 2 1 3 4 5 6 7 J. Strosberg , E. Wolin , B. Chasen , M.H. Kulke , D. Bushnell , M. Caplin , R. Baum , P. Kunz , T. 8 9 10 2 11 12 1 Hobday , A. Hendifar , K. Öberg , M. Lopera Sierra , P. Ruszniewski , E. Krenning ; Tampa, US,
2 3 4 5 6 7 8 New York, US, Boston, Ma, US, Iowa, US, London, GB, Bad Berka, DE, Stanford, AE, 9 10 11 12 Rochester, MN/US, Los Angeles, US, Uppsala, SE, Clichy, FR, Rotterdam, NL
11:30 - 11:30 439PD - Peptide receptor radionuclide therapy of neuroendocrine neoplasms using lutetium-177 and yttrium-90 labeled somatostatin analogs: A single center experience in over 1000 patients 1 1 1 1 1 1 1 A. Singh , H. Kulkarni , T. Langbein , C. Lehmann , K. Niepsch , D. Müller , M. Hommann , D.
1 2 2 1 1 1 2 Kaemmerer , A. Jochems , P. Lambin , D. Hörsch , R. Baum ; Bad Berka, DE, Maastricht, NL
11:30 - 11:30 440PD - Efficacy and safety of telotristat ethyl in patients with carcinoid syndrome inadequately controlled by somatostatin analogs: Analysis of the completed TELESTAR extension period
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 3 4 5 6 7 8 D. Hörsch , M.H. Kulke , M. Caplin , L. Anthony , E. Bergsland , K. Öberg , R. Warner , P. Kunz , E. 9 10 11 12 13 13 14 1 Grande Pulido , J. Valle , J. Dillon , P. Lapuerta , P. Banks , S. Jackson , M. Pavel ; Bad 2 3 4 5 6 7 Berka, DE, Boston, Ma, US, London, GB, Lexington, US, San Francisco, CA/US, Uppsala, SE, 8 9 10 11 12 New York, NY/US, Stanford, AE, Madrid, ES, Manchester, GB, Iowa City, IA/US, Princeton, 13 14 US, The Woodlands, Texas/US, Berlin, DE
11:30 - 11:30 441PD - Follow-up recommendations for completely resected gastroenteropancreatic neuroendocrine tumours (GEP-NETs): Consensus guidelines from the Commonwealth NET collaboration (CommNETs) in conjunction with the North American NET Society (NANETS) 1 2 3 4 5 6 1 2 S. Singh , L. Moody , D. Chan , D. Metz , J. Strosberg , E. Segelov ; Toronto, Ontario/CA, Toronto,
3 4 5 6 CA, St Leonards, AU, Philadelphia, US, Tampa, US, Melbourne, NSW/AU
11:30 - 11:50 Invited Discussant 437PD, 438PD, 439PD, 440D and 441PD R. Garcia-Carbonero, Madrid, ES
11:50 - 12:00 Q&A led by Discussant
11:00 - 11:45 Type: Young Oncologist Brunch Salamanca Auditorium Title: Critically ill cancer patients: Patient selection for admission to ICU Chair(s): J. Corral, ES; A. Tyulyandina, RU
11:00 - 11:20 Which factors influence decision making for ICU admission in cancer patients? P. Schellongowski, Vienna, AT
11:20 - 11:25 Interactive case – case presentation M.A. Ozturk, Istanbul, TR
11:25 - 11:45 Interactive case discussion (including audience) P. Schellongowski, Vienna, AT
12:30 - 14:30 Type: Patient Advocacy Track Cartagena Auditorium Title: The Hans Keulen Memorial Debate: Lost in rehabilitation Chair(s): K. Oliver, GB; F. Meunier, BE
12:30 - 14:00 Moderated discussion with special guests 1 2 3 4 1 2 3 4 I. Lebrocquy , L. Travado , T. Spanic , S. Rauh ; No City Provided, NA, Lisbon, PT, Ljubljana, SI, Esch Sur Alzette, LU
13:00 - 14:30 Type: Industry Satellite Symposium Sevilla Auditorium Title: Industry Satellite Symposium 42
Last update: 02-09-2017 06:01:33pm esmo.org 13:00 - 14:30 Type: Industry Satellite Symposium Pamplona Auditorium Title: Industry Satellite Symposium 43
13:00 - 14:30 Type: Industry Satellite Symposium Cordoba Auditorium Title: Industry Satellite Symposium 44
13:00 - 14:30 Type: ESMO Colloquium Granada Title: ESMO COLLOQUIUM – Rational for Chemo-Immunotherapy combination Auditorium treatment in Solid Tumours Chair(s): J. Bennouna, FR; J. Vansteenkiste, BE
13:00 - 13:05 Introduction J. Bennouna, Nantes, CEDEX/FR
13:05 - 13:30 Optimizing immunotherapy: Rationale for a combination therapy approach E. Giovannetti, Amsterdam, NL
13:30 - 13:55 Selecting the optimal combination partner for today’s immunotherapeutic approaches M. Del Re, Pisa, IT
13:55 - 14:20 Modulating Immune response to checkpoint inhibitor including epigenetic alteration J. Vansteenkiste, Leuven, BE
14:20 - 14:30 Summary and Conclusion J. Bennouna, Nantes, CEDEX/FR
13:00 - 14:30 Type: Industry Satellite Symposium Valencia Auditorium Title: Industry Satellite Symposium 46
13:00 - 14:30 Type: Industry Satellite Symposium Tarragona Auditorium Title: Industry Satellite Symposium 47
13:00 - 14:30 Type: Industry Satellite Symposium Bilbao Auditorium Title: Industry Satellite Symposium 48
13:00 - 14:30 Type: Industry Satellite Symposium Alicante Auditorium Title: Industry Satellite Symposium 49
13:15 - 14:15 Type: Poster Display session Hall 8 Title: Poster display session
13:15 - 13:15 BASIC SCIENCE
13:15 - 13:15 7P - GSKJ4, an H3K27me3 demethylase inhibitor, effectively suppresses the breast cancer stem cells
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 1 1 1 2 N. Yan , Y. Cao , L. Xu , F. Zhang ; Shanghai, CN, Nanchang, CN
13:15 - 13:15 8P - The impact of rotenone-modulated oxidative stress on the survival of human breast cancer stem cells (CD24-/CD44+) S. Wanandi, R. Syahrani, S. Jusman; Jakarta, ID
13:15 - 13:15 9P - Kynurenine-3-monooxygenase (KMO) protein promotes triple negative breast cancer progression C.-Y. Liu, T.-T. Huang, C.-H. Lee, W.-L. Wang, H.-C. Lee, L.-M. Tseng; Taipei, TW
13:15 - 13:15 10P - PIM1 kinase promotes cell migration via SHP2 in triple-negative breast cancer F. Braso Maristany, J. Quist, C. Wells, A. Grigoriadis, P. Marra, A. Tutt; London, GB
13:15 - 13:15 11P - SHP-1 agonist SC-43 enhanced the anti-tumor effect of docetaxel through suppressing p-STAT3 in triple negative breast cancer cells 1 1 1 2 1 1 1 1 K.-F. Chen , C.-Y. Liu , T.-I. Chao , P.-Y. Chu , T.-T. Huang , W.-L. Wang , C.-H. Lee , K.-Y. Lau ,
1 1 1 1 2 W.-C. Tsao , C.-W. Shiau , L.-M. Tseng ; Taipei, TW, Changhua City, TW
13:15 - 13:15 12P - Delineating the mechanisms of resistance to panHER inhibitors in HER2+ breast cancer cells 1 2 1 2 1 2 O. Kutuk , H. Basaga , Y. Ozmay , B. Karakas ; Adana, TR, Istanbul, TR
13:15 - 13:15 13P - AXL as a potential primary and secondary trastuzumab resistance mechanism in breast cancer cells with HER2 overexpression 1 2 2 3 2 3 3 J.M. Cejalvo , E. Tormo , A. Adam , F. Rojo , B. Pineda , S. Zazo , P. Gonzalez-Alonso , M. 4 2 4 4 1 2 2 Sabbaghi , E. Alonso , A. Rovira , J. Albanell , B. Bermejo De Las Heras , O. Burgues , A. Lluch , 1 2 1 2 3 4 J.A. Perez Fidalgo , P. Eroles ; Valencia, Valencia/ES, Valencia, ES, Madrid, ES, Barcelona, ES
13:15 - 13:15 14P - Alterations to trastuzumab-induced antibody-dependent cell-mediated cytotoxicity (T-ADCC) in a lapatinib-resistant HER2+ breast cancer cell line model 1 1 1 1 2 1 1 N. Gaynor , M. Guibourdenche , B. Browne , L. O'Driscoll , N. O'Brien , N. O'Donovan , J. Crown , D.
1 1 2 Collins ; Dublin, IE, Los Angeles, CA/US
13:15 - 13:15 15P - Estrogen-dependent breast cancer: The importance of androgen receptor in exemestane treatment 1 1 2 2 1 1 1 C. Amaral , T. Augusto , F. Roleira , E. Tavares-Da-Silva , G. Correia-Da-Silva , N. Teixeira ; Porto,
2 PT, Coimbra, PT
13:15 - 13:15 16P - Phosphatidylinositol 3-kinase (PI3Kα)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells 1 1 2 2 1 2 1 A. Diana , F. Morgillo , C.M. Della Corte , C. Di Mauro , V. Ciaramella , G. Barra , V. Belli , E. 1 1 3 2 2 1 1 2 3 Franzese , R. Bianco , E. Maiello , F. De Vita , F. Ciardiello , M. Orditura ; Napoli, IT, Naples, IT, San Giovanni Rotondo, IT
13:15 - 13:15 18P - Potential miRNAs involved in molecular pathways mediating the anticancer effects of short term starvation in breast cancer cells treated with doxorubicin D. Fanale, L. Incorvaia, R. Maragliano, N. Barraco, A. Listì, A. Galvano, S. Rizzo, V. Calò, V. Bazan, A.
Russo; Palermo, IT
Last update: 02-09-2017 06:01:33pm esmo.org 13:15 - 13:15 19P - An endothelial premetastatic-like niche is promoted by tumor-secreted factors derived from highly metastatic breast cancer cells in vitro M. Gallardo Vera, A. Zentella Dehesa; Cd De MÉxico, MX
13:15 - 13:15 20P - Selective accumulation of the rat adherent natural killer cells in mammary tumor tissues S. Gu, Hamamatsu, JP
13:15 - 13:15 21P - Inhibition of nitric oxide synthase (NOS) reduces the effect of stress hormone signalling in breast cancer 1 2 2 2 1 2 R. Flaherty , B. Patel , M. Allen , M. Flint ; Brighton, UK/GB, Brighton, GB
13:15 - 13:15 22P - The interplay between TP53 and mevalonate pathway in ovarian cancer M. Abdullah, M. Abed, A. Richardson; Stoke On Trent, GB
13:15 - 13:15 23P - Epigenomic landscape of breast cancer in very young women 1 1 1 2 1 1 3 2 S. Sanchis , M. Chilet , M. Martinez , K. Flower , E. Alonso , O. Burgues , A. Lluch , J. Flanagan , G.
1 1 2 3 Ribas ; Valencia, ES, London, GB, Valencia, Valencia/ES
13:15 - 13:15 24P - Evaluation of cell free circulating DNA in plasma by digital PCR for early diagnosis in Peruvian breast cancer patients A. Aguilar, A. Murillo, J. Ponce, J. Araujo, J. Pinto, C. Vigil, R. Fujita, J. Buleje; Lima, PE
13:15 - 13:15 25P - Breast cancer predisposing germline mutations identified by exome sequencing E. Kuligina, A. Sokolenko, I. Bizin, M. Anisimova, A. Romanko, E. Imyanitov; Saint Petersburg, RU
13:15 - 13:15 26P - Global transcriptome deregulation of breast cancer in very young women samples 1 1 1 1 1 2 1 1 V. Vidal Tomas , S. Sanchis , M. Martinez , E. Alonso , O. Burgues , A. Lluch , M. Chilet , G. Ribas ;
1 2 Valencia, ES, Valencia, Valencia/ES
13:15 - 13:15 27P - Integrated system-level analyses of androgen receptor variant networks to identify novel prostate cancer-relevant genes that serve as prognostic biomarkers 1 2 2 2 2 1 2 F. Magani , E. Bray , S. Peacock , N. Zhao , K. Burnstein ; Miami, US, Miami, FL/US
13:15 - 13:15 28P - ODM-208, a novel CYP11A1-inhibitor as a therapeutic approach for the treatment of castration-resistant prostate cancer 1 1 1 1 1 2 2 R. Oksala , M. Karimaa , M. Ramela , R. Riikonen , R. Huhtaniemi , P. Rummakko , G. Wohlfahrt , A.
2 2 1 1 2 Vuorela , M. Mustonen , P. Kallio ; Turku, FI, Espoo, FI
13:15 - 13:15 29P - Determining the role of the ETS factor ELF3 in normal and malignant prostate L. Archer, F. Frame, N. Maitland; York, GB
13:15 - 13:15 30P - Treatment-induced hypoxia attenuates enzalutamide response and promotes resistance in pre-clinical models of prostate cancer 1 1 1 1 1 1 2 P. Maxwell , M. Labonte , M. McKechnie , O. Duddy , C. Armstrong , C.W. Ong , A. Zoubeidi , J.
3 1 1 2 3 Worthington , D. Waugh ; Belfast, GB, Vancover, CA, Coleraine, GB
Last update: 02-09-2017 06:01:33pm esmo.org 13:15 - 13:15 (Withdrawn)
13:15 - 13:15 32P - Prognostic impact of KRAS mutation in cell-free DNA in patients with pancreatic cancer 1 2 2 3 2 2 2 2 1 M.K. Kim , S.M. Woo , B. Park , K.-A. Yoon , Y.H. Kim , J. Joo , S.J. Park , S.-Y. Kong ;
2 3 Gyeonggi-Do, KR, Goyang, KR, Seoul, KR
13:15 - 13:15 33P - Isoform-specific functions in pancreatic adenocarcinoma H. Arasanz, M. Zuazo-Ibarra, M. Gato-Cañas, M. Ibáñez-Vea, G. Fernández-Hinojal, J.
Fernández-Irigoyen, E. Santamaria, G. Kochan, R. Vera, D. Escors; Pamplona, ES
13:15 - 13:15 34P - High chemopreventive and therapeutic efficacy of Id1 inhibition in KRAS-mutant (KM) adenocarcinoma (AD) non-small cell lung cancer (NSCLC) M. Roman Moreno, S. Vicent, I. Lopez, I. Baraibar Argota, E. Fraile, I. Gil Bazo; Pamplona, ES
13:15 - 13:15 (Withdrawn)
13:15 - 13:15 36P - Synergistic effect of vismodegib and cisplatin in NSCLC models via autophagy 1 1 2 1 1 1 1 F. Papaccio , L. Mele , C.M. Della Corte , D. Liccardo , M. La Noce , V. Desiderio , V. Tirino , F.
2 1 1 2 Ciardiello , F. Morgillo ; Napoli, IT, Naples, IT
13:15 - 13:15 37P - Association of the rs4567312 variant in the leptin receptor gene with plasma leptin concentrations and lung cancer incidence in the PREDIMED study 1 2 2 2 2 2 J.B. Ramirez Sabio , J. Sorlí , C. Ortega-Azorín , P. Carrasco , E. Asensio , R. Barragán , R. 2 2 2 3 4 2 1 Fernández-Carrión , C. Gallego , J. González-Arráez , J.A. Perez Fidalgo , Ó. Coltell , D. Corella ; 2 3 4 Sagunt, ES, Valencia, ES, Valencia, Valencia/ES, Castellón, ES
13:15 - 13:15 38P - Two-step microarray analysis of cell-free miRNA in plasma of lung cancer patients 1 1 2 1 2 1 I. Zaporozhchenko , E. Morozkin , A. Ponomaryova , E. Rykova , N. Cherdyntseva , V. Vlassov , P.
1 1 2 Laktionov ; Novosibirsk, RU, Tomsk, RU
13:15 - 13:15 39P - DNA methylation of the CYP1A1 and GSTP1 genes and incidence of major cancers (lung, breast and colon) in the PREDIMED-Valencia study 1 2 2 2 2 2 J.B. Ramirez Sabio , J. Sorlí , C. Ortega-Azorín , I. González-Monje , E. Asensio , R. Barragán , R. 2 2 3 4 2 2 1 2 Fernández-Carrión , C. Gallego , R. Estruch , Ó. Coltell , O. Portolés , D. Corella ; Sagunt, ES, 3 4 Valencia, ES, Barcelona, ES, Castellón, ES
13:15 - 13:15 40P - Regulation of glucose transporters by protein kinases in cancer cells A. Henriques, P. Matos, P. Jordan; Lisboa, PT
13:15 - 13:15 41P - Signal transduction pathways regulating alternative splicing of tumor-related RAC1b V. Gonçalves, P. Matos, A. Henriques, J. Pereira, P. Jordan; Lisboa, PT
13:15 - 13:15 42P - Preserving tumor heterogeneity: A microfluidic reactor for ex vivo preservation of colorectal cancer biopsies G. Llamazares, C. Sostres, A. Vigueras, A. Lué, J. Calavia, C. Alcaine, R. Guerrero, A. Gonzales, M.
Ramírez, A. Lacueva, S. González, A. Lanas, I. Ochoa, L. Fernández; Zaragoza, ES
Last update: 02-09-2017 06:01:33pm esmo.org
13:15 - 13:15 (Withdrawn)
13:15 - 13:15 44P - Role of ICAM-1/LFA-1 interaction in the angiogenic and desmoplasic response in liver metastasis A. Herrero-Alonso, I. Romayor, A. Benedicto, I. Hernandez-Unzueta, J. Marquez, B. Arteta; Leioa, ES
13:15 - 13:15 45P - Role of discoidin domain receptors in extracellular matrix remodeling during tumor-host interaction in liver metastasis I. Romayor, A. Herrero-Alonso, I. Hernandez-Unzueta, A. Benedicto, J. Marquez, B. Arteta; Leioa, ES
13:15 - 13:15 46P - Novel role of apatinib as a multi-target RTK inhibitor in the direct suppression of hepatocellular carcinoma cells X. Li, A. Xu, H. Li, B. Zhang, B. Cao, J. Huang; Beijing, CN
13:15 - 13:15 47P - GATA6 exhibits tumor suppressive effects in hepatocellular carcinoma H.W. Tan, C. Leung, K. Chan, I. Ng, R. Lo; Hong Kong, HK
13:15 - 13:15 48P - The effects of 5-fluorouracil (5-FU) on TGF-β-related signaling molecules T. Wang, Y. Takikawa; Morioka, JP
13:15 - 13:15 49P - Gene mutations involved in drug resistance in liver cancer cells using a new rna-seq data analysis workflow E. AKHAN GUZELCAN, M. Shojaei, A. Acar, R. Cetin Atalay; Ankara, TR
13:15 - 13:15 50P - Camouflaging iRGD-EGFR anchored human cytotoxic T-lymphocyte membranes to the surface of nanoparticles combined with low-dose irradiation: New approach to enhance drug-delivery targeting in gastric cancer 1 1 1 1 2 1 1 2 L. Zhang , H. Sha , R. Li , J. Wei , X. Qian , B. Liu ; Nanjing, CN, Nanjing, Jiangsu Province/CN
13:15 - 13:15 51P - Delivery of paclitaxel-loaded erythrocytes-based nanoparticles using injectable albumin hydrogel for regional chemotherapy H. qian, Q. Liu, R. Li, L. Yu, B. Liu; Nanjing, CN
13:15 - 13:15 52P - Effect of apatinib combined with 5-fluorouracil (5-FU) on proliferation, apoptosis and invasiveness of gastric cancer cells 1 2 1 1 1 1 1 2 P. ZHAO , J. Zhang , X. Pang , L. Zhao , Q. Li , B. Cao ; Beijing, CN, Tai’an, CN
13:15 - 13:15 53P - One tumour, two clones: An in vitro model of intra-tumour heterogeneity 1 2 2 3 1 2 1 A. Salawu , M. Fernando , D. Hughes , M. Reed , P. Woll , K. Sisley ; Sheffield, South Yorkshire/GB,
2 3 Sheffield, GB, Brighton, GB
13:15 - 13:15 54P - Docosahexaenoic acid mediates susceptible cell death through differential regulation of p62/p-eIF2alpha/NRF2 in LMP1-expressing nasopnaryngeal carcinoma cells 1 2 1 1 1 1 1 1 1 K. Lim , K. Jing , S. Shin , S.-H. Han , Y.-S. Yoo , Y.-J. Jeon , J.-Y. Heo , G.-R. Kweon , S.-K. Park ,
1 1 2 J.-I. Park ; Daejeon, KR, Zhanjiang, CN
Last update: 02-09-2017 06:01:33pm esmo.org 13:15 - 13:15 55P - Inhibition of the ubiquitin-conjugating enzyme E2B restores the BCNU sensitivity of cancer cells by regulating MGMT ubiquitination S.H. Hsu, S.-H. Chen, L.-T. Chen, J.-Y. Chang; Tainan, TW
13:15 - 13:15 56P - Oral squamous cell carcinoma cells were sensitized to cetuximab by Eribulin via induction of the mesenchymal-to-epithelial transition H. kitahara, M. HIRAI, S. Kawashiri, H. Nakamura; Kanazawa, JP
13:15 - 13:15 57P - In vivo study of the vaccine adjuvants prothymosin alpha and prothymosin alpha(100-109) in melanoma 1 1 1 1 1 1 P. Samara , K. Ioannou , N. Kavrohorianou , S. Haralambous , P. Selemenakis , A. Kotsinas , H.
2 2 3 1 2 3 Kalbacher , W. Voelter , O. Tsitsilonis ; Athens, GR, Tuebingen, DE, Athens, Ilissia/GR
13:15 - 13:15 58P - Melanoma affects clock gene machinery of several organs in tumor-bearing mice L. de Assis, M.N. Moraes, K.K. Magalhães-Marques, S. Da Silveira Cruz-Machado, A.M. Castrucci; Sao
Paulo, BR
13:15 - 13:15 59P - Is there receptor tyrosine kinases expression on lymphocytes in patients with renal cell carcinoma? First-in-human study D. Khochenkov, M. Volkova, A. Olshanskaia, S. Aschuba, Y. Khochenkova, A. Anastasia Bondarenko, I.
Tsimafeyeu; Moscow, RU
13:15 - 13:15 60P - Understanding and targeting Met signalling in bladder cancer W. Badreldin, T. Powles, L. Menard, C. Ho-Yen, S. Kermorgant; London, GB
13:15 - 13:15 61P - Integrated molecular signatures of TERT promoter deregulation predict disease outcomes in non-muscle invasive bladder cancer 1 1 2 1 3 1 1 4 R. Leão , D. Lee , A. Figueiredo , M. Komosa , C. Zhang , J. Apolónio , N. Nunes , T. Hermanns , P. 4 4 1 1 1 1 2 3 Wild , C. Poyet , R. Hamilton , P. Castelo-Branco , U. Tabori ; Toronto, CA, Coimbra, PT, Toronto, 4 ON/CA, Zurich, CH
13:15 - 13:15 62P - Dose- and regimen-dependent effects of dexamethasone on extracellular matrix of brain tissue 1 1 2 3 1 1 A. Tsidulko , T. Pankova , C. Bezier , G. de La Bourdannaye , A. Suhovskih , G. Kazanskaya , S.
1 1 1 2 3 Aidagulova , E. Grigorieva ; Novosibirsk, RU, Paris, FR, Toulouse, FR
13:15 - 13:15 63P - Clinical dysregulation of DNA repair by the polynucleotide kinase/phosphatase-XRCC4-DNA ligase IV in neurological disease 1 1 2 2 1 2 1 3 D. Aceytuno , C. Piett , Z. Havali-Shahriari , R. Edwards , M. Rey , R. Mani , S. Fang , M. Hammel , 2 4 1 1 2 1 2 3 M. Weinfeld , J. Tainer , D. Schriemer , S. Lees-Miller , J.N. Glover ; Calgary, CA, Edmonton, CA, 4 Berkeley, US, Houston, US
13:15 - 13:15 64P - Effects of rottlerin and genistein through EF2K on proliferation, invasion and cell cycle/death in neuroblastoma cells M. Erdogan, O. Alkan Yılmaz; Izmir, TR
13:15 - 13:15 65P - Influence of emotiogenic brain structures on tumor growth in the experiment E. Korobeynikova, E. Rostorguev, N. Kuznetsova; Rostov-On-don, RU
Last update: 02-09-2017 06:01:33pm esmo.org
13:15 - 13:15 66P - Systematic evaluation of the immune microenvironment of neuroendocrine tumours (NET) 1 2 1 1 1 1 1 C. Vesely , A. Childs , Y.N.S. Wong , O. Ogunbiyi , T.V. Luong , C. Thirlwell , M. Caplin , T. Marafioti
1 1 1 1 2 , S.A. Quezada , T. Meyer ; London, GB, Bt, GB
13:15 - 13:15 67P - Developing a prediction model for response to lenalidomide treatment in refractory/relapsed multiple myeloma patients Y.-J. Chung, S.-H. Yim, S.-H. Jung; Seoul, KR
13:15 - 13:15 68P - Combinatorial inhibition of mTOR and exportin-1 (XPO1) represses cell survival via metabolic modulation of pro-survival pathways in mantle cell lymphomas 1 1 1 1 2 1 1 2 K. Sekihara , K. Saitoh , H. Yang , T. Miida , M. Andreeff , Y. Tabe ; Tokyo, JP, Houston, TX/US
13:15 - 13:15 69P - CD200 and indoleamine 2,3-dioxygenase-1 (IDO-1) overexpresion in relapsed acute myeloid leukemia patients 1 1 2 2 1 2 A. Memarian , S. Abdolmaleki , M. Mirahmadian , M. Jeddi-Tehrani ; Gorgan, IR, Tehran, IR
13:15 - 13:15 70P - Correlation between types of acute lymphoblastic leukemia with socio demographic factors M. Sen, J. Basak, A. Mukhopadhyay; Kolkata, IN
13:15 - 13:15 71P - CALR mutations and their link with cellular calcium during megakaryocyte hyperplasia in MPNs 1 2 3 3 1 1 1 M. Morlan Mairal , P. Papadopoulos , J. Hetmanski , P. Caswell , M. Krstic-Demonacos , A. Aziz ;
2 3 Salford, GB, Madrid, ES, Manchester, GB
13:15 - 13:15 72P - Approach based on magnetic nanocomplexes improves antitumor efficacy of dendritic cells immunotherapy in mice M. Inomistova, N. Khranovska, O. Skachkova, O. Makeenko, V. Orel; Kiev, UA
13:15 - 13:15 75P - Signs of tumor-specific immune processes in the regression of large rat tumors under the influence of low-intensity EMR EHF and magnetite nanoparticles G. Zhukova, A. Shikhliarova, T. Barteneva, M. Bragina, E. Shirnina, I. Novikova; Rostov-On-don, RU
13:15 - 13:15 76P - Stimulation of RAC1/PAK1 signalling upregulates DNA damage repair genes via the BCL6/STAT5-switch P. Barros, A. Amaral, L. Abrantes, T. Oliveira, H. Louro, M. Silva, P. Jordan, M. Gama-Carvalho, P.
Matos; Lisboa, PT
13:15 - 13:15 77P - Deciphering the regulation of the metastasis suppressor, NDRG1 in different cancer-types and its functional implications 1 2 2 1 2 K.C. Park , Z. Kovacevic , D. Richardson ; Sydney, AU, Sydney, NSW/AU
13:15 - 13:15 78P - Registration-based automated lesion detection and therapy evaluation of tumors in whole body PET-MR images H. Ahlström, S. Ekström, T. Sjöholm, R. Strand, J. Kullberg, E. Johansson, P. Hagmar, F. Malmberg;
Uppsala, SE
Last update: 02-09-2017 06:01:33pm esmo.org 13:15 - 13:15 79P - 1,3,5 s-triazine containing analogues a prime Src family inhibitor: Design synthesis docking, anticarcinoma and angiogenic inhibition efficacy on cancer grafted CAM 1 2 1 1 3 4 1 1 2 P. Pathak , A. Balkrishna , P. Shukla , V. Kumar , A. Kumar , A. Singh , A. Verma ; Allahabad, IN,
3 4 Haridwar, IN, Meerut, IN, Delhi, IN
13:15 - 13:15 (Withdrawn)
13:15 - 13:15 81P - A new isoquinoline alkaloid bersavine as a possible anticancer agent K. Habartová, R. Havelek, M. Seifrtova, A. Hostalkova, L. Cahlikova, M. Rezacova; Hradec Kralove, CZ
13:15 - 13:15 82P - Tactics of surgical treatment of tumors of the sacrum I. Khujanazarov, I. Alimov, S. Ishmuhammedov, M. Gafur-Akhunov; Tashkent, UZ
13:15 - 13:15 83P - The impact of co-culture of NSCLC tumor cells and fibroblasts on drug response 1 1 2 3 1 1 2 S. Abreu , V. Espírito Santo , A. Oleksijew , E. Oswald , M. Estrada , S. Rebelo , K. Vaidya , J.
3 1 2 1 1 2 3 Schuler , P. Alves , E. Boghaert , C. Brito ; Oeiras, PT, Chicago, US, Freiburg, DE
13:15 - 13:15 BIOMARKERS S. Singh, Hamilton, CA
13:15 - 13:15 88P - PALB2 reversion mutations in breast, prostate, and ovarian carcinomas 1 2 2 2 2 2 2 3 L. Gay , S. Daniel , J. Suh , S. Ramkissoon , J.-A. Vergilio , E. Severson , P. Stephens , J. Ross , J.
2 1 2 3 Elvin ; Cambridge, CA, Cambridge, MA/US, Albany, NY/US
13:15 - 13:15 89P - Pan-cancer genomic analysis of MSI-H tumors reveals commonly altered pathways 1 2 3 1 3 3 3 2 S. Trabucco , S. Maund , R. Hartmaier , K. Gowen , J. Sun , G. Frampton , P. Stephens , P. Hegde ,
2 1 2 3 S.-M. Huang ; Cambridge, US, South San Francisco, US, Cambridge, MA/US
13:15 - 13:15 90P - Molecular feature and clinical use development of gene expression profile “TP53 signature” in early stage breast cancer 1 2 3 4 5 1 5 1 S. Yamaguchi , S. Takahashi , T. Nomizu , Y. Kakugawa , T. Ishida , S. Kato , C. Ishioka ; Tokyo,
2 3 4 5 JP, Sendai, Miyagi/JP, Koriyama, JP, Natori, JP, Sendai, JP
13:15 - 13:15 91P - Potential biomarkers of response to DKK1 blockade with DKN-01 in combination with paclitaxel in advanced esophagogastric cancer (EGC) patients (pts) 1 2 1 2 D. Duda , C. Sirard ; Boston, MA/US, Cambridge, US
13:15 - 13:15 92P - Low expression of miR-20a-5p predicts benefit to bevacizumab in metastatic breast cancer patients treated within the TANIA trial 1 1 2 1 1 1 S.P. Gampenrieder , G. Rinnerthaler , H. Hackl , M. Steiner , C. Monzo Fuentes , C. Hufnagl , C.
1 1 1 1 2 Hauser-Kronberger , A. Egle , R. Greil ; Salzburg, AT, Innsbruck, AT
13:15 - 13:15 93P - Characterization of a novel tumor-suppressor gene CHL1 at 3p26.3 in esophageal squamous cell carcinoma H. Wang, Zhengzhou, CN
Last update: 02-09-2017 06:01:33pm esmo.org
13:15 - 13:15 94P - The role of vitamin D receptor polymorphisms in predicting response to therapy in non-muscle invasive bladder carcinoma K.Y. Loh, Z. Wang, Y.K. Lim, R. Mahendran, E. Kesavan, E. Chiong; Singapore, SG
13:15 - 13:15 95P - Gene signatures as potential predictive markers of response to neoadjuvant chemotherapy in ER+/HER2+ breast cancer patients 1 2 3 3 3 3 3 4 E. Risi , A. Grilli , I. Migliaccio , C. Biagioni , C. Guarducci , M. Bonechi , A. McCartney , S. Vitale , L.
3 2 3 3 1 2 3 4 Biganzoli , S. Bicciato , A. Di Leo , L. Malorni ; Prato, PO/IT, Modena, IT, Prato, IT, Siena, IT
13:15 - 13:15 96P - Predictive biomarkers for adjuvant therapy in gastric adenocarcinoma 1 2 3 4 3 3 1 2 E. Pectasides , V. Kotoula , M. Bobos , I. Chatzidakis , S. Chrisafi , G. Fountzilas ; Boston, MA/US,
3 4 Thessaloniki, Central Macedonia/GR, Thessaloniki, GR, Athens, GR
13:15 - 13:15 97P - Large-scale DNA organization is a prognostic marker of breast cancer survival 1 2 3 3 3 3 3 3 1 M. Guillaud , M. Keyes , Q. Ye , A. Carraro , A. Harrison , M. Hayes , A. Nichol , S. Leung ;
2 3 Vancouver, CA, V, CA, Vancouver, BC/CA
13:15 - 13:15 98P - Telomere associated variables and their potential in CLL prognosis N. De Pedro, J.C. Estrada, M. Chiesa, M. Diez, I. Garcia, R. González, B. Garcia, J. García, L. Esteban,
L. Otero, P. Najarro; Madrid, ES
13:15 - 13:15 99P - Micro-RNA profile in advanced metastatic breast cancer as a predictive tool for response to bevacizumab-paclitaxel M. Mendiola, V. Heredia-Soto, J. Herranz, R. Martín, P. Zamora Auñón, B. Castelo, A. Pinto Marin, M.
Miguel, R. Crespo, A. Ramírez de Molina, D. Hardisson, E. Espinosa, A. Redondo; Madrid, ES
13:15 - 13:15 100P - Biomarkers of immune therapy in CUP 1 2 1 2 J. Xiu , Z. Gatalica ; Phoenix, US, Phoenix, AZ/US
13:15 - 13:15 101P - A circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma 1 1 1 1 2 1 1 1 D. Melisi , G. Piro , F. Simionato , C. Carbone , M. Frizziero , G. Malleo , S. Zanini , R. Casolino , R. 1 1 1 1 1 1 1 1 2 Santoro , M. Mina , C. Zecchetto , V. Merz , A. Scarpa , C. Bassi , G. Tortora ; Verona, IT, Vipiteno, Bolzano/IT
13:15 - 13:15 102P - Analytic validation of a next generation sequencing assay to identify tumor mutational burden from blood (bTMB) to support investigation of an anti-PD-L1 agent, atezolizumab, in a first line non-small cell lung cancer trial (BFAST) 1 1 1 1 1 1 2 2 D. Fabrizio , C. Malboeuf , D. Lieber , S. Zhong , J. He , E. White , M. Coyne , J. Silterra , T. 2 2 2 3 3 3 3 3 Brennan , J. Ma , M. Kennedy , E. Schleifman , S. Paul , Y. Li , D. Shames , C. Cummings , E. 3 3 2 1 1 2 3 Peters , M. Kowanetz , D. Lipson , G. Otto ; Cambridge, US, Cambridge, MA/US, South San Francisco, US
13:15 - 13:15 103P - Comparison of continuous measures across diagnostic PD-L1 assays using image analysis
Last update: 02-09-2017 06:01:33pm esmo.org 1 1 2 2 2 1 1 1 T. Wiestler , M. Widmaier , J. Walker , C. Barker , M. Scott , F. Sekhavati , A. Budco , K. Schneider ,
3 4 1 2 3 4 K. Steele , M. Rebelatto ; Munich, DE, Cambridge, GB, Gaithersburg, MD/US, Gaithersburg, US
13:15 - 13:15 104P - Pharmacokinetics (PK) and pharmacodynamics (PD) of a novel carcinoembryonic antigen (CEA) T-cell bispecific antibody (CEA-CD3 TCB) for the treatment of CEA-positive solid tumors 1 2 3 4 5 5 6 6 I. Melero , N. Segal , J. Saro , W. Ros , M. Martinez-Garcia , G. Argiles , V. Moreno , S. Ponce , A. 7 8 9 10 11 12 13 Marabelle , J. Cleary , H. Hurwitz , J. Eder , C. Jamois , E. Andersson , S. Bouseida , F. 13 14 13 3 6 1 2 3 Sandoval , M. Bacac , T. Nayak , V. Karanikas , E. Calvo ; Pamplona, ES, New York, NY/US, 4 5 6 7 8 9 Schlieren, CH, Amsterdam, NL, Barcelona, ES, Madrid, ES, Villejuif, FR, Boston, Ma, US, 10 11 12 13 14 Durham, NC/US, New Haven, Ct, US, Basel, Switzerland/CH, Munich, DE, Basel, CH, Zurich, CH
13:15 - 13:15 105P - Baseline gut microbiota in metastatic melanoma patients treated with ipilimumab: Relation with clinical response and colitis 1 2 3 4 3 3 3 N. Chaput , P. Lepage , C. Coutzac , E. Soularue , V. Asvatourian , E. Lanoy , C. Mateus , F. 4 3 1 2 3 4 Carbonnel , C. Robert ; Villejuif, CEDEX/FR, Jouy-En-josas Cedex, FR, Villejuif, FR, Kremlin Bicêtre, FR
13:15 - 13:15 106P - The association between PD-L1 expression, EGFR mutation and ALK translocation in a series of 982 lung cancers 1 1 1 1 1 1 2 1 1 M. Evans , B. O'Sullivan , M. Smith , F. Hughes , N. Trim , T. Mullis , L. Pallan , P. Taniere ;
2 Birmingham, GB, Birmingham, West Midlands/GB
13:15 - 13:15 107P - Association of tumor and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with response to nivolumab treatment in NSCLC patients S. Sahba, A.-L. Niemeijer, J. De Langen, E. Thunnissen; Amsterdam, NL
13:15 - 13:15 108P - Characterisation of heterogeneity in microsatellite instable (MSI) tumours associated with distinct cell types and immune phenotypes 1 2 2 2 3 2 1 E. Fontana , P. Poudel , G. Nyamundanda , Y. Patil , C. Ragulan , A. Sadanandam ; Sutton,
2 3 Surrey/GB, Sutton, GB, London, GB
13:15 - 13:15 109P - Clinical implication of PLR and PD-L1 in breast cancer patients 1 1 1 1 1 1 1 1 1 1 S. Wang , Q. Lu , T. Qin , F. Xu , Y. Zeng , W. Xia , Q. Zheng , K. Lee , K. Zhang , G. Qin , M.T.
2 1 3 3 1 2 3 Kong , R. Hong , Y. Shi , Z. Yuan ; Guangzhou, CN, Macau, MO, Guangzhou, Guangdong/CN
13:15 - 13:15 110P - Prognostic and predictive value of lymphovascular invasion and lymph node status among breast cancer subtypes G.-S. Liao, H.-M. Hsu, M.-S. Dai, J.-C. Yu; Taipei, TW
13:15 - 13:15 111P - PD-L1 expression in TNBC: A predictive biomarker of response to neoadjuvant chemotherapy? 1 2 2 1 2 2 2 A. Botticelli , B. Cerbelli , A. Pernazza , C.E. Onesti , P. Sciattella , L. Costarelli , M. Monti , D.
2 1 2 1 2 1 2 Campagna , F. Mazzuca , L. Fortunato , P. Marchetti , G. D'Amati ; Roma, IT, Rome, IT
13:15 - 13:15 112P - Pathological evaluation of tumor infiltrating lymphocytes and the benefit of nivolumab in advanced non-small cell lung cancer (NSCLC)
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 3 4 2 2 4 I. Gataa , L. Mezquita , E. Auclin , S. Le Moulec , P. Alemany , M. Kossai , J. Massé , C. 2 2 2 5 2 2 2 CARAMELLA , J. Remon Masip , J. Lahmar , R. Ferrara , A. Gazzah , J.-C. Soria , D. Planchard , B. 2 2 1 2 3 4 5 Besse , J. Adam ; Paris, CEDEX 14/FR, Villejuif, FR, Paris, FR, Bordeaux, FR, Verona, IT
13:15 - 13:15 113P - Could a systemic inflammation response index (SIRI) predict overall survival (OS) in metastatic pancreatic cancer (PC)? 1 1 2 1 1 1 1 V. Pacheco-Barcia , O. Donnay , R. Mondejar , J. Rogado , M.D. Fenor de la Maza , R. Colomer ;
2 Madrid, ES, Cuenca, ES
13:15 - 13:15 114P - Molecular imaging with 18F-fluoroestradiol (18F-FES) to assess intra-patient heterogeneity in metastatic breast cancer (MBC): A European TRANSCAN program 1 2 3 4 5 2 3 4 A. Gennari , E. Brain , O. Nanni , E. Muñoz Couselo , N. Harbeck , R. Geiss , A. Rocca , J. Cortés , 5 1 2 3 1 1 T. Degenhardt , A. Piccardo , J.-L. Albérini , F. Matteucci , A. Decensi , D.S. Corradengo , D. Andreis 3 1 6 7 8 9 1 2 3 , D. Marra , G. Gebhart , C. Brambati , D. Amadori , P. Bruzzi ; Genova, IT, St. Cloud, FR, 4 5 6 7 8 Meldola (fc), IT, Barcelona, ES, Munich, DE, Brussels, BE, Saint Genis Pouilly, FR, Meldola, 9 Forlì-Cesena/IT, Genoa, IT
13:15 - 13:15 115P - Evaluation of a predictive radiomics signature for response to immune checkpoint inhibitors (ICIs) 1 2 2 2 2 3 3 A. Prawira , A. Stundzia , P. Dufort , J. Halankar , D. Paravasthu , A. Spreafico , A. Hansen , A.R. 4 1 1 1 1 3 3 3 Abdul Razak , P. Bedard , M. Butler , S. Lheureux , A. Oza , R. Jang , K. Suta , S. Boross-Harmer ,
3 3 3 5 1 2 3 4 J. Cipollone , H. Chow , U. Metser , L. Siu ; Toronto, Ontario/CA, Toronto, CA, Toronto, ON/CA, 5 Newcastle Upon Tyne, GB, Toronto, On, CA
13:15 - 13:15 116P - Clinical and pre-clinical biomarkers of Regorafenib (REG) efficacy in metastatic colorectal cancer (mCRC) in a phase II trial 1 2 1 1 1 1 1 K. Khan , D. Cunningham , G. Vlachogiannis , S. Hedayat , M. Rata , D.-M. Koh , N. Tunariu , Y. 1 1 3 1 3 1 2 1 1 Jamin , D. Collins , I. Chau , S. Rao , D. Watkins , N. Starling , C. Peckitt , N. Fotiadis , C. Saffery , 1 4 1 2 1 2 3 4 J. Hahne , M. Fassan , C. Braconi , N. Valeri ; London, GB, Sutton, GB, Sutton, Surrey/GB, Padua, IT
13:15 - 13:15 117P - Anti-HER2 therapy efficacy in HER2-negative metastatic breast cancer with HER2-amplified circulating tumor cells: results of the CirCe T-DM1 trial 1 1 2 3 4 5 6 F.-C. Bidard , P. cottu , C. Dubot , L. Venat-Bouvet , A. Lortholary , H. Bourgeois , M. Bollet , V. 7 8 9 10 11 12 1 Servent Hanon , E. Luporsi-Gely , M. Espie , S. Guiu , V. D'Hondt , V. Dieras , M.P. Sablin , S. 1 1 1 11 1 2 3 4 Neffati , F. Berger , J.-Y. Pierga , W. Jacot ; Paris, FR, St. Cloud, FR, Limoges, FR, Nantes, 5 6 7 8 CEDEX 2/FR, Le Mans, FR, Levallois-Perret, FR, Lille, CEDEX/FR, Vandoeuvre Les Nancy, 9 10 11 12 CEDEX/FR, Paris, CEDEX 10/FR, Montpellier, FR, Montpellier, CEDEX 5/FR, Paris, CEDEX 5/FR
13:15 - 13:15 118P - Nationwide external quality assessment (EQA) of EGFR testing in circulating tumor DNA: The French experience 1 2 2 3 4 4 4 M. Denis , A. Vallée , S. Charpentier , I. Nanni-Métellus , L. Lacroix , C. Jovelet , M. Francilette , D. 5 5 6 1 2 3 4 Fetique , J.-P. Bellocq , E. Rouleau ; Nantes, CEDEX 1/FR, Nantes, FR, Marseille, FR, Villejuif, 5 6 FR, Strasbourg, FR, Paris, CEDEX 5/FR
Last update: 02-09-2017 06:01:33pm esmo.org 13:15 - 13:15 119P - IL-8 as a pharmacodynamic biomarker for TGF-β2 antisense (trabedersen) therapy: Results of a phase II trial 1 1 1 1 1 2 1 2 L. Hwang , W. Wang , S. Qazi , K. Ng , O. D’cruz , V. Trieu ; Costa Mesa, US, Costa Mesa, CA/US
13:15 - 13:15 120P - Predictive assay for anti-angiogenic agents (AADx) identifies molecular subgroups of RASwt mCRC with differential efficacy of FOLFIRI plus bevacizumab in the FIRE-3 (AIO KRK-0306) trial 1 2 2 2 3 2 2 4 S. Stintzing , B. Price , L. Knight , A. McCavigan , S. Walker , P. Harkin , R. Kennedy , D. Neureiter , 5 6 1 1 1 2 3 S. Held , A. Jung , T. Kirchner , V. Heinemann ; Munich, DE, Craigavon, GB, New York, 4 5 6 California/US, Salzburg, AT, Leverkusen, DE, München, DE
13:15 - 13:15 121P - Influence of HIF-2alpha deregulation and overexpression of VEGF ligands on the response to aflibercept: Identification of predictive biomarkers 1 1 1 1 2 3 1 A. LARSEN , S. Thouroude , L. Louadj , M. Sabbah , E. Dochy , A. de Gramont , J. Denis , A.
1 1 2 3 Bouygues ; Paris, FR, Bruxelles, BE, Levallois-Perret, FR
13:15 - 13:15 122P - Cell-free (cf)DNA analysis identifies PIK3CA/AKT1 mutations associated with greater PFS improvement from the addition of ipatasertib (IPAT) to paclitaxel (P) in triple-negative breast cancer (TNBC) 1 2 3 4 4 5 6 6 M. Wongchenko , R. Dent , S.-B. Kim , C. Saura , M. Oliveira , J. Baselga , A. Kapp , W. Chan , S. 6 6 6 1 2 3 4 5 Singel , D. Maslyar , S. Gendreau ; Hillsboro, US, Singapore, SG, Seoul, KR, Barcelona, ES, 6 New York, US, South San Francisco, US
13:15 - 13:15 123P - Genotyping circulating tumor DNA identifies metastatic colorectal cancer (mCRC) patients highly sensitive to Sym004 1 2 3 1 4 5 C. Montagut Viladot , A. Bardelli , T. Tuxen Poulsen , R. Dienstmann , M. Kragh , S. Kopetz , K. 3 6 7 1 3 8 3 Koefoed , F. Ciardiello , C. Ding , J. Vidal , J. Clausell-Tormos , G. Siravegna , T. Lindsted , M.W. 3 8 1 3 3 1 1 2 Pedersen , G. Rospo , G. Argilés Martinez , P. Nadler , I. Horak , J. Tabernero ; Barcelona, ES, 3 4 5 6 7 8 Candiolo, (TO)/IT, Ballerup, DK, -, DK, Houston, US, Naples, IT, Somerville, New Jersey, US, Candiolo, IT
13:15 - 13:15 124P - Role of circulating miRNAs as prognostic biomarkers in resected early-stage non-small cell lung cancer 1 1 2 1 1 1 1 2 P. Ulivi , E. Petracci , V. Ludovini , G. Marisi , A. Delmonte , N. De Luigi , D. Calistri , L. Crinò , D. 3 4 4 4 1 2 3 Amadori , R. Chiari , S. Baglivo , F. Grignani ; Meldola, IT, Perugia, (PG)/IT, Meldola, 4 Forlì-Cesena/IT, Perugia, IT
13:15 - 13:15 125P - Targeted methylation sequencing of plasma cell-free DNA identifies patients with advanced breast, colorectal, non-small cell lung cancer, melanoma with poor outcomes 1 2 3 4 3 3 3 2 A. Jassowicz , L. Liu , H. Huang , D. Hong , A. Naing , V. Subbiah , S. Piha-Paul , J. Toung , R. 2 2 2 3 3 3 3 3 Vijayaraghavan , R. Zhang , H. Kang , S. Fu , A. Tsimberiodou , C. Lu , C. Eng , S. Moulder , S.
4 3 4 3 1 2 3 Kopetz , R. Amaria , F. Meric-Bernstam , F. Janku ; Heidelberg, DE, San Francisco, US, Houston, 4 TX/US, Houston, US
13:15 - 13:15 126P - Single-cell combined mutation and gene expression studies of circulating tumor-associated cells in non-small cell lung cancer
Last update: 02-09-2017 06:01:33pm esmo.org J. Mong, J. Shi, T.M. Chin, S.-W. Wong, A. Tee, D. Chan, K. Wong, S. Yeap, L. Ngo, Y.-O. Tan, M. Hu, J.
Ying, M.-H. Tan; Singapore, SG
13:15 - 13:15 127P - EGFR copy number aberrations detected in cfDNA from advanced NSCLC patients 1 2 3 3 2 2 1 2 3 G. O'Kane , T. Li , M. Tsao , G. Liu , T. Pugh , N. Leighl ; Dublin, IE, Toronto, CA, Toronto, Ontario/CA
13:15 - 13:15 128P - Detection of esophageal cancer patients using circulating serum microRNA from the result of comprehensive analysis 1 1 2 1 1 1 1 3 3 K. Kato , K. Sudo , N. Boku , S. Abe , Y. Saito , K. Koyanagi , H. Daiko , J. Kawauchi , S. Takizawa 1 4 1 1 1 1 2 , H. Sakamoto , S. Niida , F. Takeshita , J. Matsuzaki , T. Ochiya ; Tokyo, JP, Kawasaki, 3 4 Kanagawa/JP, Kamakura, JP, Ohbu, JP
13:15 - 13:15 129P - First prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis 1 2 3 4 5 6 J. Garcia Foncillas , J. Tabernero , E. Aranda Aguilar , M. Benavides , C.J. Camps , R. López , C. 2 7 8 1 1 2 1 Montagut , A. Anton Torres , G. Lopez Vivanco , E. Diaz Rubio , F. Rojo , A. Vivancos ; Madrid, ES,
2 3 4 5 6 7 Barcelona, ES, Cordoba, ES, Malaga, ES, Valencia, ES, Santiago De Compostela, ES, Zaragoza, 8 ES, Barakaldo, ES
13:15 - 13:15 130P - EGFR plasma testing in routine practice by real-time PCR in lung cancer patients: Experience of 262 patients 1 1 1 1 1 1 1 1 P. Taniere , P. Taniere , M. Smith , B. O'Sullivan , F. Hughes , T. Mullis , N. Trim , S. Baijal , Q. 2 3 1 2 3 Ghafoor , G. Middleton ; Birmingham, GB, Birmingham, Birmingham/GB, Birmingham, West Midlands/GB
13:15 - 13:15 131P - Circulating tumor cells as liquid biopsy for castration resistant prostate cancer patients treated with cabazitaxel 1 2 1 1 1 1 3 4 S. Salvi , V. Conteduca , V. Casadio , P. Fici , G. Gurioli , F. Martignano , U. Basso , G. Fornarini , 2 2 1 1 2 1 2 C. Lolli , G. Schepisi , S. Testoni , D. Calistri , U. De Giorgi ; Meldola, IT, Meldola, Forlì-Cesena/IT, 3 4 Padova, IT, Genova, IT
13:15 - 13:15 132P - Biomarker analysis using circulating tumor DNA in patients treated with sorafenib for advanced hepatocellular carcinoma 1 1 2 3 1 4 4 4 1 S.R. Park , C.R. Oh , S.-Y. Kong , M.K. Kim , K.-A. Yoon , E. Cho , J.-H. Jang , J. Lee , B.-Y. Ryoo ;
1 2 3 4 Seoul, KR, Goyang, KR, Gyeonggi-Do, KR, Yongin, KR
13:15 - 13:15 133P - Heparinase enables reliable quantification of circulating tumor DNA from heparin plasma samples by droplet digital PCR 1 1 2 1 1 1 1 1 D. Sefrioui , L. Beaussire , F. Clatot , A. Perdrix , P. Michel , F. Di Fiore , N. Sarafan-Vasseur ;
2 Rouen, FR, Rouen, CEDEX 1/FR
13:15 - 13:15 134P - Circulating tumour DNA (ctDNA) in the clinical management of patients (pts) with advanced non-small cell lung cancer (NSCLC): A single centre experience
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 3 4 2 2 M. Uccello , M. Kushnir , G. Mak , C. Murias Henriquez , C. Abbosh , D. Papadatos-Pastos , T. 2 2 2 5 6 7 2 1 Newsom-Davis , T. Ahmad , C. Swanton , M. Forster , R. Lanman , I. Faull , H.-T. Arkenau ;
2 3 4 5 6 Catania, IT, London, GB, London, UK/GB, Las Palmas, Canary Island/ES, London, London/GB, 7 Redwood City, CA/US, Madrid, Barcelona/ES
13:15 - 13:15 135P - Genome-wide methylation analysis reveals a prognostic classifier for non-metastatic colorectal cancer (ProMCol) M. Gündert, D. Edelmann, A. Benner, L. Jansen, M. Jia, V. Walter, P. Knebel, E. Herpel, J.
Chang-Claude, M. Hoffmeister, H. Brenner, B. Burwinkel; Heidelberg, DE
13:15 - 13:15 136P - Epigenetic biomarkers in breast cancer: Preliminary results from H3K27m3 assessment in endocrine-treatment resistance M. Fontes-Sousa, S. Lobo, S. Salta, P. Lopes, J. Lobo, S. Sousa, R. Henrique, C. Jeronimo; Porto, PT
13:15 - 13:15 137P - Bioinformatic estimate of biomarker-positive populations in genomics-driven trials using precision trial designer (PTD) 1 2 1 1 3 1 4 L. Mazzarella , G. Melloni , A. Guida , G. Curigliano , E. Botteri , A. Esposito , M. Kamal , C. Le
4 1 1 1 2 3 4 Tourneau , L. Riva , P. Pelicci ; Milan, IT, Boston, MA/US, Oslo, NO, Paris, FR
13:15 - 13:15 138P - Detection of microsatellite instability (MSI) in colorectal cancer samples with the automated Idylla MSI Test G. Maertens, B. De Craene, E. Rondelez, K. Peeters, L. Vandenbroeck, L. Van Puymbroeck, G.
Vandercruyssen, E. Sablon; Mechelen, BE
13:15 - 13:15 139P - Gene expression BIRC5, Erb-b2/Her2-neu, ESR1, PGR1, MMP11, MDR1, MRP1, MXR at the CTCs in the primary breast cancer Y. Shliakhtunou, Vitebsk, BY
13:15 - 13:15 140P - Metabolic syndrome and inflammation in castration resistant prostate cancer (CRPC) patients (pts) treated with abiraterone (abi) and enzalutamide (enza) 1 2 3 4 4 2 5 1 V. Conteduca , O. Caffo , L. Galli , A. Maugeri , E. Scarpi , F. Maines , V. Chiuri , C. Lolli , S. 2 1 6 7 8 4 4 1 Kinspergher , G. Schepisi , M. Santoni , D. Santini , L. Fratino , S.L. Burgio , S. Salvi , C. Menna , U.
1 1 2 3 4 5 6 7 De Giorgi ; Meldola, Forlì-Cesena/IT, Trento, IT, Pisa, IT, Meldola, IT, Lecce, IT, Ancona, IT, 8 Roma, IT, Aviano, IT
13:15 - 13:15 141P - Ischemic stroke and cancer correlation: A stroke unit experience M. Rodrigues, R. Costa, S. Brito, A. Pissarra, A. Lourenço, F. Grenho, L. Campos; Lisbon, PT
13:15 - 13:15 142P - longitudinal exploratory analysis of prior- surgery everolimus circulating and clinical biomarkers in locally advanced and metastatic renal cell carcinoma patients (RCC) 1 1 1 1 1 1 2 3 R. Elaidi , D. Helley , L. Mauge , C. Badoual , E. Tartour , E. Braychenko , L. Albiges , B. Escudier ,
1 1 2 3 S. Oudard ; Paris, FR, Villejuif, CEDEX/FR, Villejuif, FR
13:15 - 13:15 143P - A comparison of treatment recommendations by molecular tumor boards worldwide D. Rieke, S. Leyvraz, S. Burock, U. Keilholz; Berlin, DE
Last update: 02-09-2017 06:01:33pm esmo.org 13:15 - 13:15 144P - Identification of germline mutation using 30-gene sequencing and clinical characteristic of Chinese with hereditary breast cancer 1 2 3 3 3 1 2 3 A. Kwong , V. Shin , C.-H. Au , T.-L. Chan , E. Ma ; Hong Kong, HK, Pokfulam, HK, Happy Valley, HK
13:15 - 13:15 145P - Selecting patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of MGMT 1 2 3 3 4 4 4 5 S. Schwartz , F. Cecchi , Y. Tian , K. Scott , M. Di Bartolomeo , F. Morano , G. Fucà , A. Martinetti , 4 6 4 7 7 7 4 F. De Braud , F. Dominoni , M. MILIONE , M.A. Calegari , A. Orlandi , C. Barone , F. Pietrantonio , T.
2 1 2 3 4 5 6 Hembrough ; Rockville, US, New York, US, Rockville, MD/US, Milan, IT, No City Provided, NA, 7 Milano, IT, Roma, IT
13:15 - 13:15 146P - Predicting response to chemotherapy in gastric cancer patients randomized to docetaxel: A reevaluation of the ITACA-S trial 1 2 3 3 4 5 5 F. Cecchi , D. Catenacci , S. Schwartz , S. Sellappan , Y. Tian , R. Miceli , F. Pietrantonio , A. 5 6 5 1 1 2 3 Pellegrinelli , A. Martinetti , M. Di Bartolomeo , T. Hembrough ; New York, US, Chicago, IL/US, 4 5 6 Rockville, US, Rockville, MD/US, Milan, IT, No City Provided, NA
13:15 - 13:15 147P - The nationwide cancer genome screening project in Japan SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced pancreatic cancer 1 2 3 4 5 6 7 D. Naruge , C. Morizane , M. Ueno , H. Takahashi , Y. Kawamoto , K. Sudo , S. Shimizu , T. 8 9 10 11 12 6 6 2 13 Nakajima , S. Itoh , H. Ishii , T. Kato , T. Kudo , M. Izumi , T. Sudo , S. Nomura , T. Kuwata , S. 13 4 4 4 1 2 3 4 Fujii , K. Shitara , A. Ohtsu , T. Yoshino ; Mitaka, Tokyo, JP, Tokyo, JP, Yokohama, JP, 5 6 7 8 9 Kashiwa, Chiba/JP, Sapporo, Hokkaido/JP, Chiba, JP, Saitama, JP, Kanagawa, JP, Fukuoka, JP, 10 11 12 13 Matsuyama, JP, Amagasaki, Hyogo/JP, Suita, Osaka/JP, Kashiwa, JP
13:15 - 13:15 BREAST CANCER, EARLY STAGE 1 2 1 2 E. De Azambuja , M. Arnedos ; Brussels, BE, Villejuif, FR
13:15 - 13:15 164P - Impact of lack of surgery on outcomes in elderly patients with non-metastatic breast cancer (BC): A population based study using the SEER 18 data base 1 2 1 2 C. Truica , M. Yin ; New York, US, Hershey, PA/US
13:15 - 13:15 166P - Eight-year follow up results of the OTOASOR trial: The optimal treatment of the axilla – surgery or radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer. A randomized, single centre, phase III, non-inferiority trial Á. Sávolt, G. Peley, C. Polgár, B. Győrffy, Z. Mátrai; Budapest, HU
13:15 - 13:15 167P - Time to surgery in early breast cancer treated with neoadjuvant chemotherapy 1 2 1 1 1 2 2 2 M. Cinausero , G. Galli , D. Basile , L. Gerratana , G. Fasola , F. De Braud , M. Sant , B. Paolini , S.
2 1 1 2 Di Cosimo , F. Puglisi ; Udine, IT, Milan, IT
13:15 - 13:15 168P - Updated results of the Breast cancer task force phase II study of neoadjuvant weekly carboplatin (Cp) added to paclitaxel (P) followed by epirubicin (E) and cyclophosphamide (C) in triple negative breast cancer (TNBC) patients (pts)
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 3 4 5 6 2 C. Fontaine , N. Cappoen , V. Renard , H. Van Den Bulk , P. Vuylsteke , P. Glorieux , L. Decoster , 2 2 7 8 1 2 3 4 M. Vanhoeij , J. De Grève , A. Awada , H. Wildiers ; Brussels, BE, Jette, BE, Gent, BE, 5 6 7 8 Bonheiden, BE, Namur, BE, Arlon, BE, Brussel, BE, Leuven, BE
13:15 - 13:15 169P - Neoadjuvant eribulin following anthracycline and taxane in triple negative breast cancer (HOPE): A multicenter, two stage, phase II trial 1 2 3 4 1 2 1 S. Di Cosimo , N. Laverde , M. Cazzaniga , D. Generali , G.V. Bianchi , E. Tagliabue , V. Torri , F. 1 1 1 5 5 1 1 1 1 Crippa , B. Paolini , G. Scaperrotta , A. Gulino , C. Tripodo , M. Colombo , S. Folli , F. de Braud ; 2 3 4 5 Milan, IT, Milano, IT, Monza, IT, Cremona, (CR)/IT, Palermo, IT
13:15 - 13:15 170P - Impact of neoadjuvant therapy (NT) and pathological complete response (pCR) on breast-conserving surgery (BCS) in patients (pts) with breast cancer (BC): A meta-analysis 1 2 2 1 2 3 1 1 C. Criscitiello , M. Golshan , W. Barry , G. Viale , S. Wong , M. Santangelo , G. Curigliano ; Milan,
2 3 IT, Boston, US, Naples, IT
13:15 - 13:15 171P - Composite index of risk shows that benefit from adjuvant dose dense chemotherapy is not confined to triple negative breast cancer 1 2 1 3 4 2 4 F. Puglisi , M. Ceppi , L. Gerratana , F. Cognetti , S. De Placido , P. Bruzzi , M. De Laurentiis , G. 5 6 7 7 8 9 10 11 Bisagni , G. Cavazzini , A. Durando , A. Turletti , E. Valle , F. Montemurro , S. Barni , A. Ardizzoni 12 13 2 1 2 3 4 5 , G. Colantuoni , T. Gamucci , L. Del Mastro ; Udine, IT, Genova, IT, Roma, IT, Napoli, IT, 6 7 8 9 10 11 Reggio Emilia, IT, Mantova, IT, Torino, IT, Cagliari, IT, Candiolo, (TO)/IT, Treviglio, (BG)/IT, 12 13 Bologna, IT, Avellino, IT, Sora, Frosinone/IT
13:15 - 13:15 172P - The prognostic impact of chemotherapy induced amenorrhea in women treated with early stage breast cancer 1 2 2 2 2 2 2 2 2 C. Ordu , K. Pilancı , F. Elbüken , G. Alço , Ü. Köksal , S. İlgün , D. Sarsenov , A. Aydın , A. Öztürk , 2 2 2 2 2 2 1 Z. Erdoğan , F. Ağaçayak , C. Tecimer , Y. Eralp , F. Aktepe , V. Özmen ; Istanbul, Balıkesir 2 Province/TR, Istanbul, TR
13:15 - 13:15 173P - Determinants and outcomes associated with delays in adjuvant chemotherapy among breast cancer patients M. Chavez Mac Gregor, X. Lei, H. Zhao, S. Giordano; Houston, TX/US
13:15 - 13:15 174P - Adjuvant chemotherapy in pT1ab node-negative triple negative breast carcinomas: Results of a national multi-institutional retrospective study 1 2 2 2 3 4 5 A. De Nonneville , A. Gonçalves , C. Zemmour , M. Cohen , J.M. Classe , F. Reyal , P.E. Colombo , 6 7 8 1 1 2 2 1 E. Jouve , S. Giard , E. Barranger , R. Sabatier , F. Bertucci , J.M. Boher , G. Houvenaeghel ;
2 3 4 5 6 Marseille, CEDEX 9/FR, Marseille, FR, Saint Herbain, FR, Paris, FR, Montpellier, FR, Toulouse, 7 8 FR, Lille, FR, Nice, CEDEX 2/FR
13:15 - 13:15 175P - OHERA: A real world study of cardiac events in & 1 2 3 4 5 5 5 E. Lidbrink , J. Erfan , E. Chmielowska , B. Otremba , A. Bouhlel , S. Lauer , M. Liste Hermoso , E. 5 6 7 1 2 3 4 5 Nüesch , M. Shing , V. Misra ; Stockholm, SE, Nyiregyhaza, HU, Torun, PL, Oldenburg, DE, 6 7 Basel, CH, San Francisco, US, Manchester, GB
Last update: 02-09-2017 06:01:33pm esmo.org 13:15 - 13:15 176P - Clinical outcomes of delayed start of trastuzumab treatment in patients with early breast cancer: ml25232 study 1 1 1 1 1 1 1 S. Beslija , T. Ceric , B. Hasanbegovic , A. Kurtovic-Kozaric , A. Pasic , N. Mahic , M. Kalamujic , A. 1 2 3 4 1 2 3 Cardzic , J. Alidzanovic , I. Marjanovic , A. Mekic-Abazovic ; Sarajevo, BA, Tuzla, BA, Mostar, BA, 4 Zenica, BA
13:15 - 13:15 177P - Effects of neratinib (N) on health-related quality of life (HRQoL) in early-stage HER2+ breast cancer (BC): longitudinal analyses from the phase III ExteNET trial 1 2 3 4 5 6 7 8 9 S. Delaloge , Y. Ye , D. Cella , M. Buyse , A. Chan , C. Barrios , F.A. Holmes , J. Mansi , H. Iwata , 10 11 12 13 14 15 16 B. Ejlertsen , B. Moy , G. von Minckwitz , S. Chia , M. Gnant , S. Smichkoska , A. Ciceniene 2 2 17 18 1 2 3 , S. Moran , A. Auerbach , L. Fallowfield , M. Martin Jimenez ; Villejuif, FR, Los Angeles, CA/US,
4 5 6 7 8 Chicago, IL/US, San Francisco, CA/US, Perth, AU, Porto Alegre, BR, Houston, TX/US, London, 9 10 11 12 13 GB, Chikusa-Ku, Nagoya, JP, Copenhagen, DK, Boston, MA/US, Neu-Isenburg, DE, 14 15 16 17 18 Vancouver, BC/CA, Vienna, AT, Skopje, MK, Vilnius, LT, Brighton, GB, Madrid, ES
13:15 - 13:15 178P - Second interim analysis of HerSCin, a German non-interventional study of subcutaneous trastuzumab for HER2-positive early breast cancer in routine clinical practice 1 2 3 4 5 6 K. Lüdtke-Heckenkamp , S. Kümmel , A. Ruf-Dördelmann , A. Distelrath , J. Wacker , S. Schmatloch , 7 8 1 2 3 4 5 S. Busch-Liles , M. Schmidt ; Georgsmarienhütte, DE, Essen, DE, Karlsruhe, DE, Fulda, DE, 6 7 8 Bruchsal, DE, Kassel, DE, Grenzach Wyhlen, DE, Mainz, DE
13:15 - 13:15 179P - Timing of initiation of trastuzumab (T) and long-term outcome of patients (pts) with early-stage (ES) HER2-positive (HER2+) breast cancer (BrCa): Impact of neo-adjuvant (NAdj) versus adjuvant (Adj) strategy 1 1 1 2 1 1 1 G. Gullo , N. Walsh , D. Fennelly , D. Tryphonopoulos , J. Walshe , K. O'Mahony , N. Silva , L.
1 1 1 1 1 1 2 Hammond , J. Ballot , C. Quinn , C. Buckley , J. Crown ; Dublin, IE, Athens, GR
13:15 - 13:15 180P - Adjuvant endocrine treatment: Stop or continue? 1 2 1 1 2 E. Muller , A. van de Wouw , D. van Dreuten ; Doetinchem, NL, Venlo, NL
13:15 - 13:15 181P - Use and effectiveness of adjuvant ovarian function suppression (OFS) in premenopausal women with early breast cancer 1 1 1 1 1 1 1 A. Ferreira , J. Ribeiro , A. Mayer , M. Brito , A. Miranda , J. Fernandes , J. Passos-Coelho , L. Costa
1 2 1 2 , I. Vaz-Luís ; Lisbon, PT, Villejuif, FR
13:15 - 13:15 182P - A phase II randomised study of Adjuvant hypo-fractionated radiotherapy with concurrent vs sequential letrozole in post-menopausal women with hormone receptor positive breast cancer: Report of pulmonary toxicity and cosmetic outcome 1 2 2 2 1 2 R. Upadhyay , D.N. Sharma , P. Julka , G. Rath ; New Delhi, Delhi/IN, New Delhi, IN
13:15 - 13:15 183P - Intrinsic tumor features underlying clinical subtype discordance in early breast cancer 1 2 1 1 1 1 1 V. Kotoula , E. Giannoulatou , K. Papadopoulou , I. Tikas , K. Manousou , M. Bobos , S. Lakis , G. 1 1 1 3 4 1 1 Lazaridis , I. Efstratiou , F. Zagouri , G. Pentheroudakis , H. Gogas , C. Christodoulou , A. Koutras ,
1 5 1 1 1 6 1 A. Psyrri , C. Papandreou , P. Papakostas , D. Bafaloukos , D. Pectasides , G. Fountzilas ; Athens, 2 3 4 5 6 GR, Darlinghurst, NSW/AU, Ioannina, GR, Athens, Attiki/GR, Larissa, GR, Thessaloniki, GR
Last update: 02-09-2017 06:01:33pm esmo.org
13:15 - 13:15 184P - Distribution of genomically defined recurrence risk in luminal A and B breast tumors defined by inmunohistochemistry: A retrospective study in Spanish population S. Perez Ramirez, M. del Monte-Millán, S. López-Tarruella, I. Márquez-Rodas, Y. Jerez, F. Lobo Samper, Y. Izarzugaza Peron, N. Martínez Jañez, J.A. García-Saenz, F. Moreno Antón, P. Zamora Auñón, M.
Arroyo Yustos, M.Á. Lara Álvarez, E.M. Ciruelos Gil, L. Manso Sánchez, M.J. Echarri González, J.A. Guerra Martínez, C. Jara Sánchez, V. Valentín Maganto, M. Martin Jimenez; Madrid, ES
13:15 - 13:15 185P - The first report of multicenter validation study of 95-gene classifier, a multi-gene prognostic assay of estrogen receptor positive and node negative breast cancer patients 1 2 2 3 3 4 4 5 T. Kinoshita , K. Aogi , M. Takahashi , K.-I. Ito , T. Oba , N. Shiroma , K. Arihiro , F. Tsukamoto , S. 1 1 2 1 2 3 4 5 Shiino , M. Yoshida , S. Ohsumi ; Tokyo, JP, Matsuyama, JP, Matsumoto, JP, Hiroshima, JP, Osaka, Osaka/JP
13:15 - 13:15 186P - Breast cancer PAM50 subtypes: Correlation between RNA-Seq and multiplexed gene expression platforms 1 1 1 1 1 A. Picornell , I. Echavarria Diaz-Guardamino , E. Alvarez Castillo , S. Lopez-Tarruella Cobo , Y. Jerez 2 2 1 1 1 1 , K. Hoadley , J. Parker , M. del Monte-Millán , R. Ramos Medina , J. Gayarre , I. Ocaña , M. 1 1 1 1 3 Cebollero , T. Massarrah , F. Moreno Antón , J.A. García-Saenz , H. Gomez Moreno , A.I. Ballesteros 1 4 2 1 1 2 3 Garcia , M. Ruíz-Borrego , C. Perou , M. Martin Jimenez ; Madrid, ES, Chapel Hill, NC/US, Lima, 4 PE, Sevilla, ES
13:15 - 13:15 187P - Summary of head-to-head comparisons of patient (pt) risk classifications by the 21-gene recurrence score (RS) assay and other genomic assays for early breast cancer (EBC) 1 2 3 3 3 3 3 4 1 Z. Varga , P. Sinn , D. McCullough , A. Lau , M. Stöppler , F. Baehner , C. Chao , A. Seidman ;
2 3 4 Pecs, HU, Heidelberg, DE, Redwood City, CA/US, New York, NY/US
13:15 - 13:15 188P - The impact of Oncotype DX breast cancer assay results on clinical practice: A UK experience 1 2 3 1 4 5 1 1 V. Crolley , H. Marashi , S. Rawther , M. Parton , J. Graham , A. Vinayan , S. Sutherland , A. Rigg , 6 7 1 8 1 1 1 2 A. Wadhawan , C. Harper-Wynne , E. Spurrell , H. Bond , F. Raja , J. King ; London, GB, Glasgow, 3 4 5 6 7 8 GB, Sheffield, GB, Northallerton, GB, Stevenage, GB, Cardiff, GB, Maidstone, GB, Truro, GB
13:15 - 13:15 189P - Enhancing decision-making about adjuvant chemotherapy in ER+, HER2- early breast cancer (EBC) following EndoPredict testing 1 1 1 1 2 1 1 3 L. Fallowfield , S. May , L. Matthews , V. Jenkins , J. Mackay , A. Arbon , B. Hack , J. Hall , C. 4 5 6 7 8 1 1 Harper-Wynne , S. Hinde , A. Moss , E. Thanopoulou , S. Westwell , D. Wlaszly , R. Simcock , D.
1 9 1 2 3 4 5 Bloomfield , G. Patel ; Brighton, GB, London, London/GB, Dartford, GB, Maidstone, GB, York, 6 7 8 9 GB, Brighton, Merseyside/GB, Guildford, GB, Eastbourne, GB, London, GB
13:15 - 13:15 190P - Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients 1 1 1 1 1 1 V. Allouchery , L. Beaussire , A. Perdrix , D. Sefrioui , L. Augusto , C. Guillemet , N. Sarafan-Vasseur
1 1 2 1 2 , F. Di Fiore , F. Clatot ; Rouen, FR, Rouen, CEDEX 1/FR
13:15 - 13:15 191P - Pathological proliferation score to predict genomic risk categories in early stage breast cancer
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 1 3 4 5 1 1 A. Bulbul , D. Tsao-Wei , E.A. Mino , A. Mustafa , S. Rashad , H. Abboud , S. Chouial , T. Braik , K. 1 6 1 2 3 4 5 Masoud , D. Tripathy ; Carlsbad, NM/US, Los Angeles, CA/US, Jammu, IN, Chicago, IL/US, 6 Monee, IL/US, Houston, TX/US
13:15 - 13:15 192P - Population sizes of patients (pts) with node negative (N0), HR+, HER2− primary breast cancer (BC), using standard and TAILORx 21-gene recurrence score (RS) cut-off values (COV) 1 2 3 3 4 1 2 J.-U. Blohmer , M. Verrill , C. Fortmann , C. Chao , J. Gligorov ; Berlin, DE, Newcastle Upon Tyne,
3 4 GB, Redwood City, CA/US, Paris, FR
13:15 - 13:15 193P - Oncotype DX score, menopausal status and body mass index 1 2 1 3 1 1 1 2 S. Picardo , J. Sui , M. Greally , B. Woulfe , L. Prior , L. Corrigan , C. O'Leary , W. Mullally , J. 1 1 4 5 1 3 5 1 2 Walshe , J. McCaffrey , M. O'Connor , D. O'Mahony , L. Coate , R. Gupta , S. O'Reilly ; Dublin, IE, 3 4 5 Cork, IE, Limerick, IE, Waterford, CO/IE, Cork, Cork/IE
13:15 - 13:15 194P - Comparisons of tumor-infiltrating lymphocytes and 21-gene recurrence score in ER-positive/HER2-negative breast cancer S.G. Ahn, Y.J. Cha, C. Yoon, S.J. Bae, J. Kim, J. Jeong; Seoul, KR
13:15 - 13:15 195P - The 70-gene signature in node positive breast cancer: 10-year follow-up of the observational RASTER study 1 1 2 1 1 1 S. Vliek , V. Retel , C. Drukker , J.M. Bueno-De-Mesquita , E. Rutgers , H. van Tinteren , M.J. van de
1 1 1 1 1 2 Vijver , J. Wesseling , W. van Harten , S. Linn ; Amsterdam, NL, Dordrecht, NL
13:15 - 13:15 196P - Higher expression of estrogen response genes in the primary tumor is associated with a greater risk for late recurrence in patients with ER+/HER2-breast cancer 1 2 1 1 1 2 R. Bense , E.G.E. de Vries , C. Schröder , R. Fehrmann ; Groningen, NL, Cluj-Napoca, RO
13:15 - 13:15 197P - Understanding BRCA1 and BRCA2 mutated breast cancer cases in Romania: First report on founder mutations in Romanians 1 1 1 1 1 2 2 1 A. Eniu , L. Pop , A. Stoian , E. Dronca , R. Matei , M. Ligtenberg , H. Ouchene , A. Onisim , O.
1 3 1 1 2 3 Rotaru , R. Eniu , N. Antone ; Cluj-Napoca, RO, Nijmegen, NL, Cardiff, GB
13:15 - 13:15 198P - The prevalence of CD146 expression in breast cancer subtypes and its relation to outcome I. de Kruijff, A. Timmermans, M. den Bakker, A. Trapman, R. Foekens, E. Oomen-De Hoop, M. Smid, A. Tjon A Fat - Hollestelle, C. van Deurzen, M. Meijer - van Gelder, J. Foekens, J. Martens, S. Sleijfer; Rotterdam, NL
13:15 - 13:15 199P - Neutrophil-to-lymphocyte and lymphocyte-to-monocyte ratios in breast cancer L. Gerratana, D. Basile, S. Zago, M.G. Vitale, G. Pelizzari, M. Bonotto, C. Bozza, M. Bartoletti, V. Fanotto, C. Lisanti, M. Cinausero, S. Barban, M. Lera, I. Venuti, M. Mansutti, A.M. Minisini, G. Fasola, F. Curcio; Udine, IT
13:15 - 13:15 200P - Vitamin D as a prognostic factor in triple negative early breast cancer S. Morales, A. Gasol Cudos, A. Novell Alvarez, F. Vilardell Villellas, M.J. Panades Siurana, C. Canosa
Morales, J. Mele Olive, E. Iglesias Martinez; Lleida, ES
13:15 - 13:15 201P - CDK12: New breast and ovarian cancer predisposition gene in Tatar population?
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 1 1 1 2 1 E. Shagimardanova , O. Brovkina , M. Gordiev , R. Enikeev , L. Shigapova , D. Khodyrev , O. Gusev
2 2 2 1 2 , A. Kedrova , V. Kosiy , A. Nikitin ; Kazan, RU, Moscow, RU
13:15 - 13:15 202P - Prognostic value of master transcriptional regulators (MTRs) in early stage breast cancer 1 2 2 2 2 1 1 S. Barron , K. Jirström , B. Nodin , H. Jernström , C. Ingvar , B. Moran , C.-J.A. Wang , T. Loughman
1 1 1 1 1 1 2 , B. Fender , P. Dynoodt , C. Lopez-Ruiz , W. Gallagher ; Dublin, IE, Lund, SE
13:15 - 13:15 203P - Survival outcomes of all patients treated with breast carcinosarcoma at a UK specialist cancer centre over a 10 year period (2004–2014) 1 2 2 1 2 M. Alameddine , J. Chan , F. Alam ; Wirral, Merseyside/GB, Wirral, GB
13:15 - 13:15 204P - ESR1, Ph-mTOR, CDK4/6 and PD-L1 expression as prognostic (and potentially druggable) drivers for pure invasive lobular breast carcinoma (ILC): Preliminary results of prognostic outliers according to a clinical-pathological model 1 1 1 1 2 3 3 4 L. Carbognin , M. Brunelli , E. Manfrin , A. Caliò , I. Sperduti , M.V. Dieci , G. Griguolo , V. Guarneri , 1 1 1 1 3 1 1 3 R. Nortilli , S. Pilotto , E. Fiorio , V. Parolin , E. Orvieto , F. Pellini , G. Pollini , P.F. Conte , A. Scarpa 1 1 1 1 2 3 4 , G. Tortora , E. Bria ; Verona, IT, Rome, IT, Padova, IT, Padua, IT
13:15 - 13:15 205P - The pregnancy and fertility (PREFER) study: A prospective cohort study on fertility-preserving (FP) strategies in young early breast cancer (EBC) patients (pts) 1 2 1 1 1 1 1 C. Dellepiane , M. Lambertini , V. Fontana , F. Poggio , E. Blondeaux , B. Conte , A. D'Alonzo , M. 1 1 1 1 1 1 1 1 1 Vaglica , C. Bighin , G. Iacono , A. Abate , S. Pastorino , M.C. Pescio , P. Anserini , L. Del Mastro ; 2 Genova, IT, Brussels, BE
13:15 - 13:15 206P - Incidence of permanent alopecia following adjuvant chemotherapy in women with early stage breast cancer J. Crown, J. Walshe, D. Fennelly, J.-C. Long, S. Cairney, D. McDonnell, J. Ballot, D. Wildes, E. Sills, G.
Gullo; Dublin, IE
13:15 - 13:15 207P - Significant changes in dietary intake and physical activity after breast cancer diagnosis in a Chinese breast cancer cohort study Y. Lei, W. Yeo, S.C. Ho, C.-K.I. Lee, K.L. Cheung, R. Lee, Y.-Q. He; Hong Kong, HK
13:15 - 13:15 208P - Prevention of cardiotoxicity in breast cancer patients: A randomized prospective study A. Elkhateeb, D. Diab, H. Ibrahim, N. Gado, Y. Ali, A. Ibrahim; Cairo, EG
13:15 - 13:15 209P - Quality-of-life results from a randomized, phase-II-study of the therapeutic cancer vaccine L-BLP25 (Stimuvax®) in the preoperative treatment of women with primary breast cancer (ABCSG-34) 1 2 2 3 2 1 4 1 V. Bjelic-Radisic , C. Singer , G. Pfeiler , M. Hubalek , R. Bartsch , H. Stöger , A. Pichler , E. Petru , 5 6 7 2 8 2 7 2 1 R. Greil , V. Wette , A. Petzer , P. Sevelda , D. Egle , P. Dubsky , F. Fitzal , R. Jakesz , M. Balic , S.
2 2 2 1 2 3 4 5 6 Frantal , L. Sölkner , M. Gnant ; Graz, AT, Vienna, AT, Schwaz, AT, Leoben, AT, Salzburg, AT, 7 8 No City Provided, NA, Linz, AT, Innsbruck, AT
13:15 - 13:15 210P - Dedicated breast PET for predicting residual disease after breast cancer neoadjuvant chemotherapy
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 2 2 2 2 2 2 S. Sasada , T. Kadoya , N. Goga , A. Emi , K. Kajitani , N. Masumoto , R. Haruta , T. Kataoka , M.
2 1 2 Okada ; Hiroshima, Hiroshima/JP, Hiroshima, JP
13:15 - 13:15 212TiP - IMpassion031: A phase III study comparing neoadjuvant atezolizumab (atezo) vs placebo in combination with anthracycline/nab-paclitaxel (nab-pac)–based chemotherapy in early triple-negative breast cancer (eTNBC) 1 2 3 4 5 6 7 8 E.A. Mittendorf , C. Barrios , N. Harbeck , K.H. Jung , D. Miles , S. Saji , H. Zhang , A.-N. Duc , S. 9 10 1 2 3 4 5 6 Rafii , C. Lai ; Houston, US, Porto Alegre, BR, Munich, DE, Seoul, KP, Northwood, GB, 7 8 9 10 Fukushima, JP, Houston, TX/US, Basel, CH, Welwyn Garden City, GB, South San Francisco, US
13:15 - 13:15 213TiP - PIONEER- Pre-operative wIndOw study of letrozole plus PR agonist megestrol acetate versus letrozole aloNE in post-menopausal patients with ER-positive breast cancer 1 2 2 2 2 1 1 S. Kumar , G. Dougall , A.-L. Vallier , L. Jones , W. Qian , E. Provenzano , C. Caldas , P. Pantziarka 3 2 1 1 2 3 , J. Carroll , R. Baird ; Cambridge, Cambridgeshire/GB, Cambridge, GB, Kingston Upon Thames, GB
13:15 - 13:15 214TiP - VENTANA (SOLTI-1501): Antiproliferative effect of the addition of oral metronomic vinorelbine to endocrine therapy in luminal/HER2-negative early breast cancer: A window of opportunity trial 1 2 3 4 5 6 4 B. Adamo , J.A. Perez Fidalgo , E. Ciruelos , M. Vidal , S. Blanch , A. Lopez , P. Gomez Pardo , L. 7 8 3 4 9 4 1 2 Murillo , K. Amillano , N. Martínez Jañez , X. Gonzalez , J. Canes , A. Prat ; Messina, IT, Valencia, 3 4 5 6 7 8 9 Valencia/ES, Madrid, ES, Barcelona, ES, Valencia, ES, Leon, ES, Zaragoza, ES, Reus, ES, Barcelona, BARCELONA/ES
13:15 - 13:15 215TiP - PALLAS: PALbociclib CoLlaborative adjuvant study: A randomized phase 3 trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for HR+/HER2- early breast cancer 1 2 3 1 4 5 6 1 E. Mayer , A. Demichele , G. Pfeiler , W. Barry , O. Metzger , P. Rastogi , F. Symmans , H. Burstein 7 8 9 10 10 3 11 , K. Miller , S. Loibl , S. Schmatloch , T. Goulioti , D. Zardavas , C. Fesl , M. Koehler , C. Huang 11 12 10 1 3 1 2 3 Bartlett , X. Huang , M. Piccart , E. Winer , M. Gnant ; Boston, MA/US, Philadelphia, PA/US, 4 5 6 7 8 Vienna, AT, Boston, US, Pittsburgh, US, Houston, TX/US, Indianapolis, IN/US, Neu-Isenburg, DE, 9 10 11 12 Kassel, DE, Brussels, BE, New York City, US, San Diego, US
13:15 - 13:15 216TiP - OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm) 1 2 3 4 5 6 7 8 A. Tutt , B. Kaufman , J. Garber , R. Gelber , E. McFadden , C. Goessl , G. Viale , C. Geyer , D. 9 9 9 9 9 6 10 Zardavas , A. Arahmani , D. Fumagalli , E. De Azambuja , N. Ponde , P. Herbolsheimer , W. Wu , J. 11 12 1 2 3 4 5 Constantino , P. Rastogi ; London, GB, Ramat Gan, IL, Boston, Ma, US, Boston, MA/US, 6 7 8 9 10 Inverness, GB, Gaithersburg, US, Milan, IT, Richmond, VA/US, Brussels, BE, Gaithersburg, 11 12 MD/US, Philadelphia, US, Pittsburgh, US
13:15 - 13:15 BREAST CANCER, LOCALLY ADVANCED 1 2 1 2 F. André , L. Yates ; Villejuif, CEDEX/FR, Cambridge, Kent/GB
13:15 - 13:15 218P - Prognostic estimates of Ki-67 percentage drop after neoadjuvant chemotherapy (NAC) in luminal B (lumB) and triple negative breast cancer (TNBC)
Last update: 02-09-2017 06:01:33pm esmo.org J. Pascual, B. Rojas-Garcia, V. Peg, S. Diaz-Botero, E. Zamora, E. Muñoz Couselo, M. Oliveira, P. Gomez Pardo, J. Perez Garcia, F. Ruiz-Pace, C. VIAPLANA, S. Escrivá, L. Garrigos, M. Arumi, M. Espinosa-Bravo, J. Cortés, I. Rubio, C. Saura, R. Dienstmann, M. Bellet Ezquerra; Barcelona, ES
13:15 - 13:15 219P - Immune function and response to neoadjuvant chemotherapy in hormone receptor positive, HER2-negative breast cancer 1 1 2 2 2 1 3 A. Matikas , J. Lövrot , A. Ramberg , M. Eriksson , T. Lindsten , T. Lekberg , I. Hedenfalk , N. Loman 3 4 5 4 1 1 2 3 4 , J. Bergh , A. Erlandsson , T. Hatschek , T. Foukakis ; Stockholm, SE, Karlstad, SE, Lund, SE, 5 Stockholm, Solna/SE, Örebro, SE
13:15 - 13:15 220P - Safe resection margins in breast-conserving surgery 1 2 2 2 2 1 2 Y. Kostiuchenko , I. Motuzyuk , O. Sydorchuk , N. Kovtun , M. Krotevich ; Kiev, UA, Kyiv, UA
13:15 - 13:15 221P - A clinically applicable model to predict risk of relapse in patients treated for locally advanced breast cancer: Potential utilization in future clinical trials 1 2 2 2 1 2 O. Aseyev , L. Simmonds , M. Gertler , S. Verma ; Ottawa, CA, Ottawa, ON/CA
13:15 - 13:15 222P - Role of radiotherapy and its impact on survival of male breast cancer: Experience from a tertiary cancer center 1 2 2 1 2 R. Upadhyay , P. Julka , G. Rath ; New Delhi, Delhi/IN, New Delhi, IN
13:15 - 13:15 223P - Early characteristics of breast neoplasms on contrast-enhanced ultrasonography and its clinical value S. Qin, Z. Jie; Nanjing, CN
13:15 - 13:15 224P - Synchronous and metachronous breast cancer in Ukraine 1 1 1 2 1 2 I. Motuzyuk , O. Sydorchuk , N. Kovtun , Y. Kostiuchenko ; Kyiv, UA, Kiev, UA
13:15 - 13:15 225P - Clinical outcomes of single versus double hormone receptor positive breast cancer patients treated with neoadjuvant chemotherapy 1 2 2 1 2 J. Raphael , S. Nofech-Mozes , M. Trudeau ; Toronto, Ontario/CA, Toronto, ON/CA
13:15 - 13:15 226P - The correlation between toll-like receptor genes polymorphisms, tumor microenvironment characteristics and the effectiveness of preoperative chemotherapy for locally advanced breast cancer N. Verovkina, L. Sivak, S. Lyalkin, Z. Rossokcha, P. Fedorovna; Kiev, UA
13:15 - 13:15 227P - Triple negative breast cancer: 10-year survival update of the applied treatment strategy in Kuwait 1 2 3 1 4 1 2 3 M.S. Fayaz , G. Demian , M. El-Sherify , M. Aziz , H. Eissa ; Shuwaikh, KW, Kuwait, KW,
4 Damietta, El-Gamalia/EG, Cairo, EG
13:15 - 13:15 228P - A decade of HER2-targeted therapy in older patients with invasive breast cancer at Institut Curie 1 2 2 1 2 2 1 1 R. Geiss , J.-Y. Pierga , E. Auclin , G. De Lempdes , F. Rollot Trad , P. cottu , C. Giard , D. Stevens
1 1 2 , E. Brain ; St. Cloud, FR, Paris, FR
13:15 - 13:15 229P - Dedicated breast PET to predict pathological complete response after neoadjuvant chemotherapy for breast cancer
Last update: 02-09-2017 06:01:33pm esmo.org M. Fujiwara, N. masumoto, S. Sasada, T. Kadoya, M. Okada; Hiroshima, JP
13:15 - 13:15 230P - Efficacy and safety profile of the adriamycin/cyclophosphamide (AC) followed by docetaxel/cisplatin (DC) in locally advanced breast cancer 1 2 2 1 1 1 1 T. Abdelhamid , M. Saber , A. Abdel-Samie Gaber , M. Selim , O. Youssef , A. Salama , N. Aly Eldin ;
1 2 Cairo, EG, Giza, EG
13:15 - 13:15 (Withdrawn)
13:15 - 13:15 232P - Pregnancy associated breast cancer spotlights M. Shalaby, S. Lasheen, S. Talima; Cairo, EG
13:15 - 13:15 233TiP - KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC) 1 2 3 4 5 6 7 8 P. Schmid , J. Cortes Castan , J. Bergh , L. Pusztai , C. Denkert , S. Verma , H. McArthur , J. Zhao , 9 10 11 1 2 3 4 G. Aktan , T. Dang , R. Dent ; London, GB, Madrid, ES, Stockholm, Solna/SE, New Haven,
5 6 7 8 9 CT/US, Heidelberg, DE, Calgary, Alberta/CA, Los Angeles, US, Kenilworth, NJ/US, North Wales, 10 11 PA/US, North Wales, US, Singapore, SG
13:15 - 13:15 234TiP - KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (PBO) + chemo for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC) 1 2 2 2 1 2 J. Cortes Castan , Z. Guo , V. Karantza , G. Aktan ; Madrid, ES, Kenilworth, NJ/US
13:15 - 13:15 235TiP - A Phase Ib trial of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumours, hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer (BC; +/-endocrine therapy), or non-small-cell lung cancer (NSCLC) 1 2 3 4 5 6 1 7 A. Prat , D. Yee , M.P. Sablin , H. Iwata , E. Johnston , T. Bogenrieder , J. Serra , K. Stucke-Straub , 8 1 2 3 4 5 6 P. Lo Russo ; Barcelona, ES, Minnesota, MN/US, Paris, FR, Nagoya, JP, Indianapolis, IN/US, 7 8 Vienna, AT, Biberach, DE, Connecticut, CT/US
13:15 - 13:15 BREAST CANCER, METASTATIC 1 2 1 2 F. André , L. Yates ; Villejuif, CEDEX/FR, Cambridge, Kent/GB
13:15 - 13:15 247P - A single-arm, phase ii study assessing the efficacy of pembrolizumab (pembro) plus radiotherapy (RT) in metastatic triple negative breast cancer (mTNBC) 1 2 3 2 2 2 2 H. McArthur , C. Barker , A. Gucalp , L. Lebron Zapata , Y.H. Wen , A. Phung , M. Wilgucki , M.
2 1 2 1 1 2 3 Henrich , B. Arnold , Z. Zhang , A. Ho ; Los Angeles, US, New York, US, New York, NY/US
13:15 - 13:15 248P - Impact of prior treatment on palbociclib plus letrozole (P+L) efficacy and safety in patients (pts) with estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2–) first-line advanced breast cancer (ABC): A PALOMA-2 subgroup analysis
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 3 4 5 6 7 8 R. Finn , K. Gelmon , J. Ettl , J. Asselah , A. Castrellon , A. Ruiz Simón , A. Joy , D. Lu , E. Gauthier 9 10 11 12 1 2 3 , A. Mori , H. Rugo , V. Diéras ; Los Angeles, CA/US, Vancouver, British Columbia/CA,
4 5 6 7 8 Munich, DE, Montreal, QC/CA, Hollywood, FL/US, València, ES, Edmonton, AB/CA, La Jolla, 9 10 11 12 CA/US, San Francisco, US, Milan, IT, San Francisco, CA/US, Rennes, FR
13:15 - 13:15 249P - Analysis of overall survival by tumor response in MONARCH 1, a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, in women with HR+/HER2- metastatic breast cancer (MBC) after chemotherapy for advanced disease 1 2 3 4 5 6 7 8 J. Cortés , H. Rugo , S. Tolaney , V. Dieras , D. Patt , H. Wildiers , S. Nanda , A. Koustenis , M. 9 10 1 2 3 4 Dickler , J. Baselga ; Barcelona, ES, San Francisco, CA/US, Boston, MA/US, Paris, CEDEX 5/FR, 5 6 7 8 9 10 Austin, TX/US, Leuven, BE, Bridgewater, US, New York, Indiana/US, New York, US, New York, NY/US
13:15 - 13:15 250P - A global phase III clinical study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients 1 2 3 4 5 1 6 7 8 T. Saeki , H. Mukai , J. Ro , Y.-C. Lin , Y. Fujiwara , S. Nagai , K.S. Lee , J. Watanabe , S. Ohtani , 6 9 10 11 12 6 13 5 1 S.B. Kim , K. Kuroi , K. Tsugawa , Y. Tokuda , H. Iwata , Y.H. Park , Y. Yang , Y. Nambu ; 2 3 4 5 6 7 8 Saitama, JP, Kashiwa, JP, Goyang, KR/KR, Taoyuan, TW, Tokyo, JP, Seoul, KR, Shizuoka, JP, 9 10 11 12 13 Hiroshima, Hiroshima/JP, Bunkyo, JP, Kawasaki, JP, Isehara, Kanagawa/JP, Nagoya, JP, Taichung, TW
13:15 - 13:15 251P - Efficacy and safety of olaparib combined with eribulin in patients with advanced or metastatic triple negative breast cancer (TNBC) previously treated with anthracyclines and taxanes: The final analysis of a Japanese phase I/II trial 1 2 3 4 2 5 6 K. Aogi , K. Yonemori , M. Takahashi , N. Masuda , Y. Naito , S. Shimizu , R. Nakamura , H. 7 2 2 2 2 2 2 1 Yamamoto , A. Hamada , H. Michimae , K. Tamura , T. Sukigara , R. Nagasaka , Y. Fujiwara ; 2 3 4 5 6 7 Matsuyama, JP, Tokyo, JP, Sapporo, JP, Osaka, JP, Yokohama, JP, Chiba, JP, Kumamoto, JP
13:15 - 13:15 252P - Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy 1 1 1 1 1 1 1 2 N. Iyengar , L. Smyth , D. Lake , A. Gucalp , J. Singh , T. Traina , P. Defusco , M. Dickler , M. 1 1 2 1 1 1 1 1 Fornier , S. Goldfarb , K. Jhaveri , S. Modi , T. Troso-Sandoval , K. Jack , G. Ulaner , M. Jochelson , 1 1 1 1 1 2 J. Baselga , L. Norton , C. Hudis , C. Dang ; New York, NY/US, New York, US
13:15 - 13:15 253P - Abemaciclib plus fulvestrant in patients (pts) with HR+/HER2- endocrine therapy naïve (EN) advanced breast cancer - an exploratory analysis of MONARCH 2 1 2 3 4 5 6 7 8 P. Kaufman , H. Iwata , P. Nikolinakos , J. Beck , H. Koh , J. Gonzalez-Trujillo , Y. Lin , S. Barriga , 7 9 10 11 1 2 3 D. Headley , N. Bourayou , A. Llombart Cussac , G. Sledge Jr. ; Lebanon, NH/US, Nagoya, JP,
4 5 6 7 8 Athens, US, Fayetteville, US, Bellflower, US, Leon Guanajuato, MX, Indianapolis, US, 9 10 11 Windlesham, GB, Neuilly-Sur-seine, FR, Valencia, ES, Stanford, CA/US
13:15 - 13:15 254P - Matching-adjusted indirect treatment comparison of ribociclib and palbociclib as first-line treatments for HR+, HER2– ABC 1 2 1 1 3 1 2 A. Forsythe , D. Chandiwana , M. Dolph , G. Tremblay , M. Monaco ; New York, US, East Hanover,
3 US, Camberley, GB
Last update: 02-09-2017 06:01:33pm esmo.org 13:15 - 13:15 255P - Phase 1 dose-escalation study of single-agent ZW25, a HER2-targeted bispecific antibody, in patients (pts) with HER2-expressing cancers 1 2 3 4 2 5 1 M. Beeram , E. Hamilton , M. Blum Murphy , D. Hausman , J. Infante , R. Korn , A. Patnaik , S. 6 1 7 8 1 3 1 Piha-Paul , D. Rasco , G. Rowse , J. Thimmarayappa , A. Tolcher , F. Meric-Bernstam ; San
2 3 4 5 6 Antonio, TX/US, Nashville, TN/US, Houston, US, Seattle, US, Scottsdale, AZ/US, Houston, TX/US, 7 8 Vancouver, BC/CA, Seattle, WA/US
13:15 - 13:15 256P - Efficacy of palbociclib plus fulvestrant in advanced Hormone Receptor-positive (HR+) metastatic breast cancer (MBC) pretreated with everolimus: Real-life data from the french temporary authorization for use (TAU) at the Institut de Cancérologie de l’Ouest 1 1 1 2 2 1 3 P. Du Rusquec , C. Palpacuer , L. Campion , A. Patsouris , P. Augereau , C. Gourmelon , M. Robert 1 2 3 3 1 2 3 , L. Dumas , C. Folliard , M. Campone , J.-S. Frenel ; Nantes, FR, Angers, FR, Saint-Herblain, CEDEX/FR
13:15 - 13:15 257P - A phase 1 study of BYL719, an α-isoform selective PI3K inhibitor, in Japanese patients with advanced solid malignancies 1 1 2 1 1 2 2 1 J. Tomomatsu , S. Iwasa , H. Saka , S. Takahashi , K. Nakano , S. Morita , M. Inoue , H. Nakahama 2 1 1 1 3 1 4 1 2 , Y. Kogure , T. Kakizume , K. Natsume , T. Aoki , C. Quadt , Y. Yamada , Y. Ando ; Tokyo, JP, 3 4 Nagoya, JP, Basel, CH, Nagoya, Aichi/JP
13:15 - 13:15 258P - Phase 1 study of RX-5902, a novel orally bioavailable inhibitor of phosphorylated P68, which prevents β-catenin translocation in advanced solid tumors 1 2 3 4 5 6 5 1 J. Diamond , G. Eckhardt , L. Gluck , M. Gutierrez , C. Peterson , R. Pila , E. Benaim ; Aurora,
2 3 4 5 6 CO/US, Aurora, US, Greenville, US, Hackensack, US, Rockville, MD/US, Rockville, US
13:15 - 13:15 259P - Adherence to International ESO-ESMO (ABC) guide-lines in HER2-ve metastatic breast cancer (MBC) patients (pts): Preliminary results of the GIM 13 - AMBRA Study 1 2 3 4 5 6 7 M. Cazzaniga , G. Mustacchi , M. Giordano , O. Garrone , M. Donadio , L. del mastro , L. Livi , C. 8 9 5 10 10 11 Natoli , A. Michelotti , A. Turletti , R. Ferdinando , M. De Laurentiis , P. Marchetti , M. Montemurro 12 13 10 14 15 16 17 1 , E. Romagnoli , S. De Placido , P. Pronzato , L. Biganzoli , G. Bisagni , E. Bria ; Monza,
2 3 4 5 6 7 IT, Trieste, IT, San Fermo Della Battaglia, CO/IT, Cuneo, IT, Torino, IT, Genova, IT, Florence, IT, 8 9 10 11 12 13 14 15 Chieti, IT, Pisa, IT, Napoli, IT, Roma, IT, Lausanne, CH, Macerata, IT, La Spezia, IT, 16 17 Prato, IT, Reggio Emilia, IT, Verona, IT
13:15 - 13:15 260P - M-bioscore: A practical tool for predicting outcomes among patients with previously untreated metastatic breast cancer O. Abdel-Rahman, Cairo, EG
13:15 - 13:15 261P - Is PFS a more relevant endpoint than OS in 1L HR+, HER2– MBC? A systematic literature review 1 2 3 3 4 1 1 1 A. Forsythe , D. Chandiwana , J. Barth , M. Thabane , J. Baeck , A. Shor , G. Tremblay ; New York,
2 3 4 US, East Hanover, US, Dorval, QC/CA, East Hanover, NJ/US
13:15 - 13:15 262P - PFS/TTP as a potential surrogate for OS in HR+, HER2– MBC 1 2 3 3 4 1 1 1 A. Forsythe , D. Chandiwana , J. Barth , M. Thabane , J. Baeck , A. Shor , G. Tremblay ; New York,
2 3 4 US, East Hanover, US, Dorval, QC/CA, East Hanover, NJ/US
Last update: 02-09-2017 06:01:33pm esmo.org
13:15 - 13:15 263P - Survival gains from advances in first-line systemic therapy for HER2-positive metastatic breast cancer in the U.S., 1995-2015 1 2 3 2 4 2 5 3 1 J. Roth , P. Bajaj , S. Sullivan , C. Reyes , V. Antao , A. Stein , R. Mahtani , S. Ramsey ; Seattle, 2 3 4 5 US, South San Francisco, US, Seattle, WA/US, South San Francisco, CA/US, Deerfield Beach, FL/US
13:15 - 13:15 264P - Progression-free survival (PFS) and site of first progression in HER2+ metastatic breast cancer (MBC) patients (pts) with (w) or without (w/o) brain metastases: A pooled analysis of tucatinib phase I studies 1 2 3 4 5 6 6 7 1 S. Moulder , E. Hamilton , C. Ferrario , A. Conlin , I. Krop , M. Chamberlain , T. Gray , V. Borges ; 2 3 4 5 6 7 Houston, TX/US, Nashville, TN/US, Montreal, QC/CA, Portland, US, Boston, US, Seattle, US, Aurora, CO/US
13:15 - 13:15 265P - Survival of patients with aromatase inhibitors sensitive, HR+/HER2- metastatic breast cancer treated with a first-line endocrine therapy or chemotherapy in a multicenter national observational study 1 1 2 3 2 4 5 E. JACQUET , A. Lardy-Cleaud , B. PISTILLI , P. Cottu , S. Delaloge , M. Debled , L. Vanlemmens , 6 7 8 9 10 11 G. Anne-Valérie , M. Leheurteur , L. Laborde , W. Jacot , D. Berchery , B. Coudert , J.-M. Ferrero 12 13 14 15 16 16 17 1 2 , D. Parent , V. Diéras , M. Velten , C. Courtinard , M. Robain , T. Bachelot ; Lyon, FR,
3 4 5 6 7 Villejuif, FR, Paris, CEDEX 5/FR, Bordeaux, CEDEX/FR, Lille, CEDEX/FR, Caen, FR, Rouen, FR, 8 9 10 11 12 Marseille, FR, Montpellier, CEDEX 5/FR, Toulouse, FR, Dijon, Cedex/FR, Nice, CEDEX 2/FR, 13 14 15 16 17 Reims, FR, Rennes, FR, Strasbourg, FR, Paris, FR, Lyon, CEDEX/FR
13:15 - 13:15 266P - Use of everolimus in advanced hormone receptor positive metastatic breast cancer in a multicenter national observational study 1 2 3 1 1 4 5 6 A. Lardy-Cleaud , P. cottu , S. Frank , O. Le Saux , S. Chabaud , D. Parent , B. Pistilli , M. Debled , 7 8 9 10 11 12 13 14 A. Mailliez , C. Veyret , T. Petit , L. Uwer , S. Guiu , M. Ung , E. Chamorey , P. Arveux , T. 2 15 2 16 1 2 3 4 Guesmia , P. Augereau , G. Simon , T. Bachelot ; Lyon, FR, Paris, FR, Paris, CEDEX 10/FR,
5 6 7 8 9 Reims, FR, Macerata, IT, Bordeaux, CEDEX/FR, Lille, CEDEX/FR, Rouen, CEDEX 1/FR, 10 11 12 13 Strasbourg, CEDEX/FR, Vandoeuvre Les Nancy, CEDEX/FR, Mont Pellier, FR, Toulouse, FR, 14 15 16 Nice, FR, Dijon, FR, Angers, FR, Lyon, CEDEX/FR
13:15 - 13:15 267P - Can contemporary trials in HER2-negative metastatic breast cancer (mBC) detect overall survival (OS) benefit? 1 2 3 4 5 6 1 2 S. Kümmel , C. Jackisch , V. Müller , A. Schneeweiss , S. Klawitter , M. Lux ; Essen, DE,
3 4 5 6 Offenbach, DE, Hamburg, DE, Heidelberg, DE, Grenzach Wyhlen, DE, Erlangen, DE
13:15 - 13:15 268P - What are the treatment patterns and overall survival (OS) in patients with metastatic triple-negative breast cancer (mTNBC) in US clinical practice? 1 2 2 1 1 3 1 1 P. Bajaj , D. Latremouille-Viau , A. Guerin , C. Reyes , A. Stein , A. Kurian , P. Cortazar ; South San
2 3 Francisco, US, Montreal, CA, Stanford, US
13:15 - 13:15 269P - Outcomes of systemic therapy for advanced triple-negative breast cancer: A single centre experience 1 2 2 2 2 2 1 N. Battisti , D. Okonji , T. Manickavasagar , K. Mohammed , M. Allen , A. Ring ; Sutton, Surrey/GB,
2 London, GB
Last update: 02-09-2017 06:01:33pm esmo.org
13:15 - 13:15 270P - Untreated hormone receptor positive/HER2-negative metastatic breast cancer survival with front-line chemotherapy and maintenance endocrine therapy 1 1 2 1 2 2 1 R. Sabatier , A. Meskine , M.A. Cappiello , J.-M. Extra , C. Tarpin , F. Rousseau , M. Provansal , F.
2 2 1 1 2 Bertucci , P. Viens , A. Gonçalves ; Marseille, FR, Marseille, CEDEX 9/FR
13:15 - 13:15 271P - Can we predict subsequent brain metastasis in patients with metastatic breast cancer? S.F. El Zawawy, Alexandria, EG
13:15 - 13:15 272P - Pathological characteristics and prognosis of a cohort of 57 patients (pts) with de novo oligometastatic breast cancer (OMBC) 1 2 1 3 2 1 1 1 S. Chretien , N. Kotecki , J. Wallet , C. Desmedt , A. Mailliez , C. Regis , D. Pasquier , Y.-M. Robin ,
2 1 2 3 J. Bonneterre ; Lille, FR, Lille, CEDEX/FR, Brussels, BE
13:15 - 13:15 273P - External validation of modified breast graded prognostic assessment for breast cancer patients with brain metastases 1 2 3 1 4 3 5 G. Griguolo , W. Jacot , E. Kantelhardt , M.V. Dieci , C. Bourgier , C. Thomssen , C. Bailleux , F. 1 2 1 6 7 4 1 2 Miglietta , A. Braccini , P.F. Conte , J.-M. Ferrero , V. Guarneri , A. Darlix ; Padova, IT, Montpellier, 3 4 5 6 7 CEDEX 5/FR, Halle, DE, Montpellier, FR, Nice, FR, Nice, CEDEX 2/FR, Padua, IT
13:15 - 13:15 274P - Baseline characteristics and first-line (1L) treatment of patients with HER2+ metastatic breast cancer (MBC) from the SystHERs registry 1 2 3 4 5 6 7 P. Kaufman , S. Hurvitz , J. O'Shaughnessy , G. Mason , D. Yardley , A. Brufsky , H. Rugo , M. 8 9 10 11 11 11 12 1 Cobleigh , S. Swain , D. Tripathy , L. Chu , V. Antao , B. Yoo , M. Jahanzeb ; Lebanon, 2 3 4 5 6 NH/US, Los Angeles, CA/US, Dallas, US, West Lafayette, IN/US, Nashville, TN/US, Pittsburgh, 7 8 9 10 11 PA/US, San Francisco, CA/US, Chicago, IL/US, Washington Dc, DC/US, Houston, TX/US, 12 South San Francisco, CA/US, Deerfield Beach, FL/US
13:15 - 13:15 275P - First-line treatment patterns by age for patients (pts) with HER2+ metastatic breast cancer (MBC) in the SystHERs registry 1 2 3 4 5 6 7 M. Jahanzeb , D. Tripathy , S. Hurvitz , J. O'Shaughnessy , G. Mason , D. Yardley , A. Brufsky , H. 8 9 10 11 11 11 12 1 Rugo , M. Cobleigh , S. Swain , L. Chu , V. Antao , B. Yoo , P. Kaufman ; Deerfield Beach, 2 3 4 5 6 FL/US, Houston, TX/US, Los Angeles, CA/US, Dallas, US, West Lafayette, IN/US, Nashville, 7 8 9 10 11 TN/US, Pittsburgh, PA/US, San Francisco, CA/US, Chicago, IL/US, Washington Dc, DC/US, 12 South San Francisco, CA/US, Lebanon, NH/US
13:15 - 13:15 276P - Defining priorities for research: Interim results of the Canadian metastatic breast cancer priority setting partnership 1 2 3 4 1 2 3 N. Nixon , S. Verma , C. Simmons , J. Lemieux ; Calgary, CA, Calgary, Alberta/CA, Vancouver,
4 CA, Quebec, CA
13:15 - 13:15 277P - Real-world treatment patterns and outcomes among elderly metastatic triple negative breast cancer patients in the United States 1 2 2 3 3 2 2 1 S. Satram-Hoang , P. Bajaj , A. Stein , K. Hoang , F. Momin , P. Cortazar , C. Reyes ; Granite Bay,
2 3 US, South San Francisco, US, Granite Bay, CA/US
Last update: 02-09-2017 06:01:33pm esmo.org
13:15 - 13:15 278P - Effect of neoadjuvant chemotherapy on disease free survival and over all survival in triple-negative breast cancer patients 1 2 1 2 J. Gill , A. Mishra ; Bhopal, IN, Bhopal, Madhya Pradesh/IN
13:15 - 13:15 279P - Real-world everolimus experience in postmenopausal HR+ HER2- advanced breast cancer women: Treat ER+ight Canadian prospective observational study 2nd subgroup analysis 1 2 3 4 5 6 1 2 C. Doyle , N. Califaretti , S. Dent , E. Chouinard , S. Perri , S. Chia ; Quebec City, CA, Kitchener,
3 4 5 6 ON/CA, Ottawa, Ontario/CA, Cambridge, CA, Dorval, CA, Vancouver, BC/CA
13:15 - 13:15 280P - FICHE-YOUNG: FIrst-line treatment CHoicE in hormone receptor positive (HR+)/HER2- negative metastatic breast cancer patients (MBC) ≤45 years old. A large observational multicenter cohort survival analysis 1 2 2 1 3 4 5 B. PISTILLI , A. Lardy-Cleaud , E. JACQUET , S. Delaloge , P. Cottu , M. Debled , L. Vanlemmens , 6 7 8 9 10 11 12 M. Leheurteur , F. Divanon , A. Gonçalves , C. Laurent , B. Coudert , E. Chamorey , L. Campion , 13 14 15 16 16 17 1 M.-A. Mouret-Reynier , M. Breton , T. Petit , G. Simon , C. Cailliot , T. Bachelot ; Villejuif, FR,
2 3 4 5 6 7 Lyon, FR, Paris, CEDEX 5/FR, Bordeaux, CEDEX/FR, Lille, CEDEX/FR, Rouen, CEDEX 1/FR, 8 9 10 11 12 13 Caen, FR, Marseille, FR, Nancy, FR, Dijon, Cedex/FR, Nice, FR, Nantes, FR, 14 15 16 17 Clermont-Ferrand, FR, Rennes, FR, Strasbourg, CEDEX/FR, Paris, FR, Lyon, CEDEX/FR
13:15 - 13:15 281P - Cell-free circulating DNA as independent prognostic markers in metastatic breast cancer 1 1 1 1 1 1 1 2 J. Cheng , H. Surowy , M. Wallwiener , T. Holland-Letz , K. Cuk , S. Schott , A. Trumpp , K. Pantel ,
1 1 1 1 2 C. Sohn , A. Schneeweiss , B. Burwinkel ; Heidelberg, DE, Hamburg, DE
13:15 - 13:15 282P - Gene alteration in triple negative breast cancer patients in a phase I/II study of combination therapy with eribulin and olaparib 1 1 2 3 4 1 5 A. Shimomura , K. Yonemori , N. Masuda , K. Aogi , M. Takahashi , Y. Naito , S. Shimizu , R. 6 1 1 1 7 1 1 Nakamura , A. Hamada , H. Michimae , J. Hashimoto , H. Yamamoto , C. Shimizu , K. Tamura , Y. 1 1 2 3 4 5 6 7 Fujiwara ; Tokyo, JP, Osaka, JP, Matsuyama, JP, Sapporo, JP, Yokohama, JP, Chiba, JP, Kumamoto, JP
13:15 - 13:15 283P - Neutrophil-lymphocyte ratio (NLR) as a prognostic factor in metastatic breast cancer F. Ayala de la Peña, J.C. Yufera Soler, M.A. Ivars, A. Fernandez Sanchez, E. Navarro Manzano, P. De la Morena Barrio, E. Garcia-Garre, E. Garcia-Martinez, G. Marin Zafra, R. Salguero Aguilar, T. Garcia Garcia; Murcia, ES
13:15 - 13:15 284P - Real-life study of BRCA genetic screening in metastatic breast cancer 1 2 2 2 2 3 G. Meynard , C. Villanueva , A. Thiery-Vuillemin , L. Mansi , P. Montcuquet , N. Meneveau , L. 3 2 2 2 2 2 1 Chaigneau , F. Bazan , H. Almotlak , E. Dobi , T. Nguyen Tan Hon , E. Klajer , C. Fagnoni-Legat , S.
1 1 1 1 2 2 1 Paget-Bailly , A. Meurisse , M.-A. Collonge-Rame , C. Populaire-Ventron , X. Pivot , E. Curtit ; 2 3 Besançon, FR, Besançon, CEDEX/FR, Besancon, FR
13:15 - 13:15 285P - Higher MCTS1 mRNA level in breast cancer may associate with an unfavorable outcome Y. Shi, N. Liao, G. Zhang, C. Ren, L. Wen, W. Zhu, X. Chen; Guangzhou, CN
Last update: 02-09-2017 06:01:33pm esmo.org 13:15 - 13:15 286P - Holistic therapeutic strategy of TNBC necessitates in depth molecular classification: A prospective study R. Bhattacharyya, K. Banerjee, M. Sen, A. Mukhopadhyay; Kolkata, IN
13:15 - 13:15 287P - Neutrophil-to-lymphocyte ratio in metastatic breast cancer: Association with clinico-pathological features and outcome M. Bartoletti, L. Gerratana, S. Zago, D. Basile, M.G. Vitale, G. Pelizzari, M. Bonotto, C. Bozza, V. Fanotto, C. Lisanti, M. Cinausero, S. Barban, M. Lera, I. Venuti, M. Mansutti, A.M. Minisini, G. Fasola, F. Curcio, F. Puglisi; Udine, IT
13:15 - 13:15 288P - Prognosis after loco-regional recurrence of breast cancer: 35 years longitudinal data from the Stockholm cancer register 1 1 1 2 1 1 1 1 C. Falato , L. Eriksson , A. Sofiadis , S. Taylor , A. Nordblom , I. Fredriksson , J. Hartman , J. Bergh ,
1 1 2 T. Foukakis ; Stockholm, SE, Toronto, CA
13:15 - 13:15 289P - The CAN BEAR study: A systematic review and meta-analysis investigating adverse events (AEs) of targeted agents added to endocrine therapy (ET) in patients (pts) with hormone-receptor positive (HR+) metastatic breast cancer (MBC) 1 2 2 3 3 4 5 S. Martel , M. Bruzzone , M. Ceppi , C. Maurer , N. Falbel Ponde , A. Ferreira , G. Viglietti , L. 6 1 5 5 1 2 3 Delmastro , C. Prady , E. De Azambuja , M. Lambertini ; Greenfield Park, CA, Genova, IT, 4 5 6 Bruxelles, BE, Lisbon, PT, Brussels, BE, San Martino-Ist, IT
13:15 - 13:15 290P - OlympiAD: Health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice (TPC) 1 2 3 4 5 6 7 M. Robson , K. Ruddy , S.-A. Im , E. Senkus-Konefka , B. Xu , S. Domchek , N. Masuda , S. 8 9 10 11 12 12 12 13 1 Delaloge , W. Li , N. Tung , A. Armstrong , W. Wu , C. Goessl , A. Degboe , P.F. Conte ; 2 3 4 5 6 7 New York, US, Rochester, US, Seoul, KR, Gdańsk, PL, Beijing, CN, Philadelphia, US, Osaka, JP, 8 9 10 11 12 13 Villejuif, FR, Changchun, CN, Boston, MA/US, Manchester, GB, Gaithersburg, US, Padova, IT
13:15 - 13:15 291P - PALOMA-2: Neutropenia (NP) patterns in patients (Pts) with estrogen receptor−positive (ER+)/human epidermal growth factor receptor 2−negative (HER2–) first-line advanced breast cancer (ABC) receiving palbociclib + letrozole (P+L) 1 2 3 4 5 6 7 8 9 V. Diéras , N. Harbeck , A. Joy , K. Gelmon , J. Ettl , S. Verma , D. Lu , E. Gauthier , P. Schnell , A. 10 11 12 1 2 3 4 Mori , H. Rugo , R. Finn ; Rennes Cedex, FR, München, DE, Edmonton, AB/CA, Vancouver,
5 6 7 8 9 British Columbia/CA, Munich, DE, Calgary, Alberta/CA, La Jolla, CA/US, San Francisco, US, New 10 11 12 York, NY/US, Milan, IT, San Francisco, CA/US, Santa Monica, CA/US
13:15 - 13:15 292P - Prospective observational study of peripheral neuropathy in breast cancer patients treated with eribulin Y. Sakata, H. Iwata, H. Ikezawa, R. Fudetani, D. Tonoda, Y. Uchida, H. Hasegawa, T. Matsuoka; Tokyo,
JP
13:15 - 13:15 293P - Overall survival and quality of life in patients with metastatic breast cancer treated with nab-paclitaxel: Final results of the non-interventional study NABUCCO 1 2 3 4 5 6 6 6 1 K. Potthoff , A. Nusch , U. Söling , R. Hansen , C. Salat , S. Grebhardt , J. Harde , N. Marschner ;
2 3 4 5 6 Heidelberg, DE, Velbert, DE, Kassel, DE, Kaiserslautern, DE, München, DE, Freiburg, DE
Last update: 02-09-2017 06:01:33pm esmo.org
13:15 - 13:15 294P - Assessment of gastric pH changes and food intake on ribociclib bioavailability: In silico and clinical evaluations 1 2 3 2 4 2 4 T. Samant , M. Elmeliegy , S. Dhuria , Y. Lu , M. Laisney , S. Yang , A. Grandeury , M. 4 4 4 2 2 1 2 Mueller-Zsigmondy , K.-I. Umehara , F. Huth , M. Miller , C. Germa ; Bangkok, TH, East Hanover, 3 4 NJ/US, South San Francisco, US, Basel, CH
13:15 - 13:15 295P - Pneumocystis jiroveci pneumonia (PCP) in patients receiving weekly chemotherapy for metastatic breast cancer 1 1 1 1 1 2 2 2 1 S. Wijaya , E. Harrison , M. Moody , C. Wilson , L. Hughes-Davies , C. Caldas , H. Earl , R. Baird ;
2 Cambridge, GB, Cambridge, Cambridgeshire/GB
13:15 - 13:15 296P - Detection of early cardiac effects of docetaxel plus trastuzumab and pertuzumab through strain rate imaging in patients with HER2-positive metastatic breast cancer 1 1 1 1 1 2 1 V. Michalaki , G. Koutroulis , I. Psychogios , E. Karvouni , I. Vasiliou , C. Papadimitriou ; Athens,
2 GR, Athens, Attiki/GR
13:15 - 13:15 297P - Evaluation of drug-drug interactions (DDI) between tucatinib and capecitabine (C) in patients with advanced HER2+ metastatic breast cancer from a phase 1b study 1 2 1 2 2 1 1 1 2 A. Vo , D. Leviten , M. Insko , T. Sierra , A. Dozier , L. Walker , S. Peterson ; Seattle, US, Seattle, WA/US
13:15 - 13:15 298P - Outcomes of intracranial stereotactic radiotherapy (SRT) in metastatic breast cancer (BC) G. Kothari, K. Mohammed, G. Ross; London, GB
13:15 - 13:15 299P - Eribulin is safe and efficient in metastatic breast cancer in elderly patients. Results from the REPROLINE multicentric retro-prospective cohort 1 2 3 4 4 5 6 J. MARTIN-BABAU , M. Robert , V. Seegers , M.-J. Paillard , X. Pivot , C. Gourmelon , L. Uwer , C. 7 8 9 10 10 11 11 Korenbaum , T. Petit , J.-C. Thery , M. Som , C. Lefeuvre-Plesse , C. Perret , H. Simon , A.-C. 1 12 13 2 14 3 1 Hardy-Bessard , H. Desclos , H. Bourgeois , M. Campone , O. Tredan , A. Patsouris ; St. Brieuc,
2 3 4 5 6 FR, Saint-Herblain, CEDEX/FR, Angers, FR, Besançon, CEDEX/FR, Nantes, FR, Vandoeuvre Les 7 8 9 10 11 Nancy, CEDEX/FR, Strasbourg, FR, Strasbourg, CEDEX/FR, Rouen, FR, Rennes, FR, Brest, 12 13 14 FR, St. Malo, FR, Le Mans, FR, Lyon, CEDEX/FR
13:15 - 13:15 300P - Long-term responders to trastuzumab monotherapy in the first-line metastatic setting: characteristics and survival data (SAKK 22/99 Trial) 1 2 3 1 3 3 4 S. Schmid , D. Klingbiel , A. Goldhirsch , C. Oehlschlegel , E. Munzone , F. Nolè , B. Pestalozzi , S. 5 6 7 8 9 1 1 10 Aebi , C. Rochlitz , R. von Moos , K. Zaman , C. Mamot , P. Weder , B. Thuerlimann , O. Pagani ,
1 1 2 3 4 5 6 7 T. Ruhstaller ; St. Gallen, CH, Berne, CH, Milan, IT, Zürich, CH, Luzern, CH, Basel, CH, Chur, 8 9 10 CH, Lausanne, CH, Aarau, CH, Bellinzona, CH
13:15 - 13:15 301P - Metronomic chemotherapy (mCHT) in HER2-ve advanced breast cancer (ABC) patients (pts): Old drugs, new opportunities Preliminary results of the VICTOR-6 study
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 3 4 5 6 7 M. Cazzaniga , K. Cagossi , M.R. Valerio , S. Russo , V. Casadei , G. Scognamiglio , L. Cavanna , D. 8 9 10 11 12 13 14 Toniolo , E. De Conciliis , E. Melegari , L. Stocchi , V. Gebbia , A.M. Vandone , M.C. Cursano , 15 16 17 18 19 20 1 2 G. Pinotti , R. Rossello , S. Ortu , B. Pellegrino , S. Saracchini , V. Torri ; Monza, IT,
3 4 5 6 7 8 9 Modena, IT, No City Provided, NA, Gela, IT, Pesaro, IT, Como, IT, Piacenza, IT, Rho, (MI)/IT, 10 11 12 13 14 15 16 Asti, IT, Meldola, IT, Cattolica, IT, Palermo, IT, Cuneo, IT, Roma, IT, Varese, IT, 17 18 19 20 Taormina, IT, Olbia, IT, Parma, IT, Aviano, IT, Milan, IT
13:15 - 13:15 302P - Factors associated with prolonged time to treatment failure with fulvestrant 500 mg in patients with postmenopausal estrogen receptor-positive advanced/metastatic breast cancer (JBCRG-C06; Safari): A subgroup analysis 1 1 2 2 3 4 5 3 H. Kawaguchi , K. Aogi , N. Masuda , T. Nakayama , Y. Ito , S. Ohtani , N. Sato , T. Takano , S. Saji 6 7 8 9 10 11 12 , E. Tokunaga , Y. Hasegawa , M. Hattori , T. Fujisawa , S. Morita , H. Yamashita , T. Yamashita 13 14 15 11 16 1 2 3 , Y. Yamamoto , D. Yotsumoto , M. Toi , S. Ohno ; Matsuyama, JP, Osaka, JP, Tokyo, JP,
4 5 6 7 8 9 Hiroshima, Hiroshima/JP, Niigata, JP, Fukushima, JP, Fukuoka, JP, Hirosaki, JP, Nagoya, 10 11 12 13 14 15 Aichi/JP, Gunma, JP, Kyoto, JP, Sapporo, JP, Yokohama, JP, Kumamoto, JP, 16 Kagoshima, JP, Fukuoka, Fukuoka/JP
13:15 - 13:15 303P - Durable complete response in HER2-positive breast cancer: A multicenter retrospective analysis 1 2 1 3 4 5 6 A. Shimomura , N. Niikura , Y. Fukatsu , M. Sawaki , R. Ogiya , H. Yasojima , T. Fujisawa , M. 7 8 9 10 11 12 13 Yamamoto , M. Tsuneizumi , A. Kitani , J. Watanabe , A. Matsui , Y. Takahashi , S. Takashima , 12 1 14 5 2 3 1 2 T. Shien , K. Tamura , S. Saji , N. Masuda , Y. Tokuda , H. Iwata ; Tokyo, JP, Isehara, 3 4 5 6 7 8 9 Kanagawa/JP, Nagoya, JP, Isehara, JP, Osaka, JP, Gunma, JP, Sapporo, JP, Shizuoka, JP, 10 11 12 13 14 Kagoshima, JP, Shizuoka, Shizuoka/JP, Meguro, JP, Okayama, JP, Matsuyama, JP, Fukushima, JP
13:15 - 13:15 304P - Characterization of breast cancer responses to metformin A. Makhtar, Sheffield, GB
13:15 - 13:15 305P - Paclitaxel every-3-weeks versus weekly paclitaxel and versus weekly vinorelbine in metastatic breast cancer L. Katselashvili, I. Kiladze, M. Katcharava, N. Jokhadze, T. Melkadze, A. Matitashvili, M. Zhvania, N.
Sharikadze, F. Todua; Tbilisi, GE
13:15 - 13:15 306P - All oral combination of vinorelbine and capecitabine as a first line treatment in patients (pts) with metastatic breast cancer (MBC) S. Shehata, M. Khalaf; Assiut, EG
13:15 - 13:15 307P - Retrospective observational study to evaluate the use of halaven plus trastuzumab for the treatment of HER2(+) metastatic breast cancer (MBC) in Spain: HALATRUST study 1 2 3 3 M.J. Echarri González , F. Ayala de la Peña , R. Márquez Vázquez , J.A. García-Saenz , E. Galve 4 5 6 7 8 Calvo , J.J. Illarramendi Mañas , E. Millastre Bocos , M. Margelí Vila , P. Sánchez Rovira , J.I. Chacón 9 10 6 3 López-Muñiz , P. Cerezuela Fuentes , R. Andrés Conejero , L. Cerrato Crespan , I. Marrodán Ciordia 11 12 13 14 15 , A. Ocana Fernandez , I. Álvarez López , J.E. Alés Martínez , L. Palomar Abad , L. Orcajo 3 3 1 2 3 4 5 Rincon , J. Rodríguez-Villanueva ; Leganés, ES, Murcia, ES, Madrid, ES, Bilbao, ES, Pamplona, 6 7 8 9 10 11 12 ES, Zaragoza, ES, Badalona, ES, Jaén, ES, Toledo, ES, Cartagena, ES, Baracaldo, ES, 13 14 15 Albacete, ES, Donostia, ES, Ávila, ES, Valencia, ES
Last update: 02-09-2017 06:01:33pm esmo.org
13:15 - 13:15 308P - Lower response to T-DM1 in metastatic breast cancer patients with HER2 IHC score of 2 and FISH positive compared with IHC score of 3 S. Yazaki, J. Hashimoto, S. Ogita, E. Nakano, T. Yamauchi; Tokyo, JP
13:15 - 13:15 309P - Nab-paclitaxel (Nab-P) in HER2-ve advanced breast cancer (ABC) patients (pts): From randomized trials to real-life setting: Results from GIM13 - AMBRA study 1 2 3 4 5 6 7 G. Mustacchi , M. Cazzaniga , E. Bria , G. Bisagni , L. Biganzoli , P. Pronzato , S. De Placido , E. 8 9 10 7 7 11 Romagnoli , F. Montemurro , P. Marchetti , M. De Laurentiis , F. Riccardi , A. Turletti , A. Michelotti 12 13 14 15 11 16 17 1 2 , C. Natoli , L. Livi , L. Del Mastro , M. Donadio , O. Garrone , M. Giordano ; Trieste, IT,
3 4 5 6 7 8 9 Monza, IT, Verona, IT, Reggio Emilia, IT, Prato, IT, La Spezia, IT, Napoli, IT, Macerata, IT, 10 11 12 13 14 15 16 Candiolo, (TO)/IT, Roma, IT, Torino, IT, Pisa, IT, Chieti, IT, Florence, IT, Genova, IT, 17 Cuneo, IT, San Fermo Della Battaglia, CO/IT
13:15 - 13:15 310P - Everolimus-exemestane (EE) vs palbociclib-letrozole (PL) or palbociclib-fulvestrant (PF) in the treatment of metastatic HR+, HER2- breast cancer. An indirect comparison with network meta-analysis 1 1 2 1 3 1 1 1 C. Cherubini , L. Gianni , L. Stocchi , V. Arcangeli , O. Carminati , M. Papi , G. Pasini , M. Fantini ,
1 1 1 2 3 S.V.L. Nicoletti , D. Tassinari ; Rimini, IT, Cattolica, IT, Vittorio Veneto, (TV)/IT
13:15 - 13:15 311TiP - FRIEND: A randomized pilot study to compare the efficacy and tolerability of fulvestrant 500mg with exemestane as first line endocrine therapy for post-M ER positive HER2 negative ABC patients relapse after adjuvant non-steroidal aromatase inhibitors (NSAI) J. wang, B. Xu, Q. Li, P. Zhang, P. Yuan, F. Ma, Y. Luo, R. Cai, Y. Fan, S. Chen, Q. Li; Beijing, CN
13:15 - 13:15 312TiP - VinoMetro: Phase II study of metronomic daily oral vinorelbine as first-line chemotherapy in advanced/metastatic hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer resistant to endocrine therapy 1 2 3 4 5 6 7 8 T. Elger , T. Decker , T. Fehm , S. Fuxius , N. Harbeck , I. Juhasz-Böss , V. Möbus , C. Thomssen , 1 1 1 1 1 2 3 M. Seehase , L. Schollenberger , C. Ruckes , M. Schmidt ; Mainz, DE, Ravensburg, DE, Tübingen, 4 5 6 7 8 DE, Berlin, DE, Munich, DE, Homburg, DE, Frankfurt, DE, Halle, DE
13:15 - 13:15 313TiP - Open-label phase II study of everolimus plus endocrine therapy in post-menopausal women with ER+, HER2- metastatic breast cancer (Chloe trial) 1 2 2 3 4 5 6 7 T. Shien , A. Shimomura , Y. Uemura , H. Kato , M. Kitada , Y. Kikawa , E. Shiba , T. Yoshida , T. 6 8 6 9 1 2 3 4 Morimoto , T. Toyama , T. Aihara , H. Mukai ; Okayama, JP, Tokyo, JP, Sapporo, JP, Asahikawa, 5 6 7 8 9 JP, Kobe, JP, Osaka, JP, Kanagawa, JP, Nagoya, JP, Kashiwa, JP
13:15 - 13:15 314TiP - Selecting patients with oligo-metastatic breast cancer harboring homologous recombination deficiency (HRD) for intensified chemotherapy: The OLIGO-study T. Steenbruggen, A. Scholten, M.-J. Vrancken-Peeters, I. Mandjes, M. Holtkamp, J. Wesseling, S. Linn,
G. Sonke; Amsterdam, NL
13:15 - 13:15 315TiP - AGATA molecular screening program: Implementing precision medicine in patients with advanced breast cancer in Spain
Last update: 02-09-2017 06:01:33pm esmo.org 1 1 1 1 2 3 S. Pernas Simon , P. Villagrasa Gonzalez , A. Vivancos , A. Prat , M. Scaltriti , O. Burgues , J. Rodon 1 4 5 6 7 8 1 9 , J. Canes , A. Lluch , A. Llombart , J. Dorca , A. Perelló Martorell , M. Oliveira , A. Montaño , L. 10 1 3 10 11 10 1 Garcia-Estevez , P. Nuciforo , G. Ribas , I. Rapado , L. de la Pena , E. Ciruelos ; Barcelona, 2 3 4 5 6 ES, New York, NY/US, Valencia, ES, Barcelona, BARCELONA/ES, Valencia, Valencia/ES, Lerida, 7 8 9 10 11 ES, Girona, ES, Palma De Mallorca, ES, Sevilla, ES, Madrid, ES, Barcelona, Spain/ES
13:15 - 13:15 316TiP - BREAKOUT: A cross-sectional, prospective, observational study of germline BRCA mutation (gBRCAm) prevalence and real-world outcomes among patients (pts) with HER2-negative (HER2-ve) metastatic breast cancer (mBC) 1 2 3 4 5 6 7 7 1 T. Dalvi , K. Gelmon , R. Dent , M. Pegram , S. Loibl , Y. Tazir , A. Milner , J. Lewis ; Gaithersburg, 2 3 4 5 6 US, Vancouver, British Columbia/CA, Singapore, SG, Stanford, CA/US, Neu-Isenburg, DE, Wedel, 7 DE, Cambridge, GB
13:15 - 13:15 317TiP - IMpassion131: Phase III study comparing 1L atezolizumab with paclitaxel vs placebo with paclitaxel in treatment-naive patients with inoperable locally advanced or metastatic triple negative breast cancer (mTNBC) 1 2 3 4 5 6 7 8 D. Miles , F. Andre , J. Gligorov , S. Verma , B. Xu , D. Cameron , C. Barrios , A. Schneeweiss , V. 9 9 10 1 2 3 4 Easton , I. Dolado , J. O'Shaughnessy ; Northwood, Middlesex/GB, Villejuif, FR, Paris, FR, 5 6 7 8 9 10 Calgary, Alberta/CA, Beijing, CN, Edinburgh, GB, Porto Alegre, BR, Heidelberg, DE, Basel, CH, Dallas, US
13:15 - 13:15 (Withdrawn)
13:15 - 13:15 319TiP - CompLEEment-1: Phase 3b study of ribociclib + letrozole for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) in patients with no prior endocrine therapy (ET) for ABC 1 2 3 4 5 5 6 M. De Laurentiis , M. Martin Jimenez , A. Ring , P. Cottu , K. Zhou , J. Wu , J.P. Zarate , C. Zamagni 7 1 2 3 4 5 6 7 ; Naples, IT, Madrid, ES, London, GB, Paris, CEDEX 5/FR, East Hanover, US, Alger, DZ, Bologna, IT
13:15 - 13:15 320TiP - A phase II trial of mirvetuximab soravtansine in patients with localized triple-negative breast cancer (TNBC) with tumors predicted insensitive to standard neoadjuvant chemotherapy (NACT) including a lead-in cohort to establish activity in patients with metastatic TNBC 1 2 1 1 2 2 1 S. Damodaran , F. Symmans , T. Helgason , E.A. Mittendorf , D. Tripathy , K. Hess , J. Litton , S.
2 1 2 Moulder ; Houston, US, Houston, TX/US
13:15 - 13:15 321TiP - SOLTI-1303 PATRICIA: A phase II study of palbociclib and trastuzumab (with or without letrozole in ER+) in previously trastuzumab-pretreated, postmenopausal patients with HER2-positive metastatic breast cancer 1 1 1 2 1 3 P. Villagrasa Gonzalez , A. Prat , M. Oliveira , L. de la Pena , X. Gonzalez , J. Cortes Castan , J. Rios 3 1 3 4 4 5 , J. Vázquez , N. Martínez Jañez , A. Perelló Martorell , I. Garau , E. Martinez de Dueñas , S.
6 7 8 3 1 2 3 Morales , M. Melé , B. Bermejo De Las Heras , E. Ciruelos ; Barcelona, ES, Barcelona, Spain/ES, 4 5 6 7 8 Madrid, ES, Palma De Mallorca, ES, Castellon, ES, Lleida, ES, Reus, ES, Valencia, Valencia/ES
13:15 - 13:15 322TiP - PYTHIA: A phase II study of palbociclib plus fulvestrant for pretreated patients with ER+/HER2- metastatic breast cancer
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 3 3 3 3 2 D. Zardavas , M. Regan , R. Maibach , B. Ruepp , A. Hiltbrunner , L. Blacher , R. Gelber , G. Gebhart 1 4 1 5 6 7 8 1 1 , A. Di Leo , F. Hilbers , M. Colleoni , G. Zoppoli , G. Bertelli , J. Bliss , F. Duhoux , M. Piccart , L.
4 1 2 3 4 5 6 7 Malorni ; Brussels, BE, Boston, MA/US, Bern, CH, Prato, IT, Milan, IT, Genova, GE/IT, 8 Swansea, GB, Sutton, GB
13:15 - 13:15 323TiP - EarLEE-1: A phase 3 study of ribociclib + endocrine therapy (ET) for adjuvant treatment of patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), high-risk, early breast cancer (EBC) 1 2 3 4 5 6 7 M. Martin Jimenez , T. Bachelot , C. Barrios , K. Blackwell , S. Chia , M. De Laurentiis , S. Hurvitz , 8 9 10 11 12 13 13 13 W. Janni , B. Kaufman , S. Loi , P. Schmid , D. Slamon , K. Hazell , S. Mondal , M. Shilkrut , 14 15 1 2 3 4 5 C. Germa , G. Hortobagyi ; Madrid, ES, Lyon, CEDEX/FR, Porto Alegre, BR, Durham, NC/US, 6 7 8 9 10 Vancouver, BC/CA, Naples, IT, Los Angeles, US, Ulm, DE, Ramat Gan, IL, Melbourne, VIC/AU, 11 12 13 14 15 London, GB, Los Angeles, CA/US, East Hanover, US, East Hanover, NJ/US, Houston, TX/US
13:15 - 13:15 324TiP - PATINA: A randomized open label phase III trial to evaluate the efficacy and safety of palbociclib + anti HER2 therapy + endocrine therapy vs anti HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive, HER2-positive metastatic breast cancer 1 2 3 4 5 6 7 O. Metzger , S. Mandrekar , E. Ciruelos , S. Loibl , P. Valagussa , A. Demichele , E. Lim , D. Tripathy 8 9 10 10 11 12 13 9 2 , E. Winer , C. Huang , M. Khoeler , L. Carey , P. Francis , K. Miller , S. Goel , M. Goetz , A. 14 12 1 5 1 2 3 4 5 Prat , S. Loi , I. Krop , L. Gianni ; Boston, US, Rochester, US, Madrid, ES, Neu-Isenburg, DE, 6 7 8 9 10 11 Milan, IT, Philadelphia, PA/US, Sydney, AU, Houston, TX/US, Boston, MA/US, New York, US, 12 13 14 Chapel Hill, NC/US, Melbourne, VIC/AU, Indianapolis, IN/US, Barcelona, ES
13:15 - 13:15 DEVELOPMENTAL THERAPEUTICS 1 2 1 2 R. Plummer , U. Lassen ; Newcastle Upon Tyne, Tyne and Wear/GB, Copenhagen, DK
13:15 - 13:15 376P - Preclinical evaluation of the anti-CLDN18.2 antibody, IMAB362, in pancreatic carcinoma C. Heinz, R. Mitnacht-Kraus, M. Kreuzberg, S. Wöll, U. Sahin, Ö. Türeci; Mainz, DE
13:15 - 13:15 377P - Preclinical characterization of IMAB362-vcMMAE, an anti-CLDN18.2 antibody–drug conjugate M. Kreuzberg, R. Mitnacht-Kraus, U. Sahin, Ö. Türeci; Mainz, DE
13:15 - 13:15 378P - Preclinical characterization of IMAB362 for the treatment of gastric carcinoma R. Mitnacht-Kraus, M. Kreuzberg, M. Utsch, U. Sahin, Ö. Türeci; Mainz, DE
13:15 - 13:15 379P - A novel mRNA-based patient selection strategy identifies fibroblast growth factor receptor (FGFR) inhibitor-sensitive tumors: Results from rogaratinib Phase-1 study 1 2 3 4 5 6 2 3 7 M. Joerger , R. Soo , B.C. Cho , A. Navarro , C.M. Sayehli , H. Richly , D. Tai , D.-W. Kim , J. Wolf , 8 9 9 10 10 11 6 1 P. Cassier , S. Bender , P. Ellinghaus , S. Ince , P. Rajagopalan , M. Ocker , M. Schuler ; St.
2 3 4 5 6 7 8 Gallen, CH, Singapore, SG, Seoul, KR, Barcelona, ES, Würzburg, DE, Essen, DE, Köln, DE, La 9 10 11 Défense, FR, Wuppertal, DE, Whippany, US, Berlin, DE
13:15 - 13:15 380P - A phase 1b study evaluating the safety and pharmacokinetics (PK) of regorafenib (REG) in combination with cetuximab (CTX) in patients with advanced solid tumors
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 3 4 5 6 5 1 2 C. Weekes , A. Lockhart , H.-J. Lenz , J. Lee , A. Cleton , F. Huang , I. Sturm ; Boston, MA/US,
3 4 5 6 Miami, FL/US, Los Angeles, CA/US, Pitsburgh, PA/US, Berlin, DE, Whippany, NJ/US
13:15 - 13:15 381P - Clinical study of apatinib in the treatment of malignant pleural effusion and malignant celiac effusion M. Xin, Shijiazhuang, CN
13:15 - 13:15 382P - Evaluation of NRP-1 TM domain targeting peptide in melanoma M. PIERDANT, L. Aurore, V.D.H. Michael, D. Bagnard; Strasbourg, FR
13:15 - 13:15 383P - A phase I dose-escalation study of the novel peptide ALM201 in patients (pts) with advanced solid tumours 1 2 3 4 5 3 5 3 A. El-Helali , R. Plummer , G. Jayson , V. Coyle , Y. Drew , N. Mescallado , N. Harris , A. Clamp , J. 1 6 6 1 1 2 McCann , R. Kennedy , A. Cranston , R. Wilson ; Belfast, GB, Newcastle Upon Tyne, Tyne and 3 4 5 6 Wear/GB, Manchester, GB, Belfast, UK/GB, Newcastle Upon Tyne, GB, Craigavon, GB
13:15 - 13:15 (Withdrawn)
13:15 - 13:15 385P - Interim pharmacokinetic (PK) and pharmacodynamic (PD) data from the first-in-human study of NUC-3373, a pyrimidine nucleotide analogue, in patients with advanced solid tumors 1 2 3 2 4 4 E. Ghazaly , V. Woodcock , P. Spilipoulou , L. Spiers , J. Moschandreas , L. Griffiths , C. 1 5 3 4 1 2 3 Gnanaranjan , D. Harrison , T.R.J. Evans , S. Blagden ; London, GB, Oxford, Oxfordshire/GB, 4 5 Glasgow, GB, Oxford, GB, Fife, GB
13:15 - 13:15 386P - Efficacy of pembrolizumab in phase 2 KEYNOTE-164 and KEYNOTE-158 studies of microsatellite instability high cancers 1 2 3 4 5 6 7 8 L. Diaz , A. Marabelle , T.W. Kim , R. Geva , E. Van Cutsem , T. André , P. Ascierto , M. Maio , J.-P. 9 10 11 12 13 14 15 15 Delord , M. Gottfried , R. Guimbaud , D. Jaeger , E. Elez , T. Yoshino , A. Joe , B. Lam , J. 15 16 15 17 1 2 3 4 Ding , S. Pruitt , S.P. Kang , D. Le ; New York City, US, Villejuif, FR, Seoul, KR, Tel Aviv, IL,
5 6 7 8 9 10 Leuven, BE, Paris, CEDEX 12/FR, Napoli, IT, Siena, IT, Toulouse, Haute-Garonne/FR, Kfar 11 12 13 14 15 Saba, IL, Toulouse, CEDEX 3/FR, Heidelberg, DE, Barcelona, ES, Kashiwa, Chiba/JP, 16 17 Kenilworth, NJ/US, Kenilworth, US, Baltimore, MD/US
13:15 - 13:15 387P - Preliminary results from subsets of patients (pts) with advanced gastric cancer (GC) and esophageal carcinoma (EC) in a dose-escalation/expansion study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb) 1 2 3 4 5 1 6 J. Desai , M. Millward , Y. Chao , H. Gan , M. Voskoboynik , B. Markman , A. Townsend , V. Atkinson 7 8 9 10 10 11 1 2 3 , A. Zhu , J. Song , Q. Qi , A. Kang , S. Deva ; Melbourne, VIC/AU, Nedlands, WA/AU, Taipei,
4 5 6 7 8 9 TW, Heidelberg, VIC/AU, Melbourne, AU, Woodville, SA/AU, Woolloongabba, AU, Boston, US, 10 11 Fort Lee, US, Beijing, CN, Auckland, NZ
13:15 - 13:15 388P - Preliminary results from a subset of patients (pts) with advanced head and neck squamous carcinoma (HNSCC) in a dose-escalation and dose-expansion study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb)
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 2 3 4 5 2 6 L. Horvath , J. Desai , S. Sandhu , A. O'Donnell , A. Hill , S. Deva , B. Markman , M. Jameson , Z. 7 7 8 9 1 2 3 4 Chen , X. Tan , J. Hou , A. Lim ; Camperdown, AU, Melbourne, VIC/AU, Wellington, NZ, 5 6 7 8 9 Southport, AU, Auckland, NZ, Hamilton, NZ, Beijing, CN, Emeryville, US, Nedlands, AU
13:15 - 13:15 389P - Preliminary results from a subset of patients (pts) with advanced ovarian cancer (OC) in a dose-escalation/expansion study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb) 1 2 3 4 5 6 7 T. Meniawy , G. Richardson , A. Townsend , J. Desai , H. Gan , M. Friedlander , L. Horvath , M. 8 4 9 10 10 4 1 2 Jameson , S. Sandhu , Z. Wu , Z. Qin , K. Kang , B. Markman ; Nedlands, WA/AU, Cabrini
3 4 5 6 7 Hospital Malvern, AU, Woodville, SA/AU, Melbourne, VIC/AU, Heidelberg, VIC/AU, Randwick, AU, 8 9 10 Camperdown, AU, Hamilton, NZ, Fort Lee, US, Beijing, CN
13:15 - 13:15 390P - A phase I study of durvalumab (D) in combination with olaparib (O) and cediranib (C) in recurrent women’s cancers 1 2 2 2 3 3 2 2 A. Zimmer , C. Peer , L. Cao , E. Kohn , S. Lipkowitz , C. Annunziata , J. Trepel , M.-J. Lee , L. 2 2 2 2 2 3 3 3 1 Mikkilineni , M. Gatti-Mays , A. Nunes , S. Soltani , W. Figg , N. Houston , E. Nichols , J.-M. Lee ; 2 3 Cairo, EG, Bethesda, MD/US, Bethesda, US
13:15 - 13:15 391P - Phase I expansion of olaparib (PARP inhibitor) and AZD5363 (AKT inhibitor) in recurrent ovarian, endometrial and triple negative breast cancer 1 1 2 2 2 2 1 2 S. Westin , J. Litton , R. Williams , P. Soliman , M. Frumovitz , K. Schmeler , A. Jazaeri , A. Sood , 2 2 2 2 2 2 2 3 K. Lu , S. Moulder , R. Murthy , A. Rodriguez , C. Samuel , L. Engerman , A. Cyriac , P. Rugman , J.
4 5 2 2 1 2 3 Lindemann , E. McMurtry , G. Mills , R. Coleman ; Houston, US, Houston, TX/US, Cambridge, GB, 4 5 Melbourn, UK/GB, Macclesfield, GB
13:15 - 13:15 392P - Generation of a novel preclinical PK/PD model provides insights into PARP inhibitor clinical monotherapy activity M. O'Connor, E. Cadogan, E. Leo, A. Hughes, M. Learoyd, H. Xu, J. Li, J. Yates; Cambridge, GB
13:15 - 13:15 393P - Pharmacodynamic (PD) biomarkers for the p70S6K/Akt inhibitor, M2698: Translation from animal to human and relevance to dose selection 1 2 2 2 2 3 2 1 2 W. Xiong , H. Tian , A. Clark , J. Shaw , R. Kaleta , I. Celik , P. Girard ; Lausanne, CH, Billerica,
3 US, Darmstadt, DE
13:15 - 13:15 394P - Phase 1 study of ipatasertib (AKT inhibitor) for investigating safety, tolerability, pharmacokinetics (PK), efficacy, and biomarkers in Japanese patients (pts) with solid tumors including castration-resistant prostate cancer (CRPC) 1 1 2 1 1 1 1 S. Takahashi , Y. Fujiwara , N. Matsubara , J. Tomomatsu , S. Iwasa , A. Yamasaki , C. Endo , S.
1 2 1 2 Yokoyama , T. Doi ; Tokyo, JP, Kashiwa, Chiba/JP
13:15 - 13:15 395P - DS-1205b, a novel, selective, small-molecule inhibitor of AXL, delays the onset of resistance and overcomes acquired resistance to EGFR-TKIs in a human EGFR-mutant NSCLC (T790M-negative) xenograft model T. Jimbo, T. Taira, T. Komatsu, K. Kumazawa, N. Maeda, N. Haginoya, T. Suzuki, M. Ota, Y. Totoki, C.
Wada, K. Inaki, T. Isoyama, M. Uno; Tokyo, JP
13:15 - 13:15 (Withdrawn)
Last update: 02-09-2017 06:01:33pm esmo.org
13:15 - 13:15 397P - Immune related adverse events (irAEs) in early phase immunotherapy (IO) trials: Implications for recommended phase 2 dose (RP2D) determination 1 2 1 2 3 2 2 2 Y. Kanjanapan , D. Day , M. Butler , L. Wang , A. Joshua , D. Hogg , N. Leighl , A. Razak , A. 4 4 2 4 4 2 4 4 Hansen , S. Boujos , M.A. Chappell , K. Chow , M. Paolo , B. Sherwin , L.-A. Stayner , L. Soultani ,
2 5 1 4 1 2 3 4 A. Zambrana , L. Siu , P. Bedard , A. Spreafico ; Toronto, Ontario/CA, Toronto, CA, Sydney, AU, 5 Toronto, ON/CA, Toronto, On, CA
13:15 - 13:15 398P - Drug-induced electrolyte abnormalities in oncology phase I trials: Analysis of 1088 cases treated at The Royal Marsden Hospital 1 2 3 2 2 4 A. Ingles Garces , J.E. Ang , M. Ameratunga , M. Chenard-Poirier , D. Dolling , N. Diamantis , S. 3 5 3 4 4 1 2 3 Seeramreddi , R. Sundar , J. de Bono , J. Lopez , U. Banerji ; Rio De Janeiro, RJ/BR, Sutton, GB, 4 5 London, GB, Sutton, Surrey/GB, Lyngby, DK
13:15 - 13:15 (Withdrawn)
13:15 - 13:15 400P - LCZ 696, administered during doxorubicin, trastuzumab or pertuzumab treatment, prevents cardiotoxicity in our in vitro model 1 2 1 1 1 1 1 N. Maurea , R. Paciello , G. Piscopo , A. Rienzo , G. Sorrentino , C. Maurea , R. Caputo , M. De
1 1 1 2 1 2 Laurentiis , P. Maiolino , C. Coppola , C. De Lorenzo ; Napoli, IT, Naples, IT
13:15 - 13:15 401P - MEK inhibitor retinopathy T. Shukair, Madrid, ES
13:15 - 13:15 402P - A Phase I/II study everolimus in combination with paclitaxel-carboplatin in patients with advanced adenocarcinoma of the stomach 1 2 2 2 2 2 2 2 2 2 H. Loong , F. Mo , L. Li , C. Lee , K.-C. Lam , J. Koh , P. Chiu , A. Teoh , A. Chan , E. Ng , W. Yeo
2 1 2 ; Shatin, HK, Hong Kong, HK
13:15 - 13:15 403P - Phase I studies of the novel carcinoembryonic antigen T-cell bispecific (CEA-CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients (pts) with metastatic colorectal cancer (mCRC) 1 2 3 4 5 6 3 5 N. Segal , J. Saro , I. Melero , W. Ros , G. Argiles , A. Marabelle , M. Rodriguez Ruiz , J. Albanell , 7 7 8 9 2 10 10 E. Calvo , V. Moreno , J. Cleary , J. Eder , V. Karanikas , S. Bouseida , F. Sandoval , D. Sabanes 10 10 11 7 5 1 2 3 , S. Sreckovic , H. Hurwitz , L. Paz-Ares , J. Tabernero ; New York, NY/US, Schlieren, CH, 4 5 6 7 8 9 Pamplona, ES, Amesterdam, NL, Barcelona, ES, Villejuif, FR, Madrid, ES, Boston, Ma, US, New 10 11 Haven, Ct, US, Basel, CH, Durham, NC/US
13:15 - 13:15 404P - Dose escalation study of vemurafenib with crizotinib or sorafenib in patient with BRAF-mutated advance cancers 1 2 3 3 3 3 3 3 D. Sakamuri , S. Kato , H. Huang , A. Naing , V. Holley , S. Patel , S. Piha-Paul , A. Tsimberidou , D.
1 1 3 1 2 3 Hong , F. Meric-Bernstam , F. Janku ; Houston, US, La Jolla, US, Houston, TX/US
13:15 - 13:15 405P - Hepatic functional imaging and genomics to predict irinotecan pharmacokinetics and pharmacodynamics: The PREDICT IR study
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 1 3 3 3 3 M. MICHAEL , W. Liauw , S.-A. McLachlan , E. Link , A. Matera , M. Thompson , M. Jefford , R. 3 3 3 4 5 6 7 1 2 Hicks , C. Cullinane , I. Campbell , P. Beale , C. Karapetis , T. Price , M. Burge ; Melbourne, AU, 3 4 5 6 7 Sydney, AU, Melbourne, VIC/AU, Sydney, NSW/AU, Adelaide, SA/AU, Woodville, SA/AU, Brisbane, QLD/AU
13:15 - 13:15 406P - Ongoing phase 1 trial of SL-801, a novel XPO-1 inhibitor, in patients with advanced solid tumors; Interim results 1 2 3 4 5 6 6 J. Wang , J. Nemunaitis , G. Chiorean , P. Lorusso , K. Courtney , A. Olguin , J. Bullington , S. 6 6 7 8 1 2 3 4 Shemesh , J. Chen , C. Brooks , T. Bauer ; Sarasota, FL/US, Dallas, US, Seattle, WA/US, New 5 6 7 8 Haven, CT/US, Dallas, TX/US, New York, NY/US, New York, US, Nashville, TN/US
13:15 - 13:15 407P - Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM-151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cells 1 1 2 2 1 1 1 S. Napolitano , G. Martini , E. Martinelli , C.M. Della Corte , V. Belli , N. Matrone , F. Morgillo , F.
2 1 1 2 Ciardiello , T. Troiani ; Napoli, IT, Naples, IT
13:15 - 13:15 408P - Validation of the Royal Marsden Hospital (RMH) prognostic score on an enriched early treatment line cohort for phase I trial patients M. Blanco Codesido, A. Calvo Ferrandiz, S. Lopez-Tarruella Cobo, R. Alvarez, Y. Jerez, I. Marquez Rodas, S. Perez Ramirez, A. Muñoz, A. Calles, P. Sabin Domínguez, C. López, A. Picornell, B. Puente, C. Rubio, M. Herencia, T. Massarrah, M. Martin Jimenez; Madrid, ES
13:15 - 13:15 409P - Updated results of phase 1 study of DS-8201a in patients with HER2 expressing non-breast, non-gastric malignancies 1 2 3 4 5 4 2 6 J. Tsurutani , T. Doi , H. Iwata , S. Takahashi , S. Modi , K. Tamura , K. Shitara , H. Taniguchi , S. 4 5 4 4 4 4 7 8 1 1 Taira , B. Li , A. Shimomura , Y. Sato , K. Akiyama , Y. Fujisaki , C. Lee , A. Yver , K. Nakagawa ;
2 3 4 5 6 7 Osaka, JP, Kashiwa, Chiba/JP, Nagoya, JP, Tokyo, JP, New York, NY/US, Nagoya, Aichi/JP, 8 Edison, NJ/US, Edison, US
13:15 - 13:15 410P - Phase I study of the investigational, oral pan-RAF kinase inhibitor TAK-580 (MLN2480) in patients with advanced solid tumors (ST) or melanoma (MEL): Final analysis 1 2 3 4 5 6 7 A. Olszanski , R. Gonzalez , P. Corrie , A. Pavlick , M. Middleton , P. Lorigan , R. Plummer , S. 8 9 10 11 12 13 13 Skaria , C. Herbert , M. Gore , S. Agarwala , A. Daud , S. Zhang , B. Bahamon , L. Rangachari 13 13 13 14 1 2 3 , E. Hoberman , M. Kneissl , D. Rasco ; Philadelphia, PA/US, Denver, US, Cambridge,
4 5 6 7 Cambridgeshire/GB, New York, US, Oxford, GB, Manchester, GB, Newcastle Upon Tyne, Tyne and 8 9 10 11 12 13 Wear/GB, Chelmsford, GB, Bristol, GB, London, GB, Pennsylvania, US, San Francisco, US, 14 Cambridge, US, San Antonio, TX/US
13:15 - 13:15 411P - Pharmacological activity of CB-103: An oral pan-NOTCH inhibitor with a novel mode of action 1 1 2 3 1 1 4 1 D. Weber , R. Lehal , V. Frismantas , J.-P. Bourquin , M. Bauer , M. Murone , F. Radtke ; Basel,
2 3 4 CH, Zürich, CH, Zuerich, CH, Lausanne, CH
13:15 - 13:15 412P - Design and development of potent E1 ubiquitin activating enzyme inhibitor, CPL-410-005, as novel anticancer therapy 1 2 2 2 2 2 1 A. Stanczak , A. Górnicka , B. Stypik , M. Mroczkiewicz , J. Pieczykolan , K. Dubiel , M. Wieczorek ;
1 2 Warsaw, PL, Lomianki, PL
Last update: 02-09-2017 06:01:33pm esmo.org
13:15 - 13:15 413P - RX-3117, a novel hypomethylating agent, shows promising therapeutic activity in combination with nab-paclitaxel and check-point inhibitors in preclinical models 1 1 2 1 1 2 J. Frank , Y.B. Lee , D.J. Kim , E. Benaim ; Rockville, MD/US, Rockville, US
13:15 - 13:15 414P - A phase Ib trial of JX-594 (Pexa-Vec), a targeted multimechanistic oncolytic vaccinia virus, in combination with low-dose cyclophosphamide in patients with advanced solid tumors 1 2 3 4 5 5 3 M. Toulmonde , S. Cousin , A. Bessede , M. Homerin , N. Stojkowitz , M. Lusky , M. Pulido , A.
3 1 2 3 4 5 Italiano ; Bordeaux, CEDEX/FR, Lille, FR, Bordeaux, FR, Paris, FR, Illkirch-Graffenstaden, FR
13:15 - 13:15 415P - Population pharmacokinetic analysis of OT-101 (trabedersen) in patients with advanced tumors 1 1 1 2 3 1 2 3 W. Wang , K. Ng , D. Nam , V. Trieu , L. Hwang ; Costa Mesa, US, Teheran, IR, City Of Industry, CA/US
13:15 - 13:15 416P - An open-label, multicenter phase 1b study of radium-223 + paclitaxel in cancer patients with bone metastases 1 2 3 4 5 6 7 8 R. Geva , J. Lopez , S. Danson , H. Joensuu , A. Peer , S. Harris , F. Souza , B.A. Ploeger , K. 9 5 1 2 3 4 5 Pereira , R. Perets ; Tel Aviv, IL, Sutton, Surrey/GB, Sheffield, South Yorkshire/GB, Helsinki , FI, 6 7 8 9 Haifa, IL, Sutton, GB, Whippany, US, Berlin, DE, São Paulo, BR
13:15 - 13:15 417TiP - A phase 1 study of oral LOXO 292 in adult patients with advanced solid tumors, including RET-fusion non-small cell lung cancer, medullary thyroid cancer and other tumors with increased RET activity 1 2 3 3 4 5 6 7 A. Drilon , T. Bauer , V. Subbiah , M. Cabanillas , N. Lahkani , L. Wirth , G. Oxnard , S. Smith , T. 7 8 7 9 1 2 3 Eary , S. Cruickshank , M. Nguyen , S. Rothenberg ; New York, NY/US, Nashville, TN/US,
4 5 6 7 8 Houston, TX/US, Grand Rapids, MI/US, Boston, MA/US, Boston, US, Stamford, CT/US, Palo Alto, 9 US, Stamford, US
13:15 - 13:15 418TiP - Phase 1/2 study of the selective TRK inhibitor larotrectinib, in pediatric patients with cancer 1 2 3 4 5 6 S. Gallego Mélcon , M. Casanova , S. Bielack , J. Chisholm , C. van Tilburg , N. Federman , C. Albert 7 8 9 10 11 12 13 , L. Mascarenhas , B. Turpin , R. Nagasubramanian , N. Shukla , S. Spunt , M. Cox , D. 14 15 16 17 18 19 20 1 Hawkins , A. Pappo , F. Doz , G. Bisogno , S. Dubois , T. Laetsch , B. Geoerger ; 2 3 4 5 6 7 Barcelona, ES, Milano, IT, Stuttgart, DE, Sutton, GB, Heidelberg, DE, Los Angeles, US, Seattle, 8 9 10 11 12 US, Los Angeles, CA/US, Cincinnati, OH/US, Orlando, FL/US, New York City, NY/US, Palo 13 14 15 16 17 Alto, CA/US, South San Francisco, CA/US, Seattle, WA/US, Memphis, TN/US, Paris, FR, 18 19 20 Padova, IT, Boston, MA/US, Dallas, US, Villejuif, FR
13:15 - 13:15 419TiP - Chemosensitization of carboplatin by NOX66: Pharmacokinetics and safety I. Minns, G. Kelly; Sydney, AU
13:15 - 13:15 420TiP - Phase 1b/2 study to assess the safety, tolerability, and clinical activity of BGB-290 in combination with temozolomide in patients with locally advanced or metastatic solid tumors 1 2 2 2 3 1 2 3 M. Johnson , B. Benson , R. Wei , R. Brachmann , M. Galsky ; Nashville, TN/US, Emeryville, US, New York, US
Last update: 02-09-2017 06:01:33pm esmo.org 13:15 - 13:15 421TiP - Phase 1b/2 study to assess the clinical effects of BGB-290 in combination with radiation therapy (RT) and/or temozolomide (TMZ) in patients with first-line or recurrent/refractory glioblastoma 1 2 3 2 2 4 1 2 P. Wen , K. Shih , D. Schiff , R. Brachmann , R. Weitzman , T. Cloughesy ; Boston, MA/US,
3 4 Emeryville, US, Charlottesville, US, Los Angeles, US
13:15 - 13:15 422TiP - PROCLAIM-CX-2009: A first-in-human trial to evaluate CX-2009 in adults with metastatic or locally advanced unresectable solid tumors 1 2 3 3 4 5 6 J. Garcia-Corbacho , A. Spira , V. Boni , J. Feliu , M. Middleton , H. Burris , A. Yang Weaver , M. Will 6 7 8 9 1 2 3 4 , J. Harding , F. Meric-Bernstam , V. Heinemann ; Barcelona, ES, Fairfax, US, Madrid, ES, 5 6 7 8 9 Oxford, GB, Nashville, US, South San Francisco, US, New York, US, Houston, US, Munich, DE
13:15 - 13:15 423TiP - The first-in-human, dose-finding PROCLAIM-CX-072 trial to assess the antitumor activity and tolerability of the probody therapeutic CX-072 as monotherapy and in combination with ipilimumab or vemurafenib in solid advanced tumors and lymphomas 1 2 1 3 4 5 6 V. Boni , J. Garcia-Corbacho , J. Feliu , J. Wydmanski , Z. Horvath , I. Bondarenko , B. Irving , M. 6 7 8 1 2 3 4 Will , E.G.E. de Vries , F. Thistlethwaite ; Madrid, ES, Barcelona, ES, Katowice, PL, Debrecen, 5 6 7 8 HU, Dnepropetrovsk, UA, South San Francisco, US, Cluj-Napoca, RO, Manchester, GB
13:15 - 13:15 424TiP - Phase 1b multi-indication study of the antibody drug conjugate anetumab ravtansine in patients with mesothelin-expressing advanced or recurrent malignancies 1 2 3 3 4 5 3 1 2 A.A. Adjei , A. Walter , L. Cupit , J. Siegel , A. Holynskyj , B. Childs , C. Elbi ; Rochester, MN/US,
3 4 5 Berlin, DE, Whippany, NJ/US, Whippany, US, New York, New York/US
13:15 - 13:15 425TiP - A phase 1 study of SY-1365, a selective CDK7 inhibitor, in adult patients with advanced solid tumors 1 2 3 3 3 3 2 1 A. Tolcher , K. Do , E. di Tomaso , N. Waters , K. Stephens , D. Roth , G. Shapiro ; San Antonio,
2 3 TX/US, Boston, US, Cambridge, US
13:15 - 13:15 426TiP - First-in-human study of AMC303 as monotherapy in patients with advanced solid tumor of epithelial origin 1 2 3 1 2 3 4 5 E. Calvo , P. Aftimos , A. Azaro , M. de Miguel , C. Jungels , P. Nuciforo , P. Ehmer , H. Bender , K. 5 1 2 3 4 5 Dembowsky ; Madrid, ES, Brussels, BE, Barcelona, ES, Saarbrücken, DE, Eggenstein-Leopoldshafen, DE
13:15 - 13:15 NEW DIAGNOSTIC TOOLS J. Seoane, Barcelona, ES
13:15 - 13:15 1261P - mRNA capture sequencing enabled liquid biopsy screening J. Vandesompele, Ghent, BE
13:15 - 13:15 1262P - Use of droplet digital PCR for quantitative and automatic analysis of the HER2 status in breast cancer patients 1 1 1 1 1 2 1 1 K. Otsuji , T. Sasaki , A. Tanaka , A. Kunita , M. Ikemura , K. Matsusaka , K. Tada , M. Fukayama ,
1 1 2 Y. Seto ; Tokyo, JP, Chiba, JP
Last update: 02-09-2017 06:01:33pm esmo.org 13:15 - 13:15 1263P - BRCA1 large gene rearrangements (LGRs) in Russian breast cancer patients: the development of the droplet digital PCR assay for LGR detection and the identification of recurrent exon 8 deletions 1 2 2 2 1 2 2 E. Imyanitov , E. Preobrazhenskaya , I. Bizin , E. Kuligina , E. Anisimova , S. Laptiyev , E. Suspitsin ,
2 2 2 1 2 S. Aleksakhina , A. Togo , A. Sokolenko ; Saint Petersburg, RU, St.-Petersburg, RU
13:15 - 13:15 1264P - Clinical evaluation of low density array based EGFR mutation detecting kit using tissue samples and liquid biopsies 1 2 1 2 1 2 1 J. Hernández-Losa , Y. Ruano , R. Somoza , A. Muro , S. Ramón Y Cajal , J.L. Rodríguez-Peralto ;
2 Barcelona, ES, Madrid, ES
13:15 - 13:15 1265P - Correlation of somatic genomic alterations between tissue genomics and circulating tumor DNA (ctDNA) employing next generation sequencing (NGS) analysis in lung and gastrointestinal cancers 1 2 1 1 3 1 1 1 M. Toor , W. bahaj , Z. Ahmed , L. Kujtan , T. Pluard , M. McNally , L. Cummings , E. Island , J. 1 3 3 4 1 2 3 Forster , K. Kennedy , J. Subramanian , A. Masood ; Kansas City, US, Mecca, SA, Kansas City, 4 MO/US, Baltimore, MD/US
13:15 - 13:15 1266P - Analytical and clinical validation of a next-generation sequencing-based circulating tumor DNA (ctDNA) assay assures its clinical application W. Liu, S. Mu, J. Yao, H. Chen, Z. Hu, J. Hu, G. Chirn, H. Kang, K. Wang, M. Yao; Shanghai, CN
13:15 - 13:15 1267P - Combination of solid and liquid biopsy genomic profiling for tumor heterogeneity characterization J. Garcia Foncillas, L. Álvarez, A. Rodrigo, A. Terrádez; Madrid, ES
13:15 - 13:15 1268P - Retrospective analysis of a SHIVA01 trial cohort using functional mutational analysis successfully predicted treatment outcome 1 2 2 1 1 1 2 1 G. Tarcic , C. Le Tourneau , M. Kamal , O. Edelheit , Z. Barbash , M. Vidne , S. Dureau , B. Miron ,
2 2 2 1 2 C. Callens , N. Servant , I. Bieche ; Jerusalem, IL, Paris, FR
13:15 - 13:15 1269P - Integrative multi-platform meta-analysis of gene expression profiles in pancreatic ductal adenocarcinoma patients for identifying novel diagnostic biomarkers 1 2 3 4 3 5 3 O. Caba , A.L. Irigoyen , C. Jimenez-Luna , M. Benavides , F. Ortuño , C. Guillen-Ponce , I. Rojas , 6 3 1 2 3 4 5 6 E. Aranda Aguilar , J.C. Prados ; Jaen, ES, Toledo, ES, Granada, ES, Malaga, ES, Madrid, ES, Cordoba, ES
13:15 - 13:15 1270P - 3D Cultured Tumour from Patients to Predict Treatment Response W. Vader, L. Price, B. Herpers, S. Basten; Leiden, NL
13:15 - 13:15 1271P - 5-ALA administration for photodynamic diagnosis of peritoneal metastases due to advanced gastric cancer: A randomised, double-blind, multicentre phase I/II study 1 2 2 2 3 4 5 T. Takahashi , K. Fujitani , T. Omori , K. Nishikawa , T. Hayashi , T. Namikawa , E. Otsuji , S.
6 1 1 2 3 4 5 6 Takiguchi , Y. Doki ; Suita, JP, Osaka, JP, Ibaraki, JP, Nankoku, JP, Kyoto, JP, Nagoya, JP
13:15 - 13:15 1272P - Diagnostic performance of dedicated breast PET scanner with a ring detector R. HASHIMOTO, S. Akashi-Tanaka, C. Watanabe, H. Masuda, K. Taruno, T. Takamaru, Y. Ide, T.
Kuwayama, Y. Hirota, Y. Kobayashi, T. Sawada, M. Hirose, S. Nakamura; Tokyo, JP
Last update: 02-09-2017 06:01:33pm esmo.org 13:15 - 13:15 SARCOMA H. Gelderblom, Leiden, NL
13:15 - 13:15 1485P - Localized undifferentiated endometrial sarcomas (LUES): Results of a French Sarcoma Group (FSG) retrospective series of 39 patients (pts) 1 2 1 3 4 5 6 7 M. Meurer , F. Duffaud , S. Salas , F. Bertucci , A. Floquet , N. Penel , I. Ray-Coquard , A. Italiano , 8 9 10 11 1 12 1 J.-Y. Blay , P. Pautier , M. Delannes , S. Piperno-Neumann , J. Mancini , M. Auriche ; Marseille, 2 3 4 5 6 FR, Marseille, CEDEX 5/FR, Marseille, CEDEX 9/FR, Bordeaux, CEDEX/FR, Lille, CEDEX/FR, 7 8 9 10 11 Lyon, CEDEX/FR, Bordeaux, FR, Lyon, FR, Villejuif, CEDEX/FR, Toulouse, FR, Paris, CEDEX 12 5/FR, Villejuif, FR
13:15 - 13:15 1486P - An epidemiological insight into epithelioid sarcoma (ES): The open issue of distal-type (DES) versus proximal-type (PES) A.M. Frezza, L. Botta, S. Pasquali, S. Stacchiotti, A. Gronchi, P.G. Casali, A. Trama, W.G. Rarecarenet;
Milan, IT
13:15 - 13:15 1487P - Natural history of alveolar soft part sarcoma (ASPS): Impact of brain metastases and role of anti-angiogenic therapies (AAT) 1 2 3 3 3 4 3 5 G. Malouf , G. Beinse , O. Mir , J. Adam , P. Terrier , J.-P. Spano , C. Honore , A. Italiano , J.-M. 5 6 3 1 2 3 4 5 Coindre , J.-Y. Blay , A. Lecesne ; Paris, FR, Créteil, FR/FR, Villejuif, FR, Paris, CEDEX 13/FR, 6 Bordeaux, FR, Lyon, FR
13:15 - 13:15 1488P - Treatment patterns, clinical outcomes and prognostic factors of visceral angiosarcoma (V-AS): A report from the Asian Sarcoma Consortium (ASC) 1 2 1 3 4 1 1 5 A. Pang , R. Ngan , S.H. Tan , T. Hirose , M. Endo , M. Farid , W.L. Goh , H. Loong , S. 6 7 1 8 2 9 1 3 Mingmalairak , C.-C. Chang , S. Teo , M. Maw , A. Leung , J. Chan , M. Puhaindran , A. Kawai , T.
7 1 6 1 2 3 4 5 Chen , R. Quek , V. Sriuranpong ; Singapore, SG, Hong Kong, HK, Tokyo, JP, Fukuoka, JP, 6 7 8 9 Shatin, HK, Bangkok, TH, Taipei, TW, Yangon, MM, Hong Kong Sar, HK
13:15 - 13:15 1489P - High dose loco-regional chemotherapy for locally advanced angiosarcoma: A multicenter study 1 2 2 1 3 1 E. Huis in 't Veld , D. Grunhagen , K. Verhoef , H. Smith , A. van Akkooi , R. Jones , F. Van
3 1 1 1 2 3 Coevorden , A. Hayes , W. van Houdt ; London, GB, Rotterdam, NL, Amsterdam, NL
13:15 - 13:15 1490P - Primary cardiac sarcoma (PCS): A multi-national retrospective review of clinical experience 1 2 3 4 4 4 1 1 T. Chen , H. Loong , A. Zer , R. Barua , J. Buttany , R. Cusimano , Y.-C. Liang , C.-H. Chang , Z. 3 5 6 1 2 3 4 5 Iakobishvili , A. Razak , J. Lewin ; Taipei, TW, Shatin, HK, Tel Aviv, IL, Toronto, ON/CA, Toronto, 6 CA, Nassau, BS
13:15 - 13:15 1491P - Primary cardiac sarcoma: A retrospective study in two Korean tertiary centers 1 2 1 1 2 1 2 H. Ahn , H.K. Kim , K.H. Yoo , Y.S. Kim , S.J. Lee ; Incheon, KR, Seoul, KR
13:15 - 13:15 1492P - The differences in recurrence and survival of extremity liposarcoma subtypes 1 2 2 1 2 2 M. Vos , H. Kosela Paterczyk , P. Rutkowski , G. van Leenders , M. Normantowicz , A. Lecyk , S.
1 1 1 1 2 Sleijfer , K. Verhoef , D. Grünhagen ; Rotterdam, NL, Warsaw, PL
Last update: 02-09-2017 06:01:33pm esmo.org 13:15 - 13:15 1493P - The sarcoma policy checklist: Focusing policy efforts on sarcoma 1 2 3 4 5 2 6 B. Kasper , P.G. Casali , N. Drove , S. Dumont , M. Eriksson , A. Gronchi , E. Lecointe , C. Valverde 7 8 9 9 10 1 2 3 Morales , R. Wilson , S. Boldon , S. Wait , M. Wartenberg ; Mannheim, DE, Milan, IT, Madrid, ES, 4 5 6 7 8 9 10 Paris, CEDEX 12/FR, Lund, SE, Rennes, FR, Barcelona, ES, Shropshire, GB, London, GB, DE
13:15 - 13:15 1494P - Dermatofibrosarcoma protuberans might not benefit from postoperative radiotherapy after local resection with negative margin J. Chen, K.X. Du, J.Y. He, Q.Q. Peng, L.R. Tan, J.L. Li, K.X. Du; Fuzhou, CN
13:15 - 13:15 1495P - Low-dose chemotherapy with methotrexate and vinblastine for desmoid tumors: A single institution experience J. Souza, H. Lourenço, G. Mendes; Rio De Janeiro, BR
13:15 - 13:15 1496P - EORTC experience with advanced/metastatic epithelioid sarcoma patients treated in prospective trials: Clinical profile and response to systemic therapy 1 2 1 3 4 5 6 N. Touati , P. Schoffski , S. Litière , I. Judson , S. Sleijfer , W. van der Graaf , A. Italiano , N. Isambert 7 1 8 9 10 1 11 1 2 , T. Gil , J.-Y. Blay , D. Stark , T. Brodowicz , S. Marreaud , A. Gronchi ; Brussels, BE, Leuven,
3 4 5 6 7 8 9 BE, London, GB, Rotterdam, NL, Sutton, GB, Bordeaux, FR, Dijon, Cedex/FR, Lyon, FR, Leeds, 10 11 Yorkshire/GB, Vienna, AT, Milan, IT
13:15 - 13:15 1497P - Efficacy and safety of patients treated long-term with trabectedin (t) on the expanded access program: A retrospective analysis 1 2 3 4 5 6 7 8 E. Davis , S. Schuetze , S. Patel , R. Maki , R. Jones , C.R. Shin , R. Knoblauch , G. Wang , M. 9 10 10 1 2 3 4 Smith , G.D. Demetri , P. Merriam ; Ann Arbor, US, Ann Arbor, MI/US, Houston, TX/US, New
5 6 7 8 9 York, Ny, US, London, GB, Horsham, US, Raritan, New Jersey/US, Spring House, US, Raritan, 10 US, Boston, MA/US
13:15 - 13:15 1498P - Efficacy and safety of trabectedin in an elderly patient subgroup (≥65 years) with advanced leiomyosarcoma (LMS) or liposarcoma (LPS) from the Expanded Access Program (EAP) 1 2 3 4 5 6 7 1 2 R. Jones , R. Maki , S. Patel , G. Wang , C.R. Shin , R. Knoblauch , G.D. Demetri ; London, GB, 3 4 5 6 7 New York, Ny, US, Houston, TX/US, Spring House, US, Horsham, US, Raritan, New Jersey/US, Boston, MA/US
13:15 - 13:15 1499P - The routine real-life use of trabectedin (T) in patients with advanced soft tissue sarcoma (STS) across Europe: An analysis of overall vs. per country results from Y-IMAGE study 1 2 3 4 1 2 3 N. Penel , C. Benson , B. Kasper , A. Buonadonna ; Lille, CEDEX/FR, London, GB, Mannheim, DE,
4 Aviano, PN/IT
13:15 - 13:15 (Withdrawn)
13:15 - 13:15 1501P - Safety and efficacy of pazopanib (PAZ) in advanced soft tissue carcinoma (aSTS) by prior lines of therapy, age, and dose modifications: PALETTE subgroup analyses 1 2 3 4 5 6 6 A. Le Cesne , S. Bauer , G.D. Demetri , W. van der Graaf , G. Han , L. Dezzani , Q. Ahmad , H. 7 1 2 3 4 5 6 Gelderblom ; Villejuif, FR, Essen, DE, Boston, MA/US, Sutton, GB, East Hanover, NJ/US, East 7 Hanover, US, Leiden, NL
Last update: 02-09-2017 06:01:33pm esmo.org 13:15 - 13:15 1502P - Evolution in neutrophil-to-lymphocyte ratio (NLR) among advanced soft tissue sarcoma (STS) patients treated with pazopanib within EORTC 62043/62072 trials 1 1 1 2 3 4 5 E. De Maio , N. Touati , S. Litière , S. Sleijfer , W. van der Graaf , A. Le Cesne , L. D'Ambrosio , P.G. 6 7 8 6 1 2 3 4 Casali , A. Italiano , I. Desar , A. Gronchi ; Brussels, BE, Rotterdam, NL, Sutton, GB, Villejuif, FR, 5 6 7 8 Candiolo, (TO)/IT, Milan, IT, Bordeaux, FR, Nijmegen, NL
13:15 - 13:15 1503P - Benefit of the use of tyrosine kinase inhibitors (TKIs) in patients (pts) with METAstatic Soft Tissue SARComa (STS) in a Real-Life Setting: an ancillary analysis of the METASARC Study 1 2 3 4 5 3 6 S. Cousin , M. Savina , A. Le Cesne , J.-Y. Blay , I. Ray-Coquard , O. Mir , M. Toulmonde , P. Terrier 3 4 5 2 3 2 4 , D. Ranchere-Vince , P. Meeus , E. Stoeckle , C. Honore , P. Sargos , M.P. Sunyach , C. Le
7 2 2 2 2 1 2 3 4 Pechoux , A. Giraud , C. Bellera , F. le loarer , A. Italiano ; Lille, FR, Bordeaux, FR, Villejuif, FR, 5 6 7 Lyon, FR, Lyon, CEDEX/FR, Bordeaux, CEDEX/FR, Villejuif, CEDEX/FR
13:15 - 13:15 1504P - Response to apatinib in advanced alveolar soft part sarcoma C. Tu, F. Tang, Y. Zhou, L. Min, Y. Luo, W. Zhang, R. Shi, H. Duan; Chengdu, CN
13:15 - 13:15 1505P - Analysis of expression of immunomodulation factors in alveolar soft-part sarcoma: a retrospective study from the Spanish Group for Research on Sarcoma (GEIS) 1 2 3 1 4 N. Hindi , A. Fernandez-Serra , J. Martinez-Trufero , A. Carranza-Carranza , A. Lopez-Pousa , J. 2 5 3 6 4 7 Lavernia , J.L. Arranz , R. López Alegret , J. Martinez-Garcia , C. Valverde Morales , J.M. Cano , M.A.
5 1 4 1 2 1 1 Vaz , D. Moura , S. Bagué , R. Gonzalez-Campora , J.A. Lopez-Guerrero , J. Martin-Broto ; Sevilla, 2 3 4 5 6 7 ES, Valencia, ES, Zaragoza, ES, Barcelona, ES, Madrid, ES, Murcia, ES, Ciudad Real, ES
13:15 - 13:15 1506P - PD-L1 inhibition – a new therapeutic opportunity in cutaneous angiosarcoma? 1 2 3 4 5 4 5 R. Hamacher , D. Kämpfe , M. Ahrens , K. Reuter-Jessen , M. Schuler , H.-U. Schildhaus , S. Bauer ;
1 2 3 4 5 Vienna, AT, Lüdenscheid, DE, Frankfurt Am Main, DE, Göttingen, DE, Essen, DE
13:15 - 13:15 1507P - Pembrolizumab (PEM) in patients with advanced/metastatic bone sarcoma (BS) or soft tissue sarcoma (STS): Named patient use by the Medical University of Vienna S. Schur, T. Brodowicz, B. Gad, R. Hamacher, G. Amann, S. Lang; Vienna, AT
13:15 - 13:15 1509P - Characteristics and prognosis of gastrointestinal stromal tumor in the pre-imatinib era: An analysis based on the Kinki GIST registry in Japan 1 1 2 3 4 5 6 1 T. Hashimoto , T. Takahashi , Y. Kurokawa , J. Fujita , S. Hirota , T. Nishida , T. Tsujinaka ; Suita,
2 3 4 5 6 JP, Suita, Osaka/JP, Sakai, JP, Nishinomiya, JP, Tokyo, JP, Kaizuka, Osaka/JP
13:15 - 13:15 1510P - Early response evaluation by 18F-FDG-PET influences management in gastrointestinal stromal tumor patients treated with neo-adjuvant intent 1 2 3 1 4 5 S. Farag , L.-F. de Geus-Oei , W. van der Graaf , F. Van Coevorden , D. Grunhagen , A. Reyners , P. 5 6 2 1 1 2 3 4 Boonstra , I. Desar , H. Gelderblom , N. Steeghs ; Amsterdam, NL, Leiden, NL, Sutton, GB, 5 6 Rotterdam, NL, Groningen, NL, Nijmegen, NL
13:15 - 13:15 1511P - Surgery in the treatment of metastatic and recurrent Gastrointestinal Stromal Tumors 1 2 1 1 2 M. Gluzman , R. Orlova , V. Kashchenko ; Saint-Petersburg, RU, Saint Petersburg, RU
Last update: 02-09-2017 06:01:33pm esmo.org 13:15 - 13:15 1512P - Clinicopathologic features and long-term follow-up of metastatic gastrointestinal stromal tumor (GIST) patients (pts) with durable response (≥ 5 years) to frontline imatinib (IM): A case-control study from GEIS 1 2 3 2 4 5 C. Serrano , A. Lopez Pousa , I. Pajares , C. Valverde Morales , J. Duran , J. Rubió-Casadevall , M.J. 6 7 6 8 9 2 9 Safont , V. Martinez , R. Díaz Beveridge , A. Estival , D. Vicente Baz , A. Sebio Garcia , N. Hindi , S. 2 2 2 4 2 2 Landolfi , D. Olivares , A. Garcia-Valverde , P. Ledesma , J. Arribas , J. Carles Galceran , J. Martin 10 1 2 3 4 5 6 Broto ; Barcelona, Barcelona/ES, Barcelona, ES, Zaragoza, ES, Palma, ES, Gerona, ES, 7 8 9 10 Valencia, ES, Madrid, ES, Badalona, Barcelona/ES, Sevilla, ES, Seville, ES
13:15 - 13:15 1513P - Tumor growth rate analysis of progression-free survival (PFS) and overall survival (OS) for patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) receiving placebo or regorafenib in the phase 3 GRID trial 1 1 2 1 2 C. Kappeler , A. Wagner , G.D. Demetri ; Berlin, DE, Boston, MA/US
13:15 - 13:15 1514P - Serum miRNA abundances discriminate imatinib-naive patients with advanced gastrointestinal stromal tumors (GIST) from those in remission on Imatinib therapy H. Kosela Paterczyk, A. Paziewska, M. Kulecka, J. Karczmarski, M. Dabrowska, A. Kluska, A. Balabas,
M. Piatkowska, M. Mikula, P. Rutkowski, J. Ostrowski; Warsaw, PL
13:15 - 13:15 1515P - LncRNA H19, HOTAIR and MALAT1 as prognostic molecular biomarkers in GIST N. Barraco, L. Incorvaia, G. Badalamenti, F. Passiglia, A. Listì, R. Maragliano, E. Musso, E. Bronte, D. Cabibi, V. Calò, M. Castiglia, D. Fanale, A. Galvano, V. Gristina, S. Ingrao, L. Insalaco, D. Massihnia, A. Perez, V. Bazan, A. Russo; Palermo, IT
13:15 - 13:15 1516P - Predictive factors of response to Sunitinib in metastatic Gastrointestinal Stromal Tumors (mGISTs): A retrospective analysis 1 1 1 1 1 1 1 L. Incorvaia , G. Badalamenti , E. Musso , I. de luca , A. Casarin , G. Assanto , A. Galvano , F. 1 1 2 3 4 4 1 1 Passiglia , N. Barraco , B. Vincenzi , G. Grignani , M. Pantaleo , L. Gatto , S. Rizzo , D. Fanale , M. 1 1 1 1 2 3 4 Castiglia , A. Guarini , A. Russo ; Palermo, IT, Roma, IT, Candiolo, (TO)/IT, Bologna, IT
13:15 - 13:15 1517P - Analysis of PD-L1 Expression in Patients with Gastrointestinal Stromal Tumors 1 2 2 2 1 2 A.B. Kinupe Abrahao , R. Jamani , E. Hsieh , Y.-J. Ko ; Toronto, CA, Toronto, ON/CA
13:15 - 13:15 1518P - Gastrointestinal stromal tumors secrete Ghrelin and express ghrelin receptors – needs linguistic correction C. zhu, Beijing, CN
13:15 - 13:15 1519P - Primary pleomorphic sarcoma (PS) and leiomyosarcoma (LMS) of bone: Retrospective analysis of an original series 1 2 2 2 2 2 2 3 G.G. Baldi , A. Franchi , G. Soccianti , D. Campanacci , D. Greto , L. Livi , G. Roselli , F. Galardi , S.
3 1 2 3 Bazzurri ; Prato, PO/IT, Florence, IT, Prato, IT
13:15 - 13:15 1520P - Development of a new promising rescue agent for high dose methotrexate (HDMTX) treatment in osteosarcoma: A safety and dose finding study 1 2 3 4 5 1 2 M. Eriksson , M. Rychłowska-Pruszyńska , M. Csoka , E. Kabickova , P. Mudry ; Lund, SE,
3 4 5 Warsaw, PL, Budapest, HU, Prague, CZ, Brno, CZ
Last update: 02-09-2017 06:01:33pm esmo.org 13:15 - 13:15 1521P - Role of intraarterial cisplatin and intravenous adriamycin as neoadjuvant and adjuvant chemotherapy in non-metastatic osteosarcoma 1 2 2 1 2 A. Mishra , J. Gill , Y. Mishra ; Bhopal, Madhya Pradesh/IN, Bhopal, IN
13:15 - 13:15 1522P - Biomarkers of malignant cell growth used to assess the risk of osteosarcoma development B. Sultonov, D. Polatova, K. Abdikarimov, U. Islamov; Tashkent, UZ
13:15 - 13:15 1523P - Efficacy of second line treatment with etoposide and ifosfamide in adult patients with advanced Ewing Sarcoma family tumors 1 1 2 1 1 1 3 1 M. Nardo , E. Zambrano , M.F. Vicentini , D. Toloi , V. Camargo , O. Feher , R. Munhoz ; Sao
2 3 Paulo, BR, São Paulo, BR, Sao Paulo, SP/BR
13:15 - 13:15 1524P - AG-120, a novel IDH1 targeted molecule, inhibits invasion and migration of chondrosarcoma cells in vitro V. HEREDIA, M. Mendiola, E. Ortiz, D. Bernabéu, J. Pozo-Kreilinger, M. Miguel, R. Crespo, A. Berjón, V.
Martínez-Marín, A. Redondo; Madrid, ES
13:15 - 13:15 1525TiP - Geriatric assessment of elderly chemotherapy-naïve patients treated with trabectedin for advanced soft tissue sarcomas (STS): The E-TRAB study of the German Interdisciplinary Sarcoma Group (GISG-13) 1 2 3 1 1 2 3 B. Kasper , P. Reichardt , M. Schuler , P. Hohenberger ; Mannheim, DE, Berlin-Buch, DE, Berlin-Zehlendorf, DE
13:15 - 13:15 1526TiP - CDK4/6 inhibition in locally advanced/metastatic chordoma (NCT PMO-1601) 1 2 1 3 3 2 2 S. Fröhling , T. Barth , S. Gröschel , G. Folprecht , S. Richter , R. Mayer-Steinacker , M. Schultheiss , 2 4 4 1 1 1 1 1 P. Möller , S. Bauer , J. Siveke , S. Dettmer , D. Richter , C. Heining , P. Horak , H. Glimm , D. Jäger 1 1 1 1 2 3 4 , C. Von Kalle , R. Schlenk ; Heidelberg, DE, Ulm, DE, Dresden, DE, Essen, DE
13:15 - 13:15 TRANSLATIONAL RESEARCH R. Giavazzi, Milan, IT
13:15 - 13:15 1634P - FGFR pathway genomic aberrations and response to FGFRs inhibitors 1 2 3 2 2 1 2 3 M. Faure , A. Hollebecque , R. Bahleda , J.-C. Soria , V. Dyevre ; Marseille, FR, Villejuif, FR, Villejuif, CEDEX/FR
13:15 - 13:15 1635P - FGFR 360° resistance: Establishing a translational research framework in FGFR-altered (FGFRalt) patients (pt) treated with fibroblast growth factor receptor inhibitors (FGFRinh) 1 1 1 1 1 1 1 C. Hierro , M. Sánchez-Guixé , F. Ruiz-Pace , J. Jimenez , L. Maynes , A. Azaro , J. Martin-Liberal , 1 1 1 2 1 1 1 M. Ochoa de Olza , I. Braña , M. Vieito , A. Villanueva , H.G. Palmer , J. Arribas , P. Nuciforo , A. 1 1 1 1 1 1 1 2 Vivancos , E. Garralda , R. Dienstmann , J. Tabernero , V. Serra , J. Rodon ; Barcelona, ES, Hospitalet De Llobregat, ES
13:15 - 13:15 1636P - EPHA2 receptor is involved in in vivo acquired resistance to anti-Epidermal Growth Factor Receptor (EGFR) treatment in metastatic colorectal cancer (mCRC)
Last update: 02-09-2017 06:01:33pm esmo.org 1 1 1 1 2 1 1 1 G. Martini , V. Belli , P.P. Vitiello , T. Troiani , C. Cardone , S. Napolitano , N. Matrone , V. Sforza , 2 1 1 1 1 1 1 2 R. Franco , F. Morgillo , D. Ciardiello , E. Giunta , V. De Falco , N. Zanaletti , P. Vitale , E. Martinelli , 2 1 2 F. Ciardiello ; Napoli, IT, Naples, IT
13:15 - 13:15 1637P - Eph A2 expression is a predictive biomarker of poorer activity and efficacy of FOLFIRI + cetuximab in RAS WT metastatic colorectal cancer (mCRC) patients (pts) in the CAPRI GOIM trial 1 2 2 1 1 1 1 C. Cardone , M.C. Paul , V. Moreno-Viedma , G. Martini , P.P. Vitiello , D. Ciardiello , V. Sforza , T. 1 1 1 1 1 3 4 1 Troiani , S. Napolitano , P. Vitale , N. Zanaletti , A. Rachiglio , D. Rizzi , E. Maiello , N. Normanno ,
2 5 5 1 2 3 4 M. Sibilia , F. Ciardiello , E. Martinelli ; Napoli, IT, Vienna, AT, Bari, IT, San Giovanni Rotondo, IT, 5 Naples, IT
13:15 - 13:15 1638P - Clinical value of cfDNA and CTCs in EGFR mutations detected in advanced NSCLC 1 1 1 2 1 S. Calabuig Fariñas , E. Jantus-Lewintre , A. Fernández , C. Mayo de las Casas , A. Blasco , C. 1 2 2 2 1 1 2 3 Aguilar , N. Jordana , A. Balada , M. Garzón Ibañez , F. Zhang , N. Dong , M.A. Molina , R. Rosell , 1 1 2 3 C. Camps Herrero ; Valencia, ES, Barcelona, ES, Badalona, Barcelona/ES
13:15 - 13:15 1639P - Tucatinib, a HER2 selective kinase inhibitor, is active in patient derived xenograft (PDX) models of HER2-amplified colorectal, esophageal and gastric cancers 1 2 2 2 1 2 S. Peterson , P. de Vries , J. Piasecki , R. Rosler ; Seattle, US, Seattle, WA/US
13:15 - 13:15 1640P - PI3K/RICTOR-mTORC2 axis as a driver of prognosis and potential druggable target in squamous cell lung carcinoma (SqCLC) 1 1 1 1 2 3 4 S. Pilotto , M. Simbolo , A. Gkountakos , C. Vicentini , I. Sperduti , V. Ludovini , R. Chiari , S. Novello 5 6 1 1 1 1 1 1 , M. Milella , A. Mafficini , L. Carbognin , E. Caregnato , A. Santo , M. Infante , M. Brunelli , V. Corbo
1 1 1 1 1 2 3 4 5 , A. Scarpa , G. Tortora , E. Bria ; Verona, IT, Rome, IT, Perugia, (PG)/IT, Perugia, IT, Torino, 6 IT, Roma, IT
13:15 - 13:15 1641P - Combination of duligotuzumab, anti HER3 antibody or taselisib, Pi3k inhibitor with trastuzumab shows synergistic antitumoral activity in HER2 positive gastric cancer cells (GCC) 1 1 1 1 1 1 1 M.M. Laterza , V. Ciaramella , F. Morgillo , V. Belli , G. Tirino , L. Pompella , A. Petrillo , B.
1 1 1 2 2 1 2 Savastano , A. Pappalardo , M. Orditura , F. Ciardiello , F. De Vita ; Napoli, IT, Naples, IT
13:15 - 13:15 1642P - The TLR9 agonist lefitolimod modulates tumor microenvironment and improves anti-tumor effect of checkpoint inhibitors in vivo K. Kapp, B. Volz, D. Oswald, B. Wittig, M. Schmidt; Berlin, DE
13:15 - 13:15 1643P - Circulating immune-profile as predictor of outcome in advanced NSCLC patients treated with nivolumab 1 1 1 1 1 1 1 M. Tiseo , F. Facchinetti , F. Gelsomino , S. Buti , M. Veneziani , A. Squadrilli , P. Bordi , M. 2 1 1 1 1 1 1 Bersanelli , A. Cosenza , L. Ferri , E. Rapacchi , G. Mazzaschi , F. Leonardi , F. Quaini , A. Ardizzoni 3 1 1 2 3 , G. Missale ; Parma, IT, Noceto, PR/IT, Bologna, IT
13:15 - 13:15 1644P - Monitoring the effect of cytostatic treatment by immune activity T. Hansen, L. Nederby, T. Bechmann, E. Jakobsen, A. Zedan, I. Mejlholm, J. Henriksen, K. Steffensen,
C. Thomsen, L. Raunkilde, L.H. Jensen, A. Jakobsen; Vejle, DK
Last update: 02-09-2017 06:01:33pm esmo.org
13:15 - 13:15 1645P - Analysis of programmed death-ligand 1 (PD-L1) expression, transforming growth factor (TGF)-β gene expression signatures (GES) and tumor-infiltrating immune cells (IC) in hepatocellular carcinoma (HCC): Rationale for targeting PD-L1- and TGF-β 1 2 2 3 2 4 3 1 Y. Zhang , B. Naughton , P.A. Rolfe , E. Frick-Krieger , I. Dussault , L. Terracciano , C. Ihling ;
2 3 4 Billerica, US, Billerica, MA/US, Darmstadt, DE, Basel, CH
13:15 - 13:15 1646P - Integrative analysis of NSCLC identifies tumor genetic profiles associated with PD-L1 expression 1 2 2 2 2 2 2 2 A. Ono , M. Serizawa , K. Omae , M. Isaka , H. Kojima , S. Takahashi , K. Nakashima , S. Omori , K. 2 2 2 2 2 2 2 2 Wakuda , H. Kenmotsu , T. Naito , H. Murakami , K. Urakami , Y. Ohde , T. Nakajima , M. Kusuhara 2 2 1 2 , K. Yamaguchi , T. Takahashi ; Shizuoka, Shizuoka/JP, Shizuoka, JP
13:15 - 13:15 1647P - Integrative analysis of NSCLC identifies tumor genetic profiles associated with PD-L1 expression. 1 2 2 3 2 2 2 M. Saigi , C. Pereira , E. Pros , E. Brambilla , J. Alburquerque , N. Baixeras , M. Sánchez-Céspedes ,
1 1 2 3 E. Nadal ; Barcelona, Barcelona/ES, Hospitalet De Llobregat, ES, La Tronche, CEDEX 9/FR
13:15 - 13:15 1648P - B7-H3 (CD276) on circulating epithelial tumor cells (CETCs) correlates with proliferation marker Ki-67 and may be associated with aggressiveness of tumor in breast cancer patients M. Pizon, D. Schott, U. Pachmann, K. Pachmann; Bayreuth, DE
13:15 - 13:15 1649P - Survival of non-small cell lung cancer patients predicted from expression of PD-L1, HLA class I and MICA/B on tumor cells 1 2 2 2 2 2 2 1 R. Okita , A. Maeda , T. Yukawa , K. Shimizu , Y. Nojima , S. Saisho , M. Nakata ; Kurashiki,
2 Okayama/JP, Kurashiki, JP
13:15 - 13:15 1650P - YKL-39 induces monocytes migration and angiogenesis and inversely correlates with metastasis in patients with breast cancer 1 2 1 1 1 1 I. Mitrofanova , L. Tengfei , M. Zavyalova , N. Litviakov , M. Buldakov , N. Cherdyntseva , J.
2 1 2 Kzhyshkowska ; Tomsk, RU, Mannheim, DE
13:15 - 13:15 1651P - Pre-treatment neutrophil lymphocyte ratio/platelet lymphocyte ratio as surrogate markers of survival in non-metastatic head and neck cancer patients: An observational study V. Agarwal, R. Rao, H.R. Abin, V. Rao, R. Nayar, V. Mani, A. Ram, B. Ajaikumar; Bangalore, IN
13:15 - 13:15 1652P - Enhanced antitumor activity of fixed-dose combinations of celecoxib and antihypertensives 1 2 1 1 3 1 2 3 C. Lee , L. Hwang , O. D'Cruz , K. Ng , V. Trieu ; Costa Mesa, US, City Of Industry, CA/US, Teheran, IR
13:15 - 13:15 1653P - Overexpression of toll-like receptor 9 (TLR9) in elderly cancer patients when compared to cancer-free elderly control group 1 1 1 1 1 L. Torres , L. Sales , M. Santaliz de Godoy Moreno , C. Resende Lira , G. Delgado Soriano , E. 1 1 1 2 3 1 2 Bezerra Cintra Jr , K. Jatahy , M.J. Mello , L.C. Thuler , J. Oliveira Lima ; Recife, BR, Rio De 3 Janeiro, BR, Recife, PE/BR
Last update: 02-09-2017 06:01:33pm esmo.org 13:15 - 13:15 1654P - NSCLC patient immune cell profiling and response of tumor antigen specific CD8 T cells to checkpoint receptor antagonists 1 2 2 2 1 1 1 1 1 2 1 J. Lee , X. Wu , L. Liu , M. Breyer , H.K. Kim , J.H. Cho , J. Lee , Y.S. Shin , J. Kim , Y. Zhao ;
2 Seoul, KR, Indianapolis, IN/US
13:15 - 13:15 1655P - Effect of neoadjuvant chemotherapy on correlation of tumor-associated macrophages with angiogenesis and lymphangiogenesis in human breast cancer 1 1 1 1 2 1 2 I. Mitrofanova , M. Zavyalova , M. Buldakov , N. Cherdyntseva , J. Kzhyshkowska ; Tomsk, RU, Mannheim, DE
13:15 - 13:15 1656P - Myeloid-derived suppressor cells are associated with a decrease of tumor antigen-specific Th1 immunity in non-small cell lung cancer 1 2 2 2 3 2 O. Adotevi , E. Lauret Marie Joseph , C. Laheurte , M. Dosset , E. Fabre-Guillevin , P. Jacoulet , G. 2 2 2 2 2 1 1 2 Eberts , G. Helluin , L. Boullerot , L. Rangan , Y. Godet , V. Westeel ; Besançon, CEDEX/FR, 3 Besançon, FR, La Défense, FR
13:15 - 13:15 1657P - Revealing potential immune responses (IRs) in patients with advanced colorectal cancer (aCRC) on first line chemotherapy: A prospective study of neutrophil to lymphocyte ratio, immune function and outcome 1 1 1 1 2 3 3 3 1 S. Turnbull , E. West , K. Scott , E. Tidswell , A. Melcher , M. Seymour , C. Ralph , J. Seligmann ;
2 3 Leeds, GB, London, GB, Leeds, Yorkshire/GB
13:15 - 13:15 1658P - Somatic loss of the wild-type BRCA1 allele is not necessarily the first event in the pathogenesis of hereditary ovarian cancer: Implications for novel mechanism of acquired platinum resistance 1 2 3 4 4 4 E. Imyanitov , E. Savonevich , A. Ivantsov , G. Raskin , E. Kuligina , T. Gorodnova , E. 4 4 4 4 4 1 2 Preobrazhenskaya , M. Kleshchov , V. Tiurin , A. Togo , A. Sokolenko ; Saint Petersburg, RU, 3 4 Grodno, BY, Saint-Petersburg, RU, St.-Petersburg, RU
13:15 - 13:15 1659P - Role of UBR5 mutations in DNA damage response in mantle cell lymphoma O. Kutovaya, S. Hung, E. Vigano, R. Gascoyne, G. Morin, C. Steidl; Vancouver, CA
13:15 - 13:15 1660P - ATM role in prostate cancer (PrCa) progression and survival 1 1 2 3 1 Y. Cendón Flórez , P. Nombela Blanco , A. Medina , N. Romero Laorden , J. Puente , P. López Casas 1 4 5 1 6 7 , A. Gutierrez Pecharromán , R. Sanchez-Escribano , L. Magraner , E. Gallardo Diaz , N. Lainez , P. 8 9 10 11 12 Jiménez Gallego , R. Lozano Mejorada , E. Almagro Casado , R. Luque Caro , M. Domenech , A. 13 1 1 1 1 Hernández Jorge , E. Castro Marcos , M.D.P. González-Peramato Gutierrez , D. Olmos Hidalgo ; 2 3 4 5 6 7 Madrid, ES, A Coruña, ES, Madrid, Madrid/ES, Móstoles, ES, Burgos, ES, Sabadell, ES, 8 9 10 11 Pamplona, ES, Las Palmas De Gran Canaria, ES, Salamanca, ES, Majadahonda, Madrid/ES, 12 13 Granada, ES, Manresa, ES, Donostia, ES
13:15 - 13:15 1661P - Synergistic inhibition of CEP55 induces mitotic catastrophe and specifically targets aggressive breast cancer 1 2 2 2 1 2 D. Sinha , M. Kalimutho , A. Lopez , K.K. Khanna ; Brisbane, AU, Brisbane, QLD/AU
13:15 - 13:15 1662P - Synergistic antitumor effects of OT-101 (trabedersen), a transforming growth factor-beta 2 (TGF-β2) antisense oligonucleotide (ASO) and chemotherapy in preclinical tumor models
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 2 1 1 2 O. D'Cruz , C. Lee , V. Trieu , L. Hwang ; Costa Mesa, US, Costa Mesa, CA/US
13:15 - 13:15 1663P - Targeting thioredoxin reductase 1 in novel combination therapies in p53 mutant triple negative breast cancer P. Raninga, M. Kalimutho, D. Sinha, A. Bain, K. Tonissen, K.K. Khanna; Brisbane, AU
13:15 - 13:15 1664P - Liprin-α4 could be a potential therapeutic target for pancreatic cancer 1 2 1 1 2 A. Yamasaki , H. Onishi , M. Kawamoto ; Fukuoka, JP, Fukuoka, Fukuoka/JP
13:15 - 13:15 1665P - Dual targeting of cystathionine β-synthase (CBS) and cystathionine γ-lyase (CSE) by miR-4317 displays a synergistic efficacy in repressing breast cancer progression R. Youness, R. Assal, E. Khallaf, H. Hafez, A. Abdelmotaal, M. Gad; Cairo, EG
13:15 - 13:15 1666P - Met/Axl system as a dual target in the mesothelioma pathway and invasiveness 1 1 2 1 1 2 1 G. Viscardi , V. Ciaramella , C.M. Della Corte , F. Papaccio , G. Esposito , R. Di Liello , T. Troiani ,
1 2 1 1 2 M. Orditura , F. Ciardiello , F. Morgillo ; Napoli, IT, Naples, IT
13:15 - 13:15 1667P - Targeting CXCR4 and FAK in non-small cell lung carcinomas with co-inactivated p53 and PTEN tumor suppressors 1 1 1 1 1 2 A. Podolski-Renic , M. Dragoj , S. Stojkovic , J. Dinic , J. Bankovic , E. Sereti , S. Jovanovic Stojanov
1 2 1 1 1 2 , K. Dimas , M. Pesic , T. Stankovic ; Belgrade, RS, Larissa, GR
13:15 - 13:15 1668P - Pin1 protein: A druggable target in high grade serous ovarian cancer 1 1 1 2 1 2 C. Russo Spena , L. De Stefano , B. Salis , F. Rizzolio ; Trieste, IT, Venice, IT
13:15 - 13:15 1669P - RalB GTPase: A potential novel target for RAS mutant colorectal cancer H. Khawaja, P. O'Reilly, D. McArt, T. Harrison, P. Johnston, S. Van Schaeybroeck; Belfast, GB
13:15 - 13:15 1670P - Serial genotypic characterization of circulating tumor cells (CTCs) in patients with metastatic castration resistant prostate cancer (mCRPC) undergoing treatment with abiraterone acetate (abi) or enzalutamide (enza) 1 2 3 2 2 4 3 4 N. Dizman , J. Patel , M. He , B. Foulk , D. Smirnov , J. Hsu , P. Twardowski , M. Kortylewski , V.
2 3 3 1 2 3 4 Bhargava , J. Jones , S. Pal ; Istanbul, TR, Spring House, US, Duarte, CA/US, Duarte, US
13:15 - 13:15 1671P - A novel circulating cell free DNA-based assay can predict tumor response to systematic chemotherapy 1 1 1 1 1 1 1 1 T. Toshima , T. Nagasaka , Y. Mori , T. Kawai , K. YASUI , T. Fuji , F. Taniguchi , K. Kimura , H.
1 1 2 1 1 2 Kishimoto , Y. Umeda , A. Goel , T. Fujiwara ; Okayama, JP, Texas, TX/US
13:15 - 13:15 1672P - ctDNA might expand therapeutic options for second line treatment of KRAS mutant mCRC 1 1 1 2 1 1 2 P. gazzaniga , C. Raimondi , C. Nicolazzo , A. Gradilone , E. Cortesi ; Roma, IT, Rome, IT
13:15 - 13:15 1673P - Ex vivo expansion of circulating tumor cells for individualized drug susceptibility in patients with advanced or recurrent oesophageal cancer 1 2 2 1 2 V. Kumar , R. Sagar , P. Kumar ; Bangalore, Karnatka/IN, Bangalore, IN
Last update: 02-09-2017 06:01:33pm esmo.org
13:15 - 13:15 1674P - Exploratory study of CK-M30 and pHH3 expression in Circulating Tumor Cells (CTCs) as biomarkers of docetaxel (DOC) efficacy in metastatic castration resistant prostate cancer (mCRPC) 1 2 3 4 5 P. Nombela Blanco , R. Lozano Mejorada , D. Lorente Estelles , A. Reid , N. Romero Laorden , G. 4 1 6 7 8 9 6 10 Attard , Y. Cendón Flórez , J. Mateo , S. Sandhu , C. Massard , A. Montesa , P. Flohr , M.I. Sáez , 1 1 11 1 1 2 3 M.I. Pacheco , E. Castro Marcos , J. de Bono , D. Olmos Hidalgo ; Madrid, ES, Salamanca, ES, 4 5 6 7 8 Valencia, ES, Sutton, Surrey/GB, Madrid, Madrid/ES, Sutton, GB, Melbourne, VIC/AU, Villejuif, FR, 9 10 11 Málaga, ES, Malaga, ES, London, GB
13:15 - 13:15 1675P - Risk of recurrence prediction and optimum treatment planning for early stage breast cancer patients: A cost-effective, accurate and broad based solution for Asia 1 2 2 2 2 2 S. Somashekhar , M.M. Bakre , C. Ramkumar , C. Basavaraj , A. Arun Kumar , L. Madhav , C.
2 2 1 2 Prakash , N. Naidu ; Bengaluru, IN, Banglore, IN
13:15 - 13:15 1676P - Comparison of progression-free survival (PFS) on comprehensive multiplatform profiling-guided therapy to PFS on prior therapy: A pooled analysis from 4 contemporary prospective studies 1 2 2 3 3 4 5 1 A. Seeber , G. Chahine , F. Nasr , A. Dean , M. Miranova , G. Jameson , N. Robert , G. Gastl , H.
1 1 2 3 4 5 Zwierzina ; Innsbruck, AT, Beirut, LB, Subiaco, AU, Scottsdale, US, Fairfax, US
13:15 - 13:15 1677P - Effect of enoxaparin, omeprazole, gemcitabine and bortezomib in refractory patients J. Marquez-Manriquez, Ciudad Obregon, Washington/MX
13:15 - 13:15 1678P - A new chemotherapy-based combination to prevent osteosarcoma progression 1 2 2 3 2 2 1 M. Monchanin , P. Berchard , M. Vienne , J.B. Langlois , N. Gadot , A. Bernet , J.-Y. Blay , A. Dutour
4 1 2 3 4 ; Lyon, FR, Lyon Cedex, FR, Bron, FR, Lyon, CEDEX/FR
13:15 - 13:15 1679P - Mutant KIT translocates into the nucleus and induces NFKBIB expression that leads to KIT expression in imatinib-resistant gastrointestinal stromal tumors 1 1 1 1 2 1 1 1 Y.-S. Hsueh , H.H. Chang , Y.-S. Shan , H.S. Sun , J.A. Fletcher , C.-F. Li , L.-T. Chen ; Tainan,
2 TW, Boston, MA/US
13:15 - 13:15 1680P - Reversion of epithelial–mesenchymal transition (EMT) as a mechanism of action of cabazitazel in castration-resistant prostate cancer N. Jiménez, M. Marín-Aguilera, O. Reig, P. Fernández, S. García-Recio, M. Pereira, A. Prat, B. Mellado
Gonzalez; Barcelona, ES
13:15 - 13:15 1681P - Globally optimizing therapeutic combinations against bortezomib-resistant multiple myeloma using a quantitative parabolic optimization platform (QPOP) 1 1 1 2 1 1 1 1 1 M. Rashid , T.B. Toh , N.L. Abdullah , A. Silva , Y. Zhang , P.F. Tan , A.L. Teh , N. Karnani , S. Jha
2 1 1 1 1 2 , C.-M. Ho , W.J. Chng , H. Dean , E. Chow ; Singapore, SG, Los Angeles, US
13:15 - 13:15 1682P - Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer J. Chen, I. Guccini, D. Di Mitri, D. Brina, A. Alimonti; Bellinzona, CH
13:15 - 13:15 1683P - Metabolomics in cancer cachexia
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 1 2 1 2 J. Lopez-Martin , M. Cala , E. Prieto-García , C. Gonzalez Riano , C.V. Díaz-García , A. García , V. 1 2 1 1 1 1 Pardo Marqués , F. Ruperez Pascualena , I. García-Ruiz , C. Pernaut , I. Otero , L. Parrilla Rubio , M. 1 1 2 1 1 2 Riesco , J. Adeva Alfonso , C. Barbas , M.T. Agulló-Ortuño ; Madrid, ES, Boadilla Del Monte, ES
13:15 - 13:15 1684P - Association between the Dietary Inflammatory Index (DII), urinary enterolignans and C-reactive protein in the National Health and Nutrition Examination Survey-2003-2008 1 2 2 2 2 1 2 N. Shivappa , M. Wirth , A. Murphy , T. Hurley , J. Hebert ; Columbia, US, Columbia, SC/US
13:15 - 13:15 1685P - Fullerenol/iron nanocomposite modulates doxorubicin-induced cardiotoxicity 1 2 1 3 3 3 3 M. Seke , D. Petrovic , M. Labudovic Borovic , D. Jović , I. Borisev , Z. Kanacki , D. Zikic , A.
3 1 2 3 Djordjevic ; Belgrade, RS, Sombor, RS, Novi Sad, RS
13:15 - 13:15 1686P - Ability of TMPRSS2-ERG (TE) expression to predict taxane benefit depending on prior abiraterone or enzalutamide therapy in castration-resistant prostate cancer 1 1 2 1 1 1 1 M. Marín-Aguilera , O. Reig , A. Font , A. Rodríguez-Vida , C. Suárez , M. Domenech , N. Jiménez , 1 1 1 2 2 1 1 I. Victoria , S. López , M. Milà-Guasch , E. Felip , O. Etxaniz , J. Carles , F. Racca , N.
3 4 1 1 1 1 2 Sala-González , A. González del Alba , P. Fernández , A. Prat , B. Mellado ; Barcelona, ES, 3 4 Badalona, ES, Girona, ES, Palma De Mallorca, ES
13:15 - 13:15 1688P - Identification of patient population with longer survival when treated with S-1 plus cisplatin via predictive enrichment strategy analysis of the FLAGS and DIGEST phase III trial 1 1 2 1 2 M. Takeuchi , M. Takeuchi , J. Ajani ; Tokyo, JP, Lyngby, DK
13:15 - 13:15 1689P - HMGA1 is a new biomarker of liposarcoma progression 1 1 1 1 2 1 2 1 R. Loria , V. Laquintana , G. Bon , D. Trisciuoglio , R. Covello , C. Amoreo , V. Ferraresi , C. Zoccali
3 2 1 1 2 3 , M. D'Incalci , R. Biagini , R. Falcioni ; Rome, IT, Roma, IT, Milan, IT
13:15 - 13:15 1690P - hsa_circ_0004870 is related to AR-V7 expression and may confer resistance to enzalutamide in castration-resistant prostate cancer 1 2 3 3 3 1 1 J. Greene , A.-M. Baird , L. Brady , S. Gray , S. Finn , R. McDermott ; Dublin, Belgard Square
2 3 North/IE, Brisbane, Queensland/AU, Dublin, IE
13:15 - 13:15 1691P - Analysis of DPYD and UGT1A1 genotype in patients with advanced pancreatic cancer treated with modified FOLFIRINOX C. Vivaldi, E. Arrigoni, R. Morganti, S. Catanese, L. Fidilio, I. Pecora, G. Restante, L. Fornaro, S. Crucitta,
M. Lencioni, E. Rofi, E. Vasile, A. Falcone, R. Danesi, M. Del Re; Pisa, IT
13:15 - 13:15 1692P - Clinical significance of the expression of membrane receptors of the alternative nuclear factor-kappaB pathway in non-small cell lung cancer 1 2 1 2 1 1 F.-I. Dimitrakopoulos , V. Tzelepi , A. Kottorou , A. Antonacopoulou , A. Koutras , T. Makatsoris , H.
1 1 2 Kalofonos ; Patras, Rion/GR, Patras, GR
13:15 - 13:15 1693P - Development of TP53 signature diagnostic system using multiplex RT-PCR and observational study to confirm the prognostic value of TP53 signature in breast cancer
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 3 4 5 6 6 5 S. Takahashi , T. Fukui , T. Nomizu , Y. Kakugawa , T. Ishida , S. Yamaguchi , S. Kato , N. Ohuchi , 2 5 1 2 3 4 5 6 N. Gondo , C. Ishioka ; Sendai, Miyagi/JP, Kyoto, JP, Koriyama, JP, Natori, JP, Sendai, JP, Tokyo, JP
13:15 - 13:15 1694P - Expression of estrogen receptors and beta-III tubulin in non-small cell lung cancer tissue E. Ponomarenko, I. Mamichev, T. Bogush, O. Ryabinina, J. Dyakova, D. Novikov, B. Polotsky, M.
Davydov; Moscow, RU
13:15 - 13:15 1695P - Deciphering the antitumor efficacy and mechanistic delineation of epigenetic inhibitors in AML using patient tumor derived ex vivo phenotypic assay based platform 1 2 3 3 3 2 P. Majumder , P. Radhakrishnan , S. Thiagarajan , M. Biswas , D. Malhotra , B. Ulaganathan , B.
3 3 1 2 3 Majumder , G. Babu ; Woburn, US, Woburn, MA/US, Bangalore, IN
13:15 - 13:15 1696P - Proteomics of triple negative breast cancer developing metastases to central nervous system 1 1 1 1 1 K. Rojas , L. Trilla-Fuertes , A. Gámez , J. Sepulveda Sanchez , L. Manso Sánchez , G. 1 2 1 1 1 2 Prado-Vásquez , C. Chiva , A. Zapater-Moros , S. Llorente-Armijo , D.C. Mendiola , E. Sabidó , J.A. 1 1 1 1 2 Fresno , E.M. Ciruelos Gil , L. Paz-Ares ; Madrid, ES, Barcelona, ES
13:15 - 13:15 1697P - Assessing functional Androgen Receptor (AR) pathway activity using a computational model A. van Brussel, M. Inda, E. Den Biezen, D. van Strijp, J. Wrobel, H. van Ooijen, R. Hoffmann, W.
Verhaegh, A. van de Stolpe; Eindhoven, NL
13:15 - 13:15 1698P - Evaluation of deamination bias from formalin-fixed tissues of small cell lung cancer with a dual strand targeted amplicon sequence 1 2 3 4 2 2 1 2 T. Amano , H. Nishihara , H. Yokouchi , H. Suzuki , H. Akita , N. Sato ; Sapporo, Hokkaido/JP,
3 4 Sapporo, JP, Fukushima, Fukushima/JP, Fukushima, JP
13:15 - 13:15 1699P - Functional genomic mRNA (FGmRNA) profiling of & 1 1 2 1 1 2 K. Moek , D.J. de Groot , E.G.E. de Vries , R. Fehrmann ; Groningen, NL, Cluj-Napoca, RO
13:15 - 13:15 TUMOUR BIOLOGY AND PATHOLOGY A. Bardelli, Candiolo, (TO)/IT
13:15 - 13:15 1708P - Anti-tumor activity of alectinib in the orthotopic in vivo imaging model with NCOA4-RET fusion positive tumor cells 1 2 2 2 2 1 2 S. Yano , S. Arai , K. Kita , A. Tanimoto , S. Takeuchi ; Kanazawa, Ishikawa/JP, Kanazawa, JP
13:15 - 13:15 (Withdrawn)
13:15 - 13:15 1710P - Cathepsin S regulates cell migration and invasion through mediating store-operated calcium entry and the focal adhesion proteins H.-H. Lin, M.-R. Shen, J.-Y. Chang; Tainan, TW
13:15 - 13:15 1711P - Type VI collagen (COL6) as part of tumorgenesis: Focus on quantifying specific COL6 protein fragments in serum A. Wardak, N. Willumsen, D. Mogensen, S. Nielsen, C. Jensen, S. Kehlet, M. Karsdal; Herlev, DK
Last update: 02-09-2017 06:01:33pm esmo.org
13:15 - 13:15 1712P - The combination analysis of tumor infiltration lymphocyte with Neutrophil to lymphocyte ratio may predict prognosis of colorectal cancer in stage I-III 1 1 2 1 2 S.M.R. Mortazavizadeh , Y. Ayoughi , M. Moghimi ; Yazd, IR, Safaieeh, IR
13:15 - 13:15 1713P - Prognostic value of NK and T-lymphocyte markers in operable non-small cell lung cancer (NSCLC) 1 1 1 1 2 2 M. Skrzypski , A. Szymanowska-Narloch , A. Kowalczyk , A. Maciejewska , M. Marczyk , J. Polańska
1 1 3 1 2 3 , W. Biernat , W. Rzyman , J. Jassem ; Gdansk, PL, Gliwice, PL, Gdańsk, PL
13:15 - 13:15 1714P - KRAS in non-small cell lung cancer 1 1 1 2 2 2 2 I. Amanam , R. Gupta , I. Mambetsariev , M. Koczywas , M. Cristea , E. Massarelli , K. Reckamp , R.
3 1 2 3 Salgia ; Duarte, US, Duarte, CA/US, Chicago, IL/US
13:15 - 13:15 1715P - PIK3CA mutation and PDL1 expression in lung squamous cell carcinoma surgically resected 1 2 2 2 3 3 3 L. Gutierrez Sanz , C. Salas , I. Martinez , D. García , F.F. Franco , I. Curto , M. Mendez , L.
3 3 2 1 2 3 Gonzalez , M. Provencio , P. Martin ; Majadahonda, Madrid/ES, Madrid, ES, Majadahonda, ES
13:15 - 13:15 1716P - TRKA expression and NTRK1 gene copy number across solid tumors 1 2 2 1 1 2 2 G. Mauri , E. Valtorta , A. Sartore-Bianchi , G. Cerea , A. Amatu , M. Schirru , G. Marrapese , V. 2 2 2 1 2 2 2 2 1 Fiorillo , P. Recchimuzzo , I. Stella , S. Veronese , F. Tosi , M. Maiolani , M. Truini , S. Siena ; 2 Milan, IT, Milano, IT
13:15 - 13:15 1717P - The correlation between MMR gene expression MSH2/MSH6 and VEGF A/VEGF B in gastro-esophageal cancer A. Dracea, M. Danciulescu, A. Dricu, F. Burada, M. Ioana; Craiova, RO
13:15 - 13:15 1718P - Liver-type glutaminase (GAB) suppresses malignant phenotype of glioblastoma cells 1 1 2 1 1 2 E. Majewska , M. Szeliga , J. Márquez , J. Albrecht ; Warsaw, PL, Malaga, ES
13:15 - 13:15 1719P - Alteration of p53 mRNA expression in neuroblastoma and its impact in disease outcome M. Inomistova, N. Khranovska, O. Skachkova, G. Klymniuk, S. Pavlyk; Kiev, UA
13:15 - 13:15 1720P - Downregulation of BRCA1 protein in clear cell renal cellular carcinoma E. Sarnowska, N. Rusetska, M. Szymanski, I. Jancewicz, M. Chmielarczyk, R. Konopinski, M.
Leszczynski, A. Chrzan, M. Ligaj, A. Maassen, T. Sarnowski, J. Siedlecki; Warsaw, PL
13:15 - 13:15 1721P - The role of PD-L1 in a high-grade invasive human oral squamous cell carcinoma microenvironment M. HIRAI, H. kitahara, Y. Kobayashi, S. Kawashiri, H. Nakamura; Kanazawa, JP
13:15 - 13:15 1722P - Loss of SWI/SNF chromatin remodelling complex is linked to advanced urinary bladder cancer M. Szymanski, E. Sarnowska, A. Ornoch, N. Rusetska, S. Abramowicz, A. Chrzan, M. Ligaj, A. Maassen,
J. Siedlecki, T. Sarnowski; Warsaw, PL
Last update: 02-09-2017 06:01:33pm esmo.org 13:15 - 13:15 1723P - The role of hepatocyte nuclear factor 1 homeobox B (HNF1B) loss in chromophobe RCC (ChRCC) development 1 1 1 1 1 1 2 3 3 E. Jonasch , G. Fuller , I. McCutcheon , Z. Ding , L. Zhou , X. Liu , W. Kong , R. Powell , I.-Y. Park , 1 4 2 1 3 2 1 1 3 N. Tannir , W. Rathmell , B. Dong , S. Matin , X. Tong , Y. Huang , P. Tong , J. Wang , C. Walker , 1 1 2 3 4 M. Sun ; Houston, TX/US, Shanghai, CN, Houston, US, Nashville, US
13:15 - 13:15 1724P - Some mechanisms of increasing malignancy of B16/F10 melanoma in female mice with chronic pain I. Kotieva, O. Kit, E. Frantsiyants, I. Kaplieva, L. Trepitaki, V. Bandovkina, N. Cheryarina, Y. Pogorelova,
L. Vladimirova; Rostov-On-don, RU
13:15 - 13:15 1725P - Impact of global epigenetics machinery on clinical outcome of colorectal cancer patients treated with fluoropyrimidine-based therapy M. Fouad, S. Salem, M. Hussein, A.-R. Zekri, D. Mohammed, H. Hafez, S. Shouman; Cairo, EG
13:15 - 13:15 1726P - Comparison of breast cancer subtypes between young and elderly women I. Kiladze, A. Mariamidze, M. McHedlishvili, K. Tsomaia, F. Todua; Tbilisi, GE
13:15 - 13:15 1727P - Distribution of the PAM50 breast cancer subtypes within each pathology-based group: a combined analysis of 15,339 patients across 29 studies 1 2 3 4 3 3 3 J.M. Cejalvo , T. Pascual , A. Fernández-Martínez , B. Adamo , N. Chic , M. Vidal , L. Rodelo , M.
3 3 1 2 3 4 Muñoz , A. Prat ; Valencia, Valencia/ES, Madrid, ES, Barcelona, ES, Messina, IT
13:15 - 13:15 1728P - Genetic association of matrix metalloproteinase MMP- 1, MMP-3 and MMP-9 Genes with HCV-related hepatocellular carcinoma in Egyptian patients 1 2 2 2 2 1 2 A. Alhanafy , B. Montaser , W. Fathy , N. Elabd , S. Tayel ; Shebin El Kom, EG, Sheben Elkom, EG
13:15 - 13:15 1729P - Heterogenity of epigenetic and EMT marks observed in hepatocellular carcinoma with keratin 19 proficiency 1 1 2 1 1 1 1 1 T. Nagasaka , T. Okada , N. Yokomichi , F. Taniguchi , T. Toshima , K. YASUI , T. Fuji , Y. Mori , T.
1 1 1 1 3 1 2 3 Kawai , Y. Umeda , T. Yagi , T. Fujiwara , A. Goel ; Okayama, JP, Hamamatsu, JP, Texas, TX/US
13:15 - 13:15 (Withdrawn)
13:15 - 13:15 1731P - Rare malignancy rare site: Extranodal lymphomas S. Gupta, A. Murali; Faridabad, IN
13:15 - 13:15 1732P - Descriptive analysis of families with TP53 mutations: Is there a genotype/phenotype correlation? 1 1 1 1 2 1 1 1 1 1 J. Silva , B. Filipe , A. Luís , A. Clara , S. Bento , P. Machado , P. Rodrigues , J. Parreira , F. Vaz ;
2 Lisbon, PT, Santarem, Santarem/PT
Last update: 02-09-2017 06:01:33pm esmo.org 14:15 - 15:45 Type: Young Oncologist Special session Salamanca Auditorium Title: Fellowships in Europe: Educational opportunities for Young Oncologists Chair(s): C. Zielinski, AT; V. Guarneri, IT
14:15 - 14:20 Introduction V. Guarneri, Padua, IT
14:20 - 14:35 Overview ESMO Fellowship Programme and Leaders Generation Programme C. Zielinski, Vienna, AT
14:35 - 14:50 Practical tips from a former fellow V. Gambardella, Valencia, ES
14:50 - 15:00 Best fellowship project 1 V. Conteduca, Meldola, Forlì-Cesena/IT
15:00 - 15:10 Best fellowship project 2 P. Szturz, Brno, South Moravian/CZ
15:10 - 15:25 How my ESMO Fellowship impacted my career L. De Mattos-Arruda, Barcelona, ES
15:25 - 15:45 Awards: Presentation of the 2017 fellows and Best Exam Award 2016
14:45 - 16:15 Type: Educational session Barcelona Auditorium Title: Challenges in oncogene addicted NSCLC Chair(s): S. Peters, CH; P. Jänne, US
14:45 - 15:10 New drivers, new perspectives T.S.K. Mok, Shatin, HK
15:10 - 15:35 Strategies against mechanisms of resistance P. Jänne, Boston, Ma, US
15:35 - 16:00 The role of immunotherapy in oncogene addicted NSCLC S. Peters, Lausanne, CH
16:00 - 16:15 Discussion
Last update: 02-09-2017 06:01:33pm esmo.org 14:45 - 16:15 Type: Special Symposium Cordoba Auditorium Title: Emerging topics in developmental therapeutics Chair(s): A. Chalmers, GB; U. Lassen, DK
14:45 - 14:50 Introduction U. Lassen, Copenhagen, DK
14:50 - 15:05 DNA and RNA basic strategies in early drug development R. Bernards, Amsterdam, NL
15:05 - 15:20 Combined modality of radiation DDR A. Chalmers, Glasgow, GB
15:20 - 15:35 Targeting metabolism E. Gottlieb, Technion, IL
15:35 - 15:50 Developmental therapeutics in rare tumours N. Gaspar, Villejuif, FR
15:50 - 16:05 Targeting the P53 pathway L. Saraiva, Porto, PT
16:05 - 16:15 Conclusions and clinical perspectives A. Chalmers, Glasgow, GB
Last update: 02-09-2017 06:01:33pm esmo.org 14:45 - 16:15 Type: Joint Symposium Bilbao Title: ESMO-ESOI: Colorectal cancer imaging: New opportunities to guide treatment Auditorium decisions Chair(s): E. Voest, NL; R. Beets-Tan, NL
14:45 - 14:50 Introduction E. Voest, Amsterdam, NL
14:50 - 15:10 Rectal cancer: Organ preservation and the role of imaging R. Beets-Tan, Amsterdam, NL
15:10 - 15:30 CRC liver metastases: Detection & treatment response evaluation with modern imaging D. Regge, Candiolo, IT
15:30 - 15:50 CRC liver metastases: Interventional treatment T. Helmberger, Munich, DE
15:50 - 16:10 PET/MRI: Combining molecular and functional imaging V. Goh, London, GB
16:10 - 16:15 Conclusions and clinical perspectives R. Beets-Tan, Amsterdam, NL
14:45 - 16:15 Type: Educational session Alicante Title: The “micro-economics” of cancer: How the medical oncologist should Auditorium micro-manage limited resources Chair(s): F. De Lorenzo, IT; P.G. Casali, IT
14:45 - 15:10 The ethics of micro-allocation of limited resources
15:10 - 15:35 Micro-allocation of limited resources in the clinic P.G. Casali, Milan, IT
15:35 - 16:00 How should the medical oncologist negotiate with local health administrators J. Borras, Barcelona, ES
16:00 - 16:15 Discussion
14:45 - 16:15 Type: Special Session Madrid Title: When clinical practice demands to go beyond statistics: Adjuvant chemotherapy of Auditorium colon cancer. The 3 vs 6 month story Chair(s): A. Sobrero, IT; A. Cervantes, ES
Last update: 02-09-2017 06:01:33pm esmo.org 14:45 - 14:50 Introduction A. Sobrero, Genova, IT
14:50 - 14:55 LBA22 - Updated results of the SCOT study: An International Phase III Randomised (1:1) Non-inferiority Trial Comparing 3 versus 6 months of oxaliplatin based adjuvant chemotherapy for colorectal cancer 1 2 3 4 5 6 7 8 T. Iveson , R. Kerr , M. Saunders , N. Hollander , J. Tabernero , A. Haydon , B. Glimelius , A. Harkin 9 8 8 10 11 12 13 , C. Scudder , K. Boyd , A. Waterston , L. Medley , C. Wilson , R. Ellis , S. Essapen , A. Dhadda 14 15 16 17 8 1 2 , M. Harrison , S. Falk , S. Abdel-Raouf , J. Paul ; Southampton, GB, Oxford, Oxfordshire/GB,
3 4 5 6 7 8 9 Manchester, GB, Naestved, DK, Barcelona, ES, Melbourne, AU, Uppsala, SE, Glasgow, GB, 10 11 12 13 14 Oxford, GB, London, Cheltenham/GB, Cambridge, GB, Truro, Cornwall/GB, Guildford, GB, 15 16 17 Cottingham, East Yorkshire/GB, Middlesex, GB, Bristol, GB, Essex, GB
14:55 - 15:00 LBA23 - FOLFOX4/XELOX in stage II–III colon cancer: efficacy and safety results of the Italian Three Or Six Colon Adjuvant (TOSCA) trial. 1 2 3 4 4 5 6 R. Labianca , S. Lonardi , G. Rosati , M. Di Bartolomeo , M. Ronzoni , N. Pella , M. Scartozzi , M. 7 4 8 9 10 11 12 Banzi , M.G. Zampino , F. Pasini , P. Marchetti , M. Cantore , A. Zaniboni , L. Rimassa , L. 13 14 2 15 16 17 1 2 Ciuffreda , S. Barni , V. Zagonel , E. Maiello , E. Rulli , A. Sobrero ; Parabiago (milano), IT,
3 4 5 6 7 8 9 Padova, IT, Potenza, IT, Milan, IT, Udine, IT, Ancona, IT, Reggio Emilia, IT, Rovigo, RO/IT, 10 11 12 13 14 15 Roma, IT, Carrara, IT, Brescia, IT, Rozzano, (MI)/IT, Torino, IT, Treviglio, (BG)/IT, San 16 17 Giovanni Rotondo, IT, Milano, IT, Genova, IT
15:00 - 15:05 LBA24 - Efficacy of 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for Stage III colon cancer (CC): Results from phase III ACHIEVE trial as part of the International Duration Evaluation of Adjuvant therapy (IDEA) Collaboration 1 2 3 4 5 6 7 T. Yoshino , T. Yamanaka , M. Kotaka , D. MANAKA , T. Eto , J. Hasegawa , A. Takagane , M. 8 9 10 11 12 4 13 Nakamura , T. Kato , Y. Munemoto , F. Nakamura , H. Bando , H. Taniguchi , M. Gamoh , M. 14 15 15 16 1 17 1 2 Shiozawa , J. Sakamoto , S. Saji , T. Mizushima , A. Ohtsu , M. Mori ; Kashiwa, Chiba/JP,
3 4 5 6 7 8 Yokohama, JP, Kobe, Hyogo/JP, Kyoto, JP, Tsuchiura, JP, Saki, JP, Hakodate, JP, Matsumoto, 9 10 11 12 13 JP, Amagasaki, Hyogo/JP, Fukui, Fukui/JP, Sapporo, JP, Kanazawa, JP, Osaki, Miyagi/JP, 14 15 16 17 Kanagawa, JP, Tokyo, JP, Suita, Osaka/JP, Suita, JP
15:05 - 15:10 473O - Three versus six months’ adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer: Per-protocol, subgroups and long-lasting neuropathy results 1 2 3 4 5 6 7 8 J. Taieb , F. Bonnetain , L. Mineur , J. Bennouna , J. Desrame , R. Faroux , S. Fratte , J. Dauba , D. 9 1 1 10 11 12 13 Vernerey , C. Louvet , C. Lepere , O. Dupuis , Y. Becouarn , M. Mabro , J. Egreteau , O. 14 15 16 17 18 1 2 Bouche , G. Deplanque , M. Ychou , A. de Gramont , T. André ; Paris, FR, Besançon, 3 4 5 6 CEDEX/FR, Avignon, FR, Nantes, CEDEX/FR, Lyon, CEDEX 8/FR, La Roche Sur Yon, CEDEX 7 8 9 10 11 12 9/FR, Belfort, FR, Mont De Marsan, FR, Besançon, FR, Le Mans, FR, Bordeaux, CEDEX/FR, 13 14 15 16 17 Suresnes, FR, Lorient, FR, Reims, FR, Vevey, CH, Montpellier, CEDEX 5/FR, 18 Levallois-Perret, FR, Paris, CEDEX 12/FR
15:10 - 15:20 LBA21_PR - Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): Updated results of IDEA (International Duration Evaluation of Adjuvant chemotherapy)
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 3 4 5 6 7 8 A. Grothey , A. Sobrero , J. Meyerhardt , T. Yoshino , J. Paul , J. Taieb , I. Souglakos , R. Kerr , R. 9 10 11 12 13 1 1 Labianca , A. Shields , F. Bonnetain , T. Yamanaka , I. Boukovinas , Q. Shi , J. Meyers , D. 14 15 1 16 17 1 2 3 Niedzwiecki , V. Torri , D. Sargent , T. André , T. Iveson ; Rochester, MN/US, Genova, IT,
4 5 6 7 8 Boston, MA/US, Kashiwa, Chiba/JP, Glasgow, GB, Paris, FR, Heraklion, Crete/GR, Oxford, 9 10 11 12 13 Oxfordshire/GB, Bergamo, IT, Detroit, US, Besançon, CEDEX/FR, Yokohama, JP, Athens, 14 15 16 17 GR, Durham, NC/US, Milan, IT, Paris, CEDEX 12/FR, Southampton, GB
15:20 - 15:30 Discussion by the clinician T. Maughan, Oxford, GB
15:30 - 15:40 Discussion by the statistician M. Buyse, San Francisco, CA/US
15:40 - 16:15 Moderated panel discussion on clinical conditions and Q&A 1 2 3 4 5 1 2 A. Cervantes , J. Meyerhardt , A. Shields , A. Sobrero , I. Souglakos ; Valencia, Valencia/ES,
3 4 5 Boston, MA/US, Detroit, US, Genova, IT, Heraklion, GR
14:45 - 16:15 Type: Special Symposium Sevilla Auditorium Title: Cancer evolution and metastasis: From single cells to population dynamics Chair(s): I. Bozic, US; R. Giavazzi, IT
14:45 - 14:50 Introduction R. Giavazzi, Milan, IT
14:50 - 15:10 Cancer evolution and metastasis: from single cells to population dynamics I. Bozic, Seattle, Wa, US
15:10 - 15:30 Quantifying the evolutionary dynamics of tumor growth and metastasis C. Curtis, Standford, Ca, US
15:30 - 15:50 Metastasis as an evolutionary process S. Turajlic, London, GB
15:50 - 16:10 Single cell analysis and cancer T. Voet, Leuven, BE
16:10 - 16:15 Conclusions and clinical perspectives I. Bozic, Seattle, Wa, US
14:45 - 16:15 Type: Poster Discussion session Pamplona Auditorium Title: Non-metastatic NSCLC and other thoracic malignancies Chair(s): M. Garassino, IT; C. Le Pechoux, FR; F. Blackhall, GB; P. Baas, NL
Last update: 02-09-2017 06:01:33pm esmo.org 14:45 - 14:45 1278PD - Major pathological response after preoperative chemotherapy as a surrogate marker of survival in early-stage non-small cell lung cancer: cohort of NATCH phase III trial 1 1 2 1 1 J. Remon , A. Martinez-Marti , E. Carcereny Costa , J. Zeron-Medina Cuairan , I. Sansano , J.L. Mate 3 1 1 1 1 3 1 1 , N. Pardo , S. Cedres , A. Navarro , A.M. Martinez de castro , T. Moran , E. Felip Font ; Barcelona, 2 3 ES, Badalona, Barcelona/ES, Badalona, ES
14:45 - 14:45 1274PD - Analysis of immunoregulatory biomarkers in early stages of non-small cell lung cancer 1 1 1 1 2 A. Moreno Manuel , S. Calabuig Fariñas , A. Herreros Pomares , S. Gallach Garcia , F. Aranda , A. 1 2 2 1 1 1 Blasco , E. Carreras , F. Lozano , A. Cunquero Tomas , M. Martorell , E. Jantus-Lewintre , C. Camps 1 1 2 Herrero ; Valencia, ES, Barcelona, ES
14:45 - 14:45 1275PD - Stemness characterization of tumorspheres from non-small cell lung cancer: Differential expression in CSC-related markers and signaling pathways A. Herreros Pomares, S. Calabuig Fariñas, E. Escorihuela, H. Amado, R. Guijarro, S. Gallach Garcia, A.
Navarro, E. Jantus-Lewintre, C. Camps Herrero; Valencia, ES
14:45 - 14:55 Invited Discussant 1278PD, 1274PD and 1275PD M. Garassino, Milan, IT
14:55 - 15:00 Q&A led by Discussant
15:00 - 15:00 1287PD - Preoperative chemotherapy and radiotherapy concomitant to cetuximab in stage IIIB NSCLC: A multicenter phase II SAKK 1 2 3 2 4 5 6 A. Curioni-Fontecedro , H.-B. Ris , A. Xyrafas , H. Bouchaab , H. Gelpke , N. Mach , O. Matzinger , 3 7 8 3 9 4 10 N. Stojcheva , M. Frueh , R. Cathomas , S. Berardi Vilei , L. Bubendorf , M. Pless , D. Betticher , S.
2 1 2 3 4 5 6 7 Peters ; Zurich, CH, Lausanne, CH, Bern, CH, Winterthur, CH, Geneva, CH, Vevey, CH, St. 8 9 10 Gallen, CH, Chur, CH, Basel, CH, Fribourg, CH
15:00 - 15:00 1277PD - A phase II randomized trial of adjuvant chemotherapy for the patients completely resected pathological stage IB (T & 1 2 3 3 3 1 3 T. Okamoto , T. Yano , M. Shimokawa , S. Takeo , K. Yamazaki , K. Sugio , M. Takenoyama , A. 4 3 3 3 1 2 3 4 Nagashima , T. Tagawa , Y. Emi , Y. Maehara ; Yufu, JP, Beppu, JP, Fukuoka, JP, Kitakyushu, JP
15:00 - 15:00 1288PD - Randomized phase ii trial comparing chemoradiotherapy with chemotherapy for completely resected unsuspected N2-positive non-small cell lung cancer J.-M. Sun, M.-J. Ahn, J.S. Ahn, H.K. Kim, Y.C. Ahn, J.I. Zo, Y.M. Shim, K. Park; Seoul, KR
15:00 - 15:00 1289PD - Clinical course in patients with stage III non-small cell lung cancer and interstitial lung disease treated with chemoradiotherapy: a retrospective analysis in a single institute 1 1 2 1 1 1 3 1 H. Kobayashi , T. Naito , K. Omae , S. Omori , K. Nakashima , K. Wakuda , A. Ono , H. Kenmotsu , 3 1 1 1 1 2 3 H. Murakami , M. Endo , H. Harada , T. Takahashi ; Shizuoka, JP, Sunto-Gun, JP, Shizuoka, Shizuoka/JP
15:00 - 15:20 Invited Discussant 1287PD, 1277PD, 1278PD, 1288PD and 1289PD
Last update: 02-09-2017 06:01:33pm esmo.org C. Le Pechoux, Villejuif, CEDEX/FR
15:20 - 15:30 Q&A led by Discussant
15:30 - 15:30 1528PD - Initial results of BMS-986012, a first-in-class fucosyl-GM1 mAb, in combination with nivolumab, in pts with relapsed/refractory (rel/ref) small-cell lung cancer (SCLC) 1 2 3 4 5 6 7 Q.S.-C. Chu , C. van Herpen , N. Leighl , B. Markman , S. Clarke , R. Juergens , P. Basciano , D. 7 7 7 7 7 7 7 Lathers , S. Tannenbaum-Dvir , K. Urbanska , G. Kollia , C. Darby , D. Williams , G. Kolaitis , N.
8 1 2 3 4 5 6 Ready ; Edmonton, CA, Nijmegen, NL, Toronto, CA, Melbourne, VIC/AU, St Leonards, NSW/AU, 7 8 Hamilton, ON/CA, Princeton, NJ/US, Durham, NC/US
15:30 - 15:30 1529PD - 1 2 1 1 1 M.E. Olmedo Garcia , M. Forster , E. Calvo , V. Moreno , M.P. Lopez Criado , J.A. Lopez-Vilarino de 1 3 4 1 1 1 2 Ramos , C. Kahatt , P. Lardelli , X.E. Luepke-Estefan , A. Soto-Matos ; Madrid, ES, London, 3 4 London/GB, Colmenar Viejo, ES, Colmenar Viejo, Madrid/ES
15:30 - 15:30 1530PD - Results of a randomized, placebo-controlled, phase 2 study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC) 1 2 3 4 5 6 7 8 D. Daniel , C. Rudin , L. Hart , D. Spigel , M. Edelman , J. Goldschmidt , R. Bordoni , B. Glisson , T. 9 10 11 12 13 14 15 16 17 Burns , A. Dowlati , G. Dy , T. Beck , R. Jotte , S. Liu , A. Kapoun , L. Faoro , A. Chiang ; 1 2 3 4 5 6 Chattanooga, US, New York, NY/US, Fort Myers, FL/US, Nashville, TN/US, Philadelphia, US,
7 8 9 10 11 12 Blacksburg, US, Marietta, US, Houston, US, Pittsburgh, US, Cleveland, OH/US, Buffalo, US, 13 14 15 16 Fayetteville, US, Denver, US, Washington, US, Redwood City, US, South San Francisco, 17 CA/US, New Haven, US
15:30 - 15:30 1531PD - Clinical outcomes for EGFR-mutant adenocarcinomas (AC) that transform to small cell lung cancer (SCLC) 1 1 2 2 2 2 2 N. Marcoux , Z. Piotrowska , A. Farago , A. Hata , M. Mooradian , B. Drapkin , A. Muzikansky , S.
3 2 2 1 2 3 Gettinger , M. Mino-Kenudson , L. Sequist ; Boston, US, Boston, MA/US, New Haven, CT/US
15:30 - 15:50 Invited Discussant 1528PD, 1529PD, 1530PD and 1531PD F. Blackhall, Manchester, GB
15:50 - 16:00 Q&A led by Discussant
16:00 - 16:00 1617PD - Multiplexed targeted proteomics signature for serum diagnostic of malignant pleural mesothelioma 1 2 3 3 1 1 4 F. Cerciello , M. Choi , K. Lomeo , J. Amann , E. Felley-Bosco , R. Stahel , B. Robinson , J. Creaney 4 5 2 3 1 2 3 4 , H. Pass , O. Vitek , D. Carbone ; Zürich, CH, Boston, MA/US, Columbus, OH/US, Nedlands, 5 AU, New York, US
Last update: 02-09-2017 06:01:33pm esmo.org 16:00 - 16:00 1618PD - Overall survival (OS) and forced vital capacity (FVC) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM) 1 2 3 4 5 6 7 8 9 S. Novello , A. Nowak , F. Grosso , N. Steele , S. Popat , L. Greillier , T. John , N. Leighl , M. Reck , 10 11 12 13 14 15 N. Pavlakis , J.B. Sorensen , D. Planchard , G.L. Ceresoli , B. Hughes , J. Mazieres , M. 16 17 18 19 1 1 2 Socinski , U. von Wangenheim , J. Barrueco , N. Morsli , G. Scagliotti ; Torino, IT, Crawley, 3 4 5 6 7 8 WA/AU, Alessandria, IT, Glasgow, GB, London, GB, Marseille, FR, Heidelberg, VIC/AU, Toronto, 9 10 11 12 13 CA, Grosshansdorf, DE, St Leonards, NSW/AU, Copenhagen, DK, Villejuif, FR, Bergamo, IT, 14 15 16 17 18 19 North Ryde, AU, Toulouse, FR, Pittsburgh, PA/US, Biberach, DE, Ridgefield, US, Paris, FR
16:00 - 16:00 1619PD - Malignant pleural mesothelioma immune microenvironment and checkpoint expression before and after systemic cytotoxic treatment G. Zago, F. Lunardi, F. Calabrese, S. Vuljan, L. Urso, S. Frega, A. Pavan, V. Polo, L. Bonanno, I. Attili, F.
Rea, P.F. Conte, G. Pasello; Padova, IT
16:00 - 16:10 Invited Discussant 1617PD, 1618PD and 1619PD P. Baas, Amsterdam, NL
16:10 - 16:15 Q&A led by Discussant
Last update: 02-09-2017 06:01:33pm esmo.org 15:00 - 16:20 Type: Proffered Paper session Granada Auditorium Title: Head and neck cancer, excluding thyroid Chair(s): A. Psyrri, GR; C. Le Tourneau, FR
15:00 - 15:12 LBA45_PR - Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial 1 2 3 4 5 6 7 8 E. Cohen , K. Harrington , C. Le Tourneau , J. Dinis , L. Licitra , M.-J. Ahn , A. Soria , J.-P. Machiels 9 10 11 12 12 12 13 1 , N. Mach , R. Mehra , B. Burtness , Y. Wang , A. Tuozzo , R. Swaby , D. Soulieres ; La
2 3 4 5 6 7 8 Jolla, IL/US, London, GB, Paris, FR, Porto, PT, Milan, IT, Seoul, KR, Madrid, ES, Brussels, BE, 9 10 11 12 13 Geneva, CH, Philadelphia, PA/US, New Haven, CT/US, Kenilworth, NJ/US, Montreal, CA
15:12 - 15:24 1043O - Treatment beyond progression with nivolumab in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the phase 3 checkmate 141 study: A biomarker analysis and updated clinical outcomes 1 2 3 4 5 6 7 R. Haddad , G. Blumenschein Jr , J. Fayette , J. Guigay , A. Colevas , L. Licitra , S. Kasper , E. 8 9 10 11 12 13 13 Vokes , F. Worden , N. Saba , M. Tahara , F. Concha-Benavente , M. Monga , M. Lynch , L. Li 13 14 15 16 12 1 2 3 , J. Shaw , M. Gillison , K. Harrington , R. Ferris ; Boston, MA/US, Houston, US, Lyon, FR,
4 5 6 7 8 9 Nice, CEDEX 2/FR, Stanford, CA/US, Milan, IT, Essen, DE, Chicago, IL/US, Ann Arbor, MI/US, 10 11 12 13 14 15 Atlanta, GA/US, Kashiwa, Chiba/JP, Pittsburgh, PA/US, Princeton, US, New York, US, 16 Columbus, US, London, GB
15:24 - 15:39 Invited Discussant LBA45 and 1043O S. Faivre, Paris, FR
15:39 - 15:51 1042O - Durvalumab for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Preliminary results from a single-arm, phase 2 study 1 2 3 4 5 6 7 8 D. Zandberg , A. Algazi , A. Jimeno , J. Good , J. Fayette , N. Bouganim , N. Ready , P. Clement , T. 9 9 9 9 10 11 1 2 Goswmi , A. Jarkowski , J. Armstrong , K. Asubonteng , G. Melillo , R. Mesía ; Baltimore, US,
3 4 5 6 7 San Francisco, US, Colorado, US, Birmingham, GB, Lyon, CEDEX/FR, Montreal, CA, Durham, 8 9 10 11 NC/US, Leuven, BE, Gaithersburg, US, Gaithersburg, Maryland/US, Barcelona, ES
15:51 - 16:03 1044O - Long-Term Safety and Clinical Outcomes of Atezolizumab in Head and Neck Cancer: Phase Ia Trial Results 1 2 3 4 5 6 7 7 R. Bahleda , F. Braiteh , A. Balmanoukian , I. Braña , F.S. Hodi , L. Garbo , B. Liu , L. Molinero , C. 7 8 9 1 2 3 4 O'Hear , X. Shen , A. Colevas ; Villejuif, CEDEX/FR, Las Vegas, US, Los Angeles, CA/US,
5 6 7 8 Barcelona, ES, Boston, US, Albany, NY/US, South San Francisco, CA/US, South San Francisco, 9 US, Stanford, CA/US
16:03 - 16:18 Invited Discussant 1042O and 1044O L. Licitra, Milan, IT
Last update: 02-09-2017 06:01:33pm esmo.org 15:00 - 16:00 Type: Multidisciplinary Session Valencia Auditorium Title: Management of brain metastases Chair(s): T. Bachelot, FR
15:00 - 15:05 Presentation of case/condition T. Bachelot, Lyon, CEDEX/FR
15:05 - 15:15 The medical oncology perspective T. Bachelot, Lyon, CEDEX/FR
15:15 - 15:25 The radiation therapy perspective F. Dhermain, Villejuif, FR
15:25 - 15:35 The neurosurgery perspective C. Watts, Cambridge, GB
15:35 - 16:00 General Discussion
15:00 - 16:00 Type: Multidisciplinary Session Tarragona Auditorium Title: Management of M0 patient with rising PSA Chair(s): K. Fizazi, FR
15:00 - 15:05 Presentation of case/condition K. Fizazi, Villejuif, FR
15:05 - 15:15 The clinical problem: A multi-disciplinary issue K. Fizazi, Villejuif, FR
15:15 - 15:25 How can PET imaging help? U. Haberkorn, Heidelberg, DE
15:25 - 15:35 How can MRI imaging help? N. Tunariu, London, GB
15:35 - 16:00 General Discussion
Last update: 02-09-2017 06:01:33pm esmo.org 16:00 - 17:30 Type: Young Oncologist Forum Salamanca Auditorium Title: Management skills that help you organise your everyday life in oncology Chair(s): R. Vidra, RO; M. Petrova, BG
16:00 - 16:20 How to profit from opportunities in a competitive environment E. Martinelli, Naples, IT
16:20 - 16:20 Session Shooter G. Argiles Martinez, Barcelona, ES
16:20 - 16:40 Time management: Handling priorities and necessities E. De Azambuja, Brussels, BE
16:40 - 16:40 Session Shooter C. Cardone, Naples, IT
16:40 - 17:00 Finding a mentor R.A. Stahel, Zurich, CH
17:00 - 17:00 Session Shooter M.A. Ozturk, Istanbul, TR
17:00 - 17:20 Leadership: How to run a complex team C. Zielinski, Vienna, AT
17:20 - 17:20 Session Shooter T. Amaral, Lisbon, PT
17:20 - 17:30 Discussion
Last update: 02-09-2017 06:01:33pm esmo.org 16:30 - 18:00 Type: Educational session Sevilla Auditorium Title: Update on new therapies for triple negative breast cancer (TNBC) Chair(s): P. Schmid, GB; F. Penault-Llorca, FR
16:30 - 16:55 PARP inhibitors J. Garber, Boston, Ma, US
16:55 - 17:20 Immunotherapeutics P. Schmid, London, GB
17:20 - 17:45 Androgen receptor H. Bonnefoi, Bordeaux, CEDEX/FR
17:45 - 18:00 Discussion
16:30 - 18:00 Type: Educational session Pamplona Auditorium Title: Lung cancer screening Chair(s): K. Nackaerts, BE; E. Felip Font, ES
16:30 - 16:55 Overview of clinical trials: What are the randomised data? K. Nackaerts, Leuven, BE
16:55 - 17:20 Implementation issues of lung cancer screening in Europe U. Pastorino, Milan, IT
17:20 - 17:45 Biomarkers in lung cancer screening L. Montuenga, Pamplona, ES
17:45 - 18:00 Discussion
16:30 - 18:00 Type: Poster Discussion session Cordoba Auditorium Title: Gastrointestinal tumours, non-colorectal Chair(s): S. Cascinu, IT; Y.-K. Kang, KR; D. Cunningham, GB; E. Van Cutsem, BE
16:30 - 16:30 620PD - YOSEMITE: A 3 arm double-blind randomized phase 2 study of gemcitabine, paclitaxel protein-bound particles for injectable suspension, and placebo (GAP) versus gemcitabine, paclitaxel protein-bound particles for injectable suspension and either 1 or 2 truncated courses of demcizumab (GAD)
Last update: 02-09-2017 06:01:33pm esmo.org 1 2 1 1 3 4 A. Cubillo Gracian , A. Dean , A. Muñoz , M. Hidalgo , R. Pazo-Cid , M. Martin , T. Macarulla Mercade 5 6 7 8 5 1 9 10 , L. Lipton , M. Harris , J.L. Manzano-Mozo , J. Maurel , C. Guillen-Ponce , N. Tebbutt , P. Cooray , 11 12 13 14 15 1 2 D. Sohal , M. Zalupski , T. Kolevska , R. Stagg , D. Goldstein ; Madrid, ES, Subiaco, WA/AU,
3 4 5 6 7 8 9 Zaragoza, ES, Sant Pau, ES, Barcelona, ES, Melbourne, VIC/AU, Monash, AU, Badalona, ES, 10 11 12 13 14 Heidelberg, VIC/AU, Box Hill, VIC/AU, Cleveland, US, Ann Arbor, US, Vallejo, US, New 15 York, CA/US, Sydney, NSW/AU
16:30 - 16:30 621PD - A Phase 2b of eryaspase in combination with gemcitabine or FOLFOX as second-line therapy in patients with metastatic pancreatic adenocarcinoma (NCT02195180) 1 2 3 4 5 6 7 P. Hammel , J.-B. Bachet , F. Portales , L. Mineur , J.-P. Metges , C. de la Fouchardiere , C. Louvet , 8 9 10 11 12 13 14 F. El Hajbi , R. Faroux , R. Guimbaud , D. Tougeron , J. Volet , T. Lecomte , C. Tournigand , 15 16 17 1 18 16 1 2 C. Rebischung , W. Berlier , A. Gupta , J. Cros , T. André , I. El-Hariry ; Clichy, FR, Paris, 3 4 5 6 7 8 9 CEDEX 13/FR, Montpellier, FR, Avignon, FR, Brest, FR, Lyon, CEDEX/FR, Paris, FR, Lille, FR, 10 11 12 13 La Roche Sur Yon, CEDEX 9/FR, Toulouse, CEDEX 3/FR, Poitiers, CEDEX/FR, Reims, FR, 14 15 16 17 18 Chambray-Lès-tours, FR, Creteil Cedex, FR, Grenoble, FR, Lyon, FR, Cambridge, US, Paris, CEDEX 12/FR
16:30 - 16:30 622PD - nab-Paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC): Interim efficacy and safety results from the Phase 2 LAPACT Trial 1 2 3 4 5 6 7 P. Philip , J. Lacy , F. Portales , A. Sobrero , R. Pazo-Cid , J.L. Manzano-Mozo , E. Kim , S. Dowden 8 9 10 11 12 13 13 , A. Zakari , C. Borg , E. Terrebonne , F. Rivera Herrero , J. Shiansong Li , T.J. Ong , T. 14 15 1 2 3 4 5 Nydam , P. Hammel ; Detroit, MI/US, New Haven, CT/US, Montpellier, FR, Genova, IT, 6 7 8 9 10 Zaragoza, ES, Badalona, ES, Charlotte, NC/US, Calgary, Alberta/CA, Orlando, FL/US, Besançon, 11 12 13 14 15 FR, Giround, FR, Santander, ES, Summit, NJ/US, Summit, US, Clichy, FR
16:30 - 16:30 623PD - A phase I and randomized phase II trial to evaluate the efficacy and safety of nab-paclitaxel (nab-P) in combination with gemcitabine (G) for the treatment of patients with ECOG 2 advanced pancreatic cancer (PDAC) 1 2 1 3 4 5 1 M. Hidalgo , R. Pazo-Cid , C. Guillen-Ponce , R. López , R. Vera , M. Reboredo , A. Muñoz , E. 6 7 8 1 1 Martinez de Castro , R. Díaz Beveridge , A. La Casta , J. Martin-Valades , A. Cubillo , J. 9 10 1 11 1 2 3 Martínez-Galán , I. Ales , J. Sastre , T. Macarulla Mercade ; Madrid, ES, Zaragoza, ES, Santiago 4 5 6 7 8 9 De Compostela, ES, Pamplona, ES, A Coruna, ES, Santander, ES, Valencia, ES, Donostia, ES, 10 11 Granada, ES, Málaga, ES, Barcelona, ES
16:30 - 16:50 Invited Discussant 620PD, 621PD, 622PD and 623PD S. Cascinu, Ancona, IT
16:50 - 17:00 Q&A led by Discussant
17:00 - 17:00 1733PD - New promising combination therapy of a mitochondrial metabolism inhibitor with mFOLFIRINOX in pancreatic cancer 1 2 2 3 3 4 1 2 A. Alistar , B. Pasche , R. D'Agostino , T. Pardee , S. Luther , R. Desnoyer ; Morristown, US,
3 4 Winston Salem, US, Cranbury, US, Winston Salem, NC/US
Last update: 02-09-2017 06:01:33pm esmo.org 17:00 - 17:00 1734PD - Anti-CTGF human recombinant monoclonal antibody pamrevlumab increases resectability and resection rate when combined with gemcitabine/Nab-paclitaxel in the treatment of locally advanced pancreatic cancer patients 1 2 3 4 5 6 7 8 E. Carrier , V. Picozzi , M. Pishvaian , K. Mody , J. Winter , J. Glaspy , T. Larson , W.C. Conway , K. 9 9 9 1 2 3 4 Lipson , S. Porter , E. Kouchakji ; San Francisco, US, Seattle, WA/US, Washington, DC/US,
5 6 7 8 Jacksonville, FL/US, Philadelphia, PA/US, Los Angeles, CA/US, Minnesota, MN/US, New Orleans, 9 LA/US, San Francisco, CA/US
17:00 - 17:10 Invited Discussant 1733PD and 1734PD E. Van Cutsem, Leuven, BE
17:10 - 17:20 Q&A led by Discussant
17:20 - 17:20 624PD - A phase III trial of muparfostat (PI-88) as adjuvant therapy in patients with hepatitis virus related hepatocellular carcinoma (HV-HCC) after resection 1 1 2 3 4 1 2 1 P.-J. Chen , P.-H. Lee , K.-H. Han , J. Fan , T.T. Cheung , R.-H. Hu , S.W. Paik , W.-C. Lee , G.-Y. 1 5 2 2 6 7 1 5 2 Chau , L.-B. Jeng , H.J. Wang , J.Y. Choi , C.-L. Chen , M. Cho , M.-C. Ho , C.-C. Wu , K.S. Lee , Y.
8 1 1 1 2 3 4 5 6 Mao , F.-C. Hu , K.-L. Lai ; Taipei, TW, Seoul, KR, Shang-Hai, CN, Hk, HK, Taichung, TW, 7 8 Kaohsiung, TW, Pusan, KR, Beijing, CN
17:20 - 17:20 625PD - Protein biomarkers as predictors of outcome with regorafenib (REG) in patients (pts) with hepatocellular carcinoma (HCC) in the RESORCE trial 1 2 3 4 5 6 1 2 M. Teufel , K. Köchert , G. Meinhardt , R. Finn , J. Llovet , J. Bruix ; Whippany, NJ/US, Berlin, DE,
3 4 5 6 New York, NJ/US, Los Angeles, CA/US, New York, US, Barcelona, ES
17:20 - 17:30 Invited Discussant 624PD and 625PD D. Cunningham, Sutton, GB
17:30 - 17:40 Q&A led by Discussant
17:40 - 17:40 626PD - A randomized phase III trial comparing 4 courses and 8 courses of S-1 adjuvant chemotherapy for p-stage II gastric cancer: JCOG1104 (OPAS-1) 1 2 3 3 4 5 6 T. Yoshikawa , M. Terashima , J. Mizusawa , S. Nunobe , Y. Nishida , M. Kaji , N. Fukushima , S. 7 8 9 10 11 12 13 14 Hato , Y. Choda , H. Yabusaki , K. Yoshida , S. Ito , A. Takeno , T. Yasuda , Y. Kawachi , H. 3 3 15 3 16 1 2 Katayama , H. Fukuda , N. Boku , T. Sano , M. Sasako ; Yokohama, JP, Shizuoka, Shizuoka/JP,
3 4 5 6 7 8 Tokyo, JP, Sapporo, JP, Toyama, JP, Yamagata, Yamagata/JP, Matsuyama, JP, Hiroshima, JP, 9 10 11 12 13 14 15 Niigata, JP, Gifu, JP, Nagoya, JP, Amagasaki, Hyogo/JP, Akashi, JP, Nagaoka, JP, 16 Kawasaki, Kanagawa/JP, Nishinomiya, JP
17:40 - 17:40 627PD - Comparison of the eighth and seventh editions of the American Joint Committee on Cancer TNM staging systems for gastric cancer: Proposal for a simplified and improved TNM staging system J. Lin, H. Chang-Ming, J. Lin, C. Zheng, P. Li; Fuzhou, CN
17:40 - 17:50 Invited Discussant 626PD and 627PD
Last update: 02-09-2017 06:01:33pm esmo.org Y.-K. Kang, Seoul, Songpa-gu/KR
17:50 - 18:00 Q&A led by Discussant
16:30 - 18:00 Type: Educational session Granada Title: Neuroendocrine neoplasms of the gastroenteropancreatic system: From the Auditorium bench to the bed Chair(s): J. Valle, GB; I. Chau, GB
16:30 - 16:55 Pathological characterisation of gastroenteropancreatic neuroendocrine neoplasms: Present and future A. Couvelard, Clichy, FR
16:55 - 17:20 Present and future of nuclear medicine approach in neuroendocrine tumour management: From diagnosis to treatment L. Bodei, Milan, IT
17:20 - 17:45 Evidence-based decisions in systemic management of gastroenteropancreatic neuroendocrine tumours J. Valle, Manchester, GB
17:45 - 18:00 Discussion
Last update: 02-09-2017 06:01:33pm esmo.org 16:30 - 17:45 Type: Presidential Symposium Madrid Auditorium Title: Presidential Symposium III Chair(s): F. Ciardiello, IT; R. Marais, GB
16:30 - 16:45 LBA7_PR - BRIM8: a randomized, double-blind, placebo-controlled study of adjuvant vemurafenib in patients (pts) with completely resected, BRAFV600+ melanoma at high risk for recurrence 1 2 3 4 5 6 7 K. Lewis , M. Maio , L. Demidov , M. Mandala , P. Ascierto , C. Herbert , A. Mackiewicz , P. 8 9 10 10 10 10 11 1 Rutkowski , A. Guminski , G. Goodman , B. Simmons , C. Ye , Y. Yan , D. Schadendorf ;
2 3 4 5 6 7 8 Aurora, CO/US, Siena, IT, Moscow, RU, Bergamo, IT, Napoli, IT, Bristol, GB, Poznan, PL, 9 10 11 Warsaw, PL, St Leonards, NSW/AU, South San Francisco, US, Essen, DE
16:45 - 17:00 LBA6_PR - COMBI-AD: Adjuvant Dabrafenib (D) Plus Trametinib (T) for Resected Stage III BRAF V600E/K–Mutant Melanoma 1 2 3 4 5 6 7 A. Hauschild , M. Santinami , G. Long , V. Atkinson , M. Mandala , V. Chiarion Sileni , M. Nyakas , C. 8 9 10 11 12 13 13 14 Dutriaux , A. Haydon , C. Robert , L. Mortier , J. Schachter , R. Ji , P. Zhang , B. Mookerjee , 15 16 17 18 1 2 3 J. Legos , R. Kefford , R. Dummer , J. Kirkwood ; Kiel, Schleswig-Holstein/DE, Milan, IT,
4 5 6 7 8 9 Sydney, AU, Woolloongabba, AU, Bergamo, IT, Padova, IT, Oslo, NO, Bordeaux, FR, Melbourne, 10 11 12 13 14 15 AU, Villejuif, FR, Lille, CEDEX/FR, Ramat Gan, IL, East Hanover, US, New Jersey, US, 16 17 18 East Hanover, New Jersey/US, Macquarie Park, NSW/AU, Zürich, CH, Pittsburgh, PA/US
17:00 - 17:15 Invited Discussant LBA7_PR and LBA6_PR A.M.M. Eggermont, Villejuif, FR
17:15 - 17:30 LBA8_PR - Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: a randomized, double-blind, phase 3 trial (CheckMate 238) 1 2 3 4 5 6 7 8 J. Weber , M. Mandala , M. Del Vecchio , H. Gogas , A. Arance , L. Cowey , S. Dalle , M. Schenker , 9 10 11 12 13 14 V. Chiarion-Sileni , I. Márquez-Rodas , J.-J. Grob , M. Butler , M. Middleton , M. Maio , V. 15 16 17 17 18 19 1 2 Atkinson , P. Queirolo , V. de Pril , A. Qureshi , J. Larkin , P. Ascierto ; New York, US,
3 4 5 6 7 8 Bergamo, IT, Milan, IT, Athens, Attiki/GR, Barcelona, ES, Dallas, TX/US, Pierre Bénite, FR, 9 10 11 12 13 Craiova, RO, Padua, IT, Madrid, ES, Marseille, FR, Toronto, ON/CA, Oxford, Oxfordshire/GB, 14 15 16 17 18 19 Siena, IT, Queensland, AU, Genova, IT, Princeton, NJ/US, London, GB, Napoli, IT
17:30 - 17:45 Invited Discussant LBA8_PR R. Dummer, Zürich, CH
Last update: 02-09-2017 06:01:33pm esmo.org 16:30 - 17:30 Type: Multidisciplinary Session Valencia Auditorium Title: Clinical challenges in head and neck cancer Chair(s): M. Merlano, IT
16:30 - 16:35 Presentation of case/condition M. Merlano, Cuneo, IT
16:35 - 16:45 The medical oncology perspective M. Merlano, Cuneo, IT
16:45 - 16:55 The radiation therapy perspective V. Grégoire, Brussels, BE
16:55 - 17:05 The surgery perspective C. Simon, Lausanne, CH
17:05 - 17:30 General Discussion
16:30 - 17:50 Type: Poster Discussion session Tarragona Auditorium Title: Haematological malignancies Chair(s): E. Terpos, GR; C. Buske, DE; L. De La Cruz Merino, ES
16:30 - 16:30 997PD - Split dosing of daratumumab (D) in a phase 1b study of D plus carfilzomib (K)-based regimens in patients (pts) with multiple myeloma (MM) 1 2 3 4 5 6 7 S. Usmani , A. Jakubowiak , A. Chari , S. Lonial , M.-V. Mateos , L. Benboubker , K. Wu , N. Khokhar 7 8 7 9 1 2 3 4 , J. Wang , P. Doshi , P. Moreau ; Charlotte, US, Chicago, IL/US, New York, NY/US, Atlanta, 5 6 7 8 9 GA/US, Salamanca, ES, Tours, FR, Spring House, PA/US, Raritan, NJ/US, Nantes, FR
16:30 - 16:30 998PD - Management of infusion-related reactions (IRRs) in patients (pts) receiving daratumumab plus standard of care for the treatment of multiple myeloma (MM) in the phase 3 studies CASTOR and POLLUX 1 2 3 4 5 6 7 7 P. Moreau , N. Rabin , T. Plesner , K. Weisel , P. Sonneveld , M.-V. Mateos , J. Schecter , H. Amin , 8 9 1 2 3 4 5 6 S. Trivedi , M. Dimopoulos ; Nantes, FR, London, GB, Vejle, DK, Tübingen, DE, Rotterdam, NL, 7 8 9 Salamanca, ES, Raritan, Nj, US, Spring House, Pa, US, Athens, GR
16:30 - 16:30 999PD - Comparison of efficacy of new therapies between younger and older patients with relapsed and refractory multiple myeloma: A meta-analysis 1 2 1 1 1 2 T. LANDRE , C. Al-Nawakil , F. Karaoud , C. Taleb ; Sevran, FR, Bobigny, FR
16:30 - 16:45 Invited Discussant 997PD, 998PD and 999PD E. Terpos, Athens, Neo Psychiko/GR
16:45 - 16:50 Q&A led by Discussant
Last update: 02-09-2017 06:01:33pm esmo.org
16:50 - 16:50 1000PD - Copanlisib treatment in patients with relapsed or refractory indolent B-cell lymphoma: Subgroup analyses from the CHRONOS-1 study 1 2 3 4 5 6 7 8 M. Provencio Pulla , A. Santoro , L. Mollica , S. Leppä , G. Follows , G. Lenz , W.S. Kim , A. Nagler , 9 10 11 12 13 14 P. Panayiotidis , J. Demeter , M. Özcan , M. Kosinova , K. Bouabdallah , F. Morschhauser , T. 15 16 16 17 18 19 1 Ishida , L. Huang , J. Garcia-Vargas , B. Childs , P.L. Zinzani , M. Dreyling ; Majadahonda, 2 3 4 5 6 7 Madrid/ES, Rozzano, (MI)/IT, Montreal, CA, Helsinki, FI, Cambridge, GB, Münster, DE, Seoul, 8 9 10 11 12 13 KR, Tel-Hashomer, IL, Athens, GR, Budapest, HU, Ankara, TR, Kemerovo, RU, Pessac, FR, 14 15 16 17 18 19 Lille, FR, São Paulo, BR, Whippany, NJ/US, New York, New York/US, Bologna, IT, Munich, DE
16:50 - 16:50 1001PD - Tumor gene expression signatures of BCR/PI3K dependence in association with copanlisib monotherapy activity in heavily pretreated patients with indolent NHL and follicular lymphoma 1 2 2 1 3 4 5 L. Liu , K. Köchert , H. Seidel , J. Garcia-Vargas , B. Childs , G. Follows , K. Bouabdallah , M. 6 1 1 2 3 4 5 Dreyling , C. Peña ; Whippany, NJ/US, Berlin, DE, New York, New York/US, Cambridge, GB, 6 Pessac, FR, Munich, DE
16:50 - 16:50 1002PD - Standardized mortality ratios and event-free survival as new prediction tools of early increase in mortality in follicular lymphoma 1 1 1 2 3 4 F. Franco , A. Royuela , M. Torrente , J. Gómez-Codina , M. Llanos Rodríguez , J. Gumá Padró , C. 5 6 7 8 1 2 3 Quero Blanco , D. Aguiar , A. Rueda Domínguez , M. Provencio Pulla ; Madrid, ES, Valencia, ES,
4 5 6 7 Santa Cruz De Tenerife, ES, Reus, ES, Malaga, ES, Las Palmas De Gran Canaria, ES, Marbella, 8 ES, Majadahonda, Madrid/ES
16:50 - 17:05 Invited Discussant 1000PD, 1001PD and 1002PD L. De la Cruz Merino, Sevilla, ES
17:05 - 17:10 Q&A led by Discussant
17:10 - 17:10 1003PD - A multicentre phase II trial addressing lenalidomide (LEN) maintenance in patients with relapsed diffuse large b-cell lymphoma (rDLBCL) who are not eligible for autologous stem cell transplantation (ASCT) 1 2 3 4 5 6 7 8 M. Sassone , F. Zaja , A. Re , M. Spina , A. Di Rocco , A. Fabbri , C. Stelitano , M. Frezzato , C. 9 10 1 1 1 2 1 Rusconi , R. Zambello , T. Calimeri , L. Scarfò , C. Cecchetti , M. Chiozzotto , M. Ponzoni , A.
1 1 2 3 4 5 6 7 Ferreri ; Milan, IT, Udine, IT, Brescia, IT, Aviano, PN/IT, Roma, IT, Siena, IT, Reggio Calabria, 8 9 10 IT, Vicenza, IT, Milano, IT, Padova, IT
17:10 - 17:10 1004PD - Follicular lymphoma: clinical and mollecular characteristics of histologic transformation 1 2 2 3 M. Mendez Garcia , M. Sánchez-Beato Gomez , J. González Rincón , J. Gomez Codina , M. Llanos 4 5 6 7 8 Rodríguez , A. Rueda Domínguez , C. Quero Blanco , L. De la Cruz Merino , J. Gumá Padró , M.
9 1 2 3 4 5 Provencio Pulla ; Madrid, ES, Majadahonda, ES, Valencia, ES, Santa Cruz De Tenerife, ES, 6 7 8 9 Marbella, ES, Malaga, ES, Sevilla, ES, Reus, ES, Majadahonda, Madrid/ES
17:10 - 17:10 1005PD - Prognostic nomogram for overall survival in previously untreated patients with diffuse large B-cell lymphoma
Last update: 02-09-2017 06:01:33pm esmo.org Y. Han, Y. Qin, P. Liu, J. Yang, X. He, S. Zhou, L. Gui, S. Yang, C. Zhang, Y. Huang, S. Jiang, Y. Shi, Q.
Wang, Y. Sun, Y.-K. Shi; Beijing, CN
17:10 - 17:10 1006PD - Does the omission of vincristine affect outcome and survival in patients with diffuse large B-cell lymphoma? 1 1 2 2 2 2 1 2 C. Mörth , A. Valachis , A. Abu Sabaa , G. Hedström , M. Flogegård , G. Enblad ; Eskilstuna, SE, Uppsala, SE
17:10 - 17:25 Invited Discussant 1003PD, 1004PD, 1005PD and 1006PD C. Buske, Ulm, DE
17:25 - 17:30 Q&A led by Discussant
17:30 - 17:30 1007PD - Preliminary results of novel safety interventions in adult patients (pts) with relapsed/refractory acute lymphoblastic leukemia (R/R ALL) in the ZUMA-3 Trial 1 2 3 4 5 6 7 8 B. Shah , W. Stock , W. Wierda , M. Topp , M.J. Kersten , R. Houot , N. Boissel , H. Holmes , G. 9 10 10 10 10 11 10 12 Schiller , A. Mardiros , J. Rossi , Y. Jiang , T. Shen , J. Aycock , S. Stout , J. Wiezorek , R. 12 1 2 3 4 5 6 7 Jain ; Tampa, US, Chicago, US, Houston, US, Wurzburg, DE, Amsterdam, NL, Rennes, FR, 8 9 10 11 12 Paris, FR, Dallas, US, Los Angeles, US, Santa Monica, CA/US, Santa Monica, US, Thousand Oaks, CA/US
17:30 - 17:30 1008PD - ZUMA-4 preliminary results: phase 1 study of KTE-C19 chimeric antigen receptor T cell therapy in pediatric and adolescent patients (pts) with relapsed/refractory acute lymphoblastic leukemia (R/R ALL) 1 2 3 4 5 6 7 D. Lee , A. Wayne , V. Huynh , R. Handgretinger , R. Pieters , G. Michele , A. Baruchel , T. 8 9 10 11 12 12 12 12 Feuchtinger , Y. Bertrand , M. Hemiston , P. Brown , J. Rossi , Y. Jiang , L. Navale , S. Stout 13 12 14 14 1 2 3 , J. Aycock , A. Mardiros , J. Wiezorek , R. Jain ; Charlottsville, US, Los Angeles, CA/US, 4 5 6 7 8 9 10 Irvine, US, Tübingen, DE, Utrecht, NL, Marseille, FR, Paris, FR, Tuebingen, NL, Lyon, FR, San 11 12 13 14 Francisco, CA/US, Baltimore, MD/US, Santa Monica, CA/US, Santa Monica, US, Thousand Oaks, CA/US
17:30 - 17:30 1009PD - Treatment patterns in elderly patients (pts) with acute myeloid leukemia (AML) in routine clinical care in the united states (US) 1 1 2 3 2 2 2 4 J. Bell , A. Galaznik , E. Farrelly , M. Pollack , A. Raju , A. Ogbonnaya , M. Eaddy , R. Fram , D.
1 1 2 3 4 Faller ; Cambridge, MA/US, Palm Harbor, FL/US, Tampa, US, Waltham, MA 02451/US
17:30 - 17:45 Invited discussant 1007PD, 1008PD and 1009PD J. De La Serna, Madrid, ES
17:45 - 17:50 Q&A led by Discussant
Last update: 02-09-2017 06:01:33pm esmo.org 16:30 - 18:00 Type: Proffered Paper session Alicante Auditorium Title: Public health policy and health economics Chair(s): R. Giuliani, IT; C. Uyl-De Groot, NL
16:30 - 16:42 1435O_PR - Comparison of the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) in Clinical Trials Supporting US Food and Drug Administration (FDA) Approval of Orphan vs. Non-orphan Drugs. 1 1 2 3 1 C. Molto Valiente , A. Tibau , A. Ocana Fernandez , A. Templeton , L. del Carpio Huerta , J. Del 4 1 5 6 1 2 3 4 Paggio , A. Barnadas , C. Booth , E. Amir ; Barcelona, ES, Albacete, ES, Basel, CH, Kingston, 5 6 CA, Kingston, Ontario/CA, Toronto, Ontario/CA
16:42 - 16:54 1436O_PR - How to assess a cancer therapy? Feedback from the French HTA body on the ESMO-MCBS 1 1 1 1 2 1 1 M. Grande , J. Fernandez , B. Dahmani , S. Stanel , N. Albin , L. Guillevin , C. Belorgey , A.
1 1 2 D'ANDON ; St. Denis, FR, Rouen, CEDEX/FR
16:54 - 17:06 1437O_PR - Clinical Benefit of Randomized Controlled Trials (RCT) Supporting US Food and Drug Administration (FDA) Conversion from Accelerated to Full Approval 1 1 2 3 4 1 M. Borrell Puy , C. Molto Valiente , A. Ocana Fernandez , A. Templeton , B. Seruga , I. Gich , A. 1 5 1 1 2 3 4 5 Barnadas , E. Amir , A. Tibau ; Barcelona, ES, Albacete, ES, Basel, CH, Ljubljana, SI, Toronto, Ontario/CA
17:06 - 17:21 Invited Discussant 1435O, 1436O and 1437O C. Uyl-De Groot, Rotterdam, NL
17:21 - 17:33 1438O_PR - Report on ESMO/SIOPE European Landscape project key results: Mapping the status and needs in AYA cancer care. 1 2 3 4 5 6 7 E. Saloustros , D. Stark , K. Michailidou , G. Mountzios , L. Brugières , F. Peccatori , S. Jezdic , S. 8 9 10 1 2 3 4 Essiaf , J.-Y. Douillard , S. Bielack ; Heraklion, Crete, GR, Leeds, GB, Nicosia, CY, Athens, GR, 5 6 7 8 9 10 Villejuif, FR, Milan, IT, Lugano - Viganello, CH, Brussels, BE, Lugano - Viganello, CEDEX/CH, Stuttgart, CH
17:33 - 17:45 1439O_PR - Paediatric radiation therapy across Europe – a European questionnaire survey supported by the SIOPe, ESTRO, PROS and several national paediatric hematology-oncology societies (NAPHOS) 1 2 3 4 5 6 C. demoor-goldschmidt , C. Carrie , G. Whitfield , P. Meijinders , K. Dieckmann , B. Timmermann , L. 7 8 9 10 11 12 13 Zaletel , P. Banovic , M. Solak Mekic , Y. Lassen , K. Alexopoulou , J. Giralt , J. Vizkeleti , L. 14 15 16 17 18 19 Jarusevicius , B. Ondrova , P. Daly , P. Brandal , G. Janssens , U. Ricardi , R. 20 1 2 3 4 5 6 Dieter-Kortmann ; Villejuif, FR, Lyon, FR, Manchester, GB, Antwerp, BE, Vienna, AT, Essen, 7 8 9 10 11 12 13 DE, Ljublajna, SI, Banja Luka, BA, Zagreb, HR, Aarhus, DK, Athens, GR, Barcelona, ES, 14 15 16 17 18 19 20 Budapest, HU, Kaunas, LT, Prague, CZ, Dublin, IE, Oslo, NO, Utrecht, NL, Turin, IT, Leipzig, DE
17:45 - 18:00 Invited Discussant 1438O_PR and 1439O_PR P. Bruzzi, Genoa, IT
Last update: 02-09-2017 06:01:33pm esmo.org 18:30 - 20:00 Type: Industry Satellite Symposium Pamplona Auditorium Title: Industry Satellite Symposium 50
18:30 - 20:00 Type: Industry Satellite Symposium Cordoba Auditorium Title: Industry Satellite Symposium 51
18:30 - 20:00 Type: Awards session Granada Auditorium Title: Industry Satellite Symposium 52
18:30 - 20:00 Type: Industry Satellite Symposium Valencia Auditorium Title: Industry Satellite Symposium 53
18:30 - 20:00 Type: Industry Satellite Symposium Tarragona Auditorium Title: Industry Satellite Symposium 54
18:30 - 20:00 Type: Industry Satellite Symposium Bilbao Auditorium Title: Industry Satellite Symposium 55
18:30 - 20:00 Type: Industry Satellite Symposium Alicante Auditorium Title: Industry Satellite Symposium 56
12-09-2017
Last update: 02-09-2017 06:01:33pm esmo.org 09:00 - 12:30 Type: Congress highlights Barcelona Auditorium Title: Congress Highlights 1 - The best of ESMO 2017 Chair(s): R. Marais, GB; F. Ciardiello, IT
09:00 - 09:20 Basic Science A. Berns, Amsterdam, NL
09:20 - 09:40 Translational research I. Malanchi, London, GB
09:40 - 10:10 GU tumours A. Omlin, St. Gallen, CH
10:10 - 10:30 CNS tumours M. Preusser, Vienna, AT
10:30 - 10:50 Break
10:50 - 11:10 Head and neck cancer J.-P. Machiels, Brussels, BE
11:10 - 11:30 Developmental therapeutics J. Schellens, Amsterdam, NL
11:30 - 12:00 Breast cancer early and metastatic G. Curigliano, Milan, IT
12:00 - 12:30 Thoracic malignancies L. Paz-Ares, Madrid, ES
Last update: 02-09-2017 06:01:33pm esmo.org 09:00 - 12:30 Type: Congress highlights Sevilla Auditorium Title: Congress Highlights 2 - The best of ESMO 2017 Chair(s): A. Sobrero, IT; J. Tabernero, ES
09:00 - 09:20 Gastrointestinal tumours, colorectal R. Adams, Cardiff, GB
09:20 - 09:50 GI non-colorectal and NETs and endocrine tumours M. Ducreux, Villejuif, FR
09:50 - 10:10 Sarcoma H. Gelderblom, Leiden, NL
10:10 - 10:30 Gynaecological cancers A. Oaknin, Barcelona, ES
10:30 - 10:50 Break
10:50 - 11:10 Supportive and palliative care F. Scotté, Paris, FR
11:10 - 11:30 Public health and health economics C. Uyl-De Groot, Rotterdam, NL
11:30 - 11:50 Haematological malignancies F. Peyrade, Nice, CEDEX 2/FR
11:50 - 12:10 Immunotherapy of cancer I.-M. Svane, Herlev, DK
12:10 - 12:30 Melanoma and other skin tumours S. Martin Algarra, Pamplona, ES
Last update: 02-09-2017 06:01:33pm esmo.org